Improved	O
risk	O
stratification	O
for	O
patients	O
with	O
high-grade	O
urothelial	O
carcinoma	O
following	O
application	O
of	O
the	O
Paris	O
System	O
for	O
Reporting	O
Urinary	B-P
Cytology	I-P
.	O

The	O
Paris	O
System	O
for	O
Reporting	O
Urinary	B-P
Cytology	I-P
(	O
TPS	B-P
)	O
requires	O
4	O
cytomorphologic	O
criteria	O
for	O
a	O
definitive	O
diagnosis	O
of	O
high-grade	O
urothelial	O
carcinoma	O
(	O
HGUC	O
)	O
in	O
urinary	B-P
tract	I-P
cytology	I-P
(	O
UTC	B-P
)	O
specimens	O
:	O
an	O
elevated	O
nuclear-to-cytoplasmic	O
(	O
N/C	O
)	O
ratio	O
(	O
at	O
or	O
above	O
0.7	O
)	O
,	O
markedly	O
atypical	O
nuclear	O
borders	O
,	O
moderate	O
to	O
severe	O
hyperchromasia	O
,	O
and	O
coarse	O
chromatin	O
.	O

However	O
,	O
malignant	O
UTC	B-P
specimens	O
often	O
contain	O
degenerative	O
changes	O
,	O
and	O
this	O
limits	O
the	O
number	O
of	O
malignant	O
cells	O
meeting	O
all	O
4	O
TPS	B-P
cytomorphologic	O
criteria	O
.	O

One	O
hundred	O
twelve	O
UTC	B-P
specimens	O
from	O
patients	O
with	O
a	O
subsequent	O
diagnosis	O
of	O
HGUC	O
were	O
reviewed	O
and	O
reclassified	O
according	O
to	O
TPS	B-P
criteria	O
.	O

The	O
presence	O
of	O
TPS	B-P
cytomorphologic	O
criteria	O
for	O
HGUC	O
in	O
each	O
specimen	O
was	O
recorded	O
,	O
as	O
was	O
the	O
proportion	O
of	O
atypical	O
cells	O
meeting	O
all	O
4	O
criteria	O
.	O

The	O
number	O
of	O
specimens	O
definitively	O
diagnosed	O
as	O
HGUC	O
did	O
not	O
significantly	O
change	O
upon	O
reclassification	O
.	O

However	O
,	O
approximately	O
40	O
%	O
of	O
indeterminate	O
specimens	O
(	O
21	O
of	O
51	O
)	O
were	O
reclassified	O
into	O
a	O
higher	O
risk	O
category	O
.	O

The	O
most	O
restrictive	O
cytomorphologic	O
criterion	O
was	O
an	O
N/C	O
ratio	O
of	O
0.7	O
or	O
higher	O
(	O
seen	O
in	O
78	O
%	O
of	O
specimens	O
)	O
,	O
and	O
approximately	O
half	O
of	O
specimens	O
containing	O
all	O
4	O
cytomorphologic	O
criteria	O
did	O
not	O
meet	O
TPS	B-P
's	O
numerical	O
criterion	O
for	O
HGUC	O
(	O
at	O
least	O
5	O
malignant	O
cells	O
)	O
.	O

In	O
the	O
majority	O
of	O
specimens	O
qualifying	O
for	O
HGUC	O
by	O
TPS	B-P
standards	O
,	O
only	O
a	O
small	O
fraction	O
of	O
atypical	O
cells	O
(	O
10	O
%	O
-20	O
%	O
)	O
met	O
all	O
the	O
criteria	O
.	O

When	O
applied	O
to	O
malignant	O
UTC	B-P
specimens	O
,	O
TPS	B-P
criteria	O
improved	O
specimen	O
risk	O
stratification	O
by	O
upgrading	O
approximately	O
40	O
%	O
of	O
indeterminate	O
specimens	O
into	O
higher	O
risk	O
categories	O
while	O
not	O
significantly	O
changing	O
the	O
frequency	O
of	O
HGUC	O
diagnoses	O
.	O

Cancer	O
Cytopathol	O
2017	O
.	O

Â©	O
2017	O
American	O
Cancer	O
Society	O
.	O

Identification	O
and	O
characterization	O
of	O
Dichelobacter	O
nodosus	O
serogroup	O
H	O
from	O
ovine	O
footrot	O
in	O
India	O
.	O

A	O
total	O
of	O
56	O
foot	O
swabs	O
were	O
collected	O
from	O
inter	O
digital	O
spaces	O
of	O
sheep	O
with	O
footrot	O
lesions	O
were	O
screened	B-P
for	O
16	O
rRNA	O
of	O
Dichelobacter	O
nodosus	O
by	O
PCR	O
.	O

Out	O
of	O
the	O
56	O
samples	O
,	O
38	O
(	O
67.85	O
%	O
)	O
were	O
found	O
to	O
be	O
positive	O
.	O

All	O
the	O
positive	O
samples	O
were	O
subjected	O
to	O
multiplex	O
PCR	O
targeting	O
fimA	O
gene	O
for	O
identification	O
of	O
serogroups	O
of	O
D.	O
nodosus	O
.	O

Serogroup	O
H	O
was	O
found	O
along	O
with	O
serogroup	O
B	O
in	O
12	O
(	O
55.26	O
%	O
)	O
samples	O
and	O
with	O
serogroup	O
I	O
in	O
8	O
(	O
22.2	O
%	O
)	O
samples	O
.	O

The	O
serogroup	O
H	O
was	O
identified	O
for	O
the	O
first	O
time	O
from	O
the	O
Indian	O
subcontinent	O
.	O

The	O
phylogenetic	O
analysis	O
of	O
the	O
present	O
sequence	O
with	O
the	O
available	O
serogroup	O
H	O
sequences	O
of	O
GenBank	O
revealed	O
to	O
be	O
in	O
close	O
association	O
with	O
the	O
serotype	O
H1	O
.	O

Farnesylthiosalicylic	O
acid	O
-loaded	O
lipid-polyethylene	O
glycol-polymer	O
hybrid	O
nanoparticles	O
for	O
treatment	O
of	O
glioblastoma	O
.	O

We	O
aimed	O
to	O
develop	O
lipid-polyethylene	O
glycol	O
(	O
PEG	O
)	O
-polymer	O
hybrid	O
nanoparticles	O
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	O
tissue	O
with	O
active	O
ingredient	O
,	O
a	O
new	O
generation	O
antineoplastic	O
drug	O
,	O
farnesylthiosalicylic	O
acid	O
(	O
FTA	O
)	O
for	O
treatment	O
of	O
glioblastoma	O
.	O

Farnesylthiosalicylic	O
acid	O
-loaded	O
poly	O
(	O
lactic-co-glycolic	O
acid	O
)	O
-1,2	O
distearoyl-glycerol-3-phospho-ethanolamine-N	O
[	O
methoxy	O
(	O
PEG	O
)	O
-2000	O
]	O
ammonium	O
salt	O
(	O
PLGA-DSPE-PEG	O
)	O
with	O
or	O
without	O
1,2-dioleoyl-3-trimethylammonium-propane	O
(	O
DOTAP	O
)	O
hybrid	O
nanoparticles	O
has	O
been	O
prepared	O
and	O
evaluated	O
for	O
in-vitro	O
characterization	O
.	O

Cytotoxicity	O
of	O
FTA-loaded	O
nanoparticles	O
along	O
with	O
its	O
efficacy	O
on	O
rat	O
glioma-2	O
(	O
RG2	O
)	O
cells	O
was	O
also	O
evaluated	O
both	O
in	O
vitro	O
(	O
in	O
comparison	O
with	O
non-malignant	O
cell	O
line	O
,	O
L929	O
)	O
and	O
in	O
vivo	O
.	O

Scanning	B-P
electron	I-P
microscopy	I-P
studies	I-P
showed	O
that	O
all	O
formulations	O
prepared	O
had	O
smooth	O
surface	O
and	O
spherical	O
in	O
shape	O
.	O

FTA	O
and	O
FTA-loaded	O
nanoparticles	O
have	O
cytotoxic	O
activity	O
against	O
RG2	O
glioma	O
cell	O
lines	O
in	O
cell	O
culture	O
studies	O
,	O
which	O
further	O
increases	O
with	O
addition	O
of	O
DOTAP	O
.	O

Magnetic	B-P
resonance	I-P
imaging	I-P
and	O
histopathologic	O
evaluation	O
on	O
RG2	O
tumour	O
cells	O
in	O
rat	O
glioma	O
model	O
(	O
49	O
female	O
Wistar	O
rats	O
,	O
250-300	O
g	O
)	O
comparing	O
intravenous	O
and	O
intratumoral	O
injections	O
of	O
the	O
drug	O
have	O
been	O
performed	O
and	O
FTA-loaded	O
nanoparticles	O
reduced	O
tumour	O
size	O
significantly	O
in	O
in-vivo	O
studies	O
,	O
with	O
higher	O
efficiency	O
of	O
intratumoral	O
administration	O
than	O
intravenous	O
route	O
.	O

Farnesylthiosalicylic	O
acid	O
-loaded	O
PLGA-DSPE-PEG-DOTAP	O
hybrid	O
nanoparticles	O
are	O
proven	O
to	O
be	O
effective	O
against	O
glioblastoma	O
in	O
both	O
in-vitro	O
and	O
in-vivo	O
experiments	O
.	O

Sarcoid-like	O
reaction	O
in	O
a	O
patient	O
with	O
uveitis	O
and	O
underlying	O
cancer	O
.	O

Sarcoidosis	O
is	O
a	O
granulomatous	O
disease	O
of	O
unknown	O
etiology	O
.	O

Occasionally	O
,	O
triggering	O
causes	O
are	O
identified	O
,	O
such	O
as	O
neoplasms	O
,	O
and	O
they	O
are	O
termed	O
sarcoid-like	O
reactions	O
,	O
which	O
may	O
appear	O
in	O
any	O
sarcoidotic	O
target	O
tissue	O
.	O

Choroidal	O
metastases	O
appear	O
as	O
part	O
of	O
widespread	O
metastatic	O
disease	O
or	O
as	O
the	O
first	O
suggestion	O
of	O
neoplastic	O
disease	O
.	O

They	O
can	O
also	O
be	O
a	O
part	O
of	O
the	O
differential	B-P
diagnosis	I-P
of	O
a	O
spectrum	O
of	O
inflammatory	O
eye	O
diseases	O
.	O

We	O
present	O
a	O
case	O
in	O
which	O
a	O
lung	O
carcinoma	O
,	O
pulmonary	O
and	O
eye	O
sarcoid-like	O
reactions	O
,	O
and	O
choroidal	O
metastasis	O
take	O
place	O
in	O
the	O
same	O
patient	O
.	O

A	O
60-	O
year-old	O
male	O
with	O
a	O
past	O
history	O
of	O
pulmonary	O
sarcoidosis	O
and	O
associated	O
anterior	O
uveitis	O
was	O
diagnosed	O
with	O
a	O
lung	O
carcinoma	O
with	O
no	O
regional	O
lymph	O
nodes	O
extension	O
,	O
so	O
that	O
the	O
resection	O
surgery	O
was	O
performed	O
without	O
additional	O
systemic	O
treatment	O
.	O

At	O
the	O
same	O
time	O
,	O
he	O
complained	O
of	O
visual	O
acuity	O
loss	O
and	O
pain	O
in	O
his	O
right	O
eye	O
.	O

An	O
intense	O
ocular	O
inflammatory	O
reaction	O
and	O
a	O
choroidal	O
mass	O
compatible	O
with	O
metastasis	O
were	O
identified	O
.	O

A	O
vitrectomy	O
with	O
an	O
accompanied	O
histological	O
exam	O
of	O
the	O
lesion	O
was	O
deemed	O
inconclusive	O
.	O

Ocular	O
symptoms	O
progressively	O
worsened	O
showing	O
mass	O
growth	O
,	O
and	O
as	O
a	O
result	O
,	O
an	O
enucleation	O
was	O
performed	O
and	O
the	O
histological	O
study	O
subsequently	O
revealed	O
metastasis	O
from	O
his	O
lung	O
carcinoma	O
.	O

Sarcoid-like	O
reactions	O
may	O
be	O
due	O
to	O
incipient	O
malignancies	O
.	O

Any	O
diagnosis	O
of	O
sarcoidosis	O
requires	O
ruling	O
out	O
other	O
diseases	O
that	O
can	O
produce	O
secondary	O
sarcoid-like	O
reactions	O
.	O

In	O
addition	O
,	O
any	O
choroidal	O
mass	O
suggestive	O
of	O
metastasis	O
requires	O
exclusion	O
of	O
metastatic	O
disease	O
even	O
in	O
the	O
absence	O
of	O
clinical	O
signs	O
indicating	O
tumor	O
extension	O
.	O

Performance	O
of	O
ANTI-HCV	B-P
testing	I-P
in	O
dried	O
blood	O
spots	O
and	O
saliva	O
according	O
to	O
HIV	O
status	O
.	O

The	O
use	O
of	O
saliva	O
and	O
dried	O
blood	O
spots	O
(	O
DBS	O
)	O
could	O
increase	O
access	O
to	O
HCV	O
diagnosis	O
for	O
high-risk	O
populations	O
,	O
such	O
as	O
HIV-infected	O
individuals	O
,	O
but	O
the	O
performance	O
of	O
these	O
assays	B-P
has	O
not	O
been	O
well	O
established	O
in	O
this	O
group	O
.	O

This	O
study	O
aims	O
to	O
evaluate	O
HIV	O
status	O
,	O
particularly	O
TCD4	O
(	O
+	O
)	O
cell	O
count	B-P
and	O
viral	B-P
load	I-P
,	O
in	O
the	O
performance	O
of	O
anti-HCV	B-P
testing	I-P
using	O
DBS	O
and	O
saliva	O
.	O

A	O
total	O
of	O
961	O
individuals	O
classified	O
as	O
HCV+	O
,	O
HIV+	O
,	O
or	O
HIV	O
/	O
HCV+	O
,	O
as	O
well	O
as	O
negative	O
controls	O
,	O
donated	O
serum	O
,	O
DBS	O
,	O
and	O
saliva	O
samples	O
for	O
anti-HCV	B-P
testing	I-P
using	O
a	O
commercial	O
enzyme	B-P
immunoassay	I-P
.	O

Sample	O
volume	O
was	O
modified	O
for	O
DBS	O
and	O
saliva	O
,	O
and	O
an	O
ROC	O
curve	O
was	O
used	O
for	O
cut-off	O
determination	B-P
in	O
saliva	O
.	O

Anti-HCV	O
sensitivities	O
were	O
greater	O
than	O
93	O
%	O
using	O
DBS	O
and	O
saliva	O
in	O
the	O
HCV+	O
group	O
,	O
while	O
they	O
were	O
83.3	O
%	O
and	O
95.6	O
%	O
for	O
HCV	O
/	O
HIV+	O
individuals	O
for	O
DBS	O
and	O
saliva	O
assays	B-P
,	O
respectively	O
.	O

Specificity	O
varied	O
from	O
91.7	O
%	O
to	O
100	O
%	O
using	O
saliva	O
and	O
DBS	O
in	O
HIV	O
monoinfected	O
and	O
control	O
subjects	O
.	O

When	O
only	O
anti-HCV	O
/	O
HCV	O
RNA+	O
serum	O
samples	O
,	O
that	O
is	O
,	O
true	O
positives	O
,	O
were	O
considered	O
,	O
the	O
sensitivities	O
were	O
98.3	O
%	O
and	O
100	O
%	O
for	O
DBS	O
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HCV+	O
group	O
and	O
91.6	O
%	O
and	O
94.8	O
%	O
for	O
DBS	O
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HIV	O
/	O
HCV+	O
group	O
.	O

High	O
absorbance	O
values	O
were	O
observed	O
among	O
those	O
presenting	O
with	O
HCV	B-P
RNA	I-P
in	O
serum	O
and	O
low	O
HIV	B-P
viral	I-P
load	I-P
(	O
less	O
than	O
50	O
copies/mL	O
)	O
.	O

In	O
conclusion	O
,	O
DBS	O
and	O
saliva	O
samples	O
could	O
be	O
used	O
for	O
anti-HCV	O
detection	O
,	O
particularly	O
to	O
identify	O
active	O
HCV	O
cases	O
,	O
but	O
low	O
sensitivity	O
was	O
observed	O
for	O
anti-HCV	B-P
testing	I-P
using	O
DBS	O
in	O
the	O
HIV	O
/	O
HCV+	O
group	O
.	O

Fractal	O
analysis	O
of	O
the	O
ischemic	O
transition	O
region	O
in	O
chronic	O
ischemic	O
heart	O
disease	O
using	O
magnetic	B-P
resonance	I-P
imaging	I-P
.	O

To	O
introduce	O
a	O
novel	O
hypothesis	O
and	O
method	O
to	O
characterise	O
pathomechanisms	O
underlying	O
myocardial	O
ischemia	O
in	O
chronic	O
ischemic	O
heart	O
disease	O
by	O
local	O
fractal	O
analysis	O
(	O
FA	O
)	O
of	O
the	O
ischemic	O
myocardial	O
transition	O
region	O
in	O
perfusion	B-P
imaging	I-P
.	O

Vascular	O
mechanisms	O
to	O
compensate	O
ischemia	O
are	O
regulated	O
at	O
various	O
vascular	O
scales	O
with	O
their	O
superimposed	B-P
perfusion	I-P
pattern	O
being	O
hypothetically	O
self-similar	O
.	O

Dedicated	O
FA	O
software	O
(	O
``	O
FraktalWandler	O
``	O
)	O
has	O
been	O
developed	O
.	O

Fractal	O
dimensions	O
during	O
first-pass	O
(	O
FDfirst-pass	O
)	O
and	O
recirculation	O
(	O
FDrecirculation	O
)	O
are	O
hypothesised	O
to	O
indicate	O
the	O
predominating	O
pathomechanism	O
and	O
ischemic	O
severity	O
,	O
respectively	O
.	O

Twenty-six	O
patients	O
with	O
evidence	O
of	O
myocardial	O
ischemia	O
in	O
108	O
ischemic	O
myocardial	O
segments	O
on	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
were	O
analysed	O
.	O

The	O
40th	O
and	O
60th	O
percentiles	O
of	O
FDfirst-pass	O
were	O
used	O
for	O
pathomechanical	O
classification	O
,	O
assigning	O
lesions	O
with	O
FDfirst-pass	O
â¤	O
2.335	O
to	O
predominating	O
coronary	O
microvascular	O
dysfunction	O
(	O
CMD	O
)	O
and	O
â¥2.387	O
to	O
predominating	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
.	O

Optimal	O
classification	O
point	O
in	O
ROC	O
analysis	O
was	O
FDfirst-pass	O
=	O
2.358	O
.	O

FDrecirculation	O
correlated	O
moderately	O
with	O
per	O
cent	O
diameter	O
stenosis	O
in	O
invasive	O
coronary	B-P
angiography	I-P
in	O
lesions	O
classified	O
CAD	O
(	O
r	O
=	O
0.472	O
,	O
p	O
=	O
0.001	O
)	O
but	O
not	O
CMD	O
(	O
r	O
=	O
0.082	O
,	O
p	O
=	O
0.600	O
)	O
.	O

The	O
ischemic	O
transition	O
region	O
may	O
provide	O
information	O
on	O
pathomechanical	O
composition	O
and	O
severity	O
of	O
myocardial	O
ischemia	O
.	O

FA	O
of	O
this	O
region	O
is	O
feasible	O
and	O
may	O
improve	O
diagnosis	O
compared	O
to	O
traditional	O
noninvasive	O
myocardial	O
perfusion	O
analysis	O
.	O

â¢	O
A	O
novel	O
hypothesis	O
and	O
method	O
is	O
introduced	O
to	O
pathophysiologically	O
characterise	O
myocardial	O
ischemia	O
.	O

â¢	O
The	O
ischemic	O
transition	O
region	O
appears	O
a	O
meaningful	O
diagnostic	O
target	O
in	O
perfusion	B-P
imaging	I-P
.	O

â¢	O
Fractal	O
analysis	O
may	O
characterise	O
pathomechanical	O
composition	O
and	O
severity	O
of	O
myocardial	O
ischemia	O
.	O

Renoprotective	O
Effect	O
of	O
Plantago	O
Major	O
Against	O
Nephrotoxicity	O
and	O
Oxidative	O
Stress	O
Induced	O
by	O
Cisplatin	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
possible	O
renoprotective	O
effect	O
of	O
Plantago	O
major	O
extract	O
against	O
cisplatin	O
-induced	O
nephrotoxicity	O
in	O
rats	O
.	O

Rats	O
were	O
divided	O
into	O
6	O
groups	O
.	O

The	O
first	O
group	O
was	O
the	O
control	O
,	O
group	O
2	O
was	O
treated	O
with	O
cisplatin	O
(	O
7	O
mg/kg	O
,	O
single	O
dose	O
)	O
,	O
and	O
groups	O
3	O
to	O
6	O
received	O
cisplatin	O
with	O
vitamin	O
E	O
(	O
100	O
mg/kg	O
)	O
and	O
Plantago	O
major	O
extract	O
at	O
doses	O
of	O
300	O
mg/kg	O
,	O
600	O
mg/kg	O
,	O
and	O
1200	O
mg/kg	O
,	O
for	O
20	O
days	O
.	O

On	O
day12	O
,	O
serum	O
concentration	O
of	O
urea	O
,	O
creatinine	O
,	O
and	O
potassium	O
significantly	O
increased	O
and	O
sodium	O
concentration	O
significantly	O
decreased	O
in	O
the	O
cisplatin	O
group	O
compared	O
with	O
the	O
control	O
rats	O
.	O

However	O
,	O
serum	O
creatinine	O
,	O
urea	O
,	O
and	O
potassium	O
concentrations	O
were	O
significantly	O
lower	O
in	O
all	O
of	O
the	O
Plantago	O
major	O
groups	O
compared	O
to	O
the	O
cisplatin	O
group	O
.	O

Also	O
,	O
there	O
was	O
a	O
significant	O
elevation	O
in	O
serum	O
sodium	O
concentration	O
in	O
the	O
Plantago	O
major	O
600	O
mg/kg	O
group	O
compared	O
to	O
the	O
cisplatin	O
group	O
on	O
day12	O
.	O

Injection	O
of	O
cisplatin	O
caused	O
a	O
significant	O
elevation	O
in	O
malondialdehyde	B-P
concentration	I-P
but	O
a	O
significant	O
decrease	O
in	O
catalase	O
activity	O
and	O
total	B-P
thiol	I-P
content	I-P
compared	O
to	O
the	O
control	O
group	O
.	O

Plantago	O
major	O
extract	O
at	O
1200	O
mg/kg	O
significantly	O
improved	O
malondialdehyde	B-P
concentration	I-P
and	O
total	B-P
thiol	I-P
content	I-P
compared	O
to	O
the	O
cisplatin	O
group	O
.	O

Catalase	O
activity	O
with	O
Plantago	O
major	O
significantly	O
increased	O
at	O
all	O
doses	O
compared	O
to	O
the	O
cisplatin	O
group	O
.	O

The	O
current	O
study	O
suggests	O
that	O
Plantago	O
major	O
extract	O
and	O
vitamin	O
E	O
are	O
able	O
to	O
improve	O
kidney	O
function	O
as	O
well	O
as	O
oxidative	O
stress	O
in	O
cisplatin	O
-induced	O
renal	O
toxicity	O
in	O
the	O
rat	O
.	O

Neoadjuvant	O
Chemotherapy	O
of	O
Ovarian	O
Cancer	O
Results	O
in	O
Three	O
Patterns	O
of	O
Tumor-Infiltrating	O
Lymphocyte	O
Response	O
with	O
Distinct	O
Implications	O
for	O
Immunotherapy	O
.	O

Purpose	O
:	O
Some	O
forms	O
of	O
chemotherapy	O
can	O
enhance	O
antitumor	O
immunity	O
through	O
immunogenic	O
cell	O
death	O
,	O
resulting	O
in	O
increased	O
T-cell	O
activation	O
and	O
tumor	O
infiltration	O
.	O

Such	O
effects	O
could	O
potentially	O
sensitize	O
tumors	O
to	O
immunotherapies	O
,	O
including	O
checkpoint	O
blockade	O
.	O

We	O
investigated	O
whether	O
platinum	O
-	O
and	O
taxane	O
-based	O
chemotherapy	O
for	O
ovarian	O
cancer	O
induces	O
immunologic	O
changes	O
consistent	O
with	O
this	O
possibility	O
.	O

Experimental	O
Design	O
:	O
Matched	O
pre	O
-	O
and	O
post	O
-	O
neoadjuvant	O
chemotherapy	O
tumor	O
samples	O
from	O
26	O
high-grade	O
serous	O
carcinoma	O
(	O
HGSC	O
)	O
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	B-P
(	O
IHC	B-P
)	O
for	O
a	O
large	O
panel	O
of	O
immune	O
cells	O
and	O
associated	O
factors	O
.	O

The	O
prognostic	O
significance	O
of	O
post	O
-	O
chemotherapy	O
TIL	O
patterns	O
was	O
assessed	O
in	O
an	O
expanded	O
cohort	O
(	O
n	O
=	O
90	O
)	O
.Results	O
:	O
Neoadjuvant	O
chemotherapy	O
was	O
associated	O
with	O
increased	O
densities	O
of	O
CD3	O
(	O
+	O
)	O
,	O
CD8	O
(	O
+	O
)	O
,	O
CD8	O
(	O
+	O
)	O
TIA-1	O
(	O
+	O
)	O
,	O
PD-1	O
(	O
+	O
)	O
and	O
CD20	O
(	O
+	O
)	O
TIL	O
.	O

Other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged	O
,	O
including	O
CD79a	O
(	O
+	O
)	O
CD138	O
(	O
+	O
)	O
plasma	O
cells	O
,	O
CD68	O
(	O
+	O
)	O
macrophages	O
,	O
and	O
MHC	O
class	O
I	O
on	O
tumor	O
cells	O
.	O

Immunosuppressive	O
cell	O
types	O
were	O
also	O
unchanged	O
,	O
including	O
FoxP3	O
(	O
+	O
)	O
PD-1	O
(	O
+	O
)	O
cells	O
(	O
putative	O
regulatory	O
T	O
cells	O
)	O
,	O
IDO-1	O
(	O
+	O
)	O
cells	O
,	O
and	O
PD-L1	O
(	O
+	O
)	O
cells	O
(	O
both	O
macrophages	O
and	O
tumor	O
cells	O
)	O
.	O

Hierarchical	O
clustering	O
revealed	O
three	O
response	O
patterns	O
:	O
(	O
i	O
)	O
TIL	O
(	O
high	O
)	O
tumors	O
showed	O
increases	O
in	O
multiple	O
immune	O
markers	O
after	O
chemotherapy	O
;	O
(	O
ii	O
)	O
TIL	O
(	O
low	O
)	O
tumors	O
underwent	O
similar	O
increases	O
,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group	O
;	O
and	O
(	O
iii	O
)	O
TIL	O
(	O
negative	O
)	O
cases	O
generally	O
remained	O
negative	O
.	O

Despite	O
the	O
dramatic	O
increases	O
seen	O
in	O
the	O
first	O
two	O
patterns	O
,	O
post-	O
chemotherapy	O
TIL	O
showed	O
limited	O
prognostic	O
significance.Conclusions	O
:	O
Chemotherapy	O
augments	O
pre-existing	O
TIL	O
responses	O
but	O
fails	O
to	O
relieve	O
major	O
immune-suppressive	O
mechanisms	O
or	O
confer	O
significant	O
prognostic	O
benefit	O
.	O

Our	O
findings	O
provide	O
rationale	O
for	O
multipronged	O
approaches	O
to	O
immunotherapy	O
tailored	O
to	O
the	O
baseline	O
features	O
of	O
the	O
tumor	O
microenvironment	O
.	O

Clin	O
Cancer	O
Res	O
;	O
23	O
(	O
4	O
)	O
;	O
925-34	O
.	O

Â©2016	O
AACR	O
.	O

Increase	O
in	O
acid	O
sphingomyelinase	O
level	O
in	O
human	O
retinal	O
endothelial	O
cells	O
and	O
CD34	O
(	O
+	O
)	O
circulating	O
angiogenic	O
cells	O
isolated	O
from	O
diabetic	O
individuals	O
is	O
associated	O
with	O
dysfunctional	O
retinal	O
vasculature	O
and	O
vascular	O
repair	O
process	O
in	O
diabetes	O
.	O

Diabetic	O
retinopathy	O
is	O
a	O
microvascular	O
disease	O
that	O
results	O
from	O
retinal	O
vascular	O
degeneration	O
and	O
defective	O
repair	O
due	O
to	O
diabetes	O
-	O
induced	O
endothelial	O
progenitor	O
dysfunction	O
.	O

Understanding	O
key	O
molecular	O
factors	O
involved	O
in	O
vascular	O
degeneration	O
and	O
repair	O
is	O
paramount	O
for	O
developing	O
effective	O
diabetic	O
retinopathy	O
treatment	O
strategies	O
.	O

We	O
propose	O
that	O
diabetes	O
-	O
induced	O
activation	O
of	O
acid	O
sphingomyelinase	O
(	O
ASM	O
)	O
plays	O
essential	O
role	O
in	O
retinal	O
endothelial	O
and	O
CD34	O
(	O
+	O
)	O
circulating	O
angiogenic	O
cell	O
(	O
CAC	O
)	O
dysfunction	O
in	O
diabetes	O
.	O

Human	O
retinal	O
endothelial	O
cells	O
(	O
HRECs	O
)	O
isolated	O
from	O
control	O
and	O
diabetic	O
donor	O
tissue	O
and	O
human	O
CD34	O
(	O
+	O
)	O
CACs	O
from	O
control	O
and	O
diabetic	O
patients	O
were	O
used	O
in	O
this	O
study	O
.	O

ASM	O
messenger	O
RNA	O
and	O
protein	O
expression	O
were	O
assessed	O
by	O
quantitative	O
polymerase	O
chain	O
reaction	O
and	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
,	O
respectively	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
diabetes	O
-	O
induced	O
ASM	O
on	O
HRECs	O
and	O
CD34	O
(	O
+	O
)	O
CACs	O
function	O
,	O
tube	O
formation	O
,	O
CAC	O
incorporation	O
into	O
endothelial	O
tubes	O
,	O
and	O
diurnal	O
release	O
of	O
CD34	O
(	O
+	O
)	O
CACs	O
in	O
diabetic	O
individuals	O
were	O
determined	O
.	O

ASM	O
expression	O
level	O
was	O
significantly	O
increased	O
in	O
HRECs	O
isolated	O
from	O
diabetic	O
compared	O
with	O
control	O
donor	O
tissue	O
,	O
as	O
well	O
as	O
CD34	O
(	O
+	O
)	O
CACs	O
and	O
plasma	O
of	O
diabetic	O
patients	O
.	O

A	O
significant	O
decrease	O
in	O
tube	O
area	O
was	O
observed	O
in	O
HRECs	O
from	O
diabetic	O
donors	O
compared	O
with	O
control	O
HRECs	O
.	O

The	O
tube	O
formation	O
deficiency	O
was	O
associated	O
with	O
increased	O
expression	O
of	O
ASM	O
in	O
diabetic	O
HRECs	O
.	O

Moreover	O
,	O
diabetic	O
CD34	O
(	O
+	O
)	O
CACs	O
with	O
high	O
ASM	O
showed	O
defective	O
incorporation	O
into	O
endothelial	O
tubes	O
.	O

Diurnal	O
release	O
of	O
CD34	O
(	O
+	O
)	O
CACs	O
was	O
disrupted	O
with	O
the	O
rhythmicity	O
lost	O
in	O
diabetic	O
patients	O
.	O

Collectively	O
,	O
these	O
findings	O
support	O
that	O
diabetes	O
-	O
induced	O
ASM	O
upregulation	O
has	O
a	O
marked	O
detrimental	O
effect	O
on	O
both	O
retinal	O
endothelial	O
cells	O
and	O
CACs	O
.	O

A	O
coarse-grained	O
model	O
for	O
assisting	O
the	O
investigation	O
of	O
structure	O
and	O
dynamics	O
of	O
large	O
nucleic	O
acids	O
by	O
ion	B-P
mobility	I-P
spectrometry-mass	I-P
spectrometry	I-P
.	O

Ion	B-P
Mobility	I-P
Spectrometry-Mass	I-P
Spectrometry	I-P
(	O
IMS-MS	B-P
)	O
is	O
a	O
rapidly	O
emerging	O
tool	O
for	O
the	O
investigation	O
of	O
nucleic	O
acid	O
structure	O
and	O
dynamics	O
.	O

IMS-MS	B-P
determinations	B-P
can	O
provide	O
valuable	O
information	O
regarding	O
alternative	O
topologies	O
,	O
folding	O
intermediates	O
,	O
and	O
conformational	O
heterogeneities	O
,	O
which	O
are	O
not	O
readily	O
accessible	O
to	O
other	O
analytical	B-P
techniques	I-P
.	O

The	O
leading	O
strategies	O
for	O
data	O
interpretation	O
rely	O
on	O
computational	B-P
and	O
experimental	O
approaches	O
to	O
correctly	O
assign	O
experimental	O
observations	O
to	O
putative	O
structures	O
.	O

A	O
very	O
effective	O
strategy	O
involves	O
the	O
application	O
of	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
to	O
predict	O
the	O
structure	O
of	O
the	O
analyte	O
molecule	O
,	O
calculate	O
its	O
collision	O
cross	O
section	O
(	O
CCS	O
)	O
,	O
and	O
then	O
compare	O
this	O
computational	O
value	O
with	O
the	O
corresponding	O
experimental	O
data	O
.	O

While	O
this	O
approach	O
works	O
well	O
for	O
small	O
nucleic	O
acid	O
species	O
,	O
analyzing	O
larger	O
nucleic	O
acids	O
of	O
biological	O
interest	O
is	O
hampered	O
by	O
the	O
computational	O
cost	O
associated	O
with	O
capturing	O
their	O
extensive	O
structure	O
and	O
dynamics	O
in	O
all-atom	O
detail	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
implementation	O
of	O
a	O
coarse	O
graining	O
(	O
CG	O
)	O
approach	O
to	O
reduce	O
the	O
cost	O
of	O
the	O
computational	O
methods	O
employed	O
in	O
the	O
data	O
interpretation	O
workflow	O
.	O

Our	O
framework	O
employs	O
a	O
five-bead	O
model	O
to	O
accurately	O
represent	O
each	O
nucleotide	O
in	O
the	O
nucleic	O
acid	O
structure	O
.	O

The	O
beads	O
are	O
appropriately	O
parameterized	O
to	O
enable	O
the	O
direct	O
calculation	O
of	O
CCS	O
values	O
from	O
CG	O
models	O
,	O
thus	O
affording	O
the	O
ability	O
to	O
pursue	O
the	O
analysis	O
of	O
larger	O
,	O
highly	O
dynamic	O
constructs	O
.	O

The	O
validity	O
of	O
this	O
approach	O
was	O
successfully	O
confirmed	O
by	O
the	O
excellent	O
correlation	O
between	O
the	O
CCS	O
values	O
obtained	O
in	O
parallel	O
by	O
all-atom	O
and	O
CG	O
workflows	O
.	O

Fabrication	O
and	O
characterization	O
of	O
poly	O
(	O
vinyl	O
alcohol	O
)	O
-	O
TiO2	O
nanocomposite	O
films	O
for	O
orthopedic	O
applications	O
.	O

Poly	O
(	O
vinyl	O
alcohol	O
)	O
(	O
PVA	O
)	O
is	O
reinforced	O
with	O
TiO2	O
nanoparticles	O
in	O
order	O
to	O
enhance	O
thermo-mechanical	O
stabilities	O
,	O
surface	O
characteristics	O
and	O
osteoblastic	O
cell	O
adhesion	O
.	O

PVA	O
-	O
TiO2	O
nanocomposite	O
films	O
with	O
desirable	O
mechanical	O
,	O
thermal	O
and	O
biocompatible	O
properties	O
are	O
fabricated	O
through	O
solution	O
casting	O
method	O
followed	O
by	O
de-hydrothermal	O
cross-linking	O
treatment	O
.	O

The	O
composition	O
of	O
TiO2	O
nanoparticles	O
was	O
standardized	O
to	O
achieve	O
mechanically	O
stable	O
nanocomposite	O
films	O
,	O
based	O
on	O
tensile	O
strength	O
measurements	O
composition	O
of	O
TiO2	O
is	O
determined	O
as	O
optimal	O
at	O
3wt	O
%	O
.	O

PVA	O
-	O
TiO2	O
nanocomposite	O
films	O
were	O
characterized	O
by	O
Scanning	B-P
electron	I-P
microscopy	I-P
,	O
Energy	B-P
dispersive	I-P
spectroscopy	I-P
,	O
Atomic	B-P
force	I-P
microscopy	I-P
,	O
Ultra	B-P
violet	I-P
and	O
Fourier	O
transform	O
infrared	O
spectroscopic	O
techniques	O
.	O

Elemental	B-P
mapping	I-P
studies	I-P
substantiate	O
incorporation	O
of	O
TiO2	O
nanoparticles	O
within	O
the	O
PVA	O
matrix	O
.	O

Dimensional	O
stability	O
evaluated	O
by	O
soaking	O
films	O
in	O
SBF	O
for	O
24h	O
insinuates	O
the	O
role	O
of	O
TiO2	O
in	O
the	O
direction	O
of	O
controlling	O
degree	O
of	O
swelling	O
.	O

In-vitro	B-P
bioactivity	I-P
test	I-P
and	O
cell	O
adhesion	O
results	O
also	O
predict	O
that	O
presence	O
of	O
TiO2	O
is	O
advantageous	O
to	O
enhance	O
apatite	O
growth	O
and	O
promote	O
cell	O
-	O
substrate	O
interaction	O
.	O

SEM	B-P
studies	I-P
illustrate	O
improved	O
surface	O
morphology	O
of	O
PVA	O
-	O
TiO2	O
nanocomposite	O
film	O
with	O
homogenously	O
distributed	O
TiO2	O
nanoparticles	O
,	O
which	O
help	O
to	O
enhance	O
thermo-mechanical	O
behavior	O
.	O

TiO2	O
nanoparticles	O
construct	O
cell-adhesive	O
hydrophilic	O
nano-domains	O
that	O
act	O
as	O
potential	O
cell	O
adhesion	O
sites	O
and	O
promotes	O
osteointegration	O
.	O

Bio	O
compatibility	O
studies	O
proved	O
that	O
thermally	O
cross-linked	O
PVA	O
is	O
non-toxic	O
in	O
relation	O
to	O
PVA	O
cross-linked	O
with	O
glutaraldehyde	O
.	O

Cytotoxicity	O
and	O
cell	O
adhesion	O
of	O
nanocomposite	O
films	O
evaluated	O
through	O
cell	O
viability	O
(	O
MMT	O
)	O
assay	O
and	O
crystal	B-P
violet	I-P
staining	I-P
revealed	O
that	O
PVA	O
-3wt	O
%	O
TiO2	O
nanocomposite	O
could	O
act	O
as	O
an	O
excellent	O
composite	O
and	O
hence	O
suitable	O
to	O
be	O
used	O
in	O
bone	O
implant	O
applications	O
.	O

Blood	O
flow	O
in	O
the	O
cerebral	O
venous	O
system	O
:	O
modeling	O
and	O
simulation	O
.	O

The	O
development	O
of	O
a	O
software	O
platform	O
incorporating	O
all	O
aspects	O
,	O
from	O
medical	B-P
imaging	I-P
data	O
,	O
through	O
three-dimensional	O
reconstruction	O
and	O
suitable	O
meshing	O
,	O
up	O
to	O
simulation	O
of	O
blood	O
flow	O
in	O
patient	O
-	O
specific	O
geometries	O
,	O
is	O
a	O
crucial	O
challenge	O
in	O
biomedical	O
engineering	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
fully	O
three-dimensional	O
blood	O
flow	O
simulation	O
is	O
carried	O
out	O
through	O
a	O
complete	O
rigid	O
macrovascular	O
circuit	O
,	O
namely	O
the	O
intracranial	O
venous	O
network	O
,	O
instead	O
of	O
a	O
reduced	O
order	O
simulation	O
and	O
partial	O
vascular	O
network	O
.	O

The	O
biomechanical	O
modeling	O
step	O
is	O
carefully	O
analyzed	O
and	O
leads	O
to	O
the	O
description	O
of	O
the	O
flow	O
governed	O
by	O
the	O
dimensionless	O
Navier-Stokes	O
equations	O
for	O
an	O
incompressible	O
viscous	O
fluid	O
.	O

The	O
equations	O
are	O
then	O
numerically	O
solved	O
with	O
a	O
free	O
finite	O
element	O
software	O
using	O
five	O
meshes	O
of	O
a	O
realistic	O
geometry	O
obtained	O
from	O
medical	O
images	O
to	O
prove	O
the	O
feasibility	O
of	O
the	O
pipeline	O
.	O

Some	O
features	O
of	O
the	O
intracranial	O
venous	O
circuit	O
in	O
the	O
supine	O
position	O
such	O
as	O
asymmetric	O
behavior	O
in	O
merging	O
regions	O
are	O
discussed	O
.	O

Clinical	O
manifestations	O
,	O
course	O
,	O
and	O
outcome	O
of	O
patients	O
with	O
neutralizing	O
anti-interferon-Î³	O
autoantibodies	O
and	O
disseminated	O
nontuberculous	O
mycobacterial	O
infections	O
.	O

Neutralizing	O
anti-interferon-Î³	O
autoantibody	O
(	O
nAIGA	O
)	O
-associated	O
immunodeficiency	O
is	O
an	O
emerging	O
medical	O
issue	O
worldwide	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
and	O
discuss	O
the	O
clinical	O
features	O
and	O
outcomes	O
of	O
patients	O
with	O
nAIGAs	O
and	O
disseminated	O
infections	O
by	O
nontuberculous	O
mycobacteria	O
(	O
dNTM	O
)	O
.We	O
thoroughly	O
reviewed	O
the	O
medical	O
records	O
of	O
all	O
patients	O
.	O

Microorganisms	O
and	O
nAIGAs	O
were	O
identified	O
using	O
previously	O
described	O
methods	O
with	O
modifications	O
.	O

All	O
data	O
were	O
calculated	O
and	O
analyzed	O
using	O
SPSS	O
software	O
.Among	O
46	O
adult	O
patients	O
with	O
dNTM	O
infections	O
,	O
we	O
identified	O
45	O
cases	O
(	O
97.8	O
%	O
)	O
with	O
nAIGAs	O
.	O

The	O
average	O
patient	O
age	O
was	O
58.6	O
years	O
,	O
and	O
there	O
was	O
no	O
sex	O
predominance	O
.	O

Cervical	O
lymphadenitis	O
(	O
81.8	O
%	O
)	O
was	O
the	O
most	O
common	O
clinical	O
manifestation	O
.	O

Endocrine	O
disorder	O
was	O
the	O
leading	O
comorbidity	O
(	O
7	O
cases	O
)	O
.	O

Malignancies	O
were	O
found	O
in	O
4	O
patients	O
,	O
and	O
all	O
of	O
the	O
malignancies	O
originated	O
from	O
the	O
T-cell	O
/	O
macrophage	O
lineage	O
.	O

More	O
than	O
half	O
of	O
the	O
identifiable	O
isolates	O
were	O
slow-growing	O
NTMs	O
.	O

Twenty-eight	O
(	O
62.2	O
%	O
)	O
and	O
18	O
(	O
40.0	O
%	O
)	O
patients	O
had	O
a	O
history	O
of	O
zoster	O
and	O
salmonellosis	O
,	O
respectively	O
.	O

A	O
high	O
proportion	O
of	O
patients	O
with	O
recurrent	O
episodes	O
of	O
NTM	O
infection	O
or	O
a	O
history	O
of	O
zoster	O
and	O
dNTM	O
infection	O
had	O
initial	O
nAIGA	B-P
titers	I-P
â¥10	O
dilution	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Twenty-seven	O
patients	O
(	O
60.0	O
%	O
)	O
required	O
long-term	O
antimycobacterial	O
therapy	O
and	O
had	O
at	O
least	O
1	O
episode	O
of	O
recurrent	O
NTM	O
disease	O
.	O

No	O
mortality	O
was	O
related	O
to	O
dNTM	O
infection	O
.In	O
Taiwan	O
,	O
nAIGAs	O
are	O
a	O
recently	O
recognized	O
mechanism	O
of	O
dNTM	O
infection	O
.	O

Long	O
term	O
of	O
antibiotic	O
treatment	O
and	O
adherence	O
to	O
medical	O
advice	O
are	O
necessary	O
to	O
improve	O
the	O
clinical	O
outcome	O
of	O
patients	O
with	O
nAIGAs	O
.	O

Influence	O
of	O
yeast	O
and	O
lactic	O
acid	O
bacterium	O
on	O
the	O
constituent	O
profile	B-P
of	O
soy	O
sauce	O
during	O
fermentation	O
.	O

Soy	O
sauce	O
is	O
a	O
Japanese	O
traditional	O
seasoning	O
composed	O
of	O
various	O
constituents	O
that	O
are	O
produced	O
by	O
various	O
microbes	O
during	O
a	O
long-term	O
fermentation	O
process	O
.	O

Due	O
to	O
the	O
complexity	O
of	O
the	O
process	O
,	O
the	O
investigation	O
of	O
the	O
constituent	O
profile	B-P
during	O
fermentation	O
is	O
difficult	O
.	O

Metabolomics	O
,	O
the	O
comprehensive	O
study	O
of	O
low	O
molecular	O
weight	O
compounds	O
in	O
biological	O
samples	O
,	O
is	O
thought	O
to	O
be	O
a	O
promising	O
strategy	O
for	O
deep	O
understanding	O
of	O
the	O
constituent	O
contribution	O
to	O
food	O
flavor	O
characteristics	O
.	O

Therefore	O
,	O
metabolomics	O
is	O
suitable	O
for	O
the	O
analysis	O
of	O
soy	O
sauce	O
fermentation	O
.	O

Unfortunately	O
,	O
only	O
few	O
and	O
unrefined	O
studies	O
of	O
soy	O
sauce	O
fermentation	O
using	O
metabolomics	O
approach	O
have	O
been	O
reported	O
.	O

Therefore	O
,	O
we	O
investigated	O
changes	O
in	O
low	O
molecular	O
weight	O
hydrophilic	O
and	O
volatile	O
compounds	O
of	O
soy	O
sauce	O
using	O
gas	B-P
chromatography/mass	I-P
spectrometry	I-P
(	O
GC/MS	B-P
)	O
-	O
based	O
non-targeted	O
metabolic	O
profiling	O
.	O

The	O
data	O
were	O
analyzed	O
by	O
statistical	O
analysis	O
to	O
evaluate	O
influences	O
of	O
yeast	O
and	O
lactic	O
acid	O
bacterium	O
on	O
the	O
constituent	O
profile	B-P
.	O

Consequently	O
,	O
our	O
results	O
suggested	O
a	O
novel	O
finding	O
that	O
lactic	O
acid	O
bacterium	O
affected	O
the	O
production	O
of	O
several	O
constituents	O
such	O
as	O
cyclotene	O
,	O
furfural	O
,	O
furfuryl	O
alcohol	O
and	O
methional	O
in	O
the	O
soy	O
sauce	O
fermentation	O
process	O
.	O

Does	O
Intrawound	O
Vancomycin	O
Application	O
During	O
Spine	O
Surgery	O
Create	O
Vancomycin-Resistant	O
Organism	O
?	O
.	O

Surgical	O
site	O
infection	O
(	O
SSI	O
)	O
following	O
spine	O
surgery	O
is	O
a	O
morbid	O
and	O
expensive	O
complication	O
.	O

The	O
use	O
of	O
intrawound	O
vancomycin	O
is	O
emerging	O
as	O
a	O
solution	O
to	O
reduce	O
SSI	O
.	O

The	O
development	O
of	O
vancomycin-resistant	O
pathogens	O
is	O
an	O
understandable	O
concern	O
.	O

To	O
determine	O
the	O
occurrence	O
of	O
vancomycin-resistant	O
SSI	O
in	O
patients	O
with	O
and	O
without	O
use	O
of	O
intrawound	O
vancomycin	O
.	O

Patients	O
undergoing	O
elective	O
spine	O
surgery	O
were	O
dichotomized	O
based	O
on	O
whether	O
intrawound	O
vancomycin	O
was	O
applied	O
.	O

Outcome	O
was	O
occurrence	O
of	O
SSI	O
requiring	O
return	O
to	O
the	O
operating	O
room	O
within	O
postoperative	O
90	O
days	O
.	O

The	O
intrawound	B-P
culture	I-P
and	O
vancomycin	O
minimal	B-P
inhibitory	I-P
concentrations	I-P
(	O
MIC	B-P
)	O
were	O
reviewed	O
.	O

Analyses	O
were	O
conducted	O
to	O
compare	O
the	O
pathogen	O
profile	O
and	O
MIC	B-P
for	O
vancomycin	O
in	O
patients	O
who	O
received	O
vancomycin	O
and	O
those	O
who	O
did	O
not	O
.	O

Of	O
the	O
total	O
2802	O
patients	O
,	O
43	O
%	O
(	O
n	O
=	O
1215	O
)	O
had	O
intrawound	O
vancomycin	O
application	O
during	O
the	O
index	O
surgery	O
.	O

The	O
use	O
of	O
vancomycin	O
was	O
associated	O
with	O
significantly	O
lower	O
deep	O
SSI	O
rates	O
(	O
1.6	O
%	O
[	O
n	O
=	O
20	O
]	O
vs	O
2.5	O
%	O
[	O
n	O
=	O
40	O
]	O
,	O
P	O
=	O
.02	O
)	O
.	O

The	O
occurrence	O
of	O
Staphylococcus	O
aureus	O
SSI	O
was	O
significantly	O
lower	O
in	O
the	O
patients	O
who	O
had	O
application	O
of	O
intrawound	O
vancomycin	O
(	O
32	O
%	O
vs	O
65	O
%	O
,	O
P	O
=	O
.003	O
)	O
.	O

None	O
of	O
the	O
patients	O
who	O
had	O
application	O
of	O
intrawound	O
vancomycin	O
powder	O
,	O
and	O
subsequently	O
developed	O
an	O
S	O
aureus	O
SSI	O
,	O
demonstrated	O
pathogens	O
with	O
resistance	O
to	O
vancomycin	O
.	O

All	O
patients	O
had	O
MIC	B-P
<	O
2	O
Î¼g/mL	O
,	O
the	O
vancomycin	O
susceptibility	O
threshold	O
.	O

The	O
occurrence	O
of	O
gram-negative	O
SSI	O
(	O
28	O
%	O
vs	O
7	O
%	O
)	O
and	O
culture	O
negative	O
fluid	O
collection	O
(	O
16	O
%	O
vs	O
5	O
%	O
)	O
was	O
higher	O
in	O
the	O
vancomycin	O
cohort	O
.	O

The	O
use	O
of	O
intrawound	O
vancomycin	O
during	O
the	O
index	O
spine	O
surgery	O
was	O
protective	O
against	O
SSI	O
following	O
spine	O
surgery	O
.	O

The	O
application	O
of	O
intrawound	O
vancomycin	O
during	O
index	O
surgery	O
does	O
not	O
appear	O
to	O
create	O
vancomycin-resistant	O
organisms	O
in	O
the	O
event	O
of	O
an	O
SSI	O
.	O

Dysphagia	O
-optimised	O
Intensity-modulated	O
Radiotherapy	O
Techniques	O
in	O
Pharyngeal	O
Cancers	O
:	O
Is	O
Anyone	O
Going	O
to	O
Swallow	O
it	O
?	O
.	O

Dysphagia	O
after	O
primary	O
chemoradiotherapy	O
or	O
radiation	O
alone	O
in	O
pharyngeal	O
cancers	O
can	O
have	O
a	O
devastating	O
impact	O
on	O
a	O
patient	O
's	O
physical	O
,	O
social	O
and	O
emotional	O
state	O
.	O

Establishing	O
and	O
validating	O
efficient	O
dysphagia	O
-	O
optimised	O
radiotherapy	O
techniques	O
is	O
,	O
therefore	O
,	O
of	O
paramount	O
importance	O
in	O
an	O
era	O
where	O
health-related	O
quality	O
of	O
life	O
measures	O
are	O
increasingly	O
influential	O
determinants	O
of	O
curative	O
management	O
strategies	O
,	O
particularly	O
as	O
the	O
incidence	O
of	O
good	O
prognosis	O
,	O
human	O
papillomavirus	O
-driven	O
pharyngeal	O
cancer	O
in	O
younger	O
patients	O
continues	O
to	O
rise	O
.	O

The	O
preferential	O
sparing	O
achievable	O
with	O
intensity-modulated	O
radiotherapy	O
(	O
IMRT	O
)	O
of	O
key	O
swallowing	O
structures	O
implicated	O
in	O
post-radiation	O
dysfunction	O
,	O
such	O
as	O
the	O
pharyngeal	O
constrictor	O
muscles	O
(	O
PCM	O
)	O
,	O
has	O
generated	O
significant	O
research	O
into	O
toxicity	O
-	O
mitigating	O
strategies	O
.	O

The	O
lack	O
of	O
randomised	O
evidence	O
,	O
however	O
,	O
means	O
that	O
there	O
remains	O
uncertainty	O
about	O
the	O
true	O
clinical	O
benefits	O
of	O
the	O
dosimetric	B-P
gains	O
offered	O
by	O
technological	O
advances	O
in	O
radiotherapy	O
.	O

As	O
a	O
result	O
,	O
we	O
feel	O
that	O
IMRT	O
techniques	O
that	O
spare	O
PCM	O
can	O
not	O
be	O
incorporated	O
into	O
routine	O
practice	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
swallowing	O
structures	O
responsible	O
for	O
functional	O
impairment	O
,	O
analyse	O
the	O
studies	O
that	O
have	O
explored	O
the	O
dose-response	O
relationship	O
between	O
these	O
critical	O
structures	O
and	O
late	O
dysphagia	O
,	O
and	O
consider	O
the	O
merits	O
of	O
reported	O
dysphagia	O
-	O
optimised	O
IMRT	O
(	O
Do-IMRT	O
)	O
approaches	O
,	O
thus	O
far	O
.	O

Finally	O
,	O
we	O
discuss	O
the	O
dysphagia	O
/	O
aspiration	O
-related	O
structures	O
(	O
DARS	O
)	O
study	O
(	O
ISRCTN	O
25458988	O
)	O
,	O
which	O
is	O
the	O
first	O
phase	O
III	O
randomised	O
controlled	O
trial	O
designed	O
to	O
investigate	O
the	O
impact	O
of	O
swallow	O
-sparing	O
strategies	O
on	O
improving	O
long-term	O
function	O
.	O

To	O
maximise	O
patient	O
benefits	O
,	O
improvements	O
in	O
radiation	O
delivery	O
will	O
need	O
to	O
integrate	O
with	O
novel	O
treatment	O
paradigms	O
and	O
comprehensive	O
rehabilitation	O
strategies	O
to	O
eventually	O
provide	O
a	O
patient	O
-centric	O
,	O
personalised	O
treatment	O
plan	O
.	O

Molecular	O
targeted	O
therapies	O
in	O
adrenal	O
,	O
pituitary	O
and	O
parathyroid	O
malignancies	O
.	O

Tumourigenesis	O
is	O
a	O
relatively	O
common	O
event	O
in	O
endocrine	O
tissues	O
.	O

Currently	O
,	O
specific	O
guidelines	O
have	O
been	O
developed	O
for	O
common	O
malignant	O
endocrine	O
tumours	O
which	O
also	O
incorporate	O
advances	O
in	O
molecular	O
targeted	O
therapies	O
(	O
MTT	O
)	O
,	O
as	O
in	O
thyroid	O
cancer	O
and	O
gastrointestinal	O
neuroendocrine	O
malignancies	O
.	O

However	O
,	O
there	O
is	O
little	O
information	O
regarding	O
the	O
role	O
and	O
efficacy	O
of	O
MTT	O
in	O
the	O
relatively	O
rare	O
malignant	O
endocrine	O
tumours	O
mainly	O
involving	O
the	O
adrenal	O
medulla	O
,	O
adrenal	O
cortex	O
,	O
pituitary	O
and	O
parathyroid	O
glands	O
.	O

Due	O
to	O
the	O
rarity	O
of	O
these	O
tumours	O
and	O
the	O
lack	O
of	O
prospective	O
studies	O
,	O
current	O
guidelines	O
are	O
mostly	O
based	O
on	O
retrospective	O
data	O
derived	O
from	O
surgical	O
,	O
loco-regional	O
and	O
ablative	O
therapies	O
,	O
and	O
studies	B-P
with	O
systemic	O
chemotherapy	O
.	O

In	O
addition	O
,	O
in	O
many	O
of	O
these	O
malignancies	O
the	O
prognosis	O
remains	O
poor	O
with	O
individual	O
patients	O
responding	O
differently	O
to	O
currently	O
available	O
treatments	O
,	O
necessitating	O
the	O
development	O
of	O
new	O
personalised	O
therapeutic	O
strategies	O
.	O

Recently	O
,	O
major	O
advances	O
in	O
the	O
molecular	O
understanding	O
of	O
endocrine	O
tumours	O
-	O
based	O
on	O
genomic	O
,	O
epigenomic	O
,	O
and	O
transcriptome	O
analysis	O
-	O
have	O
emerged	O
,	O
resulting	O
in	O
new	O
insights	O
into	O
their	O
pathogenesis	O
and	O
molecular	B-P
pathology	I-P
.	O

This	O
in	O
turn	O
has	O
led	O
to	O
the	O
use	O
of	O
novel	O
MTTs	O
in	O
increasing	O
numbers	O
of	O
patients	O
.	O

In	O
this	O
review	O
we	O
aim	O
to	O
present	O
currently	O
existing	O
and	O
evolving	O
data	O
using	O
MTT	O
in	O
the	O
treatment	O
of	O
adrenal	O
,	O
pituitary	O
and	O
malignant	O
parathyroid	O
tumours	O
,	O
and	O
explore	O
the	O
current	O
utility	O
and	O
effectiveness	O
of	O
such	O
therapies	O
and	O
their	O
future	O
evolution	O
.	O

Effects	O
of	O
high-intensity	O
training	O
on	O
cardiovascular	O
risk	O
factors	O
in	O
premenopausal	O
and	O
postmenopausal	O
women	O
.	O

Menopause	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
cardiovascular	O
disease	O
and	O
the	O
causal	O
factors	O
have	O
been	O
proposed	O
to	O
be	O
the	O
loss	O
of	O
estrogen	O
and	O
the	O
subsequent	O
alterations	O
of	O
the	O
hormonal	O
milieu	O
.	O

However	O
,	O
which	O
factors	O
contribute	O
to	O
the	O
deterioration	O
of	O
cardiometabolic	O
health	O
in	O
postmenopausal	O
women	O
is	O
debated	O
as	O
the	O
menopausal	O
transition	O
is	O
also	O
associated	O
with	O
increased	O
age	O
and	O
fat	O
mass	O
.	O

Furthermore	O
,	O
indications	O
of	O
reduced	O
cardiometabolic	O
adaptations	O
to	O
exercise	O
in	O
postmenopausal	O
women	O
add	O
to	O
the	O
adverse	O
health	O
profile	O
.	O

We	O
sought	O
to	O
evaluate	O
risk	O
factors	O
for	O
type	O
2	O
diabetes	O
and	O
cardiovascular	O
disease	O
in	O
late	O
premenopausal	O
and	O
early	O
postmenopausal	O
women	O
,	O
matched	O
by	O
age	O
and	O
body	O
composition	O
,	O
and	O
investigate	O
the	O
effect	O
of	O
high-intensity	O
training	O
.	O

A	O
3-month	O
high-intensity	O
aerobic	O
training	O
intervention	O
,	O
involving	O
healthy	O
,	O
nonobese	O
,	O
late	O
premenopausal	O
(	O
n	O
=	O
40	O
)	O
and	O
early	O
postmenopausal	O
(	O
n	O
=	O
39	O
)	O
women	O
was	O
conducted	O
and	O
anthropometrics	O
,	O
body	O
composition	O
,	O
blood	O
pressure	O
,	O
lipid	B-P
profile	I-P
,	O
glucose	O
tolerance	O
,	O
and	O
maximal	O
oxygen	O
consumption	O
were	O
determined	O
at	O
baseline	O
and	O
after	O
the	O
intervention	O
.	O

At	O
baseline	O
,	O
the	O
groups	O
matched	O
in	O
anthropometrics	O
and	O
body	O
composition	O
,	O
and	O
only	O
differed	O
by	O
4.2	O
years	O
in	O
age	O
(	O
mean	O
[	O
95	O
%	O
confidence	O
limits	O
]	O
49.2	O
[	O
48.5-49.9	O
]	O
vs	O
53.4	O
[	O
52.4-54.4	O
]	O
years	O
)	O
.	O

Time	O
since	O
last	O
menstrual	O
period	O
for	O
the	O
postmenopausal	O
women	O
was	O
(	O
mean	O
[	O
95	O
%	O
confidecnce	O
limits	O
]	O
3.1	O
[	O
2.6-3.7	O
]	O
years	O
)	O
.	O

Hormonal	O
levels	O
(	O
estrogen	O
,	O
follicle	O
stimulation	O
hormone	O
,	O
luteinizing	O
hormone	O
)	O
confirmed	O
menopausal	O
status	O
.	O

At	O
baseline	O
the	O
postmenopausal	O
women	O
had	O
higher	O
total	O
cholesterol	O
(	O
P	O
<	O
.001	O
)	O
,	O
low-density	O
lipoprotein-cholesterol	O
(	O
P	O
<	O
.05	O
)	O
,	O
and	O
high-density	O
lipoprotein-cholesterol	O
(	O
P	O
<	O
.001	O
)	O
than	O
the	O
premenopausal	O
women	O
.	O

The	O
training	O
intervention	O
reduced	O
body	O
weight	O
(	O
P	O
<	O
.01	O
)	O
,	O
waist	O
circumference	O
(	O
P	O
<	O
.01	O
)	O
,	O
and	O
improved	O
body	O
composition	O
by	O
increasing	O
lean	O
body	O
mass	O
(	O
P	O
<	O
.001	O
)	O
and	O
decreasing	O
fat	O
mass	O
(	O
P	O
<	O
.001	O
)	O
similarly	O
in	O
both	O
groups	O
.	O

Moreover	O
,	O
training	O
resulted	O
in	O
lower	O
diastolic	O
blood	O
pressure	O
(	O
P	O
<	O
.05	O
)	O
,	O
resting	O
heart	O
rate	O
(	O
P	O
<	O
.001	O
)	O
,	O
total	O
cholesterol	O
(	O
P	O
<	O
.01	O
)	O
,	O
low-density	O
lipoprotein-cholesterol	O
(	O
P	O
<	O
.01	O
)	O
,	O
total	O
cholesterol	O
/	O
high-density	O
lipoprotein-cholesterol	O
index	O
(	O
P	O
<	O
.01	O
)	O
,	O
and	O
improved	O
plasma	B-P
insulin	I-P
concentration	I-P
during	O
the	O
oral	B-P
glucose	I-P
tolerance	I-P
test	I-P
(	O
P	O
<	O
.05	O
)	O
in	O
both	O
groups	O
.	O

Cardiovascular	O
risk	O
factors	O
are	O
similar	O
in	O
late	O
premenopausal	O
and	O
early	O
postmenopausal	O
women	O
,	O
matched	O
by	O
age	O
and	O
body	O
composition	O
,	O
with	O
the	O
exception	O
that	O
postmenopausal	O
women	O
have	O
higher	O
high-	B-P
and	O
low-density	B-P
lipoprotein-cholesterol	I-P
levels	I-P
.	O

A	O
3-month	O
intervention	O
of	O
high-intensity	O
aerobic	O
training	O
reduces	O
risk	O
factors	O
for	O
type	O
2	O
.diabetes	O
and	O
cardiovascular	O
disease	O
to	O
a	O
similar	O
extent	O
in	O
late	O
premenopausal	O
and	O
early	O
postmenopausal	O
women	O
.	O

Metabolomics	O
analysis	O
of	O
anaphylactoid	O
reaction	O
reveals	O
its	O
mechanism	O
in	O
a	O
rat	O
model	O
.	O

Anaphylactoid	O
reactions	O
,	O
accounting	O
for	O
more	O
than	O
77	O
%	O
of	O
all	O
immune-mediated	O
immediate	O
hypersensitivity	O
reactions	O
,	O
have	O
become	O
a	O
serious	O
threat	O
to	O
public	O
health	O
,	O
but	O
their	O
effect	O
mechanism	O
is	O
not	O
clear	O
and	O
diagnostic	B-P
tests	I-P
are	O
limited	O
.	O

Comprehensive	O
metabolite	O
analysis	O
may	O
reveal	O
the	O
anaphylactoid	O
effect	O
mechanism	O
systematically	O
and	O
provide	O
reference	O
for	O
future	O
diagnostic	O
purposes	O
.	O

Plasma	O
from	O
Brown	O
Norway	O
rats	O
given	O
intravenous	O
injection	O
of	O
saline	O
,	O
compound	O
48/80	O
(	O
2.5	O
mL/kg	O
)	O
or	O
ovalbumin	O
(	O
20	O
mL/kg	O
)	O
in	O
20	O
s	O
for	O
the	O
first	O
time	O
was	O
used	O
to	O
study	O
the	O
effect	O
mechanism	O
of	O
anaphylactoid	O
reactions	O
through	O
metabolomics	O
(	O
UPLC-qTOF-MS/MS	O
)	O
.	O

Metabolomics	O
integrated	O
with	O
proteomics	O
data	O
were	O
used	O
to	O
analyze	O
the	O
anaphylactoid	O
pathways	O
by	O
MetaboAnalyst	O
followed	O
by	O
integrated	O
pathway	O
analysis	O
.	O

Thirty	O
metabolites	O
were	O
identified	O
through	O
the	O
METLIN	O
database	O
by	O
MS/MS	O
and	O
18	O
of	O
them	O
were	O
confirmed	O
by	O
authentic	O
standards	O
.	O

The	O
results	O
showed	O
that	O
adenosine	O
,	O
histamine	O
,	O
N-acetylhistamine	O
,	O
N	O
(	O
Î±	O
)	O
-Î³-glutamylhistamine	O
,	O
malate	O
and	O
xanthine	O
are	O
important	O
indices	O
for	O
anaphylactoid	O
reactions	O
.	O

It	O
could	O
be	O
concluded	O
that	O
the	O
effect	O
mechanism	O
is	O
mainly	O
composed	O
of	O
histidine	O
metabolism	O
,	O
arachidonic	O
acid	O
metabolism	O
,	O
energy	O
metabolism	O
,	O
purine	O
metabolism	O
and	O
other	O
small	O
molecules	O
through	O
30	O
metabolites	O
.	O

Multiple	O
linear	O
regression	O
analysis	O
indicated	O
that	O
not	O
only	O
histamine	O
but	O
also	O
N	O
(	O
Î±	O
)	O
-Î³-glutamylhistamine	O
and	O
arachidonic	O
acid	O
could	O
be	O
used	O
to	O
evaluate	O
anaphylactoid	O
symptoms	O
of	O
animals	O
.	O

Furthermore	O
,	O
the	O
citrate	O
cycle	O
,	O
histidine	O
metabolism	O
and	O
arachidonic	O
acid	O
metabolism	O
could	O
be	O
the	O
main	O
pathways	O
of	O
anaphylactoid	O
reactions	O
as	O
determined	O
by	O
MetaboAnalyst	O
.	O

The	O
results	O
may	O
provide	O
a	O
reference	O
to	O
improve	O
diagnostic	O
accuracy	O
and	O
predict	O
and	O
monitor	O
treatment	O
efficacy	O
in	O
anaphylactoid	O
reactions	O
in	O
the	O
clinical	O
setting	O
.	O

Synthesis	O
and	O
In	O
Vitro	O
Cytotoxic	O
Properties	O
of	O
Polycarbo-Substituted	O
4-	O
(	O
Arylamino	O
)	O
quinazolines	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
synthesis	O
of	O
novel	O
unsymmetrical	O
polycarbo-substituted	O
4-anilinoquinazolines	O
derived	O
from	O
the	O
2-aryl-6-bromo-8-iodoquinazolines	O
via	O
one-pot	O
three-step	O
reaction	O
sequences	O
involving	O
initial	O
amination	O
and	O
subsequent	O
double	O
cross-coupling	O
(	O
bis-Suzuki	O
,	O
Sonogashira/Stille	O
or	O
Sonogashira/Suzuki-Miyaura	O
)	O
reactions	O
with	O
different	O
cross	O
coupling	O
partners	O
for	O
the	O
two	O
carbon-carbon	O
bond	O
formation	O
steps	O
.	O

The	O
4-anilinoquinazolines	O
were	O
evaluated	O
for	O
potential	O
cytotoxicity	O
against	O
three	O
cancer	O
cell	O
lines	O
,	O
namely	O
,	O
human	O
breast	O
adenocarcinoma	O
(	O
MCF-7	O
)	O
cells	O
,	O
human	O
cervical	O
cancer	O
(	O
HeLa	O
)	O
and	O
human	O
lung	O
cancer	O
(	O
A549	O
)	O
cells	O
.	O

The	O
most	O
active	O
compounds	O
,	O
2b	O
,	O
2c	O
,	O
3c	O
,	O
4a	O
,	O
4c	O
and	O
5a	O
,	O
were	O
found	O
to	O
be	O
more	O
selective	O
against	O
the	O
MCF-7	O
and	O
HeLa	O
cell	O
lines	O
than	O
the	O
human	O
lung	O
carcinoma	O
(	O
A549	O
)	O
cells	O
.	O

We	O
selected	O
compounds	O
2c	O
,	O
3c	O
and	O
7a	O
as	O
representatives	O
for	O
further	O
evaluation	O
for	O
potential	O
to	O
induce	O
apoptosis	O
and/or	O
necrotic	O
properties	O
in	O
the	O
three	O
cancer	O
cell	O
lines	O
.	O

Compound	O
2c	O
induced	O
apoptosis	O
of	O
MCF-7	O
cells	O
through	O
cell	O
membrane	O
alteration	O
.	O

Treatment	O
of	O
Hela	O
and	O
A549	O
cell	O
lines	O
with	O
compounds	O
3c	O
and	O
7a	O
,	O
respectively	O
,	O
led	O
to	O
caspase-3	O
activation	O
in	O
both	O
cell	O
lines	O
.	O

Compound	O
3c	O
,	O
on	O
the	O
other	O
hand	O
,	O
caused	O
more	O
necrosis	O
than	O
apoptosis	O
induction	O
in	O
the	O
membrane	O
alteration	O
assay	B-P
.	O

Renal	O
Function	O
and	O
the	O
Risk	O
of	O
Stroke	O
and	O
Bleeding	O
in	O
Patients	O
With	O
Atrial	O
Fibrillation	O
:	O
An	O
Observational	O
Cohort	O
Study	O
.	O

We	O
sought	O
to	O
determine	O
the	O
risk	O
of	O
stroke	O
/	O
thromboembolism	O
and	O
bleeding	O
associated	O
with	O
reduced	O
renal	O
function	O
in	O
patients	O
with	O
atrial	O
fibrillation	O
and	O
the	O
risk	O
of	O
stroke	O
and	O
bleeding	O
associated	O
with	O
warfarin	O
treatment	O
in	O
specific	O
estimated	B-P
glomerular	I-P
filtration	I-P
rate	I-P
(	O
eGFR	B-P
)	O
groups	O
.	O

We	O
conducted	O
a	O
register-based	O
cohort	O
study	O
and	O
included	O
patients	O
discharged	O
with	O
nonvalvular	O
atrial	O
fibrillation	O
from	O
1997	O
to	O
2011	O
with	O
available	O
eGFR	B-P
.	O

A	O
total	O
of	O
17	O
349	O
patients	O
were	O
identified	O
with	O
eGFR	B-P
available	O
at	O
baseline	O
.	O

All	O
levels	O
of	O
lower	O
eGFR	B-P
were	O
associated	O
with	O
higher	O
risk	O
of	O
stroke	O
/	O
thromboembolism	O
and	O
bleeding	O
.	O

Use	O
of	O
warfarin	O
was	O
associated	O
with	O
higher	O
bleeding	O
risk	O
in	O
all	O
eGFR	B-P
groups	O
;	O
hazard	O
ratios	O
1.23	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.97-1.56	O
)	O
,	O
1.26	O
(	O
95	O
%	O
CI	O
,	O
1.14-1.40	O
)	O
,	O
1.18	O
(	O
95	O
%	O
CI	O
,	O
1.07-1.31	O
)	O
,	O
1.11	O
(	O
95	O
%	O
CI	O
,	O
0.87-1.42	O
)	O
,	O
2.01	O
(	O
95	O
%	O
CI	O
,	O
1.14-3.54	O
)	O
in	O
patients	O
with	O
eGFR	B-P
â¥90	O
,	O
60	O
to	O
89	O
,	O
30	O
to	O
59	O
,	O
15	O
to	O
29	O
,	O
and	O
<	O
15	O
mL/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
,	O
respectively	O
.	O

Use	O
of	O
warfarin	O
was	O
associated	O
with	O
lower	O
risk	O
of	O
stroke	O
/	O
thromboembolism	O
in	O
patients	O
with	O
eGFR	B-P
â¥15	O
mL/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
;	O
hazard	O
ratios	O
0.57	O
(	O
95	O
%	O
CI	O
,	O
0.43-0.76	O
)	O
,	O
0.57	O
(	O
95	O
%	O
CI	O
,	O
0.51-0.64	O
)	O
,	O
0.48	O
(	O
95	O
%	O
CI	O
,	O
0.44-0.54	O
)	O
,	O
0.60	O
(	O
95	O
%	O
CI	O
,	O
0.45-0.80	O
)	O
in	O
patients	O
with	O
eGFR	B-P
â¥90	O
,	O
60	O
to	O
89	O
,	O
30	O
to	O
59	O
,	O
and	O
15	O
to	O
29	O
mL/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
,	O
respectively	O
.	O

Use	O
of	O
warfarin	O
was	O
not	O
associated	O
with	O
lower	O
risk	O
of	O
stroke	O
/	O
thromboembolism	O
in	O
patients	O
with	O
eGFR	B-P
<	O
15	O
mL/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
;	O
hazard	O
ratio	O
1.18	O
(	O
95	O
%	O
CI	O
,	O
0.58-2.40	O
)	O
.	O

In	O
patients	O
with	O
atrial	O
fibrillation	O
,	O
the	O
risk	O
of	O
stroke	O
and	O
bleeding	O
was	O
associated	O
with	O
levels	O
of	O
renal	O
function	O
.	O

Warfarin	O
treatment	O
was	O
associated	O
with	O
higher	O
risk	O
of	O
bleeding	O
in	O
all	O
eGFR	B-P
groups	O
and	O
lower	O
risk	O
of	O
stroke	O
in	O
patients	O
with	O
eGFR	B-P
â¥15	O
mL/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
.	O

Longitudinal	B-P
live	I-P
imaging	I-P
of	O
retinal	O
Î±-synuclein	O
:	O
:	O
GFP	O
deposits	O
in	O
a	O
transgenic	O
mouse	O
model	O
of	O
Parkinson	O
's	O
Disease	O
/	O
Dementia	O
with	O
Lewy	O
Bodies	O
.	O

Abnormal	O
Î±-synuclein	O
(	O
Î±-syn	O
)	O
accumulation	O
in	O
the	O
CNS	O
may	O
underlie	O
neuronal	O
cell	O
and	O
synaptic	O
dysfunction	O
leading	O
to	O
motor	O
and	O
cognitive	O
deficits	O
in	O
synucleinopathies	O
including	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
and	O
Dementia	O
with	O
Lewy	O
Bodies	O
(	O
DLB	O
)	O
.	O

Multiple	O
groups	O
demonstrated	O
Î±-syn	O
accumulation	O
in	O
CNS	O
accessory	O
structures	O
,	O
including	O
the	O
eyes	O
and	O
olfactory	O
terminals	O
,	O
as	O
well	O
as	O
in	O
peripheral	O
organs	O
of	O
Parkinsonian	O
patients	O
.	O

Retinal	O
imaging	B-P
studies	I-P
of	O
mice	O
overexpressing	O
fused	O
Î±-syn	O
:	O
:	O
GFP	O
were	O
conducted	O
to	O
evaluate	O
the	O
presence	O
and	O
progression	O
of	O
retinal	O
pathology	O
in	O
a	O
PD	O
/	O
DLB	O
transgenic	O
mouse	O
model	O
.	O

Bright-field	B-P
image	I-P
retinal	O
maps	O
and	O
fluorescent	B-P
images	I-P
were	O
acquired	O
at	O
1-month	O
intervals	O
for	O
3	O
months	O
.	O

Retinal	O
imaging	B-P
revealed	O
the	O
accumulation	O
of	O
GFP	O
-tagged	O
Î±-syn	O
in	O
retinal	O
ganglion	O
cell	O
layer	O
and	O
in	O
the	O
edges	O
of	O
arterial	O
blood	O
vessels	O
in	O
the	O
transgenic	O
mice	O
.	O

Double	O
labeling	O
studies	O
confirmed	O
that	O
the	O
Î±-syn	O
:	O
:	O
GFP	O
-positive	O
cells	O
were	O
retinal	O
ganglion	O
cells	O
containing	O
Î±-syn	O
.	O

Accumulation	O
of	O
Î±-syn	O
persisted	O
in	O
the	O
same	O
cells	O
and	O
increased	O
with	O
age	O
.	O

Accumulation	O
of	O
Î±-syn	O
:	O
:	O
GFP	O
was	O
reduced	O
by	O
immunization	O
with	O
single	O
chain	O
antibodies	O
against	O
Î±-syn	O
.	O

In	O
conclusion	O
,	O
longitudinal	B-P
live	I-P
imaging	I-P
of	O
the	O
retina	O
in	O
the	O
PDGF	O
-	O
Î±-syn	O
:	O
:	O
GFP	O
mice	O
might	O
represent	O
a	O
useful	O
,	O
non-invasive	O
tool	O
to	O
monitor	O
the	O
fate	O
of	O
Î±-syn	O
accumulation	O
in	O
the	O
CNS	O
and	O
to	O
evaluate	O
the	O
therapeutic	O
effects	O
of	O
compounds	O
targeting	O
Î±-syn	O
.	O

Using	O
language	O
for	O
social	O
interaction	O
:	O
Communication	O
mechanisms	O
promote	O
recovery	O
from	O
chronic	O
non-fluent	O
aphasia	O
.	O

Clinical	O
research	O
highlights	O
the	O
importance	O
of	O
massed	O
practice	O
in	O
the	O
rehabilitation	O
of	O
chronic	O
post-stroke	O
aphasia	O
.	O

However	O
,	O
while	O
necessary	O
,	O
massed	O
practice	O
may	O
not	O
be	O
sufficient	O
for	O
ensuring	O
progress	O
in	O
speech-language	O
therapy	O
.	O

Motivated	O
by	O
recent	O
advances	O
in	O
neuroscience	O
,	O
it	O
has	O
been	O
claimed	O
that	O
using	O
language	O
as	O
a	O
tool	O
for	O
communication	O
and	O
social	O
interaction	O
leads	O
to	O
synergistic	O
effects	O
in	O
left	O
perisylvian	O
eloquent	O
areas	O
.	O

Here	O
,	O
we	O
conducted	O
a	O
crossover	O
randomized	O
controlled	O
trial	O
to	O
determine	O
the	O
influence	O
of	O
communicative	O
language	O
function	O
on	O
the	O
outcome	O
of	O
intensive	O
aphasia	O
therapy	O
.	O

Eighteen	O
individuals	O
with	O
left-hemisphere	O
lesions	O
and	O
chronic	O
non-fluent	O
aphasia	O
each	O
received	O
two	O
types	O
of	O
training	O
in	O
counterbalanced	O
order	O
:	O
(	O
i	O
)	O
Intensive	O
Language-Action	O
Therapy	O
(	O
ILAT	O
,	O
an	O
extended	O
form	O
of	O
Constraint-Induced	O
Aphasia	O
Therapy	O
)	O
embedding	O
verbal	O
utterances	O
in	O
the	O
context	O
of	O
communication	O
and	O
social	O
interaction	O
,	O
and	O
(	O
ii	O
)	O
Naming	O
Therapy	O
focusing	O
on	O
speech	B-P
production	I-P
per	I-P
se	I-P
.	O

Both	O
types	O
of	O
training	O
were	O
delivered	O
with	O
the	O
same	O
high	O
intensity	O
(	O
3.5	O
h	O
per	O
session	O
)	O
and	O
duration	O
(	O
six	O
consecutive	O
working	O
days	O
)	O
,	O
with	O
therapy	O
materials	O
and	O
number	O
of	O
utterances	O
matched	O
between	O
treatment	O
groups	O
.	O

A	O
standardized	O
aphasia	O
test	B-P
battery	I-P
revealed	O
significantly	O
improved	O
language	O
performance	O
with	O
ILAT	O
,	O
independent	O
of	O
when	O
this	O
method	O
was	O
administered	O
.	O

In	O
contrast	O
,	O
Naming	O
Therapy	O
tended	O
to	O
benefit	O
language	O
performance	O
only	O
when	O
given	O
at	O
the	O
onset	O
of	O
the	O
treatment	O
,	O
but	O
not	O
when	O
applied	O
after	O
previous	O
intensive	O
training	O
.	O

The	O
current	O
results	O
challenge	O
the	O
notion	O
that	O
massed	O
practice	O
alone	O
promotes	O
recovery	O
from	O
chronic	O
post-stroke	O
aphasia	O
.	O

Instead	O
,	O
our	O
results	O
demonstrate	O
that	O
using	O
language	O
for	O
communication	O
and	O
social	O
interaction	O
increases	O
the	O
efficacy	O
of	O
intensive	O
aphasia	O
therapy	O
.	O

Liquid	B-P
chromatography-mass	I-P
spectrometry	I-P
-based	O
quantitative	B-P
proteomics	I-P
analysis	I-P
reveals	O
chondroprotective	O
effects	O
of	O
astragaloside	O
IV	O
in	O
interleukin-1Î²	O
-	O
induced	O
SW1353	O
chondrocyte-like	O
cells	O
.	O

Chondrocyte	O
apoptosis	O
played	O
a	O
key	O
role	O
on	O
the	O
progression	O
of	O
Osteoarthritis	O
(	O
OA	O
)	O
.	O

Safe	O
and	O
effective	O
drugs	O
are	O
urgently	O
needed	O
for	O
the	O
treatment	O
of	O
OA	O
.	O

Previous	O
study	O
reported	O
that	O
Astragaloside	O
IV	O
(	O
ASG-IV	O
)	O
had	O
exerted	O
a	O
protective	O
effect	O
against	O
articular	O
cartilage	O
degeneration	O
by	O
promoting	O
rapid	O
proliferation	O
of	O
chondrocyte	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
our	O
study	O
is	O
to	O
explore	O
the	O
effects	O
and	O
mechanisms	O
of	O
ASG-IV	O
in	O
chondrocyte	O
apoptosis	O
.	O

Isobaric	B-P
Tags	I-P
For	I-P
Relative	I-P
And	I-P
Absolute	I-P
Quantitation	I-P
(	I-P
iTRAQ	I-P
)	I-P
-based	I-P
quantitative	I-P
proteomics	I-P
was	O
used	O
to	O
quantitatively	O
detect	O
and	O
map	O
proteins	O
in	O
SW1353	O
chondrocyte-like	O
cells	O
pre-treated	O
with	O
ASG-IV	O
or	O
interleukin-1Î²	O
(	O
IL-1Î²	O
)	O
or	O
ASG-IV	O
+	O
IL-1Î²	O
.	O

The	O
iTRAQ-labeled	O
peptides	O
were	O
fractionated	O
by	O
high-accuracy	B-P
liquid	I-P
chromatography-mass	I-P
spectrometry	I-P
(	O
LC-MS	B-P
)	O
.	O

Cell	O
apoptosis	O
and	O
differentially	O
expressed	O
proteins	O
was	O
detected	O
by	O
flow	B-P
cytometry	I-P
(	O
FCM	B-P
)	O
,	O
quantitative	O
real-time	O
polymerase	O
chain	O
reaction	O
(	O
qRT-PCR	O
)	O
,	O
and	O
western	O
blotting	O
,	O
respectively	O
.	O

The	O
apoptosis	O
of	O
the	O
IL-1Î²	O
-	O
induced	O
SW1353	O
cells	O
treated	O
with	O
ASG-IV	O
was	O
greatly	O
inhibited	O
.	O

Bioinformatics	B-P
analysis	I-P
revealed	O
that	O
gamma	O
actin	O
1	O
(	O
ACTG1	O
)	O
and	O
Yes	O
Associated	O
Protein	O
1	O
(	O
YAP1	O
)	O
,	O
participating	O
in	O
the	O
Hippo	O
signaling	O
pathway	O
and	O
Vitronectin	O
(	O
VTN	O
)	O
and	O
Collagen	O
Type	O
I	O
Alpha	O
1	O
Chain	O
(	O
COL1A1	O
)	O
,	O
involving	O
in	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
-receptor	O
interaction	O
signaling	O
pathway	O
,	O
were	O
all	O
significantly	O
up-regulated	O
in	O
the	O
IL-1Î²	O
-	O
induced	O
SW1353	O
cells	O
after	O
treatment	O
with	O
ASG-IV	O
.	O

The	O
qRT-PCR	O
and	O
Western	O
blotting	O
results	O
confirmed	O
the	O
up-regulation	O
of	O
these	O
four	O
genes	O
.	O

ASG-IV	O
played	O
a	O
positive	O
role	O
in	O
human	O
osteoarthritic	O
chondrocyte	O
apoptosis	O
,	O
possibly	O
through	O
modulation	O
of	O
the	O
Hippo	O
signaling	O
pathway	O
by	O
up-regulating	O
YAP1	O
and	O
ACTG1	O
expression	O
,	O
and	O
also	O
by	O
up-regulating	O
VTN	O
and	O
COL1A1	O
,	O
which	O
are	O
involved	O
in	O
the	O
ECM-receptor	O
interaction	O
pathway	O
.	O

Taken	O
together	O
,	O
all	O
the	O
results	O
suggested	O
that	O
ASG-IV	O
had	O
a	O
novel	O
therapeutic	O
potential	O
for	O
the	O
treatment	O
of	O
OA	O
.	O

Addressing	O
the	O
Crisis	O
in	O
the	O
Treatment	O
of	O
Osteoporosis	O
:	O
A	O
Path	O
Forward	O
.	O

Considerable	O
data	O
and	O
media	O
attention	O
have	O
highlighted	O
a	O
potential	O
``	O
crisis	O
``	O
in	O
the	O
treatment	O
of	O
osteoporosis	O
.	O

Specifically	O
,	O
despite	O
the	O
availability	O
of	O
several	O
effective	O
drugs	O
to	O
prevent	O
fractures	O
,	O
many	O
patients	O
who	O
need	O
pharmacological	O
therapy	O
are	O
either	O
not	O
being	O
prescribed	O
these	O
medications	O
or	O
if	O
prescribed	O
a	O
medication	O
,	O
are	O
simply	O
not	O
taking	O
it	O
.	O

Although	O
there	O
are	O
many	O
reasons	O
for	O
this	O
``	O
gap	O
''	O
in	O
the	O
treatment	O
of	O
osteoporosis	O
,	O
a	O
major	O
factor	O
is	O
physician	O
and	O
patient	O
concerns	O
over	O
the	O
risk	O
of	O
side	O
effects	O
,	O
especially	O
atypical	O
femur	O
fractures	O
(	O
AFFs	O
)	O
related	O
to	O
bisphosphonate	O
(	O
and	O
perhaps	O
other	O
antiresorptive	O
)	O
drug	O
therapy	O
.	O

In	O
this	O
perspective	O
,	O
we	O
review	O
the	O
current	O
state	O
of	O
undertreatment	O
of	O
patients	O
at	O
increased	O
fracture	O
risk	O
and	O
suggest	O
possible	O
short-	O
,	O
intermediate-	O
,	O
and	O
long-term	O
approaches	O
to	O
address	O
patient	O
concerns	O
,	O
specifically	O
those	O
related	O
to	O
AFF	O
risk	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	O
education	O
on	O
prodromal	O
symptoms	O
,	O
extended	O
femur	O
scans	B-P
using	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
(	O
DXA	B-P
)	O
to	O
monitor	O
patients	O
on	O
antiresorptive	O
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
DXA	B-P
and	O
other	O
risk	O
factors	O
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

Although	O
not	O
the	O
only	O
impediment	O
to	O
appropriate	O
treatment	O
of	O
osteoporosis	O
,	O
concern	O
over	O
AFFs	O
remains	O
a	O
major	O
issue	O
and	O
one	O
that	O
needs	O
to	O
be	O
resolved	O
for	O
effective	O
dissemination	O
of	O
existing	O
treatments	O
to	O
reduce	O
fracture	O
risk	O
.	O

Â©	O
2017	O
American	O
Society	O
for	O
Bone	O
and	O
Mineral	O
Research	O
.	O

A	O
randomized	O
trial	O
of	O
TLR-2	O
agonist	O
CADI-05	O
targeting	O
desmocollin-3	O
for	O
advanced	O
non-small-cell	O
lung	O
cancer	O
.	O

Randomized	O
controlled	O
trial	O
to	O
evaluate	O
synergy	O
between	O
taxane	O
plus	O
platinum	O
chemotherapy	O
and	O
CADI-05	O
,	O
a	O
Toll	O
like	O
receptor-2	O
agonist	O
targeting	O
desmocollin-3	O
as	O
a	O
first-line	O
therapy	O
in	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

Patients	O
with	O
advanced	O
NSCLC	O
(	O
stage	O
IIIB	O
or	O
IV	O
)	O
were	O
randomized	O
to	O
cisplatin-paclitaxel	O
(	O
chemotherapy	O
group	O
,	O
N	O
=	O
112	O
)	O
or	O
cisplatin-paclitaxel	O
plus	O
CADI-05	O
(	O
chemoimmunotherapy	O
group	O
,	O
N	O
=	O
109	O
)	O
.	O

CADI-05	O
was	O
administered	O
a	O
week	O
before	O
chemotherapy	O
and	O
on	O
days	O
8	O
and	O
15	O
of	O
each	O
cycle	O
and	O
every	O
month	O
subsequently	O
for	O
12	O
months	O
or	O
disease	O
progression	O
.	O

Overall	O
survival	O
was	O
compared	O
using	O
a	O
log-rank	O
test	O
.	O

Computed	B-P
tomography	I-P
was	O
carried	O
out	O
at	O
baseline	O
,	O
end	O
of	O
two	O
cycles	O
and	O
four	O
cycles	O
.	O

Response	O
rate	O
was	O
evaluated	O
using	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
criteria	O
by	O
an	O
independent	O
radiologist	O
.	O

As	O
per	O
intention-to-treat	O
analysis	O
,	O
no	O
survival	O
benefit	O
was	O
observed	O
between	O
two	O
groups	O
[	O
208	O
versus	O
196	O
days	O
;	O
hazard	O
ratio	O
,	O
0.86	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.63-1.19	O
;	O
P	O
=	O
0.3804	O
]	O
.	O

In	O
a	O
subgroup	O
analysis	O
,	O
improvement	O
in	O
median	O
survival	O
by	O
127	O
days	O
was	O
observed	O
in	O
squamous	O
NSCC	O
with	O
chemoimmunotherapy	O
(	O
hazard	O
ratio	O
,	O
0.55	O
;	O
95	O
%	O
CI	O
0.32-0.95	O
;	O
P	O
=	O
0.046	O
)	O
.	O

In	O
patients	O
receiving	O
planned	O
four	O
cycles	O
of	O
chemotherapy	O
,	O
there	O
was	O
improved	O
median	O
overall	O
survival	O
by	O
66	O
days	O
(	O
299	O
versus	O
233	O
days	O
;	O
hazard	O
ratio	O
,	O
0.64	O
;	O
95	O
%	O
CI	O
0.41	O
to	O
0.98	O
;	O
P	O
=	O
0.04	O
)	O
in	O
the	O
chemoimmunotherapy	O
group	O
compared	O
with	O
the	O
chemotherapy	O
group	O
.	O

This	O
was	O
associated	O
with	O
the	O
improved	O
survival	O
by	O
17.48	O
%	O
at	O
the	O
end	O
of	O
1	O
year	O
,	O
in	O
the	O
chemoimmunotherapy	O
group	O
.	O

Systemic	O
adverse	O
events	O
were	O
identical	O
in	O
both	O
the	O
group	O
s.	O
There	O
was	O
no	O
survival	O
benefit	O
with	O
the	O
addition	O
of	O
CADI-05	O
to	O
the	O
combination	O
of	O
cisplatin-paclitaxel	O
in	O
patients	O
with	O
advanced	O
NSCLC	O
;	O
however	O
,	O
the	O
squamous	O
cell	O
subset	O
did	O
demonstrate	O
a	O
survival	O
advantage	O
.	O

Carbon	O
nanotube	O
-based	O
self-adhesive	O
polymer	O
electrodes	O
for	O
wireless	O
long-term	O
recording	O
of	O
electrocardiogram	O
signals	O
.	O

In	O
this	O
study	O
,	O
the	O
concept	O
of	O
polymer	O
electrodes	O
integrated	O
with	O
a	O
wireless	O
electrocardiogram	O
(	O
ECG	O
)	O
system	O
was	O
described	O
.	O

Polymer	O
electrodes	O
for	O
long-term	O
ECG	O
measurements	O
were	O
fabricated	O
by	O
loading	O
high	O
content	O
of	O
carbon	O
nanotubes	O
(	O
CNTs	O
)	O
in	O
polydimethylsiloxane	O
.	O

Silver	O
nanoparticles	O
(	O
Ag	O
NPs	O
)	O
were	O
added	O
to	O
increase	O
the	O
flexibility	O
of	O
the	O
polymer	O
and	O
the	O
conductivity	O
of	O
the	O
electrode	O
.	O

An	O
ECG	O
electrode	O
patch	O
was	O
fabricated	O
by	O
integrating	O
the	O
electrodes	O
with	O
an	O
adhesive	O
polydimethylsiloxane	O
(	O
aPDMS	O
)	O
layer	O
.	O

Holes	O
in	O
the	O
electrode	O
filled	O
with	O
aPDMS	O
can	O
enable	O
robust	O
contact	O
between	O
the	O
electrode	O
and	O
skin	O
,	O
reducing	O
motion	O
artifacts	O
.	O

A	O
wireless	O
ECG	O
measurement	O
system	O
was	O
developed	O
and	O
adapted	O
to	O
the	O
polymer	O
electrodes	O
.	O

The	O
polymer	O
electrodes	O
combined	O
with	O
the	O
measurement	O
system	O
were	O
successfully	O
applied	O
in	O
wireless	O
,	O
long-term	O
recording	O
of	O
ECG	B-P
signals	I-P
.	O

An	O
eleven-	O
day	O
continuous	O
test	O
showed	O
that	O
the	O
ECG	B-P
signal	I-P
did	O
not	O
degrade	O
over	O
time	O
.	O

The	O
results	O
of	O
attach/detach	O
tests	O
demonstrated	O
that	O
the	O
ECG	B-P
signal	I-P
was	O
affected	O
by	O
motion	O
artifacts	O
after	O
six	O
attach/detach	O
cycles	O
.	O

The	O
electrodes	O
produced	O
are	O
flexible	O
and	O
exhibit	O
good	O
ECG	O
performance	O
,	O
and	O
therefore	O
can	O
be	O
used	O
in	O
wearable	O
medical	O
monitoring	O
systems	O
.	O

The	O
approach	O
proposed	O
in	O
this	O
study	O
holds	O
significant	O
promise	O
for	O
commercial	O
application	O
in	O
medical	O
fields	O
.	O

Comparative	O
proteomic	B-P
analysis	I-P
reveals	O
alterations	O
in	O
development	O
and	O
photosynthesis	O
-related	O
proteins	O
in	O
diploid	O
and	O
triploid	O
rice	O
.	O

Polyploidy	O
has	O
pivotal	O
influences	O
on	O
rice	O
(	O
Oryza	O
sativa	O
L.	O
)	O
morphology	O
and	O
physiology	O
,	O
and	O
is	O
very	O
important	O
for	O
understanding	O
rice	O
domestication	O
and	O
improving	O
agricultural	O
traits	O
.	O

Diploid	O
(	O
DP	O
)	O
and	O
triploid	O
(	O
TP	O
)	O
rice	O
shows	O
differences	O
in	O
morphological	O
parameters	O
,	O
such	O
as	O
plant	O
height	O
,	O
leaf	O
length	O
,	O
leaf	O
width	O
and	O
the	O
physiological	O
index	O
of	O
chlorophyll	O
content	O
.	O

However	O
,	O
the	O
underlying	O
mechanisms	O
determining	O
these	O
morphological	O
differences	O
are	O
remain	O
to	O
be	O
defined	O
.	O

To	O
better	O
understand	O
the	O
proteomic	O
changes	O
between	O
DP	O
and	O
TP	O
,	O
tandem	B-P
mass	I-P
tags	I-P
(	I-P
TMT	I-P
)	I-P
mass	I-P
spectrometry	I-P
(	I-P
MS	I-P
)	I-P
/	O
MS	B-P
was	O
used	O
to	O
detect	O
the	O
significant	O
changes	O
to	O
protein	O
expression	O
between	O
DP	O
and	O
TP	O
.	O

Results	O
indicated	O
that	O
both	O
photosynthesis	O
and	O
metabolic	O
pathways	O
were	O
highly	O
significantly	O
associated	O
with	O
proteomic	O
alteration	O
between	O
DP	O
and	O
TP	O
based	O
on	O
biological	O
process	O
and	O
pathway	B-P
enrichment	I-P
analysis	I-P
,	O
and	O
13	O
higher	O
abundance	O
chloroplast	O
proteins	O
involving	O
in	O
these	O
two	O
pathways	O
were	O
identified	O
in	O
TP	O
.	O

Quantitative	O
real-time	O
PCR	O
analysis	O
demonstrated	O
that	O
5	O
of	O
the	O
13	O
chloroplast	O
proteins	O
ATPF	O
,	O
PSAA	O
,	O
PSAB	O
,	O
PSBB	O
and	O
RBL	O
in	O
TP	O
were	O
higher	O
abundance	O
compared	O
with	O
those	O
in	O
DP	O
.	O

This	O
study	O
integrates	O
morphology	O
,	O
physiology	O
and	O
proteomic	B-P
profiling	I-P
alteration	O
of	O
DP	O
and	O
TP	O
to	O
address	O
their	O
underlying	O
different	O
molecular	O
mechanisms	O
.	O

Our	O
finding	O
revealed	O
that	O
ATPF	O
,	O
PSAA	O
,	O
PSAB	O
,	O
PSBB	O
and	O
RBL	O
can	O
induce	O
considerable	O
expression	O
changes	O
in	O
TP	O
and	O
may	O
affect	O
the	O
development	O
and	O
growth	O
of	O
rice	O
through	O
photosynthesis	O
and	O
metabolic	O
pathways	O
.	O

Ultrasonography	B-P
for	O
acute	O
appendicitis	O
-	O
the	O
way	O
it	O
looks	O
today	O
.	O

Despite	O
sophisticated	O
physical	O
examination	O
and	O
laboratory	B-P
support	I-P
,	O
diagnosis	O
of	O
acute	O
appendicitis	O
remained	O
challenging	O
in	O
clinical	O
practice	O
with	O
a	O
negative	O
appendectomy	O
rate	O
of	O
15	O
-	O
30	O
%	O
.	O

As	O
a	O
remarkable	O
clue	O
and	O
as	O
early	O
as	O
1986	O
,	O
ultrasonography	B-P
(	O
US	B-P
)	O
has	O
been	O
proven	O
a	O
reliable	O
diagnostic	B-P
method	I-P
that	O
is	O
also	O
explicitly	O
helpful	O
in	O
difficult	O
cases	O
with	O
atypical	O
presentation	O
and	O
enables	O
to	O
rule	O
out	O
many	O
differential	B-P
diagnoses	I-P
.Recent	O
publications	O
emphasized	O
the	O
role	O
of	O
multidetector	B-P
computed	I-P
tomography	I-P
(	O
CT	B-P
)	O
resulting	O
in	O
a	O
significant	O
reduction	O
of	O
false	O
negative	O
findings	O
at	O
operation	O
.	O

Extensive	O
as	O
well	O
as	O
uncritical	O
application	O
of	O
this	O
method	O
even	O
in	O
children	O
inevitably	O
causes	O
substantial	O
radiation	O
exposure	O
,	O
a	O
sequel	O
to	O
either	O
pure	O
ignorance	O
or	O
unqualified/	O
inadequate	O
performance	O
of	O
US	B-P
in	O
this	O
particular	O
situation	O
,	O
which	O
in	O
turn	O
can	O
be	O
considered	O
sequel	O
to	O
either	O
egocentric	O
or	O
economic	O
preponderance	O
.Recent	O
data	O
shed	O
new	O
light	O
on	O
the	O
role	O
of	O
US	B-P
(	O
and	O
CT	B-P
)	O
in	O
acute	O
appendicitis	O
.	O

Therefore	O
,	O
1	O
generation	O
after	O
US	B-P
with	I-P
graded	I-P
compression	I-P
was	O
etched	O
in	O
stone	O
as	O
the	O
method	O
of	O
choice	O
for	O
diagnosing	O
acute	O
appendicitis	O
(	O
Puylaert	O
)	O
,	O
a	O
visual	O
arousal	O
fostering	O
its	O
role	O
and	O
performance	O
in	O
clinical	O
medicine	O
appears	O
justified	O
.	O

Systems	O
Toxicology	O
:	O
Real	O
World	O
Applications	O
and	O
Opportunities	O
.	O

Systems	O
Toxicology	O
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse	O
biological	O
effects	O
of	O
xenobiotics	O
are	O
characterized	O
from	O
empirical	O
end	O
points	O
to	O
describing	O
modes	O
of	O
action	O
as	O
adverse	O
outcome	O
pathways	O
and	O
perturbed	O
networks	O
.	O

Toward	O
this	O
aim	O
,	O
Systems	O
Toxicology	O
entails	O
the	O
integration	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
toxicity	O
data	O
with	O
computational	O
modeling	O
.	O

This	O
evolving	O
approach	O
depends	O
critically	O
on	O
data	O
reliability	O
and	O
relevance	O
,	O
which	O
in	O
turn	O
depends	O
on	O
the	O
quality	O
of	O
experimental	O
models	O
and	O
bioanalysis	O
techniques	O
used	O
to	O
generate	O
toxicological	O
data	O
.	O

Systems	O
Toxicology	O
involves	O
the	O
use	O
of	O
large-scale	O
data	O
streams	O
(	O
``	O
big	O
data	O
``	O
)	O
,	O
such	O
as	O
those	O
derived	O
from	O
omics	O
measurements	O
that	O
require	O
computational	O
means	O
for	O
obtaining	O
informative	O
results	O
.	O

Thus	O
,	O
integrative	O
analysis	O
of	O
multiple	O
molecular	O
measurements	O
,	O
particularly	O
acquired	O
by	O
omics	B-P
strategies	I-P
,	O
is	O
a	O
key	O
approach	O
in	O
Systems	O
Toxicology	O
.	O

In	O
recent	O
years	O
,	O
there	O
have	O
been	O
significant	O
advances	O
centered	O
on	O
in	O
vitro	O
test	O
systems	O
and	O
bioanalytical	B-P
strategies	I-P
,	O
yet	O
a	O
frontier	O
challenge	O
concerns	O
linking	O
observed	O
network	O
perturbations	O
to	O
phenotypes	O
,	O
which	O
will	O
require	O
understanding	O
pathways	O
and	O
networks	O
that	O
give	O
rise	O
to	O
adverse	O
responses	O
.	O

This	O
summary	O
perspective	O
from	O
a	O
2016	O
Systems	O
Toxicology	O
meeting	O
,	O
an	O
international	O
conference	O
held	O
in	O
the	O
Alps	O
of	O
Switzerland	O
,	O
describes	O
the	O
limitations	O
and	O
opportunities	O
of	O
selected	O
emerging	O
applications	O
in	O
this	O
rapidly	O
advancing	O
field	O
.	O

Systems	O
Toxicology	O
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse	O
biological	O
effects	O
of	O
xenobiotics	O
are	O
characterized	O
,	O
from	O
empirical	O
end	O
points	O
to	O
pathways	O
of	O
toxicity	O
.	O

This	O
requires	O
the	O
integration	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
data	O
with	O
computational	O
modeling	O
.	O

Test	O
systems	O
and	O
bioanalytical	B-P
technologies	I-P
have	O
made	O
significant	O
advances	O
,	O
but	O
ensuring	O
data	O
reliability	O
and	O
relevance	O
is	O
an	O
ongoing	O
concern	O
.	O

The	O
major	O
challenge	O
facing	O
the	O
new	O
pathway	O
approach	O
is	O
determining	O
how	O
to	O
link	O
observed	O
network	O
perturbations	O
to	O
phenotypic	O
toxicity	O
.	O

Ultrasonographic	B-P
Assessment	I-P
of	O
the	O
Flexor	O
Pollicis	O
Longus	O
Tendon	O
After	O
Plate	O
Fixation	O
.	O

Rupture	O
of	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
is	O
a	O
major	O
complication	O
after	O
volar	O
locking	O
plate	O
fixation	O
of	O
distal	O
radius	O
fracture	O
.	O

This	O
study	O
used	O
ultrasonography	B-P
to	O
assess	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
and	O
intermediate	O
tissue	O
.	O

The	O
study	O
assessed	O
27	O
patients	O
(	O
28	O
wrists	O
)	O
who	O
underwent	O
removal	O
of	O
the	O
volar	O
locking	O
plate	O
.	O

Before	O
plate	O
removal	O
,	O
radiography	B-P
and	O
ultrasonography	B-P
were	O
performed	O
to	O
assess	O
the	O
relation	O
between	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
and	O
the	O
volar	O
locking	O
plate	O
.	O

Intraoperatively	O
,	O
the	O
authors	O
evaluated	O
the	O
intermediate	O
tissues	O
between	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
and	O
the	O
distal	O
volar	O
margin	O
of	O
the	O
plate	O
.	O

Preoperative	O
and	O
intraoperative	O
findings	O
were	O
compared	O
.	O

Intraoperative	O
findings	O
were	O
strongly	O
related	O
to	O
the	O
distance	O
between	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
and	O
the	O
volar	O
locking	O
plate	O
on	O
ultrasonography	B-P
.	O

The	O
sensitivity	O
of	O
ultrasonography	B-P
in	O
detecting	O
thin	O
,	O
membrane-like	O
intermediate	O
tissue	O
through	O
which	O
the	O
plate	O
was	O
visible	O
was	O
95	O
%	O
,	O
and	O
the	O
specificity	O
was	O
89	O
%	O
if	O
the	O
distance	O
between	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
and	O
the	O
plate	O
was	O
less	O
than	O
0.7	O
mm	O
.	O

Compression	O
of	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
was	O
seen	O
in	O
11	O
cases	O
(	O
39.3	O
%	O
)	O
,	O
and	O
this	O
finding	O
suggested	O
the	O
presence	O
of	O
thin	O
,	O
membrane-like	O
intermediate	O
tissue	O
.	O

The	O
study	O
results	O
showed	O
that	O
ultrasonography	B-P
could	O
be	O
used	O
to	O
identify	O
the	O
type	O
of	O
intermediate	O
tissue	O
between	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
and	O
the	O
volar	O
locking	O
plate	O
.	O

[	O
Orthopedics	O
.	O

2017	O
;	O
40	O
(	O
1	O
)	O
:	O
e104-e108	O
.	O

]	O
.	O

Histological	O
variability	O
and	O
consequences	O
in	O
chronic	O
bird-related	O
hypersensitivity	O
pneumonitis	O
.	O

Lobar	O
and	O
temporal	O
histological	O
variability	O
in	O
chronic	O
bird-related	O
hypersensitivity	O
pneumonitis	O
(	O
BRHP	O
)	O
has	O
not	O
been	O
clearly	O
elucidated	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
spatio-temporal	O
histopathological	O
variability	O
in	O
chronic	O
BRHP	O
.	O

Fifty-two	O
patients	O
with	O
chronic	O
BRHP	O
who	O
underwent	O
a	O
surgical	O
lung	B-P
biopsy	I-P
(	O
SLB	B-P
)	O
between	O
1992	O
and	O
2008	O
were	O
evaluated	O
.	O

The	O
histopathological	O
characteristics	O
of	O
the	O
lung	O
biopsy	O
specimens	O
were	O
classified	O
by	O
the	O
2002	O
American	O
Thoracic	O
Society	O
/	O
European	O
Respiratory	O
Society	O
(	O
ATS/ERS	O
)	O
consensus	O
classification	O
of	O
idiopathic	O
interstitial	O
pneumonias	O
(	O
IIPs	O
)	O
.	O

Autopsy	B-P
specimens	O
from	O
seven	O
patients	O
were	O
also	O
evaluated	O
to	O
examine	O
the	O
serial	O
changes	O
from	O
SLB	B-P
to	O
autopsy	B-P
.	O

In	O
a	O
study	O
of	O
lobar	O
histological	O
variability	O
based	O
on	O
the	O
findings	O
of	O
SLB	B-P
,	O
7	O
patients	O
were	O
diagnosed	O
with	O
cellular	O
nonspecific	O
interstitial	O
pneumonia	O
(	O
NSIP	O
)	O
pattern	O
,	O
16	O
with	O
fibrotic	O
NSIP	O
pattern	O
,	O
20	O
with	O
fibrotic	O
NSIP	O
pattern	O
and	O
usual	O
interstitial	O
pneumonia	O
(	O
UIP	O
)	O
(	O
discordant	O
UIP	O
)	O
pattern	O
and	O
9	O
with	O
UIP	O
(	O
concordant	O
UIP	O
)	O
pattern	O
.	O

In	O
a	O
study	O
of	O
sequential	O
changes	O
,	O
specimens	O
of	O
SLBs	B-P
with	O
fibrotic	O
NSIP	O
pattern	O
changed	O
to	O
a	O
bronchiolocentric	O
interstitial	O
pneumonia	O
(	O
BIP	O
)	O
pattern	O
or	O
UIP	O
pattern	O
.	O

Interlobar	O
and	O
intralobar	O
histological	O
variability	O
is	O
present	O
in	O
chronic	O
BRHP	O
.	O

In	O
several	O
patients	O
with	O
chronic	O
BRHP	O
,	O
a	O
fibrotic	O
NSIP	O
pattern	O
may	O
be	O
an	O
early	O
lesion	O
that	O
progresses	O
to	O
a	O
UIP	O
pattern	O
.	O

Subcellular	O
reprogramming	O
of	O
metabolism	O
during	O
cold	O
acclimation	O
in	O
Arabidopsis	O
thaliana	O
.	O

Metabolite	O
changes	O
in	O
plant	O
leaves	O
during	O
exposure	O
to	O
low	O
temperatures	O
involve	O
re-allocation	O
of	O
a	O
large	O
number	O
of	O
metabolites	O
between	O
sub-cellular	O
compartments	O
.	O

Therefore	O
,	O
metabolite	O
determination	B-P
at	O
the	O
whole	O
cell	O
level	O
may	O
be	O
insufficient	O
for	O
interpretation	O
of	O
the	O
functional	O
significance	O
of	O
cellular	O
compounds	O
.	O

To	O
investigate	O
the	O
cold	O
-	O
induced	O
metabolite	O
dynamics	O
at	O
the	O
level	O
of	O
individual	O
sub-cellular	O
compartments	O
,	O
an	O
integrative	O
platform	O
was	O
developed	O
that	O
combines	O
quantitative	O
metabolite	O
profiling	O
by	O
gas	B-P
chromatography	I-P
coupled	I-P
to	I-P
mass	I-P
spectrometry	I-P
(	O
GC-MS	B-P
)	O
with	O
the	O
non-aqueous	B-P
fractionation	I-P
technique	I-P
allowing	O
separation	O
of	O
cytosol	O
,	O
vacuole	O
and	O
the	O
plastidial	O
compartment	O
.	O

Two	O
mutants	O
of	O
Arabidopsis	O
thaliana	O
representing	O
antipodes	O
in	O
the	O
diversion	O
of	O
carbohydrate	O
metabolism	O
between	O
sucrose	O
and	O
starch	O
were	O
compared	O
to	O
Col-0	O
wildtype	O
before	O
and	O
after	O
cold	O
acclimation	O
to	O
investigate	O
interactions	O
of	O
cold	O
acclimation	O
with	O
subcellular	O
re-programming	O
of	O
metabolism	O
.	O

A	O
multivariate	O
analysis	O
of	O
the	O
data	O
set	O
revealed	O
dominant	O
effects	O
of	O
compartmentation	O
on	O
metabolite	O
concentrations	O
that	O
were	O
modulated	O
by	O
environmental	O
condition	O
and	O
genetic	O
determinants	O
.	O

While	O
for	O
both	O
,	O
the	O
starchless	O
mutant	O
of	O
plastidial	O
phospho-gluco	O
mutase	O
(	O
pgm	O
)	O
and	O
a	O
mutant	O
defective	O
in	O
sucrose-phosphate	O
synthase	O
A1	O
,	O
metabolic	O
constraints	O
,	O
especially	O
at	O
low	O
temperature	O
,	O
could	O
be	O
uncovered	O
based	O
on	O
subcellularly	O
resolved	O
metabolite	O
profiles	O
,	O
only	O
pgm	O
had	O
lowered	O
freezing	O
tolerance	O
.	O

Metabolic	O
profiles	O
of	O
pgm	O
point	O
to	O
redox	O
imbalance	O
as	O
a	O
possible	O
reason	O
for	O
reduced	O
cold	O
acclimation	O
capacity	O
.	O

Predicting	O
Sources	O
of	O
Dissolved	O
Organic	O
Nitrogen	O
to	O
an	O
Estuary	O
from	O
an	O
Agro	O
-	O
Urban	O
Coastal	O
Watershed	O
.	O

Dissolved	O
organic	O
nitrogen	O
(	O
DON	O
)	O
is	O
the	O
nitrogen	O
(	O
N	O
)	O
-containing	O
component	O
of	O
dissolved	O
organic	O
matter	O
(	O
DOM	O
)	O
and	O
in	O
aquatic	O
ecosystems	O
is	O
part	O
of	O
the	O
biologically-reactive	O
nitrogen	O
pool	O
that	O
can	O
degrade	O
water	O
quality	O
in	O
N	O
-	O
sensitive	O
waters	O
.	O

Unlike	O
inorganic	O
N	O
(	O
nitrate	O
and	O
ammonium	O
)	O
DON	O
is	O
comprised	O
of	O
many	O
different	O
molecules	O
of	O
variable	O
reactivity	O
.	O

Few	O
methods	O
exist	O
to	O
track	O
the	O
sources	O
of	O
DON	O
in	O
watersheds	O
.	O

In	O
this	O
study	O
,	O
DOM	O
excitation-emission	B-P
matrix	I-P
(	I-P
EEM	I-P
)	I-P
fluorescence	I-P
of	O
eight	O
discrete	O
DON	O
sources	O
was	O
measured	O
and	O
modeled	O
with	O
parallel	O
factor	O
analysis	O
(	O
PARAFAC	O
)	O
and	O
the	O
resulting	O
model	O
(	O
``	O
FluorMod	O
``	O
)	O
was	O
fit	O
to	O
516	O
EEMs	B-P
measured	O
in	O
surface	O
waters	O
from	O
the	O
main	O
stem	O
of	O
the	O
Neuse	O
River	O
and	O
its	O
tributaries	O
,	O
located	O
in	O
eastern	O
North	O
Carolina	O
.	O

PARAFAC	O
components	O
were	O
positively	O
correlated	O
to	O
DON	O
concentration	O
and	O
principle	O
components	O
analysis	O
(	O
PCA	O
)	O
was	O
used	O
to	O
confirm	O
separation	O
of	O
the	O
eight	O
sources	O
.	O

Model	O
validation	O
was	O
achieved	O
by	O
measurement	O
of	O
source	O
samples	O
not	O
included	O
in	O
the	O
model	O
development	O
with	O
an	O
error	O
of	O
<	O
10	O
%	O
.	O

Application	O
of	O
FluorMod	O
to	O
surface	O
waters	O
of	O
streams	O
within	O
the	O
Neuse	O
River	O
Basin	O
showed	O
while	O
>	O
70	O
%	O
of	O
DON	O
was	O
attributed	O
to	O
natural	O
sources	O
,	O
non-point	O
sources	O
,	O
such	O
as	O
soil	O
and	O
poultry	O
litter	O
leachates	O
and	O
street	O
runoff	O
,	O
accounted	O
for	O
the	O
remaining	O
30	O
%	O
.	O

This	O
result	O
was	O
consistent	O
with	O
changes	O
in	O
land	O
use	O
from	O
urbanized	O
Raleigh	O
metropolitan	O
area	O
to	O
the	O
largely	O
agricultural	O
Southeastern	O
coastal	O
plain	O
.	O

Overall	O
,	O
the	O
predicted	O
fraction	O
of	O
non-point	O
DON	O
sources	O
was	O
consistent	O
with	O
previous	O
reports	O
of	O
increased	O
organic	O
N	O
inputs	O
in	O
this	O
river	O
basin	O
,	O
which	O
are	O
suspected	O
of	O
impacting	O
the	O
water	O
quality	O
of	O
its	O
estuary	O
.	O

L-asparaginase	O
-	O
induced	O
abnormality	O
in	O
plasma	O
glucose	O
level	O
in	O
patients	O
of	O
acute	O
lymphoblastic	O
leukemia	O
admitted	O
to	O
a	O
tertiary	O
care	O
hospital	O
of	O
Odisha	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
any	O
abnormal	O
change	O
in	O
plasma	O
glucose	O
levels	O
in	O
patients	O
treated	O
with	O
L-asparaginase	O
(	O
L-Asp	O
)	O
-based	O
chemotherapy	O
regimen	O
in	O
patients	O
of	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
.	O

This	O
retrospective	O
,	O
hospital-based	O
study	O
was	O
conducted	O
in	O
patients	O
of	O
ALL	O
,	O
admitted	O
to	O
the	O
Clinical	O
Haematology	O
Department	O
of	O
a	O
tertiary	O
care	O
hospital	O
of	O
Odisha	O
from	O
August	O
2014	O
to	O
July	O
2015	O
.	O

Indoor	O
records	O
of	O
146	O
patients	O
on	O
multi-centered	O
protocol-841	O
were	O
evaluated	O
for	O
any	O
alteration	O
in	O
plasma	O
glucose	O
level	O
,	O
time	O
of	O
onset	O
of	O
hypo	O
/	O
hyperglycemia	O
,	O
and	O
persistence	O
of	O
plasma	B-P
glucose	I-P
alteration	O
.	O

Twenty-one	O
percent	O
of	O
patients	O
showed	O
abnormal	O
plasma	O
glucose	O
level	O
.	O

Most	O
of	O
these	O
patients	O
developed	O
hypoglycemia	O
and	O
were	O
of	O
lower	O
age	O
group	O
.	O

Most	O
of	O
these	O
patients	O
developed	O
hypoglycemia	O
and	O
were	O
of	O
lower	O
age	O
group	O
,	O
whereas	O
a	O
majority	O
of	O
higher	O
age	O
group	O
patients	O
developed	O
hyperglycemia	O
.	O

In	O
majority	O
of	O
the	O
cases	O
,	O
abnormal	O
glucose	O
developed	O
after	O
three	O
doses	O
of	O
L-Asp	O
.	O

Hypoglycemia	O
subsided	O
whereas	O
hyperglycemia	O
persisted	O
till	O
the	O
end	O
of	O
our	O
observation	O
period	O
.	O

L-Asp	O
produces	O
more	O
incidences	O
of	O
hypoglycemia	O
than	O
hyperglycemia	O
in	O
a	O
good	O
number	O
of	O
ALL	O
patients	O
towards	O
which	O
clinicians	O
should	O
be	O
more	O
vigilant	O
.	O

However	O
,	O
hyperglycemia	O
persists	O
for	O
a	O
longer	O
duration	O
than	O
hypoglycemia	O
.	O

Fibrinogen	O
:	O
A	O
Marker	O
in	O
Predicting	O
Diabetic	O
Foot	O
Ulcer	O
Severity	O
.	O

Aims	O
.	O

To	O
examine	O
whether	O
fibrinogen	O
levels	O
are	O
a	O
valuable	O
biomarker	O
for	O
assessing	O
disease	O
severity	O
and	O
monitoring	O
disease	O
progression	O
in	O
patients	O
with	O
diabetic	O
foot	O
ulcer	O
(	O
DFU	O
)	O
.	O

Methods	O
.	O

A	O
retrospective	O
study	O
was	O
designed	O
to	O
examine	O
the	O
utility	O
of	O
fibrinogen	O
in	O
estimating	O
disease	O
severity	O
in	O
patients	O
with	O
DFU	O
admitted	O
to	O
our	O
hospital	O
between	O
January	O
2015	O
and	O
January	O
2016	O
.	O

In	O
total	O
,	O
152	O
patients	O
with	O
DFU	O
were	O
enrolled	O
in	O
the	O
study	O
group	O
,	O
and	O
52	O
age	O
and	O
gender	O
matched	O
people	O
with	O
diabetes	O
but	O
no	O
DFU	O
were	O
included	O
as	O
the	O
control	O
group	O
.	O

DFU	O
severity	O
was	O
assessed	O
using	O
Wagner	O
criteria	O
.	O

Results	O
.	O

Patients	O
with	O
DFU	O
were	O
divided	O
into	O
2	O
subgroups	O
based	O
on	O
the	O
Wagner	O
criteria	O
.	O

Mean	O
fibrinogen	O
values	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
DFU	O
grade	O
â§	O
3	O
compared	O
to	O
those	O
with	O
DFU	O
grades	O
1-2	O
(	O
5.23	O
Â±	O
1.37	O
g/L	O
versus	O
3.61	O
Â±	O
1.04	O
g/L	O
)	O
.	O

Using	O
ROC	O
statistic	O
,	O
a	O
cut-off	O
value	O
of	O
5.13	O
g/L	O
indicated	O
the	O
possible	O
amputation	O
with	O
a	O
sensitivity	O
of	O
81.8	O
%	O
and	O
a	O
specificity	O
of	O
78.9	O
%	O
(	O
positive	O
predictive	O
value	O
[	O
PPV	O
]	O
78.6	O
%	O
,	O
negative	O
predictive	O
value	O
[	O
89.0	O
%	O
]	O
)	O
.	O

Fibrinogen	O
values	O
were	O
found	O
to	O
be	O
correlated	O
with	O
CRP	O
levels	O
,	O
neutrophil	B-P
,	O
and	O
WBC	B-P
count	I-P
.	O

Conclusions	O
.	O

Fibrinogen	O
levels	O
might	O
be	O
a	O
valuable	O
tool	O
for	O
assessing	O
the	O
disease	O
severity	O
and	O
monitoring	O
the	O
disease	O
progression	O
in	O
patients	O
with	O
DFU	O
.	O

TREK-1	O
(	O
K2P2.1	O
)	O
K	O
(	O
+	O
)	O
channels	O
are	O
suppressed	O
in	O
patients	O
with	O
atrial	O
fibrillation	O
and	O
heart	O
failure	O
and	O
provide	O
therapeutic	O
targets	O
for	O
rhythm	O
control	O
.	O

Atrial	O
fibrillation	O
(	O
AF	O
)	O
is	O
the	O
most	O
common	O
cardiac	O
arrhythmia	O
.	O

Concomitant	O
heart	O
failure	O
(	O
HF	O
)	O
poses	O
a	O
particular	O
therapeutic	O
challenge	B-P
and	O
is	O
associated	O
with	O
prolonged	O
atrial	O
electrical	O
refractoriness	O
compared	O
with	O
non-failing	O
hearts	O
.	O

We	O
hypothesized	O
that	O
downregulation	O
of	O
atrial	O
repolarizing	O
TREK-1	O
(	O
K2P2.1	O
)	O
K	O
(	O
+	O
)	O
channels	O
contributes	O
to	O
electrical	O
remodeling	O
during	O
AF	O
with	O
HF	O
,	O
and	O
that	O
TREK-1	O
gene	O
transfer	O
would	O
provide	O
rhythm	O
control	O
via	O
normalization	O
of	O
atrial	O
effective	O
refractory	O
periods	O
in	O
this	O
AF	O
subset	O
.	O

In	O
patients	O
with	O
chronic	O
AF	O
and	O
HF	O
,	O
atrial	O
TREK-1	O
mRNA	O
levels	O
were	O
reduced	O
by	O
82	O
%	O
(	O
left	O
atrium	O
)	O
and	O
81	O
%	O
(	O
right	O
atrium	O
)	O
compared	O
with	O
sinus	O
rhythm	O
(	O
SR	O
)	O
subjects	O
.	O

Human	O
findings	O
were	O
recapitulated	O
in	O
a	O
porcine	O
model	O
of	O
atrial	O
tachypacing-induced	O
AF	O
and	O
reduced	O
left	O
ventricular	O
function	O
.	O

TREK-1	O
mRNA	O
(	O
-66	O
%	O
)	O
and	O
protein	O
(	O
-61	O
%	O
)	O
was	O
suppressed	O
in	O
AF	O
animals	O
at	O
14-day	O
follow-up	O
compared	O
with	O
SR	O
controls	O
.	O

Downregulation	O
of	O
repolarizing	O
TREK-1	O
channels	O
was	O
associated	O
with	O
prolongation	O
of	O
atrial	O
effective	O
refractory	O
periods	O
versus	O
baseline	O
conditions	O
,	O
consistent	O
with	O
prior	O
observations	O
in	O
humans	O
with	O
HF	O
.	O

In	O
a	O
preclinical	O
therapeutic	O
approach	O
,	O
pigs	O
were	O
randomized	O
to	O
either	O
atrial	O
Ad-TREK-1	O
gene	O
therapy	O
or	O
sham	O
treatment	O
.	O

Gene	O
transfer	O
effectively	O
increased	O
TREK-1	O
protein	O
levels	O
and	O
attenuated	O
atrial	O
effective	O
refractory	O
period	O
prolongation	O
in	O
the	O
porcine	O
AF	O
model	O
.	O

Ad-TREK-1	O
increased	O
the	O
SR	O
prevalence	O
to	O
62	O
%	O
during	O
follow-up	O
in	O
AF	O
animals	O
,	O
compared	O
to	O
35	O
%	O
in	O
the	O
untreated	O
AF	O
group	O
.	O

In	O
conclusion	O
,	O
TREK-1	O
downregulation	O
and	O
rhythm	O
control	O
by	O
Ad-TREK-1	O
transfer	O
suggest	O
mechanistic	O
and	O
potential	O
therapeutic	O
significance	O
of	O
TREK-1	O
channels	O
in	O
a	O
subgroup	O
of	O
AF	O
patients	O
with	O
HF	O
and	O
prolonged	O
atrial	O
effective	O
refractory	O
periods	O
.	O

Functional	O
correction	O
of	O
ionic	O
remodeling	O
through	O
TREK-1	O
gene	O
therapy	O
represents	O
a	O
novel	O
paradigm	O
to	O
optimize	O
and	O
specify	O
AF	O
management	O
.	O

A	O
novel	O
cadaveric	O
study	O
of	O
the	O
morphometry	B-P
of	O
the	O
serratus	O
anterior	O
muscle	O
:	O
one	O
part	O
,	O
two	O
parts	O
,	O
three	O
parts	O
,	O
four	O
?	O
.	O

The	O
serratus	O
anterior	O
is	O
portrayed	O
as	O
a	O
homogeneous	O
muscle	O
in	O
textbooks	O
and	O
during	O
functional	O
activities	O
and	O
rehabilitation	O
exercises	O
.	O

It	O
is	O
unclear	O
whether	O
the	O
serratus	O
anterior	O
is	O
composed	O
of	O
subdivisions	O
with	O
distinctive	O
morphology	O
and	O
functions	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
serratus	O
anterior	O
could	O
be	O
subdivided	O
into	O
different	O
structural	O
parts	O
on	O
the	O
basis	O
of	O
its	O
segmental	O
architectural	O
parameters	O
.	O

Eight	O
formalin	O
-	O
embalmed	O
serratus	O
anterior	O
muscles	O
were	O
dissected	O
and	O
the	O
attachments	O
of	O
each	O
fascicle	O
documented	O
.	O

Orientation	O
and	O
size	O
of	O
each	O
fascicle	O
were	O
measured	O
and	O
the	O
physiological	O
cross-sectional	O
area	O
(	O
PCSA	O
)	O
calculated	O
.	O

Three	O
subdivisions	O
of	O
the	O
serratus	O
anterior	O
were	O
identified	O
.	O

A	O
new	O
finding	O
was	O
the	O
discovery	O
of	O
two	O
distinctive	O
fascicles	O
attached	O
to	O
the	O
superior	O
and	O
inferior	O
aspects	O
of	O
rib	O
2	O
.	O

The	O
rib	O
2	O
inferior	O
fascicle	O
had	O
the	O
largest	O
PCSA	O
(	O
mean	O
1.6	O
cm	O
(	O
2	O
)	O
)	O
and	O
attached	O
,	O
with	O
the	O
rib	O
3	O
fascicle	O
,	O
along	O
the	O
medial	O
border	O
of	O
the	O
scapula	O
to	O
form	O
the	O
middle	O
division	O
.	O

The	O
rib	O
2	O
superior	O
and	O
rib	O
1	O
fascicles	O
attached	O
to	O
the	O
superior	O
angle	O
of	O
the	O
scapula	O
(	O
upper	O
division	O
)	O
.	O

Fascicles	O
from	O
ribs	O
4-8/9	O
attached	O
to	O
the	O
inferior	O
angle	O
of	O
the	O
scapula	O
(	O
lower	O
division	O
)	O
.	O

Mean	O
fascicle	O
angle	O
relative	O
to	O
a	O
vertical	O
midline	O
reference	O
and	O
PCSA	O
for	O
each	O
division	O
were	O
29Â°	O
and	O
1.3	O
cm	O
(	O
2	O
)	O
(	O
upper	O
)	O
,	O
90Â°	O
and	O
2.2	O
cm	O
(	O
2	O
)	O
(	O
middle	O
)	O
and	O
59Â°	O
and	O
3.0	O
cm	O
(	O
2	O
)	O
(	O
lower	O
)	O
.	O

This	O
novel	O
study	O
demonstrated	O
the	O
presence	O
of	O
morphologically	O
distinct	O
serratus	O
anterior	O
subdivisions	O
.	O

The	O
results	O
of	O
this	O
study	O
will	O
inform	O
the	O
development	O
of	O
optimal	O
techniques	O
for	O
the	O
assessment	O
,	O
treatment	O
and	O
rehabilitation	O
of	O
this	O
architecturally	O
complex	O
muscle	O
in	O
shoulder	O
and	O
neck	O
pain	O
.	O

The	O
flavor	O
and	O
nutritional	O
characteristic	O
of	O
four	O
strawberry	O
varieties	O
cultured	O
in	O
soilless	O
system	O
.	O

Strawberry	O
fruits	O
(	O
cv	O
.	O

Benihoppe	O
,	O
Tochiotome	O
,	O
Sachinoka	O
,	O
and	O
Guimeiren	O
)	O
were	O
harvested	O
and	O
evaluated	O
the	O
flavor	O
and	O
nutritional	O
parameters	O
.	O

By	O
principal	O
component	O
analysis	O
and	O
hierarchical	O
clustering	O
analysis	O
,	O
differences	O
were	O
observed	O
based	O
on	O
the	O
volatile	O
compounds	O
composition	O
,	O
sugar	O
and	O
acid	O
concentration	O
,	O
sweetness	O
,	O
and	O
total	O
soluble	O
sugars	O
/	O
total	O
organic	O
acids	O
of	O
the	O
four	O
varieties	O
.	O

A	O
total	O
of	O
37	O
,	O
48	O
,	O
65	O
,	O
and	O
74	O
volatile	O
compounds	O
were	O
identified	O
and	O
determined	O
in	O
cv	O
.	O

Benihoppe	O
,	O
Tochiotome	O
,	O
Sachinoka	O
,	O
and	O
Guimeiren	O
strawberry	O
fruits	O
extracted	O
by	O
head-space	B-P
solid-phase	I-P
microextraction	I-P
(	O
HS-SPME	B-P
)	O
,	O
respectively	O
.	O

Esters	O
significantly	O
dominated	O
the	O
chemical	O
composition	O
of	O
the	O
four	O
varieties	O
.	O

Furaneol	O
was	O
detected	O
in	O
cultivars	O
of	O
Sachinoka	O
and	O
Guimeiren	O
,	O
but	O
mesifuran	O
was	O
only	O
found	O
in	O
cv	O
.	O

Tochiotome	O
.	O

Tochiotome	O
and	O
Sachinoka	O
showed	O
higher	O
content	O
of	O
linalool	O
and	O
(	O
E	O
)	O
-nerolidol	O
.	O

Sachinoka	O
showed	O
the	O
highest	O
content	O
of	O
total	O
sugars	O
and	O
total	O
acids	O
.	O

Guimeiren	O
showed	O
higher	O
sweetness	O
index	O
than	O
the	O
other	O
three	O
cultivars	O
.	O

Firmness	O
of	O
Tochiotome	O
was	O
highest	O
among	O
all	O
the	O
varieties	O
.	O

The	O
highest	O
total	O
soluble	O
solids	O
TSS	O
value	O
was	O
found	O
in	O
cv	O
.	O

Sachinoka	O
,	O
followed	O
by	O
the	O
Guimeiren	O
and	O
Tochiotome	O
varieties	O
.	O

Sachinoka	O
had	O
the	O
highest	O
titratable	O
acidity	O
TA	O
value	O
.	O

The	O
content	O
of	O
ascorbic	O
acid	O
(	O
AsA	O
)	O
of	O
cv	O
.	O

Tochiotome	O
was	O
higher	O
than	O
the	O
others	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
in	O
cultivars	O
of	O
Benihoppe	O
,	O
Tochiotome	O
,	O
and	O
Sachinoka	O
.	O

Fructose	O
and	O
glucose	O
were	O
the	O
major	O
sugars	O
in	O
all	O
cultivars	O
.	O

Citric	O
acid	O
was	O
the	O
major	O
organic	O
acid	O
in	O
cv	O
.	O

Tochiotome	O
,	O
cv	O
.	O

Sachinoka	O
,	O
and	O
cv	O
.	O

Guimeiren	O
.	O

Tochiotome	O
had	O
higher	O
ratios	O
of	O
TSS	O
/	O
TA	O
and	O
total	O
sugars	O
/	O
total	O
organic	O
acids	O
than	O
others	O
,	O
arising	O
from	O
its	O
lower	O
acid	O
content	O
.	O

The	O
order	O
of	O
the	O
comprehensive	O
evaluation	O
score	O
was	O
Sachinoka	O
>	O
Guimeiren	O
>	O
Tochiotome	O
>	O
Benihoppe	O
.	O

Surface	O
Modification	O
of	O
Porous	O
Titanium	O
Granules	O
for	O
Improving	O
Bioactivity	O
.	O

The	O
highly	O
porous	O
titanium	O
granules	O
are	O
currently	O
being	O
used	O
as	O
bone	O
substitute	O
material	O
and	O
for	O
bone	O
tissue	O
augmentation	O
.	O

However	O
,	O
they	O
suffer	O
from	O
weak	O
bone	O
bonding	O
ability	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
create	O
a	O
nanostructured	O
surface	O
oxide	O
layer	O
on	O
irregularly	O
shaped	O
titanium	O
granules	O
to	O
improve	O
their	O
bioactivity	O
.	O

This	O
could	O
be	O
achieved	O
using	O
optimized	O
electrochemical	O
anodic	O
oxidation	O
(	O
anodizing	O
)	O
and	O
heat	O
treatment	O
processes	O
.	O

The	O
anodizing	O
process	O
was	O
done	O
in	O
an	O
ethylene	O
glycol	O
-based	O
electrolyte	O
at	O
an	O
optimized	O
condition	O
of	O
60	O
V	O
for	O
3	O
hours	O
.	O

The	O
anodized	O
granules	O
were	O
subsequently	O
annealed	O
at	O
450Â°C	O
for	O
1	O
hour	O
.	O

Scanning	B-P
electron	I-P
microscopy	I-P
(	O
SEM	B-P
)	O
,	O
energy-dispersive	B-P
x-ray	I-P
spectroscopy	I-P
(	O
EDS	B-P
)	O
,	O
and	O
x-ray	B-P
diffraction	I-P
(	O
XRD	B-P
)	O
were	O
used	O
to	O
characterize	O
the	O
surface	O
structure	O
and	O
morphology	O
of	O
the	O
granules	O
.	O

The	O
in	O
vitro	O
bioactivity	O
of	O
the	O
samples	O
was	O
evaluated	O
by	O
immersion	O
of	O
specimens	O
in	O
simulated	O
body	O
fluid	O
(	O
SBF	O
)	O
for	O
1	O
,	O
2	O
,	O
and	O
3	O
weeks	O
.	O

The	O
human	O
osteoblastic	O
sarcoma	O
cell	O
line	O
,	O
MG63	O
,	O
was	O
used	O
to	O
evaluate	O
cell	O
viability	O
on	O
the	O
samples	O
using	O
dimethylthiazol-diphenyl	O
tetrazolium	O
bromide	O
(	O
MTT	O
)	O
assay	O
.	O

The	O
results	O
demonstrated	O
the	O
formation	O
of	O
amorphous	O
nanostructured	O
titanium	O
oxide	O
after	O
anodizing	O
,	O
which	O
transformed	O
to	O
crystalline	O
anatase	O
and	O
rutile	O
phases	O
upon	O
heat	O
treatment	O
.	O

After	O
immersion	O
in	O
SBF	O
,	O
spherical	O
aggregates	O
of	O
amorphous	O
calcium	O
phosphate	O
were	O
formed	O
on	O
the	O
surface	O
of	O
the	O
anodized	O
sample	O
,	O
which	O
turned	O
into	O
crystalline	O
hydroxyapatite	O
on	O
the	O
surface	O
of	O
the	O
anodized	O
annealed	O
sample	O
.	O

No	O
cytotoxicity	O
was	O
detected	O
among	O
the	O
samples	O
.	O

It	O
is	O
suggested	O
that	O
anodic	O
oxidation	O
followed	O
by	O
heat	O
treatment	O
could	O
be	O
used	O
as	O
an	O
effective	O
surface	O
treatment	O
procedure	O
to	O
improve	O
bioactivity	O
of	O
titanium	O
granules	O
implemented	O
for	O
bone	O
tissue	O
repair	O
and	O
augmentation	O
.	O

Ventricular	O
Effective	O
Refraction	O
Period	O
and	O
Ventricular	O
Repolarization	O
Analysis	O
in	O
Experimental	O
Tachycardiomyopathy	O
in	O
Swine	O
.	O

Swine	O
are	O
recognized	O
animal	O
models	O
of	O
human	O
cardiovascular	O
diseases	O
.	O

However	O
,	O
little	O
is	O
known	O
on	O
the	O
CHF	O
-associated	O
changes	O
in	O
the	O
electrophysiological	O
ventricular	O
parameters	O
of	O
humans	O
and	O
animals	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
changes	O
in	O
the	O
durations	O
of	O
ventricular	O
effective	O
refraction	O
period	O
(	O
VERP	O
)	O
,	O
QT	O
and	O
QTc	O
intervals	O
of	O
pigs	O
with	O
chronic	O
tachycardia	O
-	O
induced	O
tachycardiomyopathy	O
(	O
TIC	O
)	O
.	O

The	O
study	O
was	O
comprised	O
of	O
28	O
adult	O
pigs	O
(	O
8	O
females	O
and	O
20	O
males	O
)	O
of	O
the	O
Polish	O
Large	O
White	O
breed	O
.	O

A	O
one-chamber	O
pacemaker	O
was	O
implanted	O
in	O
each	O
of	O
the	O
28	O
pigs	O
.	O

Electrocardiographic	B-P
,	O
echocardiographic	B-P
and	O
electrophysiological	B-P
studies	I-P
were	O
carried	O
out	O
prior	O
to	O
the	O
pacemaker	O
implantation	O
and	O
at	O
subsequent	O
4-	O
week	O
intervals	O
.	O

All	O
electrocardiographic	B-P
,	O
echocardiographic	B-P
and	O
short	B-P
electrophysiological	I-P
study	I-P
measurements	O
in	O
all	O
swine	O
were	O
done	O
under	O
general	O
anesthesia	O
(	O
propofol	O
)	O
after	O
premedication	O
with	O
midazolam	O
,	O
medetomidine	O
,	O
and	O
ketamine	O
.	O

No	O
significant	O
changes	O
in	O
the	O
duration	O
of	O
QT	O
interval	O
and	O
corrected	O
QT	O
interval	O
(	O
QTc	O
)	O
were	O
observed	O
during	O
consecutive	O
weeks	O
of	O
the	O
experiment	O
.	O

The	O
duration	O
of	O
the	O
QTc	O
interval	O
of	O
female	O
pigs	O
was	O
shown	O
to	O
be	O
significantly	O
longer	O
than	O
that	O
of	O
the	O
males	O
throughout	O
the	O
whole	O
study	O
period	O
.	O

Beginning	O
from	O
the	O
12th	O
week	O
of	O
rapid	O
ventricular	O
pacing	O
,	O
a	O
significant	O
increase	O
in	O
duration	O
of	O
VERP	O
was	O
observed	O
in	O
both	O
male	O
and	O
female	O
pigs	O
.	O

Males	O
and	O
females	O
did	O
not	O
differ	O
significantly	O
in	O
terms	O
of	O
VERP	O
duration	O
determined	O
throughout	O
the	O
whole	O
study	O
period	O
.	O

Ventricular	O
pacing	O
,	O
stimulation	O
with	O
2	O
and	O
3	O
premature	O
impulses	O
at	O
progressively	O
shorter	O
coupling	O
intervals	O
and	O
an	O
imposed	O
rhythm	O
of	O
130	O
bpm	O
or	O
150	O
bpm	O
induced	O
transient	O
ventricular	O
tachycardia	O
in	O
one	O
female	O
pig	O
and	O
four	O
male	O
pigs	O
.	O

One	O
episode	O
of	O
permanent	O
ventricular	O
tachycardia	O
was	O
observed	O
.	O

The	O
number	O
of	O
induced	O
arrhythmias	O
increased	O
proportionally	O
to	O
the	O
severity	O
of	O
heart	O
failure	O
and	O
duration	O
of	O
the	O
experiment	O
.	O

However	O
,	O
relatively	O
aggressive	O
protocols	O
of	O
stimulation	O
were	O
required	O
in	O
order	O
to	O
induce	O
arrhythmia	O
in	O
the	O
studied	O
pigs	O
.	O

Cognition	O
Enhancing	O
Activity	O
of	O
Sulforaphane	O
Against	O
Scopolamine	O
Induced	O
Cognitive	O
Impairment	O
in	O
Zebra	O
Fish	O
(	O
Danio	O
rerio	O
)	O
.	O

Several	O
epidemiological	O
studies	O
have	O
shown	O
that	O
consumption	O
of	O
large	O
quantities	O
of	O
vegetables	O
especially	O
cruciferous	O
vegetables	O
(	O
Broccoli	O
and	O
Brussels	O
sprouts	O
)	O
can	O
protect	O
against	O
chronic	O
diseases	O
.	O

Sulforaphane	O
,	O
an	O
isothiocynate	O
found	O
in	O
cruciferous	O
vegetables	O
has	O
been	O
demonstrated	O
to	O
have	O
neuroprotective	O
effects	O
in	O
several	O
experimental	O
paradigms	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
examine	O
the	O
effect	O
of	O
sulforaphane	O
on	O
cognitive	O
impairment	O
in	O
zebra	O
fish	O
model	O
using	O
a	O
novel	O
method	O
of	O
fear	O
conditioning	O
.	O

Initially	O
,	O
the	O
normal	O
behaviour	O
of	O
zebra	O
fishes	O
was	O
studied	O
in	O
light-dark	O
tank	O
for	O
10	O
min	O
daily	O
for	O
10	O
days	O
.	O

Fishes	O
were	O
then	O
divided	O
into	O
seven	O
groups	O
of	O
twelve	O
in	O
each	O
.	O

Group	O
I	O
served	O
as	O
normal	O
,	O
group	O
II	O
served	O
as	O
fear	O
conditioned	O
control	O
,	O
group	O
III	O
and	O
group	O
IV	O
were	O
sulforaphane	O
(	O
25	O
ÂµM/L	O
)	O
and	O
piracetam	O
(	O
200	O
mg/L	O
)	O
treated	O
respectively	O
.	O

Group	O
V	O
served	O
as	O
scopolamine	O
(	O
400	O
ÂµM/L	O
)	O
induced	O
memory	O
impairment	O
fishes	O
.	O

Group	O
VI	O
and	O
VII	O
were	O
sulforaphane	O
(	O
25	O
ÂµM/L	O
)	O
and	O
piracetam	O
(	O
200	O
mg/L	O
)	O
treated	O
scopolamine	O
induced	O
memory	O
impairment	O
groups	O
respectively	O
.	O

In	O
normal	O
behavioural	O
analysis	O
,	O
fishes	O
preferred	O
to	O
stay	O
in	O
dark	O
compartment	O
.	O

The	O
average	O
number	O
of	O
entries	O
into	O
the	O
dark	O
and	O
time	O
spent	O
in	O
dark	O
were	O
significantly	O
more	O
.	O

Fishes	O
in	O
group	O
II	O
to	O
VII	O
were	O
individually	O
subjected	O
to	O
fear	O
conditioning	O
passive	B-P
avoidance	I-P
task	I-P
and	O
evaluated	O
for	O
learned	O
task	O
memory	O
.	O

It	O
was	O
observed	O
that	O
the	O
average	O
number	O
of	O
entries	O
into	O
dark	O
and	O
time	O
spent	O
in	O
dark	O
were	O
significantly	O
decreased	O
.	O

After	O
exposure	O
to	O
respective	O
treatment	O
fishes	O
in	O
group	O
III	O
to	O
VII	O
were	O
subjected	O
to	O
cognitive	O
evaluation	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
cognition	O
of	O
group	O
III	O
and	O
IV	O
fishes	O
exposed	O
to	O
sulforaphane	O
and	O
piracetam	O
alone	O
respectively	O
.	O

Fishes	O
exposed	O
to	O
scopolamine	O
showed	O
a	O
significant	O
cognitive	O
impairment	O
.	O

Sulforaphane	O
exposure	O
prior	O
to	O
scopolamine	O
significantly	O
retained	O
the	O
memory	O
of	O
learned	O
task	O
.	O

These	O
findings	O
suggest	O
that	O
sulforaphane	O
might	O
be	O
a	O
promising	O
therapeutic	O
agent	O
for	O
cognitive	O
enhancement	O
in	O
Alzheimer	O
's	O
disease	O
.	O

Structural	O
investigation	O
on	O
WlaRG	O
from	O
Campylobacter	O
jejuni	O
:	O
A	O
sugar	O
aminotransferase	O
.	O

Campylobacter	O
jejuni	O
is	O
a	O
Gram-negative	O
bacterium	O
that	O
represents	O
a	O
leading	O
cause	O
of	O
human	O
gastroenteritis	O
worldwide	O
.	O

Of	O
particular	O
concern	O
is	O
the	O
link	O
between	O
C.	O
jejuni	O
infections	O
and	O
the	O
subsequent	O
development	O
of	O
Guillain-BarrÃ©	O
syndrome	O
,	O
an	O
acquired	O
autoimmune	O
disorder	O
leading	O
to	O
paralysis	O
.	O

All	O
Gram-negative	O
bacteria	O
contain	O
complex	O
glycoconjugates	O
anchored	O
to	O
their	O
outer	O
membranes	O
,	O
but	O
in	O
most	O
strains	O
of	O
C.	O
jejuni	O
,	O
this	O
lipoglycan	O
lacks	O
the	O
O-antigen	O
repeating	O
units	O
.	O

Recent	O
mass	B-P
spectrometry	I-P
analyses	O
indicate	O
that	O
the	O
C.	O
jejuni	O
81116	O
(	O
Penner	O
serotype	O
HS:6	O
)	O
lipoglycan	O
contains	O
two	O
dideoxyhexosamine	O
residues	O
,	O
and	O
enzymological	B-P
assay	I-P
data	O
show	O
that	O
this	O
bacterial	O
strain	O
can	O
synthesize	O
both	O
dTDP-3-acetamido-3,6-dideoxy-d-glucose	O
and	O
dTDP-3-acetamido-3,6-dideoxy-d-galactose	O
.	O

The	O
focus	O
of	O
this	O
investigation	O
is	O
on	O
WlaRG	O
from	O
C.	O
jejuni	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
production	O
of	O
these	O
unusual	O
sugars	O
by	O
functioning	O
as	O
a	O
pyridoxal	O
5'-phosphate	O
dependent	O
aminotransferase	O
.	O

Here	O
,	O
we	O
describe	O
the	O
first	O
three-dimensional	O
structures	O
of	O
the	O
enzyme	O
in	O
various	O
complexes	O
determined	O
to	O
resolutions	O
of	O
1.7	O
Ã	O
or	O
higher	O
.	O

Of	O
particular	O
significance	O
are	O
the	O
external	O
aldimine	O
structures	O
of	O
WlaRG	O
solved	O
in	O
the	O
presence	O
of	O
either	O
dTDP-3-amino-3,6-dideoxy-d-galactose	O
or	O
dTDP-3-amino-3,6-dideoxy-d-glucose	O
.	O

These	O
models	O
highlight	O
the	O
manner	O
in	O
which	O
WlaRG	O
can	O
accommodate	O
sugars	O
with	O
differing	O
stereochemistries	O
about	O
their	O
C-4	O
'	O
carbon	O
positions	O
.	O

In	O
addition	O
,	O
we	O
present	O
a	O
corrected	O
structure	O
of	O
WbpE	O
,	O
a	O
related	O
sugar	O
aminotransferase	O
from	O
Pseudomonas	O
aeruginosa	O
,	O
solved	O
to	O
1.3	O
Ã	O
resolution	O
.	O

Combined	O
positive	O
effect	O
of	O
oocyte	O
extracts	O
and	O
brilliant	B-P
cresyl	I-P
blue	I-P
stained	I-P
recipient	O
cytoplasts	O
on	O
epigenetic	O
reprogramming	O
and	O
gene	O
expression	O
in	O
buffalo	O
nuclear	O
transfer	O
embryos	O
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
buffalo	O
oocyte	O
extracts	O
(	O
BOE	O
)	O
on	O
donor	O
cells	O
reprogramming	O
and	O
molecular	O
characterisation	O
of	O
oocytes	O
screened	O
via	O
brilliant	B-P
cresyl	I-P
blue	I-P
(	I-P
BCB	I-P
)	I-P
staining	I-P
and	O
comparison	O
of	O
gene	O
expression	O
profiles	O
of	O
developmentally	O
important	O
genes	O
in	O
blastocysts	O
from	O
IVF	O
and	O
cloned	O
derived	O
from	O
BOE	O
treated	O
donor	O
cells	O
with	O
BCB	O
selected	O
recipient	O
cytoplasts	O
.	O

Relative	O
abundance	O
(	O
RA	O
)	O
of	O
OCT4	O
and	O
NANOG	O
was	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
and	O
HDAC-1	O
,	O
DNMT-1	O
,	O
and	O
DNMT-3A	O
decreased	O
(	O
P	O
<	O
0.05	O
)	O
in	O
extract	O
treated	O
cells	O
(	O
ETCs	O
)	O
.	O

This	O
ETCs	O
dedifferentiated	O
into	O
neuron	O
-like	O
lineage	O
under	O
appropriate	O
induction	O
condition	O
.	O

The	O
RA	O
of	O
NASP	O
,	O
EEF1A1	O
,	O
DNMT1	O
,	O
ODC1	O
and	O
RPS27A	O
was	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
in	O
BCB	O
+	O
oocytes	O
,	O
whereas	O
ATP5A1	O
and	O
S100A10	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
in	O
BCB	O
-	O
oocytes	O
.	O

Total	B-P
cell	I-P
number	I-P
and	O
RA	O
of	O
OCT4	O
,	O
NANOG	O
,	O
SOX2	O
,	O
DNMT1	O
,	O
IGF2	O
,	O
IGF2R	O
,	O
MNSOD	O
,	O
GLUT1	O
,	O
BAX	O
and	O
BCL2	O
in	O
cloned	O
blastocysts	O
derived	O
from	O
BCB	O
+	O
oocytes	O
with	O
ETC	O
more	O
closely	O
followed	O
that	O
of	O
IVF	O
counterparts	O
compared	O
to	O
BCB	O
+	O
oocytes	O
with	O
extract	O
untreated	O
cell	O
and	O
BCB	O
-	O
oocytes	O
with	O
ETC	O
derived	O
blastocysts	O
.	O

In	O
conclusion	O
,	O
BOE	O
influenced	O
epigenetic	O
reprogramming	O
of	O
buffalo	O
fibroblasts	O
making	O
them	O
suitable	O
donors	O
for	O
nuclear	O
transfer	O
(	O
NT	O
)	O
.	O

BCB	B-P
staining	I-P
can	O
be	O
effectively	O
used	O
for	O
selection	O
of	O
developmentally	O
competent	O
oocytes	O
for	O
NT	O
.	O

The	O
combined	O
effects	O
of	O
epigenetic	O
reprogramming	O
of	O
donor	O
nuclei	O
by	O
BOE	O
and	O
higher	O
nuclear	O
reprogramming	O
capacity	O
of	O
BCB	O
+	O
oocytes	O
improve	O
developmentally	O
important	O
gene	O
expression	O
in	O
cloned	O
blastocysts	O
.	O

Whether	O
these	O
improvements	O
have	O
long-term	O
effects	O
on	O
buffalo	O
calves	O
born	O
following	O
embryo	O
transfer	O
remains	O
unknown	O
.	O

Circulating	O
progenitor	O
cells	O
and	O
coronary	O
microvascular	O
dysfunction	O
:	O
Results	O
from	O
the	O
NHLBI	O
-sponsored	O
Women	O
's	O
Ischemia	O
Syndrome	O
Evaluation	O
-	O
Coronary	O
Vascular	O
Dysfunction	O
Study	O
(	O
WISE-CVD	O
)	O
.	O

Ischemia	O
stimulates	O
a	O
reparative	O
response	O
resulting	O
in	O
mobilization	O
of	O
circulating	O
progenitor	O
cells	O
(	O
CPCs	O
)	O
.	O

We	O
hypothesized	O
that	O
women	O
with	O
chronic	O
myocardial	O
ischemia	O
from	O
coronary	O
microvascular	O
disease	O
(	O
CMD	O
)	O
will	O
mobilize	O
CPCs	O
.	O

In	O
123	O
women	O
with	O
ischemic	O
symptoms	O
and	O
signs	O
but	O
no	O
obstructive	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
enrolled	O
in	O
the	O
Women	O
's	O
Ischemia	O
Syndrome	O
Evaluation	O
-	O
Coronary	O
Vascular	O
Dysfunction	O
Study	O
(	O
WISE-CVD	O
)	O
,	O
we	O
measured	B-P
coronary	I-P
flow	I-P
reserve	I-P
(	O
CFR	B-P
)	O
in	O
response	O
to	O
intracoronary	O
adenosine	O
.	O

Peripheral	O
blood	O
CPCs	O
were	O
measured	O
using	O
flow	B-P
cytometry	I-P
for	O
expression	O
of	O
CD34	O
,	O
CD133	O
,	O
CXCR4	O
,	O
and	O
VEGFR2	O
.	O

Subjects	O
were	O
53	O
Â±	O
11	O
years	O
,	O
BMI	O
30	O
Â±	O
8	O
;	O
44	O
%	O
hypertensive	O
,	O
11	O
%	O
diabetic	O
,	O
23	O
%	O
hyperlipidemic	O
and	O
7	O
%	O
smokers	O
.	O

Lower	O
CFR	B-P
correlated	O
inversely	O
with	O
higher	O
levels	O
of	O
hematopoietic	O
-enriched	O
CD34+	O
(	O
r	O
=	O
-0.23	O
,	O
p	O
=	O
0.011	O
)	O
,	O
CD34+	O
/	O
CD133+	O
(	O
r	O
=	O
-0.24	O
,	O
p	O
=	O
0.008	O
)	O
,	O
and	O
CD34+	O
/	O
CXCR4+	O
(	O
r	O
=	O
-0.19	O
,	O
p	O
=	O
0.036	O
)	O
cells	O
.	O

In	O
multivariable	O
regression	O
analyses	O
,	O
after	O
adjusting	O
for	O
traditional	O
cardiovascular	O
risk	O
factors	O
,	O
lower	O
CFR	B-P
remained	O
significantly	O
associated	O
with	O
elevated	O
levels	O
of	O
CD34+	O
(	O
Î²	O
-0.18	O
,	O
p	O
=	O
0.042	O
)	O
,	O
CD34+	O
/	O
CD133+	O
(	O
Î²	O
-0.24	O
,	O
p	O
=	O
0.036	O
)	O
,	O
and	O
CD34+	O
/	O
CXCR4+	O
(	O
Î²	O
-0.22	O
,	O
p	O
=	O
0.050	O
)	O
cells	O
.	O

We	O
found	O
no	O
association	O
between	O
CFR	B-P
and	O
CD34+	O
/	O
VEGFR2+	O
cells	O
.	O

In	O
women	O
with	O
non-obstructive	O
CAD	O
,	O
impaired	O
CFR	B-P
is	O
associated	O
with	O
higher	O
levels	O
of	O
CPCs	O
,	O
suggesting	O
that	O
chronic	O
myocardial	O
ischemia	O
from	O
CMD	O
stimulates	O
CPC	O
mobilization	O
.	O

The	O
functional	O
significance	O
of	O
elevated	O
CPCs	O
in	O
these	O
subjects	O
requires	O
further	O
investigation	O
as	O
a	O
potential	O
biomarker	O
and	O
treatment	O
target	O
.	O

Motor	O
noise	O
is	O
rich	O
signal	O
in	O
autism	O
research	O
and	O
pharmacological	O
treatments	O
.	O

The	O
human	O
body	O
is	O
in	O
constant	O
motion	O
,	O
from	O
every	O
breath	O
that	O
we	O
take	O
,	O
to	O
every	O
visibly	O
purposeful	O
action	O
that	O
we	O
perform	O
.	O

Remaining	O
completely	O
still	O
on	O
command	O
is	O
a	O
major	O
achievement	O
as	O
involuntary	O
fluctuations	O
in	O
our	O
motions	O
are	O
difficult	O
to	O
keep	O
under	O
control	O
.	O

Here	O
we	O
examine	O
the	O
noise-to-signal	O
ratio	O
of	O
micro-movements	O
present	O
in	O
time-series	O
of	O
head	O
motions	O
extracted	O
from	O
resting-state	O
functional	O
magnetic	B-P
resonance	I-P
imaging	I-P
scans	I-P
in	O
1048	O
participants	O
.	O

These	O
included	O
individuals	O
with	O
autism	O
spectrum	O
disorders	O
(	O
ASD	O
)	O
and	O
healthy-controls	O
in	O
shared	O
data	O
from	O
the	O
Autism	O
Brain	O
Imaging	O
Data	O
Exchange	O
(	O
ABIDE	O
)	O
and	O
the	O
Attention-Deficit	O
Hyperactivity	O
Disorder	O
(	O
ADHD-200	O
)	O
databases	O
.	O

We	O
find	O
excess	O
noise	O
and	O
randomness	O
in	O
the	O
ASD	O
cases	O
,	O
suggesting	O
an	O
uncertain	O
motor-feedback	O
signal	O
.	O

A	O
power-law	O
emerged	O
describing	O
an	O
orderly	O
relation	O
between	O
the	O
dispersion	O
and	O
shape	O
of	O
the	O
probability	O
distribution	O
functions	O
best	O
describing	O
the	O
stochastic	O
properties	O
under	O
consideration	O
with	O
respect	O
to	O
intelligence	O
quotient	O
(	O
IQ-scores	O
)	O
.	O

In	O
ASD	O
,	O
deleterious	O
patterns	O
of	O
noise	O
are	O
consistently	O
exacerbated	O
with	O
the	O
presence	O
of	O
secondary	B-P
(	I-P
comorbid	I-P
)	I-P
neuropsychiatric	I-P
diagnoses	I-P
,	O
lower	O
verbal	O
and	O
performance	O
intelligence	O
,	O
and	O
autism	O
severity	O
.	O

Importantly	O
,	O
such	O
patterns	O
in	O
ASD	O
are	O
present	O
whether	O
or	O
not	O
the	O
participant	O
takes	O
psychotropic	O
medication	O
.	O

These	O
data	O
unambiguously	O
establish	O
specific	O
noise-to-signal	O
levels	O
of	O
head	O
micro-movements	O
as	O
a	O
biologically	O
informed	O
core	O
feature	O
of	O
ASD	O
.	O

Genomic	O
characterization	O
of	O
a	O
wild-bird	O
-	O
origin	O
pigeon	O
paramyxovirus	O
type	O
1	O
(	O
PPMV-1	O
)	O
first	O
isolated	O
in	O
the	O
northwest	O
region	O
of	O
China	O
.	O

Pigeon	O
paramyxovirus	O
type-1	O
(	O
PPMV-1	O
)	O
is	O
an	O
enzootic	O
in	O
pigeon	O
flocks	O
and	O
causes	O
severe	O
economic	O
losses	O
in	O
the	O
poultry	O
industry	O
in	O
many	O
countries	O
.	O

A	O
PPMV-1	O
isolate	O
,	O
abbreviated	O
as	O
PPMV-1/QL-01/CH/15	O
,	O
was	O
isolated	O
from	O
a	O
great	O
spotted	O
woodpecker	O
in	O
the	O
northwest	O
region	O
of	O
China	O
in	O
2015	O
.	O

The	O
complete	O
genome	O
was	O
sequenced	B-P
,	O
and	O
the	O
results	O
showed	O
that	O
the	O
virus	O
genome	O
was	O
15,192	O
nt	O
in	O
length	O
,	O
in	O
the	O
gene	O
arrangement	O
3'-NP-P-M-F-HN-L-5	O
'	O
.	O

Several	O
amino	O
acid	O
mutations	O
were	O
identified	O
in	O
the	O
functional	O
domains	O
of	O
the	O
F	O
and	O
HN	O
proteins	O
.	O

The	O
pathogenicity	O
index	O
of	O
the	O
isolate	O
was	O
evaluated	O
,	O
and	O
the	O
mean	O
death	O
time	O
(	O
MDT	O
)	O
was	O
72	O
h	O
and	O
the	O
intracerebral	O
pathogenicity	O
index	O
(	O
ICPI	O
)	O
was	O
0.925	O
,	O
indicating	O
that	O
this	O
isolate	O
was	O
mesogenic	O
.	O

Sequencing	B-P
results	O
showed	O
that	O
it	O
had	O
a	O
virulent	O
Newcastle	O
disease	O
virus	O
cleavage	O
motif	O
(	O
112	O
)	O
R-R-Q-K-R-F	O
(	O
117	O
)	O
at	O
the	O
fusion	O
protein	O
cleavage	O
site	O
.	O

Morbidity	O
and	O
mortality	O
were	O
70	O
%	O
and	O
50	O
%	O
,	O
after	O
inoculation	O
of	O
pigeons	O
,	O
whereas	O
this	O
virus	O
was	O
nonpathogenic	O
in	O
chickens	O
.	O

Different	O
immune	O
responses	O
of	O
pigeons	O
and	O
chickens	O
were	O
induced	O
in	O
vivo	O
,	O
which	O
led	O
to	O
different	O
HI	B-P
serum	I-P
antibody	I-P
titers	I-P
.	O

The	O
results	O
of	O
phylogenetic	O
and	O
evolutionary	O
distance	O
analysis	O
showed	O
that	O
this	O
PPMV-1	O
strain	O
belonged	O
to	O
sub-genotype	O
VIa	O
in	O
class	O
II	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
identification	B-P
and	O
analysis	O
of	O
PPMV-1	O
co-circulation	O
among	O
wild	O
birds	O
and	O
domestic	O
pigeon	O
flocks	O
in	O
China	O
.	O

The	O
data	O
from	O
this	O
study	O
highlight	O
the	O
important	O
role	O
of	O
wild	O
birds	O
in	O
the	O
dissemination	O
of	O
PPMV-1	O
and	O
provide	O
useful	O
references	O
for	O
improving	O
our	O
understanding	O
of	O
the	O
distribution	O
and	O
evolution	O
of	O
PPMV-1	O
in	O
China	O
.	O

2016	O
Updated	O
MASCC	O
/	O
ESMO	O
consensus	O
recommendations	O
:	O
Management	O
of	O
nausea	O
and	O
vomiting	O
in	O
advanced	O
cancer	O
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
review	O
the	O
existing	O
literature	O
related	O
to	O
the	O
management	O
of	O
nausea	O
and	O
vomiting	O
(	O
N	O
&	O
V	O
)	O
in	O
advanced	O
cancer	O
and	O
derive	O
clinical	O
evidence	O
-based	O
recommendations	O
for	O
its	O
management	O
.	O

Available	O
systematic	O
reviews	O
on	O
antiemetic	O
drug	O
effectiveness	O
were	O
used	O
.	O

One	O
generic	O
systematic	O
review	O
of	O
antiemetics	O
in	O
advanced	O
cancer	O
(	O
to	O
2009	O
)	O
was	O
updated	O
to	O
February	O
2016	O
.	O

Agreement	O
on	O
recommendations	O
was	O
reached	O
between	O
panel	O
members	O
,	O
and	O
these	O
were	O
voted	O
in	O
favor	O
unanimously	O
by	O
the	O
larger	O
antiemetic	O
committee	O
membership	O
(	O
n	O
=	O
37	O
)	O
.	O

The	O
evidence	O
base	O
in	O
this	O
field	O
is	O
minimal	O
with	O
largely	O
poor	O
quality	O
trials	O
or	O
uncontrolled	O
trials	O
and	O
case	O
studies	O
.	O

The	O
level	O
of	O
evidence	O
in	O
most	O
studies	B-P
is	O
low	O
.	O

The	O
drug	O
of	O
choice	O
for	O
managing	O
N	O
&	O
V	O
in	O
advanced	O
cancer	O
is	O
metoclopramide	O
titrated	O
to	O
effect	O
.	O

Alternative	O
options	O
include	O
haloperidol	O
,	O
levomepromazine	O
,	O
or	O
olanzapine	O
.	O

For	O
bowel	O
obstruction	O
,	O
the	O
recommendation	O
is	O
to	O
use	O
octreotide	O
given	O
alongside	O
an	O
antiemetic	O
(	O
haloperidol	O
)	O
and	O
where	O
octreotide	O
is	O
not	O
an	O
option	O
to	O
use	O
an	O
anticholinergic	O
antisecretory	O
agent	O
.	O

For	O
opioid	O
-	O
induced	O
N	O
&	O
V	O
,	O
no	O
recommendation	O
could	O
be	O
made	O
.	O

These	O
new	O
guidelines	O
,	O
based	O
on	O
the	O
existing	O
(	O
but	O
poor	O
)	O
evidence	O
,	O
could	O
help	O
clinicians	O
manage	O
more	O
effectively	O
the	O
complex	O
and	O
challenging	O
symptoms	O
of	O
N	O
&	O
V	O
in	O
advanced	O
cancer	O
.	O

Large-scale	O
synthesis	O
and	O
structural	O
analysis	O
of	O
a	O
synthetic	O
glycopeptide	O
dendrimer	O
as	O
an	O
anti-cancer	O
vaccine	O
candidate	O
.	O

Herein	O
,	O
we	O
report	O
a	O
new	O
process	O
that	O
enables	O
the	O
gram-scale	O
production	O
of	O
a	O
fully	O
synthetic	O
anti-cancer	O
vaccine	O
for	O
human	O
use	O
.	O

This	O
therapeutic	O
vaccine	O
candidate	O
,	O
named	O
MAG-Tn3	O
,	O
is	O
a	O
high-molecular-weight	O
tetrameric	O
glycopeptide	O
encompassing	O
carbohydrate	O
tumor-associated	O
Tn	O
antigen	O
clusters	O
and	O
peptidic	O
CD4	O
(	O
+	O
)	O
T-cell	O
epitopes	O
.	O

The	O
synthetic	O
process	O
involves	O
(	O
i	O
)	O
the	O
stepwise	O
solid-phase	O
assembly	O
of	O
protected	O
amino	O
acids	O
,	O
including	O
the	O
high	O
value-added	O
Tn	O
building	O
blocks	O
with	O
only	O
1.5	O
equivalents	O
,	O
(	O
ii	O
)	O
a	O
single	O
isolated	O
intermediate	O
,	O
and	O
(	O
iii	O
)	O
the	O
simultaneous	O
deprotection	O
of	O
36	O
hindered	O
protective	O
groups	O
.	O

The	O
resulting	O
MAG-Tn3	O
was	O
unambiguously	O
characterized	O
using	O
a	O
combination	O
of	O
techniques	O
,	O
including	O
a	O
structural	O
analysis	O
by	O
nuclear	B-P
magnetic	I-P
resonance	I-P
spectroscopy	I-P
.	O

The	O
four	O
peptidic	O
chains	O
are	O
flexible	O
in	O
solution	O
,	O
with	O
a	O
more	O
constrained	O
but	O
extended	O
conformation	O
at	O
the	O
Tn3	O
antigen	O
motif	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
,	O
when	O
injected	O
into	O
HLA-DR1	O
-	O
expressing	O
transgenic	O
mice	O
,	O
this	O
vaccine	O
induces	O
Tn-specific	O
antibodies	O
that	O
mediate	O
the	O
killing	O
of	O
human	O
Tn-positive	O
tumor	O
cells	O
.	O

These	O
studies	O
led	O
to	O
a	O
clinical	O
batch	O
of	O
the	O
MAG-Tn3	O
,	O
currently	O
investigated	O
in	O
breast	O
cancer	O
patients	O
(	O
phase	O
I	O
clinical	O
trial	O
)	O
.	O

The	O
current	O
study	O
demonstrates	O
the	O
feasibility	O
of	O
the	O
multigram-scale	O
synthesis	O
of	O
a	O
highly	O
pure	O
complex	O
glycopeptide	O
,	O
and	O
it	O
opens	O
new	O
avenues	O
for	O
the	O
use	O
of	O
synthetic	O
glycopeptides	O
as	O
drugs	O
in	O
humans	O
.	O

Psychometric	B-P
properties	O
of	O
the	O
Japanese	O
version	O
of	O
short	O
forms	O
of	O
the	O
Pain	O
Catastrophizing	O
Scale	O
in	O
participants	O
with	O
musculoskeletal	O
pain	O
:	O
A	O
cross-sectional	O
study	O
.	O

The	O
Pain	O
Catastrophizing	O
Scale	O
(	O
PCS	O
)	O
is	O
a	O
commonly	O
used	O
as	O
measure	O
of	O
pain	O
catastrophizing	O
.	O

The	O
scale	O
comprises	O
13	O
items	O
related	O
to	O
magnification	B-P
,	O
rumination	O
,	O
and	O
helplessness	O
.	O

To	O
facilitate	O
quick	O
screening	O
and	O
to	O
reduce	O
participant	O
's	O
burden	O
,	O
the	O
four-	O
item	O
and	O
six-	O
item	O
short	O
forms	O
of	O
the	O
English	O
version	O
of	O
the	O
PCS	O
were	O
developed	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
psychometric	B-P
properties	O
of	O
a	O
Japanese	O
version	O
of	O
the	O
short	O
forms	O
of	O
PCS	O
using	O
a	O
contemporary	O
approach	O
called	O
Rasch	O
analysis	O
.	O

A	O
total	O
of	O
216	O
patients	O
with	O
musculoskeletal	O
disorders	O
were	O
recruited	O
in	O
this	O
study	O
.	O

Participants	O
completed	O
study	O
measures	O
,	O
which	O
included	O
the	O
pain	O
intensity	O
,	O
the	O
Pain	O
Catastrophizing	O
Scale	O
(	O
PCS	O
)	O
,	O
and	O
the	O
Tampa	O
Scale	O
of	O
Kinesiophobia	O
(	O
TSK	O
)	O
.	O

Furthermore	O
,	O
the	O
four-	O
item	O
(	O
items	O
3	O
,	O
6	O
,	O
8	O
,	O
and	O
11	O
)	O
and	O
six-	O
item	O
(	O
items	O
4	O
,	O
5	O
,	O
6	O
,	O
10	O
,	O
11	O
,	O
and	O
13	O
)	O
short	O
forms	O
of	O
the	O
Japanese	O
version	O
of	O
PCS	O
were	O
measured	O
.	O

We	O
used	O
Rasch	O
analysis	O
to	O
analyze	O
the	O
psychometric	B-P
properties	O
of	O
the	O
original	O
,	O
four-	O
item	O
,	O
and	O
six-	O
item	O
short	O
forms	O
of	O
PCS	O
.	O

Rasch	O
analysis	O
showed	O
that	O
both	O
short	O
forms	O
of	O
PCS	O
had	O
acceptable	O
internal	O
consistency	O
,	O
unidimensionality	O
,	O
and	O
no	O
notable	O
DIF	O
and	O
were	O
functional	O
on	O
the	O
category	O
rating	O
scale	O
.	O

However	O
,	O
four-	O
item	O
short	O
form	O
of	O
PCS	O
had	O
two	O
misfit	O
items	O
.	O

Six-	O
item	O
short	O
form	O
of	O
PCS	O
has	O
acceptable	O
psychometric	B-P
properties	O
and	O
is	O
suitable	O
for	O
use	O
in	O
participants	O
with	O
musculoskeletal	O
pain	O
.	O

Thus	O
,	O
six-	O
item	O
can	O
be	O
used	O
as	O
brief	O
instruments	O
to	O
evaluate	O
pain	O
catastrophizing	O
.	O

HERG1	O
potassium	O
channel	O
expression	O
in	O
potentially	O
malignant	O
disorders	O
of	O
the	O
oral	O
mucosa	O
and	O
prognostic	O
relevance	O
in	O
oral	O
squamous	O
cell	O
carcinoma	O
.	O

HERG1	O
potassium	O
channel	O
plays	O
a	O
critical	O
role	O
in	O
the	O
cell	O
proliferation	O
.	O

HERG1	O
protein	O
expression	O
was	O
analyzed	O
by	O
immunohistochemistry	B-P
(	O
IHC	B-P
)	O
in	O
62	O
patients	O
with	O
oral	O
leukoplakias	O
and	O
100	O
patients	O
with	O
oral	O
squamous	O
cell	O
carcinomas	O
(	O
OSCC	O
)	O
.	O

HERG1	O
mRNA	O
levels	O
were	O
assessed	O
by	O
real-time	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
in	O
22	O
patients	O
with	O
primary	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
(	O
HNSCC	O
)	O
.	O

Statistically	O
significant	O
associations	O
were	O
found	O
between	O
HERG1	O
expression	O
and	O
tobacco	O
consumption	O
,	O
disease	B-P
stage	I-P
,	O
tumor	O
differentiation	O
,	O
tumor	O
recurrence	O
,	O
and	O
reduced	O
survival	O
.	O

There	O
was	O
no	O
association	O
between	O
HERG1	O
expression	O
and	O
the	O
risk	O
of	O
progression	O
from	O
oral	O
leukoplakia	O
to	O
OSCC	O
.	O

In	O
addition	O
,	O
a	O
high	O
proportion	O
of	O
tumors	O
(	O
80	O
%	O
)	O
showed	O
increased	O
HERG1	O
mRNA	O
levels	O
compared	O
to	O
normal	O
mucosa	O
from	O
nononcologic	O
patients	O
.	O

Aberrant	O
HERG1	O
expression	O
increases	O
as	O
oral	O
tumorigenesis	O
progresses	O
from	O
oral	O
hyperplasia	O
to	O
OSCC	O
.	O

Increased	O
HERG1	O
mRNA	O
levels	O
were	O
also	O
frequently	O
detected	O
in	O
OSCC	O
and	O
other	O
HNSCC	O
subsites	O
.	O

HERG1	O
expression	O
emerges	O
as	O
a	O
clinically	O
relevant	O
feature	O
during	O
tumor	O
progression	O
and	O
a	O
potential	O
poor	O
prognostic	O
biomarker	O
for	O
OSCC	O
.	O

Â©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Head	O
Neck	O
38	O
:	O
1708-1716	O
,	O
2016	O
.	O

Beneficial	O
Effects	O
on	O
Pregnancy	O
Outcomes	O
of	O
Thyroid	O
Hormone	O
Replacement	O
for	O
Subclinical	O
Hypothyroidism	O
.	O

Background	O
.	O

Hypothyroidism	O
and	O
raised	O
thyroid	O
antibody	O
levels	O
have	O
been	O
associated	O
with	O
adverse	O
obstetrical	O
outcomes	O
.	O

Several	O
studies	O
have	O
investigated	O
causal	O
associations	O
,	O
but	O
results	O
have	O
been	O
inconsistent	O
and	O
few	O
studies	O
have	O
reported	O
the	O
effects	O
of	O
thyroxine	O
replacement	O
therapy	O
on	O
pregnancy	O
outcomes	O
in	O
hypothyroid	O
patients	O
.	O

Objective	O
.	O

The	O
primary	O
study	O
objective	O
was	O
to	O
determine	O
the	O
outcome	O
of	O
pregnancies	O
in	O
women	O
diagnosed	O
with	O
overt	O
and	O
subclinical	O
hypothyroidism	O
(	O
SCH	O
)	O
(	O
serum	B-P
TSH	I-P
>	O
2.5	O
mIU/L	O
)	O
and	O
those	O
with	O
elevated	O
circulating	O
thyroid	O
autoantibody	O
levels	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
and	O
after	O
the	O
institution	O
of	O
appropriate	O
thyroxine	O
replacement	O
therapy	O
to	O
maintain	O
the	O
serum	B-P
TSH	I-P
â¤	O
2.5	O
mIU/L	O
.	O

Study	O
Design	O
.	O

This	O
prospective	O
observational	O
study	O
was	O
undertaken	O
between	O
2013	O
and	O
2016	O
.	O

Blood	O
samples	O
were	O
taken	O
from	O
1025	O
women	O
at	O
presentation	O
for	O
thyroid	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
,	O
anti-thyroglobulin	O
antibodies	O
(	O
TGAb	O
)	O
,	O
and	O
thyroid	O
peroxidase	O
antibodies	O
(	O
TPOAb	O
)	O
.	O

Those	O
with	O
a	O
TSH	O
>	O
2.5	O
mIU/L	O
were	O
treated	O
with	O
thyroxine	O
and	O
managed	O
appropriately	O
to	O
ensure	O
that	O
the	O
TSH	O
was	O
maintained	O
â¤2.5	O
mIU/L	O
.	O

Outcomes	O
in	O
these	O
patients	O
were	O
compared	O
to	O
those	O
in	O
euthyroid	O
patients	O
.	O

Maternal	O
antenatal	O
complications	O
and	O
perinatal	O
outcomes	O
were	O
recorded	O
.	O

Results	O
.	O

There	O
were	O
a	O
total	O
of	O
1025	O
patients	O
of	O
whom	O
382	O
(	O
37.5	O
%	O
)	O
were	O
nulliparous	O
.	O

10.1	O
%	O
had	O
a	O
TSH	O
level	O
>	O
2.5	O
mIU/L	O
and	O
18.2	O
%	O
had	O
at	O
least	O
one	O
raised	O
thyroid	O
antibody	O
level	O
.	O

No	O
differences	O
in	O
adverse	O
outcomes	O
of	O
pregnancy	O
were	O
evident	O
in	O
women	O
treated	O
for	O
SCH	O
or	O
overt	O
hypothyroidism	O
compared	O
to	O
the	O
euthyroid	O
group	O
.	O

There	O
was	O
also	O
no	O
association	O
between	O
raised	O
thyroid	O
antibodies	O
and	O
adverse	O
pregnancy	O
outcomes	O
in	O
either	O
group	O
.	O

Conclusion	O
.	O

There	O
were	O
no	O
adverse	O
outcomes	O
of	O
pregnancy	O
found	O
in	O
pregnant	O
women	O
who	O
had	O
been	O
diagnosed	O
and	O
treated	O
with	O
thyroxine	O
for	O
SCH	O
at	O
the	O
time	O
of	O
presentation	O
when	O
compared	O
to	O
euthyroid	O
patients	O
.	O

There	O
was	O
also	O
no	O
relationship	O
with	O
thyroid	O
antibodies	O
and	O
adverse	O
pregnancy	O
outcomes	O
in	O
the	O
two	O
groups	O
.	O

It	O
is	O
not	O
possible	O
to	O
unequivocally	O
advocate	O
for	O
thyroxine	O
replacement	O
in	O
pregnant	O
women	O
with	O
subclinical	O
and	O
overt	O
hypothyroidism	O
until	O
large	O
scale	O
randomized	O
controlled	O
trials	O
are	O
performed	O
.	O

Application	O
of	O
BRAF	O
V600E	O
mutation	O
-	O
specific	O
immunohistochemistry	B-P
in	O
diagnosis	O
of	O
gastrointestinal	O
stromal	O
tumors	O
.	O

To	O
evaluate	O
the	O
utility	O
of	O
BRAF	O
V600E	O
allele	O
-	O
specific	O
antibody	O
in	O
the	O
diagnosis	O
of	O
gastrointestinal	O
stromal	O
tumors	O
(	O
GISTs	O
)	O
.	O

BRAF	O
V600E	O
mutation	O
-	O
specific	O
immunohistochemistry	B-P
and	O
BRAF	O
sequencing	O
were	O
performed	O
in	O
24	O
consecutive	O
GISTs	O
,	O
including	O
14	O
cases	O
of	O
KIT	O
or	O
PDGFRA	O
mutations	O
and	O
10	O
cases	O
of	O
KIT	O
/	O
PDGFRA	O
wild	O
GISTs	O
.	O

GISTs	O
of	O
11	O
men	O
and	O
13	O
women	O
with	O
a	O
mean	O
age	O
54	O
years	O
(	O
range	O
29-75	O
years	O
)	O
were	O
included	O
with	O
tumors	O
arising	O
from	O
stomach	O
(	O
16	O
cases	O
)	O
,	O
small	O
bowel	O
(	O
7	O
cases	O
)	O
,	O
and	O
peritoneal	O
cavity	O
(	O
1	O
case	O
)	O
.	O

Strong	O
and	O
diffuse	O
cytoplasmic	O
BRAF	O
staining	O
was	O
noted	O
in	O
4	O
of	O
24	O
cases	O
(	O
17	O
%	O
)	O
,	O
while	O
1	O
of	O
24	O
cases	O
(	O
4	O
%	O
)	O
showed	O
weak	O
staining	O
,	O
and	O
19	O
of	O
24	O
cases	O
(	O
79	O
%	O
)	O
had	O
no	O
staining	O
.	O

The	O
four	O
cases	O
with	O
strong	O
BRAF	O
immunostain	O
were	O
confirmed	O
to	O
have	O
BRAF	O
mutations	O
,	O
including	O
3	O
cases	O
in	O
the	O
stomach	O
and	O
1	O
case	O
in	O
the	O
small	O
intestine	O
.	O

All	O
tumors	O
showed	O
spindle	O
cell	O
morphology	O
.	O

Only	O
one	O
case	O
had	O
progressive	O
disease	O
.	O

No	O
BRAF	O
mutations	O
were	O
detected	O
in	O
cases	O
with	O
weak	O
or	O
negative	O
BRAF	O
immunostain	O
.	O

BRAF	O
V600E	O
mutation	O
-	O
specific	O
immunohistochemistry	B-P
is	O
a	O
highly	O
sensitive	O
and	O
specific	O
marker	O
for	O
detecting	O
BRAF-mutated	O
GISTs	O
.	O

Slower	O
but	O
not	O
faster	O
unilateral	O
fatiguing	O
knee	O
extensions	O
alter	O
contralateral	O
limb	O
performance	O
without	O
impairment	O
of	O
maximal	O
torque	O
output	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
unilateral	O
fatigue	O
of	O
the	O
knee	O
extensors	O
at	O
different	O
movement	O
velocities	O
on	O
neuromuscular	O
performance	O
in	O
the	O
fatigued	O
and	O
non-fatigued	O
leg	O
.	O

Unilateral	O
fatigue	O
of	O
the	O
knee	O
extensors	O
was	O
induced	O
in	O
11	O
healthy	O
young	O
men	O
(	O
23.7	O
Â±	O
3.8	O
years	O
)	O
at	O
slower	O
(	O
60Â°/s	O
;	O
FAT60	O
)	O
and	O
faster	O
movement	O
velocities	B-P
(	O
240Â°/s	O
;	O
FAT240	O
)	O
using	O
an	O
isokinetic	O
dynamometer	O
.	O

A	O
resting	O
control	O
(	O
CON	O
)	O
condition	O
was	O
included	O
.	O

The	O
fatigue	O
protocols	O
consisted	O
of	O
five	O
sets	O
of	O
15	O
maximal	O
concentric	O
knee	O
extensions	O
using	O
the	O
dominant	O
leg	O
.	O

Before	O
and	O
after	O
fatigue	O
,	O
peak	O
isokinetic	O
torque	O
(	O
PIT	O
)	O
and	O
time	O
to	O
PIT	O
(	O
TTP	O
)	O
of	O
the	O
knee	O
extensors	O
as	O
well	O
as	O
electromyographic	O
(	O
EMG	O
)	O
activity	O
of	O
vastus	O
medialis	O
,	O
vastus	O
lateralis	O
,	O
and	O
biceps	O
femoris	O
muscles	O
were	O
assessed	O
at	O
60	O
and	O
240Â°/s	O
movement	O
velocities	B-P
in	O
the	O
fatigued	O
and	O
non-fatigued	O
leg	O
.	O

In	O
the	O
fatigue	O
d	O
leg	O
,	O
significantly	O
greater	O
PIT	O
decrements	O
were	O
observed	O
following	O
FAT60	O
and	O
FAT240	O
(	O
11-19	O
%	O
)	O
compared	O
to	O
CON	O
(	O
3-4	O
%	O
,	O
p	O
=	O
.002	O
,	O
d	O
=	O
2.3	O
)	O
.	O

Further	O
,	O
EMG	O
activity	O
increased	O
in	O
vastus	O
lateralis	O
and	O
biceps	O
femoris	O
muscle	O
following	O
FAT240	O
only	O
(	O
8-28	O
%	O
,	O
0.018	O
â¤	O
p	O
â¤	O
.024	O
,	O
d	O
=	O
1.8	O
)	O
.	O

In	O
the	O
non-fatigued	O
leg	O
,	O
shorter	O
TTP	O
values	O
were	O
found	O
after	O
the	O
FAT60	O
protocol	O
(	O
11-15	O
%	O
,	O
p	O
=	O
.023	O
,	O
d	O
=	O
2.4	O
)	O
.	O

No	O
significant	O
changes	O
were	O
found	O
for	O
EMG	O
data	O
in	O
the	O
non-fatigued	O
leg	O
.	O

The	O
present	O
study	O
revealed	O
that	O
both	O
slower	O
and	O
faster	O
velocity	B-P
fatiguing	O
contractions	O
failed	O
to	O
show	O
any	O
evidence	O
of	O
cross-over	O
fatigue	O
on	O
PIT	O
.	O

However	O
,	O
unilateral	O
knee	O
extensor	O
fatigue	O
protocols	O
conducted	O
at	O
slower	O
movement	O
velocities	B-P
(	O
i.e.	O
,	O
60Â°/s	O
)	O
appear	O
to	O
modulate	O
torque	O
production	O
on	O
the	O
non-fatigued	O
side	O
(	O
evident	O
in	O
shorter	O
TTP	O
values	O
)	O
.	O

Variation	O
analysis	O
of	O
PRIM1	O
gene	O
in	O
Chinese	O
patients	O
with	O
primary	O
ovarian	O
insufficiency	O
.	O

Insights	O
into	O
common	O
genetic	O
susceptibility	O
between	O
primary	O
ovarian	O
insufficiency	O
(	O
POI	O
)	O
and	O
natural	O
or	O
early	O
menopause	O
have	O
delivered	O
an	O
innovative	O
way	O
of	O
assessing	O
the	O
genetic	O
mechanisms	O
involved	O
in	O
POI	O
.	O

PRIM1	O
plays	O
a	O
crucial	O
role	O
in	O
DNA	O
replication	O
by	O
synthesizing	O
RNA	O
primers	O
for	O
Okazaki	O
fragments	O
.	O

It	O
is	O
closely	O
associated	O
with	O
age	O
at	O
natural	O
menopause	O
,	O
early	O
menopause	O
and	O
POI	O
in	O
European	O
women	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
whether	O
mutations	O
in	O
PRIM1	O
contribute	O
to	O
POI	O
in	O
Chinese	O
women	O
.	O

All	O
exons	O
and	O
exon-intron	O
boundaries	O
of	O
PRIM1	O
gene	O
were	O
sequenced	B-P
in	O
192	O
Han	O
Chinese	O
women	O
with	O
non-syndromic	O
POI	O
.	O

No	O
plausible	O
mutations	O
were	O
identified	O
.	O

The	O
results	O
suggest	O
that	O
the	O
perturbations	O
in	O
PRIM1	O
gene	O
are	O
not	O
a	O
common	O
explanation	O
for	O
POI	O
in	O
Chinese	O
women	O
.	O

Correlation	O
of	O
cardiopulmonary	B-P
exercise	I-P
testing	I-P
parameters	O
with	O
quality	O
of	O
life	O
in	O
stable	O
COPD	O
patients	O
.	O

The	O
precise	O
head	O
to	O
head	O
relationships	O
between	O
Cardio-pulmonary	B-P
exercise	I-P
testing	I-P
(	O
CPET	B-P
)	O
parameters	O
and	O
patients	O
'	O
daily	O
symptoms	O
/	O
activities	O
and	O
the	O
disease	O
social	O
/	O
emotional	O
impact	O
are	O
less	O
well	O
defined	O
.	O

In	O
this	O
study	O
,	O
the	O
correlation	O
of	O
COPD	O
daily	O
symptoms	O
and	O
quality	O
of	O
life	O
[	O
assessed	O
by	O
St.	O
George	O
's	O
Respiratory	O
Questionnaire	O
(	O
SGRQ	O
)	O
]	O
and	O
COPD	O
severity	O
index	O
(	O
BODE-index	O
)	O
with	O
CPET	B-P
parameters	O
were	O
investigated	O
.	O

Symptom	O
-limited	O
CPET	B-P
was	O
performed	O
in	O
37	O
consecutive	O
COPD	O
(	O
GOLD	B-P
I-III	I-P
)	O
subjects	O
during	O
non-	O
exacerbation	O
phase	O
.	O

The	O
SGRQ	O
was	O
also	O
completed	O
by	O
each	O
patient	O
.	O

SGRQ-score	O
correlated	O
negatively	O
with	O
FEV1	B-P
(	O
r=-0.49	O
,	O
P	O
<	O
0.01	O
)	O
,	O
predicted	O
maximal	O
work-rate	O
(	O
%	O
WR-max	O
)	O
(	O
r=-0.44	O
,	O
P	O
<	O
0.01	O
)	O
,	O
V'O2	O
/	O
WR	O
(	O
r=-0.52	O
,	O
P	O
<	O
0.01	O
)	O
and	O
breathing	O
reserve	O
(	O
r=-0.50	O
,	O
P	O
<	O
0.01	O
)	O
.	O

However	O
it	O
did	O
not	O
correlate	O
with	O
Peak-V'O2	O
%	O
predicted	O
(	O
r=-0.27	O
,	O
P=0.10	O
)	O
.	O

In	O
20	O
(	O
54.1	O
%	O
)	O
subjects	O
in	O
which	O
leg	O
fatigue	O
was	O
the	O
main	O
cause	O
for	O
stopping	O
the	O
test	O
,	O
Peak-V'O2	O
,	O
%	O
WR-max	O
,	O
HR-Reserve	O
and	O
Breathing	O
reserve	O
were	O
higher	O
(	O
P=0.04	O
,	O
<	O
0.01	O
,	O
0.04	O
and	O
<	O
0.01	O
respectively	O
)	O
than	O
the	O
others	O
.	O

There	O
was	O
also	O
a	O
significant	O
correlation	O
between	O
BODE-index	O
and	O
âVO2	O
/	O
âWR	O
(	O
r=-0.64	O
,	O
P	O
<	O
0.001	O
)	O
and	O
breathing-reserve	O
(	O
r=-0.38	O
,	O
P=0.018	O
)	O
.	O

The	O
observed	O
relationships	O
between	O
CPET	B-P
parameter	O
and	O
daily	O
subjective	O
complaints	O
in	O
COPD	O
were	O
not	O
strong	O
.	O

Those	O
who	O
discontinued	O
the	O
CPET	B-P
because	O
of	O
leg	O
fatigue	O
were	O
in	O
the	O
earlier	O
stages	O
of	O
COPD	O
.	O

Significant	O
negative	O
correlation	O
between	O
âVO2	O
/	O
âWR	O
and	O
BODE-index	O
suggests	O
that	O
along	O
with	O
COPD	O
progression	O
,	O
regardless	O
of	O
negative	O
past	O
history	O
,	O
other	O
comorbidities	O
such	O
as	O
cardiac	O
/	O
musculoskeletal	O
problems	O
should	O
be	O
sought	O
.	O

Pembrolizumab	O
for	O
the	O
treatment	O
of	O
non-small	O
cell	O
lung	O
cancer	O
.	O

In	O
the	O
last	O
years	O
,	O
a	O
spectacular	O
development	O
of	O
immunotherapeutic	O
agents	O
aimed	O
at	O
the	O
PD-1	O
/	O
PD-L1	O
axis	O
has	O
taken	O
place	O
.	O

This	O
development	O
of	O
these	O
checkpoint	O
inhibitors	O
has	O
greatly	O
influenced	O
our	O
approach	O
to	O
the	O
treatment	O
of	O
lung	O
cancer	O
in	O
first	O
and	O
second	O
line	O
.	O

The	O
limited	O
toxicity	O
profile	O
and	O
the	O
ability	O
to	O
treat	O
for	O
prolonged	O
periods	O
,	O
even	O
in	O
smokers	O
,	O
is	O
a	O
welcome	O
expansion	O
of	O
the	O
therapeutic	O
arsenal	O
of	O
the	O
oncologist	O
.	O

Areas	O
covered	O
:	O
This	O
review	O
highlights	O
the	O
results	O
of	O
recent	O
clinical	O
trials	O
on	O
pembrolizumab	O
for	O
the	O
treatment	O
of	O
non-small	O
cell	O
lung	O
cancer	O
.	O

The	O
authors	O
discuss	O
both	O
first	O
and	O
second	O
line	O
treatment	O
with	O
pembrolizumab	O
as	O
monotherapy	O
and	O
in	O
combination	O
therapies	O
.	O

Additionally	O
,	O
implications	O
of	O
the	O
PD-L1	O
immunohistochemistry	B-P
assay	I-P
with	O
the	O
22C3	O
antibody	O
and	O
its	O
use	O
in	O
clinical	O
practice	O
and	O
trials	O
is	O
discussed	O
.	O

Expert	O
commentary	O
:	O
A	O
higher	O
overall	O
response	O
,	O
overall	O
survival	O
and	O
a	O
moderate	O
toxicity	O
profile	O
is	O
observed	O
with	O
the	O
use	O
of	O
pembrolizumab	O
,	O
compared	O
to	O
chemotherapy	O
,	O
in	O
both	O
first	O
and	O
second	O
line	O
.	O

These	O
promising	O
results	O
have	O
already	O
translated	O
into	O
the	O
registration	O
of	O
pembrolizumab	O
in	O
first	O
and	O
second	O
line	O
in	O
patients	O
with	O
a	O
high	O
expression	O
of	O
PD-L1	O
.	O

However	O
,	O
as	O
PD-L1	O
staining	B-P
does	O
not	O
sufficiently	O
discriminate	O
responders	O
from	O
non-responders	O
for	O
all	O
checkpoint	O
inhibitors	O
,	O
there	O
still	O
is	O
a	O
need	O
for	O
a	O
better	O
predictive	O
biomarker	O
.	O

Effect	O
of	O
testosterone	O
on	O
the	O
Connexin37	O
of	O
sexual	O
mature	O
mouse	O
cumulus	O
oocyte	O
complex	O
.	O

Recent	O
researches	O
demonstrate	O
that	O
pre-treatment	O
with	O
androgen	O
could	O
increase	O
retrieved	O
oocytes	O
number	O
and	O
clinical	O
pregnancy	O
rate	O
in	O
poor	O
ovarian	O
response	O
(	O
POR	O
)	O
patients	O
.	O

In	O
view	O
of	O
gap	O
junction	O
intercellular	O
communication	O
(	O
GJIC	O
)	O
is	O
important	O
for	O
follicular	O
growth	O
,	O
and	O
androgen	O
plays	O
an	O
important	O
role	O
in	O
improving	O
prognosis	O
of	O
POR	O
patients	O
,	O
we	O
speculate	O
that	O
androgen	O
can	O
increase	O
the	O
expression	O
of	O
connexin	O
in	O
follicle	O
cells	O
,	O
and	O
improve	O
ovarian	O
microenvironment	O
,	O
thus	O
can	O
promote	O
ovarian	O
response	O
.	O

The	O
objective	O
of	O
the	O
research	O
is	O
to	O
study	O
the	O
effect	O
of	O
testosterone	O
on	O
connexin37	O
(	O
Cx37	O
)	O
expression	O
so	O
as	O
to	O
provide	O
theoretical	O
basis	O
for	O
adding	O
testosterone	O
in	O
treatment	O
of	O
POR	O
.	O

Cumulus	O
-	O
oocyte-cells	O
(	O
COCs	O
)	O
were	O
collected	O
from	O
ICR	O
mice	O
ovaries	O
,	O
and	O
were	O
cultured	B-P
in	O
vitro	O
for	O
48	O
h	O
and	O
then	O
treated	O
with	O
testosterone	O
(	O
T	O
)	O
at	O
various	O
concentration	O
.	O

To	O
assess	O
whether	O
the	O
effect	O
of	O
androgen	O
on	O
Cx37	O
expression	O
is	O
mediated	O
through	O
androgen	O
receptor	O
(	O
AR	O
)	O
pathway	O
,	O
COCs	O
were	O
cultured	B-P
in	O
vitro	O
with	O
Flutamide	O
(	O
androgen	O
receptor	O
antagonist	O
)	O
.	O

The	O
expression	O
of	O
Cx37	O
was	O
determined	O
by	O
western	B-P
blot	I-P
.	O

The	O
expression	O
of	O
Cx37	O
in	O
COCs	O
which	O
were	O
treated	O
with	O
testosterone	O
was	O
higher	O
than	O
that	O
of	O
control	O
group	O
.	O

There	O
were	O
significant	O
differences	O
(	O
P	O
<	O
0.001	O
;	O
<	O
0.001	O
;	O
<	O
0.001	O
;	O
<	O
0.001	O
)	O
.	O

Cx37	O
increased	O
with	O
the	O
elevated	O
testosterone	O
concentrations	O
.	O

Cx37	O
was	O
lower	O
in	O
androgen	O
receptor	O
antagonist	O
group	O
(	O
2.57	O
Â±	O
0.12	O
)	O
than	O
the	O
corresponding	O
testosterone	O
concentrations	O
group	O
(	O
4.42	O
Â±	O
0.28	O
)	O
.	O

There	O
were	O
significant	O
differences	O
between	O
two	O
groups	O
(	O
P	O
<	O
0.001	O
)	O
.	O

There	O
was	O
close	O
relationship	O
between	O
gap	O
junction	O
protein	O
and	O
ovarian	O
response	O
,	O
which	O
suggested	O
that	O
androgen	O
could	O
promote	O
ovarian	O
response	O
by	O
increasing	O
the	O
expression	O
of	O
Cx37	O
in	O
follicle	O
.	O

Androgen	O
plays	O
an	O
important	O
role	O
in	O
ovarian	O
response	O
through	O
the	O
AR	O
pathway	O
and	O
non-AR	O
pathway	O
.	O

Water	O
pollution	O
causes	O
ultrastructural	O
and	O
functional	O
damages	O
in	O
Pellia	O
neesiana	O
(	O
Gottsche	O
)	O
Limpr	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
evaluate	O
the	O
effects	O
of	O
freshwater	O
pollution	O
in	O
the	O
heavily	O
contaminated	O
Sarno	O
River	O
(	O
Campania	O
,	O
South	O
Italy	O
)	O
,	O
using	O
Pellia	O
neesiana	O
(	O
Pelliaceae	O
Metzgeriales	O
)	O
in	O
order	O
to	O
propose	O
this	O
liverwort	O
as	O
a	O
potential	O
bioindicator	O
,	O
able	O
to	O
record	O
the	O
effects	O
of	O
water	O
pollution	O
,	O
particularly	O
the	O
one	O
related	O
to	O
metal	O
(	O
loid	O
)	O
contamination	O
.	O

Samples	O
of	O
P.	O
neesiana	O
in	O
nylon	O
bags	O
were	O
disposed	O
floating	O
for	O
one	O
week	O
on	O
the	O
waters	O
of	O
Sarno	O
River	O
in	O
three	O
sites	O
characterised	O
by	O
an	O
increasing	O
pollution	O
.	O

As	O
control	O
,	O
some	O
specimens	O
were	O
cultured	B-P
in	O
vitro	O
in	O
Cd	O
-	O
and	O
Pb	O
-added	O
media	O
,	O
at	O
the	O
same	O
pollutants	O
'	O
levels	O
as	O
measured	O
in	O
the	O
most	O
polluted	O
site	O
.	O

P.	O
neesiana	O
cell	O
ultrastructure	O
was	O
modified	O
and	O
severe	O
alterations	O
were	O
observed	O
in	O
chloroplasts	O
from	O
samples	O
exposed	O
in	O
the	O
most	O
polluted	O
site	O
,	O
and	O
Cd	O
-	O
and	O
Pb	O
-	O
cultured	B-P
samples	I-P
.	O

Concurrently	O
,	O
a	O
strong	O
increase	O
in	O
the	O
occurrence	O
of	O
Heat	O
shock	O
proteins	O
70	O
(	O
HSP70	O
)	O
was	O
detected	O
in	O
gametophytes	O
following	O
the	O
pollution	O
gradient	O
.	O

In	O
conclusion	O
,	O
ultrastructural	O
damages	O
can	O
be	O
directly	O
related	O
to	O
HSP	O
70	O
occurrence	O
in	O
liverwort	O
tissues	O
,	O
and	O
proportional	O
to	O
the	O
degree	O
of	O
pollution	O
present	O
in	O
the	O
river	O
;	O
thus	O
our	O
study	O
suggests	O
P.	O
neesiana	O
as	O
an	O
affordable	O
bioindicator	O
of	O
freshwaters	O
pollution	O
.	O

Relationship	O
between	O
Changes	O
in	O
Physical	O
Activity	O
and	O
Changes	O
in	O
Health-related	O
Quality	O
of	O
Life	O
in	O
Patients	O
on	O
Chronic	O
Hemodialysis	O
with	O
1-Year	O
Follow-up	O
.	O

In	O
a	O
longitudinal	O
study	O
,	O
we	O
examined	O
the	O
link	O
between	O
changes	O
in	O
physical	O
activity	O
and	O
changes	O
in	O
health-related	O
quality	O
of	O
life	O
(	O
HRQOL	O
)	O
in	O
patients	O
on	O
chronic	O
hemodialysis	O
.	O

Seventy-one	O
patients	O
(	O
43	O
males	O
,	O
28	O
females	O
;	O
aged	O
70.9Â±10.6	O
years	O
)	O
on	O
chronic	O
hemodialysis	O
in	O
September	O
2013	O
were	O
enrolled	O
.	O

The	O
data	O
of	O
the	O
43	O
patients	O
whose	O
complete	O
measurements	O
were	O
taken	O
again	O
in	O
September	O
2014	O
were	O
used	O
for	O
the	O
longitudinal	O
analysis	O
.	O

Clinical	O
parameters	O
including	O
age	O
,	O
height	O
,	O
dry	O
weight	O
,	O
duration	O
of	O
hemodialysis	O
,	O
blood	O
pressure	O
(	O
BP	O
)	O
,	O
blood	B-P
triglyceride	I-P
and	O
HDL	O
cholesterol	O
levels	O
,	O
physical	O
activity	O
,	O
and	O
HRQOL	O
were	O
evaluated	O
.	O

Physical	O
activity	O
was	O
measured	O
by	O
a	O
tri-accelerometer	O
,	O
and	O
HRQOL	O
was	O
evaluated	O
by	O
the	O
EuroQol	O
questionnaire	O
(	O
EQ-5D	O
)	O
.	O

In	O
the	O
first	O
cross-sectional	O
analysis	O
,	O
EQ-5D	O
scores	O
were	O
significantly	O
correlated	O
with	O
daily	O
step	O
counts	O
(	O
steps	O
per	O
day	O
)	O
on	O
all	O
days	O
and	O
non-hemodialysis	O
days	O
.	O

In	O
the	O
second	O
longitudinal	O
analysis	O
,	O
in	O
the	O
women	O
,	O
changes	O
in	O
EQ-5D	O
scores	O
were	O
positively	O
correlated	O
with	O
changes	O
in	O
daily	O
step	O
counts	O
on	O
all	O
days	O
.	O

In	O
all	O
patients	O
,	O
changes	O
in	O
EQ-5D	O
were	O
weakly	O
and	O
negatively	O
correlated	O
with	O
changes	O
in	O
physical	O
activity	O
(	O
1-3	O
METs	O
:	O
min	O
per	O
day	O
)	O
on	O
hemodialysis	O
days	O
.	O

Promoting	O
daily	O
physical	O
activity	O
may	O
improve	O
the	O
HRQOL	O
in	O
patients	O
on	O
chronic	O
hemodialysis	O
,	O
especially	O
in	O
women	O
.	O

Mimicking	O
the	O
cell	O
membrane	O
:	O
bio-inspired	O
simultaneous	O
functions	O
with	O
monovalent	O
anion	O
selectivity	O
and	O
antifouling	O
properties	O
of	O
anion	O
exchange	O
membrane	O
.	O

A	O
new	O
bio-inspired	O
method	O
was	O
applied	O
in	O
this	O
study	O
to	O
simultaneously	O
improve	O
the	O
monovalent	O
anion	O
selectivity	O
and	O
antifouling	O
properties	O
of	O
anion	O
exchange	O
membranes	O
(	O
AEMs	O
)	O
.	O

Three-layer	O
architecture	O
was	O
developed	O
by	O
deposition	O
of	O
polydopamine	O
(	O
PDA	O
)	O
and	O
electro-deposition	O
of	O
N-O-sulfonic	O
acid	O
benzyl	O
chitosan	O
(	O
NSBC	O
)	O
.	O

The	O
innermost	O
and	O
outermost	O
layers	O
were	O
PDA	O
with	O
different	O
deposition	O
time	O
.	O

The	O
middle	O
layer	O
was	O
prepared	O
by	O
NSBC	O
.	O

Fourier	O
transform	O
infrared	O
spectroscopy	O
and	O
scanning	B-P
electron	I-P
microscopy	I-P
confirmed	O
that	O
PDA	O
and	O
NSBC	O
were	O
successfully	O
modified	O
on	O
the	O
surfaces	O
of	O
AEMs	O
.	O

The	O
contact	O
angle	O
of	O
the	O
membranes	O
indicated	O
an	O
improved	O
hydrophilicity	O
of	O
the	O
modified	O
membranes	O
.	O

A	O
series	O
of	O
electrodialysis	O
experiments	O
in	O
which	O
Cl	O
(	O
-	O
)	O
/	O
SO4	O
(	O
2-	O
)	O
separation	O
was	O
studied	O
,	O
demonstrating	O
the	O
monovalent	O
anion	O
selectivity	O
of	O
the	O
samples	O
.	O

The	O
Cl	O
(	O
-	O
)	O
/	O
SO4	O
(	O
2-	O
)	O
permselectivity	O
of	O
the	O
modified	O
membranes	O
can	O
reach	O
up	O
to	O
2.20	O
,	O
higher	O
than	O
that	O
of	O
the	O
commercial	O
membrane	O
(	O
only	O
0.78	O
)	O
during	O
90	O
minutes	O
in	O
electrodialysis	O
(	O
ED	O
)	O
.	O

The	O
increase	O
value	O
of	O
the	O
resistance	O
of	O
the	O
membranes	O
was	O
also	O
measured	O
to	O
evaluate	O
the	O
antifouling	O
properties	O
.	O

Sodium	O
dodecyl	O
benzene	O
sulfonate	O
(	O
SDBS	O
)	O
was	O
used	O
as	O
the	O
fouling	O
material	O
in	O
the	O
ED	O
process	O
and	O
the	O
membrane	O
area	O
resistance	O
of	O
modified	O
membrane	O
increase	O
value	O
of	O
was	O
only	O
0.08	O
Î©cm	O
(	O
2	O
)	O
30	O
minutes	O
later	O
.	O

Endpoints	O
for	O
screening	B-P
thyroid	O
cancer	O
in	O
the	O
Republic	O
of	O
Korea	O
:	O
thyroid	O
specialists	O
'	O
perspectives	O
.	O

Cancer	B-P
screening	I-P
is	O
aimed	O
primarily	O
at	O
reducing	O
deaths	O
from	O
the	O
specific	O
cancer	O
.	O

Thyroid-specific	O
cancer	O
mortality	O
may	O
be	O
the	O
most	O
ambitious	O
endpoint	O
for	O
obtaining	O
estimates	O
of	O
screening	O
effect	O
.	O

Numerous	O
observations	B-P
have	O
accumulated	O
over	O
the	O
years	O
,	O
indicating	O
that	O
thyroid	O
cancer	O
mortality	O
endpoint	O
has	O
been	O
difficult	O
to	O
study	O
and	O
is	O
confounded	O
by	O
population	O
heterogeneity	O
,	O
provision	O
of	O
randomization	O
,	O
and	O
requirement	O
of	O
large	O
cohorts	O
with	O
sufficiently	O
long	O
follow-up	O
due	O
to	O
the	O
excellent	O
prognosis	O
of	O
the	O
cancer	O
.	O

Accordingly	O
,	O
it	O
may	O
be	O
important	O
to	O
reconsider	O
how	O
to	O
best	O
measure	O
thyroid	O
cancer	O
screening	B-P
efficacy	O
.	O

Recommendations	O
against	O
thyroid	O
cancer	O
screening	B-P
should	O
be	O
based	O
upon	O
trials	O
designed	O
to	O
evaluate	O
its	O
effectiveness	O
not	O
only	O
in	O
significant	O
reduction	O
in	O
cancer	O
mortality	O
,	O
but	O
also	O
of	O
other	O
distinct	O
endpoint	O
s.	O
It	O
is	O
desirable	O
to	O
evaluate	O
derivative	O
endpoints	O
that	O
can	O
reliably	O
predict	O
reductions	O
in	O
mortality	O
.	O

The	O
term	O
``	O
derivative	O
''	O
means	O
a	O
variable	O
that	O
is	O
related	O
to	O
the	O
true	O
endpoint	O
and	O
is	O
likely	O
to	O
be	O
observable	O
before	O
the	O
primary	O
endpoint	O
.	O

Derivative	O
endpoints	O
may	O
include	O
thyroid	O
cancer	O
incidence	O
,	O
the	O
proportion	O
of	O
early-stage	O
tumors	O
detected	O
,	O
more	O
treatable	O
stage	O
,	O
the	O
identification	O
of	O
small	O
tumors	O
(	O
to	O
maintain	O
in	O
observation	O
)	O
,	O
decrease	O
in	O
the	O
number	O
of	O
people	O
who	O
develop	O
metastatic	O
disease	O
,	O
the	O
increased	O
chance	O
of	O
lesser	O
extent	O
surgery	O
,	O
and	O
the	O
application	O
of	O
minimally	O
invasive	O
approaches	O
,	O
as	O
well	O
as	O
no	O
need	O
for	O
lifelong	O
thyroid	O
replacement	O
therapy	O
,	O
a	O
consistent	O
follow-up	O
,	O
low-dose	O
or	O
no	O
RAI	B-P
administration	I-P
and	O
risk	O
factor	O
assessments	O
where	O
case	O
findings	O
should	O
be	O
continuous	O
.	O

The	O
Korean	O
guidelines	O
for	O
thyroid	O
cancer	O
national-level	O
screening	O
were	O
published	O
by	O
a	O
relevant	O
group	O
of	O
multidisciplinary	B-P
thyroid	I-P
experts	I-P
.	O

It	O
was	O
concluded	O
that	O
the	O
evidence	O
is	O
insufficient	O
to	O
balance	O
the	O
benefits	O
and	O
harms	O
of	O
thyroid	O
cancer	O
screening	B-P
.	O

However	O
,	O
the	O
paper	O
seems	O
to	O
raise	O
the	O
necessary	O
investments	O
in	O
future	O
research	O
and	O
demand	O
a	O
complete	O
analysis	O
for	O
derivative	O
endpoints	O
,	O
and	O
offer	O
screening	O
participants	O
with	O
complete	O
information	O
necessary	O
to	O
make	O
decisions	O
that	O
will	O
provide	O
them	O
with	O
the	O
most	O
value	O
when	O
a	O
small	O
thyroid	O
cancer	O
is	O
screen-	O
identified	O
.	O

Rotary	O
and	O
High	O
-	O
Pressure	O
Nozzle	O
Spray	O
Plume	O
Droplet	O
Analysis	O
For	O
Aerially	O
Applied	O
Mosquito	O
Adulticides	O
:	O
Laser	B-P
Diffraction	I-P
Characterization	I-P
.	O

The	O
droplet	O
spectrum	O
of	O
a	O
mosquito	O
adulticide	O
spray	O
plume	O
determines	O
its	O
ability	O
to	O
drift	O
through	O
the	O
target	O
area	O
,	O
impinge	O
on	O
the	O
mosquito	O
,	O
deliver	O
a	O
toxic	O
dose	O
,	O
and	O
the	O
risk	O
of	O
environmental	O
contamination	O
.	O

This	O
paper	O
provides	O
data	O
on	O
droplet	O
spectra	O
produced	O
from	O
6	O
nozzles	O
in	O
a	O
high	O
-	O
pressure	O
nozzle	O
spray	O
system	O
and	O
5	O
rotary	O
nozzle	O
systems	O
for	O
common	O
mosquito	O
adulticides	O
.	O

Spray	O
plume	O
spectra	O
were	O
measured	O
by	O
laser	B-P
diffraction	I-P
.	O

High	O
-	O
pressure	O
nozzles	O
were	O
evaluated	O
at	O
pressure	O
s	O
ranging	O
from	O
500	O
psi	O
to	O
6,000	O
psi	O
.	O

Rotary	O
nozzles	O
were	O
evaluated	O
at	O
rotational	O
speeds	O
ranging	O
from	O
500	O
rpm	O
to	O
24,000	O
rpm	O
.	O

Measurements	O
were	O
made	O
at	O
wind	O
speeds	O
of	O
129	O
km/h	O
(	O
80	O
mph	O
)	O
to	O
225	O
km/h	O
(	O
140	O
mph	O
)	O
.	O

Adulticides	O
included	O
were	O
Fyfanon	O
(	O
Â®	O
)	O
,	O
Aqua-Reslin	O
(	O
Â®	O
)	O
,	O
Dibrom	O
(	O
Â®	O
)	O
,	O
Duet	O
(	O
Â®	O
)	O
,	O
Permanone	O
(	O
Â®	O
)	O
,	O
and	O
the	O
inert	O
mineral	O
oil	O
,	O
Orchex	O
(	O
Â®	O
)	O
796	O
.	O

High-	O
pressure	O
nozzles	O
produced	O
spray	O
plumes	O
within	O
the	O
US	O
Environmental	O
Protection	O
Agency	O
(	O
EPA	O
)	O
label	O
requirements	O
for	O
all	O
configurations	O
tested	O
except	O
for	O
one	O
at	O
a	O
wind	O
speed	O
of	O
225	O
km/h	O
,	O
BETE	O
(	O
Â®	O
)	O
MW125	O
.	O

Air	O
speed	O
had	O
no	O
significant	O
effect	O
on	O
the	O
spray	O
plume	O
volume	O
median	O
diameter	O
(	O
Dv	O
(	O
0.5	O
)	O
)	O
at	O
the	O
speeds	O
tested	O
with	O
Fyfanon	O
(	O
Â®	O
)	O
.	O

The	O
spray	O
plume	O
90	O
%	O
drop	O
volume	O
diameter	O
(	O
Dv	O
(	O
0.9	O
)	O
)	O
significantly	O
decreased	O
,	O
13	O
%	O
at	O
the	O
higher	O
wind	O
speed	O
of	O
225	O
km/h	O
.	O

Drop	O
size	O
was	O
inversely	O
related	O
to	O
pressure	O
.	O

Dilution	O
of	O
the	O
product	O
formulations	O
increased	O
the	O
Dv	O
(	O
0.5	O
)	O
of	O
the	O
spray	O
plume	O
but	O
it	O
did	O
not	O
exceed	O
the	O
label	O
requirements	O
.	O

For	O
the	O
PJ15	O
nozzle	O
,	O
orientation	O
of	O
the	O
nozzle	O
into	O
the	O
wind	O
of	O
up	O
to	O
135Â°	O
showed	O
a	O
significant	O
increase	O
in	O
Dv	O
(	O
0.5	O
)	O
at	O
500	O
psi	O
,	O
750	O
psi	O
,	O
and	O
1,500	O
psi	O
.	O

The	O
Dv	O
(	O
0.5	O
)	O
varied	O
<	O
5	O
Î¼m	O
over	O
the	O
3	O
angles	O
examined	O
for	O
any	O
specific	O
pressure	O
.	O

Rotary	O
nozzles	O
produced	O
spray	O
plumes	O
within	O
the	O
EPA	O
label	O
requirements	O
for	O
all	O
test	O
configurations	O
examined	O
.	O

Air	O
speed	O
had	O
no	O
significant	O
effect	O
on	O
Dv	O
(	O
0.5	O
)	O
or	O
Dv	O
(	O
0.9	O
)	O
of	O
the	O
plume	O
at	O
speeds	O
tested	O
with	O
Fyfanon	O
for	O
the	O
ASC	O
A20	O
nozzle	O
.	O

The	O
rotary	O
AU5000	O
nozzle	O
using	O
Orchex	O
796	O
produced	O
plumes	O
of	O
larger	O
drops	O
in	O
all	O
configurations	O
than	O
any	O
of	O
the	O
rotary	O
nozzles	O
of	O
similar	O
configurations	O
using	O
active	O
ingredient	O
formulations	O
and	O
within	O
EPA	O
label	O
requirements	O
.	O

Comparative	O
evaluation	O
of	O
iodine-131	O
metaiodobenzylguanidine	O
and	O
18-fluorodeoxyglucose	O
positron	B-P
emission	I-P
tomography	I-P
in	O
assessing	O
neural	O
crest	O
tumors	O
:	O
Will	O
they	O
play	O
a	O
complementary	O
role	O
?	O
.	O

18-Fluorodeoxyglucose	O
positron	B-P
emission	I-P
tomography	I-P
(	O
FDG-PET	B-P
)	O
has	O
established	O
a	O
role	O
in	O
the	O
evaluation	O
of	O
several	O
malignancies	O
.	O

However	O
,	O
its	O
precise	O
clinical	O
role	O
in	O
the	O
neural	O
crest	O
cell	O
tumors	O
continues	O
to	O
evolve	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
iodine-131	O
metaiodobenzylguanidine	O
(	O
(	O
131	O
)	O
I-MIBG	O
)	O
and	O
FDG-PET	B-P
of	O
head	O
to	O
head	O
in	O
patients	O
with	O
neural	O
crest	O
tumors	O
both	O
qualitatively	O
and	O
semiquantitatively	O
and	O
to	O
determine	O
their	O
clinical	O
utility	O
in	O
disease	O
status	O
evaluation	O
and	O
further	O
management	O
.	O

A	O
total	O
of	O
32	O
patients	O
who	O
had	O
undergone	O
(	O
131	O
)	O
I-MIBG	O
and	O
FDG-PET	B-P
prospectively	O
were	O
evaluated	O
and	O
clinicopathologically	O
grouped	O
into	O
three	O
categories	O
:	O
neuroblastoma	O
,	O
pheochromocytoma	O
,	O
and	O
medullary	O
carcinoma	O
thyroid	O
.	O

In	O
18	O
patients	O
of	O
neuroblastoma	O
,	O
FDG	B-P
PET	I-P
and	O
(	O
131	O
)	O
I-MIBG	O
showed	O
patient-specific	O
sensitivity	O
of	O
84	O
%	O
and	O
72	O
%	O
,	O
respectively	O
.	O

The	O
mean	O
maximum	O
standardized	O
uptake	O
value	O
(	O
SUVmax	O
)	O
of	O
primary	O
lesions	O
in	O
patients	O
with	O
unfavorable	O
histology	O
was	O
found	O
to	O
be	O
relatively	O
higher	O
than	O
those	O
with	O
favorable	O
histology	O
(	O
5.18	O
Â±	O
2.38	O
vs.	O
3.21	O
Â±	O
1.69	O
)	O
.	O

The	O
mean	O
SUVmax	O
of	O
two	O
common	O
sites	O
(	O
posterior	O
superior	O
iliac	O
spine	O
[	O
PSIS	O
]	O
and	O
greater	O
trochanter	O
)	O
was	O
higher	O
in	O
patients	O
with	O
involved	O
marrow	O
than	O
those	O
with	O
uninvolved	O
one	O
(	O
2.36	O
and	O
2.75	O
vs.	O
1.26	O
and	O
1.34	O
,	O
respectively	O
)	O
.	O

The	O
ratio	O
of	O
SUVmax	O
of	O
the	O
involved/	O
contralateral	O
normal	O
sites	O
was	O
2.16	O
Â±	O
1.9	O
.	O

In	O
equivocal	O
bone	O
marrow	O
results	O
,	O
the	O
uptake	O
pattern	O
with	O
SUV	O
estimation	O
can	O
depict	O
metastatic	O
involvement	O
and	O
help	O
in	O
redirecting	O
the	O
biopsy	O
site	O
.	O

Among	O
seven	O
patients	O
of	O
pheochromocytoma	O
,	O
FDG-PET	B-P
revealed	O
100	O
%	O
patient-specific	O
sensitivity	O
.	O

FDG-PET	B-P
detected	O
more	O
metastatic	O
foci	O
than	O
(	O
131	O
)	O
I-MIBG	O
(	O
18	O
vs.	O
13	O
sites	O
)	O
.	O

In	O
seven	O
patients	O
of	O
medullary	O
carcinoma	O
thyroid	O
,	O
FDG-PET	B-P
localized	O
residual	O
,	O
recurrent	O
,	O
or	O
metastatic	O
disease	O
with	O
much	O
higher	O
sensitivity	O
(	O
32	O
metastatic	O
foci	O
with	O
72	O
%	O
patient	O
specific	O
sensitivity	O
)	O
than	O
(	O
131	O
)	O
I-MIBG	O
,	O
trending	O
along	O
the	O
higher	B-P
serum	I-P
calcitonin	I-P
levels	I-P
.	O

FDG-PET	B-P
is	O
not	O
only	O
a	O
good	O
complementary	O
modality	O
in	O
the	O
management	O
of	O
neural	O
crest	O
cell	O
tumors	O
but	O
also	O
it	O
can	O
even	O
be	O
superior	O
,	O
especially	O
in	O
cases	O
of	O
(	O
131	O
)	O
I-MIBG	O
nonavid	O
tumors	O
.	O

Maternal	O
depression	O
attenuates	O
newborn	O
vitamin	O
D	O
concentrations	O
in	O
winter	O
-	O
spring	O
:	O
a	O
prospective	O
population-based	O
study	O
.	O

We	O
aimed	O
to	O
investigate	O
whether	O
the	O
newborns	O
of	O
mothers	O
with	O
maternal	O
depression	O
(	O
MD	O
)	O
had	O
lower	O
vitamin	B-P
D	I-P
levels	I-P
than	O
newborns	O
of	O
non-MD	O
(	O
NMD	O
)	O
mothers	O
and	O
identify	O
the	O
potential	O
mechanism	O
underlying	O
this	O
association	O
.	O

Maternal	O
depressive	O
symptoms	O
in	O
late	O
pregnancy	O
and	O
concentrations	O
of	O
cord	O
blood	O
25	O
hydroxyvitamin	O
D	O
(	O
25	O
(	O
OH	O
)	O
D	O
)	O
were	O
measured	O
in	O
1491	O
mother	O
-	O
infant	O
pairs	O
.	O

Data	O
on	O
maternal	O
sociodemographic	O
characteristics	O
,	O
health	O
status	O
,	O
lifestyle	O
and	O
birth	O
outcomes	O
were	O
prospectively	O
collected	O
.	O

For	O
infants	O
born	O
in	O
winter	O
-	O
spring	O
,	O
the	O
infants	O
of	O
MD	O
mothers	O
had	O
significantly	O
reduced	O
concentrations	O
of	O
25	O
(	O
OH	O
)	O
D	O
(	O
adjusted	O
Î²	O
=	O
-3.51	O
nmol/L	O
;	O
95	O
%	O
CI	O
:	O
-6.19	O
,	O
-0.84	O
;	O
P	O
=	O
0.010	O
)	O
and	O
lower	O
birth	O
weight	O
(	O
3267	O
Â±	O
470	O
g	O
vs	O
3348	O
Â±	O
598	O
g	O
,	O
F	O
=	O
4.64	O
,	O
P	O
=	O
0.031	O
)	O
,	O
compared	O
with	O
the	O
infants	O
of	O
NMD	O
mothers	O
.	O

A	O
significant	O
,	O
inverse	O
linear	O
relationship	O
was	O
noted	O
between	O
maternal	O
depression	O
scores	O
and	O
the	O
concentration	O
of	O
25	O
(	O
OH	O
)	O
D	O
for	O
infants	O
born	O
in	O
winter	O
-	O
spring	O
(	O
adjusted	O
Î²	O
=	O
-0.158	O
;	O
95	O
%	O
CI	O
:	O
-0.259	O
,	O
-0.057	O
)	O
.	O

The	O
significant	O
,	O
inverse	O
linear	O
relationship	O
between	O
maternal	O
depression	O
scores	O
and	O
fetomaternal	O
ratios	O
of	O
25	O
(	O
OH	O
)	O
D	O
was	O
also	O
observed	O
among	O
the	O
infants	O
born	O
in	O
winter	O
-	O
spring	O
(	O
adjusted	O
Î²	O
=	O
-0.005	O
;	O
95	O
%	O
CI	O
:	O
-0.008	O
,	O
-0.003	O
)	O
.	O

MD	O
appears	O
to	O
significantly	O
attenuate	O
the	O
vitamin	O
D	O
concentrations	O
and	O
birth	O
weight	O
of	O
infants	O
born	O
in	O
winter	O
-	O
spring	O
.	O

A	O
decreased	O
fetomaternal	O
ratio	O
of	O
25	O
(	O
OH	O
)	O
D	O
might	O
be	O
involved	O
in	O
this	O
biological	O
pathway	O
.	O

Comparison	O
of	O
Occlusive	O
and	O
Open	O
Application	O
in	O
a	O
Psoriasis	O
Plaque	O
Test	O
Design	O
,	O
Exemplarily	O
Using	O
Investigations	O
of	O
Mapracorat	O
0.1	O
%	O
Ointment	O
versus	O
Vehicle	O
and	O
Reference	O
Drugs	O
.	O

Psoriasis	O
plaque	O
tests	O
(	O
PPTs	O
)	O
are	O
important	O
tools	O
in	O
the	O
early	O
phases	O
of	O
antipsoriatic	O
drug	O
development	O
.	O

Two	O
distinct	O
PPT	O
design	O
variants	O
(	O
open	O
vs.	O
occluded	O
drug	O
application	O
)	O
are	O
commonly	O
used	O
,	O
but	O
no	O
previous	O
work	O
has	O
aimed	O
to	O
directly	O
compare	O
and	O
contrast	O
their	O
performance	O
.	O

We	O
compared	O
the	O
antipsoriatic	O
efficacy	O
of	O
mapracorat	O
0.1	O
%	O
ointment	O
and	O
reference	O
drugs	O
reported	O
in	O
2	O
separate	O
studies	O
,	O
representing	O
open	O
and	O
occluded	O
PPT	O
designs	O
.	O

The	O
drug	O
effect	O
size	O
was	O
measured	O
by	O
sonography	B-P
(	O
mean	O
change	O
in	O
echo-poor	O
band	O
thickness	O
)	O
,	O
chromametry	B-P
,	O
and	O
standardized	O
clinical	O
assessment	O
.	O

Antipsoriatic	O
effects	O
were	O
detectable	O
for	O
the	O
study	O
drugs	O
in	O
both	O
occluded	O
and	O
open	O
PPTs	O
.	O

Differences	O
between	O
the	O
potency	O
of	O
antipsoriatic	O
drugs	O
and	O
vehicle	O
were	O
observable	O
.	O

The	O
total	O
antipsoriatic	O
effect	O
size	O
appeared	O
to	O
be	O
higher	O
in	O
the	O
occluded	O
PPT	O
than	O
the	O
open	O
PPT	O
,	O
despite	O
the	O
shorter	O
treatment	O
duration	O
(	O
2	O
vs.	O
4	O
weeks	O
)	O
.	O

Effect	O
dynamics	O
over	O
time	O
revealed	O
greater	O
differences	O
between	O
some	O
study	O
drugs	O
in	O
the	O
open	O
PPT	O
compared	O
to	O
the	O
occluded	O
PPT	O
.	O

Taking	O
the	O
higher	O
technical	O
challenges	O
for	O
the	O
open	O
PPT	O
into	O
account	O
,	O
we	O
recommend	O
the	O
occluded	O
PPT	O
as	O
a	O
standard	O
screening	O
setting	O
in	O
early	O
drug	O
development	O
.	O

In	O
special	O
cases	O
,	O
considering	O
certain	O
drug	O
aspects	O
or	O
study	O
objectives	O
that	O
would	O
require	O
procedural	O
adaptations	O
,	O
an	O
open	O
PPT	O
could	O
be	O
the	O
better-suited	O
design	O
.	O

Finally	O
,	O
both	O
PPT	O
models	O
show	O
clear	O
advantages	O
:	O
classification	O
as	O
phase	O
I	O
studies	O
,	O
small	O
number	O
of	O
psoriatic	O
subjects	O
,	O
relatively	O
short	O
study	O
duration	O
,	O
excellent	O
discrimination	O
between	O
compounds	O
and	O
concentrations	O
,	O
parallel	O
measurement	O
of	O
treatment	O
response	O
,	O
and	O
go/no	O
go	O
decisions	O
very	O
early	O
in	O
clinical	O
development	O
.	O

Identifying	O
the	O
presence	O
of	O
Parkinson	O
's	O
disease	O
using	O
low-frequency	O
fluctuations	O
in	O
BOLD	B-P
signals	I-P
.	O

Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
is	O
a	O
chronic	O
,	O
progressive	O
,	O
and	O
degenerative	O
neurological	O
disorder	O
that	O
is	O
characterized	O
by	O
the	O
degeneration	O
of	O
dopamine	O
neurons	O
in	O
the	O
substantia	O
nigra	O
and	O
the	O
formation	O
of	O
intracellular	O
Lewy	O
inclusion	O
bodies	O
.	O

Resting-state	B-P
functional	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
RS-fMRI	B-P
)	O
has	O
demonstrated	O
evidence	O
of	O
changes	O
in	O
metabolic	O
patterns	O
in	O
individuals	O
with	O
PD	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
presence	O
of	O
PD	O
could	O
be	O
``	O
predicted	O
``	O
based	O
on	O
resting	O
fluctuations	O
in	O
the	O
blood	O
oxygenation	O
level	O
dependent	O
signal	O
.	O

We	O
utilized	O
RS-fMRI	B-P
to	O
measure	O
the	O
amplitude	O
of	O
low-frequency	O
fluctuation	O
(	O
ALFF	O
)	O
and	O
the	O
fractional	O
ALFF	O
(	O
fALFF	O
)	O
in	O
51	O
patients	O
with	O
PD	O
and	O
50	O
age	O
-	O
and	O
sex	O
-matched	O
healthy	O
controls	O
.	O

Compared	O
with	O
the	O
healthy	O
controls	O
,	O
the	O
individuals	O
with	O
PD	O
exhibited	O
altered	O
ALFFs	O
in	O
the	O
bilateral	O
lingual	O
gyrus	O
and	O
left	O
putamen	O
and	O
an	O
altered	O
fALFF	O
in	O
the	O
right	O
cerebellum	O
posterior	O
lobe	O
.	O

Support	O
vector	O
machines	O
(	O
SVMs	O
)	O
,	O
which	O
comprise	O
a	O
supervised	O
pattern	O
recognition	O
method	O
that	O
enables	O
predictions	O
at	O
the	O
individual	O
level	O
,	O
were	O
trained	O
to	O
separate	O
individuals	O
with	O
PD	O
from	O
healthy	O
controls	O
based	O
on	O
the	O
ALFF	O
and	O
fALFF	O
.	O

Using	O
the	O
leave-one-out	O
cross-validation	O
method	O
to	O
analyze	O
our	O
sample	O
,	O
we	O
reliably	O
distinguished	O
the	O
participants	O
with	O
PD	O
from	O
the	O
controls	O
with	O
92	O
%	O
sensitivity	O
and	O
87	O
%	O
specificity	O
.	O

Overall	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
SVM	O
-	O
neuroimaging	B-P
approach	O
may	O
be	O
of	O
particular	O
clinical	O
value	O
because	O
it	O
enables	O
the	O
accurate	O
identification	O
of	O
PD	O
at	O
the	O
individual	O
level	O
.	O

RS-fMRI	B-P
should	O
be	O
considered	O
for	O
development	O
as	O
a	O
biomarker	O
and	O
an	O
analytical	O
tool	O
for	O
the	O
evaluation	O
of	O
PD	O
.	O

A	O
comparison	O
of	O
the	O
localization	O
of	O
rectal	O
carcinomas	O
according	O
to	O
the	O
general	O
rules	O
of	O
the	O
Japanese	O
classification	O
of	O
colorectal	O
carcinoma	O
(	O
JCCRC	O
)	O
and	O
Western	O
guidelines	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
localization	O
of	O
rectal	O
cancers	O
as	O
classified	O
according	O
to	O
the	O
general	O
rules	O
of	O
the	O
Japanese	O
classification	O
of	O
colorectal	O
carcinoma	O
(	O
JCCRC	O
)	O
and	O
also	O
according	O
to	O
the	O
European	O
Society	O
for	O
Medical	O
Oncology	O
(	O
ESMO	O
)	O
and	O
the	O
National	O
Comprehensive	O
Cancer	O
Network	O
(	O
NCCN	O
)	O
guidelines	O
,	O
which	O
are	O
based	O
on	O
rigid	B-P
endoscopic	I-P
measurements	O
.	O

The	O
medical	O
records	O
of	O
patients	O
scheduled	O
to	O
receive	O
curative	O
surgery	O
for	O
histologically	O
proven	O
rectal	O
adenocarcinoma	O
during	O
2009-2015	O
were	O
investigated	O
(	O
n	O
=	O
230	O
)	O
.	O

Rigid	B-P
proctoscopy	I-P
was	O
performed	O
in	O
patients	O
with	O
rectal	O
cancer	O
located	O
in	O
the	O
upper	O
(	O
Ra	O
)	O
or	O
lower	O
(	O
Rb	O
)	O
division	O
using	O
double-contrast	B-P
barium	I-P
enema	I-P
.	O

The	O
median	O
values	O
of	O
height	O
from	O
the	O
anal	O
verge	O
were	O
7.5	O
cm	O
(	O
range	O
2-12	O
)	O
and	O
3	O
cm	O
(	O
0-9.5	O
)	O
on	O
rigid	B-P
proctoscopy	I-P
for	O
cancers	O
assigned	O
as	O
Ra	O
and	O
Rb	O
,	O
respectively	O
.	O

All	O
159	O
cancers	O
at	O
Ra	O
or	O
Rb	O
were	O
located	O
within	O
12	O
cm	O
from	O
the	O
anal	O
verge	O
by	O
rigid	B-P
proctoscopy	I-P
,	O
while	O
only	O
79.7	O
%	O
of	O
Ra	O
or	O
82.1	O
%	O
of	O
Rb	O
cancers	O
were	O
located	O
in	O
the	O
mid	O
(	O
5.1-10	O
cm	O
)	O
or	O
low	O
(	O
â¤5	O
cm	O
)	O
rectum	O
,	O
respectively	O
.	O

Ra	O
and	O
Rb	O
cancers	O
are	O
deemed	O
to	O
be	O
rectal	O
cancers	O
according	O
to	O
NCCN	O
guidelines	O
,	O
but	O
these	O
classifications	O
are	O
not	O
interchangeable	O
with	O
mid-	O
and	O
low	O
-	O
rectal	O
cancers	O
,	O
respectively	O
,	O
according	O
to	O
the	O
ESMO	O
guidelines	O
.	O

Open-label	O
,	O
multicentre	O
safety	O
study	O
of	O
vemurafenib	O
in	O
3219	O
patients	O
with	O
BRAF	O
(	O
V600	O
)	O
mutation	O
-	O
positive	O
metastatic	O
melanoma	O
:	O
2-year	O
follow-up	O
data	O
and	O
long-term	O
responders	O
'	O
analysis	O
.	O

The	O
orally	O
available	O
BRAF	O
kinase	O
inhibitor	O
vemurafenib	O
is	O
an	O
effective	O
and	O
tolerable	O
treatment	O
option	O
for	O
patients	O
with	O
metastatic	O
melanoma	O
harbouring	O
BRAF	O
(	O
V600	O
)	O
mutations	O
.	O

We	O
assessed	O
the	O
safety	O
of	O
vemurafenib	O
in	O
a	O
large	O
population	O
of	O
patients	O
with	O
few	O
alternative	O
treatment	O
options	O
;	O
we	O
report	O
updated	O
2-year	O
safety	O
.	O

This	O
was	O
an	O
open-label	O
,	O
multicentre	O
study	O
of	O
vemurafenib	O
(	O
960	O
mg	O
bid	O
)	O
in	O
patients	O
with	O
previously	O
treated	O
or	O
untreated	O
BRAF	O
mutation	O
-	O
positive	O
metastatic	O
melanoma	O
(	O
cobas	O
(	O
Â®	O
)	O
4800	O
BRAF	B-P
V600	I-P
Mutation	I-P
Test	I-P
)	O
.	O

The	O
primary	O
end-point	O
was	O
safety	O
;	O
efficacy	O
end-points	O
were	O
secondary	O
.	O

An	O
exploratory	O
analysis	O
was	O
performed	O
to	O
assess	O
safety	O
outcomes	O
in	O
patients	O
with	O
long	O
duration	O
of	O
response	O
(	O
DOR	O
)	O
(	O
â¥12	O
or	O
â¥24	O
months	O
)	O
.	O

After	O
a	O
median	O
follow-up	O
of	O
32.2	O
months	O
(	O
95	O
%	O
CI	O
,	O
31.1-33.2	O
months	O
)	O
,	O
3079/3219	O
patients	O
(	O
96	O
%	O
)	O
had	O
discontinued	O
treatment	O
.	O

Adverse	O
events	O
(	O
AEs	O
)	O
were	O
largely	O
consistent	O
with	O
previous	O
reports	O
;	O
the	O
most	O
common	O
all-grade	O
treatment	O
-related	O
AEs	O
were	O
arthralgia	O
(	O
37	O
%	O
)	O
,	O
alopecia	O
(	O
25	O
%	O
)	O
and	O
hyperkeratosis	O
(	O
23	O
%	O
)	O
;	O
the	O
most	O
common	O
grade	O
3/4	O
treatment	O
-related	O
AEs	O
were	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
skin	O
(	O
8	O
%	O
)	O
and	O
keratoacanthoma	O
(	O
8	O
%	O
)	O
.	O

In	O
the	O
exploratory	O
analysis	O
,	O
patients	O
with	O
DOR	O
â¥12	O
months	O
(	O
n	O
=	O
287	O
)	O
or	O
â¥24	O
months	O
(	O
n	O
=	O
133	O
)	O
were	O
more	O
likely	O
to	O
experience	O
grade	O
3/4	O
AEs	O
than	O
the	O
overall	O
population	O
.	O

No	O
new	O
specific	O
safety	O
signals	O
were	O
observed	O
with	O
longer	O
vemurafenib	O
exposure	O
.	O

After	O
2	O
years	O
'	O
follow-up	O
,	O
safety	O
was	O
maintained	O
in	O
this	O
large	O
group	O
of	O
patients	O
with	O
BRAF	O
(	O
V600	O
)	O
mutation	O
-	O
positive	O
metastatic	O
melanoma	O
who	O
are	O
more	O
representative	O
of	O
routine	O
clinical	O
practice	O
than	O
typical	O
clinical	O
trial	O
populations	O
.	O

These	O
data	O
suggest	O
that	O
long-term	O
vemurafenib	O
treatment	O
is	O
effective	O
and	O
tolerable	O
without	O
the	O
development	O
of	O
new	O
safety	O
signals	O
.	O

Intracellular	O
Metabolism	O
of	O
Î±	O
,	O
Î²-Unsaturated	O
Carbonyl	O
Compounds	O
,	O
Acrolein	O
,	O
Crotonaldehyde	O
and	O
Methyl	O
Vinyl	O
Ketone	O
,	O
Active	O
Toxicants	O
in	O
Cigarette	O
Smoke	O
:	O
Participation	O
of	O
Glutathione	O
Conjugation	O
Ability	O
and	O
Aldehyde-Ketone	O
Sensitive	O
Reductase	O
Activity	O
.	O

The	O
major	O
toxicants	O
in	O
cigarette	O
smoke	O
,	O
Î±	O
,	O
Î²-unsaturated	O
aldehydes	O
,	O
such	O
as	O
acrolein	O
(	O
ACR	O
)	O
and	O
crotonaldehyde	O
(	O
CA	O
)	O
,	O
and	O
Î±	O
,	O
Î²-unsaturated	O
ketone	O
,	O
methyl	O
vinyl	O
ketone	O
(	O
MVK	O
)	O
,	O
are	O
known	O
to	O
form	O
Michael-type	O
adducts	O
with	O
glutathione	O
(	O
GSH	O
)	O
and	O
consequently	O
cause	O
intracellular	O
GSH	O
depletion	O
,	O
which	O
is	O
involved	O
in	O
cigarette	O
smoke	O
-	O
induced	O
cytotoxicity	O
.	O

We	O
have	O
previously	O
clarified	O
that	O
exposure	O
to	O
cigarette	O
smoke	O
extract	O
(	O
CSE	O
)	O
of	O
a	O
mouse	O
melanoma	O
cell	O
culture	O
medium	O
causes	O
rapid	O
reduction	O
of	O
intracellular	O
GSH	O
levels	O
,	O
and	O
that	O
the	O
GSH	O
-	O
MVK	O
adduct	O
can	O
be	O
detected	O
by	O
LC/MS	B-P
analysis	I-P
while	O
the	O
GSH	O
-	O
CA	O
adduct	O
is	O
hardly	O
detected	O
.	O

In	O
the	O
present	O
study	O
,	O
to	O
clarify	O
why	O
the	O
GSH	O
-	O
CA	O
adduct	O
is	O
difficult	O
to	O
detect	O
in	O
the	O
cell	O
medium	O
,	O
we	O
conducted	O
detailed	O
investigation	O
of	O
the	O
structures	O
of	O
the	O
reaction	O
products	O
of	O
ACR	O
,	O
CA	O
,	O
MVK	O
and	O
CSE	O
in	O
the	O
GSH	O
solution	O
or	O
the	O
cell	O
culture	O
medium	O
.	O

The	O
mass	B-P
spectra	I-P
indicated	O
that	O
in	O
the	O
presence	O
of	O
the	O
cells	O
,	O
the	O
GSH	O
-	O
CA	O
and	O
GSH	O
-	O
ACR	O
adducts	O
were	O
almost	O
not	O
detected	O
while	O
their	O
corresponding	O
alcohols	O
were	O
detected	O
.	O

On	O
the	O
other	O
hand	O
,	O
both	O
the	O
GSH	O
-	O
MVK	O
adducts	O
and	O
their	O
reduced	O
products	O
were	O
detected	O
.	O

In	O
the	O
absence	O
of	O
the	O
cells	O
,	O
the	O
reaction	O
of	O
GSH	O
with	O
all	O
Î±	O
,	O
Î²-unsaturated	O
carbonyls	O
produced	O
only	O
their	O
corresponding	O
adducts	O
.	O

These	O
results	O
show	O
that	O
the	O
GSH	O
adducts	O
of	O
Î±	O
,	O
Î²-unsaturated	O
aldehydes	O
,	O
CA	O
and	O
ACR	O
,	O
are	O
quickly	O
reduced	O
by	O
certain	O
intracellular	O
carbonyl	O
reductase	O
(	O
s	O
)	O
and	O
excreted	O
from	O
the	O
cells	O
,	O
unlike	O
the	O
GSH	O
adduct	O
of	O
Î±	O
,	O
Î²-unsaturated	O
ketone	O
,	O
MVK	O
.	O

Such	O
a	O
difference	O
in	O
reactivity	O
to	O
the	O
carbonyl	O
reductase	O
might	O
be	O
related	O
to	O
differences	O
in	O
the	O
cytotoxicity	O
of	O
Î±	O
,	O
Î²-unsaturated	O
aldehydes	O
and	O
ketones	O
.	O

Pregnancy	O
at	O
high	O
altitude	O
in	O
the	O
Andes	O
leads	O
to	O
increased	O
total	O
vessel	O
density	O
in	O
healthy	O
newborns	O
.	O

The	O
developing	O
human	O
fetus	O
is	O
able	O
to	O
cope	O
with	O
the	O
physiological	O
reduction	O
in	O
oxygen	O
supply	O
occurring	O
in	O
utero	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
if	O
microvascularization	O
of	O
the	O
fetus	O
is	O
augmented	O
when	O
pregnancy	O
occurs	O
at	O
high	O
altitude	O
.	O

Fifty-three	O
healthy	O
term	O
newborns	O
in	O
Puno	O
,	O
Peru	O
(	O
3,840	O
m	O
)	O
were	O
compared	O
with	O
sea	O
-	O
level	O
controls	O
.	O

Pre-	O
and	O
postductal	O
arterial	O
oxygen	O
saturation	O
(	O
SpO2	O
)	O
was	O
determined	O
.	O

Cerebral	O
and	O
calf	O
muscle	O
regional	O
tissue	O
oxygenation	O
was	O
measured	O
using	O
near	B-P
infrared	I-P
spectroscopy	I-P
(	O
NIRS	B-P
)	O
.	O

Skin	O
microcirculation	O
was	O
noninvasively	B-P
measured	O
using	O
incident	B-P
dark	I-P
field	I-P
imaging	I-P
.	O

Pre-	O
and	O
postductal	O
SpO2	O
in	O
Peruvian	O
babies	O
was	O
88.1	O
and	O
88.4	O
%	O
,	O
respectively	O
,	O
which	O
was	O
10.4	O
and	O
9.7	O
%	O
lower	O
than	O
in	O
newborns	O
at	O
sea	O
level	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Cerebral	O
and	O
regional	O
oxygen	O
saturation	O
was	O
significantly	O
lower	O
in	O
the	O
Peruvian	O
newborns	O
(	O
cerebral	O
:	O
71.0	O
vs.	O
74.9	O
%	O
;	O
regional	O
:	O
68.5	O
vs.	O
76.0	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Transcutaneously	O
measured	O
total	O
vessel	O
density	O
in	O
the	O
Peruvian	O
newborns	O
was	O
14	O
%	O
higher	O
than	O
that	O
in	O
the	O
newborns	O
born	O
at	O
sea	O
level	O
(	O
29.7	O
vs.	O
26.0	O
mm/mm	O
(	O
2	O
)	O
;	O
P	O
â¤	O
0.001	O
)	O
.	O

This	O
study	O
demonstrates	O
that	O
microvascular	O
vessel	O
density	O
in	O
neonates	O
born	O
to	O
mothers	O
living	O
at	O
high	O
altitude	O
is	O
higher	O
than	O
that	O
in	O
neonates	O
born	O
at	O
sea	O
level	O
.	O

Construction	O
of	O
recombinant	O
adenovirus	O
Ad-rat	O
PLCÎ³2	O
and	O
its	O
effects	O
on	O
apoptosis	O
of	O
rat	O
liver	O
cell	O
BRL-3A	O
in	O
vitro	O
.	O

Although	O
the	O
role	O
of	O
PLCÎ³2	O
in	O
apoptotic	O
response	O
has	O
been	O
reported	O
,	O
too	O
little	O
is	O
known	O
about	O
whether	O
PLCÎ³2	O
induces	O
liver	O
cell	O
apoptosis	O
during	O
liver	O
regeneration	O
.	O

Therefore	O
,	O
this	O
study	O
firstly	O
packaged	O
Ad-PLCÎ³2	O
recombinant	O
adenovirus	O
and	O
primarily	O
evaluated	O
its	O
effect	O
on	O
apoptosis	O
of	O
rat	O
liver	O
cell	O
BRL-3A	O
in	O
vitro	O
.	O

Following	O
ten	O
days	O
of	O
co-transfection	O
of	O
pHBAd-MCMV-GFP-PLCÎ³2	O
and	O
pHBAd-BHG	O
into	O
HEK293	O
cells	O
,	O
viral	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
was	O
apparent	O
.	O

Following	O
three	O
rounds	O
of	O
amplification	O
,	O
tissue	O
culture	O
infectious	O
dose	O
50	O
(	O
TCID50	O
)	O
assay	B-P
showed	O
that	O
the	O
titer	O
value	O
reached	O
1Ã1010	O
PFU/mL	O
.	O

After	O
24	O
h	O
of	O
transfection	O
of	O
recombinant	O
adenovirus	O
into	O
BRL-3A	O
cells	O
,	O
transfection	O
efficiency	O
of	O
adenovirus	O
into	O
BRL-3A	O
cells	O
was	O
above	O
90	O
%	O
when	O
obsereved	O
under	O
fluorescent	B-P
microscopy	I-P
.	O

qRT-PCR	O
and	O
Western	O
blot	O
assays	O
showed	O
mRNA	O
and	O
protein	O
levels	O
of	O
PLCÎ³2	O
were	O
significantly	O
elevated	O
in	O
the	O
transfected	O
BRL-3A	O
cells	O
.	O

Flow	B-P
cytometric	I-P
analysis	I-P
showed	O
that	O
,	O
compared	O
with	O
the	O
control	O
and	O
Ad-GFP	O
groups	O
,	O
cell	O
apoptosis	O
rate	O
of	O
Ad-PLCÎ³2	O
group	O
were	O
significantly	O
increased	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
the	O
cell	O
cycle	O
in	O
Ad-PLCÎ³2	O
group	O
was	O
arrested	O
at	O
G1	O
phase	O
which	O
was	O
manifested	O
by	O
a	O
marked	O
increase	O
(	O
P	O
<	O
0.01	O
)	O
in	O
the	O
percentage	O
of	O
G1	O
phase	O
cells	O
and	O
a	O
great	O
decrease	O
(	O
P	O
<	O
0.01	O
)	O
in	O
the	O
percentage	O
of	O
S	O
and	O
G2	O
/	O
M	O
phase	O
cells	O
.	O

It	O
was	O
concluded	O
from	O
above	O
results	O
that	O
recombinant	O
adenovirus	O
Ad-PLCÎ³2	O
was	O
packaged	O
successfully	O
,	O
and	O
could	O
promote	O
cell	O
apoptosis	O
by	O
arresting	O
the	O
transition	O
from	O
G1	O
to	O
S	O
phase	O
of	O
BRL-3A	O
cells	O
.	O

The	O
opioid	O
antagonist	O
,	O
Î²-funaltrexamine	O
,	O
inhibits	O
lipopolysaccharide	O
-induced	O
neuroinflammation	O
and	O
reduces	O
sickness	O
behavior	O
in	O
mice	O
.	O

Brain	O
pathologies	O
such	O
as	O
neurodegenerative	O
diseases	O
,	O
infection	O
,	O
traumatic	O
brain	O
injury	O
,	O
and	O
mood	O
disorders	O
produce	O
enormous	O
personal	O
and	O
economic	O
burdens	O
.	O

It	O
is	O
well	O
established	O
that	O
neuroinflammation	O
plays	O
an	O
important	O
role	O
in	O
the	O
etiology	O
and/or	O
manifestation	O
of	O
such	O
disorders	O
.	O

Previously	O
,	O
we	O
discovered	O
that	O
beta-funaltrexamine	O
(	O
Î²-FNA	O
)	O
inhibits	O
inflammatory	O
signaling	O
in	O
human	O
astrocytes	O
in	O
vitro	O
,	O
resulting	O
in	O
reduced	O
expression	O
of	O
proinflammatory	O
cytokines	O
/	O
chemokines	O
.	O

The	O
present	O
study	O
examines	O
the	O
effects	O
of	O
peripherally	O
administered	O
Î²-FNA	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
neuroinflammation	O
and	O
sickness	O
behavior	O
in	O
vivo	O
.	O

Adult	O
male	O
C57BL/6J	O
mice	O
were	O
administered	O
Î²-FNA	O
and	O
were	O
then	O
immediately	O
administered	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

At	O
24h	O
post-injections	O
,	O
sickness	O
behavior	O
was	O
assessed	O
in	O
an	O
open-field	O
test	O
.	O

Following	O
behavioral	O
analysis	O
plasma	O
and	O
brains	O
were	O
collected	O
.	O

Levels	O
of	O
interleukin-6	O
(	O
IL-6	O
)	O
,	O
interferon-Î³	O
inducible	O
protein-10	O
(	O
CXCL10	O
)	O
,	O
and	O
monocyte	O
chemoattractant	O
protein-1	O
(	O
CCL2	O
)	O
were	O
determined	O
by	O
enzyme-linked	B-P
immunosorbant	I-P
assay	I-P
(	O
ELISA	B-P
)	O
.	O

At	O
24h	O
post-	O
LPS	O
injection	O
,	O
IL-6	O
,	O
CCL2	O
and	O
CXCL10	O
were	O
increased	O
in	O
the	O
plasma	O
,	O
whereas	O
,	O
only	O
CCL2	O
and	O
CXCL10	O
were	O
elevated	O
in	O
the	O
brain	O
.	O

Î²-FNA	O
significantly	O
inhibited	O
LPS	O
-induced	O
CXCL10	O
and	O
CCL2	O
expression	O
in	O
brain	O
,	O
but	O
minimally	O
or	O
not	O
at	O
all	O
in	O
the	O
plasma	O
.	O

LPS	O
-induced	O
sickness	O
behavior	O
,	O
as	O
indicated	O
by	O
a	O
reduction	O
in	O
distance	O
moved	O
,	O
was	O
prevented	O
by	O
Î²-FNA	O
.	O

Overall	O
,	O
CXCL10	O
expression	O
in	O
the	O
brain	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
sickness	O
behavior	O
;	O
whereas	O
,	O
anxiety	O
-like	O
behavior	O
was	O
most	O
positively	O
and	O
significantly	O
correlated	O
with	O
IL-6	O
and	O
CCL2	O
levels	O
in	O
the	O
plasma	O
and	O
levels	O
of	O
CXCL10	O
and	O
CCL2	O
in	O
the	O
brain	O
.	O

The	O
reduction	O
in	O
sickness	O
behavior	O
may	O
be	O
in	O
part	O
due	O
to	O
decreased	O
chemokine	O
expression	O
in	O
the	O
brain	O
;	O
further	O
examination	O
of	O
the	O
anti-inflammatory	O
and	O
neuroprotective	O
effects	O
of	O
Î²-FNA	O
is	O
warranted	O
.	O

Calcium	O
silicate	O
nanowires	O
-	O
An	O
effective	O
alternative	O
for	O
improving	O
mechanical	O
properties	O
of	O
chitosan	O
-	O
hydroxyethyl	O
methacrylate	O
(	O
HEMA	O
)	O
copolymer	O
nanocomposites	O
.	O

Nanowires	O
of	O
calcium	O
silicate	O
were	O
successfully	O
synthesized	O
by	O
ultrasonic	O
irradiation	O
process	O
and	O
incorporated	O
into	O
chitosan	O
and	O
hydroxyetheyl	O
methacrylate	O
(	O
HEMA	O
)	O
copolymer	O
matrix	O
by	O
solution	O
blending	O
for	O
efficacious	O
preparation	O
of	O
biodegradable	O
nanocomposites	O
.	O

Remarkable	O
improvement	O
in	O
mechanical	O
properties	O
of	O
the	O
nanocomposites	O
was	O
noticed	O
after	O
micro-tensile	B-P
analysis	I-P
.	O

Enlarged	O
surface	O
area	O
and	O
higher	O
aspect	O
ratio	O
of	O
CaSiO3	O
nanowires	O
were	O
the	O
key	O
factors	O
responsible	O
for	O
such	O
improvement	O
.	O

This	O
was	O
supported	O
by	O
EDS	B-P
and	O
XRD	B-P
analysis	I-P
in	O
terms	O
of	O
proper	O
distribution	O
of	O
nanofiller	O
through	O
the	O
copolymer	O
matrix	O
and	O
corresponding	O
rise	O
in	O
percentage	O
crystallanity	O
respectively	O
.	O

Contact	O
angle	O
and	O
biodegradation	O
studies	O
further	O
clarified	O
that	O
nano	O
-	O
CaSiO3	O
did	O
not	O
affect	O
the	O
hydrophilicity	O
and	O
general	O
degradation	O
route	O
of	O
chitosan	O
copolymer	O
respectively	O
.	O

This	O
renders	O
the	O
nano	O
-	O
CaSiO3	O
as	O
an	O
ideal	O
substitute	O
for	O
preparing	O
high	O
performance	O
nanocomposites	O
to	O
be	O
applicable	O
for	O
biomedical	O
applications	O
.	O

Skeletal	O
muscle	O
metabolic	O
adaptations	O
to	O
endurance	O
exercise	O
training	O
are	O
attainable	O
in	O
mice	O
with	O
simvastatin	O
treatment	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
a	O
6-week	O
regimen	O
of	O
simvastatin	O
would	O
attenuate	O
skeletal	O
muscle	O
adaptation	O
to	O
low-intensity	O
exercise	O
.	O

Male	O
C57BL/6J	O
wildtype	O
mice	O
were	O
subjected	O
to	O
6-weeks	O
of	O
voluntary	O
wheel	O
running	O
or	O
normal	O
cage	O
activities	O
with	O
or	O
without	O
simvastatin	O
treatment	O
(	O
20	O
mg/kg/d	O
,	O
n	O
=	O
7-8	O
per	O
group	O
)	O
.	O

Adaptations	O
in	O
in	O
vivo	O
fatigue	O
resistance	O
were	O
determined	O
by	O
a	O
treadmill	B-P
running	I-P
test	I-P
,	O
and	O
by	O
ankle	O
plantarflexor	O
contractile	O
assessment	O
.	O

The	O
tibialis	O
anterior	O
,	O
gastrocnemius	O
,	O
and	O
plantaris	O
muscles	O
were	O
evaluated	O
for	O
exercised	O
-induced	O
mitochondrial	O
adaptations	O
(	O
i.e.	O
,	O
biogenesis	O
,	O
function	O
,	O
autophagy	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
weekly	O
wheel	O
running	O
distance	O
between	O
control	O
and	O
simvastatin	O
-	O
treated	O
mice	O
(	O
P	O
=	O
0.51	O
)	O
.	O

Trained	O
mice	O
had	O
greater	O
treadmill	O
running	O
distance	O
(	O
296	O
%	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
ankle	O
plantarflexor	O
contractile	O
fatigue	O
resistance	O
(	O
9	O
%	O
,	O
P	O
<	O
0.05	O
)	O
compared	O
to	O
sedentary	O
mice	O
,	O
independent	O
of	O
simvastatin	O
treatment	O
.	O

At	O
the	O
cellular	O
level	O
,	O
trained	O
mice	O
had	O
greater	O
mitochondrial	O
biogenesis	O
(	O
e.g.	O
,	O
~2-fold	O
greater	O
PGC1Î±	O
expression	O
,	O
P	O
<	O
0.05	O
)	O
and	O
mitochondrial	O
content	O
(	O
e.g.	O
,	O
25	O
%	O
greater	O
citrate	O
synthase	O
activity	O
,	O
P	O
<	O
0.05	O
)	O
,	O
independent	O
of	O
simvastatin	O
treatment	O
.	O

Mitochondrial	O
autophagy	O
-related	O
protein	O
contents	O
were	O
greater	O
in	O
trained	O
mice	O
(	O
e.g.	O
,	O
40	O
%	O
greater	O
Bnip3	O
,	O
P	O
<	O
0.05	O
)	O
,	O
independent	O
of	O
simvastatin	O
treatment	O
.	O

However	O
,	O
Drp1	O
,	O
a	O
marker	O
of	O
mitochondrial	O
fission	O
,	O
was	O
less	O
in	O
simvastatin	O
treated	O
mice	O
,	O
independent	O
of	O
exercise	O
training	O
,	O
and	O
there	O
was	O
a	O
significant	O
interaction	O
between	O
training	O
and	O
statin	O
treatment	O
(	O
P	O
<	O
0.022	O
)	O
for	O
LC3-II	O
protein	O
content	O
,	O
a	O
marker	O
of	O
autophagy	O
flux	O
.	O

These	O
data	O
indicate	O
that	O
whole	O
body	O
and	O
skeletal	O
muscle	O
adaptations	O
to	O
endurance	O
exercise	O
training	O
are	O
attainable	O
with	O
simvastatin	O
treatment	O
,	O
but	O
simvastatin	O
may	O
have	O
side	O
effects	O
on	O
muscle	O
mitochondrial	O
maintenance	O
via	O
autophagy	O
,	O
which	O
could	O
have	O
long-term	O
implications	O
on	O
muscle	O
health	O
.	O

Cognitive	B-P
assessment	I-P
of	O
pycnogenol	O
therapy	O
following	O
traumatic	O
brain	O
injury	O
.	O

We	O
have	O
previously	O
shown	O
that	O
pycnogenol	O
(	O
PYC	O
)	O
increases	O
antioxidants	O
,	O
decreases	O
oxidative	O
stress	O
,	O
suppresses	O
neuroinflammation	O
and	O
enhances	O
synaptic	O
plasticity	O
following	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
effects	O
of	O
PYC	O
on	O
cognitive	O
function	O
following	O
a	O
controlled	O
cortical	O
impact	O
(	O
CCI	O
)	O
.	O

Adult	O
Sprague-Dawley	O
rats	O
received	O
a	O
CCI	O
injury	O
followed	O
by	O
an	O
intraperitoneal	O
injection	O
of	O
PYC	O
(	O
50	O
or	O
100mg/kg	O
)	O
.	O

Seven	O
days	O
post	O
trauma	O
,	O
subjects	O
were	O
evaluated	O
in	O
a	O
Morris	B-P
water	I-P
maze	I-P
(	O
MWM	B-P
)	O
and	O
evaluated	O
for	O
changes	O
in	O
lesion	O
volume	O
.	O

Some	O
animals	O
were	O
evaluated	O
at	O
48h	O
for	O
hippocampal	O
Fluoro-jade	O
B	O
(	O
FJB	O
)	O
staining	B-P
.	O

The	O
highest	O
dose	O
of	O
PYC	O
therapy	O
significantly	O
reduced	O
lesion	O
volume	O
,	O
with	O
no	O
improvement	O
in	O
MWM	B-P
compared	O
to	O
vehicle	O
controls	O
.	O

PYC	O
failed	O
to	O
reduce	O
the	O
total	O
number	O
of	O
FJB	O
positive	O
neurons	O
in	O
the	O
hippocampus	O
.	O

These	O
results	O
suggest	O
that	O
the	O
reduction	O
of	O
oxidative	O
stress	O
and	O
neuroinflammation	O
are	O
not	O
the	O
key	O
components	O
of	O
the	O
secondary	O
injury	O
that	O
contribute	O
to	O
cognitive	O
deficits	O
following	O
TBI	O
.	O

The	O
Role	O
of	O
the	O
Iron	B-P
Stain	I-P
in	O
Assessing	O
Intracranial	O
Hemorrhage	O
.	O

The	O
timing	O
of	O
the	O
breakdown	O
of	O
red	O
blood	O
cells	O
and	O
organization	O
of	O
hemorrhage	O
has	O
significance	O
in	O
the	O
catabolism	O
of	O
heme	O
and	O
the	O
processing	O
of	O
iron	O
,	O
but	O
also	O
has	O
a	O
practical	O
application	O
in	O
terms	O
of	O
assigning	O
,	O
or	O
attempting	O
to	O
assign	O
,	O
a	O
time	O
course	O
with	O
respect	O
to	O
traumatic	O
events	O
(	O
e.g	O
.	O

contusions	O
and	O
hemorrhages	O
)	O
.	O

Attempts	O
to	O
date	O
contusions	O
,	O
however	O
,	O
have	O
generally	O
been	O
unsuccessful	O
by	O
macroscopic	B-P
observation	I-P
,	O
whereas	O
the	O
microscopic	B-P
observations	I-P
provide	O
broad	O
data	O
but	O
are	O
also	O
anatomically	O
imprecise	O
as	O
a	O
function	O
of	O
time	O
.	O

Intracranial	O
lesions	O
are	O
of	O
particular	O
significance	O
with	O
respect	O
to	O
the	O
timing	O
of	O
organizing	O
hemorrhage	O
given	O
the	O
acute	O
,	O
and	O
often	O
life-threatening	O
nature	O
of	O
the	O
hemorrhages	O
,	O
and	O
the	O
medicolegal	B-P
investigation	I-P
into	O
potential	O
crimes	O
.	O

Of	O
concern	O
is	O
that	O
the	O
Prussian	B-P
Blue	I-P
reaction	I-P
for	O
iron	O
,	O
a	O
relatively	O
straightforward	O
histochemical	B-P
reaction	O
that	O
has	O
been	O
in	O
use	O
for	O
over	O
150	O
years	O
,	O
is	O
sometimes	O
suggested	O
as	O
a	O
diagnostic	B-P
test	I-P
for	O
chronicity	O
.	O

Therefore	O
,	O
this	O
study	O
examined	O
the	O
utility	O
of	O
the	O
Prussian	O
Blue	O
iron	O
stain	O
in	O
living	O
patients	O
with	O
intracranial	O
hemorrhages	O
and	O
well-defined	O
symptom	O
onset	O
,	O
to	O
test	O
whether	O
the	O
presence	O
of	O
Prussian	O
Blue	O
reactivity	O
could	O
be	O
correlated	O
with	O
chronicity	O
.	O

It	O
was	O
found	O
that	O
out	O
of	O
12	O
cases	O
with	O
intracranial	O
hemorrhage	O
,	O
eight	O
cases	O
showed	O
at	O
least	O
focal	O
iron	O
reactivity	O
.	O

The	O
duration	O
from	O
symptom	O
onset	O
to	O
surgery	O
in	O
those	O
eight	O
cases	O
ranged	O
from	O
<	O
24	O
hours	O
to	O
more	O
than	O
3	O
days	O
.	O

Of	O
those	O
cases	O
with	O
no	O
iron	O
reactivity	O
,	O
the	O
duration	O
from	O
symptom	O
onset	O
to	O
surgery	O
ranged	O
from	O
<	O
24	O
hours	O
to	O
six	O
days	O
.	O

In	O
conclusion	O
,	O
the	O
Prussian	B-P
Blue	I-P
reaction	I-P
was	O
unreliable	O
as	O
an	O
indicator	O
of	O
timing	O
in	O
intracranial	O
hemorrhage	O
.	O

The	O
use	O
of	O
the	O
Prussian	B-P
blue	I-P
reaction	I-P
as	O
an	O
independent	O
indicator	O
of	O
chronicity	O
is	O
therefore	O
not	O
valid	O
and	O
can	O
be	O
misleading	O
.	O

Caution	O
is	O
indicated	O
when	O
employing	O
iron	B-P
staining	I-P
for	O
timing	O
purposes	O
,	O
as	O
its	O
only	O
use	O
is	O
to	O
highlight	O
,	O
as	O
opposed	O
to	O
identify	O
,	O
pre-existing	O
lesions	O
.	O

With	O
respect	O
to	O
brain	O
lesions	O
,	O
the	O
Prussian	B-P
blue	I-P
reaction	I-P
should	O
not	O
be	O
used	O
in	O
place	O
of	O
the	O
clinical	O
timing	O
of	O
the	O
neurologic	O
decline	O
,	O
or	O
clinical	O
data	O
that	O
is	O
otherwise	O
more	O
accurate	O
and	O
less	O
susceptible	O
to	O
false	O
positive	O
results	O
.	O

Yersinia	O
ruckeri	O
Isolates	O
Recovered	O
from	O
Diseased	O
Atlantic	O
Salmon	O
(	O
Salmo	O
salar	O
)	O
in	O
Scotland	O
Are	O
More	O
Diverse	O
than	O
Those	O
from	O
Rainbow	O
Trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
and	O
Represent	O
Distinct	O
Subpopulations	O
.	O

Yersinia	O
ruckeri	O
is	O
the	O
etiological	O
agent	O
of	O
enteric	O
redmouth	O
(	O
ERM	O
)	O
disease	O
of	O
farmed	O
salmonids	O
.	O

Enteric	O
redmouth	O
disease	O
is	O
traditionally	O
associated	O
with	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
,	O
Walbaum	O
)	O
,	O
but	O
its	O
incidence	O
in	O
Atlantic	O
salmon	O
(	O
Salmo	O
salar	O
)	O
is	O
increasing	O
.	O

Yersinia	O
ruckeri	O
isolates	O
recovered	O
from	O
diseased	O
Atlantic	O
salmon	O
have	O
been	O
poorly	O
characterized	O
,	O
and	O
very	O
little	O
is	O
known	O
about	O
the	O
relationship	O
of	O
the	O
isolates	O
associated	O
with	O
these	O
two	O
species	O
.	O

Phenotypic	O
approaches	O
were	O
used	O
to	O
characterize	O
109	O
Y.	O
ruckeri	O
isolates	O
recovered	O
over	O
a	O
14-year	O
period	O
from	O
infected	O
Atlantic	O
salmon	O
in	O
Scotland	O
;	O
26	O
isolates	O
from	O
infected	O
rainbow	O
trout	O
were	O
also	O
characterized	O
.	O

Biotyping	B-P
,	O
serotyping	B-P
,	O
and	O
comparison	O
of	O
outer	O
membrane	O
protein	O
profiles	O
identified	O
19	O
Y.	O
ruckeri	O
clones	O
associated	O
with	O
Atlantic	O
salmon	O
but	O
only	O
five	O
associated	O
with	O
rainbow	O
trout	O
;	O
none	O
of	O
the	O
Atlantic	O
salmon	O
clones	O
occurred	O
in	O
rainbow	O
trout	O
and	O
vice	O
versa	O
These	O
findings	O
suggest	O
that	O
distinct	O
subpopulations	O
of	O
Y.	O
ruckeri	O
are	O
associated	O
with	O
each	O
species	O
.	O

A	O
new	O
O	O
serotype	O
(	O
designated	O
O8	O
)	O
was	O
identified	O
in	O
56	O
biotype	O
1	O
Atlantic	O
salmon	O
isolates	O
and	O
was	O
the	O
most	O
common	O
serotype	O
identified	O
from	O
2006	O
to	O
2011	O
and	O
in	O
2014	O
,	O
suggesting	O
an	O
increased	O
prevalence	O
during	O
the	O
time	O
period	O
sampled	O
.	O

Rainbow	O
trout	O
isolates	O
were	O
represented	O
almost	O
exclusively	O
by	O
the	O
same	O
biotype	O
2	O
,	O
serotype	O
O1	O
clone	O
that	O
has	O
been	O
responsible	O
for	O
the	O
majority	O
of	O
ERM	O
outbreaks	O
in	O
this	O
species	O
within	O
the	O
United	O
Kingdom	O
since	O
the	O
1980s	O
.	O

However	O
,	O
the	O
identification	O
of	O
two	O
biotype	O
2	O
,	O
serotype	O
O8	O
isolates	O
in	O
rainbow	O
trout	O
suggests	O
that	O
vaccines	O
containing	O
serotypes	O
O1	O
and	O
O8	O
should	O
be	O
evaluated	O
in	O
both	O
rainbow	O
trout	O
and	O
Atlantic	O
salmon	O
for	O
application	O
in	O
Scotland	O
.	O

Vaccination	O
plays	O
an	O
important	O
role	O
in	O
protecting	O
Atlantic	O
salmon	O
against	O
the	O
bacterial	O
pathogen	O
Yersinia	O
ruckeri	O
,	O
but	O
,	O
in	O
recent	O
years	O
,	O
there	O
has	O
been	O
an	O
increasing	O
incidence	O
of	O
vaccine	O
breakdown	O
in	O
salmon	O
.	O

This	O
is	O
largely	O
because	O
current	O
vaccines	O
are	O
aimed	O
at	O
rainbow	O
trout	O
and	O
are	O
based	O
on	O
serotypes	O
specific	O
for	O
this	O
species	O
.	O

A	O
wider	O
range	O
of	O
serotypes	O
is	O
responsible	O
for	O
infection	O
in	O
Atlantic	O
salmon	O
,	O
but	O
very	O
little	O
is	O
known	O
about	O
the	O
diversity	O
of	O
these	O
strains	O
and	O
their	O
relationships	O
to	O
those	O
recovered	O
from	O
rainbow	O
trout	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
Y.	O
ruckeri	O
isolates	O
recovered	O
from	O
diseased	O
Atlantic	O
salmon	O
in	O
Scotland	O
are	O
more	O
diverse	O
than	O
those	O
from	O
rainbow	O
trout	O
;	O
furthermore	O
,	O
isolates	O
from	O
the	O
two	O
species	O
represent	O
distinct	O
subpopulations	O
.	O

In	O
addition	O
,	O
a	O
new	O
O	O
serotype	O
was	O
identified	O
that	O
is	O
responsible	O
for	O
a	O
significant	O
proportion	O
of	O
the	O
disease	O
in	O
Atlantic	O
salmon	O
.	O

Our	O
findings	O
are	O
likely	O
to	O
have	O
important	O
implications	O
for	O
the	O
development	O
of	O
improved	O
vaccines	O
against	O
Y.	O
ruckeri	O
.	O

Pesticide	O
residues	O
in	O
orange	O
fruit	O
from	O
citrus	O
orchards	O
in	O
Nuevo	O
Leon	O
State	O
,	O
Mexico	O
.	O

Some	O
international	O
organisations	O
established	O
maximum	O
residue	O
limits	O
(	O
MRLs	O
)	O
in	O
food	O
to	O
protect	O
human	O
health	O
.	O

Mexico	O
lacks	O
regulations	O
in	O
this	O
matter	O
,	O
affecting	O
national	O
and	O
international	O
trade	O
from	O
agroindustry	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
diagnose	O
pesticide	O
residues	O
in	O
oranges	O
from	O
Nuevo	O
Leon	O
,	O
MÃ©xico	O
,	O
in	O
citrus	O
orchards	O
.	O

In	O
May	O
2014	O
,	O
100	O
orange	O
fruit	O
samples	O
were	O
taken	O
randomly	O
from	O
orchards	O
and	O
subjected	O
to	O
analysis	B-P
for	O
93	O
pesticides	O
at	O
residual	O
level	O
by	O
GC	B-P
/	O
QQQ-MS	B-P
and	O
LCQ-TOF-MS	B-P
.	O

Results	O
showed	O
the	O
presence	O
of	O
15	O
pesticide	O
residues	O
in	O
the	O
samples	O
.	O

The	O
comparison	O
of	O
the	O
residual	O
levels	O
of	O
pesticides	O
found	O
in	O
orange	O
samples	O
among	O
the	O
MRLs	O
allowed	O
by	O
USA	O
,	O
EU	O
and	O
Japanese	O
regulations	O
demonstrated	O
that	O
all	O
samples	O
were	O
below	O
MRLs	O
issued	O
by	O
USA	O
and	O
Japan	O
.	O

Some	O
orange	O
samples	O
were	O
above	O
MRLs	O
issued	O
by	O
the	O
EU	O
.	O

This	O
provides	O
a	O
basis	O
to	O
establish	O
strategies	O
in	O
order	O
to	O
satisfy	O
International	O
Standards	O
to	O
protect	O
human	O
health	O
and	O
encourage	O
Food	O
Safety	O
in	O
Mexico	O
.	O

Parallel	O
artificial	O
liquid	O
membrane	O
extraction	B-P
of	O
new	O
psychoactive	O
substances	O
in	O
plasma	O
and	O
whole	O
blood	O
.	O

Parallel	O
artificial	O
liquid	O
membrane	O
extraction	B-P
(	O
PALME	B-P
)	O
was	O
combined	O
with	O
ultra-high	B-P
performance	I-P
liquid	I-P
chromatography-mass	I-P
spectrometry	I-P
(	O
UHPLC-MS	B-P
)	O
and	O
the	O
potential	O
for	O
screening	O
of	O
new	O
psychoactive	O
substances	O
(	O
NPS	O
)	O
was	O
investigated	O
for	O
the	O
first	O
time	O
.	O

PALME	B-P
was	O
performed	O
in	O
96-	O
well	O
format	O
comprising	O
a	O
donor	O
plate	O
,	O
a	O
supported	O
liquid	O
membrane	O
(	O
SLM	O
)	O
,	O
and	O
an	O
acceptor	O
plate	O
.	O

Uncharged	O
NPS	O
were	O
extracted	B-P
from	O
plasma	O
or	O
whole	O
blood	O
,	O
across	O
an	O
organic	O
SLM	O
,	O
and	O
into	O
an	O
aqueous	O
acceptor	O
solution	O
,	O
facilitated	O
by	O
a	O
pH	O
gradient	O
.	O

MDAI	O
(	O
5,6-methylenedioxy-2-aminoindane	O
)	O
,	O
methylone	O
,	O
PFA	O
(	O
para-fluoroamphetamine	O
)	O
,	O
mCPP	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C-E	O
(	O
2,5-dimethoxy-4-ethylphenethylamine	O
)	O
,	O
bromo-dragonfly	O
,	O
and	O
AH-7921	O
(	O
3,4-dichloro-N-	O
{	O
[	O
1-	O
(	O
dimethylamino	O
)	O
cyclohexyl	O
]	O
methyl	O
}	O
benzamide	O
)	O
were	O
selected	O
as	O
representative	O
NPS	O
.	O

Optimization	O
of	O
operational	O
parameters	O
was	O
necessary	O
as	O
the	O
NPS	O
were	O
novel	O
to	O
PALME	B-P
,	O
and	O
because	O
PALME	B-P
was	O
performed	O
from	O
whole	O
blood	O
for	O
the	O
very	O
first	O
time	O
.	O

In	O
the	O
PALME	B-P
method	O
developed	O
for	O
plasma	O
,	O
NPS	O
were	O
extracted	B-P
from	O
a	O
250Î¼L	O
alkalized	B-P
donor	O
solution	O
consisting	O
of	O
125Î¼L	O
plasma	O
sample	O
,	O
115Î¼L	O
40mM	O
NaOH	O
,	O
and	O
10Î¼L	O
internal	O
standard	O
.	O

In	O
the	O
PALME	B-P
method	O
from	O
whole	O
blood	O
,	O
the	O
250Î¼L	O
alkalized	B-P
donor	O
solution	O
consisted	O
of	O
100Î¼L	O
whole	O
blood	O
,	O
50Î¼L	O
deionized	O
water	O
,	O
75Î¼L	O
80mM	O
NaOH	O
,	O
and	O
25Î¼L	O
internal	O
standard	O
.	O

In	O
both	O
method	O
s	O
,	O
extraction	B-P
was	O
accomplished	O
across	O
an	O
SLM	O
of	O
5Î¼L	O
dodecyl	O
acetate	O
with	O
1	O
%	O
trioctylamine	O
(	O
w/w	O
)	O
,	O
and	O
further	O
into	O
an	O
acidic	O
acceptor	O
solution	O
of	O
50Î¼L	O
20mM	O
formic	O
acid	O
.	O

The	O
extraction	B-P
was	O
promoted	O
by	O
agitation	O
at	O
900	O
rpm	O
and	O
was	O
carried	O
out	O
for	O
120min	O
.	O

Method	O
validation	O
was	O
performed	O
and	O
the	O
following	O
parameters	O
were	O
considered	O
:	O
linearity	O
,	O
limits	O
of	O
quantification	O
(	O
LOQ	O
)	O
,	O
intra	O
-	O
and	O
inter	O
-	O
day	O
precision	O
,	O
accuracy	O
,	O
extraction	B-P
recoveries	O
,	O
carry	O
-	O
over	O
,	O
and	O
matrix	O
effects	O
.	O

The	O
validation	O
results	O
were	O
in	O
accordance	O
with	O
FDA	O
guidelines	O
.	O

The	O
relationship	O
between	O
histological	O
prostatitis	O
and	O
lower	O
urinary	O
tract	O
symptoms	O
and	O
sexual	O
function	O
.	O

This	O
prospective	O
analysis	O
assessed	O
the	O
effect	O
of	O
histological	O
prostatitis	O
on	O
lower	O
urinary	O
tract	O
functions	O
and	O
sexual	O
function	O
.	O

The	O
patients	O
were	O
separated	O
into	O
two	O
groups	O
as	O
histologically	O
observed	O
prostatitis	O
(	O
Group	O
A	O
)	O
and	O
no	O
prostatitis	O
(	O
Group	O
B	O
)	O
according	O
to	O
the	O
biopsy	B-P
outcomes	O
.	O

International	O
prostate	O
symptom	O
score	O
,	O
international	O
index	O
of	O
erectile	O
function-5	O
scores	O
,	O
maximal	O
and	O
average	O
flow	O
rate	O
,	O
and	O
residual	O
urine	O
volumes	O
were	O
compared	O
statistically	O
between	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
(	O
P	O
>	O
0.05	O
)	O
in	O
baseline	O
age	O
(	O
t=0.64	O
)	O
,	O
body	O
mass	O
index	O
value	O
(	O
t=0.51	O
)	O
,	O
prostate	O
volume	O
(	O
t=0.87	O
)	O
,	O
prostate-specific	B-P
antigen	I-P
levels	I-P
(	O
t=0.43	O
)	O
,	O
maximal	O
(	O
t=0.84	O
)	O
and	O
average	O
flow	O
rate	O
(	O
t=0.59	O
)	O
,	O
and	O
post-void	O
residual	O
urine	O
volume	O
(	O
t=0.71	O
)	O
.	O

Mean	O
international	O
prostate	O
symptom	O
score	O
in	O
patients	O
with	O
prostatitis	O
was	O
numerically	O
but	O
not	O
significantly	O
higher	O
than	O
that	O
in	O
those	O
without	O
prostatitis	O
(	O
t=0.794	O
,	O
P=0.066	O
)	O
.	O

Mean	O
international	O
index	O
of	O
erectile	O
function-5	O
score	O
in	O
the	O
prostatitis	O
group	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
those	O
without	O
prostatitis	O
(	O
t=1.854	O
,	O
P=0.013	O
)	O
.	O

Histological	O
prostatitis	O
notably	O
affected	O
sexual	O
function	O
of	O
patients	O
and	O
may	O
serve	O
as	O
a	O
major	O
risk	O
factor	O
for	O
sexual	O
dysfunction	O
while	O
having	O
little	O
effect	O
on	O
lower	O
urinary	O
tract	O
symptoms	O
.	O

NADPH	O
oxidase-produced	O
superoxide	O
mediated	O
a	O
50-Hz	O
magnetic	O
field	O
-induced	O
epidermal	O
growth	O
factor	O
receptor	O
clustering	O
.	O

A	O
50-Hz	O
magnetic	O
field	O
(	O
MF	O
)	O
was	O
found	O
to	O
induce	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
clustering	O
in	O
our	O
previous	O
study	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
that	O
mediated	O
MF	O
-induced	O
EGFR	O
clustering	O
.	O

Human	O
amniotic	O
epithelial	O
(	O
FL	O
)	O
cells	O
were	O
exposed	O
to	O
a	O
50-Hz	O
MF	O
.	O

Total	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
cytoplasmic	O
and	O
mitochondrial	O
superoxide	O
production	O
were	O
detected	O
by	O
DCFH-DA	O
,	O
DHE	O
and	O
MitoSOX	O
,	O
respectively	O
.	O

EGFR	O
clustering	O
was	O
analyzed	O
using	O
confocal	B-P
microscopy	I-P
after	O
indirect	B-P
immunofluorescence	I-P
staining	B-P
.	O

Results	O
showed	O
that	O
exposing	O
FL	O
cells	O
to	O
MF	O
at	O
intensity	O
higher	O
than	O
0.2	O
mT	O
for	O
15	O
min	O
enhanced	O
total	O
ROS	O
production	O
.	O

Additionally	O
,	O
enhanced	O
total	O
ROS	O
and	O
cytoplasmic	O
superoxide	O
production	O
were	O
observed	O
after	O
exposing	O
cells	O
to	O
MF	O
at	O
0.4	O
mT	O
for	O
5	O
,	O
15	O
,	O
or	O
30	O
min	O
,	O
while	O
mitochondrial	O
superoxide	O
production	O
for	O
15	O
or	O
30	O
min	O
.	O

Pretreatment	O
with	O
Nox	O
inhibitor	O
,	O
DPI	O
,	O
effectively	O
inhibited	O
MF	O
-induced	O
cytoplasmic	O
superoxide	O
production	O
and	O
subsequent	O
EGFR	O
clustering	O
while	O
mitochondrial	O
superoxide	O
production	O
was	O
not	O
affected	O
.	O

Nox-produced	O
superoxide	O
mediated	O
a	O
50-	O
Hz	O
magnetic	O
field	O
-induced	O
EGFR	O
clustering	O
.	O

From	O
'	O
sense	O
of	O
number	O
'	O
to	O
'	O
sense	O
of	O
magnitude	O
'	O
-	O
The	O
role	O
of	O
continuous	O
magnitudes	O
in	O
numerical	O
cognition	O
.	O

In	O
this	O
review	O
,	O
we	O
are	O
pitting	O
two	O
theories	O
against	O
each	O
other	O
:	O
the	O
more	O
accepted	O
theory	O
-the	O
'	O
number	O
sense	O
'	O
theory	O
-suggesting	O
that	O
a	O
sense	O
of	O
number	O
is	O
innate	O
and	O
non-symbolic	O
numerosity	O
is	O
being	O
processed	O
independently	O
of	O
continuous	O
magnitudes	O
(	O
e.g.	O
,	O
size	O
,	O
area	O
,	O
density	O
)	O
;	O
and	O
the	O
newly	O
emerging	O
theory	O
suggesting	O
that	O
(	O
1	O
)	O
both	O
numerosities	O
and	O
continuous	O
magnitudes	O
are	O
processed	O
holistically	O
when	O
comparing	O
numerosities	O
,	O
and	O
(	O
2	O
)	O
a	O
sense	O
of	O
number	O
might	O
not	O
be	O
innate	O
.	O

In	O
the	O
first	O
part	O
of	O
this	O
review	O
,	O
we	O
discuss	O
the	O
'	O
number	O
sense	O
'	O
theory	O
.	O

Against	O
this	O
background	O
,	O
we	O
demonstrate	O
how	O
the	O
natural	O
correlation	O
between	O
numerosities	O
and	O
continuous	O
magnitudes	O
makes	O
it	O
nearly	O
impossible	O
to	O
study	O
non-symbolic	O
numerosity	O
processing	O
in	O
isolation	O
from	O
continuous	O
magnitudes	O
,	O
and	O
therefore	O
the	O
results	O
of	O
behavioral	O
and	O
imaging	B-P
studies	I-P
with	O
infants	O
,	O
adults	O
and	O
animals	O
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
relying	O
on	O
continuous	O
magnitudes	O
.	O

In	O
the	O
second	O
part	O
,	O
we	O
explain	O
the	O
'	O
sense	O
of	O
magnitude	O
'	O
theory	O
and	O
review	O
studies	O
that	O
directly	O
demonstrate	O
that	O
continuous	O
magnitudes	O
are	O
more	O
automatic	O
and	O
basic	O
than	O
numerosities	O
.	O

Finally	O
,	O
we	O
present	O
outstanding	O
questions	O
.	O

Our	O
conclusion	O
is	O
that	O
there	O
is	O
not	O
enough	O
convincing	O
evidence	O
to	O
support	O
the	O
number	O
sense	O
theory	O
anymore	O
.	O

Therefore	O
,	O
we	O
encourage	O
researchers	O
not	O
to	O
assume	O
that	O
number	O
sense	O
is	O
simply	O
innate	O
,	O
but	O
to	O
put	O
this	O
hypothesis	O
to	O
the	O
test	O
,	O
and	O
to	O
consider	O
if	O
such	O
an	O
assumption	O
is	O
even	O
testable	O
in	O
light	O
of	O
the	O
correlation	O
of	O
numerosity	O
and	O
continuous	O
magnitudes	O
.	O

The	O
Latin	O
American	O
Biological	O
Dosimetry	O
Network	O
(	O
LBDNet	O
)	O
.	O

Biological	O
Dosimetry	B-P
is	O
a	O
necessary	O
support	O
for	O
national	O
radiation	O
protection	O
programmes	O
and	O
emergency	O
response	O
schemes	O
.	O

The	O
Latin	O
American	O
Biological	O
Dosimetry	O
Network	O
(	O
LBDNet	O
)	O
was	O
formally	O
founded	O
in	O
2007	O
to	O
provide	O
early	O
biological	O
dosimetry	B-P
assistance	O
in	O
case	O
of	O
radiation	O
emergencies	O
in	O
the	O
Latin	O
American	O
Region	O
.	O

Here	O
are	O
presented	O
the	O
main	O
topics	O
considered	O
in	O
the	O
foundational	O
document	O
of	O
the	O
network	O
,	O
which	O
comprise	O
:	O
mission	O
,	O
partners	O
,	O
concept	O
of	O
operation	O
,	O
including	O
the	O
mechanism	O
to	O
request	O
support	O
for	O
biological	O
dosimetry	B-P
assistance	O
in	O
the	O
region	O
,	O
and	O
the	O
network	O
capabilities	O
.	O

The	O
process	O
for	O
network	O
activation	O
and	O
the	O
role	O
of	O
the	O
coordinating	O
laboratory	O
during	O
biological	O
dosimetry	B-P
emergency	O
response	O
is	O
also	O
presented	O
.	O

This	O
information	O
is	O
preceded	O
by	O
historical	O
remarks	O
on	O
biological	O
dosimetry	B-P
cooperation	O
in	O
Latin	O
America	O
.	O

A	O
summary	O
of	O
the	O
main	O
experimental	O
and	O
practical	O
results	O
already	O
obtained	O
by	O
the	O
LBDNet	O
is	O
also	O
included	O
.	O

Low-intensity	O
pulsed	O
ultrasound	O
reduces	O
periodontal	O
atrophy	O
in	O
occlusal	O
hypofunctional	O
teeth	O
.	O

To	O
clarify	O
whether	O
low-intensity	O
pulsed	O
ultrasound	O
(	O
LIPUS	O
)	O
exposure	O
has	O
recovery	O
effects	O
on	O
the	O
hypofunctional	O
periodontal	O
ligament	O
(	O
PDL	O
)	O
and	O
interradicular	O
alveolar	O
bone	O
(	O
IRAB	O
)	O
.	O

Twelve-	O
week	O
-old	O
male	O
Sprague-Dawley	O
rats	O
were	O
divided	O
into	O
three	O
groups	O
(	O
n	O
=	O
5	O
each	O
)	O
:	O
a	O
normal	O
occlusion	O
(	O
C	O
)	O
group	O
,	O
an	O
occlusal	O
hypofunction	O
(	O
H	O
)	O
group	O
,	O
and	O
an	O
occlusal	O
hypofunction	O
group	O
subjected	O
to	O
LIPUS	O
(	O
HL	O
)	O
treatment	O
.	O

Hypofunctional	O
occlusion	O
of	O
the	O
maxillary	O
first	O
molar	O
(	O
M1	O
)	O
of	O
the	O
H	O
and	O
HL	O
groups	O
was	O
induced	O
by	O
the	O
bite-raising	O
technique	O
.	O

Only	O
the	O
HL	O
group	O
was	O
irradiated	O
with	O
LIPUS	O
for	O
5	O
days	O
.	O

The	O
IRAB	O
and	O
PDL	O
of	O
M1	O
were	O
examined	O
by	O
microcomputed	B-P
tomography	I-P
(	O
micro-CT	B-P
)	O
analysis	O
.	O

To	O
quantify	O
mRNA	O
expression	O
of	O
cytokines	O
involved	O
in	O
PDL	O
proliferation	O
and	O
development	O
,	O
real-time	O
reverse	O
transcription	O
quantitative	O
PCR	O
(	O
qRT-PCR	O
)	O
was	O
performed	O
for	O
twist	O
family	O
bHLH	O
transcription	O
factor	O
1	O
(	O
Twist1	O
)	O
,	O
periostin	O
,	O
and	O
connective	O
tissue	O
growth	O
factor	O
(	O
CTGF	O
)	O
in	O
the	O
PDL	O
samples	O
.	O

Micro-CT	B-P
analysis	O
showed	O
that	O
the	O
PDL	O
volume	O
was	O
decreased	O
in	O
the	O
H	O
group	O
compared	O
with	O
that	O
of	O
the	O
C	O
and	O
HL	O
groups	O
.	O

Both	O
bone	O
volume	O
per	O
tissue	O
volume	O
(	O
BV	O
/	O
TV	O
)	O
of	O
IRAB	O
was	O
decreased	O
in	O
the	O
H	O
group	O
compared	O
with	O
that	O
in	O
the	O
C	O
group	O
.	O

LIPUS	O
exposure	O
restored	O
BV	O
/	O
TV	O
in	O
the	O
IRAB	O
of	O
the	O
HL	O
group	O
.	O

qRT-PCR	O
analysis	O
showed	O
that	O
Twist1	O
,	O
periostin	O
,	O
and	O
CTGF	O
mRNA	O
levels	O
were	O
decreased	O
in	O
the	O
H	O
group	O
and	O
increased	O
in	O
the	O
HL	O
group	O
.	O

LIPUS	O
exposure	O
reduced	O
the	O
atrophic	O
changes	O
of	O
alveolar	O
bone	O
by	O
inducing	O
the	O
upregulation	O
of	O
periostin	O
and	O
CTGF	O
expression	O
to	O
promote	O
PDL	O
healing	O
after	O
induction	O
of	O
occlusal	O
hypofunction	O
.	O

Hyperuricemia	O
after	O
orthotopic	O
liver	O
transplantation	O
:	O
divergent	O
associations	O
with	O
progression	O
of	O
renal	O
disease	O
,	O
incident	O
end-stage	O
renal	O
disease	O
,	O
and	O
mortality	O
.	O

Although	O
hyperuricemia	O
is	O
common	O
after	O
orthotopic	O
liver	O
transplantation	O
(	O
OLT	O
)	O
,	O
its	O
relationship	O
to	O
mortality	O
,	O
progressive	O
kidney	O
disease	O
,	O
or	O
the	O
development	O
of	O
end	O
stage	O
renal	O
disease	O
(	O
ESRD	O
)	O
is	O
not	O
well-described	O
.	O

Data	O
from	O
304	O
patients	O
undergoing	O
OLT	O
between	O
1996	O
and	O
2010	O
were	O
used	O
to	O
assess	O
the	O
association	O
of	O
mean	O
serum	O
uric	O
acid	O
(	O
UA	O
)	O
level	O
in	O
the	O
3-	O
months	O
post-OLT	O
with	O
mortality	O
,	O
doubling	O
of	O
creatinine	O
,	O
and	O
ESRD	O
incidence	O
.	O

Post-OLT	O
survival	O
to	O
event	O
outcomes	O
according	O
to	O
UA	O
level	O
and	O
eGFR	B-P
was	O
assessed	O
using	O
the	O
Kaplan	O
Meier	O
method	O
and	O
multivariate	O
Cox	O
proportional	O
hazards	O
models	O
.	O

Mean	O
UA	O
level	O
among	O
the	O
204	O
patients	O
with	O
an	O
eGFR	B-P
level	O
â¥60	O
ml/min/1.73	O
m	O
(	O
2	O
)	O
was	O
6.4	O
mg/dl	O
compared	O
to	O
7.9	O
mg/dl	O
among	O
the	O
100	O
patients	O
with	O
eGFR	B-P
<	O
60	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

During	O
a	O
median	O
of	O
4.6	O
years	O
of	O
follow-up	O
,	O
mortality	O
rate	O
,	O
doubling	O
of	O
creatinine	O
,	O
and	O
ESRD	O
incidence	O
were	O
48.9	O
,	O
278.2	O
,	O
and	O
20.7	O
per	O
1000	O
person	O
-	O
years	O
,	O
respectively	O
.	O

In	O
the	O
first	O
5	O
years	O
of	O
follow-up	O
,	O
elevated	O
UA	O
was	O
associated	O
with	O
mortality	O
(	O
Hazard	O
Ratio	O
,	O
HR	O
=	O
1.7	O
;	O
p	O
=	O
0.045	O
)	O
.	O

However	O
,	O
among	O
those	O
with	O
eGFR	B-P
â¥	O
60	O
,	O
UA	O
level	O
did	O
not	O
predict	O
mortality	O
(	O
HR	O
=	O
1.0	O
;	O
p	O
=	O
0.95	O
)	O
,	O
and	O
among	O
those	O
with	O
eGFR	B-P
<	O
60	O
,	O
elevated	O
UA	O
was	O
a	O
strong	O
predictor	O
of	O
mortality	O
(	O
HR	O
=	O
3.7	O
[	O
1.1	O
,	O
12.0	O
]	O
;	O
p	O
=	O
0.03	O
)	O
.	O

UA	O
was	O
not	O
associated	O
with	O
ESRD	O
,	O
but	O
was	O
associated	O
with	O
doubling	O
of	O
creatinine	O
among	O
diabetics	O
(	O
HR	O
=	O
2.2	O
[	O
1.1	O
,	O
4.3	O
]	O
;	O
p	O
=	O
0.025	O
)	O
.	O

In	O
this	O
post-OLT	O
cohort	O
,	O
hyperuricemia	O
independently	O
predicted	O
mortality	O
,	O
particularly	O
among	O
patients	O
with	O
eGFR	B-P
<	O
60	O
,	O
and	O
predicted	O
doubling	O
of	O
creatinine	O
among	O
diabetics	O
.	O

Impact	O
of	O
Chemotherapy	O
on	O
Diet	O
and	O
Nutritional	O
Status	O
of	O
Women	O
with	O
Breast	O
Cancer	O
:	O
A	O
Prospective	O
Study	O
.	O

Certain	O
food	O
groups	O
are	O
often	O
rejected	O
during	O
chemotherapy	O
(	O
CT	O
)	O
due	O
to	O
the	O
side	O
effects	O
of	O
treatment	O
,	O
which	O
may	O
interfere	O
with	O
adequate	O
diet	O
and	O
nutritional	O
status	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
treatment	O
impact	O
on	O
the	O
diet	O
and	O
nutritional	O
status	O
of	O
women	O
with	O
breast	O
cancer	O
(	O
BC	O
)	O
.	O

In	O
this	O
prospective	O
longitudinal	O
study	O
,	O
conducted	O
in	O
2014-2015	O
,	O
55	O
women	O
diagnosed	O
with	O
BC	O
,	O
with	O
a	O
mean	O
age	O
51.5Â±10.1	O
years	O
,	O
were	O
followed	O
and	O
data	O
were	O
collected	O
at	O
three	O
different	O
times	O
.	O

Anthropometric	O
and	O
dietary	B-P
assessments	I-P
were	O
performed	O
,	O
the	O
latter	O
by	O
applying	O
nine	O
24h	O
dietary	O
recall	O
s	O
,	O
by	O
using	O
the	O
Brazilian	O
Healthy	O
Eating	O
Index	O
Revised	O
(	O
BHEI-R	O
)	O
,	O
and	O
calculating	O
the	O
prevalence	O
of	O
inadequacy	O
by	O
the	O
EAR	O
cut-off	O
point	O
method	O
.	O

Regarding	O
the	O
BHEI-R	O
analysis	O
,	O
the	O
majority	O
of	O
women	O
had	O
a	O
``	O
diet	O
requires	O
modification	O
'	O
,	O
both	O
at	O
the	O
beginning	O
(	O
T0	O
,	O
58.2	O
%	O
,	O
n	O
=	O
32	O
)	O
and	O
during	O
treatment	O
(	O
T1	O
,	O
54.5	O
%	O
,	O
n	O
=	O
30	O
)	O
.	O

However	O
,	O
after	O
the	O
end	O
of	O
the	O
CT	O
,	O
the	O
greater	O
percentage	O
of	O
patients	O
(	O
T2	O
,	O
49.1	O
%	O
,	O
n	O
=	O
27	O
)	O
were	O
classified	O
as	O
having	O
an	O
``	O
inadequate	O
diet	O
``	O
,	O
since	O
the	O
Total	O
Fruit	O
consumption	O
as	O
well	O
as	O
the	O
Dark	O
Green	O
and	O
Orange	O
Vegetable	O
and	O
Legume	O
consumption	O
decreased	O
significantly	O
during	O
treatment	O
(	O
p	O
=	O
0.043	O
and	O
p	O
=	O
0.026	O
,	O
respectively	O
)	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
intake	O
of	O
macro	O
and	O
micronutrients	O
,	O
with	O
a	O
high	O
prevalence	O
of	O
inadequacy	O
,	O
of	O
up	O
to	O
100	O
%	O
,	O
for	O
calcium	O
,	O
iron	O
,	O
phosphorus	O
,	O
magnesium	O
,	O
niacin	O
,	O
riboflavin	O
,	O
thiamin	O
,	O
vitamin	O
B6	O
,	O
vitamin	O
C	O
and	O
zinc	O
.	O

Assessment	B-P
of	O
the	O
nutritional	O
status	O
indicated	O
that	O
56	O
%	O
(	O
n	O
=	O
31	O
)	O
of	O
patients	O
were	O
overweight	O
at	O
these	O
three	O
different	O
times	O
.	O

Weight	O
,	O
BMI	O
and	O
Waist	O
Circumference	O
increased	O
significantly	O
,	O
indicating	O
a	O
worse	O
nutritional	O
status	O
,	O
and	O
there	O
was	O
a	O
correlation	O
between	O
poor	O
diet	O
quality	O
and	O
higher	O
values	O
for	O
BMI	O
,	O
Waist-Hip	O
Ratio	O
and	O
Waist-to-Height	O
Ratio	O
.	O

Chemotherapy	O
interferes	O
in	O
the	O
patients	O
'	O
diet	O
generating	O
a	O
negative	O
impact	O
on	O
the	O
quality	O
and	O
intake	O
of	O
micro	O
and	O
macronutrients	O
,	O
as	O
well	O
as	O
an	O
impact	O
on	O
their	O
nutritional	O
status	O
,	O
with	O
an	O
increase	O
in	O
anthropometric	O
measurements	O
.	O

Asymmetry	O
of	O
lumbopelvic	O
movement	O
patterns	O
during	O
active	O
hip	O
abduction	B-P
is	O
a	O
risk	O
factor	O
for	O
low	O
back	O
pain	O
development	O
during	O
standing	O
.	O

An	O
induced-pain	O
paradigm	O
has	O
been	O
used	O
in	O
back	O
-	O
healthy	O
people	O
to	O
understand	O
risk	O
factors	O
for	O
developing	O
low	O
back	O
pain	O
(	O
LBP	O
)	O
during	O
prolonged	O
standing	O
.	O

We	O
examined	O
asymmetry	O
of	O
lumbopelvic	O
movement	O
timing	O
during	O
a	O
clinical	O
test	O
of	O
active	O
hip	O
abduction	O
in	O
back-healthy	O
people	O
who	O
developed	O
LBP	O
symptoms	O
during	O
standing	O
(	O
Pain	O
Developers	O
;	O
PDs	O
)	O
compared	O
to	O
back-healthy	O
people	O
who	O
did	O
not	O
develop	O
LBP	O
symptoms	O
during	O
standing	O
(	O
Non	O
Pain	O
Developers	O
,	O
NPDs	O
)	O
.	O

Participants	O
completed	O
the	O
hip	O
abduction	B-P
test	I-P
while	O
movement	O
was	O
recorded	O
with	O
a	O
motion	O
capture	O
system	O
.	O

Difference	O
in	O
time	O
between	O
start	O
of	O
hip	O
and	O
lumbopelvic	O
movement	O
was	O
calculated	B-P
(	O
startdiff	O
)	O
.	O

PDs	O
moved	O
the	O
lumbopelvic	O
region	O
earlier	O
during	O
left	O
hip	O
abduction	O
than	O
right	O
hip	O
abduction	O
.	O

There	O
was	O
no	O
difference	O
between	O
sides	O
in	O
NPDs	O
.	O

In	O
PDs	O
,	O
the	O
amount	O
of	O
asymmetry	O
was	O
related	O
to	O
average	O
symptom	O
intensity	O
during	O
standing	O
.	O

Asymmetric	O
lumbopelvic	O
movement	O
patterns	O
may	O
be	O
a	O
risk	O
factor	O
for	O
LBP	O
development	O
during	O
prolonged	O
standing	O
.	O

Prostate-specific	O
antigen	O
increase	O
during	O
dutasteride	O
to	O
indicate	O
the	O
need	O
for	O
prostate	B-P
biopsy	I-P
:	O
influence	O
of	O
prostatic	O
inflammation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
significance	O
of	O
an	O
increase	O
in	O
total	B-P
prostate-specific	I-P
antigen	I-P
(	I-P
PSA	I-P
)	I-P
serum	I-P
levels	I-P
despite	O
dutasteride	O
treatment	O
as	O
a	O
predictor	O
of	O
prostate	O
cancer	O
(	O
PC	O
)	O
at	O
biopsy	B-P
.	O

We	O
focused	O
our	O
attention	O
on	O
the	O
rate	O
of	O
the	O
first	O
PSA	O
increase	O
and	O
on	O
the	O
influence	O
of	O
prostatic	O
inflammation	O
.	O

From	O
2011	O
to	O
2016	O
,	O
365	O
men	O
with	O
a	O
previous	O
negative	O
prostate	B-P
biopsy	I-P
and	O
persistent	O
elevated	O
PSA	B-P
levels	I-P
received	O
dutasteride	O
treatment	O
.	O

The	O
population	O
was	O
followed	O
for	O
a	O
range	O
of	O
12-48	O
months	O
.	O

One	O
hundred	O
twelve	O
cases	O
with	O
a	O
confirmed	O
PSA	O
increase	O
>	O
0.5	O
ng/ml	O
over	O
the	O
nadir	O
value	O
during	O
the	O
follow-up	O
were	O
included	O
in	O
Group	O
A	O
and	O
underwent	O
a	O
new	O
prostate	B-P
biopsy	I-P
.	O

In	O
Group	O
A	O
,	O
the	O
PSA	O
increase	O
was	O
associated	O
with	O
PC	O
at	O
the	O
re-biopsy	B-P
in	O
66	O
%	O
of	O
cases	O
.	O

The	O
percentage	O
of	O
PSA	O
reduction	O
after	O
6	O
months	O
of	O
treatment	O
was	O
not	O
a	O
significant	O
indicator	O
of	O
the	O
risk	O
for	O
PC	O
.	O

The	O
distribution	O
of	O
inflammatory	O
infiltrates	O
significantly	O
(	O
p	O
<	O
00.01	O
)	O
varied	O
from	O
positive	O
to	O
negative	O
prostate	B-P
biopsies	I-P
.	O

The	O
relative	O
risk	O
for	O
PC	O
at	O
biopsy	B-P
significantly	O
increase	O
d	O
according	O
to	O
PSA	B-P
level	I-P
during	O
dutasteride	O
.	O

Treatment	O
with	O
dutasteride	O
can	O
help	O
to	O
analyze	O
PSA	O
kinetic	O
.	O

A	O
persistent	O
prostatic	O
inflammation	O
is	O
a	O
factor	O
able	O
to	O
reduce	O
the	O
performance	O
of	O
PSA	O
kinetic	O
during	O
dutasteride	O
treatment	O
.	O

Jak1	O
-	O
STAT3	O
Signals	O
Are	O
Essential	O
Effectors	O
of	O
the	O
USP6	O
/	O
TRE17	O
Oncogene	O
in	O
Tumorigenesis	O
.	O

Bone	O
and	O
soft	O
tissue	O
tumors	O
(	O
BSTT	O
)	O
are	O
relatively	O
poorly	O
understood	O
,	O
hampering	O
the	O
development	O
of	O
effective	O
therapies	O
.	O

Here	O
we	O
report	O
a	O
role	O
for	O
the	O
ubiquitin-specific	O
protease	O
6	O
(	O
USP6	O
)	O
/	O
TRE17	O
oncogene	O
,	O
which	O
is	O
overexpressed	O
upon	O
chromosome	O
translocation	O
in	O
various	O
human	O
tumors	O
,	O
including	O
aneurysmal	O
bone	O
cyst	O
(	O
ABC	O
)	O
,	O
and	O
the	O
related	O
benign	O
lesion	O
nodular	O
fasciitis	O
.	O

Ectopic	O
expression	O
of	O
USP6	O
is	O
known	O
to	O
drive	O
formation	O
of	O
tumors	O
,	O
which	O
recapitulate	O
key	O
features	O
of	O
ABC	O
and	O
nodular	O
fasciitis	O
;	O
however	O
,	O
the	O
identity	O
of	O
USP6	O
's	O
relevant	O
substrates	O
has	O
been	O
obscure	O
.	O

Here	O
we	O
report	O
that	O
the	O
Jak1	O
-	O
STAT3	O
signaling	O
pathway	O
serves	O
as	O
an	O
essential	O
effector	O
of	O
USP6	O
in	O
BSTT	O
formation	O
.	O

We	O
found	O
that	O
USP6	O
directly	O
deubiquitinated	O
Jak1	O
,	O
leading	O
to	O
its	O
stabilization	O
and	O
activation	O
of	O
STAT3	O
.	O

The	O
tumorigenic	O
potential	O
of	O
USP6	O
was	O
attenuated	O
significantly	O
by	O
CRISPR	O
-mediated	O
deletion	O
of	O
Jak1	O
or	O
STAT3	O
,	O
or	O
by	O
administration	O
of	O
a	O
Jak	O
family	O
inhibitor	O
.	O

Analysis	O
of	O
primary	O
clinical	O
samples	O
of	O
nodular	O
fasciitis	O
confirmed	O
the	O
activation	O
of	O
a	O
Jak1	O
-	O
STAT3	O
gene	O
signature	O
in	O
vivo	O
Together	O
,	O
our	O
studies	B-P
highlight	O
Jak1	O
as	O
the	O
first	O
identified	O
substrate	O
for	O
USP6	O
,	O
and	O
they	O
offer	O
a	O
mechanistic	O
rationale	O
for	O
the	O
clinical	O
investigation	O
of	O
Jak	O
and	O
STAT3	O
inhibitors	O
as	O
therapeutics	O
for	O
the	O
treatment	O
of	O
bone	O
and	O
soft	O
tissue	O
tumors	O
along	O
with	O
other	O
neoplasms	O
driven	O
by	O
USP6	O
overexpression	O
.	O

Cancer	O
Res	O
;	O
76	O
(	O
18	O
)	O
;	O
5337-47	O
.	O

Â©2016	O
AACR	O
.	O

Lignans	O
from	O
the	O
fruits	O
of	O
Schisandra	O
chinensis	O
(	O
Turcz	O
.	O
)	O

Baill	O
inhibit	O
proprotein	O
convertase	O
subtilisin/kexin	O
type	O
9	O
expression	O
.	O

Bioactivity-guided	B-P
fractionation	I-P
of	O
the	O
fruits	O
of	O
Schisandra	O
chinensis	O
,	O
using	O
the	O
proprotein	O
convertase	O
subtilisin-kexin	O
type	O
9	O
(	O
PCSK9	O
)	O
mRNA	O
expression	O
screening	B-P
assay	I-P
,	O
led	O
to	O
isolation	O
of	O
two	O
previously	O
unknown	O
lignans	O
,	O
14-tigloylschinlignan	O
D	O
and	O
rel-	O
(	O
7R	O
,	O
8R	O
,	O
7	O
'	O
R	O
,	O
8	O
'	O
R	O
)	O
-manglisin	O
E	O
,	O
along	O
with	O
28	O
known	O
compounds	O
.	O

All	O
structures	O
were	O
established	O
by	O
NMR	B-P
spectroscopic	I-P
data	O
as	O
well	O
as	O
CD	B-P
and	O
MS	B-P
analysis	O
.	O

All	O
isolates	O
were	O
tested	O
for	O
their	O
inhibitory	O
activities	O
on	O
the	O
mRNA	O
expression	O
of	O
PCSK9	O
.	O

Of	O
the	O
tested	O
compounds	O
,	O
four	O
of	O
the	O
compounds	O
rel-	O
(	O
7R	O
,	O
8R	O
,	O
7	O
'	O
R	O
,	O
8	O
'	O
R	O
)	O
-manglisin	O
E	O
,	O
(	O
-	O
)	O
-schisandrin	O
C	O
,	O
schinlignan	O
D	O
,	O
and	O
(	O
+	O
)	O
-schisandrol	O
B	O
potently	O
inhibited	O
PCSK9	O
mRNA	O
expression	O
with	O
IC50	O
values	O
of	O
3.15	O
,	O
3.85	O
,	O
0.36	O
,	O
and	O
1.10	O
Î¼M	O
,	O
respectively	O
.	O

Furthermore	O
,	O
schinlignan	O
D	O
and	O
(	O
+	O
)	O
-schisandrol	O
B	O
were	O
found	O
to	O
suppress	O
PCSK9	O
protein	O
expressions	O
and	O
schinlignan	O
D	O
deemed	O
to	O
increase	O
low	O
density	O
lipoprotein	O
receptor	O
expression	O
.	O

Prediction	O
of	O
extravasation	O
in	O
pelvic	O
fracture	O
using	O
coagulation	O
biomarkers	O
.	O

To	O
evaluate	O
the	O
usefulness	O
of	O
coagulation	O
biomarkers	O
,	O
which	O
are	O
easy	O
and	O
quick	O
to	O
analyze	O
in	O
emergency	O
settings	O
,	O
for	O
prediction	O
of	O
arterial	O
extravasation	O
due	O
to	O
pelvic	O
fracture	O
.	O

The	O
medical	O
records	O
of	O
pelvic	O
fracture	O
patients	O
transferred	O
to	O
the	O
emergency	O
department	O
of	O
Gunma	O
University	O
Hospital	O
between	O
December	O
2009	O
and	O
May	O
2015	O
were	O
reviewed	O
.	O

Patients	O
were	O
divided	O
into	O
two	O
groups	O
,	O
those	O
with	O
(	O
Extra	O
(	O
+	O
)	O
)	O
and	O
without	O
(	O
Extra	O
(	O
-	O
)	O
)	O
arterial	O
extravasation	O
on	O
enhanced	O
CT	B-P
or	O
angiography	B-P
.	O

Levels	O
of	O
fibrin	B-P
degradation	I-P
products	I-P
(	O
FDP	B-P
)	O
,	O
D-dimer	B-P
,	O
fibrinogen	B-P
,	O
the	O
ratio	B-P
of	I-P
FDP	I-P
to	I-P
fibrinogen	I-P
,	O
the	O
ratio	B-P
of	I-P
D-dimer	I-P
to	I-P
fibrinogen	I-P
,	O
systolic	O
blood	O
pressure	O
,	O
heart	O
rate	O
,	O
the	O
Glasgow	O
Coma	O
Scale	O
,	O
pH	O
,	O
base	B-P
excess	I-P
,	O
hemoglobin	B-P
and	O
lactate	B-P
levels	O
,	O
the	O
pattern	O
of	O
pelvic	O
injury	O
,	O
and	O
injury	O
severity	O
score	O
were	O
measured	O
at	O
hospital	O
admission	O
,	O
and	O
compared	O
between	O
the	O
two	O
groups	O
.	O

Parameters	O
with	O
a	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
were	O
used	O
to	O
construct	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
.	O

The	O
study	O
included	O
29	O
patients	O
with	O
pelvic	O
fracture	O
.	O

FDP	O
,	O
D-dimer	O
,	O
the	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
and	O
the	O
ratio	O
of	O
D-dimer	O
to	O
fibrinogen	O
were	O
the	O
most	O
useful	O
parameters	O
for	O
predicting	O
arterial	O
extravasation	O
due	O
to	O
pelvic	O
fracture	O
.	O

FDP	O
,	O
D-dimer	O
,	O
the	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
,	O
the	O
ratio	O
of	O
D-dimer	O
to	O
fibrinogen	O
,	O
and	O
hemoglobin	O
and	O
lactate	O
levels	O
were	O
significantly	O
higher	O
in	O
the	O
Extra	O
(	O
+	O
)	O
group	O
than	O
in	O
the	O
Extra	O
(	O
-	O
)	O
group	O
(	O
FDP	O
,	O
354.8Î¼g/mL	O
[	O
median	O
]	O
versus	O
96.6Î¼g/mL	O
;	O
D-dimer	O
,	O
122.3Î¼g/mL	O
versus	O
42.1Î¼g/mL	O
;	O
the	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
,	O
3.39	O
versus	O
0.42	O
;	O
the	O
ratio	O
of	O
D-dimer	O
to	O
fibrinogen	O
,	O
1.14	O
versus	O
0.18	O
;	O
hemoglobin	O
,	O
10.5g/dL	O
versus	O
13.5g/dL	O
;	O
lactate	O
,	O
3.5mmol/L	O
versus	O
1.7mmol/L	O
)	O
.	O

The	O
area	O
under	O
the	O
ROC	O
curves	O
for	O
FDP	O
,	O
D-dimer	O
,	O
the	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
,	O
the	O
ratio	O
of	O
D-dimer	O
to	O
fibrinogen	O
,	O
hemoglobin	O
and	O
lactate	O
levels	O
were	O
0.900	O
,	O
0.882	O
,	O
0.918	O
,	O
0.900	O
,	O
0.815	O
and	O
0.765	O
,	O
respectively	O
.	O

Coagulation	O
biomarkers	O
,	O
and	O
hemoglobin	O
and	O
lactate	O
levels	O
could	O
be	O
useful	O
to	O
predict	O
the	O
existence	O
of	O
arterial	O
extravasation	O
due	O
to	O
pelvic	O
fracture	O
.	O

The	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
and	O
the	O
ratio	O
of	O
D-dimer	O
to	O
fibrinogen	O
were	O
the	O
most	O
accurate	O
markers	O
.	O

Coagulation	O
biomarkers	O
may	O
enable	O
more	O
rapid	O
and	O
specific	O
treatment	O
for	O
pelvic	O
fracture	O
.	O

Increased	O
cerebral	O
blood	O
volume	O
pulsatility	O
during	O
head-down	O
tilt	O
with	O
elevated	O
carbon	O
dioxide	O
:	O
The	O
SPACECOT	O
Study	O
.	O

Astronauts	O
aboard	O
the	O
International	O
Space	O
Station	O
(	O
ISS	O
)	O
have	O
exhibited	O
hyperopic	O
shifts	O
,	O
posterior	O
eye	O
globe	O
flattening	O
,	O
dilated	O
optic	O
nerve	O
sheaths	O
,	O
and	O
even	O
optic	O
disc	O
swelling	O
from	O
spaceflight	O
.	O

Elevated	O
intracranial	O
pressure	O
(	O
ICP	O
)	O
consequent	O
to	O
cephalad	O
fluid	O
shifts	O
is	O
commonly	O
hypothesized	O
as	O
contributing	O
to	O
these	O
ocular	O
changes	O
.	O

Head-down	O
tilt	O
(	O
HDT	O
)	O
is	O
frequently	O
utilized	O
as	O
an	O
Earth	O
-based	O
analog	O
to	O
study	O
similar	O
fluid	O
shifts	O
.	O

Sealed	O
environments	O
like	O
the	O
ISS	O
also	O
exhibit	O
elevated	O
carbon	O
dioxide	O
(	O
CO2	O
)	O
,	O
a	O
potent	O
arteriolar	O
vasodilator	O
that	O
could	O
further	O
affect	O
cerebral	O
blood	O
volume	O
and	O
flow	O
,	O
intracranial	O
compliance	O
,	O
and	O
ICP	O
.	O

A	O
collaborative	O
pilot	O
study	O
between	O
the	O
National	O
Space	O
Biomedical	O
Research	O
Institute	O
and	O
the	O
German	O
Aerospace	O
Center	O
tested	O
the	O
hypotheses	O
that	O
:	O
(	O
1	O
)	O
HDT	O
and	O
elevated	O
CO2	O
physiologically	O
interact	O
,	O
and	O
(	O
2	O
)	O
cerebrovascular	O
pulsatility	O
is	O
related	O
to	O
HDT	O
and/or	O
elevated	O
CO2	O
In	O
a	O
double-blind	O
crossover	O
study	O
(	O
n=6	O
)	O
,	O
we	O
measured	O
cerebral	O
blood	O
volume	O
(	O
CBV	O
)	O
pulsatility	O
via	O
near-infrared	B-P
spectroscopy	I-P
,	O
alongside	O
non-invasive	O
ICP	O
and	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
during	O
28-hr	O
-12Â°	O
HDT	O
at	O
both	O
nominal	O
(	O
0.04	O
%	O
)	O
and	O
elevated	O
(	O
0.5	O
%	O
)	O
ambient	O
CO2	O
In	O
our	O
cohort	O
,	O
CBV	O
pulsatility	O
increased	O
significantly	O
over	O
time	O
at	O
cardiac	O
frequencies	O
(	O
0.031Â±0.009	O
Î¼M/hr	O
increase	O
in	O
[	O
HbT	O
]	O
pulsatility	O
amplitude	O
)	O
and	O
Mayer	O
wave	O
frequencies	O
(	O
0.019Â±0.005	O
Î¼M/hr	O
increase	O
)	O
.	O

The	O
HDT	O
-	O
CO2	O
interaction	O
on	O
pulsatility	O
was	O
not	O
robust	O
,	O
but	O
rather	O
driven	O
by	O
an	O
individual	O
.	O

Significant	O
differences	O
between	O
atmospheres	O
were	O
not	O
detected	O
in	O
ICP	O
or	O
IOP	O
.	O

Further	O
work	O
is	O
needed	O
to	O
reproduce	O
these	O
findings	O
in	O
a	O
larger	O
cohort	O
,	O
to	O
determine	O
whether	O
a	O
``	O
water	O
hammer	O
''	O
effect	O
in	O
cerebral	O
pulsatility	O
is	O
also	O
present	O
during	O
spaceflight	O
,	O
and	O
whether	O
it	O
is	O
associated	O
with	O
ocular	O
changes	O
in	O
astronauts	O
.	O

Timing	O
of	O
Hormone	O
Withdrawal	O
in	O
Children	O
Undergoing	O
131I	O
Whole-Body	B-P
Scans	I-P
for	O
Thyroid	O
Cancer	O
.	O

Little	O
objective	O
pediatric	O
data	O
exist	O
to	O
guide	O
the	O
optimal	O
time	O
needed	O
to	O
achieve	O
thyroid-stimulating	O
hormone	O
(	O
TSH	O
)	O
levels	O
â¥30	O
Î¼IU/mL	O
prior	O
to	O
performing	O
131I	O
or	O
123I	O
whole-body	B-P
scan	I-P
(	I-P
WBS	I-P
)	I-P
imaging	I-P
in	O
children	O
with	O
thyroid	O
cancer	O
in	O
the	O
post	O
-	O
thyroidectomy	O
period	O
or	O
after	O
hormone	O
discontinuation	O
.	O

Retrospective	O
study	O
of	O
patients	O
aged	O
5-19	O
years	O
who	O
underwent	O
WBS	B-P
.	O

Patient	O
data	O
collection	O
included	O
type	O
and	O
duration	O
of	O
withdrawal	O
(	O
liothyronine	O
[	O
L-T3	O
]	O
,	O
levothyroxine	O
[	O
L-T4	O
]	O
,	O
or	O
post	O
-	O
thyroidectomy	O
status	O
without	O
hormonal	O
replacement	O
)	O
and	O
TSH	O
measured	O
prior	O
to	O
WBS	B-P
(	O
level	O
and	O
timing	O
)	O
.	O

A	O
total	O
of	O
175	O
TSH	B-P
level	I-P
measurements	I-P
were	O
performed	O
in	O
68	O
patients	O
.	O

Thirty-five	O
TSH	O
values	O
were	O
obtained	O
2-7	O
weeks	O
postoperatively	O
and	O
101	O
values	O
were	O
obtained	O
2-8	O
weeks	O
post	O
L-T4	O
withdrawal	O
.	O

One	O
patient	O
in	O
each	O
group	O
had	O
a	O
TSH	O
level	O
<	O
30	O
Î¼IU/mL	O
.	O

There	O
was	O
no	O
difference	O
in	O
TSH	O
levels	O
between	O
3	O
weeks	O
and	O
4	O
weeks	O
postoperatively	O
(	O
p	O
=	O
0.14	O
)	O
or	O
post	O
L-T4	O
cessation	O
(	O
p	O
=	O
0.21	O
)	O
.	O

Thirty-nine	O
TSH	B-P
measurements	I-P
were	O
obtained	O
1-28	O
days	O
post	O
L-T3	O
withdrawal	O
.	O

Three	O
patients	O
had	O
to	O
be	O
rescheduled	O
due	O
to	O
inadequate	O
TSH	O
levels	O
,	O
including	O
one	O
after	O
14	O
days	O
L-T3	O
withdrawal	O
.	O

TSH	O
levels	O
â¥30	O
Î¼IU/mL	O
were	O
achieved	O
at	O
3	O
weeks	O
post	O
thyroidectomy	O
or	O
after	O
L-T4	O
withdrawal	O
and	O
after	O
at	O
least	O
2	O
weeks	O
following	O
L-T3	O
cessation	O
.	O

Molecular	O
mechanism	O
leading	O
to	O
SAHA	O
-	O
induced	O
autophagy	O
in	O
tumor	O
cells	O
:	O
evidence	O
for	O
a	O
p53	O
-dependent	O
pathway	O
.	O

Recent	O
studies	O
indicated	O
that	O
histone	O
deacetylase	O
inhibitors	O
(	O
HDACi	O
)	O
,	O
a	O
class	O
of	O
anticancer	O
agents	O
,	O
are	O
in	O
addition	O
to	O
their	O
ability	O
of	O
apoptosis	O
induction	O
also	O
capable	O
of	O
provoking	O
autophagy	O
.	O

Promoted	O
by	O
the	O
treatment	O
of	O
malignant	O
uterine	O
sarcoma	O
cells	O
with	O
the	O
HDACi	O
suberoylanilide	O
hydroxamic	O
acid	O
(	O
SAHA	O
)	O
,	O
we	O
previously	O
demonstrated	O
predominant	O
dose-dependent	O
activation	O
of	O
autophagy	O
in	O
ESS-1	O
cells	O
,	O
but	O
prevalent	O
induction	O
of	O
apoptosis	O
in	O
MES-SA	O
cells	O
.	O

In	O
order	O
to	O
extend	O
our	O
previous	O
studies	O
,	O
SAHA	O
-	O
treated	O
ESS-1	O
and	O
MES-SA	O
cells	O
were	O
monitored	O
for	O
protein	O
expression	O
to	O
reveal	O
differences	O
in	O
known	O
markers	O
of	O
apoptosis	O
explaining	O
the	O
different	O
cytotoxic	O
responses	O
.	O

Further	O
analysis	O
of	O
the	O
identified	O
candidate	O
protein	O
included	O
cell	O
rescue	O
experiments	O
by	O
gene	O
transfer	O
followed	O
by	O
subsequent	O
screening	O
of	O
cells	O
for	O
induction	O
of	O
apoptosis	O
and	O
autophagy	O
by	O
immunoblotting	B-P
,	O
caspase	O
activity	O
as	O
well	O
as	O
LC3	O
and	O
MDC	O
/	O
PI	O
staining	B-P
.	O

LDH	O
release	O
assays	B-P
were	O
performed	O
to	O
assess	O
the	O
amount	O
of	O
cell	O
-mediated	O
cytotoxicity	O
.	O

In	O
our	O
search	O
for	O
responsible	O
autophagic	O
regulatory	O
genes	O
upstream	O
of	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
,	O
we	O
now	O
discovered	O
that	O
,	O
in	O
contrast	O
to	O
MES-SA	O
cells	O
,	O
a	O
TP53-637C	O
>	O
T	O
nonsense	O
mutation	O
located	O
in	O
the	O
transactivating	O
domain	O
of	O
the	O
oncogenic	O
suppressor	O
p53	O
causes	O
loss	O
of	O
its	O
protein	O
and	O
consequently	O
reduced	O
PUMA	O
induction	O
in	O
ESS-1	O
cells	O
.	O

Upon	O
re-introduction	O
of	O
wild-type	O
TP53	O
,	O
SAHA	O
-	O
treated	O
ESS-1	O
cells	O
underwent	O
immediate	O
apoptotic	O
cell	O
death	O
as	O
supported	O
by	O
upregulation	O
of	O
PUMA	O
and	O
caspase-9	O
as	O
well	O
as	O
by	O
activation	O
of	O
caspases-3	O
and	O
-	O
7	O
and	O
PARP-1	O
cleavage	O
.	O

Concurrent	O
downregulation	O
of	O
autophagy	O
was	O
noticed	O
by	O
upregulated	O
mTor	O
and	O
phospho-mTOR	O
expression	O
as	O
well	O
as	O
monitoring	O
autophagosome	O
formation	O
employing	O
LC3	O
and	O
MDC	O
staining	B-P
.	O

Previously	O
,	O
cytoplasmic	O
master	O
regulatory	O
activities	O
of	O
the	O
oncogenic	O
suppressor	O
p53	O
in	O
inhibiting	O
autophagy	O
and	O
triggering	O
apoptosis	O
were	O
unravelled	O
.	O

Accordingly	O
,	O
p53	O
-	O
deficiency	O
could	O
explain	O
both	O
,	O
the	O
previously	O
documented	O
apoptosis	O
resistance	O
and	O
prevailing	O
SAHA	O
-	O
induced	O
autophagy	O
in	O
ESS-1	O
cells	O
.	O

Using	O
MES-SA	O
cells	O
with	O
RNAi-silenced	O
p53	O
expression	O
and	O
several	O
p53	O
-	O
deficient	O
tumor	O
cell	O
lines	O
undergoing	O
SAHA	O
-	O
induced	O
autophagy	O
,	O
we	O
could	O
generally	O
validate	O
our	O
finding	O
suggesting	O
an	O
inhibitory	O
role	O
for	O
p53	O
in	O
the	O
autophagic	O
pathway	O
in	O
response	O
to	O
SAHA	O
treatment	O
.	O

Conclusively	O
,	O
these	O
results	O
could	O
identify	O
cytoplasmic	O
p53	O
protein	O
as	O
a	O
molecular	O
switch	O
that	O
directly	O
mediates	O
the	O
cytotoxic	O
response	O
of	O
SAHA	O
and	O
thus	O
open	O
new	O
therapeutic	O
avenues	O
.	O

Structural	O
Insight	O
into	O
Recognition	O
of	O
Methylated	O
Histone	O
H3K4	O
by	O
Set3	O
.	O

The	O
plant	O
homeodomain	O
(	O
PHD	O
)	O
finger	O
of	O
Set3	O
binds	O
methylated	O
lysine	O
4	O
of	O
histone	O
H3	O
in	O
vitro	O
and	O
in	O
vivo	O
;	O
however	O
,	O
precise	O
selectivity	O
of	O
this	O
domain	O
has	O
not	O
been	O
fully	O
characterized	O
.	O

Here	O
,	O
we	O
explore	O
the	O
determinants	O
of	O
methyllysine	O
recognition	O
by	O
the	O
PHD	O
fingers	O
of	O
Set3	O
and	O
its	O
orthologs	O
.	O

We	O
use	O
X-ray	B-P
crystallographic	I-P
and	O
spectroscopic	B-P
approaches	I-P
to	O
show	O
that	O
the	O
Set3	O
PHD	O
finger	O
binds	O
di-	O
and	O
trimethylated	O
states	O
of	O
H3K4	O
with	O
comparable	O
affinities	O
and	O
employs	O
similar	O
molecular	O
mechanisms	O
to	O
form	O
complexes	O
with	O
either	O
mark	O
.	O

Composition	O
of	O
the	O
methyllysine	O
-	O
binding	O
pocket	O
plays	O
an	O
essential	O
role	O
in	O
determining	B-P
the	I-P
selectivity	I-P
of	O
the	O
PHD	O
fingers	O
.	O

The	O
finding	O
that	O
the	O
histone-binding	O
activity	O
is	O
not	O
conserved	O
in	O
the	O
PHD	O
finger	O
of	O
Set4	O
suggests	O
different	O
functions	O
for	O
the	O
Set3	O
and	O
Set4	O
paralogs	O
.	O

Effectiveness	O
of	O
Intracavitary	O
Electrocardiogram	O
Guidance	O
in	O
Peripherally	O
Inserted	O
Central	O
Catheter	O
Tip	O
Placement	O
in	O
Neonates	O
.	O

Correct	O
tip	O
location	O
is	O
crucial	O
for	O
a	O
peripherally	O
inserted	O
central	O
catheter	O
(	O
PICC	O
)	O
to	O
maximize	O
the	O
effects	O
of	O
central	O
venous	O
infusion	O
.	O

However	O
,	O
it	O
is	O
difficult	O
to	O
place	O
the	O
tip	O
in	O
a	O
correct	O
location	O
in	O
neonates	O
because	O
of	O
the	O
unreliable	O
estimated	O
length	O
by	O
surface	O
landmark	O
.	O

Therefore	O
,	O
we	O
evaluated	O
the	O
feasibility	O
and	O
safety	O
of	O
an	O
improved	O
intracavitary	O
electrocardiogram	O
(	O
IC	O
-	O
ECG	O
)	O
technique	O
in	O
guiding	O
PICC	O
placement	O
in	O
neonates	O
based	O
on	O
the	O
ratios	O
of	O
P/R	O
wave	O
amplitudes	O
on	O
IC	O
-	O
ECG	O
.	O

The	O
results	O
showed	O
that	O
all	O
of	O
the	O
32	O
neonates	O
whose	O
PICCs	O
had	O
been	O
successfully	O
placed	O
and	O
correct	O
tip	O
position	O
verified	O
by	O
chest	B-P
radiography	I-P
acquired	O
qualified	O
P	O
wave	O
on	O
IC	O
-	O
ECG	O
.	O

The	O
average	O
ratio	O
of	O
P/R	O
wave	O
amplitude	O
was	O
0.6	O
Â±	O
0.1	O
,	O
with	O
a	O
range	O
of	O
0.4	O
to	O
0.8	O
.	O

The	O
49	O
neonates	O
who	O
received	O
IC	O
-	O
ECG	O
-guided	O
PICC	O
catheterization	O
showed	O
higher	O
success	O
rates	O
of	O
correct	O
PICC	O
tip	O
position	O
on	O
the	O
first	O
attempt	O
than	O
traditional	O
,	O
predetermined	O
length	O
estimation	O
on	O
surface	O
landmark	O
(	O
93.9	O
%	O
vs	O
62.5	O
%	O
,	O
Ï	O
=	O
18.01	O
,	O
P	O
<	O
.001	O
)	O
.	O

No	O
significant	O
complications	O
occurred	O
in	O
the	O
studied	O
neonates	O
.	O

Based	O
on	O
these	O
findings	O
,	O
IC	O
-	O
ECG	O
-guided	O
tip	O
placement	O
appears	O
to	O
be	O
a	O
promising	O
approach	O
in	O
improving	O
the	O
success	O
rate	O
of	O
tip	O
location	O
when	O
placing	O
a	O
PICC	O
in	O
neonates	O
.	O

A	O
protocol	O
for	O
pressurized	B-P
liquid	I-P
extraction	I-P
and	O
processing	O
methods	O
to	O
isolate	O
modern	O
and	O
ancient	O
bone	O
cholesterol	O
for	O
compound-specific	O
stable	O
isotope	O
analysis	B-P
.	O

Bone	O
lipid	O
compound-specific	B-P
isotope	I-P
analysis	I-P
(	O
CSIA	B-P
)	O
and	O
bone	O
collagen	O
and	O
apatite	O
stable	O
isotope	O
ratio	O
analysis	B-P
are	O
important	O
sources	O
of	O
ecological	O
and	O
paleodietary	O
information	O
.	O

Pressurized	B-P
liquid	I-P
extraction	I-P
(	O
PLE	B-P
)	O
is	O
quicker	O
and	O
utilizes	O
less	O
solvent	O
than	O
traditional	O
methods	O
of	O
lipid	O
extraction	O
such	O
as	O
soxhlet	B-P
and	O
ultrasonication	O
.	O

This	O
study	O
facilitates	O
dietary	O
analysis	B-P
by	O
optimizing	O
and	O
testing	O
a	O
standardized	O
methodology	O
for	O
PLE	B-P
of	O
bone	O
cholesterol	O
.	O

Modern	O
and	O
archaeological	O
bones	O
were	O
extracted	O
by	O
PLE	B-P
using	O
varied	O
temperatures	O
,	O
solvent	O
solutions	O
,	O
and	O
sample	O
weights	O
.	O

The	O
efficiency	O
of	O
PLE	B-P
was	O
assessed	O
via	O
quantification	O
of	O
cholesterol	O
yields	O
.	O

Stable	O
isotopic	O
ratio	O
integrity	O
was	O
evaluated	O
by	O
comparing	O
isotopic	O
signatures	O
(	O
Î´	O
(	O
13	O
)	O
C	O
and	O
Î´	O
(	O
18	O
)	O
O	O
values	O
)	O
of	O
cholesterol	O
derived	O
from	O
whole	O
bone	O
,	O
bone	O
collagen	O
and	O
bone	O
apatite	O
.	O

Gas	B-P
chromatography/mass	I-P
spectrometry	I-P
(	O
GC/MS	B-P
)	O
and	O
gas	B-P
chromatography	I-P
isotope	I-P
ratio	I-P
mass	I-P
spectrometry	I-P
(	O
GC/IRMS	B-P
)	O
were	O
conducted	O
on	O
purified	O
collagen	O
and	O
lipid	O
extracts	O
to	O
assess	O
isotopic	O
responses	O
to	O
PLE	B-P
.	O

Lipid	O
yield	O
was	O
optimized	O
at	O
two	O
PLE	B-P
extraction	I-P
cycles	O
of	O
75	O
Â°C	O
using	O
dichloromethane	O
/	O
methanol	O
(	O
2:1	O
v/v	O
)	O
as	O
a	O
solvent	O
with	O
0.25-0.75	O
g	O
bone	O
sample	O
.	O

Following	O
lipid	O
extraction	B-P
,	O
saponification	O
combined	O
with	O
the	O
derivatization	O
of	O
the	O
neutral	O
fraction	O
using	O
trimethylsilylation	O
yielded	O
nearly	O
twice	O
the	O
cholesterol	O
of	O
non-saponified	O
or	O
non-derivatized	O
samples	O
.	O

It	O
was	O
also	O
found	O
that	O
lipids	O
extracted	O
from	O
purified	O
bone	O
collagen	O
and	O
apatite	O
could	O
be	O
used	O
for	O
cholesterol	O
CSIA	B-P
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
bulk	O
Î´	O
(	O
13	O
)	O
C	O
values	O
of	O
collagen	O
extracted	O
from	O
bone	O
with	O
or	O
without	O
lipid	O
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
depletion	O
in	O
(	O
18	O
)	O
O	O
of	O
bone	O
apatite	O
due	O
to	O
lipid	O
presence	O
or	O
processing	O
.	O

These	O
results	O
should	O
assist	O
sample	O
selection	O
and	O
provide	O
an	O
effective	O
,	O
alternative	O
extraction	B-P
method	I-P
for	O
bone	O
cholesterol	O
that	O
may	O
be	O
used	O
for	O
isotopic	O
and	O
paleodietary	O
analysis	B-P
.	O

Copyright	O
Â©	O
2016	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Encaged	O
Chironomus	O
riparius	O
larvae	O
in	O
assessment	O
of	O
trace	O
metal	O
bioavailability	O
and	O
transfer	O
in	O
a	O
landfill	O
leachate	O
collection	O
pond	O
.	O

Household	O
wastes	O
may	O
constitute	O
a	O
vector	O
of	O
environmental	O
contamination	O
when	O
buried	O
,	O
in	O
particular	O
through	O
degradation	O
and	O
production	O
of	O
leachates	O
containing	O
significant	O
trace	O
metal	O
(	O
TM	O
)	O
concentrations	O
that	O
may	O
constitute	O
a	O
serious	O
risk	O
to	O
biota	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
assess	O
the	O
bioavailability	O
and	O
transfer	O
potential	O
of	O
various	O
TMs	O
present	O
in	O
water	O
and	O
sediments	O
in	O
a	O
reservoir	O
receiving	O
landfill	O
leachates	O
.	O

An	O
active	O
biomonitoring	O
approach	O
was	O
adopted	O
consisting	O
of	O
exposing	O
naive	O
laboratory	O
organisms	O
in	O
cages	O
deployed	O
in	O
the	O
field	O
.	O

Aquatic	O
insects	O
such	O
as	O
Chironomus	O
riparius	O
larvae	O
are	O
good	O
candidates	O
since	O
they	O
represent	O
key	O
organisms	O
in	O
the	O
trophic	O
functioning	O
of	O
aquatic	O
ecosystems	O
.	O

The	O
results	O
show	O
that	O
water	O
,	O
suspended	O
particles	O
,	O
and	O
sediments	O
were	O
significant	O
ly	O
contaminated	O
by	O
various	O
TMs	O
(	O
As	O
,	O
Cd	O
,	O
Cu	O
,	O
Ni	O
,	O
Pb	O
,	O
and	O
Zn	O
)	O
.	O

Their	O
contribution	O
to	O
the	O
transfer	O
of	O
TMs	O
depends	O
,	O
however	O
,	O
on	O
the	O
specific	O
element	O
considered	O
,	O
e.g.	O
,	O
Cd	O
in	O
sediments	O
or	O
Pb	O
in	O
both	O
suspended	O
particles	O
and	O
sediments	O
.	O

The	O
internal	O
fate	O
of	O
TMs	O
was	O
investigated	O
according	O
to	O
their	O
fractionation	B-P
between	O
an	O
insoluble	O
and	O
a	O
cytosolic	O
fraction	O
.	O

This	O
approach	O
revealed	O
different	O
detoxification	O
strategies	O
capable	O
of	O
preventing	O
the	O
induction	O
of	O
deleterious	O
effects	O
at	O
the	O
individual	O
scale	O
.	O

However	O
,	O
the	O
accumulation	O
of	O
several	O
TMs	O
in	O
C.	O
riparius	O
larvae	O
tissues	O
may	O
also	O
represent	O
a	O
significant	O
load	O
potentially	O
transferable	O
to	O
higher	O
trophic	O
levels	O
.	O

International	O
validation	O
of	O
a	O
urinary	O
biomarker	O
panel	B-P
for	O
identification	O
of	O
active	O
lupus	O
nephritis	O
in	O
children	O
.	O

Conventional	O
markers	O
of	O
juvenile-onset	O
systemic	O
lupus	O
erythematosus	O
(	O
JSLE	O
)	O
disease	B-P
activity	I-P
fail	O
to	O
adequately	O
identify	O
lupus	O
nephritis	O
(	O
LN	O
)	O
.	O

While	O
individual	O
novel	O
urine	O
biomarkers	O
are	O
good	O
at	O
detecting	O
LN	O
flares	O
,	O
biomarker	O
panels	B-P
may	O
improve	O
diagnostic	O
accuracy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
performance	O
of	O
a	O
biomarker	O
panel	B-P
to	O
identify	O
active	O
LN	O
in	O
two	O
international	O
JSLE	O
cohorts	O
.	O

Novel	O
urinary	O
biomarkers	O
,	O
namely	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
)	O
,	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP-1	O
)	O
,	O
lipocalin-like	O
prostaglandin	O
D	O
synthase	O
(	O
LPGDS	O
)	O
,	O
transferrin	O
(	O
TF	O
)	O
,	O
ceruloplasmin	O
,	O
alpha-1-acid	O
glycoprotein	O
(	O
AGP	O
)	O
and	O
neutrophil	O
gelatinase-associated	O
lipocalin	O
(	O
NGAL	O
)	O
,	O
were	O
quantified	O
in	O
a	O
cross-sectional	O
study	O
that	O
included	O
participants	O
of	O
the	O
UK	O
JSLE	O
Cohort	O
Study	O
(	O
Cohort	O
1	O
)	O
and	O
validated	O
within	O
the	O
Einstein	O
Lupus	O
Cohort	O
(	O
Cohort	O
2	O
)	O
.	O

Binary	O
logistic	O
regression	O
modelling	O
and	O
receiver	O
operating	O
characteristic	O
curve	O
analysis	O
[	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
]	O
were	O
used	O
to	O
identify	O
and	O
assess	O
combinations	O
of	O
biomarkers	O
for	O
diagnostic	O
accuracy	O
.	O

A	O
total	O
of	O
91	O
JSLE	O
patients	O
were	O
recruited	O
across	O
both	O
cohorts	O
,	O
of	O
whom	O
31	O
(	O
34	O
%	O
)	O
had	O
active	O
LN	O
and	O
60	O
(	O
66	O
%	O
)	O
had	O
no	O
LN	O
.	O

Urinary	O
AGP	O
,	O
ceruloplasmin	O
,	O
VCAM-1	O
,	O
MCP-1	O
and	O
LPGDS	O
levels	O
were	O
significantly	O
higher	O
in	O
those	O
patients	O
with	O
active	O
LN	O
than	O
in	O
non	O
-	O
LN	O
patients	O
[	O
all	O
corrected	O
p	O
values	O
(	O
p	O
c	O
)	O
<	O
0.05	O
]	O
across	O
both	O
cohorts	O
.	O

Urinary	O
TF	O
also	O
differed	O
between	O
patient	O
groups	O
in	O
Cohort	O
2	O
(	O
p	O
c	O
=	O
0.001	O
)	O
.	O

Within	O
Cohort	O
1	O
,	O
the	O
optimal	O
biomarker	O
panel	B-P
included	O
AGP	O
,	O
ceruloplasmin	O
,	O
LPGDS	O
and	O
TF	O
(	O
AUC	O
0.920	O
for	O
active	O
LN	O
identification	O
)	O
.	O

These	O
results	O
were	O
validated	O
in	O
Cohort	O
2	O
,	O
with	O
the	O
same	O
markers	O
resulting	O
in	O
the	O
optimal	O
urine	O
biomarker	O
panel	B-P
(	O
AUC	O
0.991	O
)	O
.	O

In	O
two	O
international	O
JSLE	O
cohorts	O
,	O
urinary	O
AGP	O
,	O
ceruloplasmin	O
,	O
LPGDS	O
and	O
TF	O
demonstrate	O
an	O
'excellent	O
'	O
ability	O
for	O
accurately	O
identifying	O
active	O
LN	O
in	O
children	O
.	O

Differences	O
in	O
pain	O
experience	O
and	O
cooperation	O
between	O
consecutive	O
surgeries	O
in	O
patients	O
undergoing	O
phacoemulsification	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
compare	O
pain	O
experience	O
and	O
cooperation	O
between	O
consecutive	O
surgeries	O
in	O
patients	O
undergoing	O
phacoemulsification	O
in	O
both	O
eyes	O
,	O
using	O
sub-Tenon	O
's	O
local	O
anesthesia	O
without	O
sedation	O
.	O

In	O
this	O
study	O
,	O
268	O
patients	O
with	O
bilateral	O
senile	O
cataracts	O
were	O
recruited	O
.	O

All	O
operations	O
were	O
performed	O
without	O
sedation	O
,	O
using	O
a	O
clear	O
corneal	O
phacoemulsification	O
technique	O
and	O
sub-Tenon	O
's	O
local	O
anesthesia	O
,	O
by	O
one	O
of	O
four	O
surgeons	O
.	O

The	O
first	O
surgery	O
was	O
performed	O
on	O
the	O
eye	O
with	O
the	O
higher	O
grade	O
cataract	O
.	O

The	O
other	O
eye	O
was	O
operated	O
on	O
within	O
3	O
months	O
by	O
the	O
same	O
surgeon	O
(	O
mean	O
interval	O
1.9	O
Â±	O
1.1	O
months	O
)	O
.	O

All	O
patients	O
were	O
asked	O
to	O
grade	O
their	O
pain	O
experience	O
during	O
induction	O
and	O
maintenance	O
of	O
anesthesia	O
and	O
also	O
during	O
the	O
phacoemulsification	O
surgery	O
,	O
using	O
a	O
visual	B-P
analogue	I-P
scale	I-P
(	O
VAS	B-P
)	O
from	O
0	O
(	O
no	O
pain	O
)	O
to	O
10	O
(	O
unbearable	O
pain	O
)	O
administered	O
after	O
the	O
surgery	O
.	O

The	O
cooperation	O
of	O
the	O
patient	O
was	O
graded	O
from	O
0	O
(	O
no	O
event	O
)	O
to	O
3	O
(	O
markedeye	O
and	O
head	O
movement	O
and	O
lid	O
squeezing	O
)	O
by	O
the	O
attending	O
surgeon	O
.	O

The	O
VAS	O
scores	O
and	O
cooperation	O
scores	O
of	O
the	O
patients	O
were	O
the	O
outcome	O
measurements	O
.	O

The	O
mean	O
pain	O
score	O
was	O
2.11	O
Â±	O
0.79	O
in	O
the	O
first	O
eye	O
and	O
3.33	O
Â±	O
0.80	O
in	O
the	O
second	O
eye	O
during	O
the	O
administration	O
of	O
sub-Tenon	O
's	O
anesthesia	O
,	O
and	O
1.50	O
Â±	O
0.60	O
in	O
the	O
first	O
eye	O
and	O
2.10	O
Â±	O
0.57	O
in	O
the	O
second	O
eye	O
during	O
the	O
phacoemulsification	O
surgery	O
.	O

The	O
patient	O
cooperation	O
score	O
was	O
1.60	O
Â±	O
0.75	O
in	O
the	O
first	O
surgery	O
and	O
2.08	O
Â±	O
0.72	O
in	O
the	O
second	O
surgery	O
.	O

The	O
differences	O
between	O
the	O
first	O
and	O
second	O
surgeries	O
were	O
statistically	O
significant	O
for	O
all	O
outcome	O
measures	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Patients	O
who	O
previously	O
underwent	O
phaco	O
surgery	O
in	O
one	O
eye	O
experienced	O
more	O
pain	O
and	O
showed	O
worse	O
cooperation	O
during	O
the	O
phaco	O
surgery	O
in	O
the	O
second	O
eye	O
,	O
especially	O
if	O
there	O
was	O
a	O
short	O
time	O
between	O
the	O
surgeries	O
,	O
viz.	O
,	O
less	O
than	O
3	O
months	O
.	O

Therefore	O
,	O
if	O
the	O
surgeon	O
has	O
difficulty	O
in	O
the	O
first	O
operation	O
gaining	O
the	O
patient	O
's	O
cooperation	O
,	O
the	O
surgeon	O
must	O
be	O
careful	O
:	O
if	O
contralateral	O
eye	O
surgery	O
is	O
required	O
,	O
the	O
addition	O
of	O
sedation	O
/	O
analgesia	O
should	O
be	O
considered	O
or	O
the	O
surgery	O
postponed	O
for	O
a	O
while	O
to	O
abolish	O
the	O
influence	O
of	O
recent	O
memory	O
on	O
the	O
patient	O
's	O
subsequent	O
pain	O
experience	O
.	O

Precision	O
Medicine	O
Starts	O
With	O
Preanalytics	O
:	O
Real-Time	O
Assessment	O
of	O
Tissue	B-P
Fixation	I-P
Quality	O
by	O
Ultrasound	O
Time-of-Flight	O
Analysis	O
.	O

Personalized	O
medicine	O
promises	O
diagnosis	O
and	O
treatment	O
of	O
disease	O
at	O
the	O
individual	O
level	O
and	O
relies	O
heavily	O
on	O
clinical	O
specimen	O
integrity	O
and	O
diagnostic	O
assay	B-P
quality	O
.	O

Preanalytics	O
,	O
the	O
collection	O
and	O
handling	B-P
steps	O
of	O
a	O
clinical	O
specimen	O
before	O
immunohistochemistry	B-P
or	O
other	O
clinical	B-P
assay	I-P
,	O
are	O
critically	O
important	O
to	O
enable	O
the	O
correct	O
diagnosis	O
of	O
disease	O
.	O

However	O
,	O
the	O
effects	O
of	O
preanalytics	O
are	O
often	O
overlooked	O
due	O
to	O
a	O
lack	O
of	O
standardization	O
and	O
limited	O
assessment	O
tools	O
to	O
quantify	O
their	O
variation	O
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
real-time	O
ultrasound	O
time-of-flight	O
instrument	O
that	O
is	O
capable	O
of	O
monitoring	O
and	O
imaging	B-P
the	O
critical	O
step	O
in	O
formalin	B-P
fixation	I-P
,	O
diffusion	O
of	O
the	O
fixative	O
into	O
tissue	O
,	O
which	O
provides	O
a	O
quantifiable	O
quality	O
metric	O
for	O
tissue	B-P
fixation	I-P
in	O
the	O
clinical	O
laboratory	O
ensuring	O
consistent	O
downstream	O
molecular	B-P
assay	I-P
results	O
.	O

We	O
analyzed	O
hundreds	O
of	O
tissue	O
specimens	O
from	O
34	O
distinct	O
human	O
tissue	O
types	O
and	O
12	O
clinically	O
relevant	O
diseased	O
tissues	O
for	O
diffusion	O
and	O
fixation	O
metrics	O
.	O

Our	O
measurements	O
can	O
be	O
converted	O
into	O
tissue	O
diffusivity	O
constants	O
that	O
correlate	O
with	O
the	O
apparent	O
diffusion	O
constant	O
calculated	O
using	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
R=0.83	O
)	O
,	O
despite	O
the	O
differences	O
in	O
the	O
approaches	O
,	O
indicating	O
that	O
our	O
approach	O
is	O
biophysically	O
plausible	O
.	O

Using	O
data	O
collected	O
from	O
time-of-flight	O
analysis	O
of	O
many	O
tissues	O
,	O
we	O
have	O
therefore	O
developed	O
a	O
novel	O
rapid	O
fixation	O
program	O
that	O
could	O
ensure	O
high-quality	O
downstream	O
assay	B-P
results	O
for	O
a	O
broad	O
range	O
of	O
human	O
tissue	O
types	O
.	O

Metabolic	O
signatures	O
of	O
birthweight	O
in	O
18	O
288	O
adolescents	O
and	O
adults	O
.	O

Lower	O
birthweight	O
is	O
associated	O
with	O
increased	O
susceptibility	O
to	O
cardiometabolic	O
diseases	O
in	O
adulthood	O
,	O
but	O
the	O
underlying	O
molecular	O
pathways	O
are	O
incompletely	O
understood	O
.	O

We	O
examined	O
associations	O
of	O
birthweight	O
with	O
a	O
comprehensive	O
metabolic	O
profile	O
measured	O
in	O
adolescents	O
and	O
adults	O
.	O

High-throughput	B-P
nuclear	O
magnetic	O
resonance	O
metabolomics	O
and	O
biochemical	B-P
assays	I-P
were	O
used	O
to	O
quantify	O
87	O
circulating	O
metabolic	O
measures	O
in	O
seven	O
cohorts	O
from	O
Finland	O
and	O
the	O
UK	O
,	O
comprising	O
altogether	O
18	O
288	O
individuals	O
(	O
mean	O
age	O
26	O
years	O
,	O
range	O
15-75	O
)	O
.	O

Metabolic	O
associations	O
with	O
birthweight	O
were	O
assessed	O
by	O
linear	O
regression	O
models	O
adjusted	O
for	O
sex	O
,	O
gestational	O
age	O
and	O
age	O
at	O
blood	B-P
sampling	I-P
.	O

The	O
metabolic	O
associations	O
with	O
birthweight	O
were	O
compared	O
with	O
the	O
corresponding	O
associations	O
with	O
adult	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
.	O

Lower	O
birthweight	O
adjusted	O
for	O
gestational	O
age	O
was	O
adversely	O
associated	O
with	O
cardiometabolic	O
biomarkers	O
,	O
including	O
lipoprotein	O
subclasses	O
,	O
fatty	O
acids	O
,	O
amino	O
acids	O
and	O
markers	O
of	O
inflammation	O
and	O
impaired	O
liver	O
function	O
(	O
P	O
<	O
0.0015	O
for	O
46	O
measures	O
)	O
.	O

Associations	O
were	O
consistent	O
across	O
cohorts	O
with	O
different	O
ages	O
at	O
metabolic	O
profiling	O
,	O
but	O
the	O
magnitudes	O
were	O
weak	O
.	O

The	O
pattern	O
of	O
metabolic	O
deviations	O
associated	O
with	O
lower	O
birthweight	O
resembled	O
the	O
metabolic	O
signature	O
of	O
higher	O
adult	O
BMI	O
(	O
R	O
(	O
2	O
)	O
=	O
0.77	O
)	O
assessed	O
at	O
the	O
same	O
time	O
as	O
the	O
metabolic	O
profiling	O
.	O

The	O
resemblance	O
indicated	O
that	O
1	O
kg	O
lower	O
birthweight	O
is	O
associated	O
with	O
similar	O
metabolic	O
aberrations	O
as	O
caused	O
by	O
0.92	O
units	O
higher	O
BMI	O
in	O
adulthood	O
.	O

Lower	O
birthweight	O
adjusted	O
for	O
gestational	O
age	O
is	O
associated	O
with	O
adverse	O
biomarker	O
aberrations	O
across	O
multiple	O
metabolic	O
pathways	O
.	O

Coherent	O
metabolic	O
signatures	O
between	O
lower	O
birthweight	O
and	O
higher	O
adult	O
adiposity	O
suggest	O
that	O
shared	O
molecular	O
pathways	O
may	O
potentially	O
underpin	O
the	O
metabolic	O
deviations	O
.	O

However	O
,	O
the	O
magnitudes	O
of	O
metabolic	O
associations	O
with	O
birthweight	O
are	O
modest	O
in	O
comparison	O
to	O
the	O
effects	O
of	O
adiposity	O
,	O
implying	O
that	O
birthweight	O
is	O
only	O
a	O
weak	O
indicator	O
of	O
the	O
metabolic	O
risk	O
profile	O
in	O
adulthood	O
.	O

A	O
Case	O
Presenting	O
with	O
Splenic	O
Infarct	O
Diagnosed	O
as	O
Primary	O
Bone	O
Marrow	O
CD5	O
Positive	O
DLBCL	O
:	O
A	O
Clinicopathological	O
Correlation	O
.	O

De	O
novo	O
CD5+	O
Diffuse	O
large	O
B	O
cell	O
lymphoma	O
(	O
DLBCL	O
)	O
is	O
a	O
rare	O
and	O
aggressive	O
subtype	O
of	O
DLBCL	O
.	O

It	O
is	O
a	O
distinct	O
clinicopathologic	O
entity	O
with	O
complex	O
molecular	O
profile	O
and	O
poor	O
prognosis	O
.	O

A	O
59	O
year	O
old	O
female	O
presented	O
with	O
pyrexia	O
of	O
unknown	O
origin	O
since	O
1	O
month	O
.	O

On	O
examination	O
,	O
there	O
was	O
severe	O
pallor	O
,	O
hepatosplenomegaly	O
and	O
no	O
palpable	O
lymphadenopathy	O
.	O

Complete	B-P
blood	I-P
count	I-P
revealed	O
bicytopenia	O
with	O
normal	O
total	O
leucocyte	O
count	O
.	O

Liver	B-P
and	O
renal	B-P
function	I-P
tests	I-P
were	O
normal	O
.	O

Ultrasonography	B-P
abdomen	I-P
revealed	O
splenic	O
enlargement	O
with	O
two	O
focal	O
lesions	O
attributed	O
to	O
either	O
splenic	O
abscess	O
or	O
infarcts	O
.	O

Patient	O
was	O
being	O
managed	O
as	O
splenic	O
infarct	O
but	O
continued	O
to	O
have	O
bicytopenia	O
.	O

Further	O
investigation	O
showed	O
elevated	O
serum	O
ferritin	O
,	O
triglycerides	O
and	O
LDH	O
.	O

With	O
a	O
clinical	O
suspicion	O
of	O
infection	O
and	O
haemophagocytic	O
lymphohistiocytosis	O
bone	B-P
bone	B-P
marrow	I-P
aspiration	I-P
(	I-P
BMA	B-P
)	I-P
and	I-P
biopsy	B-P
(	I-P
BMBx	I-P
)	I-P
was	O
done	O
.	O

BMA	O
showed	O
extensive	O
haemophagocytosis	O
and	O
~7.4	O
%	O
large	O
lymphoma-like	O
cells	O
.	O

On	O
this	O
basis	O
PET-CT	B-P
was	O
suggested	O
which	O
showed	O
enlarged	O
spleen	O
with	O
diffuse	O
uptake	O
.	O

BMBx	B-P
showed	O
nodular	O
and	O
intrasinusoidal	O
collection	O
of	O
abnormal	O
lymphoid	O
cells	O
.	O

On	O
immunohistochemistry	B-P
,	O
these	O
cells	O
were	O
positive	O
for	O
CD20	O
,	O
CD5	O
,	O
MUM1	O
,	O
BCL-2	O
,	O
BCL-6	O
and	O
negative	O
for	O
CD3	O
,	O
CD10	O
and	O
CD23	O
.	O

CD34	O
highlighted	O
focal	O
intrasinusoidal	O
pattern	O
.	O

The	O
complete	O
clinicopathological	O
profile	O
suggested	O
the	O
diagnosis	O
of	O
de	O
novo	O
CD5+	O
DLBCL	O
,	O
with	O
primary	O
hepatosplenic	O
pattern	O
of	O
involvement	O
.	O

CD5+	O
DLBCL	O
presenting	O
as	O
splenic	O
infarct	O
is	O
very	O
rare	O
.	O

This	O
case	O
was	O
unusual	O
as	O
the	O
diagnosis	O
of	O
a	O
primary	O
aggressive	O
lymphoma	O
with	O
haemophagocytosis	O
was	O
established	O
in	O
a	O
patient	O
who	O
presented	O
with	O
fever	O
and	O
splenic	O
infarct	O
without	O
lymphadenopathy	O
.	O

This	O
indicates	O
the	O
importance	O
of	O
good	O
morphological	O
assessment	O
of	O
a	O
bone	O
marrow	O
aspirate	O
and	O
biopsy	B-P
to	O
make	O
a	O
correct	O
diagnosis	O
.	O

EGFR	O
protein	O
expression	O
using	O
a	O
specific	O
intracellular	O
domain	O
antibody	O
and	O
PTEN	O
and	O
clinical	O
outcomes	O
in	O
squamous	O
cell	O
lung	O
cancer	O
patients	O
with	O
EGFR-tyrosine	O
kinase	O
inhibitor	O
therapy	O
.	O

The	O
aim	O
of	O
this	O
research	O
was	O
to	O
examine	O
the	O
molecular	O
and	O
clinical	O
features	O
that	O
are	O
related	O
with	O
EGFR-tyrosine	O
kinase	O
inhibitor	O
(	O
EGFR-TKI	O
)	O
efficacy	O
in	O
previously	O
treated	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
lung	O
(	O
SCCL	O
)	O
.	O

This	O
retrospective	O
study	O
included	O
67	O
SCCL	O
patients	O
with	O
obtainable	O
lung	O
cancer	O
tissue	O
and	O
records	O
on	O
EGFR-TKI	O
treatment	O
response	O
and	O
survival	O
.	O

EGFR	O
protein	O
expression	O
in	O
lung	O
cancer	O
tissue	O
was	O
measured	O
by	O
immunohistochemistry	B-P
with	O
a	O
specific	O
antibody	O
that	O
recognizes	O
the	O
intracellular	O
domain	O
(	O
ID	O
)	O
of	O
EGFR	O
.	O

PTEN	O
expression	O
in	O
lung	O
cancer	O
tissue	O
was	O
also	O
evaluated	O
with	O
immunohistochemistry	B-P
.	O

PI3KCA	O
gene	O
amplification	O
was	O
detected	O
by	O
quantitative	O
real-time	O
polymerase	O
chain	O
reaction	O
,	O
and	O
FGFR1	O
amplification	O
was	O
assessed	O
by	O
fluorescent	O
in	O
situ	O
hybridization	O
.	O

EGFR	O
ID	O
expression	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
0.53	O
,	O
P=0.022	O
)	O
and	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
(	O
PS	O
)	O
(	O
HR	O
0.43	O
,	O
P=0.022	O
)	O
were	O
significantly	O
related	O
with	O
progression	O
-	O
free	O
survival	O
following	O
EGFR-TKIs	O
treatment	O
.	O

PTEN	O
expression	O
(	O
HR	O
0.52	O
,	O
P=0.025	O
)	O
was	O
significantly	O
related	O
to	O
overall	O
survival	O
.	O

The	O
group	O
of	O
EGFR	O
-	O
positive	O
or	O
PTEN	O
-	O
positive	O
patients	O
with	O
ECOG	O
PS	O
of	O
0	O
or	O
1	O
had	O
better	O
clinical	O
outcomes	O
than	O
patients	O
who	O
were	O
EGFR	O
-	O
negative	O
and	O
PTEN	O
-	O
negative	O
or	O
who	O
had	O
poor	O
ECOG	O
PS	O
with	O
longer	O
median	O
progression	O
-	O
free	O
survival	O
(	O
2.1	O
vs	O
1.0	O
months	O
,	O
P=0.05	O
)	O
and	O
overall	O
survival	O
(	O
6.2	O
vs	O
2.1	O
months	O
,	O
P=0.05	O
)	O
.	O

EGFR	O
expression	O
using	O
an	O
ID	O
-specific	O
antibody	O
and	O
PTEN	O
protein	O
expression	O
may	O
be	O
used	O
to	O
identify	O
SCCL	O
patients	O
who	O
might	O
benefit	O
from	O
EGFR-TKI	O
treatment	O
.	O

miRâ221	O
targets	O
HMGA2	O
to	O
inhibit	O
bleomycin	O
âinduced	O
pulmonary	O
fibrosis	O
by	O
regulating	O
TGFâÎ²1	O
/	O
Smad3	O
-induced	O
EMT	O
.	O

MicroRNA	O
(	O
miR	O
)	O
-221	O
plays	O
an	O
essential	O
role	O
in	O
the	O
epithelial-mesenchymal	O
transition	O
(	O
EMT	O
)	O
.	O

High	O
mobility	O
group	O
AT-hook	O
2	O
(	O
HMGA2	O
)	O
,	O
is	O
a	O
key	O
regulator	O
of	O
EMT	O
.	O

However	O
,	O
the	O
role	O
of	O
miRâ221	O
in	O
pulmonary	O
fibrosis	O
,	O
and	O
the	O
association	O
between	O
miRâ221	O
and	O
HMGA2	O
remain	O
largely	O
unknown	O
.	O

For	O
this	O
purpose	O
,	O
we	O
examined	O
the	O
expression	O
of	O
miRâ221	O
and	O
HMGA2	O
in	O
human	O
idiopathic	O
pulmonary	O
fibrosis	O
(	O
IPF	O
)	O
tissues	O
and	O
pulmonary	O
cells	O
,	O
namely	O
the	O
adenocarcinoma	O
A549	O
and	O
human	O
bronchial	O
epithelium	O
(	O
HBE	O
)	O
cell	O
lines	O
,	O
and	O
found	O
that	O
the	O
expression	O
of	O
miRâ221	O
was	O
inhibited	O
in	O
both	O
tissues	O
and	O
cells	O
whereas	O
high	O
mRNA	O
and	O
protein	O
expression	O
of	O
HMGA2	O
was	O
observed	O
.	O

Additionally	O
,	O
transforming	O
growth	O
factorâÎ²1	O
(	O
TGFâÎ²1	O
)	O
induced	O
the	O
EMT	O
,	O
characterized	O
by	O
the	O
upregulated	O
expression	B-P
of	O
the	O
mesenchymal	O
markers	O
,	O
namely	O
Nâcadherin	O
,	O
vimentin	O
,	O
Î±âsmooth	O
muscle	O
actin	O
,	O
collagen	O
I	O
and	O
collagen	O
III	O
,	O
and	O
the	O
downregulated	O
expression	B-P
of	O
the	O
epithelial	O
marker	O
E-cadherin	O
in	O
A549	O
and	O
HBE	O
cells	O
.	O

We	O
then	O
performed	O
transfection	O
with	O
miRâ221	O
mimics	O
,	O
and	O
found	O
that	O
the	O
expression	O
of	O
phosphorylated	O
-	O
Smad3	O
in	O
miRâ221	O
â	O
overexpressing	O
cells	O
was	O
significantly	O
downregulated	O
,	O
compared	O
with	O
that	O
in	O
the	O
TGFâÎ²1	O
-treated	O
cells	O
without	O
transfection	O
.	O

Furthermore	O
,	O
the	O
overexpression	O
of	O
miRâ221	O
decreased	O
the	O
expression	O
of	O
HMGA2	O
,	O
suppressed	O
the	O
EMT	O
,	O
and	O
inhibited	O
the	O
proliferation	O
of	O
A549	O
and	O
HBE	O
cells	O
.	O

HMGA2	O
was	O
directly	O
targeted	O
by	O
miRâ221	O
which	O
was	O
confirmed	O
by	O
the	O
dual-luciferase	O
reporter	O
gene	B-P
assay	I-P
.	O

Finally	O
,	O
a	O
mouse	O
model	O
of	O
bleomycin	O
(	O
BLM	O
)	O
âinduced	O
pulmonary	O
fibrosis	O
was	O
used	O
to	O
confirm	O
the	O
effect	O
of	O
miRâ221	O
on	O
EMT	O
.	O

Hematoxylin	B-P
and	I-P
eosin	I-P
staining	I-P
showed	O
that	O
BLM	O
induced	O
thicker	O
alveolar	O
walls	O
and	O
more	O
collagen	O
deposition	O
,	O
whereas	O
miRâ221	O
treatment	O
reduced	O
lung	O
fibrosis	O
and	O
the	O
tissues	O
exhibited	O
thinner	O
alveolar	O
walls	O
and	O
normal	O
lung	O
alveoli	O
.	O

Furthermore	O
,	O
the	O
EMT	O
process	O
was	O
suppressed	O
following	O
miRâ221	O
injection	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
sugest	O
that	O
miRâ221	O
targets	O
HMGA2	O
to	O
inhibit	O
BLM	O
âinduced	O
pulmonary	O
fibrosis	O
through	O
the	O
TGFâÎ²1	O
/	O
Smad3	O
signaling	O
pathway	O
.	O

Clinical	O
Significance	O
of	O
Commensal	O
Gram-Positive	O
Rods	O
Routinely	O
Isolated	O
from	O
Patient	O
Samples	O
.	O

Commensal	O
bacteria	O
from	O
the	O
skin	O
and	O
mucosal	O
surfaces	O
are	O
routinely	O
isolated	O
from	O
patient	O
samples	O
and	O
considered	O
contaminants	O
.	O

The	O
majority	O
of	O
these	O
isolates	O
are	O
catalase	O
-	O
positive	O
Gram-positive	O
rods	O
from	O
multiple	O
genera	O
routinely	O
classified	O
as	O
diphtheroids	O
.	O

These	O
organisms	O
can	O
be	O
seen	O
upon	O
Gram	B-P
staining	I-P
of	O
clinical	B-P
specimens	I-P
or	O
can	O
be	O
isolated	O
as	O
the	O
predominant	O
or	O
pure	O
species	O
in	O
culture	B-P
,	O
raising	O
a	O
priori	O
suspicion	O
of	O
a	O
possible	O
involvement	O
in	O
infection	O
.	O

With	O
the	O
development	O
and	O
adoption	O
of	O
matrix-assisted	B-P
laser	I-P
desorption	I-P
ionization-time	I-P
of	I-P
flight	I-P
mass	I-P
spectrometry	I-P
(	O
MALDI-TOF	B-P
MS	I-P
)	O
,	O
suspicious	O
isolates	O
are	O
now	O
routinely	O
identified	O
to	O
the	O
species	O
level	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
a	O
retrospective	O
data	O
review	O
(	O
2012	O
to	O
2015	O
)	O
and	O
utilized	O
site-specific	O
laboratory	O
criteria	O
and	O
chart	O
reviews	O
to	O
identify	O
species	O
within	O
the	O
diphtheroid	O
classification	O
representative	O
of	O
true	O
infection	O
versus	O
contamination	O
.	O

Our	O
data	O
set	O
included	O
762	O
isolates	O
from	O
13	O
genera	O
constituting	O
41	O
bacterial	O
species	O
.	O

Only	O
18	O
%	O
represented	O
true	O
infection	O
,	O
and	O
82	O
%	O
were	O
deemed	O
contaminants	O
.	O

Clinically	O
significant	O
isolates	O
were	O
identified	O
in	O
anaerobic	B-P
wounds	I-P
(	O
18	O
%	O
)	O
,	O
aerobic	B-P
wounds	I-P
(	O
30	O
%	O
)	O
,	O
blood	O
(	O
5.5	O
%	O
)	O
,	O
urine	O
(	O
22	O
%	O
)	O
,	O
cerebrospinal	O
fluid	O
(	O
24	O
%	O
)	O
,	O
ophthalmologic	O
cultures	B-P
(	O
8	O
%	O
)	O
,	O
and	O
sterile	O
sites	O
(	O
20	O
%	O
)	O
.	O

Organisms	O
deemed	O
clinically	O
significant	O
included	O
multiple	O
Actinomyces	O
species	O
in	O
wounds	O
,	O
Propionibacterium	O
species	O
in	O
joints	O
and	O
cerebrospinal	O
fluid	O
associated	O
with	O
central	O
nervous	O
system	O
hardware	O
,	O
Corynebacterium	O
kroppenstedtii	O
(	O
100	O
%	O
)	O
in	O
breast	O
,	O
and	O
Corynebacterium	O
striatum	O
in	O
multiple	O
sites	O
.	O

Novel	O
findings	O
include	O
clinically	O
significant	O
urinary	O
tract	O
infections	O
by	O
Actinomyces	O
neuii	O
(	O
21	O
%	O
)	O
and	O
Corynebacterium	O
aurimucosum	O
(	O
21	O
%	O
)	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
species	O
-	O
level	O
identification	B-P
of	O
diphtheroids	O
isolated	O
with	O
a	O
priori	O
suspicion	O
of	O
infection	O
is	O
essential	O
to	O
accurately	O
determine	O
whether	O
an	O
isolate	O
belongs	O
to	O
a	O
species	O
associated	O
with	O
specific	O
types	O
of	O
infection	O
.	O

Delicaflavone	O
induces	O
autophagic	O
cell	O
death	O
in	O
lung	O
cancer	O
via	O
Akt	O
/	O
mTOR	O
/	O
p70S6K	O
signaling	O
pathway	O
.	O

Searching	O
for	O
potential	O
anticancer	O
agents	O
from	O
natural	O
sources	O
is	O
an	O
effective	O
strategy	O
for	O
developing	O
novel	O
chemotherapeutic	O
agents	O
.	O

In	O
this	O
study	O
,	O
data	O
supporting	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
anticancer	O
effects	O
of	O
delicaflavone	O
,	O
a	O
rarely	O
occurring	O
biflavonoid	O
from	O
Selaginella	O
doederleinii	O
,	O
were	O
reported	O
.	O

Delicaflavone	O
exhibited	O
favorable	O
anticancer	O
properties	O
,	O
as	O
shown	O
by	O
the	O
MTT	O
assay	O
and	O
xenograft	O
model	O
of	O
human	O
non-small	O
cell	O
lung	O
cancer	O
in	O
male	O
BALB/c	O
nude	O
mice	O
without	O
observable	O
adverse	O
effect	O
.	O

By	O
transmission	B-P
electron	I-P
microscopy	I-P
with	O
acridine	O
orange	O
and	O
Cyto-IDÂ®Autophagy	O
detection	O
dyes	O
,	O
Western	B-P
blot	I-P
analysis	O
,	O
and	O
RT-PCR	O
assay	O
,	O
we	O
confirmed	O
that	O
delicaflavone	O
induces	O
autophagic	O
cell	O
death	O
by	O
increasing	O
the	O
ratio	O
of	O
LC3-II	O
to	O
LC3-I	O
,	O
which	O
are	O
autophagy-related	O
proteins	O
,	O
and	O
promoting	O
the	O
generation	O
of	O
acidic	O
vesicular	O
organelles	O
and	O
autolysosomes	O
in	O
the	O
cytoplasm	O
of	O
human	O
lung	O
cancer	O
A549	O
and	O
PC-9	O
cells	O
in	O
a	O
time	O
-	O
and	O
dose-dependent	O
manner	O
.	O

Delicaflavone	O
downregulated	O
the	O
expression	O
of	O
phospho-Akt	O
,	O
phospho-mTOR	O
,	O
and	O
phospho-p70S6K	O
in	O
a	O
time	O
-	O
and	O
dose-dependent	O
manner	O
,	O
suggesting	O
that	O
it	O
induced	O
autophagy	O
by	O
inhibiting	O
the	O
Akt	O
/	O
mTOR	O
/	O
p70S6K	O
pathway	O
in	O
A549	O
and	O
PC-9	O
cells	O
.	O

Delicaflavone	O
is	O
a	O
potential	O
anticancer	O
agent	O
that	O
can	O
induce	O
autophagic	O
cell	O
death	O
in	O
human	O
non-small	O
cell	O
lung	O
cancer	O
via	O
the	O
Akt	O
/	O
mTOR	O
/	O
p70S6K	O
signaling	O
pathway	O
.	O

Delicaflavone	O
showed	O
anti-lung	O
cancer	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Delicaflavone	O
induced	O
autophagic	O
cell	O
death	O
via	O
Akt	O
/	O
mTOR	O
/	O
p70S6K	O
signaling	O
pathway	O
.	O

Delicaflavone	O
did	O
not	O
show	O
observable	O
side	O
effects	O
in	O
a	O
xenograft	O
mouse	O
model	O
.	O

Delicaflavone	O
may	O
represent	O
a	O
potential	O
therapeutic	O
agent	O
for	O
lung	O
cancer	O
.	O

Delicaflavone	O
showed	O
anti-lung	O
cancer	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Delicaflavone	O
induced	O
autophagic	O
cell	O
death	O
via	O
Akt	O
/	O
mTOR	O
/	O
p70S6K	O
signaling	O
pathway	O
.	O

Delicaflavone	O
did	O
not	O
show	O
observable	O
side	O
effects	O
in	O
a	O
xenograft	O
mouse	O
model	O
.	O

Delicaflavone	O
may	O
represent	O
a	O
potential	O
therapeutic	O
agent	O
for	O
lung	O
cancer	O
.	O

Evaluation	O
of	O
the	O
VIDAS	B-P
Anti-HCV	I-P
Assay	I-P
for	O
Detection	O
of	O
Hepatitis	O
C	O
Virus	O
Infection	O
.	O

Anti-hepatitis	O
C	O
virus	O
antibody	O
(	O
anti-HCV	O
)	O
assays	B-P
are	O
recommended	O
for	O
screening	O
HCV	O
-infected	O
persons	O
.	O

The	O
VIDAS	B-P
Anti-HCV	I-P
Assay	I-P
(	O
bioMÃ©rieux	O
,	O
France	O
)	O
,	O
based	O
on	O
the	O
enzyme-linked	B-P
fluorescence	I-P
test	I-P
principle	O
,	O
was	O
recently	O
introduced	O
in	O
Korea	O
.	O

We	O
evaluated	O
the	O
clinical	O
performance	O
of	O
the	O
VIDAS	B-P
assay	I-P
.	O

One	O
hundred	O
HCV-positive	O
and	O
1,002	O
HCV-negative	O
blood	O
samples	O
confirmed	O
by	O
Architect	B-P
anti-HCV	I-P
(	O
Abbott	O
Laboratories	O
,	O
USA	O
)	O
and	O
COBAS	O
TaqMan	O
HCV	O
real-time	O
PCR	O
(	O
Roche	O
Diagnostics	O
,	O
USA	O
)	O
or	O
the	O
Procleix	B-P
Ultrio	I-P
Plus	I-P
Assay	I-P
(	O
Gen-Probe	O
Incorporated	O
,	O
USA	O
)	O
were	O
obtained	O
from	O
the	O
Human	O
Serum	O
Bank	O
(	O
HSB	O
)	O
and	O
tested	O
by	O
VIDAS	B-P
.	O

In	O
case	O
of	O
discrepant	O
results	O
,	O
we	O
conducted	O
a	O
recombinant	B-P
immunoblot	I-P
assay	I-P
(	O
RIBA	B-P
)	O
.	O

The	O
agreement	O
rates	O
for	O
known	O
HCV-positive	O
and	O
HCV-negative	O
samples	O
between	O
the	O
VIDAS	B-P
assay	I-P
and	O
the	O
HSB	O
testing	O
were	O
100	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
96.4-100	O
%	O
)	O
and	O
99.5	O
%	O
(	O
95	O
%	O
CI	O
:	O
98.8-99.8	O
%	O
)	O
,	O
respectively	O
.	O

One	O
of	O
the	O
five	O
discrepant	O
samples	O
was	O
positive	O
for	O
Core	O
2+	O
and	O
NS3-2	O
2+	O
reactivity	O
,	O
two	O
samples	O
were	O
negative	O
,	O
and	O
the	O
other	O
two	O
were	O
indeterminate	O
regarding	O
NS4	O
2+	O
reactivity	O
in	O
RIBA	B-P
.	O

We	O
observed	O
a	O
significant	O
but	O
weak	O
positive	O
correlation	O
between	O
the	O
titers	O
of	O
VIDAS	B-P
and	O
Architect	B-P
assays	I-P
(	O
r=0.315	O
,	O
P	O
<	O
0.001	O
)	O
.	O

The	O
VIDAS	B-P
anti-HCV	I-P
assay	I-P
,	O
developed	O
on	O
the	O
VIDAS	B-P
automated	B-P
immunoassay	I-P
platform	I-P
based	O
on	O
the	O
ready-to-use	O
,	O
single-sample	O
test	O
concept	O
may	O
be	O
useful	O
in	O
small-to-medium-sized	O
laboratories	O
.	O

It	O
showed	O
good	O
agreement	O
with	O
Architect	B-P
anti-HCV	I-P
and	O
COBAS	O
PCR	O
assays	O
and	O
is	O
therefore	O
useful	O
for	O
detection	O
of	O
HCV	O
infection	O
.	O

Weakly	O
test-positive	O
(	O
ambiguous	O
)	O
samples	O
require	O
additional	O
testing	O
by	O
another	O
anti-HCV	O
,	O
RIBA	B-P
,	O
or	O
HCV	B-P
RNA	I-P
assay	I-P
.	O

Relationship	O
between	O
genetic	O
polymorphisms	O
of	O
methylenetetrahydrofolate	O
reductase	O
and	O
breast	O
cancer	O
chemotherapy	O
response	O
.	O

Activity	O
of	O
methylenetetrahydrofolate	O
reductase	O
(	O
MTHFR	O
)	O
,	O
an	O
enzyme	O
involved	O
in	O
folate	O
metabolism	O
,	O
is	O
influenced	O
by	O
mutations	O
in	O
the	O
corresponding	O
gene	O
,	O
contributing	O
to	O
a	O
decrease	O
in	O
5,10-MTHF	O
.	O

Due	O
to	O
such	O
polymorphisms	O
,	O
individuals	O
differ	O
in	O
MTHFR	O
enzyme	O
activity	O
and	O
plasma	B-P
folate	I-P
levels	I-P
.	O

We	O
investigated	O
the	O
relationship	O
between	O
two	O
common	O
MTHFR	O
polymorphisms	O
(	O
C677T	O
and	O
A1298C	O
)	O
and	O
breast	O
cancer	O
(	O
BC	O
)	O
chemotherapy	O
response	O
.	O

From	O
February	O
2013	O
to	O
January	O
2016	O
,	O
148	O
advanced	O
BC	O
patients	O
at	O
the	O
Center	O
Hospital	O
of	O
Cangzhou	O
were	O
enrolled	O
and	O
treated	O
with	O
six	O
different	O
chemotherapy	O
regimens	O
.	O

Subjects	O
were	O
genotyped	O
using	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O

Forty-one	O
(	O
27.7	O
%	O
)	O
,	O
70	O
(	O
47.3	O
%	O
)	O
,	O
and	O
37	O
(	O
25.0	O
%	O
)	O
patients	O
carried	O
the	O
C/C	O
,	O
C/T	O
,	O
and	O
T/T	O
C677T	O
genotypes	O
,	O
respectively	O
;	O
101	O
(	O
68.2	O
%	O
)	O
,	O
42	O
(	O
28.4	O
%	O
)	O
,	O
and	O
5	O
(	O
3.4	O
%	O
)	O
had	O
the	O
A/A	O
,	O
A/C	O
,	O
and	O
C/C	O
genotypes	O
of	O
A1298C	O
,	O
respectively	O
.	O

Total	O
chemotherapy	O
efficacy	O
was	O
66.9	O
%	O
(	O
99/148	O
)	O
,	O
with	O
7	O
(	O
4.7	O
%	O
)	O
,	O
92	O
(	O
62.2	O
%	O
)	O
,	O
36	O
(	O
24.3	O
%	O
)	O
,	O
and	O
13	O
(	O
8.8	O
%	O
)	O
cases	O
showing	O
complete	O
response	O
,	O
partial	O
response	O
,	O
no	O
change	O
,	O
and	O
progressive	O
disease	O
,	O
respectively	O
.	O

Chemotherapy	O
regimens	O
did	O
not	O
differ	O
in	O
effectiveness	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Efficacy	O
rates	O
associated	O
with	O
C677T	O
C/C	O
,	O
C/T	O
,	O
and	O
T/T	O
genotypes	O
were	O
58.5	O
,	O
58.6	O
,	O
and	O
91.9	O
%	O
,	O
respectively	O
,	O
with	O
T/T	O
carriers	O
exhibiting	O
significantly	O
better	O
responses	O
than	O
the	O
C/C	O
(	O
P	O
<	O
0.05	O
)	O
and	O
C/T	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Effectiveness	O
among	O
A1298C	O
A/A	O
,	O
A/C	O
,	O
and	O
C/C	O
carriers	O
was	O
70.6	O
,	O
64.3	O
,	O
and	O
0.0	O
%	O
,	O
respectively	O
,	O
but	O
no	O
difference	O
was	O
established	O
between	O
these	O
genotypes	O
in	O
this	O
regard	O
(	O
P	O
>	O
0.05	O
)	O
.	O

The	O
MTHFR	O
C677T	O
genotype	O
may	O
be	O
associated	O
with	O
BC	O
chemotherapy	O
response	O
,	O
and	O
could	O
be	O
of	O
great	O
value	O
in	O
guiding	O
individualized	O
treatment	O
for	O
this	O
disease	O
.	O

Ergonomics	O
of	O
laparoscopic	O
graspers	O
and	O
the	O
importance	O
of	O
haptic	O
feedback	O
:	O
the	O
surgeons	O
'	O
perspective	O
.	O

Haptic	O
feedback	O
is	O
drastically	O
reduced	O
in	O
laparoscopic	O
surgery	O
compared	O
to	O
open	O
surgery	O
.	O

Introducing	O
enhanced	O
haptic	O
feedback	O
in	O
laparoscopic	O
instruments	O
might	O
well	O
improve	O
surgical	O
safety	O
and	O
efficiency	O
.	O

In	O
the	O
design	O
process	O
of	O
a	O
laparoscopic	O
grasper	O
with	O
enhanced	O
haptic	O
feedback	O
,	O
handle	O
design	O
should	O
be	O
addressed	O
to	O
strive	O
for	O
optimal	O
usability	O
and	O
comfort	O
.	O

Additionally	O
,	O
the	O
surgeons	O
'	O
perspective	O
on	O
the	O
potential	O
benefits	O
of	O
haptic	O
feedback	O
should	O
be	O
assessed	O
to	O
ascertain	O
the	O
clinical	O
interest	O
of	O
enhanced	O
haptic	O
feedback	O
.	O

A	O
questionnaire	O
was	O
designed	O
to	O
determine	O
surgeons	O
'	O
use	O
and	O
preferences	O
for	O
laparoscopic	O
instruments	O
and	O
expectations	O
about	O
enhanced	O
haptic	O
feedback	O
.	O

Surgeons	O
were	O
also	O
asked	O
whether	O
they	O
experience	O
physical	O
complaints	O
related	O
to	O
laparoscopic	O
instruments	O
.	O

The	O
questionnaire	O
was	O
distributed	O
to	O
a	O
group	O
of	O
laparoscopic	O
surgeons	O
based	O
in	O
Europe	O
.	O

From	O
the	O
279	O
contacted	O
subjects	O
,	O
98	O
completed	O
the	O
questionnaire	O
(	O
response	O
rate	O
35	O
%	O
)	O
.	O

Of	O
all	O
respondents	O
,	O
77	O
%	O
reported	O
physical	O
complaints	O
directly	O
attributable	O
to	O
the	O
use	O
of	O
laparoscopic	O
instruments	O
.	O

No	O
evident	O
similarity	O
in	O
the	O
main	O
preference	O
for	O
graspers	O
was	O
found	O
,	O
either	O
with	O
or	O
without	O
haptic	O
feedback	O
.	O

According	O
to	O
respondents	O
,	O
the	O
added	O
value	O
of	O
haptic	O
feedback	O
could	O
be	O
of	O
particular	O
use	O
in	O
feeling	O
differences	O
in	O
tissue	O
consistencies	O
,	O
feeling	O
the	O
applied	O
pressure	O
,	O
locating	O
a	O
tumor	O
or	O
enlarged	O
lymph	O
node	O
,	O
feeling	O
arterial	O
pulse	O
,	O
and	O
limiting	O
strain	O
in	O
the	O
surgeon	O
's	O
hand	O
.	O

This	O
study	O
stresses	O
that	O
the	O
high	O
prevalence	O
of	O
physical	O
complaints	O
directly	O
related	O
to	O
laparoscopic	O
instruments	O
among	O
laparoscopic	O
surgeons	O
is	O
still	O
relevant	O
.	O

Furthermore	O
,	O
the	O
potential	O
benefits	O
of	O
enhanced	O
haptic	O
feedback	O
in	O
laparoscopic	O
surgery	O
are	O
recognized	O
by	O
laparoscopic	O
specialists	O
.	O

Therefore	O
,	O
haptic	O
feedback	O
is	O
considered	O
an	O
unmet	O
need	O
in	O
laparoscopy	B-P
.	O

Accurate	O
Lungs	O
Segmentation	O
on	O
CT	B-P
Chest	O
Images	O
by	O
Adaptive	O
Appearance-Guided	O
Shape	O
Modeling	O
.	O

To	O
accurately	O
segment	O
pathological	O
and	O
healthy	O
lungs	O
for	O
reliable	O
computer-aided	B-P
disease	I-P
diagnostics	I-P
,	O
a	O
stack	O
of	O
chest	O
CT	B-P
scans	B-P
is	O
modeled	O
as	O
a	O
sample	O
of	O
a	O
spatially	O
inhomogeneous	O
joint	O
3D	O
Markov-Gibbs	O
random	O
field	O
(	O
MGRF	O
)	O
of	O
voxel-wise	O
lung	O
and	O
chest	O
CT	B-P
image	O
signals	O
(	O
intensities	O
)	O
.	O

The	O
proposed	O
learnable	O
MGRF	O
integrates	O
two	O
visual	O
appearance	O
sub-models	O
with	O
an	O
adaptive	O
lung	O
shape	O
submodel	O
.	O

The	O
first-order	O
appearance	O
submodel	O
accounts	O
for	O
both	O
the	O
original	O
CT	B-P
image	O
and	O
its	O
Gaussian	O
scale	O
space	O
(	O
GSS	O
)	O
filtered	O
version	O
to	O
specify	O
local	O
and	O
global	O
signal	O
properties	O
,	O
respectively	O
.	O

Each	O
empirical	O
marginal	O
probability	O
distribution	O
of	O
signals	O
is	O
closely	O
approximated	O
with	O
a	O
linear	O
combination	O
of	O
discrete	O
Gaussians	O
(	O
LCDG	O
)	O
,	O
containing	O
two	O
positive	O
dominant	O
and	O
multiple	O
sign-alternate	O
subordinate	O
DGs	O
.	O

The	O
approximation	O
is	O
separated	O
into	O
two	O
LCDGs	O
to	O
describe	O
individually	O
the	O
lungs	O
and	O
their	O
background	O
,	O
i.e.	O
,	O
all	O
other	O
chest	O
tissues	O
.	O

The	O
second-order	O
appearance	O
submodel	O
quantifies	O
conditional	O
pairwise	O
intensity	O
dependencies	O
in	O
the	O
nearest	O
voxel	O
26-neighborhood	O
in	O
both	O
the	O
original	O
and	O
GSS-filtered	O
images	O
.	O

The	O
shape	O
submodel	O
is	O
built	O
for	O
a	O
set	O
of	O
training	O
data	O
and	O
is	O
adapted	O
during	O
segmentation	O
using	O
both	O
the	O
lung	O
and	O
chest	O
appearances	O
.	O

The	O
accuracy	O
of	O
the	O
proposed	O
segmentation	O
framework	O
is	O
quantitatively	O
assessed	O
using	O
two	O
public	O
databases	O
(	O
ISBI	O
VESSEL12	O
challenge	O
and	O
MICCAI	O
LOLA11	O
challenge	O
)	O
and	O
our	O
own	O
database	O
with	O
,	O
respectively	O
,	O
20	O
,	O
55	O
,	O
and	O
30	O
CT	B-P
images	O
of	O
various	O
lung	O
pathologies	O
acquired	O
with	O
different	O
scanners	O
and	O
protocols	O
.	O

Quantitative	O
assessment	O
of	O
our	O
framework	O
in	O
terms	O
of	O
Dice	O
similarity	O
coefficients	O
,	O
95-percentile	O
bidirectional	O
Hausdorff	O
distances	O
,	O
and	O
percentage	O
volume	O
differences	O
confirms	O
the	O
high	O
accuracy	O
of	O
our	O
model	O
on	O
both	O
our	O
database	O
(	O
98.4Â±1.0	O
%	O
,	O
2.2Â±1.0	O
mm	O
,	O
0.42Â±0.10	O
%	O
)	O
and	O
the	O
VESSEL12	O
database	O
(	O
99.0Â±0.5	O
%	O
,	O
2.1Â±1.6	O
mm	O
,	O
0.39Â±0.20	O
%	O
)	O
,	O
respectively	O
.	O

Similarly	O
,	O
the	O
accuracy	O
of	O
our	O
approach	O
is	O
further	O
verified	O
via	O
a	O
blind	O
evaluation	O
by	O
the	O
organizers	O
of	O
the	O
LOLA11	O
competition	O
,	O
where	O
an	O
average	O
overlap	O
of	O
98.0	O
%	O
with	O
the	O
expert	O
's	O
segmentation	O
is	O
yielded	O
on	O
all	O
55	O
subjects	O
with	O
our	O
framework	O
being	O
ranked	O
first	O
among	O
all	O
the	O
state-of-the-art	O
techniques	O
compared	O
.	O

TERT	O
,	O
BRAF	O
and	O
NRAS	O
in	O
primary	O
thyroid	O
cancer	O
and	O
metastatic	O
disease	O
.	O

Little	O
is	O
known	O
about	O
the	O
frequency	O
of	O
key	O
mutations	O
in	O
thyroid	O
cancer	O
metastases	O
and	O
its	O
relationship	O
with	O
the	O
primary	O
tumor	O
genotype	O
.	O

To	O
evaluate	O
the	O
frequency	O
of	O
TERT	O
promoter	O
(	O
TERTp	O
)	O
,	O
BRAF	O
and	O
NRAS	O
mutations	O
in	O
metastatic	O
thyroid	O
carcinomas	O
,	O
analyzing	O
primary	O
thyroid	O
tumors	O
,	O
lymph	O
node	O
metastases	O
(	O
LNM	O
)	O
and	O
distant	O
metastases	O
.	O

Mutation	B-P
analysis	I-P
was	O
performed	O
in	O
437	O
tissue	O
samples	O
from	O
204	O
patients	O
,	O
mainly	O
with	O
papillary	O
thyroid	O
carcinomas	O
(	O
PTC	O
)	O
(	O
n=180	O
)	O
,	O
including	O
196	O
LNM	O
and	O
56	O
distant	O
metastases	O
.	O

All	O
the	O
distant	O
metastases	O
included	O
corresponded	O
to	O
radioiodine	O
-refractory	O
metastatic	O
tissue	O
.	O

We	O
found	O
the	O
following	O
mutation	O
frequency	O
in	O
primary	O
PTC	O
,	O
LNM	O
and	O
distant	O
metastases	O
,	O
respectively	O
:	O
TERTp	O
-	O
12.9	O
%	O
,	O
10.5	O
%	O
,	O
and	O
52.4	O
%	O
;	O
BRAF	O
-	O
44.6	O
%	O
,	O
41.7	O
%	O
,	O
and	O
23.8	O
%	O
;	O
NRAS	O
-	O
1.2	O
%	O
,	O
1.3	O
%	O
,	O
and	O
14.3	O
%	O
.	O

There	O
was	O
a	O
significant	O
concordance	O
between	O
the	O
primary	O
tumor	O
genotype	O
and	O
the	O
corresponding	O
LNM	O
for	O
all	O
the	O
genes	O
,	O
in	O
particular	O
BRAF	O
-mutated	O
PTC	O
.	O

The	O
overall	O
concordance	O
between	O
primary	O
tumors	O
and	O
respective	O
distant	O
metastases	O
was	O
low	O
.	O

In	O
the	O
group	O
of	O
patients	O
with	O
PTC	O
,	O
we	O
found	O
a	O
high	O
frequency	O
of	O
TERTp	O
mutations	O
and	O
a	O
low	O
frequency	O
of	O
BRAF	O
mutations	O
in	O
distant	O
metastases	O
,	O
in	O
comparison	O
to	O
the	O
paired	O
primary	O
tumors	O
.	O

When	O
present	O
in	O
distant	O
metastases	O
,	O
BRAF	O
mutations	O
frequently	O
coexisted	O
with	O
TERTp	O
mutations	O
.	O

When	O
the	O
genotype	O
of	O
primary	O
tumors	O
is	O
compared	O
with	O
the	O
genotype	O
of	O
LNM	O
,	O
the	O
concordance	O
is	O
high	O
for	O
all	O
the	O
genes	O
studied	O
.	O

On	O
the	O
other	O
hand	O
,	O
distant	O
metastases	O
show	O
an	O
enrichment	O
in	O
TERTp	O
mutations	O
and	O
a	O
decrease	O
in	O
BRAF	O
mutations	O
.	O

TERTp	O
mutations	O
may	O
play	O
a	O
role	O
in	O
distant	O
metastases	O
.	O

Hif-1Î±	O
Overexpression	O
Improves	O
Transplanted	O
Bone	O
Mesenchymal	O
Stem	O
Cells	O
Survival	O
in	O
Rat	O
MCAO	O
Stroke	O
Model	O
.	O

Bone	O
mesenchymal	O
stem	O
cells	O
(	O
BMSCs	O
)	O
death	O
after	O
transplantation	O
is	O
a	O
serious	O
obstacle	O
impacting	O
on	O
the	O
outcome	O
of	O
cell	O
therapy	O
for	O
cerebral	O
infarction	O
.	O

This	O
study	O
was	O
aimed	O
to	O
investigate	O
whether	O
modification	O
of	O
BMSCs	O
with	O
hypoxia-inducible	O
factor	O
1Î±	O
(	O
Hif-1Î±	O
)	O
could	O
enhance	O
the	O
survival	O
of	O
the	O
implanted	O
BMSCs	O
.	O

BMSCs	O
were	O
isolated	B-P
from	O
Wistar	O
rats	O
,	O
and	O
were	O
infected	O
with	O
Hif-1Î±-GFP	O
lentiviral	O
vector	O
or	O
Hif-1Î±	O
siRNA	O
.	O

The	O
modified	O
BMSCs	O
were	O
exposed	O
to	O
oxygen-glucose	O
deprivation	O
(	O
OGD	O
)	O
condition	O
,	O
cellular	O
viability	O
and	O
apoptosis	O
were	O
then	O
assessed	O
.	O

An	O
inhibitor	O
of	O
AMPK	O
(	O
compound	O
C	O
)	O
was	O
used	O
to	O
detect	O
whether	O
AMPK	O
and	O
mTOR	O
were	O
implicated	O
in	O
the	O
functions	O
of	O
Hif-1Î±	O
on	O
BMSCs	O
survival	O
.	O

Besides	O
,	O
ultrastructure	O
of	O
BMSCs	O
was	O
observed	O
and	O
the	O
expression	O
of	O
autophagy	O
markers	O
was	O
measured	O
.	O

The	O
modified	O
BMSCs	O
were	O
transplanted	O
into	O
middle	O
cerebral	O
artery	O
occlusion	O
(	O
MCAO	O
)	O
model	O
of	O
rats	O
,	O
and	O
the	O
cerebral	O
infarction	O
volume	O
and	O
neurological	O
function	O
was	O
assessed	O
.	O

The	O
results	O
indicated	O
that	O
Hif-1Î±	O
overexpression	O
protected	O
OGD	O
induced	O
injury	O
by	O
promoting	O
cellular	O
viability	O
and	O
inhibiting	O
apoptosis	O
.	O

AMPK	O
was	O
activated	O
while	O
mTOR	O
was	O
inactivated	O
by	O
Hif-1Î±	O
overexpression	O
,	O
and	O
that	O
might	O
be	O
through	O
which	O
Hif-1Î±	O
functioned	O
BMSCs	O
survival	O
.	O

Hif-1Î±	O
overexpression	O
promoted	O
autophagy	O
;	O
more	O
important	O
,	O
compound	O
C	O
abolished	O
the	O
induction	O
of	O
Hif-1Î±	O
on	O
autophagy	O
.	O

Transplantation	O
of	O
the	O
overexpressed	O
Hif-1Î±	O
of	O
BMSCs	O
into	O
the	O
MCAO	O
rats	O
reduced	O
brain	O
infarct	O
volume	O
and	O
improved	O
neurobehavioral	O
outcome	O
;	O
besides	O
,	O
it	O
inhibited	O
pro-inflammatory	O
cytokines	O
generation	O
while	O
promoted	O
neurotrophin	O
secretion	O
.	O

In	O
conclusion	O
,	O
Hif-1Î±	O
might	O
be	O
contributed	O
in	O
the	O
survival	O
of	O
BMSCs	O
by	O
regulating	O
the	O
activation	O
of	O
AMPK	O
and	O
mTOR	O
,	O
as	O
well	O
as	O
by	O
promoting	O
autophagy	O
.	O

Assessment	O
of	O
Interleukin-17A	O
,	O
Interleukin-10	O
and	O
Transforming	O
Growth	O
Factor-Beta1	O
Serum	O
Titers	O
in	O
Relapsing	O
Remitting	O
Multiple	O
Sclerosis	O
Patients	O
Treated	O
with	O
Avonex	O
,	O
Possible	O
Biomarkers	O
for	O
Treatment	O
Response	O
.	O

Individual	O
response	O
to	O
interferon	O
beta	O
(	O
IFN-Î²	O
)	O
1a	O
treatment	O
is	O
heterogeneous	O
in	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

Our	O
objective	O
was	O
to	O
find	O
a	O
connection	O
between	O
serum	O
levels	O
of	O
interleukin	O
(	O
IL	O
)	O
-10	O
,	O
IL-17	O
and	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF-Î²	O
)	O
1	O
in	O
MS	O
patients	O
treated	O
with	O
IFN-Î²	O
in	O
order	O
to	O
identify	O
the	O
nonresponders	O
(	O
NR	O
)	O
.	O

We	O
included	O
in	O
the	O
study	O
32	O
healthy	O
subjects	O
and	O
32	O
MS	O
patients	O
:	O
10	O
naive	O
,	O
10	O
early	O
treated	O
and	O
12	O
late	O
treated	O
with	O
INF-Î²1a	O
.	O

Serum	O
determination	B-P
of	O
cytokines	O
and	O
brain	B-P
MRI	I-P
were	O
performed	O
at	O
the	O
beginning	O
of	O
the	O
study	O
,	O
after	O
6	O
and	O
12	O
months	O
.	O

Rio	O
score	O
was	O
calculated	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

MS	O
patients	O
had	O
initially	O
a	O
significant	O
higher	O
level	O
of	O
IL-17	O
and	O
a	O
lower	O
level	O
of	O
TGF-Î²1	O
compared	O
to	O
healthy	O
subjects	O
.	O

IL-17	O
level	O
in	O
early	O
treated	O
patients	O
was	O
significantly	O
lower	O
compared	O
to	O
the	O
naive	O
and	O
late	O
treated	O
groups	O
.	O

INF-Î²1a	O
treatment	O
significantly	O
increased	O
IL-10	O
and	O
decreased	O
IL-17	O
levels	O
.	O

Initial	O
low	O
levels	O
of	O
IL-10	O
were	O
associated	O
with	O
an	O
increase	O
in	O
physical	O
disability	O
.	O

IL-17	O
levels	O
positively	O
correlated	O
with	O
the	O
number	O
of	O
relapses	O
and	O
MRI	B-P
activity	O
.	O

Nine	O
patients	O
were	O
NR	O
to	O
Avonex	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL-17	O
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL-10	O
and	O
TGF-Î²1	O
.	O

IFN-Î²1a	O
decreased	O
IL-17	O
and	O
increased	O
IL-10	O
seric	O
levels	O
;	O
IL-17	O
significantly	O
correlated	O
with	O
MS	O
activity	O
;	O
TGF-Î²1	O
activity	O
is	O
titer-dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL-17	O
inhibition	O
;	O
NR	O
patients	O
to	O
IFN-Î²1a	O
will	O
have	O
initial	O
high	O
IL-17	O
and	O
low	O
IL-10	O
and	O
TGF-Î²	O
seric	O
levels	O
.	O

Child	O
death	O
and	O
maternal	O
psychosis-like	O
experiences	O
in	O
44	O
low-	O
and	O
middle-income	O
countries	O
:	O
The	O
role	O
of	O
depression	O
.	O

Studies	O
on	O
the	O
effect	O
of	O
child	O
death	O
on	O
the	O
mental	O
wellbeing	O
of	O
women	O
in	O
low-	O
and	O
middle-income	O
countries	O
(	O
LMICs	O
)	O
are	O
scarce	O
despite	O
the	O
high	O
child	O
mortality	O
rates	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
assess	O
the	O
association	O
between	O
child	O
death	O
and	O
psychosis-like	O
experiences	O
(	O
PLEs	O
)	O
,	O
as	O
well	O
as	O
the	O
role	O
of	O
depression	O
in	O
this	O
association	O
.	O

Data	O
from	O
44	O
LMICs	O
which	O
participated	O
in	O
the	O
World	O
Health	O
Survey	O
(	O
WHS	O
)	O
were	O
analyzed	O
.	O

A	O
total	O
of	O
59,444	O
women	O
who	O
ever	O
gave	O
birth	O
,	O
aged	O
18-49	O
years	O
,	O
without	O
a	O
self-reported	O
lifetime	O
psychosis	B-P
diagnosis	I-P
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O

The	O
World	O
Mental	O
Health	O
Survey	O
version	O
of	O
the	O
Composite	O
International	O
Diagnostic	O
Interview	O
(	O
CIDI	O
)	O
was	O
used	O
to	O
establish	O
the	O
diagnosis	O
of	O
past	O
12-	O
month	O
DSM-IV	O
depression	O
,	O
and	O
assess	O
four	O
positive	O
psychotic	O
symptoms	O
.	O

Depression	O
was	O
defined	O
as	O
self-reported	O
lifetime	O
depression	B-P
diagnosis	I-P
and/or	O
past	O
12-	O
month	O
depression	O
.	O

Multivariable	O
logistic	O
regression	O
analyses	O
were	O
performed	O
.	O

After	O
adjustment	O
for	O
potential	O
confounders	O
,	O
women	O
who	O
experienced	O
child	O
death	O
had	O
higher	O
odds	O
for	O
all	O
types	O
of	O
PLEs	O
(	O
when	O
unadjusted	O
for	O
depression	O
)	O
(	O
OR	O
1.20-1.71	O
;	O
p	O
<	O
0.05	O
)	O
and	O
depression	O
(	O
OR	O
=1.64	O
;	O
95	O
%	O
CI	O
=1.39-1.93	O
)	O
.	O

When	O
adjusted	O
for	O
depression	O
,	O
only	O
delusion	O
of	O
control	O
was	O
strongly	O
associated	O
with	O
child	O
death	O
(	O
OR	O
=1.54	O
;	O
95	O
%	O
CI	O
=1.20-1.97	O
)	O
.	O

Child	O
death	O
may	O
be	O
an	O
important	O
determinant	O
of	O
mental	O
wellbeing	O
among	O
women	O
in	O
LMICs	O
.	O

Given	O
the	O
known	O
adverse	O
health	O
outcomes	O
associated	O
with	O
PLEs	O
and	O
depression	O
,	O
as	O
well	O
as	O
the	O
co-occurrence	O
of	O
these	O
symptoms	O
,	O
mental	O
health	O
care	O
may	O
be	O
particularly	O
important	O
for	O
mothers	O
who	O
have	O
experienced	O
child	O
loss	O
in	O
LMICs	O
.	O

Addressing	O
reverse	O
inference	O
in	O
psychiatric	O
neuroimaging	B-P
:	O
Meta-analyses	O
of	O
task	O
-related	O
brain	O
activation	O
in	O
common	O
mental	O
disorders	O
.	O

Functional	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	B-P
fMRI	I-P
)	I-P
studies	I-P
in	O
psychiatry	O
use	O
various	O
tasks	O
to	O
identify	O
case-control	O
differences	O
in	O
the	O
patterns	O
of	O
task	O
-related	O
brain	O
activation	O
.	O

Differently	O
activated	O
regions	O
are	O
often	O
ascribed	O
disorder	O
-specific	O
functions	O
in	O
an	O
attempt	O
to	O
link	O
disease	O
expression	O
and	O
brain	O
function	O
.	O

We	O
undertook	O
a	O
systematic	O
meta-analysis	O
of	O
data	O
from	O
task	O
-	O
fMRI	B-P
studies	I-P
to	O
examine	O
the	O
effect	O
of	O
diagnosis	O
and	O
study	O
design	O
on	O
the	O
spatial	O
distribution	O
and	O
direction	O
of	O
case-control	O
differences	O
on	O
brain	O
activation	O
.	O

We	O
mapped	O
to	O
atlas	O
regions	O
coordinates	O
of	O
case-control	O
differences	O
derived	O
from	O
537	O
task	O
-	O
fMRI	B-P
studies	I-P
in	O
schizophrenia	O
,	O
bipolar	O
disorder	O
,	O
major	O
depressive	O
disorder	O
,	O
anxiety	O
disorders	O
,	O
and	O
obsessive	O
compulsive	O
disorder	O
comprising	O
observations	O
derived	O
from	O
21,427	O
participants	O
.	O

The	O
fMRI	B-P
tasks	I-P
were	O
classified	O
according	O
to	O
the	O
Research	O
Domain	O
Criteria	O
(	O
RDoC	O
)	O
.	O

We	O
investigated	O
whether	O
diagnosis	O
,	O
RDoC	O
domain	O
or	O
construct	O
and	O
use	O
of	O
regions-of-interest	O
or	O
whole-brain	O
analyses	O
influenced	O
the	O
neuroanatomical	O
pattern	O
of	O
results	O
.	O

When	O
considering	O
all	O
primary	O
studies	O
,	O
we	O
found	O
an	O
effect	O
of	O
diagnosis	O
for	O
the	O
amygdala	O
and	O
caudate	O
nucleus	O
and	O
an	O
effect	O
of	O
RDoC	O
domains	O
and	O
constructs	O
for	O
the	O
amygdala	O
,	O
hippocampus	O
,	O
putamen	O
and	O
nucleus	O
accumbens	O
.	O

In	O
contrast	O
,	O
whole-brain	O
studies	O
did	O
not	O
identify	O
any	O
significant	O
effect	O
of	O
diagnosis	O
or	O
RDoC	O
domain	O
or	O
construct	O
.	O

These	O
results	O
resonate	O
with	O
prior	O
reports	O
of	O
common	O
brain	O
structural	O
and	O
genetic	O
underpinnings	O
across	O
these	O
disorders	O
and	O
caution	O
against	O
attributing	O
undue	O
specificity	O
to	O
brain	O
functional	O
changes	O
when	O
forming	O
explanatory	O
models	O
of	O
psychiatric	O
disorders	O
.	O

Hum	O
Brain	O
Mapp	O
38:1846-1864	O
,	O
2017	O
.	O

Â©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

A	O
new	O
marker	O
for	O
breast	B-P
cancer	I-P
diagnosis	I-P
,	O
human	O
epididymis	O
protein	O
4	O
:	O
A	O
preliminary	O
study	O
.	O

Breast	O
cancer	O
is	O
the	O
most	O
frequently	O
diagnosed	O
cancer	O
type	O
in	O
women	O
.	O

Tumor	O
markers	O
have	O
been	O
widely	O
used	O
for	O
assessing	O
the	O
treatment	O
response	O
and	O
early	B-P
diagnosis	I-P
of	O
recurrence	O
.	O

Human	O
epididymis	O
protein	O
4	O
(	O
HE4	O
)	O
is	O
expressed	O
in	O
ductal	O
carcinoma	O
of	O
the	O
breast	O
tissue	O
;	O
however	O
,	O
its	O
serum	O
levels	O
and	O
their	O
diagnostic	O
and	O
prognostic	O
potential	O
in	O
breast	O
cancer	O
have	O
not	O
been	O
investigated	O
,	O
which	O
was	O
therefore	O
the	O
aim	O
of	O
the	O
present	O
study	O
.	O

The	O
serum	O
levels	O
of	O
HE4	O
were	O
determined	B-P
in	O
36	O
breast	O
cancer	O
patients	O
,	O
11	O
ovarian	O
cancer	O
patients	O
and	O
16	O
healthy	O
volunteers	O
.	O

The	O
association	O
between	O
clinicopathological	O
characteristics	O
of	O
breast	O
cancer	O
and	O
serum	O
HE4	O
levels	O
was	O
investigated	O
.	O

A	O
significant	O
difference	O
in	O
the	O
median	O
serum	O
levels	O
of	O
HE4	O
was	O
identified	O
between	O
breast	O
cancer	O
patients	O
,	O
ovarian	O
cancer	O
patients	O
and	O
healthy	O
volunteers	O
(	O
P=0.013	O
)	O
.	O

The	O
cutoff	O
value	O
for	O
the	O
prediction	O
of	O
breast	O
cancer	O
was	O
determined	B-P
at	O
>	O
13.24	O
pmol/l	O
for	O
HE4	O
,	O
with	O
a	O
sensitivity	O
of	O
61.11	O
%	O
,	O
specificity	O
of	O
68.75	O
%	O
,	O
positive	O
predictive	O
value	O
of	O
81.48	O
%	O
,	O
negative	O
predictive	O
value	O
of	O
44.0	O
%	O
and	O
accuracy	O
of	O
63.46	O
%	O
.	O

Furthermore	O
,	O
a	O
positive	O
correlation	O
between	O
the	O
serum	O
levels	O
of	O
HE4	O
and	O
cancer	O
antigen	O
15-3	O
was	O
determined	B-P
(	O
r=0.399	O
,	O
P=0.026	O
)	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
present	O
study	O
was	O
the	O
first	O
to	O
determine	B-P
the	O
diagnostic	O
value	O
of	O
serum	O
HE4	O
for	O
breast	O
cancer	O
.	O

A	O
significant	O
elevation	O
of	O
serum	O
HE4	O
levels	O
in	O
patients	O
with	O
breast	O
cancer	O
compared	O
with	O
that	O
in	O
healthy	O
controls	O
was	O
identified	O
.	O

HE4	O
may	O
serve	O
as	O
a	O
novel	O
biomarker	O
for	O
the	O
diagnosis	O
of	O
breast	O
cancer	O
.	O

Minimally	O
invasive	O
treatment	O
of	O
difficult	O
bleeding	O
lesions	O
of	O
the	O
small	O
bowel	O
.	O

Bleeding	O
lesions	O
of	O
the	O
small	O
bowel	O
are	O
often	O
difficult	O
to	O
identify	O
due	O
to	O
the	O
obscure	O
symptomatology	O
.	O

Localizing	O
these	O
lesions	O
requires	O
specific	O
techniques	O
.	O

The	O
Double-balloon	B-P
enteroscopy	I-P
(	O
DBE	B-P
)	O
could	O
be	O
used	O
to	O
precisely	O
localize	O
and	O
mark	O
lesions	O
,	O
so	O
that	O
a	O
minimally	O
invasive	O
surgical	O
treatment	O
could	O
be	O
performed	O
.	O

Twenty	O
robot	O
-	O
assisted	O
small	O
bowel	O
procedures	O
are	O
presented	O
using	O
a	O
combination	O
of	O
DBE	B-P
for	O
localization	O
and	O
robotic	O
resection	O
.	O

There	O
were	O
10	O
jejunal	O
resections	O
and	O
10	O
ileal	O
resections	O
.	O

Mean	O
age	O
was	O
58.7	O
years	O
.	O

Mean	O
operative	O
time	O
was	O
153.4	O
minutes	O
,	O
mean	O
blood	O
loss	O
of	O
46	O
mL	O
.	O

No	O
conversion-to-open	O
and	O
there	O
were	O
4	O
post-operative	O
complications	O
.	O

The	O
90-	O
day	O
mortality	O
was	O
nil	O
and	O
the	O
median	O
length	O
of	O
stay	O
was	O
4.1	O
days	O
.	O

Final	O
pathology	O
was	O
consistent	O
with	O
malignancy	O
in	O
10	O
cases	O
.	O

The	O
combination	O
of	O
double-balloon	B-P
enteroscopy	I-P
and	O
robotic	O
technology	O
allows	O
accurate	O
identification	O
and	O
selective	O
treatment	O
of	O
lesions	O
that	O
could	O
be	O
otherwise	O
difficult	O
to	O
treat	O
in	O
a	O
minimally	O
invasive	O
fashion	O
.	O

Taxonomic	O
Revision	O
of	O
Lipoptilocnema	O
(	O
Diptera	O
:	O
Sarcophagidae	O
)	O
,	O
With	O
Notes	O
on	O
Natural	O
History	O
and	O
Forensic	O
Importance	O
of	O
Its	O
Species	O
.	O

Lipoptilocnema	O
Townsend	O
is	O
a	O
small	O
genus	O
of	O
Neotropical	O
Sarcophaginae	O
with	O
a	O
distinctive	O
genitalic	O
morphology	O
.	O

This	O
genus	O
is	O
revised	O
based	O
on	O
the	O
examination	O
of	O
the	O
type	O
series	O
and	O
large	O
numbers	O
of	O
specimens	O
of	O
the	O
seven	O
previously	O
known	O
species	O
,	O
plus	O
three	O
new	O
ones	O
herein	O
described	O
,	O
one	O
from	O
Argentina	O
(	O
L.	O
delfinado	O
Mulieri	O
and	O
Mello-Patiu	O
,	O
sp	O
.	O

nov.	O
)	O
,	O
and	O
two	O
from	O
Brazil	O
(	O
L.	O
savana	O
Mulieri	O
and	O
Mello-Patiu	O
,	O
sp	O
.	O

nov.	O
and	O
L.	O
tibanae	O
Mulieri	O
and	O
Mello-Patiu	O
,	O
sp	O
.	O

nov.	O
)	O
.	O

All	O
species	O
are	O
described	O
or	O
redescribed	O
and	O
illustrated	O
.	O

Distribution	O
maps	O
and	O
a	O
key	O
for	O
male	O
identification	O
are	O
provided	O
.	O

The	O
taxonomic	O
position	O
of	O
this	O
genus	O
is	O
reviewed	O
and	O
the	O
interpretation	O
of	O
phallic	O
structures	O
is	O
discussed	O
.	O

Notes	O
on	O
the	O
natural	O
history	O
of	O
Lipoptilocnema	O
species	O
are	O
provided	O
,	O
and	O
their	O
potential	O
importance	O
as	O
PMI	O
indicators	O
is	O
highlighted	O
,	O
including	O
the	O
first	O
record	O
of	O
Lipoptilocnema	O
reared	B-P
from	O
a	O
dead	O
human	O
body	O
.	O

Establishing	O
a	O
reference	O
interval	O
for	O
serum	O
anti-dsDNA	O
antibody	O
:	O
A	O
large	O
Chinese	O
Han	O
population	O
-based	O
multi-center	O
study	O
.	O

A	O
reference	O
interval	O
(	O
RI	O
)	O
for	O
the	O
circulating	O
concentration	O
of	O
anti-dsDNA	O
antibody	O
is	O
essential	O
for	O
clinicians	O
to	O
interpret	O
laboratory	O
results	O
and	O
make	B-P
clinical	I-P
decisions	I-P
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
establish	O
the	O
RI	O
for	O
anti-dsDNA	O
antibody	O
in	O
the	O
Chinese	O
Han	O
population	O
.	O

This	O
study	O
was	O
designed	O
and	O
carried	O
out	O
in	O
accordance	O
with	O
guideline	O
C28-A3	O
,	O
which	O
is	O
proposed	O
by	O
the	O
International	O
Federation	O
of	O
Clinical	O
Chemistry	O
and	O
the	O
Clinical	O
and	O
Laboratory	O
Standards	O
Institute	O
.	O

A	O
total	O
of	O
2,880	O
apparently	O
healthy	O
individuals	O
were	O
enrolled	O
using	O
a	O
posteriori	O
sampling	O
.	O

These	O
individuals	O
were	O
recruited	O
from	O
four	O
hospitals	O
,	O
representing	O
the	O
Han	O
populations	O
of	O
north	O
,	O
south	O
,	O
east	O
,	O
and	O
west	O
China	O
.	O

Serum	O
anti-dsDNA	O
antibody	O
levels	O
were	O
measured	O
using	O
the	O
three	O
analytical	O
systems	O
AESKU	O
,	O
EUROIMMUNE	O
,	O
and	O
INOVA	O
,	O
which	O
are	O
the	O
most	O
commonly	O
used	O
systems	O
in	O
China	O
.	O

Individuals	O
were	O
stratified	O
by	O
gender	O
,	O
age	O
,	O
and	O
region	O
,	O
and	O
the	O
RIs	O
were	O
obtained	O
by	O
nonparametric	O
methods	O
.	O

Gender	O
-specific	O
RIs	O
for	O
serum	O
anti-dsDNA	O
antibody	O
in	O
the	O
Chinese	O
Han	O
population	O
were	O
established	O
.	O

This	O
is	O
the	O
first	O
exploration	O
of	O
the	O
RI	O
for	O
anti-dsDNA	O
antibody	O
in	O
the	O
Chinese	O
Han	O
population	O
.	O

We	O
have	O
established	O
gender	O
-specific	O
RIs	O
for	O
each	O
assay	B-P
method	I-P
commonly	O
used	O
in	O
China	O
.	O

Impact	O
of	O
CYP2C19	O
Variants	O
on	O
Clinical	O
Efficacy	O
of	O
Clopidogrel	O
and	O
1-	O
Year	O
Clinical	O
Outcomes	O
in	O
Coronary	O
Heart	O
Patients	O
Undergoing	O
Percutaneous	O
Coronary	O
Intervention	O
.	O

The	O
impact	O
of	O
pharmacogenetic	O
variants	O
of	O
cytochrome	O
P450	O
2C19	O
(	O
CYP2C19	O
)	O
on	O
clopidogrel	O
-mediated	O
effects	O
on	O
platelet	O
inhibition	O
,	O
inflammatory	O
response	O
and	O
endothelial	B-P
function	I-P
,	O
as	O
well	O
as	O
risk	O
of	O
major	O
adverse	O
cardiovascular	O
events	O
(	O
MACE	O
)	O
,	O
in	O
coronary	O
heart	O
patients	O
undergoing	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
was	O
investigated	O
.	O

To	O
this	O
end	O
,	O
we	O
assessed	O
the	O
residual	B-P
platelet	I-P
aggregation	I-P
rate	I-P
(	O
RPA	B-P
)	O
,	O
maximal	O
aggregation	O
rate	O
(	O
MAR	O
)	O
and	O
plasma	B-P
levels	I-P
of	O
sCD40L	B-P
,	O
sP-selectin	B-P
,	O
MMP-9	O
,	O
sVCAM-1	O
and	O
sE-selectin	B-P
after	O
24	O
h	O
of	O
PCI	O
in	O
559	O
patients	O
treated	O
with	O
clopidogrel	O
and	O
followed	O
up	O
for	O
1	O
year	O
for	O
evidence	O
of	O
MACE	O
.	O

CYP2C19	O
(	O
*	O
)	O
2	O
and	O
(	O
*	O
)	O
3	O
variants	O
were	O
identified	O
using	O
a	O
clopidogrel	O
-sensitive	O
gene	O
detection	O
kit	O
.	O

Our	O
results	O
showed	O
higher	O
RPA	O
and	O
MAR	O
as	O
well	O
as	O
increased	O
sE-selectin	O
,	O
sCD40L	O
,	O
sP-selectin	O
,	O
MMP-9	O
,	O
and	O
sVCAM-1	O
levels	O
in	O
CYP2C19	O
intermediate	O
metabolizer	O
(	O
IM	O
,	O
CYP2C19	O
(	O
*	O
)	O
1	O
/	O
(	O
*	O
)	O
2	O
,	O
or	O
(	O
*	O
)	O
1	O
/	O
(	O
*	O
)	O
3	O
)	O
,	O
poor	O
metabolizer	O
(	O
PM	O
,	O
CYP2C19	O
(	O
*	O
)	O
2	O
/	O
(	O
*	O
)	O
2	O
,	O
(	O
*	O
)	O
2	O
/	O
(	O
*	O
)	O
3	O
,	O
or	O
(	O
*	O
)	O
3	O
/	O
(	O
*	O
)	O
3	O
)	O
and	O
combined	O
IM+PM	O
groups	O
,	O
relative	O
to	O
those	O
in	O
extensive	O
metabolizers	O
(	O
EM	O
,	O
CYP2C19	O
(	O
*	O
)	O
1	O
/	O
(	O
*	O
)	O
1	O
)	O
.	O

In	O
total	O
,	O
519	O
patients	O
completed	O
1	O
year	O
of	O
follow-up	O
,	O
among	O
which	O
69	O
(	O
13.3	O
%	O
)	O
experienced	O
MACE	O
.	O

The	O
risk	O
of	O
MACE	O
in	O
CYP2C19	O
IM+PM	O
patients	O
was	O
2.664	O
times	O
higher	O
than	O
that	O
in	O
CYP2C19	O
EM	O
patients	O
(	O
OR	O
=	O
2.664	O
(	O
1.397-5.193	O
)	O
,	O
P	O
=	O
0.004	O
)	O
.	O

The	O
data	O
suggest	O
that	O
CYP2C19	O
(	O
*	O
)	O
2	O
and	O
(	O
*	O
)	O
3	O
variants	O
modulate	O
the	O
drug	O
efficacy	O
of	O
clopidogrel	O
in	O
coronary	O
heart	O
patients	O
undergoing	O
PCI	O
and	O
further	O
enhance	O
the	O
risk	O
of	O
MACE	O
.	O

Accordingly	O
,	O
CYP2C19	O
pharmacogenetic	O
profiling	O
may	O
be	O
beneficial	O
for	O
coronary	O
heart	O
patients	O
undergoing	O
PCI	O
to	O
predict	O
the	O
efficacy	O
of	O
treatment	O
with	O
clopidogrel	O
.	O

We	O
propose	O
that	O
IM	O
and	O
PM	O
patients	O
should	O
benefit	O
from	O
treatment	O
with	O
higher	O
clopidogrel	O
doses	O
to	O
improve	O
efficacy	O
and	O
reduce	O
the	O
incidence	O
of	O
MACE	O
.	O

Decreased	O
Frequencies	O
of	O
Peripheral	O
Blood	O
CD4+CD25+CD127-Foxp3+	O
in	O
Patients	O
with	O
Graves	O
'	O
Disease	O
and	O
Graves	O
'	O
Orbitopathy	O
:	O
Enhancing	O
Effect	O
of	O
Insulin	O
Growth	O
Factor-1	O
on	O
Treg	O
Cells	O
.	O

Graves	O
'	O
orbitopathy	O
(	O
GO	O
)	O
is	O
characterized	O
by	O
orbital	O
T	O
cell	O
infiltration	O
.	O

We	O
evaluated	O
the	O
regulatory	O
T	O
(	O
Treg	O
)	O
cell	O
fractions	O
induced	O
with	O
IGF-1	O
in	O
Graves	O
'	O
disease	O
(	O
GD	O
)	O
with	O
and	O
without	O
GO	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
were	O
obtained	O
from	O
13	O
patients	O
with	O
GD	O
without	O
eye	O
manifestations	O
;	O
10	O
patients	O
with	O
active	O
GO	O
;	O
and	O
12	O
patients	O
with	O
nodular	O
goiter	O
(	O
NG	O
)	O
.	O

All	O
the	O
patients	O
from	O
GD	O
,	O
GO	O
,	O
and	O
NG	O
were	O
subclinical	O
hyperthyroid	O
.	O

We	O
analyzed	O
the	O
expression	B-P
of	I-P
Treg	I-P
cell	I-P
markers	I-P
(	O
CD4	O
,	O
CD25	O
,	O
CD127	O
(	O
-	O
)	O
,	O
Foxp3	O
)	O
on	O
T	O
cells	O
and	O
their	O
ability	O
to	O
respond	O
to	O
IGF-1	O
stimulation	O
.	O

In	O
patients	O
with	O
GD	O
without	O
GO	O
,	O
we	O
found	O
lowered	O
percentages	O
of	O
CD4	O
(	O
+	O
)	O
Foxp3	O
(	O
+	O
)	O
cells	O
,	O
as	O
compared	O
to	O
nodular	O
goiter	O
1.77	O
vs.	O
5.42	O
%	O
(	O
p=0.0276	O
)	O
.	O

Similarly	O
,	O
significantly	O
reduced	O
frequencies	O
of	O
CD4	O
(	O
+	O
)	O
CD25	O
(	O
+	O
)	O
CD127	O
(	O
-	O
)	O
Foxp3	O
(	O
+	O
)	O
and	O
CD4	O
(	O
+	O
)	O
CD25	O
(	O
+	O
)	O
CD127	O
(	O
-	O
)	O
cells	O
were	O
observed	O
in	O
GD	O
patients	O
as	O
compared	O
to	O
nodular	O
goiter	O
patients	O
with	O
hyperthyreosis	O
,	O
(	O
0.7	O
vs.	O
1.48	O
%	O
)	O
(	O
p=0.0071	O
)	O
and	O
(	O
14.5	O
vs.	O
37.2	O
%	O
)	O
(	O
p=0.0051	O
)	O
,	O
respectively	O
.	O

In	O
GO	O
with	O
active	O
GO	O
,	O
only	O
the	O
percentage	O
of	O
CD4	O
(	O
+	O
)	O
CD25	O
(	O
+	O
)	O
CD127	O
(	O
-	O
)	O
cells	O
was	O
found	O
to	O
be	O
decreased	O
versus	O
nodular	O
goiter	O
(	O
9.35	O
vs.	O
37.2	O
)	O
(	O
p=0.0275	O
)	O
.	O

Stimulation	O
of	O
PBMC	O
derived	O
from	O
GO	O
patients	O
with	O
IGF-1	O
resulted	O
in	O
significant	O
increase	O
of	O
frequency	O
of	O
both	O
CD4	O
(	O
+	O
)	O
Foxp3	O
(	O
+	O
)	O
and	O
CD4	O
(	O
+	O
)	O
CD25	O
(	O
+	O
)	O
CD127	O
(	O
-	O
)	O
Foxp3	O
cells	O
.	O

Decreased	O
frequencies	O
of	O
peripheral	O
blood	O
CD4	O
(	O
+	O
)	O
CD25	O
(	O
+	O
)	O
CD127	O
(	O
-	O
)	O
Foxp3	O
(	O
+	O
)	O
in	O
patients	O
with	O
GD	O
and	O
GO	O
could	O
be	O
an	O
useful	O
marker	O
of	O
autoimmune	O
process	O
and	O
perhaps	O
a	O
possible	O
target	O
for	O
future	O
therapies	O
.	O

This	O
is	O
the	O
first	O
study	O
demonstrating	O
Treg	O
-	O
enhancing	O
effects	O
of	O
IGF-1	O
.	O

Thus	O
IGF-1	O
can	O
be	O
accounted	O
for	O
modulating	O
Treg	O
cell	O
-related	O
action	O
in	O
GO	O
.	O

Single-cell	B-P
analyses	I-P
of	O
X	O
Chromosome	O
inactivation	O
dynamics	O
and	O
pluripotency	O
during	O
differentiation	O
.	O

Pluripotency	O
,	O
differentiation	O
,	O
and	O
X	O
Chromosome	O
inactivation	O
(	O
XCI	O
)	O
are	O
key	O
aspects	O
of	O
embryonic	O
development	O
.	O

However	O
,	O
the	O
underlying	O
relationship	O
and	O
mechanisms	O
among	O
these	O
processes	O
remain	O
unclear	O
.	O

Here	O
,	O
we	O
systematically	O
dissected	O
these	O
features	O
along	O
developmental	O
progression	O
using	O
mouse	O
embryonic	O
stem	O
cells	O
(	O
mESCs	O
)	O
and	O
single-cell	O
RNA	O
sequencing	O
with	O
allelic	O
resolution	O
.	O

We	O
found	O
that	O
mESCs	O
grown	O
in	O
a	O
ground	O
state	O
2i	O
condition	O
displayed	O
transcriptomic	O
profiles	O
diffused	O
from	O
preimplantation	B-P
mouse	O
embryonic	O
cells	O
,	O
whereas	O
EpiStem	O
cells	O
closely	O
resembled	O
the	O
post-implantation	B-P
epiblast	O
.	O

Sex	O
-related	O
gene	O
expression	O
varied	O
greatly	O
across	O
distinct	O
developmental	O
states	O
.	O

We	O
also	O
identified	O
novel	O
markers	O
that	O
were	O
highly	O
enriched	O
in	O
each	O
developmental	O
state	O
.	O

Moreover	O
,	O
we	O
revealed	O
that	O
several	O
novel	O
pathways	O
,	O
including	O
PluriNetWork	O
and	O
Focal	O
Adhesion	O
,	O
were	O
responsible	O
for	O
the	O
delayed	O
progression	O
of	O
female	O
EpiStem	O
cells	O
.	O

Importantly	O
,	O
we	O
``	O
digitalized	O
``	O
XCI	O
progression	O
using	O
allelic	O
expression	O
of	O
active	O
and	O
inactive	O
X	O
Chromosomes	O
and	O
surprisingly	O
found	O
that	O
XCI	O
states	O
exhibited	O
profound	O
variability	O
in	O
each	O
developmental	O
state	O
,	O
including	O
the	O
2i	O
condition	O
.	O

XCI	O
progression	O
was	O
not	O
tightly	O
synchronized	O
with	O
loss	O
of	O
pluripotency	O
and	O
increase	O
of	O
differentiation	O
at	O
the	O
single-cell	O
level	O
,	O
although	O
these	O
processes	O
were	O
globally	O
correlated	O
.	O

In	O
addition	O
,	O
highly	O
expressed	O
genes	O
,	O
including	O
core	O
pluripotency	O
factors	O
,	O
were	O
in	O
general	O
biallelically	O
expressed	O
.	O

Taken	O
together	O
,	O
our	O
study	O
sheds	O
light	O
on	O
the	O
dynamics	O
of	O
XCI	O
progression	O
and	O
the	O
asynchronicity	O
between	O
pluripotency	O
,	O
differentiation	O
,	O
and	O
XCI	O
.	O

The	O
effect	O
of	O
single	O
incision	O
laparoscopic	O
cholecystectomy	O
on	O
systemic	O
oxidative	O
stress	O
:	O
a	O
prospective	O
clinical	O
trial	O
.	O

Single	O
incision	O
laparoscopic	O
cholecystectomy	O
(	O
SILC	O
)	O
has	O
become	O
a	O
more	O
frequently	O
performed	O
method	O
for	O
benign	O
gallbladder	O
diseases	O
all	O
over	O
the	O
world	O
.	O

The	O
effects	O
of	O
SILC	O
technique	O
on	O
oxidative	O
stress	O
have	O
not	O
been	O
well	O
documented	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
laparoscopic	O
cholecystectomy	O
techniques	O
on	O
systemic	O
oxidative	O
stress	O
by	O
using	O
ischemia	O
modified	O
albumin	O
(	O
IMA	O
)	O
.	O

In	O
total	O
,	O
70	O
patients	O
who	O
had	O
been	O
diagnosed	O
with	O
benign	O
gallbladder	O
pathology	O
were	O
enrolled	O
for	O
this	O
prospective	O
study	O
.	O

Twenty-one	O
patients	O
underwent	O
SILC	O
and	O
49	O
patients	O
underwent	O
laparoscopic	O
cholecystectomy	O
(	O
LC	O
)	O
.	O

All	O
operations	O
were	O
performed	O
under	O
a	O
standard	O
anesthesia	O
protocol	O
.	O

Serum	B-P
IMA	I-P
levels	I-P
were	O
analysed	O
before	O
operation	O
,	O
45	O
minutes	O
and	O
24	O
hours	O
after	O
operation	O
.	O

Demographics	O
and	O
preoperative	O
characteristics	O
of	O
the	O
patients	O
were	O
similiar	O
in	O
each	O
group	O
.	O

The	O
mean	O
duration	O
of	O
operation	O
was	O
37.5	O
Â±	O
12.5	O
and	O
44.6	O
Â±	O
14.3	O
minutes	O
in	O
LC	O
and	O
SILC	O
group	O
,	O
respectively	O
.	O

In	O
both	O
groups	O
,	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
hospital	O
stay	O
,	O
operative	O
time	O
,	O
or	O
conversion	O
to	O
open	O
surgery	O
.	O

Operative	O
technique	O
did	O
not	O
effect	O
the	O
45th	O
minute	O
and	O
24th	O
hour	O
IMA	B-P
levels	I-P
.	O

However	O
,	O
prolonged	O
operative	O
time	O
(	O
>	O
30	O
minutes	O
)	O
caused	O
an	O
early	O
increase	O
in	O
the	O
level	B-P
of	I-P
IMA	I-P
.	O

Twenty-fourth	O
hour	O
IMA	B-P
levels	I-P
were	O
not	O
different	O
.	O

SILC	O
is	O
an	O
effective	O
and	O
safe	O
surgical	O
prosedure	O
for	O
benign	O
gallbladder	O
diseases	O
.	O

Independent	O
of	O
the	O
surgical	O
technique	O
for	O
cholecystectomy	O
,	O
the	O
prolonged	O
operative	O
time	O
could	O
increase	O
the	O
tissue	O
ischemia	O
.	O

Expressions	O
of	O
CD8	O
+	O
TILs	O
,	O
PD-L1	O
and	O
Foxp3	O
+	O
TILs	O
in	O
stage	O
I	O
NSCLC	O
guiding	O
adjuvant	O
chemotherapy	O
decisions	O
.	O

Currently	O
,	O
adjuvant	O
chemotherapy	O
is	O
recommended	O
for	O
patients	O
with	O
high	O
risk	O
stage	O
I	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

However	O
,	O
identifying	O
high	O
risk	O
patients	O
remains	O
a	O
challenge	O
.	O

This	O
study	O
aims	O
to	O
identify	O
the	O
patient	O
cohorts	O
more	O
likely	O
to	O
benefit	O
from	O
adjuvant	O
chemotherapy	O
based	O
on	O
the	O
tumor	O
micro-immune	O
environment	O
.	O

CD8	O
+	O
TILs	O
significantly	O
associated	O
with	O
disease-free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survial	O
(	O
OS	O
)	O
(	O
p=0.002	O
;	O
0.040	O
)	O
.	O

Patients	O
with	O
high	O
risk	O
factors	O
may	O
also	O
predict	O
shorter	O
DFS	O
(	O
P=0.056	O
)	O
.	O

When	O
compared	O
together	O
,	O
patients	O
with	O
high	O
-	O
CD8	O
+	O
TILs	O
showed	O
better	O
DFS	O
than	O
patients	O
with	O
low	O
-	O
CD8	O
+	O
TILs	O
,	O
no	O
matter	O
their	O
risk	O
factors	O
status	O
.	O

There	O
's	O
no	O
correlation	O
between	O
PD-L1	O
expressions	O
and	O
survival	O
.	O

PD-L1	O
was	O
highly	O
expressed	O
in	O
men	O
,	O
squamous	O
and	O
well	O
differentiated	O
carcinoma	O
.	O

In	O
addition	O
,	O
Foxp3	O
+	O
TILs	O
alone	O
did	O
n't	O
show	O
any	O
prognostic	O
effects	O
,	O
but	O
low	O
-	O
Foxp3	O
/	O
high	O
-	O
CD8	O
+	O
TILs	O
were	O
associated	O
with	O
prolonged	O
DFS	O
(	O
p=0.031	O
)	O
.	O

A	O
total	O
of	O
126	O
patients	O
with	O
surgically	O
resected	O
stage	O
I	O
NSCLC	O
were	O
included	O
to	O
perform	O
immunohistochemistry	B-P
of	O
CD8	O
+	O
tumor	O
infiltrating	O
lymphocytes	O
(	O
TILs	O
)	O
,	O
programmed	O
death	O
ligand-1	O
(	O
PD-L1	O
)	O
and	O
forkhead	O
box	O
P3	O
(	O
Foxp3	O
)	O
+	O
TILs	O
.	O

CD8	O
+	O
TILs	O
are	O
effective	O
prognostic	O
predictors	O
.	O

Patients	O
with	O
surgically	O
resected	O
stage	O
I	O
NSCLC	O
showing	O
low	O
CD8	O
+	O
TILs	O
could	O
be	O
considered	O
for	O
adjuvant	O
chemotherapy	O
,	O
even	O
if	O
they	O
have	O
no	O
high	O
risk	O
features	O
.	O

Cross	O
reactivity	O
of	O
immune	O
responses	O
to	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
infection	O
.	O

Because	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
exhibits	O
extensive	O
genetic	O
variation	O
among	O
field	O
isolates	O
,	O
characterizing	O
the	O
extent	O
of	O
cross	O
reactivity	O
of	O
immune	O
responses	O
,	O
and	O
most	O
importantly	O
cell-mediated	O
immunity	O
(	O
CMI	O
)	O
,	O
could	O
help	O
in	O
the	O
development	O
of	O
broadly	O
cross-protective	O
vaccines	O
.	O

We	O
infected	O
12	O
PRRSV	O
-naÃ¯ve	O
pigs	O
with	O
PRRSV	O
strain	O
FL12	O
and	O
determined	O
the	O
number	O
of	O
interferon	O
(	O
IFN	O
)	O
-Î³	O
secreting	O
cells	O
(	O
SC	O
)	O
by	O
ELISpot	B-P
assay	I-P
using	O
ten	O
type	O
2	O
and	O
one	O
type	O
1	O
PRRSV	O
isolates	O
as	O
recall	O
antigens	O
.	O

The	O
number	O
of	O
IFN-Î³	O
SC	O
was	O
extremely	O
variable	O
among	O
animals	O
,	O
and	O
with	O
exceptions	O
,	O
late	O
to	O
appear	O
.	O

Cross	O
reactivity	O
of	O
IFN-Î³	O
SC	O
among	O
type	O
2	O
isolates	O
was	O
broad	O
,	O
and	O
we	O
found	O
no	O
evidence	O
of	O
an	O
association	O
between	O
increased	O
genetic	O
distance	O
among	O
isolates	O
and	O
the	O
intensity	O
of	O
the	O
CMI	O
response	O
.	O

Comparable	O
to	O
IFN-Î³	O
SC	O
,	O
total	O
antibodies	O
evaluated	O
by	O
indirect	B-P
immunofluorescence	I-P
assay	I-P
(	O
IFA	B-P
)	O
were	O
cross	O
reactive	O
,	O
however	O
,	O
neutralizing	O
antibody	O
titers	O
could	O
only	O
be	O
detected	O
against	O
the	O
strain	O
used	O
for	O
infection	O
.	O

Finally	O
,	O
we	O
observed	O
a	O
moderate	O
association	O
between	O
homologous	O
IFN-Î³	O
SC	O
and	O
neutralizing	O
antibodies	O
.	O

Analysis	B-P
of	O
tilianin	O
and	O
acacetin	O
in	O
Agastache	O
rugosa	O
by	O
high-performance	B-P
liquid	I-P
chromatography	I-P
with	O
ionic	O
liquids	O
-	O
ultrasound	O
based	O
extraction	B-P
.	O

Ionic	O
liquid	O
1-butyl-3-methylimidazolium	O
bromide	O
-	O
methanol	O
-based	O
ultrasonic	O
-assisted	O
extraction	B-P
(	O
ILUAE	B-P
)	O
was	O
used	O
to	O
extract	B-P
tilianin	O
and	O
acacetin	O
from	O
the	O
aerial	O
parts	O
of	O
Agastache	O
rugose	O
(	O
A.	O
rugose	O
)	O
,	O
and	O
simultaneously	O
determined	O
by	O
reversed	B-P
phase	I-P
high	I-P
performance	I-P
liquid	I-P
chromatographic	I-P
(	O
RP-HPLC	B-P
)	O
method	O
with	O
ultraviolet	O
detection	O
(	O
RP-HPLC-UV	O
)	O
.	O

An	O
InertSustain	O
RP-C18	O
column	O
was	O
used	O
with	O
the	O
mobile	O
phase	O
consisting	O
of	O
methanol	O
and	O
0.2	O
%	O
acetic	O
acid	O
as	O
gradient	O
elution	B-P
at	O
the	O
detection	O
wavelength	O
of	O
332	O
nm	O
.	O

The	O
flow	O
rate	O
was	O
0.8	O
mL/min	O
,	O
and	O
the	O
column	O
temperature	O
was	O
30	O
Â°C	O
.	O

Under	O
the	O
optimized	O
conditions	O
,	O
tilianin	O
and	O
acacetin	O
displayed	O
good	O
linearity	O
in	O
the	O
ranges	O
of	O
0.0595-4.76	O
and	O
0.0585-4.68	O
Î¼g/mL	O
,	O
respectively	O
,	O
with	O
the	O
average	O
recoveries	O
being	O
96.93	O
and	O
97.88	O
%	O
,	O
respectively	O
.	O

The	O
method	O
of	O
ILUAE	B-P
was	O
compared	O
with	O
the	O
traditional	O
methods	O
,	O
it	O
exhibited	O
higher	O
efficiency	O
,	O
higher	O
reproducibility	O
and	O
environmental	O
friendly	O
in	O
analyzing	O
the	O
active	O
compounds	O
in	O
traditional	O
Chinese	O
medicines	O
(	O
TCMs	O
)	O
.	O

Polymeric	O
Nanostructure	O
Compiled	O
with	O
Multifunctional	O
Components	O
To	O
Exert	O
Tumor	O
-	O
Targeted	O
Delivery	O
of	O
Antiangiogenic	O
Gene	O
for	O
Tumor	O
Growth	O
Suppression	O
.	O

Nucleic	O
acid-based	O
therapy	O
has	O
emerged	O
as	O
a	O
revolutionary	O
methodology	O
for	O
treatment	O
of	O
the	O
diseases	O
related	O
to	O
protein	O
dysfunction	O
;	O
however	O
,	O
lack	O
of	O
systemically	O
applicable	O
synthetic	O
delivery	O
systems	O
limits	O
its	O
current	O
usage	O
in	O
local	O
applications	O
,	O
particularly	O
for	O
DNA-based	O
therapy	O
with	O
regard	O
to	O
the	O
poor	O
bioavailability	O
in	O
the	O
systemic	O
administrations	O
.	O

To	O
overcome	O
this	O
obstacle	O
,	O
we	O
compiled	O
multiple	O
chemistry-based	B-P
strategies	I-P
into	O
the	O
manufacture	O
of	O
the	O
gene	O
delivery	O
formulations	O
to	O
pursue	O
improved	O
tolerability	O
of	O
DNA	O
to	O
the	O
enzymatic	O
degradation	O
in	O
the	O
biological	O
milieu	O
and	O
prolonged	O
retention	O
in	O
the	O
systemic	O
circulation	O
.	O

Here	O
,	O
we	O
constructed	O
a	O
distinctive	O
multilayered	O
functional	O
architecture	O
:	O
plasmid	O
DNA	O
(	O
pDNA	O
)	O
was	O
electrostatically	O
complexed	O
with	O
cationic	O
poly	O
(	O
lysine	O
)	O
(	O
polyplex	O
)	O
as	O
the	O
interior	O
pDNA	O
reservoir	O
,	O
which	O
was	O
further	O
cross-linked	O
by	O
redox	O
-	O
responsive	O
disulfide	O
cross-linking	O
to	O
minimize	O
the	O
occurrence	O
of	O
polyplex	O
disassembly	O
through	O
exchange	O
reaction	O
with	O
the	O
biological	O
charged	O
components	O
.	O

Still	O
,	O
the	O
pDNA	O
reservoir	O
was	O
spatially	O
protected	O
by	O
a	O
sequential	O
thermoresponsive	O
poly	O
(	O
N-isopropylacrylamide	O
)	O
palisade	O
as	O
the	O
intermediate	O
barrier	O
and	O
a	O
biocompatible	O
hydrophilic	O
poly	O
(	O
ethylene	O
glycol	O
)	O
(	O
PEG	O
)	O
shell	O
with	O
the	O
aim	O
of	O
preventing	O
the	O
accessibility	O
of	O
the	O
biological	O
species	O
,	O
particularly	O
the	O
nuclease	O
degradation	O
to	O
the	O
pDNA	O
payload	O
.	O

Subsequent	O
investigations	O
validated	O
the	O
utilities	O
of	O
these	O
strategies	O
in	O
accomplishing	O
prolonged	O
blood	O
retention	O
.	O

In	O
an	O
attempt	O
to	O
apply	O
this	O
method	O
for	O
tumor	O
therapy	O
,	O
ligand	O
cyclic	O
(	O
Arg-Gly-Asp	O
)	O
peptide	O
was	O
attached	O
at	O
the	O
distal	O
end	O
of	O
PEG	O
,	O
validating	O
prompted	O
tumor	O
-	O
targeted	O
delivery	O
and	O
gene	O
expression	O
of	O
the	O
loaded	O
antiangiogenic	O
gene	O
at	O
the	O
targeted	O
tumor	O
cells	O
and	O
accordingly	O
exerting	O
antiangiogenesis	O
of	O
the	O
tumors	O
for	O
abrogation	O
of	O
tumor	O
growth	O
.	O

Together	O
with	O
its	O
excellent	O
safe	O
profile	O
,	O
the	O
proposed	O
formulation	O
suggests	O
potential	O
utility	O
as	O
a	O
practical	O
gene	O
delivery	O
system	O
for	O
treatment	O
of	O
intractable	O
diseases	O
.	O

The	O
Correlation	O
of	O
Arterial	O
Stiffness	O
with	O
Biophysical	O
Parameters	O
and	O
Blood	O
Biochemistry	O
.	O

Type	O
2	O
diabetes	O
presents	O
with	O
numerous	O
macrovascular	O
and	O
microvascular	O
impairments	O
,	O
which	O
in	O
turn	O
lead	O
to	O
various	O
co-morbidities	O
.	O

Vascular	O
co-morbidities	O
can	O
be	O
seen	O
when	O
examining	O
arterial	O
stiffness	O
(	O
AS	O
)	O
,	O
which	O
is	O
a	O
predictor	O
for	O
endothelial	O
health	O
and	O
cardiovascular	O
disease	O
risk	O
.	O

Pulse	B-P
wave	I-P
analysis	I-P
(	O
PWA	B-P
)	O
and	O
pulse	O
wave	O
velocity	O
(	O
PWV	O
)	O
are	O
two	O
tests	O
that	O
are	O
commonly	O
used	O
to	O
measure	O
AS	O
.	O

Currently	O
,	O
disease	O
states	O
and	O
progression	O
are	O
tracked	O
via	O
blood	O
biochemistry	O
.	O

These	O
gold	O
standards	O
in	O
monitoring	O
diabetes	O
are	O
expensive	O
and	O
need	O
optimization	O
.	O

To	O
investigate	O
which	O
biophysical	O
and	O
biochemical	O
parameters	O
correlated	O
best	O
with	O
AS	O
,	O
which	O
may	O
reduce	O
the	O
number	O
of	O
biochemical	B-P
tests	I-P
and	O
biophysical	O
parameter	O
measurements	O
needed	O
to	O
track	O
disease	O
progression	O
.	O

Data	O
from	O
42	O
subjects	O
with	O
type	O
2	O
diabetes	O
mellitus	O
for	O
â¤10	O
years	O
,	O
aged	O
40-70	O
years	O
,	O
were	O
analyzed	O
at	O
a	O
single	O
time	O
point	O
.	O

We	O
investigated	O
various	O
blood	O
biochemistry	O
,	O
body	O
composition	O
,	O
and	O
AS	O
parameters	O
.	O

A	O
combination	O
of	O
fat	O
mass	O
and	O
fat-free	O
mass	O
was	O
most	O
associated	O
with	O
PWA	B-P
over	O
any	O
other	O
parameters	O
.	O

Leptin	O
and	O
high-sensitivity	O
C-reactive	O
protein	O
seem	O
to	O
be	O
the	O
next	O
two	O
parameters	O
that	O
correlate	O
with	O
augmentation	O
index	O
.	O

No	O
other	O
parameters	O
had	O
strong	O
correlations	O
to	O
either	O
PWA	B-P
or	O
PWV	O
values	O
.	O

Body	B-P
composition	I-P
methods	I-P
seemed	O
to	O
be	O
better	O
predictors	O
of	O
type	O
2	O
diabetes	O
mellitus	O
patient	O
's	O
vascular	O
disease	O
progression	O
.	O

Our	O
study	O
indicates	O
that	O
body	O
composition	O
measurements	O
may	O
help	O
replace	O
expensive	B-P
tests	I-P
.	O

This	O
may	O
have	O
public	O
health	O
and	O
health	O
surveillance	O
implications	O
in	O
countries	O
facing	O
financial	O
challenges	O
.	O

The	O
endocannabinoid	O
hydrolysis	O
inhibitor	O
SA-57	O
:	O
Intrinsic	O
antinociceptive	O
effects	O
,	O
augmented	O
morphine	O
-induced	O
antinociception	O
,	O
and	O
attenuated	O
heroin	O
seeking	O
behavior	O
in	O
mice	O
.	O

Although	O
opioids	O
are	O
highly	O
efficacious	O
analgesics	O
,	O
their	O
abuse	O
potential	O
and	O
other	O
untoward	O
side	O
effects	O
diminish	O
their	O
therapeutic	O
utility	O
.	O

The	O
addition	O
of	O
non-opioid	O
analgesics	O
offers	O
a	O
promising	O
strategy	O
to	O
reduce	O
required	O
antinociceptive	O
opioid	O
doses	O
that	O
concomitantly	O
reduce	O
opioid-related	O
side	O
effects	O
.	O

Inhibitors	O
of	O
the	O
primary	O
endocannabinoid	O
catabolic	O
enzymes	O
fatty	O
acid	O
amide	O
hydrolase	O
(	O
FAAH	O
)	O
and	O
monoacylglycerol	O
lipase	O
(	O
MAGL	O
)	O
show	O
opioid	O
-	O
sparing	O
effects	O
in	O
preclinical	O
models	O
of	O
pain	O
.	O

As	O
simultaneous	O
inhibition	O
of	O
these	O
enzymes	O
elicits	O
enhanced	O
antinociceptive	O
effects	O
compared	O
with	O
single	O
enzyme	O
inhibition	O
,	O
the	O
present	O
study	O
tested	O
whether	O
the	O
dual	O
FAAH	O
-	O
MAGL	O
inhibitor	O
SA-57	O
[	O
4-	O
[	O
2-	O
(	O
4-chlorophenyl	O
)	O
ethyl	O
]	O
-1-piperidinecarboxylic	O
acid	O
2-	O
(	O
methylamino	O
)	O
-2-oxoethyl	O
ester	O
]	O
produces	O
morphine	O
-sparing	O
antinociceptive	O
effects	O
,	O
without	O
major	O
side	O
effects	O
associated	O
with	O
either	O
drug	O
class	O
.	O

SA-57	O
dose	O
-dependently	O
reversed	O
mechanical	O
allodynia	O
in	O
the	O
constriction	O
injury	O
(	O
CCI	O
)	O
of	O
the	O
sciatic	O
nerve	O
model	O
of	O
neuropathic	O
pain	O
and	O
carrageenan	O
inflammatory	O
pain	O
model	O
.	O

As	O
previously	O
reported	O
,	O
SA-57	O
was	O
considerably	O
more	O
potent	O
in	O
elevating	O
anandamide	O
(	O
AEA	O
)	O
than	O
2-arachidonyl	O
glycerol	O
(	O
2-AG	O
)	O
in	O
brain	O
.	O

Its	O
anti-allodynic	O
effects	O
required	O
cannabinoid	O
(	O
CB	O
)	O
1	O
and	O
CB2	O
receptors	O
;	O
however	O
,	O
only	O
CB2	O
receptors	O
were	O
necessary	O
for	O
the	O
anti-edematous	O
effects	O
in	O
the	O
carrageenan	O
assay	B-P
.	O

Although	O
high	O
doses	O
of	O
SA-57	O
alone	O
were	O
required	O
to	O
produce	O
antinociception	O
,	O
low	O
doses	O
of	O
this	O
compound	O
,	O
which	O
elevated	O
AEA	O
and	O
did	O
not	O
affect	O
2-AG	O
brain	O
levels	O
,	O
augmented	O
the	O
antinociceptive	O
effects	O
of	O
morphine	O
,	O
but	O
lacked	O
cannabimimetic	O
side	O
effects	O
.	O

Because	O
of	O
the	O
high	O
abuse	O
liability	O
of	O
opioids	O
and	O
implication	O
of	O
the	O
endocannabinoid	O
system	O
in	O
the	O
reinforcing	O
effects	O
of	O
opioids	O
,	O
the	O
final	O
experiment	O
tested	O
whether	O
SA-57	O
would	O
alter	O
heroin	O
seeking	O
behavior	O
.	O

Strikingly	O
,	O
SA-57	O
reduced	O
heroin	O
-	O
reinforced	O
nose	O
poke	O
behavior	O
and	O
the	O
progressive	O
ratio	O
break	O
point	O
for	O
heroin	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
inhibition	O
of	O
endocannabinoid	O
degradative	O
enzymes	O
represents	O
a	O
promising	O
therapeutic	O
approach	O
to	O
decrease	O
effective	O
doses	O
of	O
opioids	O
needed	O
for	O
clinical	O
pain	O
control	O
,	O
and	O
may	O
also	O
possess	O
therapeutic	O
potential	O
to	O
reduce	O
opioid	O
abuse	O
.	O

EASL	O
Clinical	O
Practice	O
Guidelines	O
:	O
The	O
diagnosis	O
and	O
management	O
of	O
patients	O
with	O
primary	O
biliary	O
cholangitis	O
.	O

Primary	O
biliary	O
cholangitis	O
(	O
PBC	O
)	O
is	O
a	O
chronic	O
inflammatory	O
autoimmune	O
cholestatic	O
liver	O
disease	O
,	O
which	O
when	O
untreated	O
will	O
culminate	O
in	O
end-stage	O
biliary	O
cirrhosis	O
.	O

Diagnosis	O
is	O
usually	O
based	O
on	O
the	O
presence	O
of	O
serum	B-P
liver	I-P
tests	I-P
indicative	O
of	O
a	O
cholestatic	O
hepatitis	O
in	O
association	O
with	O
circulating	O
antimitochondrial	O
antibodies	O
.	O

Patient	O
presentation	O
and	O
course	O
can	O
be	O
diverse	O
and	O
risk	O
stratification	O
is	O
important	O
to	O
ensure	O
all	O
patients	O
receive	O
a	O
personalised	O
approach	O
to	O
their	O
care	O
.	O

The	O
goals	O
of	O
treatment	O
and	O
management	O
are	O
the	O
prevention	O
of	O
end-stage	O
liver	O
disease	O
,	O
and	O
the	O
amelioration	O
of	O
associated	O
symptoms	O
.	O

Pharmacologic	O
approaches	O
in	O
practice	O
,	O
to	O
reduce	O
the	O
impact	O
of	O
the	O
progressive	O
nature	O
of	O
disease	O
,	O
currently	O
include	O
licensed	O
therapies	O
(	O
ursodeoxycholic	O
acid	O
and	O
obeticholic	O
acid	O
)	O
and	O
off-label	O
therapies	O
(	O
fibric	O
acid	O
derivatives	O
,	O
budesonide	O
)	O
.	O

These	O
clinical	O
practice	O
guidelines	O
summarise	O
the	O
evidence	O
for	O
the	O
importance	O
of	O
a	O
structured	O
,	O
life-long	O
and	O
individualised	O
,	O
approach	O
to	O
the	O
care	O
of	O
patients	O
with	O
PBC	O
,	O
providing	O
a	O
framework	O
to	O
help	O
clinicians	O
diagnose	O
and	O
effectively	O
manage	O
patients	O
.	O

Cell	O
Electrical	O
Impedance	O
as	O
a	O
Novel	O
Approach	O
for	O
Studies	O
on	O
Senescence	O
Not	O
Based	O
on	O
Biomarkers	O
.	O

Senescence	O
of	O
cardiac	O
myocytes	O
is	O
frequently	O
associated	O
with	O
heart	O
diseases	O
.	O

To	O
analyze	O
senescence	O
in	O
cardiac	O
myocytes	O
,	O
a	O
number	O
of	O
biomarkers	O
have	O
been	O
isolated	O
.	O

However	O
,	O
due	O
to	O
the	O
complex	O
nature	O
of	O
senescence	O
,	O
multiple	O
markers	O
are	O
required	O
for	O
a	O
single	O
assay	B-P
to	O
accurately	O
depict	O
complex	O
physiological	O
changes	O
associated	O
with	O
senescence	O
.	O

In	O
single	O
cells	O
,	O
changes	O
in	O
both	O
cytoplasm	O
and	O
cell	O
membrane	O
during	O
senescence	O
can	O
affect	O
the	O
changes	O
in	O
electrical	O
impedance	O
.	O

Based	O
on	O
this	O
phenomenon	O
,	O
we	O
developed	O
MEDoS	B-P
,	O
a	O
novel	O
microelectrochemical	B-P
impedance	I-P
spectroscopy	I-P
for	O
diagnosis	O
of	O
senescence	O
,	O
which	O
allows	O
us	O
to	O
precisely	O
measure	O
quantitative	O
changes	O
in	O
electrical	O
properties	O
of	O
agingf	O
cells	O
.	O

Using	O
cardiac	O
myocytes	O
isolated	O
from	O
3-	O
,	O
6-	O
,	O
and	O
18-month-old	O
isogenic	O
zebrafish	O
,	O
we	O
examined	O
the	O
efficacy	O
of	O
MEDoS	B-P
and	O
showed	O
that	O
MEDoS	B-P
can	O
identify	O
discernible	O
changes	O
in	O
electrical	O
impedance	O
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrated	O
that	O
electrical	O
impedance	O
in	O
cells	O
at	O
different	O
ages	O
is	O
distinct	O
with	O
quantitative	O
values	O
;	O
these	O
results	O
were	O
comparable	O
with	O
previously	O
reported	O
ones	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
MEDoS	B-P
be	O
used	O
as	O
a	O
new	O
biomarker	O
-	O
independent	O
methodology	O
to	O
obtain	O
quantitative	O
data	O
on	O
the	O
biological	O
senescence	O
status	O
of	O
individual	O
cells	O
.	O

Evaluation	O
of	O
the	O
Prostate	O
Imaging	O
Reporting	O
and	O
Data	O
System	O
for	O
Magnetic	B-P
Resonance	I-P
Imaging	I-P
Diagnosis	O
of	O
Prostate	O
Cancer	O
in	O
Patients	O
with	O
Prostate-specific	O
Antigen	O
<	O
20	O
ng/ml	O
.	O

The	O
European	O
Society	O
of	O
Urogenital	O
Radiology	O
has	O
built	O
the	O
Prostate	O
Imaging	O
Reporting	O
and	O
Data	O
System	O
(	O
PI-RADS	O
)	O
for	O
standardizing	O
the	O
diagnosis	O
of	O
prostate	O
cancer	O
(	O
PCa	O
)	O
.	O

This	O
study	O
evaluated	O
the	O
PI-RADS	O
diagnosis	B-P
method	I-P
in	O
patients	O
with	O
prostate-specific	O
antigen	O
(	O
PSA	O
)	O
<	O
20	O
ng/ml	O
.	O

A	O
total	O
of	O
133	O
patients	O
with	O
PSA	O
<	O
20	O
ng/ml	O
were	O
prospectively	O
recruited	O
.	O

T2-weighted	B-P
(	O
T2WI	B-P
)	O
and	O
diffusion-weighted	B-P
(	I-P
DWI	I-P
)	I-P
magnetic	I-P
resonance	I-P
images	I-P
of	O
the	O
prostate	O
were	O
acquired	O
before	O
a	O
12-core	B-P
transrectal	I-P
prostate	I-P
biopsy	I-P
.	O

Each	O
patient	O
's	O
peripheral	O
zone	O
was	O
divided	O
into	O
six	O
regions	O
on	O
the	O
images	O
;	O
each	O
region	O
corresponded	O
to	O
two	O
of	O
the	O
12	O
biopsy	B-P
cores	I-P
.	O

T2WI	B-P
,	O
DWI	B-P
,	O
and	O
T2WI	B-P
+	O
DWI	B-P
scores	O
were	O
computed	O
according	O
to	O
PI-RADS	O
.	O

The	O
diagnostic	O
accuracy	O
of	O
the	O
PI-RADS	O
score	O
was	O
evaluated	O
using	O
histopathology	O
of	O
prostate	B-P
biopsies	I-P
as	O
the	O
reference	O
standard	O
.	O

PCa	O
was	O
histologically	O
diagnosed	O
in	O
169	O
(	O
21.2	O
%	O
)	O
regions	O
.	O

Increased	O
PI-RADS	O
score	O
correlated	O
positively	O
with	O
increased	O
cancer	O
detection	O
rate	O
.	O

The	O
cancer	O
detection	O
rate	O
for	O
scores	O
1	O
to	O
5	O
was	O
2.8	O
%	O
,	O
15.0	O
%	O
,	O
34.6	O
%	O
,	O
52.6	O
%	O
,	O
and	O
88.9	O
%	O
,	O
respectively	O
,	O
using	O
T2WI	B-P
and	O
12.0	O
%	O
,	O
20.2	O
%	O
,	O
48.0	O
%	O
,	O
85.7	O
%	O
,	O
and	O
93.3	O
%	O
,	O
respectively	O
,	O
using	O
DWI	B-P
.	O

For	O
T2WI	B-P
+	O
DWI	B-P
,	O
the	O
cancer	O
detection	O
rate	O
was	O
1.5	O
%	O
(	O
score	O
2	O
)	O
,	O
13.5	O
%	O
(	O
scores	O
3-4	O
)	O
,	O
41.3	O
%	O
(	O
scores	O
5-6	O
)	O
,	O
75.9	O
%	O
(	O
scores	O
7-8	O
)	O
,	O
and	O
92.3	O
%	O
(	O
scores	O
9-10	O
)	O
.	O

The	O
area	O
under	O
the	O
curve	O
for	O
cancer	O
detection	O
was	O
0.700	O
(	O
T2WI	B-P
)	O
,	O
0.735	O
(	O
DWI	B-P
)	O
and	O
0.749	O
(	O
T2WI	B-P
+	O
DWI	B-P
)	O
.	O

The	O
sensitivity	O
and	O
specificity	O
were	O
53.8	O
%	O
and	O
89.2	O
%	O
,	O
respectively	O
,	O
when	O
using	O
scores	O
5-6	O
as	O
the	O
cutoff	O
value	O
for	O
T2WI	B-P
+	O
DWI	B-P
.	O

The	O
PI-RADS	O
score	O
correlates	O
with	O
the	O
PCa	O
detection	O
rate	O
in	O
patients	O
with	O
PSA	O
<	O
20	O
ng/ml	O
.	O

The	O
summed	O
score	O
of	O
T2WI	B-P
+	O
DWI	B-P
has	O
the	O
highest	O
accuracy	O
in	O
detection	O
of	O
PCa	O
.	O

However	O
,	O
the	O
sensitivity	O
should	O
be	O
further	O
improved	O
.	O

NADPH	O
Oxidase	O
Activation	O
Contributes	O
to	O
Heavy	O
Ion	O
Irradiation	O
-	O
Induced	O
Cell	O
Death	O
.	O

Increased	O
oxidative	O
stress	O
plays	O
an	O
important	O
role	O
in	O
heavy	O
ion	O
radiation	O
-	O
induced	O
cell	O
death	O
.	O

The	O
mechanism	O
involved	O
in	O
the	O
generation	O
of	O
elevated	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
is	O
not	O
fully	O
illustrated	O
.	O

Here	O
we	O
show	O
that	O
NADPH	O
oxidase	O
activation	O
is	O
closely	O
related	O
to	O
heavy	O
ion	O
radiation	O
-	O
induced	O
cell	O
death	O
via	O
excessive	O
ROS	O
generation	O
.	O

Cell	O
death	O
and	O
cellular	O
ROS	O
can	O
be	O
greatly	O
reduced	O
in	O
irradiated	O
cancer	O
cells	O
with	O
the	O
preincubation	B-P
of	O
diphenyleneiodium	O
,	O
an	O
inhibitor	O
of	O
NADPH	O
oxidase	O
.	O

Most	O
of	O
the	O
NADPH	O
oxidase	O
(	O
NOX	O
)	O
family	O
proteins	O
(	O
NOX1	O
,	O
NOX2	O
,	O
NOX3	O
,	O
NOX4	O
,	O
and	O
NOX5	O
)	O
showed	O
increased	O
expression	O
after	O
heavy	O
ion	O
irradiation	O
.	O

Meanwhile	O
,	O
the	O
cytoplasmic	O
subunit	O
p47	O
(	O
phox	O
)	O
was	O
translocated	O
to	O
the	O
cell	O
membrane	O
and	O
localized	O
with	O
NOX2	O
to	O
form	O
reactive	O
NADPH	O
oxidase	O
.	O

Our	O
data	O
suggest	O
for	O
the	O
first	O
time	O
that	O
ROS	O
generation	O
,	O
as	O
mediated	O
by	O
NADPH	O
oxidase	O
activation	O
,	O
could	O
be	O
an	O
important	O
contributor	O
to	O
heavy	O
ion	O
irradiation	O
-	O
induced	O
cell	O
death	O
.	O

Geolocalization	O
of	O
Influenza	O
Outbreak	O
Within	O
an	O
Acute	O
Care	O
Population	O
:	O
A	O
Layered-Surveillance	O
Approach	O
.	O

We	O
seek	O
to	O
use	O
a	O
novel	O
layered-surveillance	O
approach	O
to	O
localize	O
influenza	O
clusters	O
within	O
an	O
acute	O
care	O
population	O
.	O

The	O
first	O
layer	O
of	O
this	O
system	O
is	O
a	O
syndromic	O
surveillance	O
screen	O
to	O
guide	O
rapid	B-P
polymerase	I-P
chain	I-P
reaction	I-P
testing	I-P
.	O

The	O
second	O
layer	O
is	O
geolocalization	O
and	O
cluster	O
analysis	O
of	O
these	O
patients	O
.	O

We	O
posit	O
that	O
any	O
identified	O
clusters	O
could	O
represent	O
at-risk	O
populations	O
who	O
could	O
serve	O
as	O
high-yield	O
targets	O
for	O
preventive	O
medical	O
interventions	O
.	O

This	O
was	O
a	O
prospective	O
observational	O
surveillance	O
study	O
.	O

Patients	O
were	O
screened	O
with	O
a	O
previously	O
derived	O
clinical	O
decision	O
guideline	O
that	O
has	O
a	O
90	O
%	O
sensitivity	O
and	O
30	O
%	O
specificity	O
for	O
influenza	O
.	O

Patients	O
received	O
points	O
for	O
the	O
following	O
signs	O
and	O
symptoms	O
within	O
the	O
past	O
7	O
days	O
:	O
cough	O
(	O
2	O
points	O
)	O
,	O
headache	O
(	O
1	O
point	O
)	O
,	O
subjective	O
fever	O
(	O
1	O
point	O
)	O
,	O
and	O
documented	O
fever	O
at	O
triage	O
(	O
temperature	O
>	O
38Â°C	O
[	O
100.4Â°F	O
]	O
)	O
(	O
1	O
point	O
)	O
.	O

Patients	O
scoring	O
3	O
points	O
or	O
higher	O
were	O
indicated	O
for	O
influenza	O
testing	O
.	O

Patients	O
were	O
tested	O
with	O
Xpert	B-P
Flu	I-P
(	O
Cepheid	O
,	O
Sunnyvale	O
,	O
CA	O
)	O
,	O
a	O
rapid	B-P
polymerase	I-P
chain	I-P
reaction	I-P
test	I-P
.	O

Positive	O
results	O
were	O
mapped	O
with	O
ArcGIS	O
(	O
ESRI	O
,	O
Redlands	O
,	O
CA	O
)	O
and	O
analyzed	O
with	O
kernel	O
density	O
estimation	O
to	O
create	O
heat	O
maps	O
.	O

There	O
were	O
1,360	O
patients	O
tested	O
with	O
Xpert	B-P
Flu	I-P
with	O
retrievable	O
addresses	O
within	O
the	O
greater	O
Phoenix	O
metro	O
area	O
.	O

One	O
hundred	O
sixty-seven	O
(	O
12	O
%	O
)	O
of	O
them	O
tested	O
positive	O
for	O
influenza	O
A	O
and	O
23	O
(	O
2	O
%	O
)	O
tested	O
positive	O
for	O
influenza	O
B	O
.	O

The	O
influenza	O
A	O
virus	O
exhibited	O
a	O
clear	O
cluster	O
pattern	O
within	O
this	O
patient	O
population	O
.	O

The	O
densest	O
cluster	O
was	O
located	O
in	O
an	O
approximately	O
1-	O
square-mile	O
region	O
southeast	O
of	O
our	O
hospital	O
.	O

Our	O
layered-surveillance	O
approach	O
was	O
effective	O
in	O
localizing	O
a	O
cluster	O
of	O
influenza	O
A	O
outbreak	O
.	O

This	O
region	O
may	O
house	O
a	O
high-yield	O
target	O
population	O
for	O
public	O
health	O
intervention	O
.	O

Further	O
collaborative	O
efforts	O
will	O
be	O
made	O
between	O
our	O
hospital	O
and	O
the	O
Maricopa	O
County	O
Department	O
of	O
Public	O
Health	O
to	O
perform	O
a	O
series	O
of	O
community	O
vaccination	O
events	O
before	O
the	O
next	O
influenza	O
season	O
.	O

We	O
hope	O
these	O
efforts	O
will	O
ultimately	O
serve	O
to	O
reduce	O
the	O
burden	O
of	O
this	O
disease	O
on	O
our	O
patient	O
population	O
,	O
and	O
that	O
this	O
system	O
will	O
serve	O
as	O
a	O
framework	O
for	O
future	O
investigations	O
locating	O
at-risk	O
populations	O
.	O

Ultrasound	B-P
evaluation	O
of	O
diaphragm	O
function	O
in	O
mechanically	O
ventilated	O
patients	O
:	O
comparison	O
to	O
phrenic	O
stimulation	O
and	O
prognostic	O
implications	O
.	O

In	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
patients	O
,	O
diaphragm	O
dysfunction	O
is	O
associated	O
with	O
adverse	O
clinical	O
outcomes	O
.	O

Ultrasound	B-P
measurements	I-P
of	O
diaphragm	O
thickness	O
,	O
excursion	O
(	O
EXdi	O
)	O
and	O
thickening	O
fraction	O
(	O
TFdi	O
)	O
are	O
putative	O
estimators	O
of	O
diaphragm	O
function	O
,	O
but	O
have	O
never	O
been	O
compared	O
with	O
phrenic	O
nerve	O
stimulation	O
.	O

Our	O
aim	O
was	O
to	O
describe	O
the	O
relationship	O
between	O
these	O
variables	O
and	O
diaphragm	O
function	O
evaluated	O
using	O
the	O
change	O
in	O
endotracheal	O
pressure	O
after	O
phrenic	O
nerve	O
stimulation	O
(	O
Ptr	O
,	O
stim	O
)	O
,	O
and	O
to	O
compare	O
their	O
prognostic	O
value	O
.	O

Between	O
November	O
2014	O
and	O
June	O
2015	O
,	O
Ptr	O
,	O
stim	O
and	O
ultrasound	B-P
variables	O
were	O
measured	O
in	O
mechanically	O
ventilated	O
patients	O
<	O
24	O
hours	O
after	O
intubation	O
(	O
'	O
initiation	O
of	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
'	O
,	O
under	O
assist-control	O
ventilation	O
,	O
ACV	O
)	O
and	O
at	O
the	O
time	O
of	O
switch	O
to	O
pressure	O
support	O
ventilation	O
(	O
'switch	O
to	O
PSV	O
'	O
)	O
,	O
and	O
compared	O
using	O
Spearman	O
's	O
correlation	O
and	O
receiver	O
operating	O
characteristic	O
curve	O
analysis	O
.	O

Diaphragm	O
dysfunction	O
was	O
defined	O
as	O
Ptr	O
,	O
stim	O
<	O
11	O
cm	O
H2O	O
.	O

112	O
patients	O
were	O
included	O
.	O

At	O
initiation	O
of	O
MV	O
,	O
Ptr	O
,	O
stim	O
was	O
not	O
correlated	O
to	O
diaphragm	O
thickness	O
(	O
p=0.28	O
)	O
,	O
EXdi	O
(	O
p=0.66	O
)	O
or	O
TFdi	O
(	O
p=0.80	O
)	O
.	O

At	O
switch	O
to	O
PSV	O
,	O
TFdi	O
and	O
EXdi	O
were	O
respectively	O
very	O
strongly	O
and	O
moderately	O
correlated	O
to	O
Ptr	O
,	O
stim	O
,	O
(	O
r=0.87	O
,	O
p	O
<	O
0.001	O
and	O
0.45	O
,	O
p=0.001	O
)	O
,	O
but	O
diaphragm	O
thickness	O
was	O
not	O
(	O
p=0.45	O
)	O
.	O

A	O
TFdi	O
<	O
29	O
%	O
could	O
reliably	O
identify	O
diaphragm	O
dysfunction	O
(	O
sensitivity	O
and	O
specificity	O
of	O
85	O
%	O
and	O
88	O
%	O
)	O
,	O
but	O
diaphragm	O
thickness	O
and	O
EXdi	O
could	O
not	O
.	O

This	O
value	O
was	O
associated	O
with	O
increased	O
duration	O
of	O
ICU	O
stay	O
and	O
MV	O
,	O
and	O
mortality	O
.	O

Under	O
ACV	O
,	O
diaphragm	O
thickness	O
,	O
EXdi	O
and	O
TFdi	O
were	O
uncorrelated	O
to	O
Ptr	O
,	O
stim	O
.	O

Under	O
PSV	O
,	O
TFdi	O
was	O
strongly	O
correlated	O
to	O
diaphragm	O
strength	O
and	O
both	O
were	O
predictors	O
of	O
remaining	O
length	O
of	O
MV	O
and	O
ICU	O
and	O
hospital	O
death	O
.	O

Glomus	O
tumor	O
in	O
teen	O
and	O
repetition	O
pneumonia	O
:	O
Case	O
report	O
.	O

Glomus	O
tumors	O
are	O
uncommon	O
tumors	O
that	O
are	O
originated	O
from	O
smooth	O
muscle	O
cells	O
of	O
the	O
neuromioarterials	O
glomus	O
bodies	O
located	O
in	O
the	O
arteriovenous	O
anastomoses	O
subcutaneous	O
tissue	O
or	O
deep	O
dermis	O
of	O
the	O
extremities	O
,	O
mainly	O
in	O
the	O
palms	O
of	O
the	O
hands	O
,	O
wrists	O
and	O
subungual	O
areas	O
of	O
the	O
fingers	O
.	O

Carcinoid	O
tumor	O
,	O
as	O
the	O
glomus	O
tumor	O
,	O
can	O
show	O
an	O
organoid	O
pattern	O
,	O
increased	O
vascularity	O
,	O
and	O
uniform	O
,	O
round	O
cells	O
with	O
eosinophilic	O
cytoplasm	O
,	O
but	O
usually	O
are	O
positive	O
for	O
cytokeratin	O
and	O
always	O
stained	O
with	O
chromogranin	O
and	O
synaptophysin	O
showing	O
negative	O
for	O
smooth	O
muscle	O
markers	O
which	O
is	O
presented	O
in	O
our	O
case	O
.	O

Glomus	O
tumors	O
have	O
a	O
good	O
prognosis	O
and	O
surgical	O
resection	O
is	O
the	O
treatment	O
of	O
choice	O
.	O

In	O
our	O
case	O
,	O
the	O
patient	O
underwent	O
pulmonary	O
bilobectomy	O
because	O
of	O
the	O
location	O
of	O
the	O
tumor	O
in	O
the	O
transition	O
between	O
the	O
middle	O
lobe	O
and	O
the	O
basal	O
bronchial	O
trunk	O
right	O
lower	O
lobe	O
divisions	O
.	O

It	O
is	O
presented	O
thus	O
a	O
glomus	O
tumor	O
with	O
exceptional	O
localization	O
(	O
pulmonary	O
and	O
bronchial	O
)	O
of	O
benign	O
histological	O
features	O
,	O
according	O
to	O
most	O
of	O
the	O
cases	O
reported	O
in	O
the	O
literature	O
emphasizing	O
their	O
particular	O
rare	O
location	O
,	O
histological	O
,	O
and	O
immunohistochemical	B-P
profile	B-P
,	O
which	O
helps	O
the	O
differential	B-P
diagnosis	I-P
with	O
other	O
most	O
common	O
tumors	O
of	O
bronchial	O
location	O
.	O

Reduced	O
haemodynamic	O
coupling	O
and	O
exercise	O
are	O
associated	O
with	O
vascular	O
stiffening	O
in	O
pulmonary	O
arterial	O
hypertension	O
.	O

Inadequate	O
right	O
ventricular	O
(	O
RV	O
)	O
and	O
pulmonary	O
arterial	O
(	O
PA	O
)	O
functional	O
responses	O
to	O
exercise	O
are	O
important	O
yet	O
poorly	O
understood	O
features	O
of	O
pulmonary	O
arterial	O
hypertension	O
(	O
PAH	O
)	O
.	O

This	O
study	O
combined	O
invasive	O
catheterisation	O
with	O
echocardiography	B-P
to	O
assess	O
RV	O
afterload	O
,	O
RV	O
function	O
and	O
ventricular	O
-	O
vascular	O
coupling	O
in	O
subjects	O
with	O
PAH	O
.	O

Twenty-six	O
subjects	O
with	O
PAH	O
were	O
prospectively	O
recruited	O
to	O
undergo	O
right	O
heart	O
catheterisation	O
and	O
Doppler	B-P
echocardiography	I-P
at	O
rest	O
and	O
during	O
incremental	O
exercise	O
,	O
and	O
cardiac	B-P
MRI	I-P
at	O
rest	O
.	O

Measurements	O
at	O
rest	O
included	O
basic	O
haemodynamics	O
,	O
RV	O
function	O
and	O
coupling	O
efficiency	O
(	O
Î·	O
)	O
.	O

Measurements	O
during	O
incremental	O
exercise	O
included	O
pulmonary	O
vascular	O
resistance	O
(	O
Z0	O
)	O
,	O
characteristic	B-P
impedance	I-P
(	O
ZC	B-P
,	O
a	O
measure	O
of	O
proximal	O
PA	O
stiffness	O
)	O
and	O
proximal	O
and	O
distal	O
PA	O
compliance	O
(	O
CPA	O
)	O
.	O

In	O
patients	O
with	O
PAH	O
,	O
the	O
proximal	O
PAs	O
were	O
significantly	O
stiffer	O
at	O
maximum	O
exercise	O
(	O
ZC	B-P
=2.31Â±0.38	O
vs	O
1.33Â±0.15	O
WUÃm	O
(	O
2	O
)	O
at	O
rest	O
;	O
p=0.003	O
)	O
and	O
PA	O
compliance	O
was	O
decreased	O
(	O
CPA	O
=0.88Â±0.10	O
vs	O
1.32Â±0.17	O
mL/mm	O
Hg/m	O
(	O
2	O
)	O
at	O
rest	O
;	O
p=0.0002	O
)	O
.	O

Z0	O
did	O
not	O
change	O
with	O
exercise	O
.	O

As	O
a	O
result	O
,	O
the	O
resistance-compliance	O
(	O
RC	O
)	O
time	O
decreased	O
with	O
exercise	O
(	O
0.67Â±0.05	O
vs	O
1.00Â±0.07	O
s	O
at	O
rest	O
;	O
p	O
<	O
10	O
(	O
-6	O
)	O
)	O
.	O

When	O
patients	O
were	O
grouped	O
according	O
to	O
resting	O
coupling	O
efficiency	O
,	O
those	O
with	O
poorer	O
Î·	O
exhibited	O
stiffer	O
proximal	O
PAs	O
at	O
rest	O
,	O
a	O
lower	O
maximum	O
exercise	O
level	O
,	O
and	O
more	O
limited	O
CPA	O
reduction	O
at	O
maximum	O
exercise	O
.	O

In	O
PAH	O
,	O
exercise	O
causes	O
proximal	O
and	O
distal	O
PA	O
stiffening	O
,	O
which	O
combined	O
with	O
preserved	O
Z0	O
results	O
in	O
decreased	O
RC	O
time	O
with	O
exercise	O
.	O

Stiff	O
PAs	O
at	O
rest	O
may	O
also	O
contribute	O
to	O
poor	O
haemodynamic	O
coupling	O
,	O
reflecting	O
reduced	O
pulmonary	O
vascular	O
reserve	O
that	O
contributes	O
to	O
limit	O
the	O
maximum	O
exercise	O
level	O
tolerated	O
.	O

The	O
role	O
of	O
sub-hippocampal	O
versus	O
hippocampal	O
regions	O
in	O
bitemporal	O
lobe	O
epilepsies	O
.	O

We	O
aimed	O
at	O
better	O
delineating	O
the	O
functional	O
anatomical	O
organization	O
of	O
bitemporal	O
lobe	O
epilepsy	O
.	O

We	O
studied	O
the	O
epileptogenic	O
zone	O
(	O
EZ	O
)	O
by	O
quantifying	O
the	O
epileptogenicity	O
of	O
brain	O
structures	O
explored	O
by	O
depth	O
electrodes	O
in	O
patients	O
investigated	O
by	O
stereoelectroencephalography	B-P
(	O
SEEG	B-P
)	O
.	O

We	O
compared	O
15	O
patients	O
with	O
bilateral	O
mesial	O
temporal	O
lobe	O
epilepsy	O
(	O
BTLE	O
)	O
and	O
15	O
patients	O
with	O
unilateral	O
mesial	O
temporal	O
lobe	O
epilepsy	O
(	O
UTLE	O
)	O
.	O

This	O
quantification	O
was	O
performed	O
using	O
the	O
'	O
Epileptogenicity	O
Index	O
'	O
(	O
EI	O
)	O
.	O

Age	O
at	O
epilepsy	O
onset	O
,	O
and	O
epilepsy	O
duration	O
,	O
were	O
not	O
statistically	O
different	O
in	O
both	O
groups	O
.	O

UTLE	O
patients	O
more	O
frequently	O
displayed	O
maximal	O
epileptogenicity	O
in	O
hippocampal	O
structures	O
,	O
whereas	O
BTLE	O
patients	O
had	O
maximal	O
values	O
in	O
subhippocampal	O
areas	O
(	O
entorhinal	O
cortex	O
,	O
temporal	O
pole	O
,	O
parahippocampal	O
cortex	O
)	O
.	O

Our	O
results	O
suggest	O
different	O
organization	O
of	O
the	O
EZ	O
in	O
the	O
two	O
groups	O
.	O

BTLE	O
was	O
associated	O
with	O
more	O
involvement	O
of	O
subhippocampal	O
regions	O
,	O
a	O
result	O
in	O
agreement	O
with	O
known	O
anatomical	O
connections	O
between	O
the	O
two	O
temporal	O
lobes	O
.	O

The	O
Processing-Speed	O
Impairment	O
in	O
Psychosis	O
Is	O
More	O
Than	O
Just	O
Accelerated	O
Aging	O
.	O

Processing	O
speed	O
is	O
impaired	O
in	O
patients	O
with	O
psychosis	O
,	O
and	O
deteriorates	O
as	O
a	O
function	O
of	O
normal	O
aging	O
.	O

These	O
observations	O
,	O
in	O
combination	O
with	O
other	O
lines	O
of	O
research	O
,	O
suggest	O
that	O
psychosis	O
may	O
be	O
a	O
syndrome	O
of	O
accelerated	O
aging	O
.	O

But	O
do	O
patients	O
with	O
psychosis	O
perform	O
poorly	O
on	O
tasks	O
of	O
processing	O
speed	O
for	O
the	O
same	O
reasons	O
as	O
older	O
adults	O
?	O

Fifty-one	O
patients	O
with	O
psychotic	O
illnesses	O
and	O
90	O
controls	O
with	O
similar	O
mean	O
IQ	O
(	O
aged	O
19-69	O
years	O
,	O
all	O
African	O
American	O
)	O
completed	O
a	O
computerized	O
processing-speed	O
task	O
,	O
reminiscent	O
of	O
the	O
classic	O
digit-symbol	O
coding	O
task	O
.	O

The	O
data	O
were	O
analyzed	O
using	O
the	O
drift-diffusion	O
model	O
(	O
DDM	O
)	O
,	O
and	O
Bayesian	O
inference	O
was	O
used	O
to	O
determine	O
whether	O
psychosis	O
and	O
aging	O
had	O
similar	O
or	O
divergent	O
effects	O
on	O
the	O
DDM	O
parameters	O
.	O

Psychosis	O
and	O
aging	O
were	O
both	O
associated	O
with	O
poor	O
performance	O
,	O
but	O
had	O
divergent	O
effects	O
on	O
the	O
DDM	O
parameters	O
.	O

Patients	O
had	O
lower	O
information-processing	O
efficiency	O
(	O
``	O
drift	O
rate	O
``	O
)	O
and	O
longer	O
nondecision	O
time	O
than	O
controls	O
,	O
and	O
psychosis	O
per	O
se	O
did	O
not	O
influence	O
response	O
caution	O
.	O

By	O
contrast	O
,	O
the	O
primary	O
effect	O
of	O
aging	O
was	O
to	O
increase	O
response	O
caution	O
,	O
and	O
had	O
inconsistent	O
effects	O
on	O
drift	O
rate	O
and	O
nondecision	O
time	O
across	O
patients	O
and	O
controls	O
.	O

The	O
results	O
reveal	O
that	O
psychosis	O
and	O
aging	O
influenced	O
performance	O
in	O
different	O
ways	O
,	O
suggesting	O
that	O
the	O
processing-speed	O
impairment	O
in	O
psychosis	O
is	O
more	O
than	O
just	O
accelerated	O
aging	O
.	O

This	O
study	O
also	O
demonstrates	O
the	O
potential	O
utility	O
of	O
computational	O
models	O
and	O
Bayesian	O
inference	O
for	O
finely	O
mapping	O
the	O
contributions	O
of	O
cognitive	O
functions	O
on	O
simple	O
neurocognitive	B-P
tests	I-P
.	O

The	O
platelet-activating	O
receptor	O
C-type	O
lectin	O
receptor-2	O
plays	O
an	O
essential	O
role	O
in	O
liver	O
regeneration	O
after	O
partial	O
hepatectomy	O
in	O
mice	O
.	O

Essentials	O
Regeneration	O
role	O
of	O
C-type	O
lectin	O
receptor-2	O
(	O
CLEC-2	O
)	O
after	O
70	O
%	O
hepatectomy	O
(	O
HPx	O
)	O
was	O
investigated	O
.	O

Wild-type	O
or	O
CLEC-2	O
deleted	O
from	O
platelets	O
of	O
chimeric	O
mice	O
(	O
flKO	O
)	O
underwent	O
HPx	O
.	O

The	O
liver/body	O
weight	O
ratio	O
was	O
significantly	O
lower	O
in	O
the	O
flKO	O
than	O
in	O
the	O
wild-type	O
.	O

CLEC-2	O
plays	O
an	O
essential	O
role	O
in	O
liver	O
regeneration	O
after	O
HPx	O
.	O

Background	O
and	O
aim	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
C-type	O
lectin	O
receptor	O
(	O
CLEC	O
)	O
-2	O
in	O
liver	O
regeneration	O
following	O
partial	O
liver	O
resection	O
in	O
mice	O
.	O

Materials	O
and	O
methods	O
Irradiated	O
chimeric	O
mice	O
transplanted	O
with	O
fetal	O
liver	O
cells	O
from	O
wild-type	O
(	O
WT	O
)	O
mice	O
,	O
CLEC-2	O
-	O
deleted	O
(	O
KO	O
)	O
mice	O
or	O
mice	O
with	O
CLEC-2	O
deleted	O
specifically	O
from	O
platelets	O
(	O
flKO	O
)	O
were	O
generated	O
.	O

Mice	O
underwent	O
70	O
%	O
partial	O
hepatectomy	O
(	O
PH	O
)	O
.	O

Immunohistochemical	B-P
staining	I-P
was	O
performed	O
to	O
investigate	O
the	O
expression	O
of	O
the	O
endogenous	O
ligand	O
for	O
CLEC-2	O
,	O
podoplanin	O
.	O

The	O
accumulation	O
of	O
platelets	O
in	O
the	O
liver	O
was	O
also	O
quantified	O
.	O

The	O
hepatic	O
expression	O
of	O
the	O
IL-6	O
/	O
gp130	O
and	O
STAT3	O
,	O
Akt	O
and	O
ERK1/2	O
was	O
also	O
examined	O
.	O

Results	O
The	O
liver/body	O
weight	O
ratio	O
and	O
expression	O
of	O
all	O
cell	O
proliferation	O
markers	B-P
were	O
significantly	O
lower	O
in	O
the	O
flKO	O
group	O
than	O
in	O
the	O
WT	O
group	O
.	O

The	O
expression	O
of	O
phosphorylated	O
(	O
p	O
)	O
Akt	O
and	O
pERK1	O
/2	O
was	O
similar	O
in	O
the	O
WT	O
and	O
flKO	O
groups	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
expression	O
of	O
pSTAT3	O
and	O
IL-6	O
was	O
significantly	O
stronger	O
in	O
the	O
WT	O
group	O
than	O
in	O
the	O
flKO	O
group	O
.	O

The	O
expression	O
of	O
podoplanin	O
was	O
detected	O
in	O
the	O
hepatic	O
sinusoids	O
of	O
both	O
groups	O
.	O

However	O
,	O
the	O
extent	O
to	O
which	O
platelets	O
accumulated	O
in	O
hepatic	O
sinusoids	O
was	O
significantly	O
less	O
in	O
the	O
flKO	O
group	O
than	O
in	O
the	O
WT	O
group	O
.	O

Conclusion	O
CLEC-2	O
was	O
involved	O
in	O
hepatic	O
regeneration	O
after	O
liver	O
resection	O
and	O
CLEC-2	O
-related	O
liver	O
regeneration	O
was	O
attributed	O
to	O
the	O
interaction	O
between	O
platelets	O
and	O
sinusoidal	O
endothelial	O
cells	O
.	O

The	O
E3	O
Ligase	O
CHIP	O
Mediates	O
p21	O
Degradation	O
to	O
Maintain	O
Radioresistance	O
.	O

Lung	O
cancer	O
resists	O
radiotherapy	B-P
,	O
making	O
it	O
one	O
of	O
the	O
deadliest	O
forms	O
of	O
cancer	O
.	O

Here	O
,	O
we	O
show	O
that	O
human	O
lung	O
cancer	O
cell	O
lines	O
can	O
be	O
rendered	O
sensitive	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
by	O
RNAi	O
knockdown	O
of	O
C-terminus	O
of	O
Hsc70-interacting	O
protein	O
(	O
CHIP	O
/	O
STUB1	O
)	O
,	O
a	O
U-box-type	O
E3	O
ubiquitin	O
ligase	O
that	O
targets	O
a	O
number	O
of	O
stress-induced	O
proteins	O
.	O

Mechanistically	O
,	O
ubiquitin-dependent	O
degradation	O
of	O
the	O
cyclin-dependent	O
kinase	O
(	O
CDK	O
)	O
inhibitor	O
,	O
p21	O
protein	O
,	O
is	O
reduced	O
by	O
CHIP	O
knockdown	O
,	O
leading	O
to	O
enhanced	O
senescence	O
of	O
cells	O
in	O
response	O
to	O
exposure	O
to	O
IR	O
.	O

Cellular	O
senescence	O
and	O
sensitivity	O
to	O
IR	O
is	O
prevented	O
by	O
CRISPR	O
/	O
Cas9	O
-mediated	O
deletion	O
of	O
the	O
p21	O
gene	O
(	O
CDKN1A	O
)	O
in	O
CHIP	O
knockdown	O
cells	O
.	O

Conversely	O
,	O
overexpression	O
of	O
CHIP	O
potentiates	O
p21	O
degradation	O
and	O
promotes	O
greater	O
radioresistance	O
of	O
lung	O
cancer	O
cells	O
.	O

In	O
vitro	O
and	O
cell	O
-based	O
assays	B-P
demonstrate	O
that	O
p21	O
is	O
a	O
novel	O
and	O
direct	O
ubiquitylation	O
substrate	O
of	O
CHIP	O
that	O
also	O
requires	O
the	O
CHIP	O
-	O
associated	O
chaperone	O
HSP70	O
.	O

These	O
data	O
reveal	O
that	O
the	O
inhibition	O
of	O
the	O
E3	O
ubiquitin	O
ligase	O
CHIP	O
promotes	O
radiosensitivity	O
,	O
thus	O
suggesting	O
a	O
novel	O
strategy	O
for	O
the	O
treatment	O
of	O
lung	O
cancer	O
.	O

Implications	O
:	O
The	O
CHIP	O
-	O
HSP70	O
-	O
p21	O
ubiquitylation	O
/	O
degradation	O
axis	O
identified	O
here	O
could	O
be	O
exploited	O
to	O
enhance	O
the	O
efficacy	O
of	O
radiotherapy	O
in	O
patients	O
with	O
non-small	O
cell	O
lung	O
cancer	O
.	O

Mol	O
Cancer	O
Res	O
;	O
1-9	O
.	O

Â©2017	O
AACR	O
.	O

The	O
integration	O
of	O
cyanide	O
hydratase	O
and	O
tyrosinase	O
catalysts	O
enables	O
effective	O
degradation	O
of	O
cyanide	O
and	O
phenol	O
in	O
coking	O
wastewaters	O
.	O

The	O
aim	O
of	O
this	O
study	B-P
was	O
to	O
design	O
an	O
effective	O
method	O
for	O
the	O
bioremediation	O
of	O
coking	O
wastewaters	O
,	O
specifically	O
for	O
the	O
concurrent	O
elimination	O
of	O
their	O
highly	O
toxic	O
components	O
-	O
cyanide	O
and	O
phenols	O
.	O

Almost	O
full	O
degradation	O
of	O
free	O
cyanide	O
(	O
0.32-20	O
mM	O
;	O
8.3-520	O
mg	O
L	O
(	O
-1	O
)	O
)	O
in	O
the	O
model	O
and	O
the	O
real	O
coking	O
wastewaters	O
was	O
achieved	O
by	O
using	O
a	O
recombinant	O
cyanide	O
hydratase	O
in	O
the	O
first	O
step	O
.	O

The	O
removal	O
of	O
cyanide	O
,	O
a	O
strong	O
inhibitor	O
of	O
tyrosinase	O
,	O
enabled	O
an	O
effective	O
degradation	O
of	O
phenols	O
by	O
this	O
enzyme	O
in	O
the	O
second	O
step	O
.	O

Phenol	O
(	O
16.5	O
mM	O
,	O
1,552	O
mg	O
L	O
(	O
-1	O
)	O
)	O
was	O
completely	O
removed	O
from	O
a	O
real	O
coking	O
wastewater	O
within	O
20	O
h	O
and	O
cresols	O
(	O
5.0	O
mM	O
,	O
540	O
mg	O
L	O
(	O
-1	O
)	O
)	O
were	O
removed	O
by	O
66	O
%	O
under	O
the	O
same	O
conditions	O
.	O

The	O
integration	O
of	O
cyanide	O
hydratase	O
and	O
tyrosinase	O
open	O
up	O
new	O
possibilities	O
for	O
the	O
bioremediation	O
of	O
wastewaters	O
with	O
complex	O
pollution	O
.	O

Evaluation	O
of	O
Pharmacokinetics	O
,	O
and	O
Bioavailability	O
of	O
Higher	O
Doses	O
of	O
Tocotrienols	O
in	O
Healthy	O
Fed	O
Humans	O
.	O

Tocotrienols	O
has	O
been	O
known	O
to	O
lower	O
serum	O
lipid	O
parameters	O
below	O
500	O
mg/d	O
,	O
while	O
increase	O
lipid	O
parameters	O
at	O
higher	O
dose	O
of	O
750	O
mg/d	O
.	O

Î´-Tocotrienol	O
has	O
a	O
novel	O
inflammatory	O
property	O
of	O
concentration-dependent	O
inhibition	O
and	O
activation	O
.	O

Therefore	O
,	O
inhibition	O
(	O
anti-inflammatory	O
)	O
property	O
of	O
tocotrienols	O
at	O
low	O
doses	O
is	O
useful	O
for	O
cardiovascular	O
disease	O
,	O
whereas	O
,	O
activation	O
(	O
pro-inflammatory	O
)	O
property	O
using	O
high	O
dose	O
is	O
found	O
effective	O
for	O
treatments	O
of	O
various	O
types	O
of	O
cancer	O
.	O

We	O
have	O
recently	O
described	O
plasma	O
bioavailability	O
of	O
125	O
mg/d	O
,	O
250	O
mg/d	O
and	O
500	O
mg/d	O
doses	O
of	O
Î´-tocotrienol	O
in	O
healthy	O
fed	O
subjects	O
,	O
which	O
showed	O
dose-dependent	O
increases	O
in	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
and	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
.	O

Hence	O
,	O
in	O
the	O
current	O
study	O
,	O
higher	O
doses	O
of	O
tocotrienols	O
have	O
used	O
to	O
analyze	O
its	O
effect	O
on	O
plasma	O
pharmacokinetic	O
parameters	O
.	O

To	O
evaluate	O
the	O
safety	O
and	O
bioavailability	O
of	O
higher	O
doses	O
(	O
750	O
mg	O
and	O
1000	O
mg	O
)	O
of	O
annatto	O
-based	O
tocotrienols	O
in	O
healthy	O
fed	O
subjects	O
.	O

All	O
four	O
isomers	O
(	O
Î±-	O
,	O
Î²-	O
,	O
Î³-	O
,	O
Î´-	O
)	O
of	O
tocols	O
(	O
tocotrienols	O
and	O
tocopherols	O
)	O
present	O
in	O
the	O
plasmas	O
of	O
subjects	O
were	O
quantified	O
and	O
analyzed	O
for	O
various	O
pharmacokinetic	O
parameters	O
.	O

An	O
open-label	O
,	O
randomized	O
study	O
was	O
performed	O
to	O
analyze	O
pharmacokinetics	O
and	O
bioavailability	O
of	O
Î´-tocotrienol	O
in	O
6	O
healthy	O
fed	O
subjects	O
.	O

All	O
subjects	O
(	O
3/	O
dose	O
)	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
each	O
dose	O
of	O
750	O
mg	O
or	O
1000	O
mg	O
.	O

Blood	O
samples	O
were	O
collected	O
at	O
0	O
,	O
1	O
,	O
2	O
,	O
4	O
,	O
6	O
,	O
8	O
h	O
intervals	O
and	O
all	O
isomers	O
of	O
Î±-	O
,	O
Î²-	O
,	O
Î³-	O
,	O
Î´-tocotrienols	O
,	O
and	O
tocopherols	O
in	O
plasmas	O
were	O
quantified	O
by	O
HPLC	B-P
.	O

Oral	O
administration	O
of	O
750	O
and	O
1000	O
mg/d	O
of	O
tocotrienols	O
resulted	O
in	O
dose-dependent	O
increases	O
in	O
plasmas	O
(	O
ng/ml	O
)	O
AUC	O
t0-t8	O
6621	O
,	O
7450	O
;	O
AUC	O
t0-â	O
8688	O
,	O
9633	O
;	O
AUMC	O
t0-â	O
52497	O
,	O
57199	O
;	O
MRT	O
6.04	O
,	O
5.93	O
;	O
Cmax	O
1444	O
,	O
1592	O
(	O
P	O
<	O
0.05	O
)	O
,	O
respectively	O
,	O
of	O
Î´-tocotrienol	O
isomer	O
.	O

Moreover	O
,	O
both	O
doses	O
also	O
resulted	O
in	O
plasmas	O
Tmax	O
3.33-4	O
h	O
;	O
elimination	O
half-life	O
(	O
t1/2	O
h	O
)	O
2.74	O
,	O
2.68	O
;	O
time	O
of	O
clearance	O
(	O
Cl-T	O
,	O
l/h	O
)	O
0.086	O
,	O
0.078	O
;	O
volume	O
of	O
distribution	O
(	O
Vd/f	O
,	O
mg/h	O
)	O
0.34	O
,	O
0.30	O
;	O
and	O
elimination	O
rate	O
constant	O
(	O
ke	O
;	O
h	O
(	O
-1	O
)	O
)	O
0.25	O
,	O
0.17	O
,	O
respectively	O
of	O
Î´-	O
tocotrienol	O
isomer	O
.	O

Similar	O
results	O
of	O
these	O
parameters	O
were	O
reported	O
for	O
Î³-tocotrienol	O
,	O
Î²-	O
tocotrienol	O
,	O
Î±-tocotrienol	O
,	O
Î´-tocopherol	O
,	O
Î³-tocopherol	O
,	O
and	O
Î²-tocopherol	O
,	O
except	O
for	O
Î±-	O
tocopherol	O
.	O

This	O
study	O
has	O
described	O
pharmacokinetics	O
using	O
higher	O
doses	O
of	O
750	O
mg/d	O
and	O
1000	O
mg/d	O
of	O
Î´-tocotrienol	O
.	O

These	O
results	O
confirmed	O
earlier	O
findings	O
that	O
Tmax	O
was	O
3-4	O
h	O
for	O
all	O
isomers	O
of	O
tocotrienols	O
and	O
tocopherols	O
except	O
for	O
Î±-tocopherol	O
(	O
6	O
h	O
)	O
.	O

These	O
higher	O
doses	O
of	O
tocotrienols	O
were	O
found	O
safe	O
in	O
humans	O
and	O
may	O
be	O
useful	O
for	O
treatments	O
of	O
various	O
types	O
of	O
cancer	O
,	O
diabetes	O
,	O
and	O
Alzheimer	O
's	O
disease	O
.	O

Genome-Wide	O
SNP	O
Linkage	O
Mapping	O
and	O
QTL	O
Analysis	B-P
for	O
Fiber	O
Quality	O
and	O
Yield	O
Traits	O
in	O
the	O
Upland	O
Cotton	O
Recombinant	O
Inbred	O
Lines	O
Population	O
.	O

It	O
is	O
of	O
significance	O
to	O
discover	O
genes	O
related	O
to	O
fiber	O
quality	O
and	O
yield	O
traits	O
and	O
tightly	O
linked	O
markers	O
for	O
marker-assisted	O
selection	O
(	O
MAS	O
)	O
in	O
cotton	O
breeding	O
.	O

In	O
this	O
study	O
,	O
188	O
F8	O
recombinant	O
inbred	O
lines	O
(	O
RILs	O
)	O
,	O
derived	O
from	O
a	O
intraspecific	O
cross	O
between	O
HS46	O
and	O
MARCABUCAG8US-1-88	O
were	O
genotyped	O
by	O
the	O
cotton	O
63K	O
single	B-P
nucleotide	I-P
polymorphism	I-P
(	I-P
SNP	I-P
)	I-P
assay	I-P
.	O

Field	O
trials	O
were	O
conducted	O
in	O
Sanya	O
,	O
Hainan	O
Province	O
,	O
during	O
the	O
2014-2015	O
cropping	O
seasons	O
under	O
standard	O
conditions	O
.	O

Results	O
revealed	O
significant	O
differences	O
(	O
P	O
<	O
0.05	O
)	O
among	O
RILs	O
,	O
environments	O
and	O
replications	O
for	O
fiber	O
quality	O
and	O
yield	O
traits	O
.	O

Broad-sense	O
heritabilities	O
of	O
all	O
traits	O
including	O
fiber	O
length	O
,	O
fiber	O
uniformity	O
,	O
micronaire	O
,	O
fiber	O
elongation	O
,	O
fiber	O
strength	O
,	O
boll	O
weight	O
,	O
and	O
lint	O
percentage	O
ranged	O
from	O
0.26	O
to	O
0.66	O
.	O

A	O
1784.28	O
cM	O
(	O
centimorgans	O
)	O
linkage	O
map	O
,	O
harboring	O
2618	O
polymorphic	O
SNP	O
markers	O
,	O
was	O
constructed	O
,	O
which	O
had	O
0.68	O
cM	O
per	O
marker	O
density	O
.	O

Seventy-one	O
quantitative	O
trait	O
locus	O
(	O
QTLs	O
)	O
for	O
fiber	O
quality	O
and	O
yield	O
traits	O
were	O
detected	O
on	O
21	O
chromosomes	O
,	O
explaining	O
4.70~32.28	O
%	O
phenotypic	O
variance	O
,	O
in	O
which	O
16	O
were	O
identified	O
as	O
stable	O
QTLs	O
across	O
two	O
environments	O
.	O

Meanwhile	O
,	O
12	O
certain	O
regions	O
were	O
investigated	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
one	O
(	O
hotspot	O
)	O
or	O
more	O
(	O
cluster	O
)	O
traits	O
,	O
mainly	O
focused	O
on	O
Chr05	O
,	O
Chr09	O
,	O
Chr10	O
,	O
Chr14	O
,	O
Chr19	O
,	O
and	O
Chr20	O
.	O

Nineteen	O
pairs	O
of	O
epistatic	O
QTLs	O
(	O
e-QTLs	O
)	O
were	O
identified	O
,	O
of	O
which	O
two	O
pairs	O
involved	O
in	O
two	O
additive	O
QTLs	O
.	O

These	O
additive	O
QTLs	O
,	O
e-QTLs	O
,	O
and	O
QTL	O
clusters	O
were	O
tightly	O
linked	O
to	O
SNP	O
markers	O
,	O
which	O
may	O
serve	O
as	O
target	O
regions	O
for	O
map-based	O
cloning	O
,	O
gene	O
discovery	O
,	O
and	O
MAS	O
in	O
cotton	O
breeding	O
.	O

Autonomous	O
assembly	O
of	O
ordered	O
metastable	O
DNA	O
nanoarchitecture	O
and	O
in	O
situ	O
visualizing	O
of	O
intracellular	O
microRNAs	O
.	O

Facile	O
assembly	O
of	O
intelligent	O
DNA	O
nanoobjects	O
with	O
the	O
ability	O
to	O
exert	O
in	O
situ	O
visualization	O
of	O
intracellular	O
microRNAs	O
(	O
miRNAs	O
)	O
has	O
long	O
been	O
concerned	O
in	O
the	O
fields	O
of	O
DNA	O
nanotechnology	O
and	O
basic	O
medical	O
study	O
.	O

Here	O
,	O
we	O
present	O
a	O
driving	O
primer	O
(	O
DP	O
)	O
-triggered	O
polymerization	O
-mediated	O
metastable	O
assembly	O
(	O
PMA	O
)	O
strategy	O
to	O
prepare	O
a	O
well-ordered	O
metastable	O
DNA	O
nanoarchitecture	O
composed	O
of	O
only	O
two	O
hairpin	O
probes	O
(	O
HAPs	O
)	O
,	O
which	O
has	O
never	O
been	O
explored	O
by	O
assembly	O
methods	O
.	O

Its	O
structural	O
features	O
and	O
functions	O
are	O
characterized	O
by	O
atomic	B-P
force	I-P
microscope	I-P
(	O
AFM	B-P
)	O
and	O
gel	B-P
electrophoresis	I-P
.	O

Even	O
if	O
with	O
a	O
metastable	O
molecular	O
structure	O
,	O
this	O
nanoarchitecture	O
is	O
relatively	O
stable	O
at	O
physiological	O
temperature	O
.	O

The	O
assembly	O
strategy	O
can	O
be	O
expanded	O
to	O
execute	O
microRNA-21	O
(	O
miRNA-21	O
)	O
in	O
situ	O
imaging	B-P
inside	O
cancer	O
cells	O
by	O
labelling	O
one	O
of	O
the	O
HAPs	O
with	O
fluorophore	O
and	O
quencher	O
.	O

Compared	O
with	O
the	O
conventional	O
fluorescence	O
probe	O
-based	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
technique	O
,	O
confocal	B-P
images	I-P
revealed	O
that	O
the	O
proposed	O
DNA	O
nanoassembly	O
can	O
not	O
only	O
achieve	O
greatly	O
enhanced	O
imaging	B-P
effect	I-P
within	O
cancer	O
cells	O
,	O
but	O
also	O
reflect	O
the	O
miRNA-21	O
expression	O
level	O
sensitively	O
.	O

We	O
believe	O
that	O
the	O
easily	O
constructed	O
DNA	O
nanoarchitecture	O
and	O
in	O
situ	O
profiling	O
strategy	O
are	O
significant	O
progresses	O
in	O
DNA	O
assembly	O
and	O
molecule	B-P
imaging	I-P
in	O
cells	O
.	O

Intracellular	O
localization	O
of	O
Saffold	O
virus	O
Leader	O
(	O
L	O
)	O
protein	O
differs	O
in	O
Vero	O
and	O
HEp-2	O
cells	O
.	O

The	O
Saffold	O
virus	O
(	O
SAFV	O
)	O
genome	O
is	O
translated	O
as	O
a	O
single	O
long	O
polyprotein	O
precursor	O
and	O
co-translationally	O
cleaved	O
to	O
yield	O
12	O
separate	O
viral	O
proteins	O
.	O

Little	O
is	O
known	O
about	O
the	O
activities	O
of	O
SAFV	O
proteins	O
although	O
their	O
homologs	O
in	O
other	O
picornaviruses	O
have	O
already	O
been	O
described	O
.	O

To	O
further	O
support	O
research	O
on	O
functions	O
and	O
activities	O
of	O
respective	O
viral	O
proteins	O
,	O
we	O
investigated	O
the	O
spatio-temporal	O
distribution	O
of	O
SAFV	O
proteins	O
in	O
Vero	O
and	O
HEp-2	O
cells	O
that	O
had	O
been	O
either	O
transfected	O
with	O
plasmids	O
that	O
express	O
individual	O
viral	O
proteins	O
or	O
infected	O
with	O
live	O
SAFV	O
.	O

Our	O
results	O
revealed	O
that	O
,	O
with	O
the	O
exception	O
of	O
the	O
Leader	O
(	O
L	O
)	O
protein	O
,	O
all	O
viral	O
proteins	O
were	O
localized	O
in	O
the	O
cytoplasm	O
at	O
all	O
the	O
time	O
points	O
assayed	B-P
.	O

The	O
L	O
protein	O
was	O
found	O
in	O
the	O
cytoplasm	O
at	O
an	O
early	O
time	O
point	O
but	O
was	O
subsequently	O
translocated	O
to	O
the	O
nucleus	O
of	O
HEp-2	O
,	O
but	O
not	O
Vero	O
,	O
cells	O
.	O

This	O
was	O
observed	O
in	O
both	O
transfected	O
and	O
infected	O
cells	O
.	O

Further	O
mutational	B-P
analysis	I-P
of	O
L	O
protein	O
revealed	O
that	O
Threonine	O
58	O
of	O
the	O
Ser	O
/	O
Thr	O
-rich	O
domain	O
of	O
L	O
protein	O
is	O
crucial	O
for	O
protein	O
trafficking	O
between	O
the	O
cytoplasm	O
and	O
nucleus	O
in	O
HEp-2	O
cells	O
.	O

These	O
findings	O
contribute	O
to	O
a	O
deeper	O
understanding	O
and	O
stimulate	O
investigation	O
of	O
the	O
differetial	O
cellular	O
responses	O
of	O
HEp-2	O
cells	O
in	O
comparison	O
to	O
other	O
mammalian	O
cell	O
lines	O
during	O
SAFV	O
infection	O
.	O

Neonatal	O
diffusion	B-P
tensor	I-P
brain	I-P
imaging	I-P
predicts	O
later	O
motor	O
outcome	O
in	O
preterm	O
neonates	O
with	O
white	O
matter	O
abnormalities	O
.	O

White	O
matter	O
(	O
WM	O
)	O
abnormalities	O
associated	O
with	O
prematurity	O
are	O
one	O
of	O
the	O
most	O
important	O
causes	O
of	O
neurological	O
disability	O
that	O
involves	O
spastic	O
motor	O
deficits	O
in	O
preterm	O
newborns	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
regional	O
microstructural	O
changes	O
in	O
diffusion	B-P
tensor	I-P
imaging	I-P
(	O
DTI	B-P
)	O
associated	O
with	O
WM	O
abnormalities	O
.	O

We	O
prospectively	O
studied	O
extremely	O
low	O
birth	O
weight	O
(	O
ELBW	O
;	O
<	O
1000	O
g	O
)	O
preterm	O
infants	O
who	O
were	O
admitted	O
to	O
the	O
Neonatal	O
Intensive	O
Care	O
Unit	O
of	O
Hanyang	O
University	O
Hospital	O
between	O
February	O
2011	O
and	O
February	O
2014	O
.	O

WM	O
abnormalities	O
were	O
assessed	O
with	O
conventional	O
magnetic	B-P
resonance	I-P
(	I-P
MR	I-P
)	I-P
imaging	I-P
and	O
DTI	B-P
near	O
term-equivalent	O
age	O
before	O
discharge	O
.	O

Region-of-interests	O
(	O
ROIs	O
)	O
measurements	O
were	O
performed	O
to	O
examine	O
the	O
regional	O
distribution	O
of	O
fractional	O
anisotropy	O
(	O
FA	O
)	O
values	O
.	O

Thirty-two	O
out	O
of	O
72	O
ELBW	O
infants	O
underwent	O
conventional	O
MR	B-P
imaging	I-P
and	O
DTI	B-P
at	O
term-equivalent	O
age	O
.	O

Ten	O
of	O
these	O
infants	O
developed	O
WM	O
abnormalities	O
associated	O
with	O
prematurity	O
.	O

Five	O
of	O
ten	O
of	O
those	O
with	O
WM	O
abnormalities	O
developed	O
cerebral	O
palsy	O
(	O
CP	O
)	O
.	O

DTI	B-P
in	O
the	O
WM	O
abnormalities	O
with	O
CP	O
showed	O
a	O
significant	O
reduction	O
of	O
mean	O
FA	O
in	O
the	O
genu	O
of	O
the	O
corpus	O
callosum	O
(	O
p	O
=	O
0.022	O
)	O
,	O
the	O
ipsilateral	O
posterior	O
limb	O
of	O
the	O
internal	O
capsule	O
(	O
p	O
=	O
0.019	O
)	O
,	O
and	O
the	O
ipsilateral	O
centrum	O
semiovale	O
(	O
p	O
=	O
0.012	O
)	O
compared	O
to	O
normal	O
WM	O
and	O
WM	O
abnormalities	O
without	O
CP	O
.	O

In	O
infants	O
having	O
WM	O
abnormalities	O
with	O
CP	O
,	O
early	O
FA	O
values	O
in	O
neonatal	O
DTI	B-P
revealed	O
abnormalities	O
of	O
the	O
WM	O
regions	O
prior	O
to	O
the	O
manifestation	O
of	O
hemiparesis	O
.	O

DTI	B-P
performed	O
at	O
term	O
equivalent	O
age	O
shows	O
different	O
FA	O
values	O
in	O
WM	O
regions	O
among	O
infants	O
with	O
or	O
without	O
WM	O
abnormalities	O
associated	O
with	O
prematurity	O
and/or	O
CP	O
.	O

Low	O
FA	O
values	O
of	O
ROIs	O
in	O
DTI	B-P
are	O
related	O
with	O
later	O
development	O
of	O
spastic	O
CP	O
in	O
preterm	O
infants	O
with	O
WM	O
abnormalities	O
.	O

Electrochemically	O
assisted	O
deposition	O
of	O
strontium	O
modified	O
magnesium	O
phosphate	O
on	O
titanium	O
surfaces	O
.	O

Electrochemically	O
assisted	O
deposition	O
was	O
utilized	O
to	O
produce	O
ceramic	O
coatings	O
on	O
the	O
basis	O
of	O
magnesium	O
ammonium	O
phosphate	O
(	O
struvite	O
)	O
on	O
corundum	O
-	O
blasted	O
titanium	O
surfaces	O
.	O

By	O
the	O
addition	O
of	O
defined	O
concentrations	O
of	O
strontium	O
nitrate	O
to	O
the	O
coating	O
electrolyte	O
Sr	O
(	O
2+	O
)	O
ions	O
were	O
successfully	O
incorporated	O
into	O
the	O
struvite	O
matrix	O
.	O

By	O
variation	O
of	O
deposition	O
parameters	O
it	O
was	O
possible	O
to	O
fabricate	O
coatings	O
with	O
different	O
kinetics	O
of	O
Sr	O
(	O
2+	O
)	O
into	O
physiological	O
media	O
,	O
whereas	O
the	O
release	O
of	O
therapeutically	O
relevant	O
strontium	O
doses	O
could	O
be	O
sustained	O
over	O
several	O
weeks	O
.	O

Morphological	O
and	O
crystallographic	B-P
examinations	I-P
of	O
the	O
immersed	O
coatings	O
revealed	O
that	O
the	O
degradation	O
of	O
struvite	O
and	O
the	O
release	O
of	O
Sr	O
(	O
2+	O
)	O
ions	O
were	O
accompanied	O
by	O
a	O
transformation	O
of	O
the	O
coating	O
to	O
a	O
calcium	O
phosphate	O
based	O
phase	O
similar	O
to	O
low-crystalline	O
hydroxyapatite	O
.	O

These	O
findings	O
showed	O
that	O
strontium	O
doped	O
struvite	O
coatings	O
may	O
provide	O
a	O
promising	O
degradable	O
coating	O
system	O
for	O
the	O
local	O
application	O
of	O
strontium	O
or	O
other	O
biologically	O
active	O
metal	O
ions	O
in	O
the	O
implant-bone	O
interface	O
.	O

A	O
pilot	O
study	O
on	O
transient	O
ischemic	O
stroke	O
induced	O
with	O
endothelin-1	O
in	O
the	O
rhesus	O
monkeys	O
.	O

Endothelin-1	O
(	O
ET-1	O
)	O
,	O
a	O
vasoconstrictor	O
,	O
has	O
recently	O
been	O
used	O
to	O
induce	O
focal	O
ischemia	O
in	O
rodents	O
and	O
marmoset	O
monkeys	O
.	O

The	O
rhesus	O
monkey	O
,	O
however	O
,	O
has	O
numerous	O
advantages	O
to	O
the	O
rodent	O
and	O
marmoset	O
that	O
make	O
it	O
a	O
superior	O
and	O
irreplaceable	O
animal	O
model	O
for	O
studying	O
stroke	O
in	O
the	O
brain	O
.	O

In	O
the	O
present	O
study	O
,	O
after	O
mapping	O
the	O
preferred	O
hand	O
representation	O
in	O
two	O
healthy	O
male	O
monkeys	O
with	O
intracortical	O
micro-stimulation	O
,	O
ET-1	O
was	O
microinjected	O
into	O
the	O
contralateral	O
motor	O
cortex	O
(	O
M1	O
)	O
to	O
its	O
preferred	O
hand	O
.	O

The	O
monkeys	O
had	O
been	O
trained	O
in	O
three	O
manual	O
dexterity	O
tasks	O
before	O
the	O
microinjection	O
and	O
were	O
tested	O
for	O
these	O
tasks	O
following	O
the	O
ET-1	O
injection	O
.	O

Brain	B-P
Magnetic	I-P
Resonance	I-P
Imaging	I-P
scans	I-P
were	O
performed	O
1	O
,	O
7	O
,	O
14	O
and	O
28	O
days	O
post	O
ischemia	O
.	O

It	O
was	O
found	O
that	O
ET-1	O
impaired	O
the	O
manual	O
dexterity	O
of	O
the	O
monkeys	O
in	O
the	O
vertical	O
slot	O
and	O
rotating	O
Brinkman	O
board	O
tasks	O
3-8	O
days	O
after	O
the	O
injection	O
.	O

Brain	B-P
imaging	I-P
found	O
that	O
severe	O
edema	O
was	O
present	O
7	O
days	O
after	O
the	O
focal	O
ischemia	O
.	O

This	O
data	O
suggest	O
that	O
ET-1	O
can	O
induce	O
transient	O
ischemic	O
stroke	O
in	O
rhesus	O
monkey	O
and	O
that	O
ET-1	O
induced	O
focal	O
ischemia	O
in	O
non-human	O
primates	O
is	O
a	O
potential	O
model	O
to	O
study	O
the	O
mechanism	O
of	O
stroke	O
and	O
brain	O
repair	O
after	O
stroke	O
.	O

Body	O
burden	O
of	O
heavy	O
metals	O
among	O
HIV	O
high	O
risk	O
population	O
in	O
USA	O
.	O

HIV	O
high	O
risk	O
population	O
may	O
face	O
not	O
only	O
the	O
threat	O
of	O
HIV	O
infection	O
but	O
also	O
a	O
higher	O
chance	O
of	O
exposure	O
to	O
environmental	O
contaminants	O
.	O

However	O
,	O
no	O
previous	O
studies	O
have	O
examined	O
the	O
body	O
burden	O
of	O
environmental	O
pollutants	O
including	O
heavy	O
metals	O
among	O
HIV	O
high	O
risk	O
populations	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
adults	O
aged	O
20-59	O
years	O
old	O
at	O
high	O
risk	O
of	O
HIV	O
infection	O
have	O
higher	O
blood	O
levels	O
of	O
heavy	O
metals	O
compared	O
to	O
those	O
with	O
low	O
risk	O
of	O
HIV	O
infection	O
in	O
United	O
States	O
.	O

We	O
used	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
)	O
1999-2010	O
to	O
compare	O
exposures	O
to	O
heavy	O
metals	O
including	O
cadmium	O
,	O
lead	O
,	O
and	O
total	O
mercury	O
by	O
HIV	O
risk	O
status	O
.	O

The	O
results	O
showed	O
that	O
people	O
at	O
high	O
risk	O
of	O
HIV	O
had	O
higher	O
blood	O
concentrations	O
of	O
all	O
heavy	O
metals	O
compared	O
to	O
their	O
counterparts	O
with	O
lower	O
HIV	O
risks	O
.	O

In	O
multivariate	O
linear	O
regression	O
models	O
,	O
HIV	O
risk	O
status	O
was	O
significantly	O
associated	O
with	O
increased	O
blood	B-P
cadmium	I-P
,	O
lead	B-P
,	O
and	O
total	B-P
mercury	I-P
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
race	O
,	O
education	O
,	O
and	O
poverty	O
income	O
ratio	O
.	O

Our	O
study	O
suggests	O
that	O
people	O
at	O
high	O
risk	O
of	O
HIV	O
have	O
significantly	O
higher	O
body	O
burden	O
of	O
heavy	O
metals	O
including	O
cadmium	O
,	O
lead	O
,	O
and	O
mercury	O
compared	O
to	O
those	O
with	O
low	O
risk	O
of	O
HIV	O
.	O

Further	O
longitudinal	O
study	O
collecting	O
more	O
pollutants	O
are	O
warranted	O
to	O
determine	O
the	O
potential	O
health	O
effects	O
of	O
these	O
elevated	O
pollutants	O
on	O
both	O
HIV-infected	O
and	O
HIV	O
high-risk	O
populations	O
.	O

Impact	O
of	O
Abnormal	O
DNA	O
Methylation	O
of	O
Imprinted	O
Loci	O
on	O
Human	O
Spontaneous	O
Abortion	O
.	O

Currently	O
,	O
there	O
is	O
a	O
growing	O
concern	O
regarding	O
the	O
safety	O
of	O
assisted	O
reproductive	O
technology	O
(	O
ART	O
)	O
due	O
to	O
increased	O
risk	O
of	O
spontaneous	O
abortion	O
(	O
SA	O
)	O
and	O
imprinting	O
disorders	O
in	O
ART	O
-	O
conceived	O
offspring	O
.	O

Early	O
investigations	O
suggested	O
that	O
aberrant	O
genetic	O
imprinting	O
may	O
be	O
related	O
to	O
pregnancy	O
loss	O
;	O
however	O
,	O
few	O
studies	O
have	O
used	O
human	O
tissue	O
specimens	O
.	O

Here	O
the	O
DNA	O
methylation	O
patterns	O
of	O
3	O
imprinted	O
genes	O
,	O
including	O
maternally	O
inherited	O
GRB10	O
and	O
the	O
paternally	O
inherited	O
IGF2	O
and	O
PEG3	O
genes	O
,	O
were	O
evaluated	O
in	O
human	O
chorionic	O
villus	O
samples	O
by	O
pyrosequencing	B-P
and	O
bisulfite	O
sequencing	O
polymerase	O
chain	O
reaction	O
.	O

The	O
samples	O
were	O
divided	O
into	O
4	O
groups	O
:	O
(	O
1	O
)	O
SA	O
of	O
natural	O
conception	O
(	O
NC	O
;	O
n	O
=	O
84	O
)	O
,	O
(	O
2	O
)	O
induced	O
abortion	O
of	O
NC	O
(	O
n	O
=	O
94	O
)	O
,	O
(	O
3	O
)	O
SA	O
after	O
ART	O
(	O
n	O
=	O
73	O
)	O
,	O
and	O
(	O
4	O
)	O
fetal	O
reduction	O
after	O
ART	O
(	O
n	O
=	O
86	O
)	O
.	O

The	O
methylation	O
levels	O
and	O
the	O
percentages	O
of	O
abnormal	O
methylation	O
of	O
the	O
IGF2	O
,	O
GRB10	O
,	O
and	O
PEG3	O
genes	O
between	O
the	O
ART	O
group	O
and	O
the	O
NC	O
group	O
showed	O
no	O
significant	O
difference	O
.	O

Both	O
IGF2	O
and	O
GRB10	O
genes	O
showed	O
higher	O
methylation	O
levels	O
in	O
the	O
SA	O
group	O
compared	O
to	O
the	O
non-SA	O
group	O
.	O

Additionally	O
,	O
determining	O
the	O
single-nucleotide	O
polymorphisms	O
of	O
4	O
loci	O
,	O
including	O
IGF2	O
rs3741205	O
,	O
rs3741206	O
,	O
rs3741211	O
,	O
and	O
GRB10	O
rs2237457	O
,	O
showed	O
that	O
the	O
TC+CC	O
genotype	O
of	O
IGF2	O
rs3741211	O
had	O
a	O
1.91-fold	O
increased	O
risk	O
of	O
SA	O
after	O
ART	O
.	O

However	O
,	O
there	O
was	O
no	O
association	O
between	O
the	O
mutant	O
genotype	O
of	O
IGF2	O
rs3741211	O
and	O
the	O
methylation	O
levels	O
of	O
IGF2	O
and	O
H19	O
,	O
and	O
ART	O
might	O
not	O
affect	O
the	O
distribution	O
of	O
the	O
abovementioned	O
genotypes	O
.	O

It	O
provides	O
support	O
for	O
the	O
opinion	O
that	O
genetic	O
imprinting	O
defects	O
may	O
be	O
associated	O
with	O
SA	O
,	O
which	O
might	O
not	O
be	O
due	O
to	O
ART	O
treatments	O
.	O

Cross-reactivity	O
features	O
of	O
deoxynivalenol	O
(	O
DON	O
)	O
-targeted	O
immunoaffinity	B-P
columns	O
aiming	O
to	O
achieve	O
simultaneous	O
analysis	B-P
of	O
DON	O
and	O
major	O
conjugates	O
in	O
cereal	O
samples	O
.	O

Immunoafï¬nity	B-P
columns	O
(	O
IACs	O
)	O
are	O
a	O
well-established	O
tool	O
in	O
the	O
determination	O
of	O
regulated	O
mycotoxins	O
in	O
food	O
and	O
feed	O
commodities	O
.	O

However	O
,	O
they	O
also	O
have	O
the	O
potential	O
to	O
become	O
attractive	O
pre-concentration	O
and	O
clean-up	O
materials	O
for	O
the	O
determination	O
of	O
masked	O
(	O
also	O
called	O
modified	O
)	O
mycotoxins	O
,	O
which	O
have	O
been	O
recognised	O
as	O
important	O
contributors	O
to	O
the	O
toxicological	O
hazard	O
deriving	O
from	O
fungal	O
spoilage	O
of	O
goods	O
.	O

However	O
,	O
the	O
information	O
available	O
in	O
the	O
literature	O
concerning	O
the	O
cross-reactivity	O
of	O
DON	O
-	O
IACs	O
against	O
the	O
major	O
conjugates	O
(	O
DON-3-G	O
,	O
15-AcDON	O
and	O
3-AcDON	O
)	O
is	O
incomplete	O
and	O
often	O
contradictory	O
.	O

We	O
have	O
carried	O
out	O
a	O
detailed	O
characterisation	O
of	O
the	O
cross-reactivity	O
of	O
the	O
four	O
main	O
IACs	O
brands	O
against	O
DON	O
and	O
its	O
conjugates	O
as	O
well	O
as	O
an	O
assessment	O
of	O
the	O
competition	O
among	O
the	O
analytes	O
.	O

Only	O
one	O
IAC	O
enabled	O
the	O
simultaneous	O
analysis	B-P
of	O
all	O
relevant	O
DON	O
forms	O
while	O
two	O
missed	O
15-AcDON	O
and	O
the	O
fourth	O
one	O
missed	O
DON-3-G	O
and	O
3-AcDON	O
.	O

In	O
the	O
case	O
of	O
the	O
multivalent	O
IAC	O
,	O
the	O
analytes	O
modified	O
at	O
the	O
C-3	O
position	O
compete	O
for	O
the	O
antibody	O
binding	O
with	O
preference	O
for	O
3-AcDON	O
(	O
less	O
spatially	O
hindered	O
)	O
while	O
DON-3-G	O
has	O
the	O
more-hindered	O
access	O
to	O
the	O
active	O
sites	O
.	O

Taking	O
into	O
consideration	O
the	O
levels	O
of	O
DON	O
conjugates	O
existing	O
in	O
real	O
samples	O
,	O
the	O
cross-reactivity	O
of	O
one	O
DON	O
-	O
IAC	O
allows	O
a	O
quantitative	O
analysis	O
of	O
all	O
of	O
these	O
analytes	O
.	O

Important	O
but	O
rather	O
neglected	O
aspects	O
such	O
as	O
the	O
continuous	O
supply	O
of	O
IACs	O
with	O
identical	O
characteristics	O
,	O
and	O
of	O
columns	O
which	O
are	O
strictly	O
blank	O
,	O
are	O
also	O
addressed	O
in	O
this	O
paper	O
.	O

The	O
biological	O
effect	O
of	O
metal	O
ions	O
on	O
the	O
granulation	B-P
of	O
aerobic	O
granular	O
activated	O
sludge	O
.	O

As	O
a	O
special	O
biofilm	O
structure	O
,	O
microbial	O
attachment	O
is	O
believed	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
granulation	B-P
of	O
aerobic	O
granular	O
activated	O
sludge	O
(	O
AGAS	O
)	O
.	O

This	O
experiment	O
was	O
to	O
investigate	O
the	O
biological	O
effect	O
of	O
Ca	O
(	O
2+	O
)	O
,	O
Mg	O
(	O
2+	O
)	O
,	O
Cu	O
(	O
2+	O
)	O
,	O
Fe	O
(	O
2+	O
)	O
,	O
Zn	O
(	O
2+	O
)	O
,	O
and	O
K	O
(	O
+	O
)	O
which	O
are	O
the	O
most	O
common	O
ions	O
present	O
in	O
biological	O
wastewater	O
treatment	O
systems	O
,	O
on	O
the	O
microbial	O
attachment	O
of	O
AGAS	O
and	O
flocculent	O
activated	O
sludge	O
(	O
FAS	O
)	O
,	O
from	O
which	O
AGAS	O
is	O
always	O
derived	O
,	O
in	O
order	O
to	O
provide	O
a	O
new	O
strategy	O
for	O
the	O
rapid	O
cultivation	O
and	O
stability	O
control	O
of	O
AGAS	O
.	O

The	O
result	O
showed	O
that	O
attachment	O
biomass	O
of	O
AGAS	O
was	O
about	O
300	O
%	O
higher	O
than	O
that	O
of	O
FAS	O
without	O
the	O
addition	O
of	O
metal	O
ions	O
.	O

Different	O
metal	O
ions	O
had	O
different	O
effects	O
on	O
the	O
process	O
of	O
microbial	O
attachment	O
.	O

FAS	O
and	O
AGAS	O
reacted	O
differently	O
to	O
the	O
metal	O
ions	O
as	O
well	O
,	O
and	O
in	O
fact	O
,	O
AGAS	O
was	O
more	O
sensitive	O
to	O
the	O
metal	O
ions	O
.	O

Specifically	O
,	O
Ca	O
(	O
2+	O
)	O
,	O
Mg	O
(	O
2+	O
)	O
,	O
and	O
K	O
(	O
+	O
)	O
could	O
increase	O
the	O
microbial	O
attachment	O
ability	O
of	O
both	O
AGAS	O
and	O
FAS	O
under	O
appropriate	O
concentrations	O
,	O
Cu	O
(	O
2+	O
)	O
,	O
Fe	O
(	O
2+	O
)	O
,	O
and	O
Zn	O
(	O
2+	O
)	O
were	O
also	O
beneficial	O
to	O
the	O
microbial	O
attachment	O
of	O
FAS	O
at	O
low	O
concentrations	O
,	O
but	O
Cu	O
(	O
2+	O
)	O
,	O
Fe	O
(	O
2+	O
)	O
,	O
and	O
Zn	O
(	O
2+	O
)	O
greatly	O
inhibited	O
the	O
attachment	O
process	O
of	O
AGAS	O
even	O
at	O
extremely	O
low	O
concentrations	O
.	O

In	O
addition	O
,	O
the	O
acylated	O
homoserine	O
lactone	O
(	O
AHL	O
)	O
-based	O
quorum	O
sensing	O
system	O
,	O
the	O
content	O
of	O
extracellular	O
polymeric	O
substances	O
and	O
the	O
relative	O
hydrophobicity	O
of	O
the	O
sludges	O
were	O
greatly	O
influenced	O
by	O
metal	O
ions	O
.	O

As	O
all	O
these	O
parameters	O
had	O
close	O
relationships	O
with	O
the	O
microbial	O
attachment	O
process	O
,	O
the	O
microbial	O
attachment	O
may	O
be	O
affected	O
by	O
changes	O
of	O
these	O
parameters	O
.	O

Lack	O
of	O
evidence	O
of	O
lower	O
30-day	O
all-cause	O
readmission	O
in	O
Medicare	O
beneficiaries	O
with	O
heart	O
failure	O
and	O
reduced	O
ejection	O
fraction	O
discharged	O
on	O
spironolactone	O
.	O

Therapy	O
with	O
evidence	O
-based	O
heart	O
failure	O
(	O
HF	O
)	O
medications	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
lower	O
risk	O
of	O
30-day	O
all-cause	O
readmission	O
in	O
patients	O
with	O
HF	O
and	O
reduced	O
ejection	O
fraction	O
(	O
HFrEF	O
)	O
.	O

We	O
examined	O
the	O
association	O
of	O
aldosterone	O
antagonist	O
use	O
with	O
30-day	O
all-cause	O
readmission	O
in	O
this	O
population	O
.	O

Of	O
the	O
2443	O
Medicare	O
beneficiaries	O
with	O
HF	O
and	O
left	O
ventricular	O
EF	O
â¤35	O
%	O
discharged	O
home	O
from	O
106	O
Alabama	O
hospitals	O
during	O
1998-2001	O
,	O
2060	O
were	O
eligible	O
for	O
spironolactone	O
therapy	O
(	O
serum	O
creatinine	O
â¤2.5	O
for	O
men	O
and	O
â¤2mg/dl	O
for	O
women	O
,	O
and	O
serum	B-P
potassium	I-P
<	O
5mEq/L	O
)	O
.	O

After	O
excluding	O
186	O
patients	O
already	O
receiving	O
spironolactone	O
on	O
admission	O
,	O
the	O
inception	O
cohort	O
consisted	O
of	O
1874	O
patients	O
eligible	O
for	O
a	O
new	O
discharge	O
prescription	O
for	O
spironolactone	O
,	O
of	O
which	O
329	O
received	O
one	O
.	O

Using	O
propensity	O
scores	O
for	O
initiation	O
of	O
spironolactone	O
therapy	O
,	O
we	O
assembled	O
a	O
matched	O
cohort	O
of	O
324	O
pairs	O
of	O
patients	O
receiving	O
and	O
not	O
receiving	O
spironolactone	O
balanced	O
on	O
34	O
baseline	O
characteristics	O
(	O
mean	O
age	O
72years	O
,	O
42	O
%	O
women	O
,	O
33	O
%	O
African	O
American	O
)	O
.	O

Thirty-day	O
all-cause	O
readmission	O
occurred	O
in	O
17	O
%	O
and	O
19	O
%	O
of	O
matched	O
patients	O
receiving	O
and	O
not	O
receiving	O
spironolactone	O
,	O
respectively	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
0.92	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.64-1.32	O
;	O
p=0.650	O
)	O
.	O

Spironolactone	O
had	O
no	O
association	O
with	O
30-day	O
all-cause	O
mortality	O
(	O
HR	O
,	O
0.84	O
;	O
95	O
%	O
CI	O
,	O
0.38-1.88	O
;	O
p=0.678	O
)	O
or	O
HF	O
readmission	O
(	O
HR	O
,	O
0.74	O
;	O
95	O
%	O
CI	O
,	O
0.41	O
1.31	O
;	O
p=0.301	O
)	O
.	O

These	O
associations	O
remained	O
unchanged	O
during	O
12months	O
of	O
post-discharge	O
follow-up	O
.	O

A	O
discharge	O
prescription	O
for	O
spironolactone	O
had	O
no	O
association	O
with	O
30-day	O
all-cause	O
readmission	O
among	O
older	O
,	O
hospitalized	O
Medicare	O
beneficiaries	O
with	O
HFrEF	O
eligible	O
for	O
spironolactone	O
therapy	O
.	O

Rotation-Driven	O
Microfluidic	O
Disc	O
for	O
White	B-P
Blood	I-P
Cell	I-P
Enumeration	I-P
Using	O
Magnetic	O
Bead	O
Aggregation	O
.	O

We	O
recently	O
defined	O
a	O
magnetic	B-P
bead-based	I-P
assay	I-P
that	O
exploited	O
an	O
agglutination	O
-like	O
response	O
for	O
DNA	O
and	O
applied	O
it	O
to	O
DNA	O
-	O
containing	O
cell	O
enumeration	O
using	O
inexpensive	O
benchtop	O
hardware	O
[	O
J	O
.	O

Am	O
.	O

Chem	O
.	O

Soc	O
.	O

2012	O
,	O
134	O
(	O
12	O
)	O
,	O
5689	O
-	O
96	O
]	O
.	O

Although	O
cost	O
-	O
efficient	O
,	O
the	O
open-well	B-P
format	I-P
assay	I-P
required	O
numerous	O
manual	O
steps	O
,	O
and	O
the	O
magnetic	O
field	O
actuation	O
scheme	O
was	O
not	O
readily	O
adaptable	O
for	O
integration	O
.	O

Here	O
,	O
we	O
demonstrate	O
a	O
low	O
-	O
cost	O
(	O
<	O
$	O
2	O
in-lab	O
)	O
,	O
higher-throughput	B-P
``	I-P
pinwheel	I-P
assay	I-P
''	I-P
platform	O
that	O
relies	O
on	O
a	O
combination	O
of	O
a	O
disposable	O
rotation-driven	O
microdisc	O
(	O
RDM	O
)	O
,	O
and	O
a	O
simple	O
bidirectional	O
rotating	O
magnetic	O
field	O
(	O
bi-RMF	O
)	O
.	O

The	O
assay	B-P
was	O
transformed	O
into	O
an	O
integrated	B-P
microfluidic	I-P
system	I-P
using	O
a	O
multilayered	O
polyester	O
microfluidic	O
disc	O
created	O
through	O
laser	O
print	O
,	O
cut	O
and	O
laminate	O
fabrication	O
,	O
with	O
fluid	O
flow	O
controlled	O
by	O
rotation	O
speed	O
without	O
any	O
mechanical	O
valves	O
.	O

The	O
RDM	O
accepts	O
four	O
samples	O
that	O
undergo	O
on-chip	O
dilution	O
to	O
five	O
different	O
concentrations	O
that	O
cover	O
the	O
effective	O
concentration	O
range	O
needed	O
for	O
downstream	O
cell	B-P
counting	I-P
by	O
pinwheel	B-P
assay	I-P
.	O

We	O
show	O
that	O
a	O
bi-RMF	O
is	O
effective	O
for	O
the	O
simultaneous	O
actuation	O
of	O
pinwheel	B-P
assays	I-P
in	O
20	O
detection	O
chambers	O
.	O

The	O
optimization	O
of	O
the	O
bi-RMF	O
frequencies	O
allows	O
the	O
RDM	O
-based	O
pinwheel	B-P
assay	I-P
detect	O
human	O
genomic	O
DNA	O
down	O
to	O
a	O
mass	O
of	O
human	O
genomic	O
DNA	O
(	O
5.5	O
picograms	O
)	O
that	O
is	O
roughly	O
equal	O
to	O
the	O
mass	O
in	O
a	O
single	O
cell	O
.	O

For	O
proof	O
of	O
principle	O
,	O
enumeration	O
of	O
the	O
white	O
blood	O
cells	O
in	O
human	O
blood	O
samples	O
on	O
the	O
RDM	O
provided	O
data	O
correlating	O
well	O
(	O
C.V.	O
of	O
10	O
%	O
)	O
with	O
those	O
obtained	O
in	O
a	O
clinical	O
lab	O
.	O

Fusing	O
the	O
cost	O
-	O
effective	O
RDM	O
with	O
a	O
simple	O
bi-RMF	O
provides	O
a	O
promising	O
strategy	O
for	O
automation	O
and	O
multiplexing	O
of	O
magnetic	O
particle	O
-based	O
agglutination	B-P
assays	I-P
.	O

A	O
study	O
of	O
acute	O
muscle	O
dysfunction	O
with	O
particular	O
reference	O
to	O
dengue	O
myopathy	O
.	O

Acute	O
myopathy	O
is	O
a	O
common	O
cause	O
of	O
acute	O
motor	O
quadriparesis	O
which	O
has	O
various	O
etiologies	O
with	O
different	O
courses	O
of	O
illness	O
and	O
prognosis	O
depending	O
on	O
the	O
cause	O
.	O

Understanding	O
this	O
diversity	O
helps	O
us	O
in	O
proper	O
approach	O
toward	O
diagnosis	O
,	O
predicting	O
the	O
prognosis	O
,	O
and	O
possible	O
complications	O
and	O
in	O
improving	O
the	O
treatments	O
that	O
are	O
being	O
provided	O
.	O

This	O
study	O
was	O
planned	O
to	O
study	O
the	O
clinical	O
,	O
electrophysiological	B-P
,	O
and	O
etiological	O
profile	O
of	O
patients	O
presenting	O
with	O
acute	O
myopathy	O
.	O

We	O
also	O
studied	O
how	O
dengue	O
-related	O
acute	O
myopathy	O
differs	O
from	O
other	O
causes	O
and	O
also	O
difference	O
between	O
myopathy	O
due	O
to	O
myositis	O
and	O
hypokalemia	O
in	O
cases	O
of	O
dengue	O
.	O

This	O
was	O
a	O
prospective	O
,	O
observational	O
study	O
involving	O
all	O
clinically	O
suspected	O
cases	O
of	O
acute	O
myopathy	O
of	O
not	O
more	O
than	O
4	O
weeks	O
duration	O
with	O
raised	O
serum	O
creatine	O
kinase	O
(	O
CK	O
)	O
level	O
.	O

They	O
were	O
subjected	O
to	O
detailed	O
clinical	O
evaluation	O
along	O
with	O
hematological	O
,	O
biochemical	O
,	O
microbiological	O
,	O
and	O
electrophysiological	B-P
studies	I-P
and	O
followed-up	O
for	O
outcome	O
at	O
1	O
and	O
3	O
months	O
.	O

Muscle	B-P
biopsy	I-P
and	O
histopathological	O
examination	O
were	O
done	O
in	O
selected	O
patients	O
after	O
taking	O
informed	O
consent	O
.	O

Statistical	O
analysis	O
was	O
performed	O
by	O
appropriate	O
methods	O
using	O
SPSS	O
version	O
16.0	O
(	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

We	O
evaluated	O
thirty	O
patients	O
of	O
acute	O
myopathy	O
with	O
raised	O
CK	O
level	O
.	O

Seventeen	O
patients	O
had	O
fever	O
,	O
11	O
had	O
myalgia	O
,	O
and	O
5	O
had	O
skin	O
lesions	O
.	O

All	O
presented	O
with	O
symmetric	O
weakness	O
,	O
17	O
(	O
56.7	O
%	O
)	O
patients	O
having	O
predominantly	O
proximal	O
weakness	O
,	O
neck	O
or	O
truncal	O
weakness	O
in	O
6	O
(	O
20	O
%	O
)	O
,	O
hyporeflexia	O
in	O
12	O
(	O
40	O
%	O
)	O
,	O
with	O
mean	O
Medical	O
Research	O
Council	O
(	O
MRC	O
)	O
sum	O
score	O
of	O
46.67	O
Â±	O
6.0	O
.	O

Eight	O
(	O
mean	O
modified	O
Barthel	O
index	O
[	O
MBI	O
]	O
at	O
presentation	O
-	O
15	O
Â±	O
3.7	O
)	O
patients	O
had	O
poor	O
functional	O
status	O
according	O
to	O
MBI	O
and	O
15	O
according	O
to	O
modified	O
Rankin	O
scale	O
(	O
MRS	O
)	O
(	O
mean	O
MRS	O
score	O
-	O
2.5	O
Â±	O
1.2	O
)	O
.	O

Etiology	O
was	O
dengue	O
viral	O
infection	O
in	O
14	O
patients	O
;	O
hypokalemia	O
due	O
to	O
various	O
causes	O
other	O
than	O
dengue	O
in	O
8	O
;	O
pyomyositis	O
in	O
3	O
;	O
dermatomyositis	O
,	O
polymyositis	O
,	O
thyrotoxicosis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
and	O
unknown	O
etiology	O
in	O
one	O
each	O
.	O

Only	O
eight	O
patients	O
had	O
abnormal	O
electrophysiology	B-P
and	O
seven	O
among	O
nine	O
biopsies	B-P
done	O
were	O
abnormal	O
.	O

At	O
1	O
month	O
,	O
24	O
(	O
80.0	O
%	O
)	O
and	O
23	O
(	O
76.7	O
%	O
)	O
patients	O
had	O
achieved	O
normal	O
MBI	O
and	O
MRS	O
scores	O
with	O
28	O
(	O
93.3	O
)	O
and	O
27	O
(	O
90	O
%	O
)	O
patients	O
,	O
respectively	O
,	O
at	O
3	O
months	O
.	O

Dengue	O
with	O
hypokalemia	O
had	O
less	O
myalgia	O
,	O
more	O
of	O
hyporeflexia	O
,	O
and	O
lower	O
serum	O
CK	O
compared	O
to	O
those	O
without	O
hypokalemia	O
.	O

Dengue	O
infection	O
and	O
hypokalemia	O
due	O
to	O
various	O
causes	O
are	O
the	O
most	O
common	O
causes	O
of	O
acute	O
myopathy	O
and	O
are	O
associated	O
with	O
rapid	O
and	O
complete	O
recovery	O
within	O
1	O
month	O
.	O

Shorter	O
duration	O
of	O
illness	O
,	O
higher	O
MRC	O
sum	O
score	O
,	O
better	O
disability	O
status	O
at	O
presentation	O
,	O
lower	O
serum	O
CK	O
correlate	O
with	O
better	O
outcome	O
.	O

Biopsy	B-P
was	O
decisive	O
in	O
<	O
20	O
%	O
cases	O
;	O
hence	O
,	O
it	O
is	O
not	O
primary	O
investigation	O
in	O
acute	O
myopathy	O
.	O

Bone	O
Degeneration	O
and	O
Its	O
Recovery	O
in	O
SMP30/GNL	O
-	O
Knockout	O
Mice	O
.	O

Senescence	O
marker	O
protein-30	O
(	O
SMP30	O
)	O
decreases	O
androgen	O
-independently	O
with	O
aging	O
and	O
is	O
a	O
lactone	O
-	O
hydrolyzing	O
enzyme	O
gluconolactonase	O
(	O
GNL	O
)	O
that	O
is	O
involved	O
in	O
vitamin	O
C	O
biosynthesis	O
.	O

In	O
the	O
present	O
study	O
,	O
bone	O
properties	O
of	O
SMP30/GNL	O
knockout	O
(	O
KO	O
)	O
mice	O
with	O
deficiency	O
in	O
vitamin	O
C	O
synthesis	O
were	O
investigated	O
to	O
reveal	O
the	O
effects	O
of	O
SMP30/GNL	O
and	O
exogenous	O
vitamin	O
C	O
supplementation	O
on	O
bone	O
formation	O
.	O

Mineral	O
content	O
(	O
BMC	O
)	O
and	O
mineral	O
density	O
(	O
BMD	O
)	O
of	O
the	O
mandible	O
and	O
femur	O
of	O
SMP30/GNL	O
KO	O
and	O
wild-type	O
mice	O
at	O
2	O
and	O
3	O
months	O
of	O
age	O
with	O
or	O
without	O
vitamin	O
C	O
supplementation	O
were	O
measured	O
by	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
.	O

Body	O
and	O
bone	O
weight	O
of	O
both	O
age	O
groups	O
decreased	O
and	O
became	O
significantly	O
lower	O
than	O
those	O
of	O
wild-type	O
mice	O
.	O

The	O
bones	O
of	O
SMP30/GNL	O
KO	O
mice	O
were	O
rough	O
and	O
porous	O
,	O
with	O
BMC	O
and	O
BMD	O
significantly	O
below	O
wild-type	O
.	O

Oral	O
supplementation	O
with	O
vitamin	O
C	O
eliminated	O
differences	O
in	O
body	O
weight	O
,	O
bone	O
weight	O
,	O
BMC	O
,	O
and	O
BMD	O
between	O
SMP30/GNL	O
KO	O
and	O
wild-type	O
mice	O
at	O
each	O
age	O
.	O

These	O
results	O
indicate	O
that	O
bone	O
degeneration	O
in	O
SMP30/GNL	O
KO	O
mice	O
was	O
caused	O
by	O
lack	O
of	O
vitamin	O
C	O
,	O
and	O
that	O
this	O
mouse	O
strain	O
is	O
an	O
appropriate	O
model	O
for	O
bone	O
metabolism	O
in	O
humans	O
,	O
which	O
have	O
no	O
ability	O
to	O
synthesize	O
vitamin	O
C	O
.	O

The	O
EpiDermâ¢	O
3D	B-P
human	I-P
reconstructed	I-P
skin	I-P
micronucleus	I-P
(	I-P
RSMN	I-P
)	I-P
assay	I-P
:	O
Historical	O
control	O
data	O
and	O
proof	O
of	O
principle	O
studies	O
for	O
mechanistic	B-P
assay	I-P
adaptations	O
.	O

The	O
in	B-P
vitro	I-P
human	I-P
reconstructed	I-P
skin	I-P
micronucleus	I-P
(	I-P
RSMN	I-P
)	I-P
assay	I-P
in	O
EpiDermâ¢	O
is	O
a	O
promising	O
novel	O
animal	O
alternative	O
for	O
evaluating	O
genotoxicity	O
of	O
topically	O
applied	O
chemicals	O
.	O

It	O
is	O
particularly	O
useful	O
for	O
assessing	O
cosmetic	O
ingredients	O
that	O
can	O
no	O
longer	O
be	O
tested	O
using	O
in	O
vivo	O
assays	B-P
.	O

To	O
advance	O
the	O
use	O
of	O
this	O
test	O
especially	O
for	O
regulatory	O
decision-making	O
,	O
we	O
have	O
established	O
the	O
RSMN	B-P
assay	I-P
in	O
our	O
laboratory	O
according	O
to	O
Good	O
Laboratory	O
Practice	O
and	O
following	O
the	O
principles	O
of	O
the	O
OECD	O
test	O
guideline	O
487	O
in	O
vitro	O
mammalian	O
cell	O
micronucleus	O
test	O
.	O

Proficiency	O
with	O
the	O
assay	B-P
was	O
established	O
by	O
correctly	O
identifying	O
direct-acting	O
genotoxins	O
and	O
genotoxins	O
requiring	O
metabolism	O
,	O
as	O
well	O
as	O
non-genotoxic	O
/	O
non-carcinogenic	O
chemicals	O
.	O

We	O
also	O
report	O
the	O
analysis	O
of	O
our	O
historical	O
control	O
data	O
that	O
demonstrate	O
vehicle	O
control	O
and	O
positive	O
control	O
values	O
for	O
%	O
micronuclei	O
in	O
binucleated	O
cells	O
are	O
in	O
the	O
ranges	O
reported	O
previously	O
.	O

Technical	O
issues	O
including	O
evaluating	O
various	O
solvents	O
with	O
both	O
48h	O
and	O
72h	O
treatment	O
regimens	O
were	O
investigated	O
.	O

For	O
the	O
first	O
time	O
,	O
mechanistic	O
studies	O
using	O
CREST	O
analysis	O
revealed	O
that	O
the	O
RSMN	B-P
assay	I-P
is	O
suitable	O
for	O
distinguishing	O
aneugens	O
and	O
clastogens	O
.	O

Moreover	O
,	O
the	O
assay	B-P
is	O
also	O
suitable	O
for	O
measuring	O
cytokines	O
as	O
markers	O
for	O
proliferative	O
and	O
toxic	O
effects	O
of	O
chemicals	O
.	O

Iodine	O
Storage	O
and	O
Metabolism	O
of	O
Mild	O
to	O
Moderate	O
Iodine-Deficient	O
Pregnant	O
Rats	O
.	O

Severe	O
iodine	O
deficiency	O
during	O
pregnancy	O
results	O
in	O
neurodevelopmental	O
disorders	O
in	O
children	O
,	O
while	O
the	O
consequences	O
of	O
mild	O
to	O
moderate	O
iodine	O
deficiency	O
(	O
MMID	O
)	O
are	O
uncertain	O
.	O

The	O
concentration	B-P
of	I-P
iodine	I-P
in	O
the	O
thyroid	O
is	O
the	O
most	O
accurate	O
indicator	O
of	O
iodine	O
nutrition	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
whether	O
the	O
iodine	O
stores	O
in	O
the	O
thyroid	O
cover	O
the	O
needs	O
of	O
the	O
mother	O
and	O
the	O
fetus	O
in	O
iodine	O
-	O
sufficient	O
and	O
MMID	O
conditions	O
by	O
inductively	B-P
coupled	I-P
plasma-mass	I-P
spectrometry	I-P
.	O

One	O
hundred	O
four-week-old	O
female	O
Wistar	O
rats	O
were	O
randomly	O
divided	O
into	O
MMID	O
(	O
low	O
iodine	O
intake	O
[	O
L	O
]	O
)	O
and	O
normal	O
(	O
normal	O
iodine	O
intake	O
[	O
N	O
]	O
)	O
groups	O
.	O

The	O
rats	O
were	O
fed	O
for	O
the	O
next	O
three	O
months	O
,	O
and	O
after	O
pregnancy	O
they	O
were	O
further	O
divided	O
into	O
two	O
subgroups	O
,	O
respectively	O
:	O
low	O
iodine	O
pregnancy	O
(	O
LP	O
)	O
and	O
low	O
iodine	O
pregnancy	O
with	O
iodine	O
supplement	O
(	O
LP+	O
)	O
,	O
and	O
normal	O
iodine	O
intake	O
pregnancy	O
(	O
NP	O
)	O
and	O
normal	O
iodine	O
intake	O
pregnancy	O
with	O
iodine	O
supplement	O
(	O
NP+	O
)	O
.	O

The	O
iodine	O
intake	O
of	O
pregnant	O
rats	O
in	O
the	O
NP+	O
and	O
LP+	O
groups	O
was	O
twice	O
as	O
much	O
as	O
in	O
the	O
NP	O
and	O
LP	O
groups	O
.	O

The	O
rats	O
were	O
sacrificed	O
on	O
gestational	O
day	O
15	O
and	O
postnatal	O
day	O
7	O
.	O

The	O
iodine	B-P
concentration	I-P
in	O
the	O
thyroid	O
of	O
the	O
maternal	O
and	O
newborn	O
rats	O
,	O
maternal	B-P
serum	I-P
,	O
placenta	O
,	O
and	O
amniotic	O
fluid	O
were	O
determined	O
by	O
inductively	B-P
coupled	I-P
plasma-mass	I-P
spectrometry	I-P
.	O

The	O
concentration	B-P
of	I-P
iodine	I-P
in	O
the	O
thyroid	O
of	O
the	O
N	O
group	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
L	O
group	O
before	O
pregnancy	O
.	O

The	O
concentration	B-P
of	I-P
iodine	I-P
in	O
the	O
maternal	O
thyroids	O
of	O
the	O
LP	O
group	O
decreased	O
during	O
pregnancy	O
,	O
whereas	O
that	O
of	O
the	O
NP	O
group	O
did	O
not	O
change	O
significantly	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
iodine	B-P
concentration	I-P
in	O
the	O
thyroid	O
of	O
mothers	O
and	O
offspring	O
between	O
the	O
NP	O
and	O
NP+	O
groups	O
,	O
but	O
it	O
was	O
significant	O
between	O
LP	O
and	O
LP+	O
groups	O
.	O

The	O
concentration	B-P
of	I-P
iodine	I-P
in	O
amniotic	O
fluid	O
was	O
significantly	O
different	O
between	O
the	O
four	O
groups	O
.	O

There	O
is	O
sufficient	O
iodine	O
storage	O
in	O
the	O
thyroid	O
of	O
maternal	O
rats	O
with	O
normal	O
iodine	O
intake	O
during	O
pregnancy	O
,	O
and	O
there	O
is	O
no	O
need	O
for	O
iodine	O
supplementation	O
.	O

However	O
,	O
iodine	O
stores	O
are	O
insufficient	O
in	O
rats	O
with	O
MMID	O
.	O

Iodine	O
supplementation	O
can	O
increase	O
the	O
iodine	B-P
concentration	I-P
in	O
the	O
thyroid	O
of	O
maternal	O
rats	O
with	O
MMID	O
and	O
their	O
offspring	O
,	O
as	O
well	O
as	O
in	O
the	O
amniotic	O
fluid	O
during	O
pregnancy	O
.	O

Quantification	O
of	O
urinary	O
mono-hydroxylated	O
metabolites	O
of	O
polycyclic	O
aromatic	O
hydrocarbons	O
by	O
on-line	B-P
solid	I-P
phase	I-P
extraction	I-P
-	O
high	B-P
performance	I-P
liquid	I-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
.	O

Human	O
exposure	O
to	O
polycyclic	O
aromatic	O
hydrocarbons	O
(	O
PAHs	O
)	O
can	O
be	O
assessed	O
through	O
monitoring	O
of	O
urinary	O
mono-hydroxylated	O
PAHs	O
(	O
OH-PAHs	O
)	O
.	O

Gas	B-P
chromatography	I-P
(	O
GC	B-P
)	O
has	O
been	O
widely	O
used	O
to	O
separate	O
OH-PAHs	O
before	O
quantification	O
by	O
mass	B-P
spectrometry	I-P
in	O
biomonitoring	O
studies	O
.	O

However	O
,	O
because	O
GC	B-P
requires	O
derivatization	O
,	O
it	O
can	O
be	O
time	O
consuming	O
.	O

We	O
developed	O
an	O
on-line	B-P
solid	I-P
phase	I-P
extraction	I-P
coupled	O
to	O
isotope	O
dilution	O
-	O
high	B-P
performance	I-P
liquid	I-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
(	O
on-line-SPE	B-P
-	O
HPLC-MS	B-P
/	O
MS	B-P
)	O
method	O
for	O
the	O
quantification	O
in	O
urine	O
of	O
1-OH-naphthalene	O
,	O
2-OH-naphthalene	O
,	O
2-OH-fluorene	O
,	O
3-OH-fluorene	O
,	O
1-OH-phenanthrene	O
,	O
the	O
sum	O
of	O
2-OH	O
and	O
3-OH-phenanthrene	O
,	O
4-OH-phenanthrene	O
,	O
and	O
1-OH-pyrene	O
.	O

The	O
method	O
,	O
which	O
employed	O
a	O
96-	O
well	O
plate	O
platform	O
and	O
on-line	B-P
SPE	I-P
,	O
showed	O
good	O
sensitivity	O
(	O
i.e.	O
,	O
limits	O
of	O
detection	O
ranged	O
from	O
0.007	O
to	O
0.09	O
ng/mL	O
)	O
and	O
used	O
only	O
100	O
Î¼L	O
of	O
urine	O
.	O

Accuracy	O
,	O
calculated	B-P
from	O
the	O
recovery	O
percentage	O
at	O
three	O
spiking	O
levels	O
,	O
varied	O
from	O
94	O
to	O
113	O
%	O
,	O
depending	O
on	O
the	O
analyte	O
.	O

The	O
inter	O
-	O
and	O
intra	O
-	O
day	O
precision	O
,	O
calculated	B-P
from	O
20	O
repeated	O
measurements	O
of	O
two	O
quality	O
control	O
materials	O
,	O
varied	O
from	O
5.2	O
to	O
16.7	O
%	O
.	O

Adequate	O
method	O
performance	O
was	O
also	O
confirmed	O
by	O
acceptable	O
recovery	O
(	O
83-102	O
%	O
)	O
of	O
two	O
NIST	O
standard	O
reference	O
materials	O
(	O
3672	O
and	O
3673	O
)	O
.	O

This	O
high-throughput	O
on-line-SPE	B-P
-	O
HPLC-MS	B-P
/	O
MS	B-P
method	O
can	O
be	O
applied	O
in	O
large	O
-	O
scale	O
epidemiological	O
studies	O
.	O

Graphical	O
abstract	O
Example	O
LC-MS	O
chromatogram	O
of	O
urinary	O
mono-hydroxylated	O
PAH	O
metabolites	O
.	O

Fracture	O
Resistance	O
of	O
Endodontically	O
Treated	O
Teeth	O
Restored	O
With	O
Bulk	O
Fill	O
,	O
Bulk	O
Fill	O
Flowable	O
,	O
Fiber-reinforced	O
,	O
and	O
Conventional	O
Resin	O
Composite	O
.	O

The	O
aim	O
of	O
this	O
in	O
vitro	O
study	O
was	O
to	O
evaluate	O
the	O
fracture	O
resistance	O
of	O
endodontically	O
treated	O
teeth	O
restored	O
with	O
different	O
types	O
of	O
restorative	O
resins	O
.	O

Seventy-two	O
sound	O
maxillary	O
premolar	O
teeth	O
were	O
randomly	O
divided	O
into	O
six	O
groups	O
(	O
n=12	O
)	O
.	O

The	O
teeth	O
in	O
the	O
first	O
group	O
were	O
left	O
intact	O
and	O
tested	O
as	O
unprepared	O
negative	O
control	O
(	O
group	O
I	O
)	O
specimens	O
.	O

The	O
teeth	O
in	O
the	O
remaining	O
five	O
groups	O
were	O
prepared	O
with	O
MOD	O
cavities	O
and	O
endodontically	O
treated	O
.	O

The	O
teeth	O
in	O
one	O
of	O
the	O
five	O
groups	O
(	O
positive	O
control	O
group	O
II	O
)	O
were	O
unrestored	O
.	O

The	O
rest	O
of	O
the	O
prepared	O
cavities	O
were	O
restored	O
as	O
follows	O
:	O
group	O
III	O
:	O
bulk	O
fill	O
resin	O
composite	O
/	O
Filtek	O
Bulk	O
Fill	O
(	O
3M	O
ESPE	O
)	O
;	O
group	O
IV	O
:	O
bulk	O
fill	O
flowable	O
resin	O
composite	O
+	O
nanohybrid	O
/	O
SureFil	O
SDR	O
Flow	O
+	O
Ceram.X	O
Mono	O
(	O
Dentsply	O
)	O
;	O
group	O
V	O
:	O
fiber-reinforced	O
composite	O
+	O
posterior	O
resin	O
composite	O
/	O
GC	O
everX	O
posterior	O
+	O
G-aenial	O
posterior	O
(	O
GC	O
Corp	O
.	O

)	O
;	O
and	O
group	O
VI	O
:	O
nanohybrid	O
resin	O
composite	O
/	O
Tetric	O
N-Ceram	O
(	O
Ivoclar/Vivadent	O
)	O
.	O

Each	O
restorative	O
material	O
was	O
used	O
with	O
its	O
respective	O
adhesive	O
system	O
.	O

The	O
restored	O
teeth	O
were	O
stored	O
in	O
distilled	O
water	O
for	O
24	O
hours	O
at	O
37Â°C	O
and	O
were	O
then	O
thermocycled	O
(	O
5-55Â°C	O
,	O
1000Ã	O
)	O
.	O

Specimens	O
were	O
subjected	O
to	O
a	O
compressive	O
load	O
until	O
fracture	O
at	O
a	O
crosshead	O
speed	O
of	O
0.5	O
mm/min	O
.	O

The	O
data	O
were	O
analyzed	O
using	O
one-way	O
analysis	O
of	O
variance	O
followed	O
by	O
the	O
post	O
hoc	O
Tukey	O
honestly	O
significantly	O
different	O
test	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Sound	O
premolar	O
teeth	O
(	O
group	O
I	O
negative	O
control	O
)	O
showed	O
significantly	O
higher	O
fracture	O
resistance	O
than	O
did	O
the	O
other	O
tested	O
groups	O
(	O
p	O
<	O
0.05	O
)	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	O
in	O
the	O
fracture	O
resistance	O
values	O
of	O
the	O
restored	O
groups	O
(	O
groups	O
III	O
,	O
IV	O
,	O
V	O
,	O
and	O
VI	O
)	O
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
lowest	O
values	O
were	O
obtained	O
in	O
the	O
positive	O
control	O
group	O
(	O
group	O
II	O
)	O
;	O
these	O
values	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
the	O
other	O
groups	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
fracture	O
resistance	O
values	O
of	O
endodontically	O
treated	O
teeth	O
restored	O
with	O
either	O
bulk	O
fill	O
/	O
bulk	O
fill	O
flowable	O
or	O
fiber-reinforced	O
composite	O
were	O
not	O
different	O
from	O
those	O
restored	O
with	O
conventional	O
nanohybrid	O
resin	O
composite	O
.	O

Differences	O
in	O
eosinophil	O
molecular	O
profiles	O
between	O
children	O
and	O
adults	O
with	O
eosinophilic	O
esophagitis	O
.	O

Eosinophilic	O
esophagitis	O
(	O
EoE	O
)	O
afflicts	O
both	O
children	O
and	O
adults	O
.	O

It	O
has	O
been	O
debated	O
whether	O
pediatric	O
EoE	O
and	O
adult	O
EoE	O
represent	O
different	O
disease	O
entities	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
whether	O
the	O
blood	O
eosinophil	O
molecular	O
pattern	O
of	O
children	O
with	O
EoE	O
is	O
(	O
i	O
)	O
distinct	O
from	O
that	O
of	O
healthy	O
children	O
;	O
and	O
(	O
ii	O
)	O
different	O
from	O
that	O
of	O
adults	O
with	O
EoE	O
.	O

Blood	O
eosinophils	O
from	O
children	O
and	O
adults	O
with	O
EoE	O
,	O
and	O
healthy	O
controls	O
,	O
were	O
analyzed	O
with	O
flow	B-P
cytometry	I-P
regarding	O
levels	O
of	O
CD23	O
,	O
CD44	O
,	O
CD54	O
,	O
CRTH2	O
,	O
FOXP3	O
,	O
and	O
galectin-10	O
.	O

Eosinophil	O
FOXP3	O
and	O
galectin-10	O
mRNA	O
levels	O
were	O
determined	O
by	O
qPCR	O
.	O

The	O
data	O
were	O
analyzed	O
using	O
a	O
multivariate	O
method	O
of	O
pattern	O
recognition	O
.	O

An	O
eosinophil	O
molecular	O
pattern	O
capable	O
of	O
distinguishing	O
children	O
with	O
EoE	O
from	O
control	O
children	O
was	O
identified	O
.	O

A	O
smaller	O
fraction	O
of	O
eosinophils	O
from	O
children	O
with	O
EoE	O
expressed	O
CD44	O
and	O
a	O
larger	O
fraction	O
expressed	O
CRTH2	O
than	O
the	O
controls	O
.	O

Eosinophils	O
from	O
children	O
with	O
EoE	O
also	O
had	O
higher	O
levels	O
of	O
galectin-10	O
mRNA	O
and	O
lower	O
levels	O
of	O
FOXP3	O
mRNA	O
.	O

The	O
eosinophils	O
from	O
children	O
with	O
EoE	O
had	O
lower	O
levels	O
of	O
surface	O
CD54	O
and	O
of	O
FOXP3	O
mRNA	O
compared	O
with	O
the	O
eosinophils	O
from	O
the	O
adult	O
patients	O
.	O

A	O
key	O
finding	O
was	O
the	O
detection	O
in	O
healthy	O
individuals	O
of	O
age-related	O
differences	O
in	O
the	O
levels	O
of	O
several	O
eosinophil	O
markers	B-P
.	O

Children	O
with	O
EoE	O
can	O
be	O
distinguished	O
from	O
healthy	O
children	O
based	O
on	O
the	O
molecular	O
patterns	O
of	O
their	O
blood	O
eosinophils	O
.	O

Age-related	O
physiologic	O
differences	O
in	O
eosinophil	O
molecular	O
patterns	O
may	O
partly	O
explain	O
the	O
different	O
blood	O
eosinophil	O
phenotypes	O
in	O
children	O
vs	O
adults	O
with	O
EoE	O
.	O

Left	O
ventricular	O
rotational	O
mechanics	O
in	O
infants	O
with	O
hypoxic	O
ischemic	O
encephalopathy	O
and	O
preterm	O
infants	O
at	O
36	O
weeks	O
postmenstrual	O
age	O
:	O
A	O
comparison	O
with	O
healthy	O
term	O
controls	O
.	O

There	O
is	O
a	O
paucity	O
of	O
data	O
on	O
left	O
ventricle	O
(	O
LV	O
)	O
rotational	O
physiology	O
in	O
neonates	O
.	O

We	O
aimed	O
to	O
assess	O
rotational	O
mechanics	O
in	O
infants	O
with	O
hypoxic	O
ischemic	O
encephalopathy	O
(	O
HIE	O
)	O
and	O
premature	O
infants	O
(	O
<	O
32	O
weeks	O
)	O
at	O
36	O
weeks	O
postmenstrual	O
age	O
(	O
PMA	O
)	O
(	O
preterm	O
group	O
)	O
and	O
compare	O
them	O
with	O
healthy	O
term	O
controls	O
(	O
term	O
controls	O
)	O
.	O

We	O
also	O
compared	O
the	O
parameters	O
in	O
preterm	O
infants	O
with	O
and	O
without	O
chronic	O
lung	O
disease	O
(	O
CLD	O
)	O
.	O

Echocardiography	B-P
was	O
performed	O
within	O
48	O
hours	O
of	O
birth	O
or	O
at	O
36	O
weeks	O
PMA	O
.	O

LV	O
basal	O
and	O
apical	O
rotation	O
,	O
twist	O
(	O
and	O
torsion	O
=	O
twist	O
/	O
LV	O
length	O
)	O
,	O
twist	O
rate	O
(	O
LVTR	O
)	O
,	O
and	O
untwist	O
rate	O
(	O
LVUTR	O
)	O
were	O
measured	O
.	O

One-way	O
ANOVA	O
was	O
used	O
to	O
compare	O
values	O
.	O

There	O
was	O
no	O
difference	O
in	O
gestation	O
(	O
40.0	O
[	O
39.1-40.3	O
]	O
vs	O
39.9	O
[	O
39.0-40.9	O
]	O
,	O
P	O
>	O
.05	O
)	O
or	O
birthweight	O
(	O
3.7	O
[	O
3.4-4.1	O
]	O
vs	O
3.5	O
[	O
3.2-3.9	O
]	O
,	O
P	O
>	O
.05	O
)	O
between	O
the	O
HIE	O
group	O
(	O
n=16	O
)	O
and	O
term	O
controls	O
(	O
n=30	O
)	O
.	O

The	O
preterm	O
group	O
(	O
n=35	O
)	O
had	O
a	O
gestation	O
and	O
weight	O
of	O
36.0	O
[	O
34.6-36.3	O
]	O
weeks	O
and	O
2.3	O
[	O
2.0-2.4	O
]	O
kg	O
.	O

The	O
HIE	O
group	O
had	O
lower	O
twist	O
,	O
torsion	O
,	O
LVTR	O
,	O
and	O
LVUTR	O
than	O
the	O
other	O
two	O
groups	O
.	O

The	O
preterm	O
group	O
had	O
a	O
more	O
negative	O
(	O
clockwise	O
)	O
basal	O
rotation	O
while	O
the	O
term	O
group	O
had	O
a	O
more	O
positive	O
(	O
counterclockwise	O
)	O
apical	O
rotation	O
.	O

Preterm	O
infants	O
with	O
CLD	O
had	O
higher	O
apical	O
rotation	O
,	O
twist	O
,	O
and	O
torsion	O
when	O
compared	O
to	O
infants	O
without	O
CLD	O
.	O

Infants	O
with	O
HIE	O
have	O
reduced	O
rotational	O
mechanics	O
.	O

Preterm	O
infants	O
at	O
36	O
weeks	O
PMA	O
have	O
comparable	O
measurements	O
of	O
twist	O
to	O
term	O
infants	O
.	O

This	O
is	O
achieved	O
by	O
predominant	O
basal	O
rather	O
than	O
apical	O
rotation	O
.	O

Infants	O
with	O
CLD	O
have	O
increased	O
apical	O
rotation	O
.	O

Evaluation	O
of	O
changes	O
in	O
anthropometric	O
indexes	O
due	O
to	O
intermaxillary	O
fixation	O
following	O
facial	O
fractures	O
.	O

Background	O
.	O

One	O
of	O
the	O
treatment	O
modalities	O
for	O
facial	O
fractures	O
is	O
closed	O
reduction	O
technique	O
,	O
but	O
treatment	O
with	O
intermaxillary	O
fixation	O
(	O
IMF	O
)	O
interferes	O
with	O
normal	O
nutrition	O
,	O
and	O
malnutrition	O
can	O
affect	O
the	O
patient	O
's	O
recovery	O
.	O

Anthropometric	O
measurements	O
such	O
as	O
skinfold	B-P
thickness	I-P
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
are	O
universal	O
indexes	O
for	O
diagnosing	O
malnutrition	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
we	O
explain	O
how	O
treatment	O
with	O
IMF	O
changes	O
the	O
anthropometric	O
indexes	O
.	O

Methods	O
.	O

In	O
this	O
study	O
60	O
patients	O
were	O
treated	O
with	O
4	O
weeks	O
of	O
IMF	O
.	O

Skinfold	B-P
thickness	I-P
and	O
BMI	O
of	O
these	O
patients	O
were	O
measured	O
and	O
compared	O
before	O
and	O
after	O
the	O
treatment	O
.	O

Results	O
.	O

Patients	O
'	O
weight	O
,	O
BMI	O
and	O
skinfold	B-P
thickness	I-P
decreased	O
during	O
the	O
IMF	O
period	O
,	O
and	O
this	O
decrease	O
was	O
statistically	O
significant	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Conclusion	O
.	O

Although	O
no	O
severe	O
and	O
acute	O
malnutrition	O
was	O
seen	O
among	O
our	O
patients	O
,	O
IMF	O
led	O
to	O
mild	O
to	O
moderate	O
malnutrition	O
in	O
some	O
cases	O
,	O
making	O
it	O
necessary	O
to	O
use	O
nutritional	O
supplements	O
.	O

Neural	O
correlates	O
to	O
automatic	O
behavior	O
estimations	O
from	O
RGB-D	O
video	O
in	O
epilepsy	O
unit	O
.	O

To	O
augment	O
neural	O
monitoring	O
,	O
a	O
minimally	B-P
intrusive	I-P
multi-modal	I-P
capture	I-P
system	I-P
was	O
designed	O
and	O
implemented	O
in	O
the	O
epilepsy	O
clinic	O
.	O

This	O
system	O
provides	O
RGB-D	O
audio-video	O
synchronized	O
with	O
patient	O
electrocorticography	B-P
(	O
ECoG	B-P
)	O
,	O
which	O
records	O
neural	O
activity	O
across	O
cortex	O
.	O

We	O
propose	O
an	O
automated	O
approach	O
to	O
studying	O
the	O
human	O
brain	O
in	O
a	O
naturalistic	O
setting	O
.	O

We	O
demonstrate	O
coarse	B-P
functional	I-P
mapping	I-P
of	O
ECoG	B-P
electrodes	O
correlated	O
to	O
contralateral	O
arm	O
movements	O
.	O

Motor	B-P
electrode	I-P
mapping	I-P
was	O
generated	O
by	O
analyzing	O
continuous	O
movement	O
data	O
recorded	O
over	O
several	O
hours	O
from	O
epilepsy	O
patients	O
in	O
hospital	O
rooms	O
.	O

From	O
these	O
recordings	O
we	O
estimate	O
the	O
kinematics	O
of	O
patient	O
hand	O
movement	O
behaviors	O
using	O
computer	O
vision	O
algorithms	O
.	O

We	O
compare	O
movement	O
behaviors	O
to	O
neural	O
data	O
collected	O
from	O
ECoG	B-P
,	O
specifically	O
high-Î³	O
(	O
70-110	O
Hz	O
)	O
spectral	O
features	O
.	O

We	O
present	O
a	O
functional	B-P
map	I-P
of	I-P
electrode	I-P
responses	I-P
to	O
natural	O
arm	O
movements	O
,	O
generated	O
using	O
a	O
statistical	O
test	O
.	O

We	O
demonstrate	O
that	O
our	O
approach	O
has	O
the	O
potential	O
to	O
aid	O
in	O
the	O
development	O
of	O
automated	B-P
functional	I-P
brain	I-P
mapping	I-P
using	O
continuous	O
video	O
and	O
neural	O
recordings	O
of	O
patients	O
in	O
clinical	O
settings	O
.	O

Severe	O
respiratory	O
depression	O
and	O
bradycardia	O
before	O
induction	O
of	O
anesthesia	O
and	O
onset	O
of	O
Takotsubo	O
cardiomyopathy	O
after	O
cardiopulmonary	O
resuscitation	O
.	O

A	O
69-	O
year	O
-old	O
woman	O
undergoing	O
treatment	O
for	O
hypertension	O
and	O
epilepsy	O
was	O
scheduled	O
to	O
undergo	O
cataract	O
surgery	O
.	O

All	O
preoperative	O
examination	O
results	O
were	O
within	O
normal	O
limits	O
.	O

Despite	O
being	O
tense	O
,	O
she	O
walked	O
to	O
the	O
operating	O
room	O
.	O

Approximately	O
2	O
minutes	O
after	O
an	O
intravenous	O
line	O
was	O
established	O
by	O
an	O
anesthesia	O
resident	O
,	O
severe	O
hypoxia	O
and	O
bradycardia	O
developed	O
,	O
and	O
she	O
lost	O
consciousness	O
.	O

Cardiopulmonary	O
resuscitation	O
was	O
initiated	O
immediately	O
,	O
and	O
after	O
1	O
minute	O
,	O
she	O
regained	O
consciousness	O
,	O
and	O
her	O
breathing	O
and	O
circulation	O
recovered	O
.	O

After	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
,	O
emergency	O
coronary	B-P
angiography	I-P
was	O
performed	O
.	O

The	O
blood	O
flow	O
in	O
all	O
the	O
coronary	O
arteries	O
was	O
normal	O
.	O

However	O
,	O
a	O
decrease	O
in	O
the	O
apical	O
left	O
ventricular	O
wall	O
motion	O
and	O
an	O
increase	O
in	O
the	O
basal	O
wall	O
motion	O
were	O
observed	O
.	O

Based	O
on	O
these	O
findings	O
,	O
Takotsubo	O
cardiomyopathy	O
was	O
diagnosed	O
.	O

The	O
wall	O
motion	O
gradually	O
improved	O
and	O
the	O
patient	O
was	O
discharged	O
from	O
the	O
hospital	O
on	O
postoperative	O
day	O
15	O
.	O

The	O
respiratory	O
depression	O
and	O
bradycardia	O
were	O
thought	O
to	O
be	O
due	O
to	O
an	O
inadvertent	O
bolus	O
of	O
remifentanil	O
.	O

We	O
surmised	O
that	O
the	O
patient	O
had	O
received	O
a	O
slight	O
amount	O
of	O
retained	O
medication	O
when	O
the	O
anesthesia	O
resident	O
established	O
the	O
intravenous	O
line	O
,	O
which	O
caused	O
severe	O
respiratory	O
depression	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
adverse	O
effects	O
such	O
as	O
severe	O
respiratory	O
depression	O
and	O
bradycardia	O
can	O
be	O
caused	O
by	O
even	O
small	O
doses	O
of	O
remifentanil	O
.	O

Sulfur	O
and	O
Zinc	O
Availability	O
from	O
Co-granulated	O
Zn	O
-Enriched	O
Elemental	O
Sulfur	O
Fertilizers	O
.	O

Acidification	O
by	O
oxidation	O
of	O
elemental	O
sulfur	O
(	O
ES	O
)	O
can	O
solubilize	O
ZnO	O
,	O
providing	O
slow	O
release	O
of	O
both	O
sulfur	O
(	O
S	O
)	O
and	O
zinc	O
(	O
Zn	O
)	O
in	O
soil	O
.	O

For	O
this	O
study	O
,	O
a	O
new	O
granular	O
fertilizer	O
with	O
ES	O
and	O
ZnO	O
was	O
produced	O
and	O
evaluated	O
.	O

The	O
effect	O
of	O
incorporating	O
microorganisms	O
or	O
a	O
carbon	O
source	O
in	O
the	O
granule	O
was	O
also	O
evaluated	O
.	O

Four	O
granulated	O
ES-Zn	O
fertilizers	O
with	O
and	O
without	O
S-oxidizing	O
microorganisms	O
,	O
a	O
commercial	O
ES	O
pastille	O
,	O
ZnSO4	O
,	O
and	O
ZnO	O
were	O
applied	O
to	O
the	O
center	O
of	O
Petri	O
dishes	O
containing	O
two	O
contrasting	O
pH	O
soils	O
.	O

Soil	O
pH	O
,	O
CaCl2	O
-extractable	O
S	O
and	O
Zn	O
,	O
and	O
remaining	O
ES	O
were	O
evaluated	O
at	O
30	O
and	O
60	O
days	O
in	O
two	O
soil	O
sections	O
(	O
0-5	O
and	O
5-9	O
mm	O
from	O
the	O
fertilizer	O
application	O
site	O
)	O
.	O

A	O
visualization	B-P
test	I-P
was	O
performed	O
to	O
evaluate	O
Zn	O
diffusion	O
over	O
time	O
.	O

A	O
significant	O
pH	O
decrease	O
was	O
observed	O
in	O
the	O
acidic	O
soil	O
for	O
all	O
ES-Zn	O
fertilizer	O
treatments	O
and	O
in	O
the	O
alkaline	O
soil	O
for	O
the	O
Acidithiobacillus	O
thiooxidans	O
-	O
inoculated	O
treatment	O
only	O
.	O

In	O
agreement	O
with	O
Zn	O
visualization	B-P
tests	I-P
,	O
extractable-	O
Zn	O
concentrations	O
were	O
higher	O
from	O
the	O
point	O
of	O
application	O
in	O
the	O
acidic	O
(	O
62.9	O
mg	O
dm	O
(	O
-3	O
)	O
)	O
compared	O
to	O
the	O
alkaline	O
soil	O
(	O
5.5	O
mg	O
dm	O
(	O
-3	O
)	O
)	O
.	O

Elemental	O
S	O
oxidation	O
was	O
greater	O
in	O
the	O
acidic	O
soil	O
(	O
20.9	O
%	O
)	O
than	O
slightly	O
alkaline	O
soil	O
(	O
12	O
%	O
)	O
.	O

The	O
ES-Zn	O
granular	O
fertilizers	O
increased	O
S	O
and	O
Zn	O
concentrations	O
in	O
soil	O
and	O
can	O
provide	O
a	O
strategically	O
slow	O
release	O
of	O
nutrients	O
to	O
the	O
soil	O
.	O

Beneficial	O
effects	O
of	O
dark	O
chocolate	O
on	O
exercise	O
capacity	O
in	O
sedentary	O
subjects	O
:	O
underlying	O
mechanisms	O
.	O

A	O
double	O
blind	O
,	O
randomized	O
,	O
placebo	O
controlled	O
trial	O
.	O

In	O
heart	O
failure	O
patients	O
the	O
consumption	O
of	O
(	O
-	O
)	O
-epicatechin	O
(	O
(	O
-	O
)	O
-Epi	O
)	O
-rich	O
cocoa	O
can	O
restore	O
skeletal	O
muscle	O
(	O
SkM	O
)	O
mitochondrial	O
structure	O
and	O
decrease	O
biomarkers	O
of	O
oxidative	O
stress	O
.	O

However	O
,	O
nothing	O
is	O
known	O
about	O
its	O
effects	O
on	O
exercise	O
capacity	O
and	O
underlying	O
mechanisms	O
in	O
normal	O
,	O
sedentary	O
subjects	O
.	O

Twenty	O
normal	O
,	O
sedentary	O
subjects	O
(	O
â¼50	O
years	O
old	O
)	O
were	O
randomized	O
to	O
placebo	O
or	O
dark	O
chocolate	O
(	O
DC	O
)	O
groups	O
and	O
consumed	O
20	O
g	O
of	O
the	O
products	O
for	O
3	O
months	O
.	O

Subjects	O
underwent	O
before	O
and	O
after	O
treatment	O
,	O
bicycle	B-P
ergometry	I-P
to	O
assess	O
VO2	O
max	O
and	O
work	O
,	O
SkM	B-P
biopsy	I-P
to	O
assess	O
changes	O
in	O
mitochondrial	O
density	O
,	O
function	O
and	O
oxidative	O
stress	O
and	O
blood	B-P
sampling	I-P
to	O
assess	O
metabolic	O
endpoints	O
.	O

Seventeen	O
subjects	O
completed	O
the	O
trial	O
.	O

In	O
the	O
DC	O
group	O
(	O
n	O
=	O
9	O
)	O
,	O
VO2	O
max	O
increased	O
(	O
17	O
%	O
increase	O
,	O
p	O
=	O
0.056	O
)	O
as	O
well	O
as	O
maximum	O
work	O
(	O
watts	O
)	O
achieved	O
(	O
p	O
=	O
0.026	O
)	O
with	O
no	O
changes	O
with	O
placebo	O
(	O
n	O
=	O
8	O
)	O
.	O

The	O
DC	O
group	O
evidenced	O
increases	O
in	O
HDL	O
levels	O
(	O
p	O
=	O
0.005	O
)	O
and	O
decreased	O
triglycerides	O
(	O
p	O
=	O
0.07	O
)	O
.	O

With	O
DC	O
,	O
SkM	O
evidenced	O
significant	O
increases	O
in	O
protein	O
levels	O
for	O
LKB1	O
,	O
AMPK	O
and	O
PGC1Î±	O
and	O
in	O
their	O
active	O
forms	O
(	O
phosphorylated	O
AMPK	O
and	O
LKB1	O
)	O
as	O
well	O
as	O
in	O
citrate	O
synthase	O
activity	O
while	O
no	O
changes	O
were	O
observed	O
in	O
mitochondrial	O
density	O
.	O

With	O
DC	O
,	O
significant	O
increases	O
in	O
SkM	O
reduced	O
glutathione	O
levels	O
and	O
decreases	O
in	O
protein	O
carbonylation	O
were	O
observed	O
.	O

Improvements	O
in	O
maximum	O
work	O
achieved	O
and	O
VO2	O
max	O
may	O
be	O
due	O
to	O
DC	O
activation	O
of	O
upstream	O
control	O
systems	O
and	O
enhancement	O
of	O
SkM	O
mitochondria	O
efficiency	O
.	O

Larger	O
clinical	O
studies	O
are	O
warranted	O
to	O
confirm	O
these	O
observations	O
.	O

Structure	O
of	O
Carbon	O
Nanotube	O
Porins	O
in	O
Lipid	O
Bilayers	O
:	O
An	O
in	O
Situ	O
Small-Angle	B-P
X-ray	I-P
Scattering	I-P
(	O
SAXS	B-P
)	O
Study	O
.	O

Carbon	O
nanotube	O
porins	O
(	O
CNTPs	O
)	O
,	O
small	O
segments	O
of	O
carbon	O
nanotubes	O
capable	O
of	O
forming	O
defined	O
pores	O
in	O
lipid	O
membranes	O
,	O
are	O
important	O
future	O
components	O
for	O
bionanoelectronic	O
devices	O
as	O
they	O
could	O
provide	O
a	O
robust	O
analog	O
of	O
biological	O
membrane	O
channels	O
.	O

In	O
order	O
to	O
control	O
the	O
incorporation	O
of	O
these	O
CNT	O
channels	O
into	O
lipid	O
bilayers	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
structure	O
of	O
the	O
CNTPs	O
before	O
and	O
after	O
insertion	O
into	O
the	O
lipid	O
bilayer	O
as	O
well	O
as	O
the	O
impact	O
of	O
such	O
insertion	O
on	O
the	O
bilayer	O
structure	O
.	O

Here	O
we	O
employed	O
a	O
noninvasive	O
in	O
situ	O
probe	O
,	O
small-angle	B-P
X-ray	I-P
scattering	I-P
,	O
to	O
study	O
the	O
integration	O
of	O
CNT	O
porins	O
into	O
dioleoylphosphatidylcholine	O
bilayers	O
.	O

Our	O
results	O
show	O
that	O
CNTPs	O
in	O
solution	O
are	O
stabilized	O
by	O
a	O
monolayer	O
of	O
lipid	O
molecules	O
wrapped	O
around	O
their	O
outer	O
surface	O
.	O

We	O
also	O
demonstrate	O
that	O
insertion	O
of	O
CNTPs	O
into	O
the	O
lipid	O
bilayer	O
results	O
in	O
decreased	O
bilayer	O
thickness	O
with	O
the	O
magnitude	O
of	O
this	O
effect	O
increasing	O
with	O
the	O
concentration	O
of	O
CNTPs	O
.	O

Solifenacin	O
in	O
the	O
Elderly	O
:	O
Results	O
of	O
an	O
Observational	O
Study	O
Measuring	O
Efficacy	O
,	O
Tolerability	O
and	O
Cognitive	O
Effects	O
.	O

The	O
study	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
solifenacin	O
in	O
older	O
patients	O
with	O
overactive	O
bladder	O
(	O
OAB	O
)	O
.	O

Observational	O
data	O
on	O
patients	O
aged	O
â¥70	O
years	O
and	O
the	O
prescribed	O
flexible	O
dose	O
of	O
solifenacin	O
for	O
OAB	O
were	O
collected	O
at	O
294	O
offices	O
of	O
German	O
general	O
practitioners	O
.	O

Baseline	O
and	O
week	O
12	O
data	O
included	O
type	O
and	O
severity	O
of	O
OAB	O
symptoms	O
,	O
adverse	O
events	O
,	O
quality	O
of	O
life	O
,	O
and	O
change	O
in	O
cognitive	O
function	O
per	O
Mini	B-P
Mental	I-P
State	I-P
Examination	I-P
(	O
MMSE	B-P
)	O
.	O

Mean	O
age	O
of	O
774	O
patients	O
was	O
78	O
Â±	O
6	O
years	O
.	O

A	O
decrease	O
was	O
observed	O
in	O
all	O
OAB	O
symptoms	O
including	O
a	O
reduction	O
of	O
urinary	O
urgency	O
and	O
micturition	O
,	O
each	O
by	O
4	O
episodes	O
per	O
24	O
h.	O
No	O
change	O
in	O
mean	O
MMSE	O
score	O
s	O
was	O
apparent	O
at	O
week	O
12	O
.	O

Adverse	O
events	O
and	O
treatment	O
discontinuations	O
were	O
low	O
at	O
5.8	O
and	O
0.5	O
%	O
,	O
respectively	O
.	O

Solifenacin	O
was	O
well-tolerated	O
while	O
OAB	O
symptoms	O
declined	O
at	O
week	O
12	O
.	O

No	O
relevant	O
effect	O
of	O
solifenacin	O
on	O
cognitive	O
function	O
was	O
observed	O
in	O
this	O
elderly	O
population	O
.	O

Improved	O
protocol	O
for	O
the	O
isolation	B-P
of	O
naÃ¯ve	O
follicular	O
dendritic	O
cells	O
.	O

Follicular	O
dendritic	O
cells	O
(	O
FDCs	O
)	O
in	O
lymphoid	O
organs	O
play	O
an	O
important	O
role	O
in	O
the	O
humoral	O
immune	O
response	O
.	O

However	O
,	O
because	O
the	O
isolation	O
of	O
FDCs	O
is	O
difficult	O
due	O
to	O
their	O
very	O
small	O
population	O
size	O
and	O
fragility	O
under	O
mechanical	O
and	O
chemical	O
stresses	O
,	O
the	O
genetic	O
and	O
biochemical	O
characteristics	O
of	O
FDCs	O
remain	O
unclear	O
.	O

Previously	O
,	O
we	O
identified	O
FDCs	O
as	O
ICAM-1	O
(	O
+	O
)	O
cells	O
in	O
the	O
CD45	O
(	O
-	O
)	O
non-hematopoietic	O
cell	O
fraction	O
from	O
naÃ¯ve	O
mouse	O
spleen	O
after	O
cell	B-P
separation	I-P
by	O
means	O
of	O
digestion	O
with	O
a	O
combination	O
of	O
enzymes	O
.	O

In	O
the	O
present	O
study	O
,	O
using	O
a	O
new	O
combination	O
of	O
enzymes	O
,	O
we	O
found	O
that	O
FDCs	O
are	O
highly	O
enriched	O
in	O
the	O
CD45	O
(	O
-	O
)	O
ICAM-1	O
(	O
+	O
)	O
CD21	O
/	O
35	O
(	O
+	O
)	O
cell	O
fraction	O
.	O

CD45	O
(	O
-	O
)	O
ICAM-1	O
(	O
+	O
)	O
CD21	O
/	O
35	O
(	O
+	O
)	O
cells	O
in	O
the	O
mouse	O
spleen	O
retained	O
an	O
antigen	O
administered	O
in	O
vivo	O
for	O
more	O
than	O
7	O
days	O
.	O

Moreover	O
,	O
CD45	O
(	O
-	O
)	O
ICAM-1	O
(	O
+	O
)	O
CD21	O
/	O
35	O
(	O
+	O
)	O
cells	O
isolated	O
from	O
the	O
spleen	O
of	O
mice	O
administered	O
with	O
a	O
cognate	O
antigen	O
enhanced	O
the	O
survival	O
and	O
proliferation	O
of	O
antigen-specific	O
B	O
cells	O
in	O
vitro	O
.	O

Our	O
improved	O
protocol	O
for	O
the	O
isolation	B-P
of	O
naÃ¯ve	O
FDCs	O
will	O
be	O
useful	O
for	O
the	O
analysis	O
of	O
FDCs	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
role	O
of	O
p62	O
/	O
SQSTM1	O
in	O
sporadic	O
inclusion	O
body	O
myositis	O
.	O

We	O
examined	O
selective	O
autophagy	O
against	O
ubiquitinated	O
protein	O
aggregates	O
in	O
sporadic	O
inclusion	O
body	O
myositis	O
(	O
s-IBM	O
)	O
patients	O
.	O

The	O
form	O
of	O
autophagy	O
requires	O
phosphorylation	O
of	O
serine	O
403	O
in	O
p62	O
/	O
SQSTM1	O
to	O
bind	O
to	O
Lys63	O
-linked	O
ubiquitin	O
and	O
the	O
binding	O
of	O
the	O
p62	O
-	O
ubiquitinated	O
protein	O
conjugates	O
to	O
LC3	O
.	O

In	O
muscle	O
biopsy	O
specimens	O
from	O
16	O
s-IBM	O
patients	O
,	O
we	O
compared	O
the	O
distribution	O
of	O
p62	O
(	O
aa120-440	O
)	O
with	O
1	O
)	O
Ser403	O
-	O
phosphorylated	O
p62	O
(	O
S403	O
-	O
p	O
p62	O
)	O
,	O
2	O
)	O
Lys63	O
-linked	O
ubiquitin	O
and	O
3	O
)	O
LC3	O
in	O
double-colour	B-P
immunofluorescence	I-P
microscopy	I-P
.	O

S403	O
-	O
p	O
p62	O
,	O
Lys63	O
-linked	O
ubiquitin	O
and	O
LC3	O
colocalised	O
with	O
p62	O
aggregates	O
,	O
79.05	O
%	O
Â±	O
13.64	O
%	O
(	O
mean	O
Â±	O
SD	O
)	O
,	O
66.54	O
%	O
Â±	O
19.91	O
%	O
and	O
51.84	O
%	O
Â±	O
14.1	O
%	O
,	O
respectively	O
.	O

Although	O
positive	O
deposits	O
of	O
S403	O
-	O
p	O
p62	O
and	O
Lys63	O
-linked	O
ubiquitin	O
were	O
always	O
observed	O
within	O
p62	O
aggregates	O
,	O
LC3	O
often	O
showed	O
dissociated	O
distribution	O
from	O
p62	O
.	O

We	O
also	O
found	O
fibres	O
containing	O
small	O
,	O
numerous	O
p62	O
-	O
positive	O
dots	O
that	O
were	O
negative	O
for	O
all	O
three	O
markers	O
and	O
were	O
also	O
observed	O
in	O
myositis	O
controls	O
.	O

The	O
results	O
indicate	O
that	O
p62	O
,	O
Lys63	O
-linked	O
ubiquitin	O
and	O
LC3	O
in	O
s-IBM	O
join	O
to	O
perform	O
selective	O
autophagy	O
.	O

p62	O
could	O
be	O
induced	O
by	O
some	O
cellular	O
stresses	O
in	O
all	O
types	O
of	O
myositis	O
;	O
however	O
,	O
in	O
s-IBM	O
,	O
compromised	O
binding	O
of	O
the	O
p62	O
-	O
ubiquitinated	O
protein	O
complex	O
to	O
LC3	O
could	O
stop	O
the	O
autophagy	O
process	O
in	O
its	O
initial	O
stages	O
,	O
which	O
causes	O
the	O
formation	O
of	O
aggregates	O
of	O
p62	O
-	O
oligomers	O
with	O
Lys63	O
-	O
ubiquitinated	O
proteins	O
.	O

Fabrication	O
of	O
gelatin	O
methacrylate	O
/	O
nanohydroxyapatite	O
microgel	O
arrays	O
for	O
periodontal	O
tissue	O
regeneration	O
.	O

Periodontitis	O
is	O
a	O
chronic	O
infectious	O
disease	O
and	O
is	O
the	O
major	O
cause	O
of	O
tooth	O
loss	O
and	O
other	O
oral	O
health	O
issues	O
around	O
the	O
world	O
.	O

Periodontal	O
tissue	O
regeneration	O
has	O
therefore	O
always	O
been	O
the	O
ultimate	O
goal	O
of	O
dentists	O
and	O
researchers	O
.	O

Existing	O
fabrication	O
methods	O
mainly	O
focused	O
on	O
a	O
top-down	O
tissue	O
engineering	O
strategy	O
in	O
which	O
several	O
drawbacks	O
remain	O
,	O
including	O
low	O
throughput	O
and	O
limited	O
diffusion	O
properties	O
resulting	O
from	O
a	O
large	O
sample	O
size	O
.	O

Gelatin	O
methacrylate	O
(	O
GelMA	O
)	O
is	O
a	O
kind	O
of	O
photocrosslinkable	O
and	O
biocompatible	O
hydrogel	O
,	O
with	O
the	O
capacities	O
of	O
enabling	O
cell	B-P
encapsulation	I-P
and	O
regeneration	O
of	O
functional	O
tissues	O
.	O

Here	O
,	O
we	O
developed	O
a	O
novel	O
method	O
to	O
fabricate	O
GelMA	O
/	O
nanohydroxylapatite	O
(	O
nHA	O
)	O
microgel	O
arrays	O
using	O
a	O
photocrosslinkable	O
strategy	O
.	O

The	O
viability	O
,	O
proliferation	O
,	O
and	O
osteogenic	O
differentiation	O
and	O
in	O
vivo	O
osteogenesis	O
of	O
human	O
periodontal	O
ligament	O
stem	O
cells	O
(	O
hPDLSCs	O
)	O
encapsulated	O
in	O
microgels	O
were	O
evaluated	O
.	O

The	O
results	O
suggested	O
that	O
such	O
microgels	O
provide	O
great	O
potential	O
for	O
periodontal	O
tissue	O
repair	O
and	O
regeneration	O
.	O

Microgel	O
arrays	O
were	O
fabricated	O
by	O
blending	O
different	O
weight	O
ratios	O
of	O
GelMA	O
and	O
nHA	O
.	O

hPDLSCs	O
were	O
encapsulated	O
in	O
GelMA	O
/	O
nHA	O
microgels	O
of	O
various	O
ratios	O
for	O
a	O
systematic	O
evaluation	O
of	O
cell	O
viability	O
,	O
proliferation	O
,	O
and	O
osteogenic	O
differentiation	O
.	O

In	O
vivo	O
osteogenesis	O
in	O
nude	O
mice	O
was	O
also	O
studied	O
.	O

The	O
GelMA	O
/	O
nHA	O
microgels	O
exhibited	O
appropriate	O
microarchitecture	O
,	O
mechanical	O
strength	O
,	O
and	O
surface	O
roughness	O
,	O
thus	O
enabling	O
cell	O
adhesion	O
and	O
proliferation	O
.	O

Additionally	O
,	O
the	O
GelMA	O
/	O
nHA	O
microgels	O
(	O
10	O
%	O
/2	O
%	O
w/v	O
)	O
enhanced	O
the	O
osteogenic	O
differentiation	O
of	O
hPDLSCs	O
by	O
elevating	O
the	O
expression	O
levels	O
of	O
osteogenic	O
biomarker	O
genes	O
,	O
such	O
as	O
ALP	O
,	O
BSP	O
,	O
OCN	O
,	O
and	O
RUNX2	O
.	O

In	O
vivo	O
ectopic	O
transplantation	O
results	O
showed	O
that	O
GelMA	O
/	O
nHA	O
microgels	O
(	O
10	O
%	O
/2	O
%	O
w/v	O
)	O
increased	O
mineralized	O
tissue	O
formation	O
with	O
abundant	O
vascularization	O
,	O
compared	O
with	O
the	O
1	O
%	O
,	O
3	O
%	O
,	O
and	O
the	O
pure	O
GelMA	O
group	O
.	O

The	O
GelMA	O
/	O
nHA	O
microgels	O
(	O
10	O
%	O
/2	O
%	O
w/v	O
)	O
facilitated	O
hPDLSCs	O
viability	O
,	O
proliferation	O
,	O
and	O
osteogenic	O
differentiation	O
in	O
vitro	O
and	O
further	O
promoted	O
new	O
bone	O
formation	O
in	O
vivo	O
,	O
suggesting	O
that	O
the	O
GelMA	O
/	O
nHA	O
microgels	O
(	O
10	O
%	O
/2	O
%	O
w/v	O
)	O
provide	O
great	O
potential	O
for	O
periodontal	O
tissue	O
regeneration	O
.	O

Presence	O
of	O
metallo-beta-lactamases	O
(	O
MBL	O
)	O
,	O
extended-spectrum	O
beta-lactamase	O
(	O
ESBL	O
)	O
&	O
AmpC	O
positive	O
non-fermenting	O
Gram-negative	O
bacilli	O
among	O
Intensive	O
Care	O
Unit	O
patients	O
with	O
special	O
reference	O
to	O
molecular	B-P
detection	I-P
of	O
blaCTX-M	O
&	O
blaAmpC	O
genes	O
.	O

Non-fermenting	O
Gram-negative	O
bacilli	O
(	O
NFGNB	O
)	O
including	O
Pseudomonas	O
aeruginosa	O
and	O
Acinetobacter	O
baumannii	O
have	O
been	O
implicated	O
in	O
a	O
variety	O
of	O
infections	O
,	O
particularly	O
in	O
the	O
Intensive	O
Care	O
Units	O
(	O
ICUs	O
)	O
.	O

This	O
study	O
was	O
aimed	O
to	O
overview	O
the	O
burden	O
of	O
multidrug-resistant	O
NFGNB	O
causing	O
infections	O
in	O
ICU	O
and	O
also	O
to	O
assess	O
the	O
occurrence	O
of	O
extended-spectrum	O
beta-lactamases	O
(	O
ESBLs	O
)	O
,	O
AmpC	O
and	O
metallo-beta-lactamases	O
(	O
MBLs	O
)	O
among	O
these	O
isolates	O
.	O

Bacterial	B-P
culture	I-P
,	O
identification	O
and	O
antibiotic	O
susceptibility	O
were	O
carried	O
out	O
.	O

ESBL	O
s	O
and	O
AmpC	O
were	O
detected	O
both	O
phenotypically	B-P
and	O
genotypically	B-P
.	O

MBL	O
was	O
detected	O
by	O
modified	O
Hodge	B-P
and	I-P
imipenem-ethylenediaminetetraacetic	I-P
acid	I-P
double-disc	I-P
synergy	I-P
test	I-P
.	O

NFGNB	O
represented	O
45	O
(	O
37	O
%	O
)	O
of	O
total	O
121	O
Gram	O
negative	O
isolates	O
.	O

Multidrug	O
resistance	O
was	O
observed	O
in	O
66.9	O
per	O
cent	O
and	O
72.5	O
per	O
cent	O
isolates	O
of	O
P.	O
aeruginosa	O
and	O
A.	O
baumannii	O
,	O
respectively	O
.	O

Detection	O
by	O
phenotypic	B-P
methods	I-P
showed	O
presence	O
of	O
ESBL	O
,	O
AmpC	O
and	O
MBL	O
in	O
21.4	O
,	O
51.1	O
and	O
21.4	O
per	O
cent	O
isolates	O
,	O
respectively	O
.	O

When	O
detected	O
genotypically	B-P
by	O
polymerase	O
chain	O
reaction	O
,	O
ESBL	O
and	O
AmpC	O
were	O
detected	O
in	O
21.4	O
and	O
41.4	O
per	O
cent	O
of	O
NFGNB	O
isolates	O
,	O
respectively	O
.	O

BlaCTX-M	O
(	O
21.4	O
%	O
)	O
was	O
the	O
most	O
prevalent	O
gene	O
responsible	O
for	O
ESBL	O
production	O
.	O

Most	O
of	O
the	O
NFGNB	O
isolated	O
from	O
ICU	O
patients	O
were	O
multidrug-resistant	O
and	O
producers	O
of	O
ESBL	O
,	O
AmpC	O
and	O
MBL	O
.	O

A	O
regular	O
surveillance	O
is	O
required	O
to	O
detect	O
ESBL	O
,	O
AmpC	O
and	O
MBL	O
producers	O
,	O
especially	O
in	O
ICU	O
patients	O
.	O

Multiplex	O
Biomarker	O
Approaches	O
to	O
Enable	O
Point-of-Care	O
Testing	O
and	O
Personalized	O
Medicine	O
.	O

This	O
chapter	O
describes	O
how	O
current	O
and	O
future	O
innovations	O
driven	O
by	O
application	O
of	O
multiplex	O
biomarker	O
techniques	O
can	O
help	O
in	O
earlier	O
and	O
more	O
efficacious	O
treatment	O
of	O
patients	O
,	O
suffering	O
from	O
the	O
world	O
's	O
most	O
devastating	O
and	O
costly	O
diseases	O
.	O

The	O
application	O
of	O
new	O
miniaturized	O
biosensors	O
and	O
transducers	O
will	O
enable	O
point-of-care	O
testing	O
by	O
facilitating	O
analysis	O
of	O
a	O
single	O
drop	O
of	O
a	O
blood	O
within	O
the	O
time	O
span	O
of	O
a	O
visit	O
to	O
the	O
doctor	O
's	O
office	O
.	O

It	O
is	O
anticipated	O
that	O
the	O
scoring	O
algorithms	O
used	O
with	O
future	O
tests	O
will	O
incorporate	O
both	O
biochemical	O
and	O
clinical	O
data	O
,	O
resulting	O
in	O
specific	O
profiles	B-P
for	O
each	O
patient	O
or	O
tested	O
subject	O
to	O
enable	O
personalized	O
medicine	O
approaches	O
.	O

Biomarkers	O
for	O
predicting	O
spontaneous	O
preterm	O
birth	O
:	O
an	O
umbrella	O
systematic	O
review	O
.	O

To	O
identify	O
all	O
systematic	O
reviews	O
investigating	O
the	O
role	O
of	O
maternal	O
and	O
fetal	O
biomarkers	O
for	O
predicting	O
spontaneous	O
preterm	O
birth	O
(	O
SPTB	O
)	O
.	O

Medline	O
and	O
Web	O
of	O
Sciences	O
databases	O
were	O
searched	O
electronically	O
.	O

Studies	O
exploring	O
the	O
association	O
between	O
maternal	O
biomarkers	O
and	O
spontaneous	O
delivery	O
were	O
considered	O
suitable	O
for	O
inclusion	O
.	O

A	O
synthesis	O
of	O
the	O
systematic	O
reviews	O
was	O
performed	O
with	O
the	O
umbrella	O
methodology	O
.	O

Statistical	O
measures	O
of	O
association	O
(	O
Odd	O
ratio	O
,	O
OR	O
,	O
relative	O
risk	O
,	O
RR	O
)	O
and	O
predictive	O
accuracy	O
(	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
and	O
negative	O
likelihood	O
ratios	O
were	O
used	O
to	O
synthesize	O
results	O
of	O
the	O
included	O
studies	O
.	O

21,614	O
articles	O
were	O
identified	O
,	O
542	O
were	O
assessed	O
with	O
respect	O
to	O
their	O
eligibility	O
for	O
inclusion	O
and	O
14	O
systematic	O
reviews	O
included	O
.	O

Cervical	O
fibronectin	O
was	O
the	O
biomarkers	O
which	O
showed	O
the	O
highest	O
strength	O
of	O
association	O
with	O
the	O
occurrence	O
of	O
SPTB	O
(	O
delivery	O
within	O
24	O
h	O
OR	O
7	O
,	O
95	O
%	O
CI	O
3-17	O
;	O
delivery	O
<	O
7	O
days	O
(	O
OR	O
12	O
,	O
95	O
%	O
CI	O
8-16	O
)	O
.	O

Maternal	B-P
serum	I-P
alpha	I-P
fetoprotein	I-P
,	O
was	O
associated	O
with	O
an	O
OR	O
of	O
4	O
and	O
3	O
for	O
early	O
and	O
late	O
SPTB	O
.	O

C-reactive	O
protein	O
had	O
an	O
OR	O
of	O
2	O
(	O
95	O
%	O
CI	O
1-2	O
)	O
and	O
8	O
(	O
95	O
%	O
CI	O
4-16	O
)	O
when	O
detected	O
in	O
maternal	O
plasma	O
and	O
amniotic	O
fluid	O
,	O
respectively	O
.	O

Among	O
cytokines	O
,	O
interleukin-6	O
had	O
an	O
OR	O
and	O
an	O
LR	O
+	O
for	O
SPTB	O
of	O
2	O
and	O
12	O
when	O
detected	O
in	O
maternal	O
serum	O
.	O

Cervical	O
fetal	O
fibronectin	O
,	O
alpha	O
fetoprotein	O
,	O
C-	O
reactive	O
protein	O
and	O
interleukin	O
6	O
can	O
have	O
an	O
overall	O
good	O
diagnostic	O
accuracy	O
in	O
identifying	O
pregnancies	O
at	O
risk	O
of	O
SPTB	O
.	O

Large	O
prospective	O
studies	O
in	O
different	O
sub-set	O
of	O
women	O
are	O
needed	O
to	O
ascertain	O
whether	O
the	O
combination	O
of	O
different	O
serological	O
and	O
imaging	O
marker	O
can	O
improve	O
antenatal	O
prediction	O
of	O
this	O
condition	O
.	O

Renieramycin	O
M	O
Attenuates	O
Cancer	O
Stem	O
Cell	O
-like	O
Phenotypes	O
in	O
H460	O
Lung	O
Cancer	O
Cells	O
.	O

Cancer	O
stem	O
cells	O
(	O
CSCs	O
)	O
are	O
a	O
subpopulation	O
of	O
cancer	O
cells	O
that	O
possess	O
self-renewal	O
and	O
differentiation	O
capacities	O
.	O

CSCs	O
contribute	O
to	O
drug-resistance	O
,	O
cancer	O
recurrence	O
and	O
metastasis	O
,	O
thus	O
development	O
of	O
CSC	O
-targeted	O
therapeutic	O
strategies	O
has	O
recently	O
received	O
significant	O
attention	O
in	O
cancer	O
research	O
.	O

In	O
this	O
study	O
,	O
the	O
potential	O
efficacy	O
of	O
renieramycin	O
M	O
(	O
RM	O
)	O
isolated	O
from	O
the	O
sponge	O
Xestospongia	O
species	O
,	O
was	O
examined	O
against	O
lung	O
CSCs	O
.	O

Colony	B-P
and	I-P
spheroid	I-P
formation	I-P
assays	I-P
,	O
as	O
well	O
as	O
western	O
blotting	O
analysis	O
of	O
lung	O
CSC	O
protein	O
markers	O
were	O
employed	O
to	O
determine	O
the	O
CSC	O
-like	O
phenotypes	O
of	O
H460	O
lung	O
cancer	O
cells	O
after	O
treatment	O
with	O
RM	O
at	O
non-toxic	O
concentrations	O
.	O

RM	O
treatment	O
reduced	O
significantly	O
colony	B-P
and	I-P
spheroid	I-P
formation	I-P
of	O
H460	O
cells	O
.	O

Moreover	O
,	O
the	O
CSC	O
markers	O
CD133	O
,	O
CD44	O
and	O
ALDH1A1	O
of	O
CSC	O
-enriched	O
H460	O
cells	O
were	O
reduced	O
significantly	O
following	O
RM	O
treatment	O
.	O

RM	O
could	O
be	O
a	O
potent	O
anti-metastatic	O
agent	O
by	O
suppressing	O
lung	O
CSC	O
-like	O
phenotypes	O
in	O
H460	O
cells	O
.	O

Successful	O
treatment	O
with	O
hyperbaric	O
oxygen	O
therapy	O
for	O
severe	O
brain	O
edema	O
characterized	O
by	O
radiological	O
appearance	O
of	O
pseudosubarachnoid	O
hemorrhage	O
in	O
a	O
child	O
.	O

Pseudosubarachnoid	O
hemorrhage	O
(	O
PSAH	O
)	O
is	O
a	O
rare	O
neuroradiological	O
finding	O
,	O
particularly	O
in	O
pediatric	O
patients	O
.	O

The	O
appearance	O
of	O
PSAH	O
is	O
commonly	O
associated	O
with	O
poor	O
clinical	O
outcome	O
due	O
to	O
refractory	O
cerebral	O
edema	O
.	O

Recent	O
clinical	O
trials	O
have	O
favored	O
hyperbaric	O
oxygen	O
therapy	O
(	O
HBOT	O
)	O
as	O
a	O
promising	O
therapeutic	O
strategy	O
for	O
adult	O
patients	O
with	O
severe	O
head	O
injuries	O
.	O

The	O
present	O
report	O
describes	O
a	O
pediatric	O
case	O
of	O
diffuse	O
brain	O
edema	O
characterized	O
by	O
the	O
radiological	O
appearance	O
of	O
PSAH	O
successfully	O
treated	O
with	O
HBOT	O
.	O

An	O
adolescent	O
boy	O
collapsed	O
unconscious	O
following	O
convulsion	O
for	O
3-5	O
min	O
with	O
fever	O
and	O
headache	O
for	O
2	O
days	O
.	O

A	O
brain	B-P
computed	I-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
scan	I-P
provided	O
an	O
image	O
compatible	O
with	O
subarachnoid	O
hemorrhage	O
(	O
SAH	O
)	O
.	O

Lumbar	O
puncture	O
was	O
conducted	O
on	O
admission	O
to	O
hospital	O
and	O
showed	O
no	O
evidence	O
of	O
SAH	O
.	O

The	O
CT	B-P
scan	I-P
was	O
again	O
considered	O
and	O
eventually	O
interpreted	O
as	O
PSAH	O
.	O

The	O
patient	O
received	O
drug	O
treatment	O
including	O
acyclovir	O
and	O
mannitol	O
,	O
but	O
the	O
condition	O
deteriorated	O
rapidly	O
.	O

HBOT	O
was	O
administered	O
at	O
72	O
h	O
post	O
admission	O
and	O
the	O
condition	O
was	O
clearly	O
improved	O
following	O
the	O
initial	O
therapy	O
.	O

The	O
patient	O
was	O
discharged	O
with	O
20	O
sessions	O
of	O
HBOT	O
and	O
recovered	O
completely	O
after	O
1	O
year	O
.	O

The	O
appearance	O
of	O
PSAH	O
indicates	O
severe	O
cerebral	O
edema	O
refractory	O
to	O
treatment	O
with	O
conventional	O
internal	O
medicine	O
.	O

HBOT	O
maybe	O
an	O
effective	O
therapeutic	O
strategy	O
for	O
this	O
condition	O
.	O

Group	O
III/IV	O
muscle	O
afferents	O
limit	O
the	O
intramuscular	O
metabolic	O
perturbation	O
during	O
whole	O
body	O
exercise	O
in	O
humans	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	B-P
the	O
role	O
of	O
group	O
III/IV	O
muscle	O
afferents	O
in	O
limiting	O
the	O
endurance	O
exercise	O
-	O
induced	O
metabolic	O
perturbation	O
assayed	B-P
in	O
muscle	O
biopsy	O
samples	O
taken	O
from	O
locomotor	O
muscle	O
.	O

Lumbar	O
intrathecal	O
fentanyl	O
was	O
used	O
to	O
attenuate	O
the	O
central	O
projection	O
of	O
Î¼-opioid	O
receptor	O
-	O
sensitive	O
locomotor	O
muscle	O
afferents	O
during	O
a	O
5	O
km	O
cycling	O
time	O
trial	O
.	O

The	O
findings	O
suggest	O
that	O
the	O
central	O
projection	O
of	O
group	O
III/IV	O
muscle	O
afferent	O
feedback	O
constrains	O
voluntary	O
neural	O
'	O
drive	O
'	O
to	O
working	O
locomotor	O
muscle	O
and	O
limits	O
the	O
exercise	O
-	O
induced	O
intramuscular	O
metabolic	O
perturbation	O
.	O

Therefore	O
,	O
the	O
CNS	O
might	O
regulate	O
the	O
degree	O
of	O
metabolic	O
perturbation	O
within	O
locomotor	O
muscle	O
and	O
thereby	O
limit	O
peripheral	O
fatigue	O
.	O

It	O
appears	O
that	O
the	O
group	O
III/IV	O
muscle	O
afferents	O
are	O
an	O
important	O
neural	O
link	O
in	O
this	O
regulatory	O
mechanism	O
,	O
which	O
probably	O
serves	O
to	O
protect	O
locomotor	O
muscle	O
from	O
the	O
potentially	O
severe	O
functional	O
impairment	O
as	O
a	O
consequence	O
of	O
severe	O
intramuscular	O
metabolic	O
disturbance	O
.	O

To	O
investigate	O
the	O
role	O
of	O
metabo	O
-	O
and	O
mechanosensitive	O
group	O
III/IV	O
muscle	O
afferents	O
in	O
limiting	O
the	O
intramuscular	O
metabolic	O
perturbation	O
during	O
whole	O
body	O
endurance	O
exercise	O
,	O
eight	O
subjects	O
performed	O
5	O
km	O
cycling	O
time	O
trials	O
under	O
control	O
conditions	O
(	O
CTRL	O
)	O
and	O
with	O
lumbar	O
intrathecal	O
fentanyl	O
impairing	O
lower	O
limb	O
muscle	O
afferent	O
feedback	O
(	O
FENT	O
)	O
.	O

Vastus	O
lateralis	O
muscle	O
biopsies	O
were	O
obtained	O
before	O
and	O
immediately	O
after	O
exercise	O
.	O

Motoneuronal	O
output	B-P
was	I-P
estimated	I-P
through	O
vastus	O
lateralis	O
surface	O
electromyography	B-P
(	O
EMG	B-P
)	O
.	O

Exercise	O
-	O
induced	O
changes	O
in	O
intramuscular	O
metabolites	O
were	O
determine	B-P
d	O
using	O
liquid	O
and	O
gas	B-P
chromatography-mass	I-P
spectrometry	I-P
.	O

Quadriceps	O
fatigue	O
was	O
quantified	O
by	O
pre	O
-	O
to	O
post	O
-	O
exercise	O
changes	O
in	O
potentiated	O
quadriceps	O
twitch	O
torque	O
(	O
ÎQTsingle	O
)	O
evoked	O
by	O
electrical	O
femoral	O
nerve	O
stimulation	O
.	O

Although	O
motoneuronal	O
output	O
was	O
21	O
Â±	O
12	O
%	O
higher	O
during	O
FENT	O
compared	O
to	O
CTRL	O
(	O
P	O
<	O
0.05	O
)	O
,	O
time	O
to	O
complete	O
the	O
time	O
trial	O
was	O
similar	O
(	O
â¼8.8	O
min	O
)	O
.	O

Compared	O
to	O
CTRL	O
,	O
power	O
output	O
during	O
FENT	O
was	O
10	O
Â±	O
4	O
%	O
higher	O
in	O
the	O
first	O
half	O
of	O
the	O
time	O
trial	O
,	O
but	O
11	O
Â±	O
5	O
%	O
lower	O
in	O
the	O
second	O
half	O
(	O
both	O
P	O
<	O
0.01	O
)	O
.	O

The	O
exercise	O
-	O
induced	O
increase	O
in	O
intramuscular	O
inorganic	O
phosphate	O
,	O
H	O
(	O
+	O
)	O
,	O
adenosine	O
diphosphate	O
,	O
lactate	O
and	O
phosphocreatine	O
depletion	O
was	O
55	O
Â±	O
30	O
,	O
62	O
Â±	O
18	O
,	O
129	O
Â±	O
63	O
,	O
47	O
Â±	O
14	O
(	O
P	O
<	O
0.001	O
)	O
and	O
27	O
Â±	O
14	O
%	O
(	O
P	O
<	O
0.01	O
)	O
greater	O
in	O
FENT	O
than	O
CTRL	O
.	O

ÎQTsingle	O
was	O
greater	O
following	O
FENT	O
than	O
CTRL	O
(	O
-52	O
Â±	O
2	O
vs	O
-31	O
Â±	O
1	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
this	O
difference	O
was	O
positively	O
correlated	O
with	O
the	O
difference	O
in	O
inorganic	O
phosphate	O
(	O
r	O
(	O
2	O
)	O
=	O
0.79	O
;	O
P	O
<	O
0.01	O
)	O
and	O
H	O
(	O
+	O
)	O
(	O
r	O
(	O
2	O
)	O
=	O
0.92	O
;	O
P	O
<	O
0.01	O
)	O
.	O

In	O
conclusion	O
,	O
during	O
whole	O
body	O
exercise	O
,	O
group	O
III/IV	O
muscle	O
afferents	O
provide	O
feedback	O
to	O
the	O
CNS	O
which	O
,	O
in	O
turn	O
,	O
constrains	O
motoneuronal	O
output	O
to	O
the	O
active	O
skeletal	O
muscle	O
.	O

This	O
regulatory	O
mechanism	O
limits	O
the	O
exercise	O
-	O
induced	O
intramuscular	O
metabolic	O
perturbation	O
,	O
preventing	O
an	O
abnormal	O
homeostatic	O
challenge	O
and	O
excessive	O
peripheral	O
fatigue	O
.	O

Randomized	O
Controlled	O
Trial	O
of	O
Mineralocorticoid	O
Receptor	O
Blockade	O
in	O
Children	O
with	O
Chronic	O
Kidney	O
Allograft	O
Nephropathy	O
.	O

We	O
showed	O
that	O
mineralocorticoid	O
receptor	O
blockade	O
(	O
MRB	O
)	O
prevented	O
acute	O
and	O
chronic	O
cyclosporine	O
nephropathy	O
(	O
CsA-Nx	O
)	O
in	O
the	O
rat	O
.	O

The	O
aim	O
of	O
this	O
translational	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
long-term	O
eplerenone	O
administration	O
on	O
renal	O
allograft	O
function	O
in	O
children	O
with	O
biopsy	B-P
-proven	O
chronic	O
allograft	O
nephropathy	O
(	O
CAN	O
)	O
.	O

Renal	O
transplant	O
children	O
<	O
18	O
years	O
,	O
biopsy	B-P
-proven	O
CAN	O
,	O
and	O
a	O
GFR	B-P
>	O
40	O
ml/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
were	O
included	O
.	O

Patients	O
with	O
BK	O
virus	O
active	O
nephritis	O
,	O
recurrence	O
of	O
renal	O
disease	O
,	O
GFR	O
decline	O
in	O
previous	O
3	O
months	O
,	O
or	O
treated	O
with	O
calcium	O
antagonists	O
or	O
antifungal	O
drugs	O
were	O
excluded	O
.	O

They	O
were	O
randomized	O
to	O
receive	O
placebo	O
(	O
n=10	O
)	O
or	O
eplerenone	O
25	O
mg/d	O
for	O
24	O
months	O
(	O
n=13	O
)	O
.	O

Visits	O
were	O
scheduled	O
at	O
baseline	O
,	O
6	O
,	O
12	O
,	O
and	O
24	O
months	O
.	O

At	O
each	O
period	O
,	O
a	O
complete	O
clinical	O
examination	O
was	O
performed	O
and	O
blood	O
and	O
urine	O
samples	O
were	O
taken	O
.	O

Urine	B-P
creatinine	I-P
,	O
8-hydroxylated-guanosine	O
,	O
heat	O
shock	O
protein	O
72	O
(	O
HSP72	O
)	O
,	O
and	O
kidney	B-P
injury	I-P
molecule	I-P
(	I-P
KIM-1	I-P
)	I-P
levels	I-P
were	O
also	O
assessed	O
.	O

In	O
kidney	O
biopsy	O
samples	O
,	O
the	O
tubulo-interstitial	B-P
area	I-P
affected	I-P
by	I-P
fibrosis	I-P
(	O
TIF	B-P
)	O
and	O
glomerulosclerosis	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
24	O
months	O
.	O

The	O
baseline	O
eGFR	B-P
was	O
80Â±6	O
in	O
the	O
placebo	O
and	O
86Â±6	O
ml/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
in	O
the	O
eplerenone	O
group	O
;	O
at	O
24	O
months	O
it	O
was	O
66Â±8	O
and	O
81Â±7	O
ml/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
,	O
respectively	O
(	O
P=0.33	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
-18	O
to	O
33	O
at	O
baseline	O
,	O
and	O
-11	O
to	O
40	O
after	O
24	O
months	O
)	O
.	O

The	O
albumin-to-creatinine	O
ratio	O
was	O
110Â±74	O
in	O
the	O
placebo	O
,	O
and	O
265Â±140	O
mg/g	O
in	O
the	O
eplerenone	O
group	O
;	O
and	O
after	O
24	O
months	O
it	O
was	O
276Â±140	O
and	O
228Â±88	O
mg/g	O
,	O
respectively	O
(	O
P=0.15	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
-283	O
to	O
593	O
,	O
and	O
-485	O
to	O
391	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
the	O
placebo	O
exhibited	O
a	O
greater	O
TIF	B-P
,	O
glomerulosclerosis	O
,	O
and	O
urinary	O
HSP72	O
compared	O
with	O
the	O
eplerenone	O
group	O
.	O

Although	O
this	O
study	O
was	O
underpowered	O
to	O
provide	O
definitive	O
evidence	O
that	O
long-term	O
eplerenone	O
administration	O
attenuates	O
the	O
progression	O
of	O
CAN	O
in	O
pediatric	O
transplant	O
patients	O
,	O
it	O
encourages	O
testing	O
the	O
potential	O
benefit	O
of	O
MRB	O
in	O
this	O
pediatric	O
population	O
.	O

Low	O
copy	O
numbers	O
of	O
FCGR3A	O
and	O
FCGR3B	O
associated	O
with	O
Chinese	O
patients	O
with	O
SLE	O
and	O
AASV	O
.	O

Low-affinity	O
FcÎ³	O
receptors	O
(	O
FcÎ³R	O
)	O
act	O
as	O
key	O
mediators	O
of	O
the	O
pathogenic	O
effects	O
of	O
autoantibodies	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
determine	O
whether	O
copy	O
number	O
variations	O
(	O
CNVs	O
)	O
in	O
FCGR3A	O
and	O
FCGR3B	O
were	O
associated	O
with	O
systemic	O
lupus	O
nephritis	O
(	O
SLE	O
)	O
and	O
ANCA-associated	O
systemic	O
vasculitis	O
(	O
AASV	O
)	O
in	O
Chinese	O
individuals	O
.	O

A	O
total	O
of	O
1118	O
individuals	O
were	O
enrolled	O
,	O
including	O
415	O
SLE	O
patients	O
,	O
139	O
AASV	O
patients	O
,	O
and	O
564	O
healthy	O
controls	O
.	O

FCGR3A	O
and	O
FCGR3B	O
copy	O
numbers	O
(	O
CNs	O
)	O
were	O
determined	O
by	O
both	O
a	O
paralogue	B-P
ratio	I-P
test	I-P
and	O
TaqMan	B-P
quantitative	I-P
PCR	I-P
assay	I-P
.	O

In	O
the	O
susceptibility	O
associations	O
,	O
a	O
low	O
FCGR3B	O
CN	O
was	O
significantly	O
associated	O
with	O
SLE	O
(	O
p	O
=	O
5.01	O
Ã	O
10	O
(	O
-3	O
)	O
;	O
odds	O
ratio	O
(	O
OR	O
)	O
1.71	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.17-2.48	O
)	O
and	O
AASV	O
(	O
p	O
=	O
0.04	O
;	O
OR	O
=	O
1.72	O
;	O
95	O
%	O
CI	O
1.02-2.88	O
)	O
.	O

A	O
low	O
FCGR3A	O
CN	O
was	O
also	O
significantly	O
associated	O
with	O
SLE	O
(	O
p	O
=	O
6.02	O
Ã	O
10	O
(	O
-3	O
)	O
;	O
OR	O
2.72	O
;	O
95	O
%	O
CI	O
1.30-5.71	O
)	O
and	O
AASV	O
(	O
p	O
=	O
0.042	O
;	O
OR	O
2.64	O
;	O
95	O
%	O
CI	O
1.00-6.93	O
)	O
.	O

Further	O
subphenotype	O
analysis	O
revealed	O
that	O
low	O
CNs	O
of	O
FCGR3A	O
and	O
FCGR3B	O
were	O
significantly	O
associated	O
with	O
clinical	O
manifestations	O
in	O
SLE	O
and	O
AASV	O
patients	O
.	O

Therefore	O
,	O
in	O
this	O
case-control	O
study	O
,	O
we	O
identified	O
low	O
CNs	O
of	O
FCGR2A	O
and	O
FCGR3B	O
to	O
be	O
common	O
risk	O
factors	O
for	O
SLE	O
and	O
AASV	O
.	O

Complete	O
Genome	B-P
Sequences	I-P
of	O
the	O
Endophytic	O
Streptomyces	O
Strains	O
EN16	O
,	O
EN23	O
,	O
and	O
EN27	O
,	O
Isolated	O
from	O
Wheat	O
Plants	O
.	O

The	O
complete	O
genome	B-P
sequences	I-P
of	O
three	O
endophytic	O
Streptomyces	O
species	O
were	O
compared	O
.	O

Strains	O
EN16	O
,	O
EN23	O
,	O
and	O
EN27	O
were	O
isolated	O
from	O
surface-	O
sterilized	O
roots	O
of	O
wheat	O
plants	O
from	O
South	O
Australia	O
.	O

In	O
field	O
trials	O
,	O
these	O
strains	O
are	O
effective	O
in	O
suppressing	O
fungal	O
root	O
diseases	O
of	O
wheat	O
when	O
added	O
as	O
spore	O
coatings	O
to	O
wheat	O
seed	O
.	O

Establishment	O
and	O
application	O
of	O
a	O
flow	B-P
cytometry	I-P
-based	O
method	O
for	O
detecting	O
histone	O
acetylation	O
levels	O
.	O

Histone	O
deacetylase	O
inhibitors	O
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
AIDS	O
and	O
other	O
diseases	O
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	O
drugs	O
developed	O
in	O
recent	O
years	O
.	O

However	O
,	O
there	O
is	O
still	O
a	O
lack	O
of	O
a	O
unified	O
and	O
reliable	O
method	O
for	O
detecting	O
histone	O
acetylation	O
levels	O
in	O
basic	O
and	O
clinical	O
research	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	B-P
cytometry	I-P
-based	O
method	O
to	O
detect	O
histone	O
acetylation	O
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	O
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	B-P
titration	I-P
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	O
of	O
Chidamide	O
(	O
the	O
only	O
China	O
FDA	O
approved	O
HDACi	O
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	B-P
cytometry	I-P
-based	O
method	O
for	O
detecting	O
histone	O
acetylation	O
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	O
.	O

Association	O
of	O
Autoimmune	O
Encephalitis	O
With	O
Combined	O
Immune	O
Checkpoint	O
Inhibitor	O
Treatment	O
for	O
Metastatic	O
Cancer	O
.	O

Paraneoplastic	O
encephalitides	O
usually	O
precede	O
a	O
diagnosis	B-P
of	I-P
cancer	I-P
and	O
are	O
often	O
refractory	O
to	O
immunosuppressive	O
therapy	O
.	O

Conversely	O
,	O
autoimmune	O
encephalitides	O
are	O
reversible	O
conditions	O
that	O
can	O
occur	O
in	O
the	O
presence	O
or	O
absence	O
of	O
cancer	O
.	O

To	O
report	O
the	O
induction	O
of	O
autoimmune	O
encephalitis	O
in	O
2	O
patients	O
after	O
treatment	O
of	O
metastatic	O
cancer	O
with	O
a	O
combination	O
of	O
the	O
immune	O
checkpoint	O
inhibitors	O
nivolumab	O
and	O
ipilimumab	O
.	O

A	O
retrospective	O
case	O
study	O
was	O
conducted	O
of	O
the	O
clinical	O
and	O
management	O
course	O
of	O
2	O
patients	O
with	O
progressive	O
,	O
treatment	O
-	O
refractory	O
metastatic	O
cancer	O
who	O
were	O
treated	O
with	O
a	O
single	O
dose	O
each	O
(	O
concomitantly	O
)	O
of	O
the	O
immune	O
checkpoint	O
inhibitors	O
nivolumab	O
,	O
1	O
mg/kg	O
,	O
and	O
ipilimumab	O
,	O
3	O
mg/kg	O
.	O

Nivolumab	O
and	O
ipilimumab	O
.	O

The	O
clinical	O
response	O
to	O
immunosuppressive	O
therapy	O
in	O
suspected	O
autoimmune	O
encephalitis	O
in	O
the	O
setting	O
of	O
immune	O
checkpoint	O
inhibitor	O
use	O
.	O

Autoantibody	B-P
testing	I-P
confirmed	O
identification	O
of	O
anti-N-methyl-D-aspartate	O
receptor	O
antibodies	O
in	O
the	O
cerebrospinal	O
fluid	O
of	O
1	O
patient	O
.	O

Withdrawal	O
of	O
immune	O
checkpoint	O
inhibitors	O
and	O
initiation	O
of	O
immunosuppressive	O
therapy	O
,	O
consisting	O
of	O
intravenous	O
methylprednisolone	O
sodium	O
succinate	O
equivalent	O
to	O
1000	O
mg	O
of	O
methylprednisolone	O
for	O
5	O
days	O
,	O
0.4	O
mg/kg/d	O
of	O
intravenous	O
immunoglobulin	O
for	O
5	O
days	O
,	O
and	O
2	O
doses	O
of	O
rituximab	O
,	O
1000	O
mg	O
,	O
in	O
1	O
patient	O
and	O
oral	O
prednisone	O
,	O
60	O
mg/d	O
,	O
in	O
the	O
other	O
patient	O
,	O
resulted	O
in	O
improved	O
neurologic	O
symptoms	O
.	O

Immune	O
checkpoint	O
inhibition	O
may	O
favor	O
the	O
development	O
of	O
immune	O
responses	O
against	O
neuronal	O
antigens	O
,	O
leading	O
to	O
autoimmune	O
encephalitis	O
.	O

Early	O
recognition	O
and	O
treatment	O
of	O
autoimmune	O
encephalitis	O
in	O
patients	O
receiving	O
immune	O
checkpoint	O
blockade	O
therapy	O
will	O
likely	O
be	O
essential	O
for	O
maximizing	O
clinical	O
recovery	O
and	O
minimizing	O
the	O
effect	O
of	O
drug-related	O
toxic	O
effects	O
.	O

The	O
mechanisms	O
by	O
which	O
immune	O
checkpoint	O
inhibition	O
may	O
contribute	O
to	O
autoimmune	O
encephalitis	O
require	O
further	O
study	O
.	O

Depressive	O
symptoms	O
and	O
long-term	O
income	O
:	O
The	O
Young	O
Finns	O
Study	O
.	O

Higher	O
depressive	O
symptoms	O
have	O
been	O
associated	O
with	O
lower	O
future	O
income	O
.	O

However	O
,	O
studies	B-P
examining	O
this	O
issue	O
have	O
had	O
limited	O
follow-up	O
times	O
and	O
have	O
used	O
self-reported	O
measures	O
of	O
income	O
.	O

Also	O
,	O
possible	O
confounders	O
or	O
mediators	O
have	O
not	O
been	O
accounted	O
.	O

971	O
women	O
and	O
738	O
men	O
were	O
selected	O
from	O
the	O
ongoing	O
prospective	O
Young	O
Finns	O
Study	O
(	O
YFS	O
)	O
that	O
began	O
in	O
1980	O
.	O

Depressive	O
symptoms	O
were	O
measured	O
in	O
1992	O
when	O
participants	O
were	O
from	O
15	O
to	O
30	O
years	O
old	O
.	O

Information	O
on	O
annual	O
income	O
and	O
earnings	O
from	O
1993	O
to	O
2010	O
were	O
obtained	O
from	O
the	O
Finnish	O
Longitudinal	O
Employer-Employee	O
Data	O
(	O
FLEED	O
)	O
of	O
Statistics	O
Finland	O
and	O
linked	O
to	O
the	O
YFS	O
.	O

Higher	O
depressive	O
symptoms	O
were	O
associated	O
with	O
lower	O
future	O
income	O
and	O
earnings	O
.	O

For	O
men	O
,	O
the	O
associations	O
were	O
robust	O
for	O
controlling	O
childhood	O
parental	O
socioeconomic	O
status	O
,	O
history	O
of	O
unemployment	O
,	O
and	O
adulthood	O
health	O
behavior	O
,	O
but	O
attenuated	O
circa	O
35	O
%	O
when	O
three	O
major	O
temperament	O
traits	O
were	O
taken	O
into	O
account	O
.	O

For	O
women	O
,	O
similar	O
pattern	O
was	O
found	O
,	O
however	O
,	O
in	O
the	O
models	O
adjusted	O
for	O
temperament	O
traits	O
the	O
associations	O
did	O
not	O
remain	O
statistically	O
significant	O
.	O

The	O
association	O
between	O
depressive	O
symptoms	O
and	O
earnings	O
was	O
three	O
times	O
stronger	O
for	O
men	O
than	O
women	O
.	O

Previous	O
depressive	O
episodes	O
could	O
have	O
influenced	O
on	O
some	O
participants	O
'	O
economic	O
and	O
educational	O
choices	O
.	O

Higher	O
depressive	O
symptoms	O
in	O
adolescence	O
and	O
early	O
adulthood	O
lead	O
to	O
significant	O
future	O
losses	O
of	O
total	O
income	O
and	O
earnings	O
,	O
and	O
this	O
association	O
is	O
particularly	O
strong	O
for	O
men	O
.	O

Chondrocyte	O
proliferation	O
,	O
viability	O
and	O
differentiation	O
is	O
declined	O
following	O
administration	O
of	O
methylphenidate	O
utilized	O
for	O
the	O
treatment	O
of	O
attention-deficit/hyperactivity	O
disorder	O
.	O

Methylphenidate	O
(	O
MPH	O
)	O
derivative	O
drugs	O
are	O
used	O
because	O
of	O
psychostimulants	O
effects	O
on	O
attention-deficit	O
hyperactivity	O
disorder	O
in	O
children	O
and	O
adults	O
.	O

As	O
far	O
as	O
we	O
know	O
,	O
toxic	O
or	O
anti-proliferative	O
effects	O
of	O
MPH	O
against	O
cartilage	O
tissue	O
were	O
not	O
studied	O
in	O
the	O
literature	O
.	O

The	O
present	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
possible	O
effects	O
of	O
MPH	O
on	O
the	O
proliferation	O
,	O
viability	O
and	O
differentiation	O
of	O
primary	O
human	O
chondrocytes	O
,	O
in	O
vitro	O
.	O

Monolayer	O
primary	O
chondrocyte	O
cultures	B-P
were	O
prepared	O
using	O
osteochondral	O
tissue	O
obtained	O
from	O
patients	O
who	O
underwent	O
a	O
total	O
knee	O
prosthesis	O
operation	O
.	O

Stock	O
solution	O
of	O
MPH	O
was	O
prepared	O
and	O
aliquots	O
having	O
1-1000	O
ÂµM	O
concentrations	O
of	O
the	O
drug	O
was	O
composed	O
.	O

These	O
solutions	O
were	O
applied	O
to	O
the	O
wells	O
containing	O
cultured	O
chondrocyte	O
samples	O
within	O
the	O
well	O
plates	O
.	O

Control	O
groups	O
were	O
composed	O
of	O
pure	O
chondrocyte	O
culture	B-P
and	O
no	O
solution	O
was	O
added	O
into	O
them	O
.	O

All	O
groups	O
were	O
evaluated	O
at	O
24	O
,	O
48	O
and	O
72	O
h	O
in	O
order	O
to	O
determine	O
the	O
possible	O
negative	O
effects	O
of	O
the	O
drug	O
on	O
the	O
chondrocytes	O
.	O

The	O
data	O
were	O
evaluated	O
by	O
Tukey	O
's	O
honestly	O
significantly	O
different	O
test	O
following	O
analysis	O
of	O
variance	O
.	O

In	O
the	O
group	O
where	O
MPH	O
was	O
applied	O
,	O
it	O
was	O
found	O
that	O
viability	O
,	O
proliferation	O
and	O
stage-specific	O
embryonic	O
antigen-1	O
protein	O
expression	O
were	O
decreased	O
in	O
comparison	O
to	O
the	O
control	O
group	O
.	O

It	O
was	O
emphasized	O
that	O
clinicians	O
should	O
not	O
disregard	O
the	O
fact	O
that	O
this	O
drug	O
might	O
suppress	O
chondrocyte	O
cell	O
proliferation	O
and	O
chondrogenic	O
differentiation	O
.	O

An	O
electrochemically	B-P
reduced	I-P
graphene	O
oxide	O
chemiresistive	O
sensor	O
for	O
sensitive	O
detection	O
of	O
Hg	O
(	O
2+	O
)	O
ion	O
in	O
water	O
samples	O
.	O

Divalent	O
mercuric	O
(	O
Hg	O
(	O
2+	O
)	O
)	O
ion	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
forms	O
of	O
mercury	O
species	O
in	O
waters	O
with	O
high	O
toxicity	O
and	O
bioaccumulation	O
in	O
the	O
human	O
body	O
,	O
for	O
which	O
sensitive	O
and	O
selective	O
detection	O
methods	O
are	O
highly	O
necessary	O
to	O
carry	O
out	O
its	O
recognition	O
and	O
quantification	O
.	O

Here	O
an	O
electrochemically	B-P
reduced	I-P
graphene	O
oxide	O
(	O
RGO	O
)	O
based	O
chemiresistive	O
sensor	O
was	O
constructed	O
and	O
used	O
for	O
the	O
detection	O
of	O
Hg	O
(	O
2+	O
)	O
ion	O
in	O
various	O
water	O
samples	O
.	O

Monolayer	O
GO	O
sheets	O
were	O
assembled	O
onto	O
interdigitated	O
electrodes	O
,	O
followed	O
by	O
reduction	O
through	O
linear	O
sweep	O
voltammetry	O
and	O
then	O
modification	O
with	O
a	O
single-stranded	O
DNA	O
aptamer	O
.	O

The	O
electrochemically	B-P
derived	O
RGO	O
based	O
sensor	O
showed	O
selective	O
response	O
to	O
as	O
low	O
as	O
0.5nM	O
Hg	O
(	O
2+	O
)	O
ion	O
in	O
presence	O
of	O
other	O
metal	O
ions	O
and	O
matrices	O
.	O

A	O
comparison	O
between	O
chemiresistive	O
sensors	O
prepared	O
with	O
electrochemically	B-P
and	O
chemically	O
derived	O
RGO	O
showed	O
that	O
the	O
former	O
had	O
better	O
response	O
performance	O
for	O
sensing	O
Hg	O
(	O
2+	O
)	O
ion	O
.	O

The	O
proposed	O
method	O
provides	O
a	O
simple	O
tool	O
for	O
rapid	O
,	O
selective	O
and	O
sensitive	O
monitoring	O
of	O
Hg	O
(	O
2+	O
)	O
ion	O
in	O
environmental	O
samples	O
.	O

Graph-theoretical	O
model	O
of	O
global	O
human	O
interactome	O
reveals	O
enhanced	O
long-range	O
communicability	O
in	O
cancer	O
networks	O
.	O

Malignant	O
transformation	O
is	O
known	O
to	O
involve	O
substantial	O
rearrangement	O
of	O
the	O
molecular	O
genetic	O
landscape	O
of	O
the	O
cell	O
.	O

A	O
common	O
approach	O
to	O
analysis	O
of	O
these	O
alterations	O
is	O
a	O
reductionist	O
one	O
and	O
consists	O
of	O
finding	O
a	O
compact	O
set	O
of	O
differentially	O
expressed	O
genes	O
or	O
associated	O
signaling	O
pathways	O
.	O

However	O
,	O
due	O
to	O
intrinsic	O
tumor	O
heterogeneity	O
and	O
tissue	O
specificity	O
,	O
biomarkers	O
defined	O
by	O
a	O
small	O
number	O
of	O
genes	O
/	O
pathways	O
exhibit	O
substantial	O
variability	O
.	O

As	O
an	O
alternative	O
to	O
compact	O
differential	O
signatures	O
,	O
global	O
features	O
of	O
genetic	O
cell	O
machinery	O
are	O
conceivable	O
.	O

Global	O
network	O
descriptors	O
suggested	O
in	O
previous	O
works	O
are	O
,	O
however	O
,	O
known	O
to	O
potentially	O
be	O
biased	O
by	O
overrepresentation	O
of	O
interactions	O
between	O
frequently	O
studied	O
genes	O
-	O
proteins	O
.	O

Here	O
,	O
we	O
construct	O
a	O
cellular	O
network	O
of	O
74538	O
directional	O
and	O
differential	O
gene	O
expression	O
weighted	O
protein-protein	O
and	O
gene	O
regulatory	O
interactions	O
,	O
and	O
perform	O
graph-theoretical	O
analysis	O
of	O
global	O
human	O
interactome	O
using	O
a	O
novel	O
,	O
degree-independent	O
feature-the	O
normalized	O
total	O
communicability	O
(	O
NTC	O
)	O
.	O

We	O
apply	O
this	O
framework	O
to	O
assess	O
differences	O
in	O
total	O
information	O
flow	O
between	O
different	O
cancer	O
(	O
BRCA	O
/	O
COAD	O
/	O
GBM	O
)	O
and	O
non-cancer	O
interactomes	O
.	O

Our	O
experimental	O
results	O
reveal	O
that	O
different	O
cancer	O
interactomes	O
are	O
characterized	O
by	O
significant	O
enhancement	O
of	O
long-range	O
NTC	O
,	O
which	O
arises	O
from	O
circulation	O
of	O
information	O
flow	O
within	O
robustly	O
organized	O
gene	O
subnetworks	O
.	O

Although	O
enhancement	O
of	O
NTC	O
emerges	O
in	O
different	O
cancer	O
types	O
from	O
different	O
genomic	B-P
profiles	I-P
,	O
we	O
identified	O
a	O
subset	O
of	O
90	O
common	O
genes	O
that	O
are	O
related	O
to	O
elevated	O
NTC	O
in	O
all	O
studied	O
tumors	O
.	O

Our	O
ontological	O
analysis	O
shows	O
that	O
these	O
genes	O
are	O
associated	O
with	O
enhanced	O
cell	O
division	O
,	O
DNA	O
replication	O
,	O
stress	O
response	O
,	O
and	O
other	O
cellular	O
functions	O
and	O
processes	O
typically	O
upregulated	O
in	O
cancer	O
.	O

We	O
conclude	O
that	O
enhancement	O
of	O
long-range	O
NTC	O
manifested	O
in	O
the	O
correlated	O
activity	O
of	O
genes	O
whose	O
tight	O
coordination	O
is	O
required	O
for	O
survival	O
and	O
proliferation	O
of	O
all	O
tumor	O
cells	O
,	O
and	O
,	O
thus	O
,	O
can	O
be	O
seen	O
as	O
a	O
graph-theoretical	O
equivalent	O
to	O
some	O
hallmarks	O
of	O
cancer	O
.	O

The	O
computational	O
framework	O
for	O
differential	O
network	O
analysis	O
presented	O
herein	O
is	O
of	O
potential	O
interest	O
for	O
a	O
wide	O
range	O
of	O
network	O
perturbation	O
problems	O
given	O
by	O
single	O
or	O
multiple	O
gene-protein	O
activation-inhibition	O
.	O

Molecular	O
detection	O
of	O
infection	O
homogeneity	O
and	O
impact	O
of	O
miltefosine	O
treatment	O
in	O
a	O
Syrian	O
golden	O
hamster	O
model	O
of	O
Leishmania	O
donovani	O
and	O
L.	O
infantum	O
visceral	O
leishmaniasis	O
.	O

Control	O
of	O
visceral	O
leishmaniasis	O
caused	O
by	O
Leishmania	O
infantum	O
and	O
Leishmania	O
donovani	O
primarily	O
relies	O
on	O
chemotherapy	O
using	O
an	O
increasingly	O
compromised	O
repertoire	O
of	O
antileishmanial	O
compounds	O
.	O

For	O
evaluation	O
of	O
novel	O
drugs	O
,	O
the	O
Syrian	O
golden	O
hamster	O
is	O
considered	O
as	O
a	O
clinically	O
relevant	O
laboratory	O
model	O
.	O

In	O
this	O
study	O
,	O
two	O
molecular	B-P
parasite	I-P
detection	I-P
assays	I-P
were	O
developed	O
targeting	O
cathepsin-like	O
cysteine	O
protease	O
B	O
(	O
CPB	O
)	O
DNA	O
and	O
18S	O
rRNA	O
to	O
achieve	O
absolute	O
amastigote	O
quantification	O
in	O
the	O
major	O
target	O
organs	O
liver	O
and	O
spleen	O
.	O

Both	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
techniques	O
showed	O
excellent	O
agreement	O
with	O
a	O
strong	O
correlation	O
with	O
the	O
conventional	O
microscopic	B-P
reading	I-P
of	O
Giemsa-stained	B-P
tissue	O
smears	B-P
.	O

Using	O
multiple	O
single	O
tissue	O
pieces	O
and	O
all	O
three	O
detection	O
methods	O
,	O
we	O
confirmed	O
homogeneity	O
of	O
infection	O
in	O
liver	O
and	O
spleen	O
and	O
the	O
robustness	O
of	O
extrapolating	O
whole	O
organ	O
burdens	O
from	O
a	O
small	O
single	O
tissue	O
piece	O
.	O

Comparison	O
of	O
pre	O
-	O
and	O
post-treatment	O
burdens	O
in	O
infected	O
hamsters	O
using	O
the	O
three	O
detection	O
methods	O
consistently	O
revealed	O
a	O
stronger	O
parasite	O
reduction	O
in	O
the	O
spleen	O
compared	O
to	O
the	O
liver	O
,	O
indicating	O
an	O
organ	O
-	O
dependent	O
clearance	O
efficacy	O
for	O
miltefosine	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
in	O
the	O
hamster	O
demonstrated	O
high	O
homogeneity	O
of	O
infection	O
in	O
liver	O
and	O
spleen	O
and	O
advocates	O
the	O
use	O
of	O
molecular	O
detection	O
methods	O
for	O
assessment	O
of	O
low	O
(	O
post-treatment	O
)	O
tissue	O
burdens	O
.	O

Development	O
of	O
the	O
four-item	O
Letter	O
and	O
Shape	O
Drawing	O
test	O
(	O
LSD-4	O
)	O
:	O
A	O
brief	O
bedside	B-P
test	I-P
of	O
visuospatial	O
function	O
.	O

Conventional	O
bedside	B-P
tests	I-P
of	O
visuospatial	O
function	O
such	O
as	O
the	O
Clock	O
Drawing	O
(	O
CDT	O
)	O
and	O
Intersecting	O
Pentagons	O
(	O
IPT	O
)	O
lack	O
consistency	O
in	O
delivery	O
and	O
interpretation	O
.	O

We	O
compared	O
performance	O
on	O
a	O
novel	O
test	O
of	O
visuospatial	O
ability	O
-	O
the	O
LSD	O
-	O
with	O
the	O
IPT	O
,	O
CDT	O
and	O
MMSE	B-P
in	O
180	O
acute	O
elderly	O
medical	O
inpatients	O
[	O
mean	O
age	O
79.7Â±7.1	O
(	O
range	O
62-96	O
)	O
;	O
91	O
females	O
(	O
50.6	O
%	O
)	O
]	O
.	O

124	O
(	O
69	O
%	O
)	O
scored	O
â¤23	O
on	O
the	O
MMSE	B-P
;	O
60	O
with	O
mild	O
(	O
score	O
18-23	O
)	O
and	O
64	O
with	O
severe	O
(	O
score	O
â¤17	O
)	O
impairment	O
.	O

78	O
(	O
43	O
%	O
)	O
scored	O
â¥6	O
on	O
the	O
CDT	O
,	O
while	O
for	O
the	O
IPT	O
,	O
87	O
(	O
47	O
%	O
)	O
scored	O
â¥4	O
.	O

The	O
CDT	O
and	O
IPT	O
agreed	O
on	O
the	O
classification	O
of	O
138	O
patients	O
(	O
77	O
%	O
)	O
with	O
modest-	O
strong	O
agreement	O
with	O
the	O
MMSE	B-P
categories	O
.	O

Correlation	O
between	O
the	O
LSD	O
and	O
visuospatial	O
tests	O
was	O
high	O
.	O

A	O
four-item	O
version	O
of	O
the	O
LSD	O
incorporating	O
items	O
1,10,12,15	O
had	O
high	O
correlation	O
with	O
the	O
LSD-15	O
and	O
strong	O
association	O
with	O
MMSE	B-P
categories	O
.	O

The	O
LSD-4	O
provides	O
a	O
brief	O
and	O
easily	O
interpreted	O
bedside	B-P
test	I-P
of	O
visuospatial	O
function	O
that	O
has	O
high	O
coverage	O
of	O
elderly	O
patients	O
with	O
neurocognitive	O
impairment	O
,	O
good	O
agreement	O
with	O
conventional	O
tests	O
of	O
visuospatial	O
ability	O
and	O
favourable	O
ability	O
to	O
identify	O
significant	O
cognitive	O
impairment	O
.	O

[	O
181	O
words	O
]	O
.	O

The	O
Iboga	O
Alkaloids	O
.	O

Iboga	O
alkaloids	O
are	O
a	O
particular	O
class	O
of	O
indolomonoterpenes	O
most	O
often	O
characterized	O
by	O
an	O
isoquinuclidine	O
nucleus	O
.	O

Their	O
first	O
occurrence	O
was	O
detected	O
in	O
the	O
roots	O
of	O
Tabernanthe	O
iboga	O
,	O
a	O
sacred	O
plant	O
to	O
the	O
people	O
of	O
Gabon	O
,	O
which	O
made	O
it	O
cult	O
object	O
.	O

Ibogaine	O
is	O
the	O
main	O
representative	O
of	O
this	O
class	O
of	O
alkaloids	O
and	O
its	O
psychoactive	O
properties	O
are	O
well	O
documented	O
.	O

It	O
has	O
been	O
proposed	O
as	O
a	O
drug	O
cessation	O
treatment	O
and	O
has	O
a	O
wide	O
range	O
of	O
activities	O
in	O
targeting	O
opioids	O
,	O
cocaine	O
,	O
and	O
alcohol	O
.	O

The	O
purpose	O
of	O
this	O
chapter	O
is	O
to	O
provide	O
a	O
background	O
on	O
this	O
molecule	O
and	O
related	O
compounds	O
and	O
to	O
update	O
knowledge	O
on	O
the	O
most	O
recent	O
advances	O
made	O
.	O

Difficulties	O
linked	O
to	O
the	O
status	O
of	O
ibogaine	O
as	O
a	O
drug	O
in	O
several	O
countries	O
have	O
hampered	O
its	O
development	O
,	O
but	O
18-methoxycoronaridine	O
is	O
currently	O
under	O
evaluation	O
for	O
the	O
same	O
purposes	O
and	O
for	O
the	O
treatment	O
of	O
leishmaniasis	O
.	O

The	O
chapter	O
is	O
divided	O
into	O
six	O
parts	O
:	O
an	O
introduction	O
aiming	O
at	O
defining	O
what	O
is	O
called	O
an	O
iboga	O
alkaloid	O
,	O
and	O
this	O
is	O
followed	O
by	O
current	O
knowledge	O
on	O
their	O
biosynthesis	O
,	O
which	O
unfortunately	O
remains	O
a	O
``	O
black	O
box	O
``	O
as	O
far	O
as	O
the	O
key	O
construction	O
step	O
is	O
concerned	O
.	O

Many	O
of	O
these	O
alkaloids	O
are	O
still	O
being	O
discovered	O
and	O
the	O
third	O
and	O
fourth	O
parts	O
of	O
the	O
chapter	O
discuss	O
the	O
analytical	O
tools	O
in	O
use	O
for	O
this	O
purpose	O
and	O
give	O
lists	O
of	O
new	O
monomeric	O
and	O
dimeric	O
alkaloids	O
belonging	O
to	O
this	O
class	O
.	O

When	O
necessary	O
,	O
the	O
structures	O
are	O
discussed	O
especially	O
with	O
regard	O
to	O
absolute	O
configuration	O
determinations	B-P
,	O
which	O
remain	O
a	O
point	O
of	O
weakness	O
in	O
their	O
assignments	O
.	O

Part	O
V	O
gives	O
an	O
account	O
of	O
progress	O
made	O
in	O
the	O
synthesis	O
,	O
partial	O
and	O
total	O
,	O
which	O
the	O
authors	O
believe	O
is	O
key	O
to	O
providing	O
solid	O
solutions	O
to	O
the	O
industrial	O
development	O
of	O
the	O
most	O
promising	O
molecules	O
.	O

The	O
last	O
part	O
of	O
the	O
chapter	O
is	O
devoted	O
to	O
the	O
biological	O
properties	O
of	O
iboga	O
alkaloids	O
,	O
with	O
particular	O
emphasis	O
on	O
ibogaine	O
and	O
18-methoxycoronaridine	O
.	O

Laparascopic	O
Splenectomy	O
Due	O
to	O
Splenic	O
Injury	O
after	O
Colonoscopy	B-P
.	O

Colonoscopy	B-P
,	O
which	O
is	O
routinely	O
performed	O
in	O
diagnosis	O
and	O
treatment	O
of	O
colorectal	O
disorders	O
,	O
is	O
a	O
reliable	O
procedure	O
.	O

Its	O
most	O
frequent	O
complications	O
are	O
bleeding	O
and	O
perforation	O
.	O

Splenic	O
rupture	O
is	O
a	O
very	O
rarely	O
met	O
complication	O
of	O
colonoscopy	B-P
,	O
and	O
delay	O
in	O
its	O
diagnosis	O
leads	O
to	O
increased	O
morbidity	O
and	O
mortality	O
.	O

We	O
presented	O
a	O
69	O
years	O
old	O
female	O
patient	O
,	O
who	O
was	O
diagnosed	O
by	O
computerized	B-P
abdominal	I-P
tomography	I-P
,	O
performed	O
for	O
her	O
abdominal	O
pain	O
,	O
which	O
started	O
following	O
the	O
colonoscopy	B-P
.	O

After	O
15	O
days	O
of	O
medical	O
treatment	O
and	O
follow-up	O
,	O
laparoscopic	O
splenectomy	O
was	O
performed	O
one	O
month	O
after	O
her	O
colonoscopy	B-P
.	O

The	O
patient	O
was	O
discharged	O
on	O
her	O
4	O
(	O
th	O
)	O
postoperative	O
day	O
,	O
with	O
uneventful	O
recovery	O
.	O

In	O
patients	O
who	O
have	O
complaint	O
of	O
abdominal	O
pain	O
following	O
colonoscopy	B-P
,	O
an	O
intraabdominal	O
pathological	O
condition	O
should	O
be	O
considered	O
and	O
computerized	B-P
abdominal	I-P
tomography	I-P
should	O
be	O
performed	O
.	O

If	O
there	O
is	O
no	O
detected	O
intraperitoneal	O
bleeding	O
,	O
in	O
other	O
words	O
,	O
if	O
there	O
is	O
a	O
sub-capsular	O
hematoma	O
of	O
the	O
spleen	O
,	O
medical	O
management	O
by	O
monitoring	O
the	O
vital	O
signs	O
may	O
be	O
preferred	O
.	O

Then	O
,	O
splenectomy	O
should	O
be	O
performed	O
at	O
an	O
appropriate	O
time	O
.	O

Cocaine	O
Use	O
Reverses	O
Striatal	O
Plasticity	O
Produced	O
During	O
Cocaine	O
Seeking	O
.	O

Relapse	O
is	O
a	O
two	O
-	O
component	O
process	O
consisting	O
of	O
a	O
highly	O
motivated	O
drug-seeking	O
phase	O
that	O
,	O
if	O
successful	O
,	O
is	O
followed	O
by	O
a	O
drug-using	O
phase	O
resulting	O
in	O
temporary	O
satiation	O
.	O

In	O
rodents	O
,	O
cue-induced	O
drug	O
seeking	O
requires	O
transient	O
synaptic	O
potentiation	O
(	O
t-SP	O
)	O
of	O
cortical	O
glutamatergic	O
synapses	O
on	O
nucleus	O
accumbens	O
core	O
medium	O
spiny	O
neurons	O
,	O
but	O
it	O
is	O
unknown	O
how	O
achieving	O
drug	O
use	O
affects	O
this	O
plasticity	O
.	O

We	O
modeled	O
the	O
two	O
phases	O
of	O
relapse	O
after	O
extinction	O
from	O
cocaine	O
self-administration	O
to	O
assess	O
how	O
cocaine	O
use	O
affects	O
t-SP	O
associated	O
with	O
cue-induced	O
drug	O
seeking	O
.	O

Rats	O
were	O
trained	O
to	O
self-administer	O
cocaine	O
(	O
n	O
=	O
96	O
)	O
or	O
were	O
used	O
as	O
yoked	O
-	O
saline	O
control	O
animals	O
(	O
n	O
=	O
21	O
)	O
.	O

After	O
extinction	O
,	O
reinstatement	O
was	O
initiated	O
by	O
10	O
minutes	O
of	O
cue-induced	O
drug	O
seeking	O
,	O
followed	O
by	O
45	O
minutes	O
with	O
contingent	O
cocaine	O
access	O
,	O
after	O
which	O
cocaine	O
was	O
discontinued	O
and	O
unreinforced	O
lever	O
pressing	O
ensued	O
.	O

Three	O
measures	O
of	O
t-SP	O
were	O
assayed	B-P
during	O
reinstatement	O
:	O
dendritic	O
spine	O
morphology	O
,	O
alpha-amino-3-hydroxy-5-methyl-4-isoxazole	O
propionic	O
acid	O
(	O
AMPA	O
)	O
to	O
N-methyl-D-aspartate	O
(	O
NMDA	O
)	O
ratios	O
,	O
and	O
matrix	O
metalloproteinase	O
activity	O
.	O

We	O
found	O
that	O
cocaine	O
use	O
for	O
10	O
minutes	O
collapsed	O
all	O
three	O
measures	O
of	O
cue-potentiated	O
t-SP	O
back	O
to	O
baseline	O
.	O

Moreover	O
,	O
when	O
cocaine	O
use	O
was	O
discontinued	O
45	O
minutes	O
later	O
,	O
dendritic	O
spine	O
morphology	O
and	O
AMPA	O
to	O
NMDA	O
ratios	O
were	O
restored	O
as	O
animals	O
became	O
motivated	O
to	O
engage	O
unrewarded	O
lever	O
pressing	O
.	O

Nonreinforced	O
drug	O
seeking	O
was	O
positively	O
correlated	O
with	O
changes	O
in	O
spine	O
morphology	O
,	O
and	O
cocaine	O
access	O
reversed	O
this	O
relationship	O
.	O

Using	O
a	O
novel	O
modification	O
of	O
the	O
reinstatement	O
paradigm	O
,	O
we	O
show	O
that	O
achieving	O
cocaine	O
use	O
reversed	O
the	O
synaptic	O
plasticity	O
underpinning	O
the	O
motivation	O
to	O
seek	O
the	O
drug	O
.	O

Evolution	O
of	O
Cardiac	O
Biomodels	O
from	O
Computational	O
to	O
Therapeutics	O
.	O

Biomodeling	O
the	O
human	O
anatomy	O
in	O
exact	O
structure	O
and	O
size	O
is	O
an	O
exciting	O
field	O
of	O
medical	O
science	O
.	O

Utilizing	O
medical	O
data	O
from	O
various	O
medical	B-P
imaging	I-P
topography	I-P
,	O
the	O
data	O
of	O
an	O
anatomical	O
structure	O
can	O
be	O
extracted	O
and	O
converted	O
into	O
a	O
three-dimensional	O
virtual	O
biomodel	O
;	O
thereafter	O
a	O
physical	O
biomodel	O
can	O
be	O
generated	O
utilizing	O
rapid	O
prototyping	O
machines	O
.	O

Here	O
,	O
we	O
have	O
reviewed	O
the	O
utilization	O
of	O
this	O
technology	O
and	O
have	O
provided	O
some	O
guidelines	O
to	O
develop	O
biomodels	O
of	O
cardiac	O
structures	O
.	O

Cardiac	O
biomodels	O
provide	O
insights	O
for	O
cardiothoracic	O
surgeons	O
,	O
cardiologists	O
,	O
and	O
patients	O
alike	O
.	O

Additionally	O
,	O
the	O
technology	O
may	O
have	O
future	O
usability	O
for	O
tissue	O
engineering	O
,	O
robotic	O
surgery	O
,	O
or	O
routine	O
hospital	O
usage	O
as	O
a	O
diagnostic	B-P
and	I-P
therapeutic	I-P
tool	I-P
for	O
cardiovascular	O
diseases	O
(	O
CVD	O
)	O
.	O

Given	O
the	O
broad	O
areas	O
of	O
application	O
of	O
cardiac	O
biomodels	O
,	O
attention	O
should	O
be	O
given	O
to	O
further	O
research	O
and	O
development	O
of	O
their	O
potential	O
.	O

Visual	O
outcome	O
,	O
endocrine	O
function	O
and	O
tumor	O
control	O
after	O
fractionated	O
stereotactic	O
radiation	O
therapy	O
of	O
craniopharyngiomas	O
in	O
adults	O
:	O
findings	O
in	O
a	O
prospective	O
cohort	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
visual	O
outcome	O
,	O
endocrine	O
function	O
and	O
tumor	O
control	O
in	O
a	O
prospective	O
cohort	O
of	O
craniopharyngioma	O
patients	O
,	O
treated	O
with	O
fractionated	O
stereotactic	O
radiation	O
therapy	O
(	O
FSRT	O
)	O
.	O

Sixteen	O
adult	O
patients	O
with	O
craniopharyngiomas	O
were	O
eligible	O
for	O
analysis	O
.	O

They	O
were	O
treated	O
with	O
linear	O
accelerator-based	O
FSRT	O
during	O
1999-2015	O
.	O

In	O
all	O
cases	O
,	O
diagnosis	O
was	O
confirmed	O
by	O
histological	O
analysis	O
.	O

The	O
prescription	O
dose	O
to	O
the	O
tumor	O
was	O
54	O
Gy	O
(	O
median	O
,	O
range	O
48-54	O
)	O
in	O
1.8	O
or	O
2.0	O
Gy	O
per	O
fraction	O
,	O
and	O
the	O
maximum	O
radiation	O
dose	O
to	O
the	O
optic	O
nerves	O
and	O
chiasm	O
was	O
54.2	O
Gy	O
(	O
median	O
,	O
range	O
48.6-60.0	O
)	O
for	O
the	O
cohort	O
.	O

Serial	O
ophthalmological	O
and	O
endocrine	O
evaluations	O
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
scans	B-P
were	O
performed	O
at	O
regular	O
intervals	O
.	O

Median	O
follow-up	O
was	O
3.3	O
years	O
(	O
range	O
1.1-14.1	O
)	O
,	O
3.7	O
years	O
(	O
range	O
0.8-15.2	O
)	O
,	O
and	O
3.6	O
years	O
(	O
range	O
0.7-13.1	O
)	O
for	O
visual	O
outcome	O
,	O
endocrine	O
function	O
,	O
and	O
tumor	O
control	O
,	O
respectively	O
.	O

Visual	O
acuity	O
impairment	O
was	O
present	O
in	O
10	O
patients	O
(	O
62.5	O
%	O
)	O
and	O
visual	O
field	O
defects	O
were	O
present	O
in	O
12	O
patients	O
(	O
75	O
%	O
)	O
before	O
FSRT	O
.	O

One	O
patient	O
developed	O
radiation-induced	O
optic	O
neuropathy	O
at	O
seven	O
years	O
after	O
FSRT	O
.	O

Thirteen	O
of	O
16	O
patients	O
(	O
81.3	O
%	O
)	O
had	O
pituitary	O
deficiency	O
before	O
FSRT	O
,	O
and	O
did	O
not	O
develop	O
further	O
pituitary	O
deficiency	O
after	O
FSRT	O
.	O

Mean	O
tumor	O
volume	O
pre-	O
FSRT	O
was	O
2.72	O
cm	O
(	O
3	O
)	O
(	O
range	O
0.20-9.90	O
)	O
and	O
post-	O
FSRT	O
1.2	O
cm	O
(	O
3	O
)	O
(	O
range	O
0.00-13.10	O
)	O
.	O

Tumor	O
control	O
rate	O
was	O
81.3	O
%	O
at	O
two	O
,	O
five	O
,	O
and	O
10	O
years	O
after	O
FSRT	O
.	O

FSRT	O
was	O
relatively	O
safe	O
in	O
this	O
prospective	O
cohort	O
of	O
craniopharyngiomas	O
,	O
with	O
only	O
one	O
case	O
of	O
radiation-induced	O
optic	O
neuropathy	O
and	O
no	O
case	O
of	O
new	O
endocrinopathy	O
.	O

Tumor	O
control	O
rate	O
was	O
acceptable	O
.	O

Hybrid	O
automata	O
models	O
of	O
cardiac	O
ventricular	O
electrophysiology	B-P
for	O
real-time	O
computational	O
applications	O
.	O

Virtual	O
heart	O
models	O
have	O
been	O
proposed	O
for	O
closed	O
loop	O
validation	O
of	O
safety	O
-	O
critical	O
embedded	O
medical	O
devices	O
,	O
such	O
as	O
pacemakers	O
.	O

These	O
models	O
must	O
react	O
in	O
real-time	O
to	O
off-the-shelf	O
medical	O
devices	O
.	O

Real-time	O
performance	O
can	O
be	O
obtained	O
by	O
implementing	O
models	O
in	O
computer	O
hardware	O
,	O
and	O
methods	O
of	O
compiling	O
classes	O
of	O
Hybrid	O
Automata	O
(	O
HA	O
)	O
onto	O
FPGA	O
have	O
been	O
developed	O
.	O

Models	O
of	O
ventricular	O
cardiac	O
cell	O
electrophysiology	B-P
have	O
been	O
described	O
using	O
HA	O
which	O
capture	O
the	O
complex	O
nonlinear	O
behavior	O
of	O
biological	O
systems	O
.	O

However	O
,	O
many	O
models	O
that	O
have	O
been	O
used	O
for	O
closed-loop	O
validation	O
of	O
pacemakers	O
are	O
highly	O
abstract	O
and	O
do	O
not	O
capture	O
important	O
characteristics	O
of	O
the	O
dynamic	O
rate	O
response	O
.	O

We	O
developed	O
a	O
new	O
HA	O
model	O
of	O
cardiac	O
cells	O
which	O
captures	O
dynamic	O
behavior	O
and	O
we	O
implemented	O
the	O
model	O
in	O
hardware	O
.	O

This	O
potentially	O
enables	O
modeling	O
the	O
heart	O
with	O
over	O
1	O
million	O
dynamic	O
cells	O
,	O
making	O
the	O
approach	O
ideal	O
for	O
closed	O
loop	O
testing	O
of	O
medical	O
devices	O
.	O

Diagnostic	O
Yield	O
of	O
Routine	O
Stress	B-P
Testing	I-P
in	O
Low	O
and	O
Intermediate	O
Risk	O
Chest	O
Pain	O
Patients	O
Under	O
40	O
Years	O
:	O
A	O
Systematic	O
Review	O
.	O

Chest	O
pain	O
is	O
one	O
of	O
the	O
most	O
frequent	O
causes	O
for	O
presentation	O
to	O
emergency	O
departments	O
(	O
EDs	O
)	O
.	O

The	O
majority	O
of	O
patients	O
will	O
undergo	O
diagnostic	B-P
workup	I-P
including	O
stress	B-P
testing	I-P
to	O
rule	O
out	O
an	O
acute	O
coronary	O
syndrome	O
,	O
but	O
very	O
few	O
patients	O
will	O
be	O
diagnosed	O
with	O
a	O
cardiac	O
cause	O
for	O
their	O
pain	O
.	O

Patients	O
under	O
40	O
years	O
represent	O
a	O
lower	O
risk	O
group	O
in	O
which	O
routine	O
stress	B-P
testing	I-P
may	O
be	O
of	O
little	O
benefit	O
.	O

This	O
systematic	O
review	O
sought	O
to	O
determine	O
the	O
diagnostic	O
yield	O
of	O
routine	O
stress	B-P
testing	I-P
in	O
low	O
-	O
and	O
intermediate-risk	O
chest	O
pain	O
patients	O
under	O
40	O
years	O
.	O

Electronic	O
databases	O
were	O
searched	O
for	O
relevant	O
studies	O
.	O

The	O
quality	O
of	O
the	O
included	O
primary	O
studies	O
was	O
assessed	O
using	O
the	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
evidence	O
hierarchy	O
and	O
the	O
McMaster	O
Critical	O
Appraisal	O
Tool	O
for	O
Quantitative	O
Studies	O
.	O

Descriptive	O
statistics	O
summarized	O
the	O
findings	O
.	O

Five	O
primary	O
studies	O
were	O
included	O
in	O
the	O
review	O
(	O
all	O
level	O
III-3	O
evidence	O
)	O
;	O
7	O
additional	O
sources	O
of	O
relevant	O
data	O
were	O
also	O
included	O
.	O

Diagnostic	O
yield	O
of	O
routine	O
stress	B-P
testing	I-P
in	O
low	O
-	O
and	O
intermediate-risk	O
patients	O
under	O
40	O
years	O
is	O
reported	O
between	O
0	O
%	O
and	O
1.1	O
%	O
.	O

Combined	O
data	O
from	O
included	O
primary	O
studies	O
demonstrated	O
just	O
4	O
out	O
of	O
1683	O
true	O
positive	O
stress	B-P
tests	I-P
(	O
0.24	O
%	O
)	O
,	O
only	O
one	O
of	O
which	O
was	O
definitively	O
confirmed	O
by	O
coronary	B-P
angiogram	I-P
;	O
additional	O
data	O
sources	O
identified	O
just	O
1	O
out	O
of	O
310	O
true	O
positive	O
stress	B-P
tests	I-P
(	O
0.32	O
%	O
)	O
.	O

Diagnostic	O
yield	O
of	O
routine	O
stress	B-P
testing	I-P
in	O
low	O
-	O
and	O
intermediate-risk	O
chest	O
pain	O
patients	O
under	O
40	O
years	O
is	O
low	O
.	O

However	O
,	O
better	O
quality	O
studies	O
are	O
required	O
to	O
be	O
able	O
to	O
draw	O
definitive	O
conclusions	O
.	O

Management	O
of	O
precipitated	O
opiate	O
withdrawal	O
syndrome	O
induced	O
by	O
nalmefene	O
mistakenly	O
prescribed	O
in	O
opiate	O
-	O
dependent	O
patients	O
:	O
a	O
review	O
for	O
clinicians	O
.	O

Nalmefene	O
,	O
a	O
long-acting	O
Âµ-opioid	O
antagonist	O
approved	O
to	O
treat	O
alcohol	O
use	O
disorder	O
,	O
is	O
occasionally	O
mistakenly	O
prescribed	O
to	O
opiate	O
-	O
dependent	O
or	O
opioid	O
-	O
treated	O
patients	O
.	O

We	O
review	O
recent	O
literature	O
on	O
drug-drug	O
interactions	O
between	O
nalmefene	O
and	O
opioids	O
that	O
lead	O
to	O
precipitated	O
opioid	O
withdrawal	O
,	O
and	O
focus	O
on	O
its	O
management	O
and	O
planning	O
for	O
care	O
at	O
discharge	O
.	O

Areas	O
covered	O
:	O
This	O
article	O
provides	O
a	O
brief	O
and	O
comprehensive	O
review	O
of	O
management	O
of	O
precipitated	O
opioid	O
withdrawal	O
syndrome	O
when	O
nalmefene	O
is	O
associated	O
with	O
an	O
opioid	O
,	O
whether	O
misused	O
or	O
legally	O
prescribed	O
.	O

Expert	O
opinion	O
:	O
When	O
treating	O
an	O
opiate	O
-	O
dependent	O
patient	O
with	O
co-occurring	O
alcohol	O
use	O
disorder	O
,	O
both	O
conditions	O
need	O
to	O
be	O
a	O
focus	O
of	O
clinical	O
attention	O
.	O

New	O
drugs	O
for	O
alcohol	O
use	O
disorder	O
have	O
been	O
approved	O
,	O
but	O
must	O
be	O
given	O
cautiously	O
and	O
with	O
a	O
full	O
understanding	O
of	O
their	O
potential	O
drug-drug	O
interactions	O
with	O
opioid	O
medications	O
.	O

Opiate	O
-	O
dependent	O
patients	O
should	O
be	O
intensively	O
monitored	O
for	O
risk	O
factors	O
of	O
alcohol	O
use	O
disorder	O
and	O
should	O
be	O
continuously	O
motivated	O
for	O
treatment	O
maintenance	O
.	O

When	O
nalmefene	O
is	O
administered	O
to	O
opiate	O
-	O
dependent	O
patients	O
,	O
acute	O
opioid	O
withdrawal	O
syndrome	O
may	O
occur	O
.	O

Management	O
of	O
precipitated	O
acute	O
opioid	O
withdrawal	O
may	O
include	O
short	O
or	O
long-acting	O
Âµ-opioid	O
agonists	O
during	O
hospitalization	O
,	O
in	O
addition	O
to	O
supportive	O
treatment	O
.	O

The	O
best	O
management	O
of	O
polydrug	O
abusers	O
is	O
based	O
on	O
a	O
multidisciplinary	B-P
approach	I-P
,	O
which	O
should	O
be	O
pursued	O
and	O
improved	O
through	O
continuing	O
medical	O
education	O
.	O

Delayed	O
Axillary	O
Artery	O
Occlusion	O
after	O
Reverse	O
Total	O
Shoulder	O
Arthroplasty	O
.	O

Axillary	O
artery	O
injury	O
has	O
been	O
associated	O
with	O
shoulder	O
dislocation	O
and	O
surgery	O
.	O

We	O
describe	O
a	O
case	O
of	O
delayed	O
axillary	O
artery	O
occlusion	O
after	O
reverse	O
total	O
shoulder	O
arthroplasty	O
.	O

The	O
injury	O
was	O
confirmed	O
by	O
Doppler	B-P
and	O
angiography	B-P
and	O
was	O
treated	O
with	O
angioplasty	O
and	O
stenting	O
.	O

Early	B-P
recognition	I-P
and	O
treatment	O
of	O
this	O
injury	O
are	O
mandatory	O
for	O
patients	O
'	O
recovery	O
.	O

Extended	O
use	O
of	O
Prostate	B-P
Health	I-P
Index	I-P
and	O
percentage	O
of	O
[	O
-2	O
]	O
pro-prostate-specific	O
antigen	O
in	O
Chinese	O
men	O
with	O
prostate	O
specific	O
antigen	O
10-20	O
ng/mL	O
and	O
normal	O
digital	B-P
rectal	I-P
examination	I-P
.	O

We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate	B-P
Health	I-P
Index	I-P
(	O
PHI	B-P
)	O
and	O
percentage	O
of	O
[	O
-2	O
]	O
pro-prostate-specific	O
antigen	O
(	O
%	O
p2PSA	O
)	O
in	O
Chinese	O
men	O
with	O
prostate-specific	O
antigen	O
(	O
PSA	O
)	O
10-20	O
ng/mL	O
and	O
normal	O
digital	B-P
rectal	I-P
examination	I-P
(	O
DRE	B-P
)	O
.	O

All	O
consecutive	O
Chinese	O
men	O
with	O
PSA	O
10-20	O
ng/mL	O
and	O
normal	O
DRE	B-P
who	O
agreed	O
for	O
transrectal	B-P
ultrasound	I-P
(	O
TRUS	B-P
)	O
-guided	O
10-core	O
prostate	B-P
biopsy	I-P
were	O
recruited	O
.	O

Blood	O
samples	O
were	O
taken	O
immediately	O
before	O
TRUS	B-P
-guided	O
prostate	B-P
biopsy	I-P
.	O

The	O
performances	O
of	O
total	B-P
PSA	I-P
(	O
tPSA	B-P
)	O
,	O
%	O
free-to-total	B-P
PSA	I-P
(	O
%	O
fPSA	B-P
)	O
,	O
%	O
p2PSA	O
,	O
and	O
PHI	B-P
were	O
compared	O
using	O
logistic	O
regression	O
,	O
receiver	O
operating	O
characteristic	O
,	O
and	O
decision	O
curve	O
analyses	O
(	O
DCA	O
)	O
.	O

From	O
2008	O
to	O
2015	O
,	O
312	O
consecutive	O
Chinese	O
men	O
were	O
included	O
.	O

Among	O
them	O
,	O
53	O
out	O
of	O
312	O
(	O
17.0	O
%	O
)	O
men	O
were	O
diagnosed	O
to	O
have	O
prostate	O
cancer	O
on	O
biopsy	B-P
.	O

The	O
proportions	O
of	O
men	O
with	O
positive	O
biopsies	B-P
were	O
6.7	O
%	O
in	O
PHI	B-P
<	O
35	O
,	O
22.8	O
%	O
in	O
PHI	B-P
35-55	O
,	O
and	O
54.5	O
%	O
in	O
PHI	B-P
>	O
55	O
(	O
chi-square	O
test	O
,	O
p	O
<	O
0.001	O
)	O
.	O

The	O
area	O
under	O
curves	O
(	O
AUC	O
)	O
of	O
the	O
base	O
model	O
including	O
age	O
,	O
tPSA	B-P
and	O
status	O
of	O
initial/repeated	O
biopsy	B-P
was	O
0.64	O
.	O

Adding	O
%	O
p2PSA	O
and	O
PHI	B-P
to	O
the	O
base	O
model	O
improved	O
the	O
AUC	O
to	O
0.79	O
(	O
p	O
<	O
0.001	O
)	O
and	O
0.78	O
(	O
p	O
<	O
0.001	O
)	O
,	O
respectively	O
,	O
and	O
provided	O
net	O
clinical	O
benefit	O
in	O
DCA	O
.	O

The	O
positive	O
biopsy	B-P
rates	O
of	O
Gleason	O
7	O
or	O
above	O
prostate	O
cancers	O
were	O
2.2	O
%	O
for	O
PHI	B-P
<	O
35	O
,	O
7.9	O
%	O
for	O
PHI	B-P
35-55	O
,	O
and	O
36.4	O
%	O
for	O
PHI	B-P
>	O
55	O
(	O
chi-square	O
test	O
,	O
p	O
<	O
0.001	O
)	O
.	O

By	O
utilizing	O
the	O
PHI	B-P
cutoff	O
of	O
35	O
to	O
men	O
with	O
PSA	O
10-20	O
ng/mL	O
and	O
normal	O
DRE	B-P
,	O
57.1	O
%	O
(	O
178	O
of	O
312	O
)	O
biopsies	B-P
could	O
be	O
avoided	O
.	O

Both	O
PHI	B-P
and	O
%	O
p2PSA	O
performed	O
well	O
in	O
predicting	O
prostate	O
cancer	O
and	O
high	O
grade	O
prostate	O
cancer	O
.	O

The	O
use	O
of	O
PHI	B-P
and	O
%	O
p2PSA	O
should	O
be	O
extended	O
to	O
Chinese	O
men	O
with	O
PSA	O
10-20	O
ng/mL	O
and	O
normal	O
DRE	B-P
.	O

Hippocampal	O
and	O
Deep	O
Gray	O
Matter	O
Nuclei	O
Atrophy	O
Is	O
Relevant	O
for	O
Explaining	O
Cognitive	O
Impairment	O
in	O
MS	O
:	O
A	O
Multicenter	O
Study	O
.	O

The	O
structural	B-P
MR	I-P
imaging	I-P
correlates	O
of	O
cognitive	O
impairment	O
in	O
multiple	O
sclerosis	O
are	O
still	O
debated	O
.	O

This	O
study	O
assessed	O
lesional	O
and	O
atrophy	O
measures	O
of	O
white	O
matter	O
and	O
gray	O
matter	O
involvement	O
in	O
patients	O
with	O
MS	O
acquired	O
in	O
7	O
European	O
sites	O
to	O
identify	O
the	O
MR	B-P
imaging	I-P
variables	O
most	O
closely	O
associated	O
with	O
cognitive	O
dysfunction	O
.	O

Brain	O
dual-echo	B-P
,	O
3D	B-P
T1-weighted	I-P
,	O
and	O
double	B-P
inversion	I-P
recovery	I-P
scans	I-P
were	O
acquired	O
at	O
3T	B-P
from	O
62	O
patients	O
with	O
relapsing-remitting	O
MS	O
and	O
65	O
controls	O
.	O

Patients	O
with	O
at	O
least	O
2	O
neuropsychological	B-P
tests	I-P
with	O
abnormal	O
findings	O
were	O
considered	O
cognitively	O
impaired	O
.	O

Focal	O
WM	O
and	O
cortical	O
lesions	O
were	O
identified	O
,	O
and	O
volumetric	O
measures	O
from	O
WM	O
,	O
cortical	O
GM	O
,	O
the	O
hippocampus	O
,	O
and	O
deep	O
GM	O
nuclei	O
were	O
obtained	O
.	O

Age	O
-	O
and	O
site	O
-adjusted	O
models	O
were	O
used	O
to	O
compare	O
lesion	O
and	O
volumetric	O
MR	B-P
imaging	I-P
variables	O
between	O
patients	O
with	O
MS	O
who	O
were	O
cognitively	O
impaired	O
and	O
cognitively	O
preserved	O
.	O

A	O
multivariate	O
analysis	O
identified	O
MR	B-P
imaging	I-P
variables	O
associated	O
with	O
cognitive	O
scores	O
and	O
disability	O
.	O

Twenty-three	O
patients	O
(	O
38	O
%	O
)	O
were	O
cognitively	O
impaired	O
.	O

Compared	O
with	O
those	O
with	O
who	O
were	O
cognitively	O
preserved	O
,	O
patients	O
with	O
MS	O
with	O
cognitive	O
impairment	O
had	O
higher	O
T2	B-P
and	O
T1	B-P
lesion	O
volumes	O
and	O
a	O
trend	O
toward	O
a	O
higher	O
number	O
of	O
cortical	O
lesions	O
.	O

Significant	O
brain	O
,	O
cortical	O
GM	O
,	O
hippocampal	O
,	O
deep	O
GM	O
nuclei	O
,	O
and	O
WM	O
atrophy	O
was	O
found	O
in	O
patients	O
with	O
MS	O
with	O
cognitive	O
impairment	O
versus	O
those	O
who	O
were	O
cognitively	O
preserved	O
.	O

Hippocampal	O
and	O
deep	O
GM	O
nuclei	O
atrophy	O
were	O
the	O
best	O
predictors	O
of	O
cognitive	O
impairment	O
,	O
while	O
WM	O
atrophy	O
was	O
the	O
best	O
predictor	O
of	O
disability	O
.	O

Hippocampal	O
and	O
deep	O
GM	O
nuclei	O
atrophy	O
are	O
key	O
factors	O
associated	O
with	O
cognitive	O
impairment	O
in	O
MS	O
.	O

These	O
MR	B-P
imaging	I-P
measures	O
could	O
be	O
applied	O
in	O
a	O
multicenter	O
context	O
,	O
with	O
cognition	O
as	O
clinical	O
outcome	O
.	O

Sleep	O
Quantity	O
and	O
Quality	O
during	O
Acute	O
Concussion	O
:	O
A	O
Pilot	O
Study	O
.	O

A	O
number	O
of	O
subjective	O
and	O
objective	O
studies	O
provide	O
compelling	O
evidence	O
of	O
chronic	O
post-concussion	O
changes	O
in	O
sleep	O
,	O
yet	O
very	O
little	O
is	O
known	O
about	O
the	O
acute	O
effects	O
of	O
concussion	O
on	O
sleep	O
quality	O
and	O
quantity	O
.	O

Therefore	O
,	O
the	O
purpose	O
of	O
this	O
prospective	O
pilot	O
study	O
was	O
to	O
use	O
actigraphy	B-P
to	O
examine	O
the	O
changes	O
in	O
sleep	O
quality	O
and	O
quantity	O
acutely	O
following	O
concussion	O
at	O
home	O
rather	O
than	O
in	O
a	O
hospital	O
or	O
sleep	O
laboratory	O
.	O

Seventeen	O
young	O
adults	O
(	O
7	O
with	O
acute	O
concussion	O
,	O
10	O
controls	O
)	O
were	O
recruited	O
for	O
this	O
study	O
.	O

All	O
participants	O
completed	O
two	O
5-	O
day	O
testing	O
sessions	O
separated	O
by	O
30	O
days	O
from	O
intake	O
(	O
controls	O
)	O
or	O
day	O
of	O
injury	O
(	O
concussion	O
)	O
.	O

Participants	O
wore	O
actigraphs	O
and	O
kept	O
a	O
sleep	O
journal	O
.	O

Sleep	O
parameter	O
outcomes	O
included	O
nighttime	O
total	O
sleep	O
time	O
(	O
nTST	O
)	O
,	O
24-	O
h	O
total	O
sleep	O
time	O
(	O
TST	O
)	O
,	O
wake	O
after	O
sleep	O
onset	O
(	O
WASO	O
)	O
,	O
and	O
sleep	O
efficiency	O
(	O
SE	O
)	O
.	O

The	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
for	O
each	O
sleep	O
parameter	O
was	O
computed	B-P
for	O
each	O
session	O
.	O

nTST	O
and	O
TST	O
CV	O
was	O
significantly	O
greater	O
in	O
the	O
concussion	O
group	O
.	O

There	O
is	O
the	O
additional	O
indication	O
that	O
individuals	O
with	O
a	O
concussion	O
may	O
require	O
and	O
obtain	O
more	O
sleep	O
shortly	O
after	O
injury	O
and	O
subsequently	O
have	O
a	O
shorter	O
duration	O
of	O
sleep	O
at	O
1	O
mo	O
post-injury	O
.	O

This	O
pattern	O
was	O
not	O
seen	O
in	O
the	O
measures	O
of	O
sleep	O
quality	O
(	O
WASO	O
,	O
SE	O
)	O
.	O

Individuals	O
with	O
a	O
concussion	O
demonstrated	O
increased	O
nighttime	O
sleep	O
duration	O
variability	O
.	O

This	O
increase	O
persisted	O
at	O
1	O
mo	O
post-injury	O
and	O
may	O
be	O
associated	O
with	O
previously	O
documented	O
self-reports	O
of	O
poor	O
sleep	O
quality	O
lasting	O
months	O
and	O
years	O
after	O
a	O
concussion	O
.	O

Additionally	O
,	O
this	O
increase	O
may	O
predispose	O
individuals	O
to	O
numerous	O
negative	O
health	O
outcomes	O
if	O
left	O
untreated	O
.	O

Effects	O
of	O
diacetyl-liensinine	O
on	O
electrophysiology	B-P
in	O
rabbit	O
ventricular	O
myocytes	O
.	O

Diacetyl-liensinine	O
is	O
a	O
chemosynthetic	O
derivative	O
of	O
liensinine	O
,	O
extracted	O
from	O
the	O
seed	O
embryo	O
of	O
Nelumbo	O
nucifera	O
Gaertn	O
,	O
in	O
China	O
.	O

It	O
has	O
been	O
found	O
to	O
have	O
extensive	O
anti-	O
arrhythmic	O
actions	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effects	O
of	O
diacetyl-liensinine	O
on	O
electro-	B-P
physiology	I-P
of	O
myocytes	O
.	O

We	O
exposed	O
rabbit	O
ventricular	O
myocytes	O
to	O
diacetyl-liensinine	O
using	O
standard	O
whole-cell	O
patch-clamp	O
technique	O
and	O
measured	O
the	O
action	O
potential	O
,	O
L-type	O
calcium	O
current	O
(	O
I	O
Ca-L	O
)	O
,	O
delayed	O
rectifier	O
potassium	O
current	O
(	O
I	O
K	O
)	O
,	O
transient	O
outward	O
potassium	O
current	O
(	O
I	O
to	O
)	O
and	O
inward	O
rectifier	O
potassium	O
current	O
(	O
I	O
K1	O
)	O
.	O

Our	O
results	O
showed	O
that	O
diacetyl-liensinine	O
significantly	O
prolonged	O
action	O
potential	O
duration	O
at	O
50	O
and	O
90	O
%	O
repolarization	O
(	O
APD50	O
,	O
APD90	O
)	O
,	O
at	O
10	O
and	O
30	O
Î¼M	O
,	O
while	O
shortened	O
APD50	O
and	O
APD90	O
at	O
100	O
Î¼M	O
.	O

In	O
addition	O
,	O
diacetyl-liensinine	O
inhibited	O
the	O
ICa-L	O
,	O
IK	O
,	O
I	O
to	O
and	O
IK1	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

The	O
results	O
suggest	O
that	O
diacetyl-liensinine	O
might	O
be	O
a	O
potential	O
anti-arrhythmic	O
agent	O
.	O

Aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
rs2066853	O
gene	O
polymorphism	O
association	O
with	O
infertile	O
oligoasthenoteratozoospermic	O
men	O
and	O
seminal	O
oxidative	O
stress	O
.	O

This	O
study	O
aimed	O
to	O
assess	O
the	O
association	O
between	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
rs2066853	O
gene	O
polymorphism	O
with	O
infertile	O
oligoasthenoteratozoospermic	O
(	O
OAT	O
)	O
men	O
and	O
seminal	O
oxidative	O
stress	O
(	O
OS	O
)	O
.	O

A	O
total	O
of	O
170	O
Egyptian	O
men	O
were	O
allocated	O
according	O
to	O
their	O
semen	B-P
analysis	I-P
into	O
fertile	O
normozoospermic	O
controls	O
(	O
n	O
=	O
50	O
)	O
and	O
infertile	O
OAT	O
men	O
(	O
n	O
=	O
120	O
)	O
.	O

They	O
were	O
subjected	O
to	O
history	O
taking	O
,	O
clinical	O
examination	O
,	O
semen	B-P
analysis	I-P
,	O
estimation	O
of	O
seminal	O
glutathione	O
peroxidase	O
(	O
GPx	O
)	O
,	O
and	O
malondialdehyde	O
(	O
MDA	O
)	O
.	O

AhR	O
rs2066853	O
gene	O
polymorphism	O
was	O
identified	O
in	O
the	O
blood	O
by	O
PCR	O
-	O
RFLP	O
.	O

Comparing	O
infertile	O
OAT	O
men	O
with	O
fertile	O
controls	O
,	O
AhR	O
rs2066853	O
genotypes	O
showed	O
decreased	O
prevalence	O
for	O
wild	O
homozygous	O
genotype	O
GG	O
(	O
35.8	O
vs	O
56	O
%	O
)	O
and	O
for	O
heterozygous	O
genotype	O
GA	O
(	O
17.5	O
vs	O
30	O
%	O
)	O
and	O
an	O
increased	O
prevalence	O
for	O
homozygous	O
genotype	O
AA	O
(	O
46.7	O
vs	O
14	O
%	O
)	O
.	O

Distribution	O
of	O
alleles	O
of	O
AhR	O
rs2066853	O
among	O
OAT	O
men	O
compared	O
with	O
fertile	O
men	O
showed	O
decreased	O
prevalence	O
of	O
G	O
allele	O
(	O
44.6	O
vs	O
71	O
%	O
)	O
and	O
an	O
increased	O
prevalence	O
of	O
A	O
allele	O
(	O
55.4	O
vs	O
29	O
%	O
)	O
.	O

Seminal	O
MDA	O
demonstrated	O
significant	O
increase	O
whereas	O
seminal	O
GPx	O
demonstrated	O
significant	O
decrease	O
in	O
cases	O
with	O
AA	O
and	O
GA	O
/	O
AA	O
genotypes	O
compared	O
to	O
cases	O
with	O
GG	O
genotype	O
.	O

It	O
is	O
concluded	O
that	O
there	O
is	O
a	O
significant	O
association	O
between	O
AhR	O
rs2066853	O
genotype	O
polymorphism	O
with	O
decreased	O
sperm	O
parameters	O
as	O
well	O
as	O
increased	O
seminal	O
oxidative	O
stress	O
in	O
infertile	O
OAT	O
men	O
.	O

Value	O
of	O
MDM2	O
,	O
CDK4	O
and	O
SATB2	O
immunohistochemistry	B-P
in	O
histologic	O
diagnosis	O
of	O
low-grade	O
osteosarcoma	O
.	O

To	O
investigate	O
the	O
value	O
of	O
combined	O
application	O
of	O
MDM2	O
,	O
CDK4	O
and	O
SATB2	O
immunohistochemistry	B-P
in	O
pathological	O
diagnosis	O
of	O
low-grade	O
osteosarcoma	O
.	O

Forty-seven	O
cases	O
of	O
low	O
grade	O
osteosarcoma	O
,	O
including	O
low	O
grade	O
central	O
osteosarcoma	O
(	O
n=20	O
)	O
and	O
parosteal	O
osteosarcoma	O
(	O
n=27	O
)	O
,	O
were	O
selected	O
from	O
Shanghai	O
Jiaotong	O
University	O
Affiliated	O
the	O
Sixth	O
People	O
's	O
Hospital	O
.	O

The	O
clinical	O
,	O
radiography	B-P
and	O
histopathology	O
were	O
reviewed	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
MDM2	O
,	O
CDK4	O
and	O
SATB2	O
immunohistochemistry	B-P
in	O
the	O
diagnosis	O
of	O
low-grade	O
osteosarcoma	O
were	O
assessed	O
along	O
with	O
an	O
evaluation	O
of	O
their	O
expressions	O
in	O
fibrous	O
dysplasia	O
,	O
desmoplastic	O
fibroma	O
,	O
low-grade	O
fibrosarcoma	O
and	O
other	O
fibrous	O
tumors	O
.	O

Low-grade	O
osteosarcoma	O
had	O
protracted	O
clinical	O
course	O
,	O
occurring	O
mostly	O
in	O
elder	O
adults	O
and	O
mainly	O
involving	O
long	O
bones	O
.	O

Radiographic	O
studies	O
showed	O
that	O
low-grade	O
central	O
osteosarcoma	O
had	O
a	O
mainly	O
malignant	O
lytic	O
presentation	O
,	O
however	O
about	O
5/18	O
of	O
t	O
umors	O
overlapping	O
with	O
intermediate	O
and	O
benign	O
bone	O
diseases	O
,	O
while	O
parosteal	O
osteosarcoma	O
was	O
characterized	O
by	O
a	O
densely	O
sclerotic	O
malignant	O
appearance	O
.	O

Histologically	O
,	O
low-grade	O
osteosarcoma	O
s	O
were	O
characterized	O
by	O
well-differentiated	O
spindle	O
tumor	O
cells	O
,	O
various	O
mature	O
tumor	O
bones	O
and	O
an	O
aggressive	O
growth	O
pattern	O
.	O

The	O
positive	O
expression	O
rates	O
of	O
MDM2	O
and	O
CDK4	O
in	O
low-grade	O
osteosarcoma	O
were	O
74.5	O
%	O
and	O
55.3	O
%	O
,	O
respectively	O
.	O

Eighty-three	O
percent	O
of	O
low-grade	O
osteosarcoma	O
expressed	O
one	O
or	O
both	O
markers	O
.	O

Low-grade	O
osteosarcoma	O
and	O
fibrous	O
dysplasia	O
were	O
both	O
positive	O
for	O
SATB2	O
,	O
while	O
desmoplastic	O
fibroma	O
,	O
low-grade	O
fibrosacoma	O
and	O
other	O
fibrous	O
tumors	O
were	O
negative	O
for	O
SATB2	O
.	O

Accurate	O
diagnosis	O
of	O
low-grade	O
osteosarcoma	O
should	O
be	O
based	O
on	O
combination	O
of	O
clinical	O
presentation	O
,	O
imaging	B-P
and	O
histopathology	O
,	O
with	O
immunohistochemistry	B-P
as	O
a	O
diagnostic	O
adjunct	O
.	O

Positive	B-P
immunostaining	I-P
for	O
CDK4	O
and/or	O
MDM2	O
supports	O
the	O
diagnosis	O
of	O
low-grade	O
osteosarcoma	O
,	O
but	O
the	O
negative	O
one	O
does	O
not	O
rule	O
out	O
such	O
lesion	O
.	O

The	O
negative	O
expression	O
of	O
SATB2	O
is	O
helpful	O
to	O
exclude	O
fibrous	O
tumors	O
originating	O
from	O
bone	O
with	O
the	O
exception	O
of	O
fibrous	O
dysplasia	O
.	O

DNA	O
barcoding	O
and	O
phylogenetic	O
relationships	O
of	O
Ardeidae	O
(	O
Aves	O
:	O
Ciconiiformes	O
)	O
.	O

The	O
avian	O
family	O
Ardeidae	O
comprises	O
long-legged	O
freshwater	O
and	O
coastal	O
birds	O
.	O

There	O
has	O
been	O
considerable	O
disagreement	O
concerning	O
the	O
intrafamilial	O
relationships	O
of	O
Ardeidae	O
.	O

Mitochondrial	O
cytochrome	O
c	O
oxidase	O
subunit	O
I	O
(	O
COI	O
)	O
was	O
used	O
as	O
a	O
marker	O
for	O
the	O
identification	O
and	O
phylogenetic	O
analysis	O
of	O
avian	O
species	O
.	O

In	O
the	O
present	O
study	B-P
,	O
we	O
analyzed	O
the	O
COI	O
barcodes	O
of	O
32	O
species	O
from	O
17	O
genera	O
belonging	O
to	O
the	O
family	O
Ardeidae	O
.	O

Each	O
bird	O
species	O
possessed	O
a	O
barcode	O
distinct	O
from	O
that	O
of	O
other	O
bird	O
species	O
except	O
for	O
Egretta	O
thula	O
and	O
E.	O
garzetta	O
,	O
which	O
shared	O
one	O
barcoding	O
sequence	O
.	O

Kimura	O
two-parameter	O
distances	O
were	O
calculated	O
between	O
barcodes	O
.	O

The	O
average	O
genetic	O
distance	O
between	O
species	O
was	O
34-fold	O
higher	O
than	O
the	O
average	O
genetic	O
distance	O
within	O
species	O
.	O

Neighbor	O
-	O
joining	O
and	O
maximum	O
likelihood	O
methods	O
were	O
used	O
to	O
construct	O
phylogenetic	O
trees	O
.	O

Most	O
species	O
could	O
be	O
discriminated	O
by	O
their	O
distinct	O
clades	O
in	O
the	O
phylogenetic	O
tree	O
.	O

Both	O
methods	O
of	O
phylogenetic	O
reconstruction	O
suggested	O
that	O
Zebrilus	O
,	O
Tigrisoma	O
,	O
and	O
Cochlearius	O
were	O
an	O
offshoot	O
of	O
the	O
primitive	O
herons	O
.	O

COI	O
gene	O
analysis	O
suggested	O
that	O
the	O
other	O
herons	O
could	O
be	O
divided	O
into	O
two	O
clades	O
:	O
Botaurinae	O
and	O
Ardeinae	O
.	O

Our	O
results	O
support	O
the	O
Great	O
Egret	O
and	O
Intermediate	O
Egret	O
being	O
in	O
separate	O
genera	O
,	O
Casmerodius	O
and	O
Mesophoyx	O
,	O
respectively	O
.	O

Access	O
to	O
Vagal	O
Projections	O
via	O
Cutaneous	O
Electrical	O
Stimulation	O
of	O
the	O
Neck	O
:	O
fMRI	B-P
Evidence	O
in	O
Healthy	O
Humans	O
.	O

Stimulation	O
of	O
the	O
vagus	O
nerve	O
via	O
implanted	O
electrodes	O
is	O
currently	O
used	O
to	O
treat	O
refractory	O
epilepsy	O
and	O
depression	O
.	O

Recently	O
,	O
a	O
non-invasive	O
approach	O
to	O
vagal	O
stimulation	O
has	O
demonstrated	O
similar	O
beneficial	O
effects	O
,	O
but	O
it	O
remains	O
unclear	O
whether	O
these	O
effects	O
are	O
mediated	O
via	O
activation	O
of	O
afferent	O
vagal	O
fibers	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
ascertain	O
whether	O
afferent	O
vagal	O
projections	O
can	O
be	O
accessed	O
non-invasively	O
by	O
transcutaneous	O
electrical	O
stimulation	O
of	O
the	O
antero-lateral	O
surface	O
of	O
the	O
neck	O
,	O
which	O
overlies	O
the	O
course	O
of	O
the	O
vagus	O
nerve	O
.	O

Thirteen	O
healthy	O
subjects	O
underwent	O
2	O
fMRI	B-P
scans	B-P
in	O
one	O
session	O
.	O

Transcutaneous	O
electrical	O
stimulation	O
was	O
applied	O
for	O
2	O
min	O
to	O
the	O
right	O
postero-lateral	O
surface	O
of	O
the	O
neck	O
during	O
scan	B-P
#	O
1	O
(	O
control	O
condition	O
,	O
sternocleidomastoid	O
stimulation	O
:	O
``	O
SCM	O
``	O
)	O
and	O
to	O
the	O
right	O
antero-lateral	O
surface	O
of	O
the	O
neck	O
during	O
scan	B-P
#	O
2	O
(	O
experimental	O
condition	O
,	O
non-invasive	O
vagus	O
nerve	O
stimulation	O
:	O
``	O
nVNS	O
``	O
)	O
.	O

Two	O
analyses	O
were	O
conducted	O
using	O
FSL	O
(	O
whole-brain	O
and	O
brainstem	O
;	O
corrected	O
,	O
p	O
<	O
0.01	O
)	O
to	O
determine	O
whether	O
nVNS	O
activated	O
vagal	O
projections	O
in	O
the	O
brainstem	O
and	O
forebrain	O
,	O
compared	O
to	O
baseline	O
and	O
SCM	O
stimulation	O
.	O

Compared	O
to	O
baseline	O
and	O
control	O
(	O
SCM	O
)	O
stimulation	O
,	O
nVNS	O
significantly	O
activated	O
primary	O
vagal	O
projections	O
including	O
:	O
nucleus	O
of	O
the	O
solitary	O
tract	O
(	O
primary	O
central	O
relay	O
of	O
vagal	O
afferents	O
)	O
,	O
parabrachial	O
area	O
,	O
primary	O
sensory	O
cortex	O
,	O
and	O
insula	O
.	O

Regions	O
of	O
the	O
basal	O
ganglia	O
and	O
frontal	O
cortex	O
were	O
also	O
significantly	O
activated	O
.	O

Deactivations	O
were	O
found	O
in	O
the	O
hippocampus	O
,	O
visual	O
cortex	O
,	O
and	O
spinal	O
trigeminal	O
nucleus	O
.	O

The	O
present	O
findings	O
provide	O
evidence	O
in	O
humans	O
that	O
cervical	O
vagal	O
afferents	O
can	O
be	O
accessed	O
non-invasively	O
via	O
transcutaneous	O
electrical	O
stimulation	O
of	O
the	O
antero-lateral	O
surface	O
of	O
the	O
neck	O
,	O
which	O
overlies	O
the	O
course	O
of	O
the	O
nerve	O
,	O
suggesting	O
an	O
alternative	O
and	O
feasible	O
method	O
of	O
stimulating	O
vagal	O
afferents	O
.	O

Effects	O
of	O
Smoke	O
Generated	O
by	O
Electrocautery	O
on	O
the	O
Larynx	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
effects	O
of	O
smoke	O
produced	O
by	O
electrocautery	O
on	O
the	O
laryngeal	O
mucosa	O
.	O

We	O
used	O
16	O
healthy	O
,	O
adult	O
female	O
Wistar	O
albino	O
rats	O
.	O

We	O
divided	O
the	O
rats	O
into	O
two	O
groups	O
.	O

Eight	O
rats	O
were	O
exposed	O
to	O
smoke	O
for	O
60	O
min/d	O
for	O
4	O
weeks	O
,	O
and	O
eight	O
rats	O
were	O
not	O
exposed	O
to	O
smoke	O
and	O
served	O
as	O
controls	O
.	O

The	O
experimental	O
group	O
was	O
maintained	O
in	O
a	O
plexiglass	O
cabin	O
during	O
exposure	O
to	O
smoke	O
.	O

At	O
the	O
end	O
of	O
4	O
weeks	O
,	O
rats	O
were	O
sacrificed	O
under	O
high-dose	O
ketamine	O
anesthesia	O
.	O

Each	O
vocal	O
fold	O
was	O
removed	O
.	O

An	O
expert	O
pathologist	O
blinded	O
to	O
the	O
experimental	O
group	O
evaluated	O
the	O
tissues	O
for	O
the	O
following	O
:	O
epithelial	O
distribution	O
,	O
inflammation	O
,	O
hyperplasia	O
,	O
and	O
metaplasia	O
.	O

Mucosal	O
cellular	O
activities	O
were	O
assessed	O
by	O
immunohistochemical	B-P
staining	I-P
for	I-P
Ki67	I-P
.	O

Results	O
taken	O
before	O
and	O
after	O
effect	O
were	O
compared	O
statistically	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
extent	O
of	O
inflammation	O
between	O
the	O
experimental	O
group	O
and	O
the	O
control	O
group	O
.	O

Squamous	O
metaplasia	O
was	O
detected	O
in	O
each	O
group	O
,	O
but	O
the	O
difference	O
was	O
not	O
significant	O
.	O

None	O
of	O
the	O
larynges	O
in	O
either	O
group	O
developed	O
hyperplasia	O
.	O

We	O
showed	O
increased	O
tissue	O
inflammation	O
due	O
to	O
irritation	O
by	O
the	O
smoke	O
.	O

Magnetic	B-P
Resonance	I-P
Imaging	I-P
Appearance	O
and	O
Mechanism	O
of	O
Action	O
of	O
Five	O
Hemostatic	O
Agents	O
Used	O
in	O
Neurosurgery	O
.	O

To	O
describe	O
the	O
magnetic	O
resonance	O
(	O
MR	O
)	O
image	O
appearance	O
of	O
5	O
hemostatic	O
agents	O
placed	O
in	O
the	O
brain	O
,	O
and	O
to	O
review	O
their	O
clinical	O
application	O
.	O

Descriptive	O
ex	O
vivo	O
and	O
in	O
vivo	O
study	O
.	O

Canine	O
cadavers	O
(	O
n=4	O
)	O
,	O
client-owned	O
dogs	O
(	O
n=4	O
)	O
.	O

Heads	O
from	O
4	O
canine	O
cadavers	O
were	O
used	O
,	O
each	O
with	O
5	O
hemostatic	O
agents	O
placed	O
in	O
specific	O
locations	O
in	O
the	O
brain	O
.	O

Hemostatic	O
agents	O
were	O
used	O
in	O
their	O
native	O
form	O
in	O
2	O
cadaveric	O
brains	O
,	O
and	O
in	O
2	O
others	O
the	O
materials	O
were	O
saturated	O
with	O
fresh	O
whole	O
blood	O
prior	O
to	O
placement	O
to	O
mimic	O
application	O
in	O
a	O
field	O
of	O
active	O
hemorrhage	O
.	O

The	O
heads	O
underwent	O
MR	B-P
imaging	I-P
and	O
the	O
images	O
were	O
reviewed	O
.	O

Postoperative	O
MRI	B-P
images	O
from	O
4	O
dogs	O
undergoing	O
brain	O
tumor	O
resection	O
were	O
retrospectively	O
reviewed	O
and	O
compared	O
to	O
the	O
images	O
from	O
the	O
cadavers	O
.	O

All	O
clinical	O
cases	O
and	O
cadaveric	O
specimens	O
underwent	O
surgical	O
closure	O
prior	O
to	O
MR	B-P
imaging	I-P
including	O
placement	O
of	O
titanium	O
mesh	O
over	O
the	O
craniotomy	O
defect	O
with	O
a	O
dural	O
graft	O
of	O
porcine	O
small	O
intestinal	O
submucosa	O
(	O
SIS	O
)	O
sealed	O
with	O
Tisseel	O
(	O
fibrin	O
sealant	O
)	O
.	O

The	O
SIS	O
and	O
Tisseel	O
used	O
in	O
the	O
dural	O
graft	O
were	O
consistently	O
indistinguishable	O
from	O
the	O
surrounding	O
tissues	O
on	O
MR	O
images	O
.	O

The	O
MR	B-P
imaging	I-P
appearance	O
of	O
the	O
remaining	O
4	O
hemostatic	O
agents	O
(	O
Gelfoam	O
,	O
Avitene	O
,	O
Surgicel	O
,	O
and	O
Floseal	O
)	O
placed	O
on	O
the	O
surface	O
or	O
in	O
the	O
parenchyma	O
of	O
canine	O
brain	O
,	O
varied	O
with	O
MR	O
sequence	O
weighting	O
and	O
blood	O
saturation	O
.	O

Accurate	O
evaluation	O
of	O
the	O
degree	O
of	O
brain	O
tumor	O
resection	O
on	O
postoperative	O
MR	O
images	O
requires	O
careful	O
differentiation	O
between	O
hemorrhage	O
,	O
residual	O
tumor	O
,	O
and	O
hemostatic	O
agents	O
implanted	O
.	O

Validation	O
of	O
the	O
NeogenÂ®	O
Fentanyl	O
ELISA	B-P
Kit	O
for	O
Blood	O
and	O
Urine	O
.	O

The	O
NeogenÂ®	O
Fentanyl	O
ready-to-use	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
kit	O
was	O
validated	O
following	O
the	O
Scientific	O
Working	O
Group	O
for	O
Forensic	O
Toxicology	O
Standard	O
Practices	O
for	O
Method	O
Validation	O
in	O
Forensic	O
Toxicology	O
Laboratory	O
Guidelines	O
.	O

Two	O
decision	O
points	O
,	O
0.5	O
and	O
1	O
ng/mL	O
,	O
were	O
successfully	O
validated	O
for	O
whole	O
blood	O
.	O

For	O
urine	O
,	O
two	O
decision	O
points	O
,	O
1	O
and	O
5	O
ng/mL	O
,	O
were	O
also	O
successfully	O
validated	O
.	O

The	O
validation	O
included	O
the	O
evaluation	O
of	O
sensitivity	O
,	O
precision	O
,	O
specificity	O
,	O
carryover	O
,	O
plate	O
drift	O
,	O
ruggedness/robustness	O
and	O
a	O
case	O
sample	O
evaluation	O
.	O

The	O
empirically	O
determined	O
limit	O
of	O
detection	O
was	O
0.25	O
ng/mL	O
for	O
blood	O
and	O
0.5	O
ng/mL	O
for	O
urine	O
.	O

Precision	O
was	O
determined	O
at	O
five	O
different	O
concentrations	O
ranging	O
from	O
0.25	O
to	O
1.5	O
ng/mL	O
with	O
15	O
replicates	O
at	O
each	O
level	O
for	O
whole	O
blood	O
and	O
demonstrated	O
a	O
<	O
2.4	O
%	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
.	O

In	O
urine	O
,	O
the	O
CV	O
was	O
<	O
5.6	O
%	O
at	O
six	O
different	O
concentrations	O
from	O
0.5	O
to	O
7.5	O
ng/mL	O
with	O
15	O
replicates	O
at	O
each	O
level	O
.	O

Cross-reactivity	O
was	O
evaluated	O
for	O
norfentanyl	O
,	O
acetyl	O
fentanyl	O
,	O
4-anilino-N-phenethylpiperidine	O
,	O
beta-hydroxythiofentanyl	O
,	O
butyryl	O
fentanyl	O
and	O
furanyl	O
fentanyl	O
.	O

PI3KÎ´	O
and	O
PI3KÎ³	O
isoforms	O
have	O
distinct	O
functions	O
in	O
regulating	O
pro-tumoural	O
signalling	O
in	O
the	O
multiple	O
myeloma	O
microenvironment	O
.	O

Phosphoinositide-3-kinase	O
and	O
protein	O
kinase	O
B	O
(	O
PI3K	O
-	O
AKT	O
)	O
is	O
upregulated	O
in	O
multiple	O
myeloma	O
(	O
MM	O
)	O
.	O

Using	O
a	O
combination	O
of	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
lentivirus	O
-mediated	O
knockdown	O
and	O
pharmacologic	O
isoform-	O
specific	O
inhibition	O
we	O
investigated	O
the	O
role	O
of	O
the	O
PI3K	O
p110Î³	O
(	O
PI3KÎ³	O
)	O
subunit	O
in	O
regulating	O
MM	O
proliferation	O
and	O
bone	O
marrow	O
microenvironment	O
-	O
induced	O
MM	O
interactions	O
.	O

We	O
compared	O
this	O
with	O
inhibition	O
of	O
the	O
PI3K	O
p110Î´	O
(	O
PI3kÎ´	O
)	O
subunit	O
and	O
with	O
combined	O
PI3kÎ´	O
/	O
Î³	O
dual	O
inhibition	O
.	O

We	O
found	O
that	O
MM	O
cell	O
adhesion	O
and	O
migration	O
were	O
PI3KÎ³	O
-	O
specific	O
functions	O
,	O
with	O
PI3kÎ´	O
inhibition	O
having	O
no	O
effect	O
in	O
MM	O
adhesion	O
or	O
migration	O
assays	B-P
.	O

At	O
concentration	O
of	O
the	O
dual	O
PI3KÎ´	O
/	O
Î³	O
inhibitor	O
duvelisib	O
,	O
which	O
can	O
be	O
achieved	O
in	O
vivo	O
we	O
saw	O
a	O
decrease	O
in	O
AKT	O
phosphorylation	O
at	O
s473	O
after	O
tumour	O
activation	O
by	O
bone	O
marrow	O
stromal	O
cells	O
(	O
BMSC	O
)	O
and	O
interleukin-6	O
.	O

Moreover	O
,	O
after	O
drug	O
treatment	O
of	O
BMSC	O
/	O
tumour	O
co-culture	B-P
activation	O
assays	B-P
only	O
dual	O
PI3kÎ´	O
/	O
Î³	O
inhibition	O
was	O
able	O
to	O
induce	O
MM	O
apoptosis	O
.	O

shRNA	O
lentiviral	O
-mediated	O
targeting	O
of	O
either	O
PI3KÎ´	O
or	O
PI3KÎ³	O
alone	O
,	O
or	O
both	O
in	O
combination	O
,	O
increased	O
survival	O
of	O
NSG	O
mice	O
xeno-transplanted	O
with	O
MM	O
cells	O
.	O

Moreover	O
,	O
treatment	O
with	O
duvelisib	O
reduced	O
MM	O
tumour	O
burden	O
in	O
vivo	O
.	O

We	O
report	O
that	O
PI3KÎ´	O
and	O
PI3KÎ³	O
isoforms	O
have	O
distinct	O
functions	O
in	O
MM	O
and	O
that	O
combined	O
PI3kÎ´	O
/	O
Î³	O
isoform	O
inhibition	O
has	O
anti	O
-	O
MM	O
activity	O
.	O

Here	O
we	O
provide	O
a	O
scientific	O
rationale	O
for	O
trials	O
of	O
dual	O
PI3kÎ´	O
/	O
Î³	O
inhibition	O
in	O
patients	O
with	O
MM	O
.	O

Spectrum-based	B-P
and	I-P
color-selective	I-P
electrochemiluminescence	I-P
immunoassay	I-P
for	O
determining	O
human	O
prostate	O
specific	O
antigen	O
in	O
near-infrared	O
region	O
.	O

The	O
conventional	O
electrochemiluminescence	B-P
(	O
ECL	B-P
)	O
analyses	O
were	O
performed	O
via	O
detecting	O
the	O
time	O
(	O
or	O
potential	O
)	O
dependent	O
ECL	B-P
intensity	O
with	O
the	O
proceeding	O
of	O
ECL	B-P
reaction	O
.	O

Herein	O
,	O
by	O
spectrally	O
recording	O
all	O
the	O
photons	O
generated	O
in	O
ECL	B-P
process	O
,	O
a	O
spectral	B-P
ECL	I-P
immunoassay	I-P
was	O
developed	O
in	O
near-infrared	O
(	O
NIR	O
)	O
region	O
with	O
human	O
prostate	O
specific	O
antigen	O
(	O
PSA	O
)	O
as	O
target	O
and	O
dual-stabilizers-capped	O
CdTe	O
nanocrystals	O
(	O
NCs	O
)	O
as	O
tags	O
.	O

The	O
CdTe	O
NCs	O
displayed	O
efficient	O
ECL	B-P
around	O
780nm	O
with	O
the	O
full	O
width	O
at	O
half-maximum	O
around	O
70nm	O
in	O
the	O
immune-complexes	O
,	O
the	O
maximum	O
intensity	O
on	O
ECL	B-P
spectrum	O
profiles	B-P
increased	O
linearly	O
with	O
the	O
logarithmic	O
increased	O
concentration	O
of	O
PSA	O
from	O
20.0fg/mL	O
to	O
100.0pg/mL	O
,	O
indicating	O
a	O
sensitive	O
and	O
color-selective	B-P
ECL	I-P
immunoassay	I-P
in	O
NIR	O
region	O
with	O
improved	O
anti-interference	O
performance	O
to	O
biological	O
autofluorescence	B-P
and	O
tissue	O
absorption	O
.	O

The	O
spectral	B-P
ECL	I-P
immunoassay	I-P
in	O
NIR	O
region	O
might	O
provide	O
an	O
important	O
technique	O
support	O
for	O
developing	O
color-selective	B-P
ECL	I-P
assay	I-P
of	O
different	O
wavebands	O
.	O

MiR-211	O
is	O
epigenetically	O
regulated	O
by	O
DNMT1	O
mediated	O
methylation	O
and	O
inhibits	O
EMT	O
of	O
melanoma	O
cells	O
by	O
targeting	O
RAB22A	O
.	O

MiR-211	O
has	O
strong	O
inhibitive	O
effects	O
on	O
melanoma	O
cell	O
growth	O
,	O
invasion	O
and	O
metastasis	O
.	O

However	O
,	O
how	O
it	O
is	O
downregulated	O
and	O
whether	O
other	O
genes	O
are	O
involved	O
its	O
downstream	O
regulation	O
in	O
melanoma	O
are	O
not	O
clear	O
.	O

In	O
this	O
study	O
,	O
we	O
firstly	O
verified	O
the	O
expression	O
of	O
miR-211	O
in	O
melanoma	O
cell	O
lines	O
and	O
observed	O
that	O
its	O
downregulation	O
is	O
associated	O
with	O
increased	O
DNMT1	O
expression	O
.	O

By	O
performing	O
qRT-PCR	O
and	O
MSP	O
analysis	O
,	O
we	O
confirmed	O
that	O
DNMT1	O
is	O
negatively	O
correlated	O
with	O
miR-211	O
expression	O
and	O
can	O
modulate	O
DNA	O
methylation	O
in	O
the	O
promoter	O
region	O
of	O
miR-211	O
.	O

By	O
performing	O
bioinformatics	O
analysis	O
,	O
we	O
found	O
that	O
RAB22A	O
is	O
a	O
possible	O
target	O
of	O
miR-211	O
,	O
which	O
has	O
two	O
broadly	O
conversed	O
binding	O
sites	O
with	O
miR-211	O
in	O
the	O
3'UTR	O
.	O

Following	O
dual	O
luciferase	O
assay	B-P
,	O
qRT-PCR	O
and	O
western	B-P
blot	I-P
analysis	I-P
confirmed	O
the	O
direct	O
binding	O
between	O
miR-211	O
and	O
RAB22A	O
and	O
the	O
suppressive	O
effect	O
of	O
miR-211	O
on	O
RAB22A	O
expression	O
.	O

Knockdown	O
of	O
RAB22A	O
increased	O
epithelial	O
properties	O
and	O
impaired	O
mesenchymal	O
properties	O
of	O
the	O
melanoma	O
cells	O
,	O
suggesting	O
that	O
miR-211	O
modulates	O
epithelial	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
of	O
melanoma	O
cells	O
via	O
downregulating	O
RAB22A	O
.	O

In	O
summary	O
,	O
the	O
present	O
study	O
firstly	O
demonstrated	O
that	O
DNMT1	O
mediated	O
promoter	O
methylation	O
is	O
a	O
mechanism	O
of	O
miRNA	O
suppression	O
in	O
melanoma	O
and	O
revealed	O
a	O
new	O
tumor	O
suppressor	O
role	O
of	O
the	O
miR-211	O
by	O
targeting	O
RAB22A	O
in	O
melanoma	O
.	O

The	O
DNMT1	O
/	O
miR-211	O
/	O
RAB22A	O
axis	O
provides	O
a	O
novel	O
insight	O
into	O
the	O
pathogenesis	O
of	O
melanoma	O
,	O
particularly	O
in	O
the	O
EMT	O
process	O
.	O

Molecular	B-P
subtyping	I-P
of	O
Treponema	O
pallidum	O
and	O
associated	O
factors	O
of	O
serofast	O
status	O
in	O
early	O
syphilis	O
patients	O
:	O
Identified	O
novel	O
genotype	O
and	O
cytokine	O
marker	O
.	O

Serofast	O
,	O
a	O
persistent	O
nontreponemal	O
serological	O
response	O
observed	O
in	O
early	O
syphilis	O
patients	O
after	O
conventional	O
treatment	O
,	O
remains	O
a	O
concern	O
of	O
clinicians	O
and	O
syphilis	O
patients	O
.	O

No	O
consensus	O
has	O
been	O
established	O
,	O
however	O
,	O
that	O
defines	O
an	O
effective	O
treatment	O
strategy	O
and	O
clarifies	O
the	O
pathogenesis	O
.	O

In	O
this	O
study	O
,	O
517	O
patients	O
with	O
early	O
syphilis	O
were	O
enrolled	O
and	O
treated	O
.	O

Twelve	O
months	O
after	O
treatment	O
,	O
79.3	O
%	O
(	O
410/517	O
)	O
of	O
patients	O
achieved	O
serological	O
cure	O
,	O
20.1	O
%	O
(	O
104/517	O
)	O
were	O
serofast	O
,	O
and	O
0.6	O
%	O
(	O
3/517	O
)	O
were	O
serological	O
failures	O
.	O

Multivariate	O
analysis	O
demonstrated	O
that	O
older	O
age	O
(	O
>	O
40	O
years	O
)	O
and	O
lower	O
baseline	O
RPR	B-P
titer	I-P
(	O
â¤	O
1:8	O
)	O
were	O
associated	O
with	O
serofast	O
status	O
.	O

We	O
also	O
identified	O
21	O
T.	O
pallidum	O
molecular	O
subtypes	O
among	O
early	O
syphilis	O
patients	O
and	O
detected	O
a	O
new	O
subtype	O
,	O
14i/a	O
.	O

We	O
found	O
that	O
the	O
proportion	O
of	O
14i/a	O
type	O
in	O
serofast	O
patients	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
patients	O
with	O
serological	O
cure	O
,	O
predicting	O
an	O
increasing	O
risk	O
of	O
serofast	O
status	O
.	O

Levels	O
of	O
chemerin	O
were	O
higher	O
in	O
the	O
serum	O
of	O
serofast	O
cases	O
than	O
serological	O
cure	O
cases	O
,	O
potentially	O
indicating	O
a	O
novel	O
cytokine	O
marker	O
for	O
serofast	O
in	O
early	O
syphilis	O
patients	O
after	O
therapy	O
.	O

We	O
hope	O
that	O
these	O
results	O
contribute	O
to	O
improve	O
guidelines	O
for	O
the	O
management	O
of	O
syphilis	O
patients	O
who	O
experience	O
serofast	O
.	O

Clinical	O
and	O
radiological	B-P
outcome	O
following	O
pneumothorax	O
after	O
endoscopic	O
lung	O
volume	O
reduction	O
with	O
valves	O
.	O

Valve	O
implantation	O
has	O
evolved	O
as	O
a	O
therapy	O
for	O
patients	O
with	O
advanced	O
emphysema	O
.	O

Although	O
it	O
is	O
a	O
minimally	O
invasive	O
treatmen	O
t	O
,	O
it	O
is	O
associated	O
with	O
complications	O
,	O
the	O
most	O
common	O
being	O
pneumothorax	O
.	O

Pneumothorax	O
occurs	O
due	O
to	O
the	O
rapid	O
target	O
lobe	O
volume	O
reduction	O
and	O
may	O
be	O
a	O
predictor	O
of	O
clinical	O
benefit	O
despite	O
this	O
complication	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
conduct	O
an	O
exploratory	O
data	O
analysis	O
of	O
patients	O
who	O
developed	O
a	O
pneumothorax	O
following	O
endoscopic	O
valve	O
therapy	O
for	O
emphysema	O
.	O

This	O
study	O
performed	O
a	O
retrospective	O
evaluation	O
of	O
pneumothorax	O
management	O
and	O
the	O
impact	O
of	O
pneumothorax	O
on	O
clinical	O
outcomes	O
in	O
70	O
patients	O
following	O
valve	O
therapy	O
in	O
381	O
consecutive	O
patients	O
.	O

Pneumothorax	O
rate	O
following	O
valve	O
therapy	O
was	O
18	O
%	O
.	O

Pneumothorax	O
management	O
consisted	O
of	O
chest	O
tube	O
insertion	O
,	O
valve	O
removal	O
,	O
and	O
surgical	O
intervention	O
in	O
87	O
%	O
(	O
61/70	O
)	O
,	O
44	O
%	O
(	O
31/70	O
)	O
,	O
and	O
19	O
%	O
(	O
13/70	O
)	O
of	O
the	O
patients	O
,	O
respectively	O
.	O

Despite	O
pneumothorax	O
,	O
patients	O
experienced	O
modest	O
but	O
significant	O
improvements	O
in	O
lung	O
function	O
parameters	O
(	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
:	O
55Â±148	O
mL	O
,	O
residual	O
volume	O
:	O
-390Â±964	O
mL	O
,	O
total	O
lung	O
capacity	O
:	O
-348Â±876	O
;	O
all	O
P	O
<	O
0.05	O
)	O
.	O

Persistent	O
lobar	O
atelectasis	O
3	O
months	O
after	O
recovering	O
from	O
pneumothorax	O
,	O
which	O
was	O
associated	O
with	O
relevant	O
clinical	O
improvement	O
,	O
was	O
observed	O
in	O
only	O
21	O
%	O
(	O
15/70	O
)	O
of	O
the	O
patients	O
.	O

Pneumothorax	O
is	O
a	O
frequent	O
severe	O
complication	O
following	O
valve	O
therapy	O
that	O
requires	O
further	O
intervention	O
.	O

Nevertheless	O
,	O
the	O
pneumothorax	O
does	O
not	O
impair	O
the	O
clinical	O
status	O
in	O
the	O
majority	O
of	O
patients	O
.	O

Patients	O
with	O
lobar	O
atelectasis	O
benefit	O
after	O
recovering	O
from	O
pneumothorax	O
in	O
terms	O
of	O
lung	O
function	O
parameters	O
.	O

Hepatitis	O
C	O
virus	O
impairs	O
natural	O
killer	O
cell	O
activity	O
via	O
viral	O
serine	O
protease	O
NS3	O
.	O

Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
is	O
characterized	O
by	O
a	O
high	O
frequency	O
of	O
chronic	O
cases	O
owing	O
to	O
the	O
impairment	O
of	O
innate	O
and	O
adaptive	O
immune	O
responses	O
.	O

The	O
modulation	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
functions	O
by	O
HCV	O
leads	O
to	O
an	O
impaired	O
innate	O
immune	O
response	O
.	O

However	O
,	O
the	O
underling	O
mechanisms	O
and	O
roles	O
of	O
HCV	O
proteins	O
in	O
this	O
immune	O
evasion	O
are	O
controversial	O
,	O
especially	O
in	O
the	O
early	O
phase	O
of	O
HCV	O
infection	O
.	O

To	O
investigate	O
the	O
role	O
of	O
HCV	O
nonstructural	O
proteins	O
especially	O
NS3	O
in	O
the	O
impairment	O
of	O
NK	O
functions	O
,	O
NK	O
cells	O
were	O
isolated	O
from	O
the	O
PBMCs	O
by	O
negative	B-P
selection	I-P
.	O

To	O
assess	O
the	O
direct	O
cytotoxicity	O
and	O
IFN-Î³	O
production	O
capability	O
of	O
NK	O
cells	O
,	O
co-cultured	B-P
with	O
uninfected	O
,	O
HCV-infected	O
,	O
HCV-NS3	O
DNA	O
-	O
transfected	O
Huh-7.5	O
,	O
or	O
HCV-NS	O
replicon	O
cells	O
.	O

To	O
determine	O
the	O
effect	O
of	O
an	O
NS3	O
serine	O
protease	O
inhibitor	O
,	O
HCV	O
-infected	O
Huh-7.5	O
cells	O
were	O
treated	O
with	O
BILN-2061	O
.	O

Then	O
,	O
NK	O
cells	O
were	O
harvested	B-P
and	O
further	O
co-cultured	B-P
with	O
K-562	O
target	O
cells	O
.	O

NK	O
cell	O
functions	O
were	O
analyzed	O
by	O
flow	B-P
cytometry	I-P
and	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
.	O

When	O
co-cultured	B-P
with	O
HCV-infected	O
Huh-7.5	O
cells	O
,	O
the	O
natural	O
cytotoxicity	O
and	O
IFN-Î³	O
production	O
capability	O
of	O
NK	O
cells	O
were	O
significantly	O
reduced	O
.	O

NK	O
cell	O
functions	O
were	O
inhibited	O
to	O
similar	O
levels	O
upon	O
co-culture	B-P
with	O
HCV-NS	O
replicon	O
cells	O
,	O
NS3	O
-	O
transfected	O
cells	O
,	O
and	O
HCV-infected	O
Huh-7.5	O
cells	O
.	O

These	O
reductions	O
were	O
restored	O
by	O
BILN-2061	O
-	O
treatment	O
.	O

Furthermore	O
,	O
BILN-2061	O
-	O
treatment	O
significantly	O
increased	O
degranulation	O
against	O
K-562	O
target	O
cells	O
and	O
IFN-Î³	O
productivity	O
in	O
NK	O
cells	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
the	O
expression	O
levels	O
of	O
activating	O
NK	O
cell	O
receptors	O
,	O
such	O
as	O
NKp46	O
and	O
NKp30	O
,	O
were	O
also	O
increased	O
.	O

In	O
HCV-infected	O
cells	O
,	O
the	O
serine	O
protease	O
NS3	O
may	O
play	O
a	O
role	O
in	O
the	O
abrogation	O
of	O
NK	O
cell	O
functions	O
in	O
the	O
early	O
phase	O
of	O
infection	O
through	O
downregulation	O
of	O
NKp46	O
and	O
NKp30	O
receptors	O
on	O
NK	O
cells	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
NS3	O
represents	O
a	O
novel	O
drug	O
target	O
for	O
the	O
treatment	O
of	O
HCV	O
infections	O
.	O

A	O
plea	O
for	O
thoracoscopic	O
resection	O
of	O
solitary	O
pulmonary	O
nodule	O
in	O
cancer	O
patients	O
.	O

Solitary	O
pulmonary	O
nodules	O
(	O
SPN	O
)	O
are	O
frequently	O
detected	O
in	O
cancer	O
patients	O
.	O

These	O
lesions	O
are	O
often	O
considered	O
as	O
pulmonary	O
metastases	O
and	O
increasingly	O
treated	O
by	O
non-surgical	O
techniques	O
without	O
histological	O
confirmation	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
histological	O
nature	O
of	O
SPN	O
resected	O
by	O
thoracoscopy	O
and	O
to	O
identify	O
risk	O
factors	O
of	O
malignancy	O
.	O

Single-institution	O
retrospective	O
analysis	O
of	O
all	O
consecutive	O
patients	O
with	O
previously	O
known	O
malignancies	O
who	O
underwent	O
thoracoscopic	O
resection	O
of	O
SPN	O
with	O
unknown	O
diagnosis	O
between	O
2001	O
and	O
2014	O
.	O

One	O
hundred	O
and	O
forty	O
cancer	O
patients	O
underwent	O
thoracoscopic	O
resection	O
of	O
a	O
SPN	O
.	O

The	O
resected	O
SPN	O
was	O
benign	O
in	O
34	O
patients	O
(	O
24.3	O
%	O
)	O
and	O
malignant	O
in	O
106	O
patients	O
.	O

The	O
latter	O
were	O
metastasis	O
in	O
70	O
patients	O
(	O
50	O
%	O
)	O
and	O
a	O
primary	O
lung	O
cancer	O
in	O
36	O
patients	O
(	O
25.7	O
%	O
)	O
.	O

Upon	O
univariate	O
analysis	O
,	O
malignancy	O
was	O
significantly	O
associated	O
with	O
age	O
>	O
60	O
years	O
,	O
disease	O
-free	O
interval	O
â¥24	O
months	O
,	O
SPN	O
size	O
>	O
8	O
mm	O
,	O
upper	O
lobe	O
localization	O
and	O
SUVmax	O
>	O
2.5	O
on	O
PET-CT	B-P
.	O

Upon	O
multivariate	O
analysis	O
,	O
upper	O
lobe	O
localization	O
and	O
SUVmax	O
>	O
2.5	O
were	O
associated	O
with	O
malignancy	O
.	O

Smoking	O
was	O
significantly	O
associated	O
with	O
SPN	O
containing	O
primary	O
lung	O
cancer	O
.	O

In	O
this	O
series	O
,	O
only	O
50	O
%	O
of	O
SPN	O
in	O
patients	O
with	O
known	O
malignant	O
disease	O
were	O
pulmonary	O
metastases	O
and	O
25	O
%	O
had	O
a	O
newly	O
diagnosed	O
NSCLC	O
.	O

Smoking	O
was	O
associated	O
with	O
primary	O
lung	O
cancer	O
but	O
no	O
other	O
predictor	O
was	O
found	O
to	O
allow	O
the	O
distinction	O
between	O
pulmonary	O
metastasis	O
and	O
lung	O
cancer	O
.	O

These	O
results	O
endorse	O
the	O
need	O
of	O
histological	O
confirmation	O
of	O
SPN	O
in	O
patients	O
with	O
previous	O
malignancies	O
to	O
avoid	O
diagnostic	O
uncertainty	O
and	O
suboptimal	O
treatments	O
.	O

Genetic	B-P
Identification	I-P
of	O
a	O
PilT	O
Motor	O
in	O
Geobacter	O
sulfurreducens	O
Reveals	O
a	O
Role	O
for	O
Pilus	O
Retraction	O
in	O
Extracellular	O
Electron	O
Transfer	O
.	O

The	O
metal	O
-	O
reducing	O
bacterium	O
Geobacter	O
sulfurreducens	O
requires	O
the	O
expression	O
of	O
conductive	O
pili	O
to	O
reduce	O
iron	O
oxides	O
and	O
to	O
wire	O
electroactive	O
biofilms	O
,	O
but	O
the	O
role	O
of	O
pilus	O
retraction	O
in	O
these	O
functions	O
has	O
remained	O
elusive	O
.	O

Here	O
we	O
show	O
that	O
of	O
the	O
four	O
PilT	O
proteins	O
encoded	O
in	O
the	O
genome	O
of	O
G.	O
sulfurreducens	O
,	O
PilT3	O
powered	O
pilus	O
retraction	O
in	O
planktonic	O
cells	O
of	O
a	O
PilT	O
-	O
deficient	O
strain	O
of	O
P.	O
aeruginosa	O
and	O
restored	O
the	O
dense	O
mutant	O
biofilms	O
to	O
wild-type	O
levels	O
.	O

Furthermore	O
,	O
PilT3	O
and	O
PilT4	O
rescued	O
the	O
twitching	O
motility	O
defect	O
of	O
the	O
PilT	O
-	O
deficient	O
mutant	O
.	O

However	O
,	O
PilT4	O
was	O
the	O
only	O
paralog	O
whose	O
inactivation	O
in	O
G.	O
sulfurreducens	O
lead	O
to	O
phenotypes	O
associated	O
with	O
the	O
hyperpiliation	O
of	O
non-retractile	O
mutants	O
such	O
as	O
enhanced	O
adhesion	O
and	O
biofilm-forming	O
abilities	O
.	O

In	O
addition	O
,	O
PilT4	O
was	O
required	O
to	O
reduce	O
iron	O
oxides	O
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
PilT4	O
is	O
the	O
motor	O
ATPase	O
of	O
G.	O
sulfurreducens	O
pili	O
and	O
reveal	O
a	O
previously	O
unrecognized	O
role	O
for	O
pilus	O
retraction	O
in	O
extracellular	O
electron	O
transfer	O
,	O
a	O
strategy	O
that	O
confers	O
on	O
Geobacter	O
spp	O
.	O

an	O
adaptive	O
advantage	O
for	O
metal	O
reduction	O
in	O
the	O
natural	O
environment	O
.	O

Mitochondrial	O
pyruvate	O
dehydrogenase	O
phosphatase	O
1	O
regulates	O
the	O
early	O
differentiation	O
of	O
cardiomyocytes	O
from	O
mouse	O
embryonic	O
stem	O
cells	O
.	O

Mitochondria	O
are	O
crucial	O
for	O
maintaining	O
the	O
properties	O
of	O
embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
and	O
for	O
regulating	O
their	O
subsequent	O
differentiation	O
into	O
diverse	O
cell	O
lineages	O
,	O
including	O
cardiomyocytes	O
.	O

However	O
,	O
mitochondrial	O
regulators	O
that	O
manage	O
the	O
rate	O
of	O
differentiation	O
or	O
cell	O
fate	O
have	O
been	O
rarely	O
identified	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
potential	O
mitochondrial	O
factor	O
that	O
controls	O
the	O
differentiation	O
of	O
ESCs	O
into	O
cardiac	O
myocytes	O
.	O

We	O
induced	O
cardiomyocyte	O
differentiation	O
from	O
mouse	O
ESCs	O
(	O
mESCs	O
)	O
and	O
performed	O
microarray	B-P
assays	I-P
to	O
assess	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O
changes	O
at	O
differentiation	O
day	O
8	O
(	O
D8	O
)	O
compared	O
with	O
undifferentiated	O
mESCs	O
(	O
D0	O
)	O
.	O

Among	O
the	O
differentially	O
expressed	O
genes	O
,	O
Pdp1	O
expression	O
was	O
significantly	O
decreased	O
(	O
27-fold	O
)	O
on	O
D8	O
compared	O
to	O
D0	O
,	O
which	O
was	O
accompanied	O
by	O
suppressed	O
mitochondrial	O
indices	O
,	O
including	O
ATP	O
levels	O
,	O
membrane	O
potential	O
,	O
ROS	O
and	O
mitochondrial	O
Ca	O
(	O
2+	O
)	O
.	O

Notably	O
,	O
Pdp1	O
overexpression	O
significantly	O
enhanced	O
the	O
mitochondrial	O
indices	O
and	O
pyruvate	O
dehydrogenase	O
activity	O
and	O
reduced	O
the	O
expression	O
of	O
cardiac	O
differentiation	O
marker	O
mRNA	O
and	O
the	O
cardiac	O
differentiation	O
rate	O
compared	O
to	O
a	O
mock	O
control	O
.	O

In	O
confirmation	O
of	O
this	O
,	O
a	O
knockdown	O
of	O
the	O
Pdp1	O
gene	O
promoted	O
the	O
expression	O
of	O
cardiac	O
differentiation	O
marker	O
mRNA	O
and	O
the	O
cardiac	O
differentiation	O
rate	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
suggest	O
that	O
mitochondrial	O
PDP1	O
is	O
a	O
potential	O
regulator	O
that	O
controls	O
cardiac	O
differentiation	O
at	O
an	O
early	O
differentiation	O
stage	O
in	O
ESCs	O
.	O

Association	O
of	O
testosterone	B-P
and	O
BDNF	B-P
serum	I-P
levels	I-P
with	O
craving	O
during	O
alcohol	O
withdrawal	O
.	O

Preclinical	O
and	O
clinical	O
studies	O
show	O
associations	O
between	O
testosterone	B-P
and	O
brain-derived	B-P
neurotrophic	I-P
growth	I-P
factor	I-P
(	I-P
BDNF	I-P
)	I-P
serum	I-P
levels	I-P
.	O

BDNF	O
and	O
testosterone	O
have	O
been	O
independently	O
reported	O
to	O
influence	O
alcohol	O
consumption	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
investigate	O
a	O
possible	O
interplay	O
of	O
testosterone	O
and	O
BDNF	O
contributing	O
to	O
alcohol	O
dependence	O
.	O

Regarding	O
possible	O
interplay	O
of	O
testosterone	O
and	O
BDNF	O
and	O
the	O
activity	O
of	O
the	O
hypothalamic	O
pituitary	O
axis	O
(	O
HPA	O
)	O
,	O
we	O
included	O
cortisol	O
serum	O
levels	O
in	O
our	O
research	O
.	O

We	O
investigated	O
testosterone	B-P
and	O
BDNF	B-P
serum	I-P
levels	I-P
in	O
a	O
sample	O
of	O
99	O
male	O
alcohol	O
-dependent	O
patients	O
during	O
alcohol	O
withdrawal	O
(	O
day	O
1	O
,	O
7	O
,	O
and	O
14	O
)	O
and	O
compared	O
them	O
to	O
a	O
healthy	O
male	O
control	O
group	O
(	O
n	O
=	O
17	O
)	O
.	O

The	O
testosterone	B-P
serum	I-P
levels	I-P
were	O
significantly	O
(	O
p	O
<	O
0.001	O
)	O
higher	O
in	O
the	O
patients	O
'	O
group	O
than	O
in	O
the	O
control	O
group	O
and	O
decreased	O
significantly	O
during	O
alcohol	O
withdrawal	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
decrease	O
of	O
testosterone	B-P
serum	I-P
levels	I-P
during	O
alcohol	O
withdrawal	O
(	O
days	O
1-7	O
)	O
was	O
significantly	O
associated	O
with	O
the	O
BDNF	B-P
serum	I-P
levels	I-P
(	O
day	O
1	O
:	O
p	O
=	O
0.008	O
)	O
.	O

In	O
a	O
subgroup	O
of	O
patients	O
showing	O
high	O
cortisol	O
serum	O
levels	O
(	O
putatively	O
mirroring	O
high	O
HPA	O
activity	O
)	O
,	O
we	O
found	O
a	O
significant	O
association	O
of	O
BDNF	O
and	O
testosterone	O
as	O
well	O
as	O
with	O
alcohol	O
craving	O
measured	O
by	O
the	O
Obsessive	O
and	O
Compulsive	O
Drinking	O
Scale	O
(	O
OCDS	O
)	O
.	O

Our	O
data	O
suggest	O
a	O
possible	O
association	O
of	O
BDNF	B-P
and	O
testosterone	B-P
serum	I-P
levels	I-P
,	O
which	O
may	O
be	O
relevant	O
for	O
the	O
symptomatology	O
of	O
alcohol	O
dependence	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
clarify	O
our	O
results	O
.	O

Bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
combine	O
with	O
Treated	O
dentin	O
matrix	O
to	O
build	O
biological	O
root	O
.	O

Treated	O
dentin	O
matrix	O
(	O
TDM	O
)	O
as	O
a	O
kind	O
of	O
scaffolding	O
material	O
has	O
been	O
proved	O
odontogenic	O
induction	O
ability	O
on	O
dental-derived	O
stem	O
cells	O
.	O

Given	O
the	O
limited	O
resources	O
of	O
dental	O
stem	O
cells	O
,	O
it	O
is	O
necessary	O
to	O
seek	O
new	O
seed	O
cell	O
which	O
easily	O
obtained	O
.	O

Jaw	O
bone	O
marrow	O
mesenchymal	O
stem	O
cell	O
(	O
JBMMSC	O
)	O
as	O
non-dental-derived	O
stem	O
cell	O
relates	O
to	O
the	O
development	O
of	O
teeth	O
and	O
jaws	O
which	O
suggest	O
us	O
JBMMSCs	O
could	O
act	O
as	O
a	O
new	O
seed	O
cell	O
for	O
tooth	O
tissue	O
engineering	O
.	O

To	O
assess	O
the	O
odontogenic	O
and	O
osteogenic	O
potential	O
of	O
JBMMSCs	O
,	O
cells	O
were	O
induced	O
by	O
TDM	O
extraction	O
in	O
vitro	O
and	O
combined	O
with	O
TDM	O
in	O
vivo	O
.	O

Results	O
were	O
analyzed	O
by	O
PCR	O
,	O
Western	O
Blotting	O
and	O
histology	B-P
.	O

PCR	O
and	O
Western	O
Blotting	O
showed	O
odontogenic	O
and	O
osteogenic	O
makers	O
were	O
significantly	O
enhanced	O
in	O
varying	O
degrees	O
after	O
induced	O
by	O
TDM	O
extraction	O
in	O
vitro	O
.	O

In	O
vivo	O
,	O
JBMMSCs	O
expressed	O
both	O
odontogenic	O
and	O
osteogenic-related	O
protein	O
,	O
and	O
the	O
latter	O
showed	O
stronger	O
positive	O
expression	O
.	O

Furthermore	O
,	O
histological	B-P
examination	I-P
of	O
the	O
harvested	O
grafts	O
was	O
observed	O
the	O
formation	O
of	O
bone-like	O
tissue	O
.	O

Therefore	O
,	O
osteogenic	O
differentiation	O
ability	O
of	O
JBMMSCs	O
were	O
enhanced	O
significantly	O
after	O
being	O
inducted	O
by	O
TDM	O
which	O
illustrates	O
that	O
non-odontogenic	O
derived	O
stem	O
cells	O
are	O
still	O
promising	O
seed	O
cells	O
in	O
tooth	O
root	O
tissue	O
engineering	O
.	O

Three-dimensional	O
morphological	O
characterization	O
of	O
malocclusions	O
with	O
mandibular	O
lateral	O
displacement	O
using	O
cone-beam	B-P
computed	I-P
tomography	I-P
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
morphologic	O
characteristics	O
of	O
MLD	O
malocclusions	O
using	O
3D	B-P
imaging	I-P
.	O

MLD	O
characteristics	O
were	O
examined	O
using	O
CBCT	B-P
data	O
in	O
40	O
subjects	O
.	O

A	O
3D	O
Cephalometric	B-P
analysis	I-P
was	O
developed	O
to	O
describe	O
the	O
spatial	O
position	O
of	O
the	O
mandible	O
and	O
temporal	O
bones	O
.	O

Vertical	O
dental	O
heights	O
were	O
shorter	O
and	O
the	O
posterior	O
occlusal	O
plane	O
(	O
POP	O
)	O
presented	O
a	O
steeper	O
sagittal	O
inclination	O
on	O
the	O
shifted	O
side	O
(	O
the	O
side	O
of	O
the	O
laterally	O
displaced	O
bony	O
chin	O
)	O
than	O
on	O
the	O
contralateral	O
side	O
.	O

(	O
p	O
<	O
0.01	O
)	O
.	O

The	O
MLD	O
was	O
related	O
to	O
a	O
superiorly	O
inclined	O
POP	O
Cant	O
in	O
the	O
same	O
direction	O
(	O
r	O
=	O
0.82	O
;	O
p	O
<	O
0.01	O
)	O
.	O

The	O
shifted	O
side	O
condyle	O
was	O
dislocated	O
medially	O
and	O
was	O
smaller	O
.	O

Temporal	O
bone	O
sagittal	O
inclination	O
showed	O
a	O
more	O
forward	O
and	O
medial	O
inclination	O
on	O
the	O
contralateral	O
side	O
(	O
p	O
<	O
0.01	O
)	O
.	O

A	O
unilateral	O
decrease	O
in	O
the	O
vertical	O
height	O
of	O
the	O
dentition	O
and	O
the	O
subsequent	O
steeper	O
occlusal	O
plane	O
inclinations	O
correlated	O
with	O
(	O
1	O
)	O
mandibular	O
rotational	O
displacement	O
and	O
condylar	O
lateral	O
displacement	O
,	O
(	O
2	O
)	O
mandibular	O
and	O
condylar	O
morphologic	O
changes	O
(	O
3	O
)	O
changes	O
in	O
temporal	O
bone	O
position	O
.	O

Kidney	O
transplant	O
recipients	O
after	O
nonrenal	O
solid	O
organ	O
transplantation	O
show	O
low	O
alloreactivity	O
but	O
an	O
increased	O
risk	O
of	O
infection	O
.	O

The	O
number	O
of	O
kidney	O
transplant	O
recipients	O
(	O
KTRs	O
)	O
after	O
nonrenal	O
solid	O
organ	O
transplantation	O
(	O
SOT	O
)	O
has	O
increased	O
to	O
almost	O
5	O
%	O
.	O

Knowledge	O
on	O
patient	O
and	O
allograft	O
outcomes	O
,	O
infections	O
,	O
and	O
alloreactivity	O
,	O
however	O
,	O
remains	O
scarce	O
.	O

We	O
studied	O
40	O
KTRs	O
after	O
nonrenal	O
SOT	O
.	O

Seven	O
hundred	O
and	O
twenty	O
primary	O
KTRs	O
and	O
119	O
repeat	O
KTRs	O
were	O
used	O
for	O
comparison	O
.	O

Samples	O
were	O
collected	O
pretransplantation	O
,	O
at	O
+1	O
,	O
+2	O
,	O
and	O
+3	O
months	O
post-transplantation	O
.	O

Alloreactive	O
and	O
CMV-specific	O
T	O
cells	O
were	O
measured	O
by	O
interferon-Î³	B-P
ELISPOT	I-P
assay	I-P
.	O

Patient	O
survival	O
in	O
KTRs	O
after	O
SOT	O
,	O
primary	O
and	O
repeat	O
KTRs	O
was	O
comparable	O
.	O

While	O
death	O
-censored	O
allograft	O
survival	O
was	O
comparable	O
between	O
KTRs	O
after	O
SOT	O
and	O
primary	O
KTRs	O
,	O
KTRs	O
after	O
SOT	O
showed	O
superior	O
5-year	O
death	O
-censored	O
allograft	O
survival	O
of	O
92.5	O
%	O
compared	O
to	O
81.2	O
%	O
in	O
repeat	O
KTRs	O
.	O

Interestingly	O
,	O
KTRs	O
after	O
SOT	O
show	O
less	O
preformed	O
panel-reactive	B-P
antibodies	I-P
,	O
frequencies	O
of	O
alloreactive	O
T	O
cells	O
,	O
and	O
acute	O
rejections	O
compared	O
to	O
repeat	O
KTRs	O
.	O

KTRs	O
after	O
SOT	O
,	O
however	O
,	O
show	O
higher	O
incidences	O
of	O
EBV	O
viremia	O
and	O
PTLD	O
,	O
sepsis	O
,	O
and	O
death	O
from	O
sepsis	O
.	O

Impaired	O
CMV-specific	O
cellular	O
immunity	O
was	O
associated	O
with	O
more	O
CMV	O
replication	O
compared	O
to	O
repeat	O
KTRs	O
.	O

Our	O
results	O
suggest	O
comparable	O
patient	O
and	O
allograft	O
outcomes	O
in	O
KTRs	O
after	O
SOT	O
and	O
primary	O
KTRs	O
.	O

The	O
observed	O
low	O
alloreactivity	O
may	O
contribute	O
to	O
excellent	O
allograft	O
outcomes	O
.	O

Caution	O
should	O
be	O
taken	O
in	O
KTRs	O
after	O
SOT	O
regarding	O
infectious	O
complications	O
due	O
to	O
overimmunosuppression	O
.	O

Effects	O
of	O
a	O
specific	O
blend	O
of	O
essential	O
oils	O
on	O
apparent	O
nutrient	O
digestion	O
,	O
rumen	O
fermentation	O
and	O
rumen	O
microbial	O
populations	O
in	O
sheep	O
fed	O
a	O
50:50	O
alfalfa	O
hay	O
:	O
concentrate	O
diet	O
.	O

An	O
experiment	O
was	O
conducted	O
to	O
investigate	O
the	O
effects	O
of	O
a	O
specific	O
mixture	O
of	O
essential	O
oils	O
(	O
MEO	O
)	O
,	O
containing	O
thyme	O
,	O
clove	O
and	O
cinnamon	O
EO	O
,	O
on	O
rumen	O
microbial	O
fermentation	O
,	O
nutrient	O
apparent	O
digestibility	O
and	O
blood	O
metabolites	O
in	O
fistulated	O
sheep	O
.	O

Six	O
sheep	O
fitted	O
with	O
ruminal	O
fistulas	O
were	O
used	O
in	O
a	O
repeated	O
measurement	O
design	O
with	O
two	O
24-d	O
periods	O
to	O
investigate	O
the	O
effect	O
of	O
adding	O
MEO	O
at	O
0	O
(	O
control	O
)	O
,	O
0.8	O
,	O
and	O
1.6	O
mL/d	O
on	O
apparent	O
nutrient	O
digestibility	O
,	O
rumen	O
fermentation	O
characteristics	O
,	O
rumen	O
microbial	O
population	O
and	O
blood	O
chemical	O
metabolites	O
.	O

Animals	O
were	O
fed	O
with	O
a	O
50:50	O
alfalfa	O
hay	O
:	O
concentrate	O
diet	O
.	O

Ruminal	O
pH	O
,	O
total	O
volatile	O
fatty	O
acids	O
(	O
VFA	O
)	O
concentration	O
,	O
molar	O
proportion	O
of	O
individual	O
VFA	O
,	O
acetate	O
:	O
propionate	O
ratio	O
and	O
methane	O
production	O
were	O
not	O
affected	O
with	O
MEO	O
.	O

Relative	O
to	O
the	O
control	O
,	O
Small	O
peptides	O
plus	O
amino	O
acid	O
nitrogen	O
and	O
large	O
peptides	O
nitrogen	O
concentration	O
in	O
rumen	O
fluid	O
were	O
not	O
affected	O
with	O
MEO	O
supplementation	O
;	O
while	O
,	O
rumen	O
fluid	O
ammonia	O
nitrogen	O
concentration	O
at	O
0	O
and	O
6	O
h	O
after	O
morning	O
feeding	O
in	O
sheep	O
fed	O
with	O
1.6	O
mL/d	O
of	O
MEO	O
was	O
lower	O
(	O
p	O
<	O
0.05	O
)	O
compared	O
to	O
the	O
control	O
and	O
0.8	O
mL/d	O
of	O
MEO	O
.	O

At	O
0	O
h	O
after	O
morning	O
feeding	O
,	O
ammonia	O
nitrogen	O
concentration	O
was	O
higher	O
(	O
p	O
<	O
0.05	O
)	O
in	O
sheep	O
fed	O
0.8	O
mL/d	O
of	O
MEO	O
relative	O
to	O
1.6	O
mL/d	O
and	O
control	O
diet	O
.	O

Ruminal	O
protozoa	O
and	O
hyper	O
ammonia	O
producing	O
(	O
HAP	O
)	O
bacteria	O
counts	B-P
were	O
not	O
affected	O
by	O
addition	O
of	O
MEO	O
in	O
the	O
diet	O
.	O

Relative	O
to	O
the	O
control	O
,	O
no	O
changes	O
were	O
observed	O
in	O
the	O
red	B-P
and	O
white	O
blood	O
cells	O
,	O
hemoglobin	B-P
,	O
hematocrit	O
,	O
glucose	B-P
,	O
beta-hydroxybutyric	O
acid	O
,	O
cholesterol	B-P
,	O
total	B-P
protein	I-P
,	O
albumin	B-P
,	O
blood	B-P
urea	I-P
nitrogen	I-P
and	O
aspartate	B-P
aminotransferase	I-P
and	O
alanine	B-P
aminotransferase	I-P
concentration	O
.	O

Apparent	O
total	O
tract	O
digestibility	O
of	O
dry	O
matter	O
,	O
crude	O
proten	O
,	O
organic	O
matter	O
,	O
and	O
neutral	O
detergent	O
fiber	O
were	O
not	O
influenced	O
by	O
MEO	O
supplementation	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
supplementation	O
of	O
MEO	O
may	O
have	O
limited	O
effects	O
on	O
apparent	O
nutrient	O
digestibility	O
,	O
ruminal	O
fermentation	O
and	O
protozoa	O
and	O
HAP	O
bacteria	O
count	B-P
,	O
blood	O
cells	O
and	O
metabolites	O
.	O

Prognostic	O
and	O
therapeutic	O
value	O
of	O
mitochondrial	O
serine	O
hydroxyl-methyltransferase	O
2	O
as	O
a	O
breast	O
cancer	O
biomarker	O
.	O

Mitochondrial	O
serine	O
hydroxylmethyltransferase	O
2	O
(	O
SHMT2	O
)	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
serine/glycine	O
synthesis	O
pathway	O
.	O

SHMT2	O
has	O
been	O
implicated	O
as	O
a	O
critical	O
component	O
for	O
tumor	O
cell	O
survival	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
prognostic	O
value	O
and	O
efficiency	O
of	O
SHMT2	O
as	O
a	O
biomarker	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

Individual	O
and	O
pooled	O
survival	O
analyses	O
were	O
performed	O
on	O
five	O
independent	O
breast	O
cancer	O
microarray	O
datasets	O
.	O

Gene	O
signatures	O
enriched	O
by	O
SHMT2	O
were	O
also	O
analyzed	O
in	O
these	O
datasets	O
.	O

SHMT2	O
protein	O
expression	O
was	O
detected	O
using	O
immunohistochemistry	B-P
(	O
IHC	B-P
)	O
assay	B-P
in	O
128	O
breast	O
cancer	O
cases	O
.	O

Gene	O
set	O
enrichment	O
analysis	O
revealed	O
that	O
SHMT2	O
was	O
significantly	O
associated	O
with	O
gene	O
signatures	O
of	O
mitochondrial	O
module	O
,	O
cancer	O
invasion	O
,	O
metastasis	O
and	O
poor	O
survival	O
among	O
breast	O
cancer	O
patients	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
clinical	O
relevance	O
of	O
SHMT2	O
was	O
validated	O
on	O
IHC	B-P
data	O
.	O

The	O
mitochondrial	O
localization	O
of	O
SHMT2	O
protein	O
was	O
visualized	O
on	O
IHC	B-P
staining	B-P
.	O

Independent	O
and	O
pooled	O
analysis	O
confirmed	O
that	O
SHMT2	O
expression	O
was	O
associated	O
with	O
breast	O
cancer	O
tumor	O
aggressiveness	O
(	O
TNM	O
staging	O
and	O
Elson	O
grade	O
)	O
in	O
a	O
dose-dependent	O
manner	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
prognostic	O
performance	O
of	O
SHMT2	O
mRNA	O
was	O
comparable	O
to	O
other	O
gene	O
signatures	O
and	O
proved	O
superior	O
to	O
TNM	O
staging	O
.	O

Further	O
analysis	O
results	O
indicated	O
that	O
SHMT2	O
had	O
better	O
prognostic	O
value	O
for	O
estrogen	O
receptor	O
(	O
ER	O
)	O
-negative	O
breast	O
cancer	O
patients	O
,	O
compared	O
to	O
ER-positive	O
patients	O
.	O

In	O
cases	O
involving	O
stage	O
IIb	O
breast	O
cancer	O
,	O
chemotherapy	O
significantly	O
extended	O
survival	O
time	O
among	O
patients	O
with	O
high	O
SHMT2	O
expression	O
.	O

These	O
results	O
indicate	O
that	O
SHMT2	O
may	O
be	O
a	O
valuable	O
prognostic	O
biomarker	O
in	O
ER-negative	O
breast	O
cancer	O
cases	O
.	O

Furthermore	O
,	O
SHMT2	O
may	O
be	O
a	O
potential	O
target	O
for	O
breast	O
cancer	O
treatment	O
and	O
drug	O
discovery	O
.	O

Plasma	O
levels	O
of	O
endothelin-1	O
and	O
renal	O
function	O
among	O
young	O
and	O
healthy	O
adults	O
.	O

Endothelin-1	O
(	O
ET-1	O
)	O
,	O
a	O
vasoconstrictive	O
and	O
pro-inflammatory	O
peptide	O
,	O
is	O
associated	O
with	O
several	O
cardiovascular	O
risk	O
factors	O
and	O
outcomes	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
association	O
of	O
plasma	O
ET-1	O
levels	O
and	O
renal	O
function	O
among	O
young	O
and	O
healthy	O
adults	O
.	O

Individuals	O
aged	O
25-41	O
years	O
were	O
enrolled	O
in	O
a	O
population-based	O
cohort	O
study	O
.	O

Main	O
exclusion	O
criteria	O
were	O
established	O
kidney	O
disease	O
,	O
cardiovascular	O
diseases	O
,	O
diabetes	O
mellitus	O
and	O
a	O
body	O
mass	O
index	O
>	O
35	O
kg/m2	O
.	O

Fasting	O
venous	O
plasma	O
samples	O
were	O
used	O
to	O
measure	B-P
creatinine	I-P
,	O
cystatin	B-P
C	I-P
and	O
ET-1	O
.	O

The	O
estimated	B-P
glomerular	I-P
filtration	I-P
rate	I-P
(	O
eGFR	B-P
)	O
was	O
calculated	B-P
using	O
the	O
creatinine	O
based	O
chronic	O
kidney	O
disease	O
epidemiology	O
collaboration	O
(	O
CKD	O
-	O
EPI	O
)	O
formula	O
.	O

Multivariable	O
regression	O
models	O
were	O
constructed	O
to	O
assess	O
interrelationships	O
of	O
plasma	O
ET-1	O
with	O
parameters	O
of	O
renal	O
function	O
.	O

Median	O
age	O
of	O
the	O
2139	O
participants	O
was	O
37	O
years	O
,	O
47	O
%	O
males	O
.	O

Median	O
creatinine	O
and	O
eGFR	B-P
were	O
67	O
Î¼mol/L	O
and	O
112	O
mL/min/1.73	O
m2	O
,	O
respectively	O
.	O

Using	O
quartile	O
one	O
as	O
the	O
reference	O
group	O
,	O
the	O
Î²-coefficients	O
(	O
95	O
%	O
confidence	O
intervals	O
[	O
CIs	O
]	O
)	O
for	O
eGFR	B-P
were	O
0.06	O
(	O
-	O
1.22	O
to	O
1.35	O
)	O
,	O
-0.66	O
(	O
-	O
1.95	O
to	O
0.62	O
)	O
and-1.70	O
(	O
-	O
3.01	O
to-0.39	O
)	O
for	O
quartiles	O
2-4	O
(	O
p-for-trend=0.0056	O
)	O
,	O
respectively	O
and	O
Î²-coefficients	O
(	O
95	O
%	O
CIs	O
)	O
for	O
cystatin	O
C	O
were	O
0.002	O
(	O
-	O
0.01	O
to	O
0.02	O
)	O
,	O
0.02	O
(	O
0.003-0.03	O
)	O
and	O
0.03	O
(	O
0.01-0.04	O
)	O
for	O
quartiles	O
2-4	O
(	O
p-for-trend	O
<	O
0.0001	O
)	O
,	O
respectively	O
.	O

Using	O
ET-1	O
as	O
a	O
continuous	O
variable	O
,	O
the	O
Î²-coefficient	O
(	O
95	O
%	O
CI	O
)	O
for	O
eGFR	B-P
per	O
1-unit	O
increase	O
was-1.82	O
(	O
-	O
3.19	O
to-0.44	O
,	O
p=0.0095	O
)	O
and	O
0.02	O
(	O
0.01-0.04	O
,	O
p=0.0003	O
)	O
for	O
cystatin	O
C.	O
Similar	O
results	O
were	O
found	O
between	O
creatinine	O
and	O
ET-1	O
levels	O
.	O

ET-1	O
levels	O
are	O
strongly	O
associated	O
with	O
parameters	O
of	O
renal	O
function	O
among	O
young	O
and	O
healthy	O
adults	O
,	O
suggesting	O
an	O
important	O
role	O
of	O
ET-1	O
and	O
endothelial	O
function	O
in	O
the	O
regulation	O
of	O
kidney	O
function	O
.	O

Effect	O
of	O
type	O
2	O
diabetes	O
mellitus	O
on	O
the	O
pharmacokinetics	O
and	O
transplacental	O
transfer	O
of	O
nifedipine	O
in	O
hypertensive	O
pregnant	O
women	O
.	O

Diabetes	O
mellitus	O
can	O
inhibit	O
cytochrome	O
P450	O
3A4	O
,	O
an	O
enzyme	O
responsible	O
for	O
the	O
metabolism	O
of	O
nifedipine	O
,	O
used	O
for	O
the	O
treatment	O
of	O
hypertension	O
in	O
pregnant	O
women	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
effect	O
of	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
on	O
the	O
pharmacokinetics	O
,	O
placental	O
transfer	O
and	O
distribution	O
of	O
nifedipine	O
in	O
amniotic	O
fluid	O
in	O
hypertensive	O
pregnant	O
women	O
.	O

The	O
study	O
was	O
conducted	O
in	O
12	O
hypertensive	O
pregnant	O
women	O
[	O
control	O
group	O
(	O
CG	O
)	O
]	O
and	O
10	O
hypertensive	O
pregnant	O
women	O
with	O
T2DM	O
taking	O
slow-release	O
nifedipine	O
(	O
20	O
mg	O
,	O
12/12	O
h	O
)	O
.	O

On	O
the	O
34th	O
week	O
of	O
gestation	O
,	O
serial	O
blood	O
samples	O
were	O
collected	O
(	O
0-12	O
h	O
)	O
after	O
administration	O
of	O
the	O
medication	O
.	O

At	O
delivery	O
,	O
samples	O
of	O
maternal	O
and	O
fetal	O
blood	O
and	O
amniotic	O
fluid	O
were	O
collected	O
for	O
determination	B-P
of	O
nifedipine	O
distribution	O
in	O
these	O
compartments	O
.	O

The	O
median	O
pharmacokinetic	O
parameters	O
of	O
CG	O
were	O
:	O
peak	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
26.41	O
ng	O
ml	O
(	O
-1	O
)	O
,	O
time	O
to	O
reach	O
Cmax	O
(	O
tmax	O
)	O
1.79	O
h	O
,	O
area	O
under	O
the	O
plasma	O
concentration	O
vs.	O
time	O
curve	O
from	O
0-12	O
h	O
(	O
AUC	O
0-12	O
)	O
235.99	O
ng.h	O
ml	O
(	O
-1	O
)	O
,	O
half-life	O
(	O
tÂ½	O
)	O
4.34	O
h	O
,	O
volume	O
of	O
distribution	O
divided	O
by	O
bioavailability	O
(	O
Vd	O
/	O
F	O
)	O
560.96	O
l	O
,	O
and	O
ClT	O
/	O
F	O
84.77	O
l	O
h	O
(	O
-1	O
)	O
.	O

The	O
parameters	O
for	O
T2DM	O
group	O
were	O
:	O
Cmax	O
23.52	O
ng	O
ml	O
(	O
-1	O
)	O
,	O
tmax	O
1.48	O
h	O
,	O
AUC	O
0-12	O
202.23	O
ng.h	O
ml	O
(	O
-1	O
)	O
,	O
tÂ½	O
5.00	O
h	O
,	O
Vd	O
/	O
F	O
609.40	O
l	O
,	O
and	O
apparent	O
total	O
clearance	O
(	O
ClT	O
/	O
F	O
)	O
98.94	O
l	O
h	O
(	O
-1	O
)	O
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
of	O
nifedipine	O
in	O
the	O
umbilical	O
vein	O
,	O
intervillous	O
space	O
and	O
amniotic	O
fluid	O
to	O
those	O
in	O
the	O
maternal	O
vein	O
for	O
CG	O
and	O
T2DM	O
were	O
0.53	O
and	O
0.44	O
,	O
0.78	O
and	O
0.87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	O
fluid	O
/	O
maternal	O
plasma	O
ratio	O
of	O
0.05	O
for	O
both	O
groups	O
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
in	O
the	O
umbilical	O
artery	O
to	O
those	O
in	O
the	O
umbilical	O
vein	O
were	O
0.82	O
for	O
CG	O
and	O
0.88	O
for	O
T2DM	O
.	O

There	O
was	O
no	O
influence	O
of	O
T2DM	O
on	O
the	O
pharmacokinetics	O
or	O
placental	O
transfer	O
of	O
nifedipine	O
in	O
hypertensive	O
women	O
with	O
controlled	O
diabetes	O
.	O

Clinical	O
Significance	O
of	O
2	O
Deep	O
Posterior	O
Perianal	O
Spaces	O
to	O
Complex	O
Cryptoglandular	O
Fistulas	O
.	O

Confusion	O
exists	O
regarding	O
the	O
clinical	O
significance	O
of	O
the	O
deep	O
posterior	O
intersphincteric	O
space	O
and	O
deep	O
postanal	O
space	O
to	O
complex	O
perianal	O
fistulas	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
significance	O
of	O
the	O
2	O
deep	O
posterior	O
perianal	O
spaces	O
and	O
to	O
describe	O
in	O
detail	O
the	O
courses	O
of	O
posterior	O
complex	O
cryptoglandular	O
fistula	O
extensions	O
.	O

This	O
was	O
a	O
retrospective	O
study	O
.	O

MRI	B-P
-	O
based	O
characteristics	O
of	O
selected	O
perianal	O
fistulas	O
were	O
independently	O
evaluated	O
by	O
examiners	O
who	O
focused	O
on	O
lesions	O
in	O
these	O
2	O
spaces	O
and	O
were	O
blinded	O
to	O
each	O
other	O
's	O
findings	O
.	O

This	O
study	O
was	O
conducted	O
in	O
the	O
colorectal	O
surgery	O
and	O
radiology	O
departments	O
of	O
a	O
large	O
university	O
teaching	O
hospital	O
in	O
China	O
.	O

Included	O
in	O
the	O
study	O
were	O
patients	O
who	O
underwent	O
pelvic	B-P
MRI	I-P
for	O
posterior	O
perianal	O
fistula	O
between	O
October	O
2012	O
and	O
December	O
2014	O
.	O

The	O
occurrence	O
rates	O
of	O
these	O
2	O
deep	O
perianal	O
space	O
lesions	O
in	O
posterior	O
cryptoglandular	O
fistulas	O
were	O
determined	O
.	O

A	O
total	O
of	O
513	O
primary	O
posterior	O
cryptoglandular	O
fistulas	O
were	O
identified	O
in	O
508	O
patients	O
,	O
including	O
167	O
deep	O
posterior	O
intersphincteric	O
space	O
lesions	O
(	O
32.6	O
%	O
)	O
and	O
23	O
deep	O
postanal	O
space	O
lesions	O
(	O
4.5	O
%	O
)	O
.	O

Of	O
those	O
,	O
173	O
fistulas	O
(	O
33.7	O
%	O
)	O
were	O
evaluated	O
as	O
complex	O
.	O

The	O
former	O
and	O
latter	O
spaces	O
were	O
involved	O
in	O
79.2	O
%	O
(	O
137/173	O
)	O
and	O
13.3	O
%	O
(	O
23/173	O
)	O
of	O
posterior	O
complex	O
fistulas	O
.	O

Compared	O
with	O
deep	O
postanal	O
space	O
lesions	O
,	O
deep	O
posterior	O
intersphincteric	O
space	O
lesions	O
were	O
more	O
common	O
in	O
cases	O
with	O
high	O
transsphincteric	O
or	O
suprasphincteric	O
fistulas	O
(	O
80.1	O
%	O
vs	O
15.8	O
%	O
)	O
,	O
synchronous	O
multiple	O
transsphincteric	O
fistulas	O
(	O
82.4	O
%	O
vs	O
20.6	O
%	O
)	O
,	O
horseshoe-like	O
fistulas	O
(	O
85.5	O
%	O
vs	O
14.5	O
%	O
)	O
,	O
and	O
supralevator	O
fistulas	O
(	O
93.5	O
%	O
vs	O
16.1	O
%	O
)	O
.	O

Similar	O
incidences	O
were	O
also	O
seen	O
in	O
cases	O
with	O
ischioanal	O
-	O
involved	O
horseshoe-like	O
fistulas	O
(	O
75.0	O
%	O
vs	O
25.0	O
%	O
)	O
.	O

This	O
study	O
was	O
limited	O
by	O
its	O
retrospective	O
nature	O
.	O

The	O
deep	O
posterior	O
intersphincteric	O
space	O
is	O
more	O
likely	O
than	O
the	O
deep	O
postanal	O
space	O
to	O
be	O
involved	O
in	O
complex	O
cryptoglandular	O
fistulas	O
and	O
is	O
likely	O
to	O
play	O
a	O
more	O
important	O
role	O
in	O
the	O
management	O
of	O
complex	O
cryptoglandular	O
fistulas	O
.	O

Genomics	O
of	O
Myeloproliferative	O
Neoplasms	O
.	O

Myeloproliferative	O
neoplasms	O
(	O
MPN	O
s	O
)	O
are	O
a	O
group	O
of	O
related	O
clonal	O
hematologic	O
disorders	O
characterized	O
by	O
excess	O
accumulation	O
of	O
one	O
or	O
more	O
myeloid	O
cell	O
lineages	O
and	O
a	O
tendency	O
to	O
transform	O
to	O
acute	O
myeloid	O
leukemia	O
.	O

Deregulated	O
JAK2	O
signaling	O
has	O
emerged	O
as	O
the	O
central	O
phenotypic	O
driver	O
of	O
BCR	O
-ABL1-negative	O
MPNs	O
and	O
a	O
unifying	O
therapeutic	O
target	O
.	O

In	O
addition	O
,	O
MPNs	O
show	O
unexpected	O
layers	O
of	O
genetic	O
complexity	O
,	O
with	O
multiple	O
abnormalities	O
associated	O
with	O
disease	O
progression	O
,	O
interactions	O
between	O
inherited	O
factors	O
and	O
phenotype	O
driver	O
mutations	O
,	O
and	O
effects	O
related	O
to	O
the	O
order	O
in	O
which	O
mutations	O
are	O
acquired	O
.	O

Although	O
morphology	O
and	O
clinical	O
laboratory	O
analysis	O
continue	O
to	O
play	O
an	O
important	O
role	O
in	O
defining	O
these	O
conditions	O
,	O
genomic	B-P
analysis	I-P
is	O
providing	O
a	O
platform	O
for	O
better	O
disease	O
definition	O
,	O
more	O
accurate	O
diagnosis	O
,	O
direction	O
of	O
therapy	O
,	O
and	O
refined	O
prognostication	O
.	O

There	O
is	O
an	O
emerging	O
consensus	O
with	O
regard	O
to	O
many	O
prognostic	O
factors	O
,	O
but	O
there	O
is	O
a	O
clear	O
need	O
to	O
synthesize	O
genomic	O
findings	O
into	O
robust	O
,	O
clinically	O
actionable	O
and	O
widely	O
accepted	O
scoring	O
systems	O
as	O
well	O
as	O
the	O
need	O
to	O
standardize	O
the	O
laboratory	O
methodologies	O
that	O
are	O
used	O
.	O

A	O
neutralizing	O
anti-G-CSFR	O
antibody	O
blocks	O
G-CSF	O
-	O
induced	O
neutrophilia	O
without	O
inducing	O
neutropenia	O
in	O
nonhuman	O
primates	O
.	O

Neutrophils	O
are	O
the	O
most	O
abundant	O
WBCs	O
and	O
have	O
an	O
essential	O
role	O
in	O
the	O
clearance	O
of	O
pathogens	O
.	O

Tight	O
regulation	O
of	O
neutrophil	O
numbers	O
and	O
their	O
recruitment	O
to	O
sites	O
of	O
inflammation	O
is	O
critical	O
in	O
maintaining	O
a	O
balanced	O
immune	O
response	O
.	O

In	O
various	O
inflammatory	O
conditions	O
,	O
such	O
as	O
rheumatoid	O
arthritis	O
,	O
vasculitis	O
,	O
cystic	O
fibrosis	O
,	O
and	O
inflammatory	O
bowel	O
disease	O
,	O
increased	O
serum	O
G-CSF	O
correlates	O
with	O
neutrophilia	O
and	O
enhanced	O
neutrophil	O
infiltration	O
into	O
inflamed	O
tissues	O
.	O

We	O
describe	O
a	O
fully	O
human	O
therapeutic	O
anti-G-CSFR	O
antibody	O
(	O
CSL324	O
)	O
that	O
is	O
safe	O
and	O
well	O
tolerated	O
when	O
administered	O
via	O
i.v	O
.	O

infusion	O
to	O
cynomolgus	O
macaques	O
.	O

CSL324	O
was	O
effective	O
in	O
controlling	O
G-CSF	O
-mediated	O
neutrophilia	O
when	O
administered	O
either	O
before	O
or	O
after	O
G-CSF	O
.	O

A	O
single	O
ascending-dose	O
study	O
showed	O
CSL324	O
did	O
not	O
alter	O
steady-state	O
neutrophil	B-P
numbers	I-P
,	O
even	O
at	O
doses	O
sufficient	O
to	O
completely	O
prevent	O
G-CSF	O
-mediated	O
neutrophilia	O
.	O

Weekly	O
infusions	O
of	O
CSL324	O
(	O
â¤10	O
mg/kg	O
)	O
for	O
3	O
wk	O
completely	O
neutralized	O
G-CSF	O
-mediated	O
pSTAT3	O
phosphorylation	O
without	O
neutropenia	O
.	O

Moreover	O
,	O
repeat	O
dosing	O
up	O
to	O
100	O
mg/kg	O
for	O
12	O
wk	O
did	O
not	O
result	O
in	O
neutropenia	O
at	O
any	O
point	O
,	O
including	O
the	O
12-wk	O
follow-up	O
after	O
the	O
last	O
infusion	O
.	O

In	O
addition	O
,	O
CSL324	O
had	O
no	O
observable	O
effect	O
on	O
basic	O
neutrophil	O
functions	O
,	O
such	O
as	O
phagocytosis	O
and	O
oxidative	O
burst	O
.	O

These	O
data	O
suggest	O
that	O
targeting	O
G-CSFR	O
may	O
provide	O
a	O
safe	O
and	O
effective	O
means	O
of	O
controlling	O
G-CSF	O
-mediated	O
neutrophilia	O
as	O
observed	O
in	O
various	O
inflammatory	O
diseases	O
.	O

Improved	O
individualized	O
prediction	O
of	O
schizophrenia	O
in	O
subjects	O
at	O
familial	O
high	O
risk	O
,	O
based	O
on	O
neuroanatomical	O
data	O
,	O
schizotypal	O
and	O
neurocognitive	O
features	O
.	O

To	O
date	O
,	O
there	O
are	O
no	O
reliable	O
markers	O
for	O
predicting	O
onset	O
of	O
schizophrenia	O
in	O
individuals	O
at	O
high	O
risk	O
(	O
HR	O
)	O
.	O

Substantial	O
promise	O
is	O
,	O
however	O
,	O
shown	O
by	O
a	O
variety	O
of	O
pattern	O
classification	O
approaches	O
to	O
neuroimaging	B-P
data	I-P
.	O

Here	O
,	O
we	O
examined	O
the	O
predictive	O
accuracy	O
of	O
support	O
vector	O
machine	O
(	O
SVM	O
)	O
in	O
later	O
diagnosing	O
schizophrenia	O
,	O
at	O
a	O
single-subject	O
level	O
,	O
using	O
a	O
cohort	O
of	O
HR	O
individuals	O
drawn	O
from	O
multiply	O
affected	O
families	O
and	O
a	O
combination	O
of	O
neuroanatomical	O
,	O
schizotypal	O
and	O
neurocognitive	O
variables	O
.	O

Baseline	O
structural	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
,	O
schizotypal	O
and	O
neurocognitive	O
data	O
from	O
17	O
HR	O
subjects	O
,	O
who	O
subsequently	O
developed	O
schizophrenia	O
and	O
a	O
matched	O
group	O
of	O
17	O
HR	O
subjects	O
who	O
did	O
not	O
make	O
the	O
transition	O
,	O
yet	O
had	O
psychotic	O
symptoms	O
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O

We	O
employed	O
recursive	O
feature	O
elimination	O
(	O
RFE	O
)	O
,	O
in	O
a	O
nested	O
cross-validation	O
scheme	O
to	O
identify	O
the	O
most	O
significant	O
predictors	O
of	O
disease	O
transition	O
and	O
enhance	O
diagnostic	O
performance	O
.	O

Classification	O
accuracy	O
was	O
94	O
%	O
when	O
a	O
self-completed	O
measure	O
of	O
schizotypy	O
,	O
a	O
declarative	O
memory	O
test	O
and	O
structural	O
MRI	B-P
data	O
were	O
combined	O
into	O
a	O
single	O
learning	O
algorithm	O
;	O
higher	O
than	O
when	O
either	O
quantitative	O
measure	O
was	O
used	O
alone	O
.	O

The	O
discriminative	O
neuroanatomical	O
pattern	O
involved	O
gray	O
matter	O
volume	O
differences	O
in	O
frontal	O
,	O
orbito-frontal	O
and	O
occipital	O
lobe	O
regions	O
bilaterally	O
as	O
well	O
as	O
parts	O
of	O
the	O
superior	O
,	O
medial	O
temporal	O
lobe	O
and	O
cerebellar	O
regions	O
.	O

Our	O
findings	O
suggest	O
that	O
an	O
early	O
SVM	O
-based	O
prediction	O
of	O
schizophrenia	O
is	O
possible	O
and	O
can	O
be	O
improved	O
by	O
combining	O
schizotypal	O
and	O
neurocognitive	O
features	O
with	O
neuroanatomical	O
variables	O
.	O

However	O
,	O
our	O
predictive	O
model	O
needs	O
to	O
be	O
tested	O
by	O
classifying	O
a	O
new	O
,	O
independent	O
HR	O
cohort	O
in	O
order	O
to	O
estimate	O
its	O
validity	O
.	O

The	O
consummatory	O
and	O
motivational	O
behaviors	O
for	O
natural	O
rewards	O
following	O
long-term	O
withdrawal	O
from	O
morphine	O
:	O
no	O
anhedonia	O
but	O
persistent	O
maladaptive	O
behaviors	O
for	O
high-value	O
rewards	O
.	O

The	O
negative	O
affective	O
state	O
,	O
e.g.	O
,	O
anhedonia	O
,	O
emerges	O
after	O
abstinence	O
from	O
abused	O
drugs	O
may	O
be	O
linked	O
to	O
the	O
motivational	O
processes	O
of	O
drug	O
craving	O
and	O
relapse	O
.	O

Although	O
anhedonia	O
diminishes	O
over	O
time	O
with	O
drug	O
abstinence	O
,	O
it	O
is	O
not	O
yet	O
rather	O
explicit	O
whether	O
anhedonia	O
exists	O
or	O
not	O
following	O
protracted	O
withdrawal	O
.	O

The	O
behavioral	O
responses	O
to	O
natural	O
rewards	O
were	O
examined	O
after	O
2	O
to	O
3	O
weeks	O
withdrawal	O
from	O
morphine	O
.	O

Male	O
rats	O
were	O
pretreated	O
with	O
either	O
a	O
binge-like	O
morphine	O
paradigm	O
or	O
daily	O
saline	O
injection	O
for	O
5	O
days	O
.	O

The	O
consummatory	O
and	O
motivational	O
behaviors	O
for	O
three	O
natural	O
rewards	O
(	O
sucrose	O
solutions	O
4	O
,	O
15	O
,	O
and	O
60	O
%	O
,	O
social	O
stimulus	O
:	O
male	O
rat	O
,	O
and	O
sexual	O
stimulus	O
:	O
estrous	O
female	O
rat	O
)	O
were	O
examined	O
under	O
varied	O
testing	O
conditions	O
.	O

The	O
morphine	O
-	O
withdrawn	O
rats	O
significantly	O
increased	O
their	O
intake	O
of	O
15	O
%	O
sucrose	O
solution	O
during	O
the	O
1-h	O
consumption	B-P
test	I-P
and	O
their	O
operant	O
responding	O
for	O
15	O
%	O
sucrose	O
solution	O
under	O
a	O
progressive	O
ratio	O
(	O
PR	O
)	O
schedule	O
of	O
reinforcement	O
.	O

When	O
obtaining	O
a	O
reinforcer	O
was	O
associated	O
with	O
a	O
0.5	O
mA	O
foot	O
shock	O
under	O
a	O
PR-punishment	O
schedule	O
,	O
the	O
morphine	O
-	O
withdrawn	O
rats	O
showed	O
a	O
higher	O
performance	O
for	O
60	O
%	O
sucrose	O
solution	O
.	O

Meanwhile	O
,	O
the	O
morphine	O
-	O
withdrawn	O
rats	O
displayed	O
a	O
higher	O
motivation	O
to	O
sexual	O
stimulus	O
during	O
the	O
free-approach	B-P
test	I-P
and	O
more	O
approaching	O
behaviors	O
towards	O
sexual	O
stimulus	O
in	O
a	O
conflict-based	B-P
approach	I-P
test	I-P
(	O
concurrent	O
presence	O
of	O
reward	O
and	O
aversive	O
stimulus	O
)	O
.	O

No	O
anhedonia	O
-like	O
behavior	O
but	O
sensitized	O
behaviors	O
for	O
natural	O
rewards	O
were	O
found	O
after	O
long-term	O
morphine	O
withdrawal	O
.	O

Notably	O
,	O
the	O
morphine	O
-	O
withdrawn	O
rats	O
displayed	O
persistent	O
motivated	O
behaviors	O
for	O
high-value	O
rewards	O
(	O
60	O
%	O
sucrose	O
and	O
sexual	O
stimulus	O
)	O
in	O
the	O
conflict	B-P
tests	I-P
suggesting	O
impairments	O
in	O
inhibitory	O
control	O
in	O
morphine	O
-	O
treated	O
rats	O
.	O

Probiotics	O
and	O
oral	O
health	O
:	O
A	O
systematic	O
review	O
.	O

Probiotics	O
are	O
microorganisms	O
,	O
mainly	O
bacteria	O
,	O
which	O
benefit	O
the	O
host	O
's	O
health	O
.	O

Many	O
studies	O
support	O
the	O
role	O
of	O
probiotics	O
as	O
a	O
contributor	O
to	O
gastrointestinal	O
health	O
,	O
and	O
nowadays	O
many	O
authors	O
are	O
trying	O
to	O
prove	O
its	O
influence	O
in	O
oral	O
health	O
maintenance	O
.	O

To	O
review	O
the	O
published	O
literature	O
with	O
the	O
purpose	O
of	O
knowing	O
the	O
importance	O
of	O
using	O
probiotics	O
as	O
a	O
preventive	O
and	O
therapeutic	O
method	O
for	O
oral	O
infectious	O
diseases	O
management	O
.	O

An	O
electronic	O
search	O
in	O
PubMed	O
database	O
with	O
the	O
keywords	O
``	O
oral	O
health	O
AND	O
probiotics	O
AND	O
dentistry	O
``	O
was	O
conducted	O
.	O

The	O
inclusion	O
criteria	O
were	O
:	O
randomized	O
clinical	O
trials	O
(	O
RCTs	O
)	O
that	O
assess	O
the	O
action	O
of	O
any	O
probiotic	O
strain	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
an	O
infectious	O
oral	O
disease	O
,	O
RCTs	O
that	O
assess	O
the	O
action	O
of	O
any	O
probiotic	O
strain	O
on	O
counting	B-P
colony	O
forming	O
units	O
(	O
CFU	O
)	O
of	O
oral	O
pathogens	O
,	O
systematic	O
reviews	O
and	O
meta-analysis	O
.	O

The	O
Jadad	O
scale	O
was	O
used	O
to	O
assess	O
the	O
high	O
quality	O
of	O
RCTs	O
.	O

Fifteen	O
articles	O
were	O
considered	O
for	O
this	O
review	O
.	O

Of	O
which	O
,	O
12	O
were	O
RCTs	O
of	O
good	O
/	O
high	O
quality	O
(	O
Jadad	O
scale	O
)	O
,	O
two	O
meta-analysis	O
and	O
one	O
systematic	O
review	O
.	O

The	O
literature	O
reviewed	O
suggests	O
probiotics	O
usage	O
could	O
be	O
beneficial	O
for	O
the	O
maintenance	O
of	O
oral	O
health	O
,	O
due	O
to	O
its	O
ability	O
to	O
decrease	O
the	O
colony	O
forming	O
units	O
(	O
CFU	O
)	O
counts	O
of	O
the	O
oral	O
pathogens	O
.	O

However	O
,	O
randomized	O
clinical	O
trials	O
with	O
long-term	O
follow-up	O
periods	O
are	O
needed	O
to	O
confirm	O
their	O
efficacy	O
in	O
reducing	O
the	O
prevalence/incidence	O
of	O
oral	O
infectious	O
diseases	O
.	O

Furthermore	O
,	O
the	O
recognition	O
of	O
specific	O
strains	O
with	O
probiotic	O
activity	O
for	O
each	O
infectious	O
oral	O
disease	O
is	O
required	O
,	O
in	O
order	O
to	O
determine	O
exact	O
dose	O
,	O
treatment	O
time	O
and	O
ideal	O
vehicles	O
.	O

Assessment	O
of	O
Vascular	O
Stent	O
Heating	O
with	O
Repetitive	O
Transcranial	O
Magnetic	O
Stimulation	O
.	O

A	O
high	O
proportion	O
of	O
patients	O
with	O
stroke	O
do	O
not	O
qualify	O
for	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
clinical	O
studies	O
due	O
to	O
the	O
presence	O
of	O
metallic	O
stents	O
.	O

The	O
ultimate	O
concern	O
is	O
that	O
any	O
metal	O
could	O
become	O
heated	O
due	O
to	O
eddy	O
currents	O
.	O

However	O
,	O
to	O
date	O
,	O
no	O
clinical	O
safety	O
data	O
are	O
available	O
regarding	O
the	O
risk	O
of	O
metallic	O
stents	O
heating	O
with	O
rTMS	O
.	O

We	O
tested	O
the	O
safety	O
of	O
common	O
rTMS	O
protocols	O
(	O
1	O
Hz	O
and	O
10	O
Hz	O
)	O
with	O
stents	O
used	O
commonly	O
in	O
stroke	O
,	O
nitinol	O
and	O
elgiloy	O
.	O

In	O
our	O
method	O
,	O
stents	O
were	O
tested	O
in	O
gelled	O
saline	O
at	O
2	O
different	O
locations	O
:	O
at	O
the	O
center	O
and	O
at	O
the	O
lobe	O
of	O
the	O
coil	O
.	O

In	O
addition	O
,	O
at	O
each	O
location	O
,	O
stent	O
heating	O
was	O
evaluated	O
in	O
3	O
different	O
orientations	O
:	O
parallel	O
to	O
the	O
long	O
axis	O
of	O
coil	O
,	O
parallel	O
to	O
the	O
short	O
axis	O
of	O
the	O
coil	O
,	O
and	O
perpendicular	O
to	O
the	O
plane	O
of	O
the	O
coil	O
.	O

We	O
found	O
that	O
stents	O
did	O
not	O
heat	O
to	O
more	O
than	O
1Â°C	O
with	O
either	O
1	O
Hz	O
rTMS	O
or	O
10	O
Hz	O
rTMS	O
in	O
any	O
configuration	O
or	O
orientation	O
.	O

Heating	O
in	O
general	O
was	O
greater	O
at	O
the	O
lobe	O
when	O
the	O
stent	O
was	O
oriented	O
perpendicularly	O
.	O

Our	O
study	O
represents	O
a	O
new	O
method	O
for	O
ex	O
vivo	O
quantification	O
of	O
stent	O
heating	O
.	O

We	O
have	O
found	O
that	O
heating	O
of	O
stents	O
was	O
well	O
below	O
the	O
Food	O
and	O
Drug	O
Administration	O
standards	O
of	O
2Â°C	O
.	O

Thus	O
,	O
our	O
study	O
paves	O
the	O
way	O
for	O
in	O
vivo	O
testing	O
of	O
rTMS	O
(	O
â¤10	O
Hz	O
)	O
in	O
the	O
presence	O
of	O
implanted	O
magnetic	B-P
resonance	I-P
imaging	I-P
-	O
compatible	O
stents	O
in	O
animal	O
studies	O
.	O

When	O
planning	O
human	O
safety	O
studies	O
though	O
,	O
geometry	O
,	O
orientation	O
,	O
and	O
location	O
relative	O
to	O
the	O
coil	O
would	O
be	O
important	O
to	O
consider	O
as	O
well	O
.	O

Patient	O
Factors	O
Associated	O
With	O
Higher	O
Expectations	O
From	O
Foot	O
and	O
Ankle	O
Surgery	O
.	O

Few	O
authors	O
have	O
investigated	O
patients	O
'	O
expectations	O
from	O
foot	O
and	O
ankle	O
surgery	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
examine	O
relationships	O
between	O
patients	O
'	O
preoperative	O
expectations	O
and	O
their	O
demographic	O
and	O
clinical	O
characteristics	O
.	O

We	O
hypothesized	O
that	O
patients	O
with	O
more	O
disability	O
and	O
those	O
with	O
anxiety	O
or	O
depressive	O
symptoms	O
would	O
have	O
greater	O
expectations	O
.	O

All	O
adult	O
patients	O
scheduled	O
for	O
elective	O
foot	O
or	O
ankle	O
surgery	O
by	O
1	O
of	O
6	O
orthopaedic	O
foot	O
and	O
ankle	O
surgeons	O
were	O
screened	O
for	O
inclusion	O
over	O
8	O
months	O
.	O

Preoperatively	O
,	O
all	O
patients	O
completed	O
the	O
Hospital	O
for	O
Special	O
Surgery	O
Foot	O
&	O
Ankle	O
Surgery	O
Expectations	O
Survey	O
in	O
addition	O
to	O
the	O
Foot	O
&	O
Ankle	O
Outcome	O
Score	O
(	O
FAOS	O
)	O
,	O
Short	O
Form	O
(	O
SF	O
)	O
-12	O
,	O
Patient	O
Health	O
Questionnaire	O
(	O
PHQ	O
)	O
-8	O
,	O
Generalized	O
Anxiety	O
Disorder	O
7-item	O
scale	O
(	O
GAD-7	O
)	O
,	O
and	O
pain	B-P
visual	I-P
analog	I-P
scale	I-P
(	O
VAS	B-P
)	O
.	O

The	O
expectations	O
survey	O
contained	O
23	O
expectations	O
categories	O
,	O
each	O
with	O
5	O
answer	O
choices	O
ranging	O
from	O
``	O
I	O
do	O
not	O
have	O
this	O
expectation	O
``	O
to	O
``	O
complete	O
improvement	O
``	O
expected	O
.	O

It	O
was	O
scored	O
from	O
0	O
to	O
100	O
,	O
with	O
higher	O
scores	O
indicating	O
more	O
expectations	O
.	O

Differences	O
in	O
expectations	O
relating	O
to	O
numerous	O
patient	O
demographic	O
and	O
clinical	O
variables	O
were	O
assessed	O
.	O

In	O
total	O
,	O
352	O
patients	O
with	O
an	O
average	O
age	O
of	O
55	O
Â±	O
15	O
(	O
range	O
,	O
18-86	O
)	O
years	O
were	O
enrolled	O
.	O

Expectations	O
scores	O
were	O
not	O
related	O
to	O
age	O
(	O
P	O
=	O
.36	O
)	O
.	O

On	O
average	O
,	O
women	O
expected	O
to	O
achieve	O
complete	O
improvement	O
more	O
often	O
than	O
men	O
(	O
P	O
=	O
.011	O
)	O
.	O

Variables	O
that	O
were	O
significantly	O
associated	O
with	O
higher	O
expectations	O
scores	O
(	O
P	O
<	O
.05	O
)	O
included	O
nonwhite	O
race	O
,	O
use	O
of	O
a	O
cane	O
or	O
other	O
assistive	O
device	O
,	O
and	O
greater	O
medical	O
comorbidity	O
.	O

Worse	O
function	O
and	O
quality	O
of	O
life	O
(	O
as	O
assessed	O
by	O
all	O
FAOS	O
subscales	O
and	O
the	O
SF-12	O
physical	O
and	O
mental	O
components	O
)	O
,	O
more	O
depressive	O
and	O
anxiety	O
symptoms	O
,	O
and	O
higher	O
pain	O
VAS	O
scores	O
were	O
associated	O
with	O
higher	O
expectations	O
scores	O
and	O
more	O
expectations	O
(	O
P	O
<	O
.01	O
for	O
all	O
)	O
.	O

The	O
results	O
of	O
this	O
study	O
may	O
help	O
inform	O
surgeons	O
'	O
preoperative	O
discussions	O
with	O
their	O
patients	O
regarding	O
realistic	O
expectations	O
from	O
surgery	O
.	O

Generally	O
,	O
patients	O
with	O
worse	O
function	O
and	O
more	O
disability	O
had	O
higher	O
expectations	O
from	O
surgery	O
.	O

Addressing	O
these	O
patients	O
'	O
expectations	O
preoperatively	O
may	O
help	O
improve	O
their	O
ultimate	O
satisfaction	O
with	O
surgery	O
.	O

Level	O
II	O
,	O
cross	O
sectional	O
study	O
.	O

Maturational	O
Patterns	O
of	O
Systolic	O
Ventricular	O
Deformation	O
Mechanics	O
by	O
Two-Dimensional	B-P
Speckle-Tracking	I-P
Echocardiography	I-P
in	O
Preterm	O
Infants	O
over	O
the	O
First	O
Year	O
of	O
Age	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
maturational	O
changes	O
in	O
systolic	O
ventricular	O
strain	O
mechanics	O
by	O
two-dimensional	B-P
speckle-tracking	I-P
echocardiography	I-P
in	O
extremely	O
preterm	O
neonates	O
from	O
birth	O
to	O
1	O
year	O
of	O
age	O
and	O
discern	O
the	O
impact	O
of	O
common	O
cardiopulmonary	O
abnormalities	O
on	O
the	O
deformation	O
measures	O
.	O

In	O
a	O
prospective	O
multicenter	O
study	O
of	O
239	O
extremely	O
preterm	O
infants	O
(	O
<	O
29	O
weeks	O
gestation	O
at	O
birth	O
)	O
,	O
left	O
ventricular	O
(	O
LV	O
)	O
global	O
longitudinal	O
strain	O
(	O
GLS	O
)	O
and	O
global	O
longitudinal	O
systolic	O
strain	O
rate	O
(	O
GLSRs	O
)	O
,	O
interventricular	O
septal	O
wall	O
(	O
IVS	O
)	O
GLS	O
and	O
GLSRs	O
,	O
(	O
RV	O
)	O
free	O
wall	O
longitudinal	O
strain	O
and	O
strain	O
rate	O
,	O
and	O
segmental	O
longitudinal	O
strain	O
in	O
the	O
RV	O
free	O
wall	O
,	O
LV	O
free	O
wall	O
,	O
and	O
IVS	O
were	O
serially	O
measured	O
on	O
days	O
1	O
,	O
2	O
,	O
and	O
5	O
to	O
7	O
,	O
at	O
32	O
and	O
36	O
weeks	O
postmenstrual	O
age	O
,	O
and	O
at	O
1	O
year	O
corrected	O
age	O
(	O
CA	O
)	O
.	O

Premature	O
infants	O
who	O
developed	O
bronchopulmonary	O
dysplasia	O
or	O
had	O
echocardiographic	B-P
findings	O
of	O
pulmonary	O
hypertension	O
were	O
analyzed	O
separately	O
.	O

In	O
uncomplicated	O
preterm	O
infants	O
(	O
n	O
=	O
103	O
[	O
48	O
%	O
]	O
)	O
,	O
LV	O
GLS	O
and	O
GLSRs	O
remained	O
unchanged	O
from	O
days	O
5	O
to	O
7	O
to	O
1	O
year	O
CA	O
(	O
P	O
=	O
.60	O
and	O
P	O
=	O
.59	O
)	O
.	O

RV	O
free	O
wall	O
longitudinal	O
strain	O
,	O
RV	O
free	O
wall	O
longitudinal	O
strain	O
rate	O
,	O
and	O
IVS	O
GLS	O
and	O
GLSRs	O
significantly	O
increased	O
over	O
the	O
same	O
time	O
period	O
(	O
P	O
<	O
.01	O
for	O
all	O
measures	O
)	O
.	O

A	O
significant	O
base-to-apex	O
(	O
highest	O
to	O
lowest	O
)	O
segmental	O
longitudinal	O
strain	O
gradient	O
(	O
P	O
<	O
.01	O
)	O
was	O
seen	O
in	O
the	O
RV	O
free	O
wall	O
and	O
a	O
reverse	O
apex-to-base	O
gradient	O
(	O
P	O
<	O
.01	O
)	O
in	O
the	O
LV	O
free	O
wall	O
.	O

In	O
infants	O
with	O
bronchopulmonary	O
dysplasia	O
and/or	O
pulmonary	O
hypertension	O
(	O
n	O
=	O
119	O
[	O
51	O
%	O
]	O
)	O
,	O
RV	O
free	O
wall	O
longitudinal	O
strain	O
and	O
IVS	O
GLS	O
were	O
significantly	O
lower	O
(	O
P	O
<	O
.01	O
)	O
,	O
LV	O
GLS	O
and	O
GLSRs	O
were	O
similar	O
(	O
P	O
=	O
.56	O
)	O
,	O
and	O
IVS	O
segmental	O
longitudinal	O
strain	O
persisted	O
as	O
an	O
RV	O
-	O
dominant	O
base-to-apex	O
gradient	O
from	O
32	O
weeks	O
postmenstrual	O
age	O
to	O
1	O
year	O
CA	O
.	O

This	O
study	O
tracks	O
the	O
maturational	O
patterns	O
of	O
global	O
and	O
regional	O
deformation	O
by	O
two-dimensional	B-P
speckle-tracking	I-P
echocardiography	I-P
in	O
extremely	O
preterm	O
infants	O
from	O
birth	O
to	O
1	O
year	O
CA	O
.	O

The	O
maturational	O
patterns	O
are	O
ventricular	O
specific	O
.	O

Bronchopulmonary	O
dysplasia	O
and	O
pulmonary	O
hypertension	O
leave	O
a	O
negative	O
impact	O
on	O
RV	O
and	O
IVS	O
strain	O
,	O
while	O
LV	O
strain	O
remains	O
stable	O
.	O

Identification	O
and	O
Quantification	O
of	O
Human	O
Brown	O
Adipose	O
Tissue	O
.	O

Brown	O
adipose	O
tissue	O
(	O
BAT	O
)	O
has	O
attracted	O
significant	O
interest	O
as	O
a	O
potential	O
target	O
tissue	O
against	O
obesity	O
and	O
its	O
associated	O
metabolic	O
perturbations	O
.	O

The	O
purpose	O
of	O
this	O
chapter	O
is	O
to	O
provide	O
an	O
overview	O
of	O
some	O
of	O
the	O
methodological	O
approaches	O
that	O
can	O
be	O
used	O
to	O
identify	O
and	O
quantify	O
BAT	O
in	O
people	O
.	O

Specifically	O
,	O
we	O
will	O
provide	O
a	O
step-by-step	O
description	O
of	O
the	O
following	O
procedures	O
:	O
quantification	O
of	O
BAT	O
in	O
vivo	O
using	O
positron	B-P
emission	I-P
tomography-computed	I-P
tomography	I-P
(	O
PET/CT	B-P
)	O
with	O
2-deoxy-2-	O
[	O
(	O
18	O
)	O
F	O
]	O
fluoroglucose	O
(	O
(	O
18	O
)	O
F-FDG	O
)	O
as	O
a	O
tracer	O
,	O
mitochondrial	O
respiration	O
,	O
and	O
uncoupling	O
protein	O
1	O
(	O
UCP1	O
)	O
gene	O
and	O
protein	O
expression	O
.	O

Urticarial	O
exanthema	O
due	O
to	O
hepatitis	O
B	O
in	O
a	O
pregnant	O
woman	O
,	O
mimicking	O
a	O
polymorphic	O
eruption	O
of	O
pregnancy	O
.	O

Hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
infection	O
in	O
pregnant	O
women	O
is	O
very	O
rare	O
in	O
western	O
countries	O
,	O
thus	O
,	O
cutaneous	O
manifestation	O
of	O
HBV	O
infection	O
may	O
be	O
confused	O
with	O
a	O
dermatosis	O
specific	O
of	O
pregnancy	O
.	O

We	O
report	O
a	O
39-year-old	O
woman	O
who	O
presented	O
in	O
her	O
20th	O
week	O
of	O
pregnancy	O
with	O
a	O
pruritic	O
rash	O
,	O
which	O
consisted	O
of	O
generalized	O
erythematous	O
plaques	O
,	O
some	O
of	O
them	O
with	O
a	O
purple	O
centre	O
.	O

Serology	B-P
testing	I-P
showed	O
acute	O
HBV	O
infection	O
,	O
and	O
a	O
biopsy	B-P
revealed	O
a	O
superficial	O
and	O
interstitial	O
perivascular	O
inflammatory	O
infiltrate	O
of	O
lymphocytes	O
and	O
eosinophils	O
.	O

A	O
diagnosis	O
of	O
exanthema	O
due	O
to	O
acute	O
hepatitis	O
B	O
infection	O
was	O
established	O
.	O

The	O
patient	O
delivered	O
a	O
clinically	O
healthy	O
boy	O
,	O
who	O
was	O
given	O
the	O
first	O
dose	O
of	O
the	O
HBV	O
vaccine	O
and	O
intravenous	O
specific	O
immunoglobulin	O
,	O
followed	O
by	O
the	O
second	O
dose	O
2	O
months	O
later	O
,	O
and	O
did	O
not	O
get	O
infected	O
with	O
HBV	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
describing	O
HBV	O
exanthema	O
in	O
a	O
pregnant	O
woman	O
,	O
which	O
led	O
to	O
early	O
action	O
for	O
the	O
newborn	O
,	O
avoiding	O
vertical	O
transmission	O
and	O
its	O
high	O
prevalence	O
of	O
cirrhosis	O
and	O
hepatocellular	O
carcinoma	O
.	O

Is	O
UV	O
-	O
Induced	O
Electron-Driven	O
Proton	O
Transfer	O
Active	O
in	O
a	O
Chemically	O
Modified	O
A	O
Â·	O
T	O
DNA	O
Base	O
Pair	O
?	O
.	O

Transient	B-P
electronic	I-P
and	I-P
vibrational	I-P
absorption	I-P
spectroscopies	I-P
have	O
been	O
used	O
to	O
investigate	O
whether	O
UV	O
-	O
induced	O
electron-driven	O
proton	O
transfer	O
(	O
EDPT	O
)	O
mechanisms	O
are	O
active	O
in	O
a	O
chemically	O
modified	O
adenine	O
-	O
thymine	O
(	O
A	O
Â·	O
T	O
)	O
DNA	O
base	O
pair	O
.	O

To	O
enhance	O
the	O
fraction	O
of	O
biologically	O
relevant	O
Watson-Crick	O
(	O
WC	O
)	O
hydrogen-bonding	O
motifs	O
and	O
eliminate	O
undesired	O
Hoogsteen	O
structures	O
,	O
a	O
chemically	O
modified	O
derivative	O
of	O
A	O
was	O
synthesized	O
,	O
8-	O
(	O
tert-butyl	O
)	O
-9-ethyladenine	O
(	O
8tBA	O
)	O
.	O

Equimolar	O
solutions	O
of	O
8tBA	O
and	O
silyl-protected	O
T	O
nucleosides	O
in	O
chloroform	O
yield	O
a	O
mixture	O
of	O
WC	O
pairs	O
,	O
reverse	O
WC	O
pairs	O
,	O
and	O
residual	O
monomers	O
.	O

Unlike	O
previous	O
transient	B-P
absorption	I-P
studies	I-P
of	O
WC	O
guanine	O
-	O
cytosin	O
e	O
(	O
G	O
Â·	O
C	O
)	O
pairs	O
,	O
no	O
clear	O
spectroscopic	O
or	O
kinetic	O
evidence	O
was	O
identified	O
for	O
the	O
participation	O
of	O
EDPT	O
in	O
the	O
excited-state	O
relaxation	O
dynamics	O
of	O
8tBA	O
Â·	O
T	O
pairs	O
,	O
although	O
ultrafast	O
(	O
sub-100	O
fs	O
)	O
EDPT	O
can	O
not	O
be	O
discounted	O
.	O

Monomer-like	O
dynamics	O
are	O
proposed	O
to	O
dominate	O
in	O
8tBA	O
Â·	O
T	O
.	O

Selenium	O
Ameliorate	O
Peripheral	O
Nerve	O
Ischemic-Reperfusion	O
Injury	O
via	O
Decreased	O
TNF-Î±	O
.	O

Selenium	O
is	O
considered	O
as	O
a	O
trace	O
element	O
that	O
plays	O
antioxidant	O
role	O
in	O
the	O
body	O
.	O

So	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
selenium	O
on	O
ameliorating	O
of	O
sciatic	O
nerve	O
ischemia-reperfusion	O
injury	O
.	O

Eighty	O
(	O
80	O
)	O
adult	O
male	O
Wistar	O
rats	O
weighing	O
250-300	O
g	O
were	O
used	O
.	O

They	O
were	O
divided	O
into	O
10	O
groups	O
(	O
n	O
=	O
8	O
)	O
.	O

Then	O
,	O
femoral	O
vessels	O
were	O
obstructed	O
by	O
using	O
4/0	O
silk	O
and	O
splitknot	O
techniques	O
.	O

After	O
3-h	O
ischemia	O
for	O
all	O
the	O
groups	O
,	O
reperfusion	O
was	O
applied	O
for	O
different	O
periods	O
:	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
28	O
days	O
.	O

In	O
half	O
of	O
each	O
experimental	O
group	O
,	O
0.2	O
mg/kg	O
selenium	O
was	O
injected	O
intraperitoneally	O
,	O
coinciding	O
with	O
ischemia	O
.	O

After	O
reperfusion	O
,	O
according	O
to	O
the	O
grouping	O
,	O
rats	O
were	O
killed	O
by	O
using	O
high	O
dose	O
of	O
anesthetic	O
drug	O
and	O
then	O
sciatic	O
nerve	O
was	O
removed	O
and	O
fixed	O
.	O

Then	O
,	O
tissue	O
samples	O
were	O
processed	O
and	O
subsequently	O
stained	B-P
with	I-P
hematoxylin-eosin	I-P
,	O
apoptosis	O
,	O
and	O
immunohistochemistry	O
stains	O
.	O

On	O
the	O
third	O
day	O
of	O
reperfusion	O
,	O
the	O
amount	O
of	O
TNF-Î±	O
as	O
an	O
inflammatory	O
marker	O
of	O
ischemia	O
-	O
reperfusion	O
acute	O
phase	O
increased	O
.	O

On	O
the	O
seventh	O
day	O
of	O
reperfusion	O
,	O
the	O
amount	O
of	O
NF-ÐºB	O
as	O
an	O
apoptotic	O
index	O
and	O
infiltration	O
of	O
mast	O
cells	O
increased	O
in	O
the	O
tissue	O
as	O
a	O
result	O
of	O
development	O
of	O
inflammation	O
.	O

But	O
,	O
on	O
the	O
14th	O
day	O
of	O
reperfusion	O
,	O
the	O
amount	O
of	O
NF-ÐºB	O
as	O
an	O
apoptotic	O
index	O
decreased	O
to	O
the	O
lowest	O
amount	O
.	O

On	O
the	O
28th	O
day	O
of	O
reperfusion	O
,	O
the	O
amount	O
of	O
TNF-Î±	O
as	O
an	O
inflammatory	O
marker	O
decreased	O
to	O
its	O
lowest	O
level	O
.	O

Prescription	O
of	O
selenium	O
concurrent	O
with	O
development	O
of	O
ischemia	O
can	O
reduce	O
the	O
damage	O
caused	O
by	O
sciatic	O
nerve	O
ischemia-reperfusion	O
.	O

Antimicrobial	O
susceptibility	O
of	O
Pseudomonas	O
aeruginosa	O
before	O
and	O
after	O
initiation	O
of	O
inhaled	O
tobramycin	O
in	O
Bulgaria	O
.	O

In	O
aim	O
to	O
achieve	O
better	O
infection	O
control	O
and	O
possible	O
eradication	O
of	O
the	O
pathogens	O
involved	O
in	O
chronic	O
infections	O
of	O
patients	O
with	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
scientists	O
have	O
developed	O
a	O
new	O
way	O
to	O
administer	O
antimicrobials	O
-	O
inhalation	O
.	O

The	O
first	O
and	O
so	O
far	O
the	O
only	O
available	O
inhalable	O
antimicrobial	O
in	O
Bulgaria	O
is	O
inhaled	O
tobramycin	O
(	O
TOBI	O
)	O
,	O
introduced	O
in	O
2009	O
.	O

We	O
aimed	O
to	O
evaluate	O
the	O
antimicrobial	O
susceptibility	O
of	O
Pseudomonas	O
aeruginosa	O
isolates	O
from	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
patients	O
before	O
and	O
after	O
initiation	O
of	O
TOBI	O
in	O
the	O
regular	O
treatment	O
regimen	O
.	O

We	O
have	O
determined	O
the	O
minimal	B-P
inhibitory	I-P
concentration	I-P
(	O
MIC	B-P
)	O
of	O
17	O
antimicrobials	O
by	O
the	O
E-test	B-P
(	O
LIOFILCHEM	O
)	O
in	O
sputa	O
samples	O
of	O
118	O
CF	O
patients	O
for	O
the	O
period	O
of	O
2005-2014	O
.	O

The	O
results	O
were	O
interpreted	O
according	O
to	O
the	O
annual	O
Clinical	O
and	O
Laboratory	O
Standards	O
Institute	O
guidelines	O
.	O

In	O
the	O
sputa	O
of	O
70	O
patients	O
a	O
total	O
of	O
102	O
P.	O
aeruginosa	O
isolates	O
were	O
found	O
.	O

Sixty-eight	O
out	O
of	O
102	O
(	O
66.7	O
%	O
)	O
were	O
susceptible	O
to	O
all	O
studied	O
antimicrobials	O
.	O

We	O
divided	O
the	O
isolates	O
in	O
two	O
chronological	O
groups	O
:	O
those	O
collected	O
before	O
the	O
introduction	O
of	O
TOBI	O
as	O
a	O
regular	O
treatment	O
in	O
2009	O
and	O
those	O
collected	O
after	O
2009	O
.	O

A	O
significant	O
reduction	O
(	O
p	O
<	O
0,001-0,02	O
)	O
in	O
susceptibility	O
for	O
the	O
strains	O
after	O
2009	O
was	O
noted	O
towards	O
piperacillin	O
(	O
100	O
%	O
vs	O
50	O
%	O
)	O
,	O
ceftazidime	O
(	O
100	O
%	O
/	O
77.3	O
%	O
)	O
,	O
cefepime	O
(	O
97.9	O
%	O
/	O
68.2	O
%	O
)	O
,	O
amikacin	O
(	O
100	O
%	O
/	O
63.6	O
%	O
)	O
,	O
gentamicin	O
(	O
95.7	O
%	O
/	O
40.9	O
%	O
)	O
,	O
tobramycin	O
(	O
93.6	O
%	O
/	O
59.1	O
%	O
)	O
and	O
ciprofloxacin	O
(	O
93.6	O
%	O
/	O
45.5	O
%	O
)	O
.	O

The	O
introduction	O
of	O
inhaled	O
tobramycin	O
as	O
a	O
regular	O
therapy	O
for	O
CF	O
patients	O
in	O
Bulgaria	O
lead	O
to	O
a	O
significant	O
change	O
in	O
antimicrobial	O
susceptibility	O
of	O
CF	O
P.	O
aeruginosa	O
.	O

Risk	O
Factors	O
of	O
Neurological	O
Deterioration	O
in	O
Patients	O
with	O
Cerebral	O
Infarction	O
due	O
to	O
Large-Artery	O
Atherosclerosis	O
.	O

In	O
some	O
patients	O
with	O
acute	O
ischemic	O
stroke	O
,	O
neurological	O
deterioration	O
(	O
ND	O
)	O
is	O
observed	O
,	O
and	O
it	O
is	O
difficult	O
to	O
predict	O
at	O
the	O
time	O
of	O
admission	O
.	O

Especially	O
in	O
some	O
patients	O
with	O
large-artery	O
atherosclerosis	O
(	O
LAA	O
)	O
,	O
aggressive	O
medical	O
treatments	O
and	O
surgical	O
interventions	O
might	O
be	O
helpful	O
to	O
prevent	O
ND	O
.	O

Therefore	O
,	O
we	O
investigated	O
factors	O
associated	O
with	O
ND	O
in	O
patients	O
with	O
LAA	O
.	O

We	O
studied	O
patients	O
with	O
LAA	O
who	O
were	O
admitted	O
to	O
our	O
hospital	O
.	O

We	O
divided	O
them	O
into	O
2	O
groups	O
with	O
(	O
group	O
1	O
)	O
and	O
without	O
deterioration	O
(	O
group	O
2	O
)	O
,	O
and	O
evaluated	O
their	O
medical	O
records	O
,	O
risk	O
factors	O
,	O
and	O
radiological	O
findings	O
,	O
such	O
as	O
number	O
of	O
diffusion	O
-	O
positive	O
lesion	O
and	O
degree	O
of	O
stenosis	O
.	O

Our	O
study	O
population	O
consisted	O
of	O
171	O
patients	O
;	O
71	O
(	O
41.5	O
%	O
)	O
did	O
and	O
100	O
(	O
58.5	O
%	O
)	O
did	O
not	O
suffer	O
deterioration	O
.	O

By	O
univariate	O
analysis	O
,	O
blood	O
pressure	O
(	O
BP	O
)	O
,	O
heart	O
rate	O
,	O
National	O
Institutes	O
of	O
Health	O
Stroke	O
Scale	O
(	O
NIHSS	O
)	O
score	O
,	O
number	O
of	O
diffusion	O
-	O
positive	O
lesion	O
,	O
count	B-P
of	I-P
red	I-P
blood	I-P
cell	I-P
,	O
high-density	O
lipoprotein	O
,	O
and	O
degree	O
of	O
stenosis	O
differed	O
significantly	O
between	O
the	O
2	O
groups	O
.	O

By	O
multivariate	O
analysis	O
,	O
systolic	O
BP	O
(	O
â¥170	O
mm	O
Hg	O
,	O
odds	O
ratio	O
:	O
7.20	O
,	O
P	O
<	O
.001	O
)	O
was	O
associated	O
with	O
ND	O
.	O

Furthermore	O
,	O
number	O
of	O
diffusion-weighted	B-P
image	I-P
(	O
DWI	B-P
)	O
-	O
positive	O
lesion	O
(	O
â¥8	O
)	O
,	O
degree	O
of	O
stenosis	O
(	O
>	O
80.0	O
%	O
)	O
,	O
and	O
NIHSS	O
score	O
(	O
â¥4	O
)	O
were	O
also	O
independent	O
factors	O
associated	O
with	O
ND	O
.	O

High	O
BP	O
,	O
severity	O
of	O
neurological	O
deficit	O
at	O
the	O
time	O
of	O
admission	O
,	O
and	O
radiological	O
findings	O
,	O
such	O
as	O
degree	O
of	O
stenosis	O
and	O
number	O
of	O
DWI	B-P
-	O
positive	O
lesion	O
,	O
are	O
independently	O
associated	O
with	O
ND	O
in	O
patients	O
with	O
LAA	O
.	O

In	O
vivo	O
Distribution	O
and	O
Clearance	O
of	O
Purified	O
Capsular	O
Polysaccharide	O
from	O
Burkholderia	O
pseudomallei	O
in	O
a	O
Murine	O
Model	O
.	O

Burkholderia	O
pseudomallei	O
is	O
the	O
causative	O
agent	O
of	O
melioidosis	O
,	O
a	O
severe	O
infection	O
prominent	O
in	O
northern	O
Australia	O
and	O
Southeast	O
Asia	O
.	O

The	O
``	O
gold	O
standard	O
``	O
for	O
melioidosis	O
diagnosis	B-P
is	O
bacterial	B-P
isolation	I-P
,	O
which	O
takes	O
several	O
days	O
to	O
complete	O
.	O

The	O
resulting	O
delay	O
in	O
diagnosis	B-P
leads	O
to	O
delayed	O
treatments	O
,	O
which	O
could	O
result	O
in	O
death	O
.	O

In	O
an	O
attempt	O
to	O
develop	O
better	O
methods	B-P
for	O
early	B-P
diagnosis	I-P
of	O
melioidosis	O
,	O
B.	O
pseudomallei	O
capsular	O
polysaccharide	O
(	O
CPS	O
)	O
was	O
identified	O
as	O
an	O
important	O
diagnostic	O
biomarker	O
.	O

A	O
rapid	O
lateral	O
flow	O
immunoassay	B-P
utilizing	O
CPS	O
-	O
specific	O
monoclonal	O
antibody	O
was	O
developed	O
and	O
tested	O
in	O
endemic	O
regions	O
worldwide	O
.	O

However	O
,	O
the	O
in	O
vivo	O
fate	O
and	O
clearance	O
of	O
CPS	O
has	O
never	O
been	O
thoroughly	O
investigated	O
.	O

Here	O
,	O
we	O
injected	O
mice	O
with	O
purified	O
CPS	O
intravenously	O
and	O
determined	O
CPS	O
concentrations	O
in	O
serum	O
,	O
urine	O
,	O
and	O
major	O
organs	O
at	O
various	O
intervals	O
.	O

The	O
results	O
indicate	O
that	O
CPS	O
is	O
predominantly	O
eliminated	O
through	O
urine	O
and	O
no	O
CPS	O
accumulation	O
occurs	O
in	O
the	O
major	O
organs	O
.	O

Immunoblot	B-P
analysis	I-P
demonstrated	O
that	O
intact	O
CPS	O
was	O
excreted	O
through	O
urine	O
.	O

To	O
understand	O
how	O
a	O
large	O
molecule	O
like	O
CPS	O
was	O
eliminated	O
without	O
degradation	O
,	O
a	O
3-dimenational	O
structure	O
of	O
CPS	O
was	O
modeled	O
.	O

The	O
predicted	O
CPS	O
structure	O
has	O
a	O
rod-like	O
shape	O
with	O
a	O
small	O
diameter	O
that	O
could	O
allow	O
it	O
to	O
flow	O
through	O
the	O
glomerulus	O
of	O
the	O
kidney	O
.	O

CPS	O
clearance	O
was	O
determined	O
using	O
exponential	B-P
decay	I-P
models	I-P
and	O
the	O
corrected	O
Akaike	O
Information	O
Criterion	O
.	O

The	O
results	O
show	O
that	O
CPS	O
has	O
a	O
relatively	O
short	O
serum	O
half-life	O
of	O
2.9	O
to	O
4.4	O
hours	O
.	O

Therefore	O
,	O
the	O
presence	O
of	O
CPS	O
in	O
the	O
serum	O
and/or	O
urine	O
suggests	O
active	O
melioidosis	O
infection	O
and	O
provides	O
a	O
marker	O
to	O
monitor	O
treatment	O
of	O
melioidosis	O
.	O

Dietary	O
administration	O
of	O
Pontogammarus	O
maeoticus	O
extract	O
affects	O
immune	O
responses	O
,	O
stress	O
resistance	O
,	O
feed	O
intake	O
and	O
growth	O
performance	O
of	O
caspian	O
roach	O
(	O
Rutilus	O
caspicus	O
)	O
fingerlings	O
.	O

Dietary	O
administration	O
of	O
immunostimulants	O
showed	O
promising	O
results	O
for	O
elevation	O
of	O
immune	O
responses	O
and	O
disease	O
resistance	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
dietary	O
Pontogammarus	O
(	O
Pontogammarus	O
maeoticus	O
)	O
extract	O
on	O
innate	O
immune	O
response	O
,	O
stress	O
resistance	O
,	O
feed	O
intake	O
and	O
growth	O
performance	O
of	O
the	O
Caspian	O
roach	O
fingerling	O
.	O

Two	O
levels	O
of	O
P.	O
maeoticus	O
extract	O
dilution	O
with	O
distilled	O
water	O
1:25	O
[	O
T1	O
]	O
and	O
1:50	O
[	O
T2	O
]	O
were	O
prepared	O
.	O

Experimental	O
diets	O
were	O
prepared	O
by	O
top-spraying	O
the	O
basal	O
diet	O
with	O
equal	O
amount	O
(	O
2	O
%	O
)	O
of	O
diluted	O
extracts	O
.	O

One	O
hundred	O
and	O
eighty	O
Caspian	O
roach	O
fingerlings	O
(	O
4.30	O
Â±	O
0.10	O
g	O
)	O
were	O
supplied	O
,	O
stocked	O
in	O
nine	O
100-L	O
tanks	O
(	O
three	O
treatment	O
repeated	O
in	O
triplicates	O
)	O
and	O
fed	O
on	O
experimental	O
diets	O
for	O
8	O
weeks	O
.	O

At	O
the	O
end	O
of	O
the	O
trial	O
,	O
serum	O
innate	O
immune	O
parameters	O
(	O
Total	B-P
Ig	I-P
,	O
ACH50	O
,	O
and	O
lysozyme	O
activity	O
)	O
,	O
resistance	O
against	O
salinity	O
stress	O
,	O
feed	O
intake	O
and	O
growth	O
parameters	O
were	O
measured	O
.	O

The	O
results	O
revealed	O
remarkable	O
increase	O
of	O
innate	O
immune	O
parameters	O
and	O
resistance	O
against	O
salinity	O
stress	O
in	O
roach	O
fed	O
P.	O
maeoticus	O
extracts	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Also	O
,	O
growth	O
performance	O
and	O
food	O
intake	O
were	O
notably	O
improved	O
in	O
P.	O
maeoticus	O
extracts	O
fed	O
fish	O
(	O
P	O
<	O
0.05	O
)	O
.	O

These	O
results	O
revealed	O
beneficial	O
effects	O
of	O
P.	O
maeoticus	O
extract	O
on	O
innate	O
immune	O
response	O
,	O
resistance	O
,	O
feed	O
intake	O
as	O
well	O
as	O
growth	O
performance	O
of	O
the	O
Caspian	O
roach	O
.	O

Computational	B-P
analysis	I-P
of	O
conserved	O
coil	O
functional	O
residues	O
in	O
the	O
mitochondrial	B-P
genomic	I-P
sequences	I-P
of	O
dermatophytes	O
.	O

Dermatophyte	O
is	O
a	O
group	O
of	O
closely	O
related	O
fungi	O
that	O
have	O
the	O
capacity	O
to	O
invade	O
keratinized	O
tissue	O
of	O
humans	O
and	O
other	O
animals	O
.	O

The	O
infection	O
known	O
as	O
dermatophytosis	O
,	O
caused	O
by	O
members	O
of	O
the	O
genera	O
Microsporum	O
,	O
Trichophyton	O
,	O
and	O
Epidermophyton	O
includes	O
infection	O
to	O
the	O
groin	O
(	O
tinea	O
cruris	O
)	O
,	O
beard	O
(	O
tinea	O
barbae	O
)	O
,	O
scalp	O
(	O
tinea	O
capitis	O
)	O
,	O
feet	O
(	O
tinea	O
pedis	O
)	O
,	O
glabrous	O
skin	O
(	O
tinea	O
corporis	O
)	O
,	O
nail	O
(	O
tinea	O
unguium	O
)	O
,	O
and	O
hand	O
(	O
tinea	O
manuum	O
)	O
.	O

The	O
identification	O
of	O
evolutionary	O
relationship	O
between	O
these	O
three	O
genera	O
of	O
dermatophyte	O
is	O
epidemiologically	O
important	O
to	O
understand	O
their	O
pathogenicity	O
.	O

Mitochondrial	O
DNA	O
evolves	O
more	O
rapidly	O
than	O
a	O
nuclear	O
DNA	O
due	O
to	O
higher	O
rate	O
of	O
mutation	O
but	O
is	O
very	O
less	O
affected	O
by	O
genetic	O
recombination	O
,	O
making	O
it	O
an	O
important	O
tool	O
for	O
phylogenetic	O
studies	O
.	O

Thus	O
,	O
here	O
we	O
present	O
a	O
novel	O
scheme	O
to	O
identify	O
the	O
conserved	O
coil	O
functional	O
residues	O
of	O
Trichophyton	O
rubrum	O
,	O
Trichophyton	O
mentagrophytes	O
,	O
Epidermophyton	O
floccosum	O
and	O
Microsporum	O
canis	O
.	O

Protein	O
coding	O
sequences	O
of	O
the	O
mitochondrial	O
genome	O
were	O
aligned	O
for	O
their	O
similar	O
sequences	O
and	O
homology	O
modelling	O
was	O
performed	O
for	O
structure	O
and	O
pocket	O
identification	O
.	O

The	O
results	O
obtained	O
from	O
comparative	O
analysis	O
of	O
the	O
protein	O
sequences	O
revealed	O
the	O
presence	O
of	O
functionally	O
active	O
sites	O
in	O
all	O
the	O
species	O
of	O
the	O
genera	O
Trichophyton	O
and	O
Microsporum	O
.	O

However	O
in	O
Epidermophyton	O
floccosum	O
it	O
was	O
observed	O
in	O
three	O
protein	O
sequences	O
of	O
the	O
five	O
studied	O
.	O

The	O
absence	O
of	O
these	O
conserved	O
coil	O
functional	O
residues	O
in	O
E.	O
floccusum	O
may	O
be	O
correlated	O
with	O
lesser	O
infectivity	O
of	O
this	O
organism	O
.	O

The	O
functional	O
residues	O
identified	O
in	O
the	O
present	O
study	O
could	O
be	O
responsible	O
for	O
the	O
disease	O
and	O
thus	O
can	O
act	O
as	O
putative	O
target	O
sites	O
for	O
drug	O
designing	O
.	O

Intestinal	O
transport	O
of	O
HDND-7	O
,	O
a	O
novel	O
hesperetin	O
derivative	O
,	O
in	O
in	O
vitro	O
MDCK	O
cell	O
and	O
in	O
situ	O
single-pass	O
intestinal	O
perfusion	O
models	O
.	O

1	O
.	O

Hesperetin	O
(	O
HDND	O
)	O
possesses	O
extensive	O
bioactivities	O
,	O
however	O
,	O
its	O
poor	O
solubility	O
and	O
low	O
bioavailability	O
limit	O
its	O
application	O
.	O

HDND-7	O
,	O
a	O
derivative	O
of	O
HDND	O
,	O
has	O
better	O
solubility	O
and	O
high	O
bioavailability	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
intestinal	O
absorption	O
mechanisms	O
of	O
HDND-7	O
.	O

2	O
.	O

MDCK	O
cells	O
were	O
used	O
to	O
examine	O
the	O
transport	O
mechanisms	O
of	O
HDND-7	O
in	O
vitro	O
,	O
and	O
a	O
rat	O
in	O
situ	O
intestinal	O
perfusion	O
model	O
was	O
used	O
to	O
characterize	O
the	O
absorption	O
of	O
HDND-7	O
.	O

The	O
concentration	O
of	O
HDND-7	O
was	O
determined	O
by	O
HPLC	B-P
.	O

3	O
.	O

In	O
MDCK	O
cells	O
,	O
HDND-7	O
was	O
effectively	O
absorbed	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
in	O
both	O
directions	O
.	O

Moreover	O
,	O
HDND-7	O
showed	O
pH	O
-	O
dependent	O
and	O
TEER	O
-	O
independent	O
transport	O
in	O
both	O
directions	O
.	O

The	O
transport	O
of	O
HDND-7	O
was	O
significantly	O
reduced	O
at	O
4	O
Â°C	O
or	O
in	O
the	O
presence	O
of	O
NaN3	O
.	O

Furthermore	O
,	O
the	O
efflux	O
of	O
HDND-7	O
was	O
apparently	O
reduced	O
in	O
the	O
presence	O
of	O
MRP2	O
inhibitors	O
MK-571	O
or	O
probenecid	O
.	O

However	O
,	O
P-gp	O
inhibitor	O
verapamil	O
had	O
no	O
effect	O
on	O
the	O
transport	O
of	O
HDND-7	O
.	O

The	O
in	O
situ	O
intestinal	O
perfusion	O
study	O
indicated	O
HDND-7	O
was	O
well-absorbed	O
in	O
four	O
intestinal	O
segments	O
.	O

Furthermore	O
,	O
MRP2	O
inhibitors	O
may	O
slightly	O
increase	O
the	O
absorption	O
of	O
HDND-7	O
in	O
jejunum	O
.	O

4	O
.	O

In	O
summary	O
,	O
all	O
results	O
indicated	O
that	O
HDND-7	O
might	O
be	O
absorbed	O
mainly	O
by	O
passive	O
diffusion	O
via	O
transcellular	O
pathway	O
,	O
MRP2	O
but	O
P-gp	O
may	O
participate	O
in	O
the	O
efflux	O
of	O
HDND-7	O
.	O

Salmonella	O
Co-opts	O
Host	O
Cell	O
Chaperone	O
-mediated	O
Autophagy	O
for	O
Intracellular	O
Growth	O
.	O

Salmonella	O
enterica	O
are	O
invasive	O
intracellular	O
pathogens	O
that	O
replicate	O
within	O
a	O
membrane	O
-	O
bound	O
compartment	O
inside	O
infected	O
host	O
cells	O
known	O
as	O
the	O
Salmonella	O
-	O
containing	O
vacuole	O
.	O

How	O
Salmonella	O
obtains	O
nutrients	O
for	O
growth	O
within	O
this	O
intracellular	O
niche	O
despite	O
the	O
apparent	O
isolation	B-P
is	O
currently	O
not	O
known	O
.	O

Recent	O
studies	O
have	O
indicated	O
the	O
importance	O
of	O
glucose	O
and	O
related	O
carbon	O
sources	O
for	O
tissue	O
colonization	O
and	O
intracellular	O
proliferation	O
within	O
host	O
cells	O
during	O
Salmonella	O
infections	O
,	O
although	O
none	O
have	O
been	O
found	O
to	O
be	O
essential	O
.	O

We	O
found	O
that	O
wild-type	O
Salmonella	O
are	O
capable	O
of	O
replicating	O
within	O
infected	O
host	O
cells	O
in	O
the	O
absence	O
of	O
both	O
exogenous	O
sugars	O
and/or	O
amino	O
acids	O
.	O

Furthermore	O
,	O
mutants	O
defective	O
in	O
glucose	O
uptake	O
or	O
dependent	O
upon	O
peptides	O
for	O
growth	O
also	O
showed	O
no	O
significant	O
loss	O
in	O
intracellular	O
replication	O
,	O
suggesting	O
host	O
-	O
derived	O
peptides	O
can	O
supply	O
both	O
carbon	O
units	O
and	O
amino	O
acids	O
.	O

Here	O
,	O
we	O
show	O
that	O
intracellular	O
Salmonella	O
recruit	O
the	O
host	O
proteins	O
LAMP-2A	O
and	O
Hsc73	O
,	O
key	O
components	O
of	O
the	O
host	O
protein	O
turnover	O
pathway	O
known	O
as	O
chaperone	O
-mediated	O
autophagy	O
involved	O
in	O
transport	O
of	O
cytosolic	O
proteins	O
to	O
the	O
lysosome	O
for	O
degradation	O
.	O

Host-	O
derived	O
peptides	O
are	O
shown	O
to	O
provide	O
a	O
significant	O
contribution	O
toward	O
the	O
intracellular	O
growth	O
of	O
Salmonella	O
The	O
results	O
reveal	O
a	O
means	O
whereby	O
intracellular	O
Salmonella	O
gain	O
access	O
to	O
the	O
host	O
cell	O
cytosol	O
from	O
within	O
its	O
membrane	O
-	O
bound	O
compartment	O
to	O
acquire	O
nutrients	O
.	O

Furthermore	O
,	O
this	O
study	O
provides	O
an	O
explanation	O
as	O
to	O
how	O
Salmonella	O
evades	O
activation	O
of	O
autophagy	O
mechanisms	O
as	O
part	O
of	O
the	O
innate	O
immune	O
response	O
.	O

Adenosine	O
and	O
the	O
adenosine	O
A2A	O
receptor	O
agonist	O
,	O
CGS21680	O
,	O
upregulate	O
CD39	O
and	O
CD73	O
expression	O
through	O
E2F-1	O
and	O
CREB	O
in	O
regulatory	O
T	O
cells	O
isolated	O
from	O
septic	O
mice	O
.	O

The	O
number	O
of	O
regulatory	O
T	O
cells	O
(	O
Treg	O
cells	O
)	O
and	O
the	O
expression	O
of	O
ectonucleoside	O
triphosphate	O
diphosphohydrolase	O
1	O
(	O
ENTPD1	O
;	O
also	O
known	O
as	O
CD39	O
)	O
and	O
5'-ectonucleotidase	O
(	O
NT5E	O
;	O
also	O
known	O
as	O
CD73	O
)	O
on	O
the	O
Treg	O
cell	O
surface	O
are	O
increased	O
during	O
sepsis	O
.	O

In	O
this	O
study	O
,	O
to	O
determine	O
the	O
factors	O
leading	O
to	O
the	O
high	O
expression	O
of	O
CD39	O
and	O
CD73	O
,	O
and	O
the	O
regulation	O
of	O
the	O
CD39	O
/	O
CD73	O
/	O
adenosine	O
pathway	O
in	O
Treg	O
cells	O
under	O
septic	O
conditions	O
,	O
we	O
constructed	O
a	O
mouse	O
model	O
of	O
sepsis	O
and	O
separated	O
the	O
Treg	O
cells	O
using	O
a	O
flow	O
cytometer	O
.	O

The	O
Treg	O
cells	O
isolated	O
from	O
the	O
peritoneal	O
lavage	O
and	O
splenocytes	O
of	O
the	O
mice	O
were	O
treated	O
with	O
adenosine	O
or	O
the	O
specific	O
adenosine	O
A2A	O
receptor	O
agonist	O
,	O
CGS21680	O
,	O
and	O
were	O
transfected	O
with	O
specific	O
siRNA	O
targeting	O
E2F	O
transcription	O
factor	O
1	O
(	O
E2F-1	O
)	O
or	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
response	O
element-binding	O
protein	O
(	O
CREB	O
)	O
,	O
which	O
are	O
predicted	O
transcription	O
regulatory	O
factors	O
of	O
CD39	O
or	O
CD73	O
.	O

The	O
regulatory	O
relationships	O
among	O
these	O
factors	O
were	O
then	O
determined	O
by	O
western	B-P
blot	I-P
analysis	I-P
and	O
dual-luciferase	B-P
reporter	I-P
assay	I-P
.	O

In	O
addition	O
,	O
changes	O
in	O
adenosine	O
metabolism	O
were	O
measured	O
in	O
the	O
treated	O
cells	O
.	O

The	O
results	O
revealed	O
that	O
adenosine	O
and	O
CGS21680	O
significantly	O
upregulated	O
CD39	O
and	O
CD73	O
expression	O
(	O
P	O
<	O
0.01	O
)	O
.	O

E2F-1	O
and	O
CREB	O
induced	O
CD39	O
and	O
CD73	O
expression	O
,	O
and	O
were	O
upregulated	O
by	O
adenosine	O
and	O
CGS21680	O
.	O

Adenosine	O
triphosphate	O
(	O
ATP	O
)	O
hydrolysis	O
and	O
adenosine	O
generation	O
were	O
inhibited	O
by	O
the	O
knockdown	O
of	O
E2F-1	O
or	O
CREB	O
,	O
and	O
were	O
accelerated	O
in	O
the	O
presence	O
of	O
CGS21680	O
.	O

Based	O
on	O
these	O
results	O
,	O
it	O
can	O
be	O
inferred	O
that	O
adenosine	O
,	O
the	O
adenosine	O
A2A	O
receptor	O
agonist	O
,	O
E2F-1	O
and	O
CREB	O
are	O
the	O
possible	O
factors	O
contributing	O
to	O
the	O
high	O
expression	O
of	O
CD39	O
and	O
CD73	O
on	O
the	O
Treg	O
cell	O
surface	O
during	O
sepsis	O
.	O

Adenosine	O
and	O
its	O
A2A	O
receptor	O
agonist	O
served	O
as	O
the	O
signal	O
transducer	O
factors	O
of	O
the	O
CD39	O
/	O
CD73	O
/	O
adenosine	O
pathway	O
,	O
accelerating	O
adenosine	O
generation	O
.	O

Our	O
study	O
may	O
benefit	O
further	O
research	O
on	O
adenosine	O
metabolism	O
for	O
the	O
treatment	O
of	O
sepsis	O
.	O

Dental	O
implants	O
and	O
bone	O
augmentation	O
in	O
HIV-infected	O
patients	O
under	O
HAART	O
:	O
Case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

The	O
present	O
study	O
reviewed	O
the	O
literature	O
regarding	O
dental	O
implants	O
in	O
HIV-infected	O
patients	O
and	O
reports	O
the	O
long-term	O
follow-up	O
of	O
three	O
clinical	O
cases	O
of	O
patients	O
under	O
HAART	O
that	O
received	O
bone	O
augmentation	O
and	O
dental	O
implants	O
.	O

The	O
first	O
case	O
presents	O
a	O
young	O
patient	O
with	O
a	O
large	O
defect	O
in	O
the	O
mandible	O
,	O
as	O
a	O
consequence	O
of	O
a	O
longitudinal	O
fracture	O
,	O
that	O
was	O
treated	O
with	O
guided	O
bone	O
regeneration	O
(	O
GBR	O
)	O
previously	O
to	O
implant	O
placement	O
.	O

The	O
second	O
case	O
reported	O
is	O
middle-aged	O
man	O
with	O
a	O
fractured	O
upper	O
lateral	O
incisor	O
treated	O
with	O
immediate	O
placement	O
and	O
simultaneous	O
GBR	O
to	O
repair	O
the	O
dehiscence	O
due	O
to	O
the	O
buccal	O
bone	O
resorption	O
.	O

The	O
third	O
case	O
shows	O
an	O
elderly	O
patient	O
that	O
underwent	O
sinus	O
lifting	O
with	O
the	O
simultaneous	O
placement	O
of	O
two	O
implants	O
.	O

All	O
cases	O
were	O
treated	O
after	O
patients	O
were	O
medically	O
controlled	O
and	O
followed	O
for	O
at	O
least	O
10	O
years	O
.	O

Controlled	O
HIV-infected	O
patients	O
undergoing	O
HAART	O
may	O
be	O
candidates	O
to	O
implant	O
rehabilitation	O
,	O
as	O
long	O
as	O
their	O
plasmatic	O
HIV	B-P
viral	I-P
load	I-P
and	O
CD4+	O
T	O
lymphocytes	O
count	O
are	O
within	O
the	O
parameters	O
that	O
indicate	O
immune	O
stability	O
.	O

Long-term	O
stability	O
of	O
soft	O
and	O
hard	O
tissues	O
can	O
be	O
obtained	O
maintaining	O
function	O
and	O
esthetics	O
.	O

However	O
,	O
stronger	O
evidence	O
,	O
based	O
on	O
prospective	O
,	O
controlled	O
clinical	O
trials	O
is	O
needed	O
to	O
provide	O
the	O
dental	O
and	O
medical	O
teams	O
with	O
conclusive	O
data	O
.	O

The	O
Therapeutic	O
Effect	O
of	O
Berberine	O
in	O
the	O
Treatment	O
of	O
Nonalcoholic	O
Fatty	O
Liver	O
Disease	O
:	O
A	O
Meta-Analysis	O
.	O

Aim	O
.	O

To	O
assess	O
the	O
efficacy	O
of	O
berberine	O
in	O
the	O
treatment	O
of	O
nonalcoholic	O
fatty	O
liver	O
disease	O
through	O
meta-analysis	O
.	O

Method	O
.	O

We	O
searched	O
Embase	O
,	O
Pubmed	O
,	O
Cochrane	O
Library	O
,	O
and	O
so	O
forth	O
,	O
until	O
March	O
2016	O
for	O
randomized	O
controlled	O
trials	O
using	O
berberine	O
to	O
treat	O
NAFLD	O
.	O

Result	O
.	O

Six	O
randomized	O
controlled	O
trials	O
involving	O
501	O
patients	O
were	O
included	O
in	O
this	O
study	O
.	O

The	O
results	O
showed	O
that	O
the	O
efficacy	O
of	O
reducing	O
TC	O
,	O
LDL	O
,	O
ALT	O
,	O
2hPG	O
,	O
and	O
HbA1c	O
in	O
NAFLD	O
patients	O
of	O
the	O
berberine	O
group	O
were	O
significantly	O
higher	O
than	O
that	O
of	O
control	O
group	O
.	O

The	O
subgroup	O
analyses	O
on	O
TG	O
,	O
AST	O
,	O
and	O
FBG	B-P
indicated	O
that	O
treatment	O
combined	O
with	O
berberine	O
decreased	O
TG	O
level	O
in	O
NAFLD	O
patients	O
significantly	O
.	O

Compared	O
with	O
other	O
drugs	O
,	O
berberine	O
alone	O
decreased	O
TG	O
level	O
in	O
NAFLD	O
patients	O
significantly	O
.	O

We	O
also	O
conducted	O
a	O
descriptive	O
analysis	O
on	O
insulin	O
resistance	O
and	O
radiography	B-P
results	O
that	O
berberine	O
can	O
improve	O
NAFLD	O
patients	O
'	O
insulin	O
resistance	O
and	O
fatty	O
liver	O
.	O

Conclusion	O
.	O

According	O
to	O
analysis	O
result	O
,	O
berberine	O
has	O
positive	O
efficacy	O
on	O
blood	O
lipids	O
,	O
blood	O
glucose	O
,	O
liver	O
function	O
,	O
insulin	O
resistance	O
,	O
and	O
fatty	O
liver	O
condition	O
of	O
NAFLD	O
patients	O
.	O

However	O
,	O
due	O
to	O
the	O
limitation	O
of	O
number	O
and	O
quality	O
of	O
trials	O
included	O
,	O
more	O
clinical	O
randomized	O
controlled	O
trials	O
with	O
high	O
quality	O
are	O
needed	O
for	O
further	O
verification	O
of	O
the	O
efficacy	O
of	O
berberine	O
on	O
NAFLD	O
patients	O
.	O

Social	O
cognition	O
in	O
schizophrenia	O
:	O
Factor	O
structure	O
of	O
emotion	O
processing	O
and	O
theory	O
of	O
mind	O
.	O

Factor	O
analytic	O
studies	O
examining	O
social	O
cognition	O
in	O
schizophrenia	O
have	O
yielded	O
inconsistent	O
results	O
most	O
likely	O
due	O
to	O
the	O
varying	O
number	O
and	O
quality	O
of	O
measures	O
.	O

With	O
the	O
recent	O
conclusion	O
of	O
Phase	O
3	O
of	O
the	O
Social	O
Cognition	O
Psychometric	B-P
Evaluation	I-P
(	I-P
SCOPE	I-P
)	I-P
Study	I-P
,	O
the	O
most	O
psychometrically	B-P
sound	B-P
measures	I-P
of	O
social	O
cognition	O
have	O
been	O
identified	O
.	O

Therefore	O
,	O
the	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
:	O
1	O
)	O
examine	O
the	O
factor	O
structure	O
of	O
social	O
cognition	O
in	O
schizophrenia	O
through	O
the	O
utilization	O
of	O
psychometrically	B-P
sound	B-P
measures	I-P
,	O
2	O
)	O
examine	O
the	O
stability	O
of	O
the	O
factor	O
structure	O
across	O
two	O
study	O
visits	O
,	O
3	O
)	O
compare	O
the	O
factor	O
structure	O
of	O
social	O
cognition	O
in	O
schizophrenia	O
to	O
that	O
in	O
healthy	O
controls	O
,	O
and	O
4	O
)	O
examine	O
the	O
relationship	O
between	O
the	O
factors	O
and	O
relevant	O
outcome	O
measures	O
including	O
social	O
functioning	O
and	O
symptoms	O
.	O

Results	O
supported	O
a	O
one-factor	O
model	O
for	O
the	O
patient	O
and	O
healthy	O
control	O
samples	O
at	O
both	O
visits	O
.	O

This	O
single	O
factor	O
was	O
significantly	O
associated	O
with	O
negative	O
symptoms	O
in	O
the	O
schizophrenia	O
sample	O
and	O
with	O
social	O
functioning	O
in	O
both	O
groups	O
at	O
both	O
study	O
visits	O
.	O

Pathways	O
to	O
Suicide	O
in	O
Australian	O
Farmers	O
:	O
A	O
Life	O
Chart	O
Analysis	O
.	O

Farmers	O
have	O
been	O
found	O
to	O
be	O
at	O
increased	O
risk	O
of	O
suicide	O
in	O
Australia	O
.	O

The	O
Interpersonal-Psychological	O
Theory	O
of	O
Suicidal	O
Behaviour	O
suggests	O
that	O
the	O
proximal	O
factors	O
leading	O
to	O
the	O
suicidal	O
desire	O
or	O
ideation	O
include	O
an	O
individual	O
's	O
experiences	O
of	O
both	O
perceived	O
burdensomeness	O
and	O
thwarted	O
belongingness	O
.	O

Suicidal	O
desire	O
with	O
acquired	O
capability	O
to	O
engage	O
in	O
lethal	O
self-injury	O
is	O
predictive	O
of	O
suicidal	O
behaviour	O
.	O

This	O
study	O
investigates	O
the	O
pathways	O
to	O
suicide	O
of	O
18	O
Australian	O
male	O
farmers	O
in	O
order	O
to	O
understand	O
the	O
suicidal	O
process	O
and	O
antecedents	O
to	O
suicide	O
in	O
Australian	O
male	O
farmers	O
.	O

The	O
psychological	B-P
autopsy	I-P
(	O
PA	B-P
)	O
method	O
was	O
used	O
to	O
generate	O
life	O
charts	O
.	O

Two	O
pathways	O
with	O
distinct	O
suicidal	O
processes	O
were	O
identified	O
:	O
acute	O
situational	O
(	O
romantic	O
relationship	O
problems	O
and	O
financial	O
concerns	O
/	O
pending	O
retirement	O
)	O
and	O
protracted	O
(	O
long-term	O
psychiatric	O
disorder	O
)	O
.	O

Long	O
working	O
hours	O
,	O
interpersonal	O
conflicts	O
,	O
physical	O
illnesses	O
and	O
pain	O
,	O
alcohol	O
abuse	O
,	O
access	O
to	O
firearms	O
,	O
and	O
exposure	O
to	O
drought	O
were	O
additional	O
common	O
factors	O
identified	O
.	O

An	O
understanding	O
of	O
the	O
interrelatedness	O
of	O
diverse	O
distal	O
and	O
proximal	O
risk	O
factors	O
on	O
suicidal	O
pathways	O
in	O
the	O
wider	O
environmental	O
context	O
for	O
male	O
farmers	O
is	O
required	O
when	O
developing	O
and	O
implementing	O
rural	O
suicide	O
prevention	O
activities	O
.	O

Serum	B-P
C-Reactive	I-P
Protein	I-P
in	O
Children	O
with	O
Liver	O
Disease	O
and	O
Ascites	O
.	O

The	O
diagnosis	O
of	O
peritonitis	O
as	O
a	O
complication	O
of	O
cirrhosis	O
is	O
an	O
important	O
clinical	O
problem	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
serum	B-P
C-reactive	I-P
protein	I-P
levels	I-P
as	O
a	O
diagnostic	O
factor	O
for	O
spontaneous	O
bacterial	O
peritonitis	O
(	O
SBP	O
)	O
in	O
child	O
patients	O
with	O
liver	O
disease	O
.	O

In	O
this	O
study	O
,	O
150	O
children	O
diagnosed	O
with	O
liver	O
disease	O
and	O
ascites	O
upon	O
admission	O
to	O
Nemazee	O
Teaching	O
Hospital	O
(	O
Shiraz	O
,	O
Iran	O
)	O
were	O
examined	O
.	O

Patients	O
were	O
divided	O
into	O
spontaneous	O
bacterial	O
peritonitis	O
and	O
sterile	O
ascetic	O
fluid	O
groups	O
according	O
to	O
the	O
PMN	B-P
count	I-P
â¥	O
250/mm	O
(	O
3	O
)	O
in	O
the	O
ascetic	O
fluids	O
.	O

Routine	B-P
laboratory	I-P
tests	I-P
were	O
conducted	O
and	O
quantitative	O
C-reactive	B-P
protein	I-P
(	I-P
CRP	I-P
)	I-P
levels	I-P
were	O
measured	O
for	O
all	O
of	O
the	O
patients	O
.	O

Accuracy	O
,	O
sensitivity	O
,	O
and	O
specificity	O
of	O
CRP	B-P
was	O
evaluated	O
for	O
diagnosis	O
of	O
SBP	O
.	O

Of	O
150	O
cirrhotic	O
patients	O
,	O
109	O
patients	O
presented	O
without	O
SBP	O
(	O
52.29	O
%	O
male	O
,	O
mean	O
age	O
:	O
5.02	O
Â±	O
4.49	O
years	O
)	O
and	O
41	O
patients	O
presented	O
with	O
SBP	O
(	O
51.21	O
%	O
male	O
,	O
mean	O
age	O
:	O
4.71	O
years	O
)	O
.	O

Cell	B-P
counts	I-P
,	O
protein	O
levels	O
,	O
albumin	O
levels	O
,	O
and	O
lactate	B-P
dehydrogenize	I-P
(	I-P
LDH	I-P
)	I-P
levels	I-P
of	O
the	O
ascetic	O
fluid	O
and	O
serum	O
samples	O
in	O
the	O
SBP	O
group	O
were	O
higher	O
than	O
the	O
rates	O
for	O
those	O
without	O
SBP	O
(	O
P	O
<	O
0.05	O
(	O
.	O

The	O
mean	O
Â±	O
SD	O
of	O
CRP	B-P
in	O
the	O
SBP	O
group	O
(	O
36.89	O
Â±	O
23.43	O
)	O
increased	O
significantly	O
compared	O
to	O
the	O
rate	O
among	O
those	O
without	O
SBP	O
(	O
21.59	O
Â±	O
15.43	O
,	O
P	O
=	O
0.001	O
)	O
.	O

The	O
percentages	O
for	O
sensitivity	O
and	O
specificity	O
of	O
CRP	B-P
,	O
the	O
diagnosis	O
of	O
SBP	O
based	O
on	O
the	O
PMN	B-P
count	I-P
â¥	O
250/mm	O
(	O
3	O
)	O
,	O
and	O
cultured	O
ascites	O
were	O
69.23	O
%	O
,	O
90.25	O
%	O
,	O
88.43	O
%	O
,	O
and	O
84.32	O
%	O
,	O
respectively	O
.	O

The	O
areas	O
under	O
the	O
curve	O
of	O
CRP	B-P
for	O
SBP	O
based	O
on	O
the	O
PMN	B-P
count	I-P
â¥	O
250/mm	O
(	O
3	O
)	O
and	O
cultured	O
ascites	O
was	O
0.94	O
(	O
CI	O
95	O
%	O
:	O
0.90	O
to	O
0.96	O
)	O
and	O
0.85	O
(	O
CI	O
95	O
%	O
:	O
0.84	O
to	O
0.92	O
)	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Our	O
study	O
showed	O
that	O
CRP	B-P
is	O
a	O
marker	O
with	O
high	O
sensitivity	O
and	O
specificity	O
for	O
the	O
diagnosis	O
of	O
SBP	O
in	O
cirrhotic	O
children	O
.	O

Inhibition	O
of	O
Drp1	O
protects	O
against	O
senecionine	O
-	O
induced	O
mitochondria	O
-mediated	O
apoptosis	O
in	O
primary	O
hepatocytes	O
and	O
in	O
mice	O
.	O

Pyrrolizidine	O
alkaloids	O
(	O
PAs	O
)	O
are	O
a	O
group	O
of	O
compounds	O
found	O
in	O
various	O
plants	O
and	O
some	O
of	O
them	O
are	O
widely	O
consumed	O
in	O
the	O
world	O
as	O
herbal	O
medicines	O
and	O
food	O
supplements	O
.	O

PAs	O
are	O
potent	O
hepatotoxins	O
that	O
cause	O
irreversible	O
liver	O
injury	O
in	O
animals	O
and	O
humans	O
.	O

However	O
,	O
the	O
mechanisms	O
by	O
which	O
PAs	O
induce	O
liver	O
injury	O
are	O
not	O
clear	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
hepatotoxicity	O
and	O
molecular	O
mechanisms	O
of	O
senecionine	O
,	O
one	O
of	O
the	O
most	O
common	O
toxic	O
PAs	O
,	O
in	O
primary	O
cultured	B-P
mouse	O
and	O
human	O
hepatocytes	O
as	O
well	O
as	O
in	O
mice	O
.	O

We	O
found	O
that	O
senecionine	O
administration	O
increased	O
serum	O
alanine	O
aminotransferase	O
levels	O
in	O
mice	O
.	O

H	B-P
&	I-P
E	I-P
and	O
TUNEL	O
staining	O
of	O
liver	O
tissues	O
revealed	O
increased	O
hemorrhage	O
and	O
hepatocyte	O
apoptosis	O
in	O
liver	O
zone	O
2	O
areas	O
.	O

Mechanistically	O
,	O
senecionine	O
induced	O
loss	O
of	O
mitochondrial	O
membrane	O
potential	O
,	O
release	O
of	O
mitochondrial	O
cytochrome	O
c	O
as	O
well	O
as	O
mitochondrial	O
JNK	O
translocation	O
and	O
activation	O
prior	O
to	O
the	O
increased	O
DNA	O
fragmentation	O
and	O
caspase-3	O
activation	O
in	O
primary	O
cultured	B-P
mouse	O
and	O
human	O
hepatocyte	O
s.	O
SP600125	O
,	O
a	O
specific	O
JNK	O
inhibitor	O
,	O
and	O
ZVAD-fmk	O
,	O
a	O
general	O
caspase	O
inhibitor	O
,	O
alleviated	O
senecionine	O
-induced	O
apoptosis	O
in	O
primary	O
hepatocytes	O
.	O

Interestingly	O
,	O
senecionine	O
also	O
caused	O
marked	O
mitochondria	O
fragmentation	O
in	O
hepatocytes	O
.	O

Pharmacological	O
inhibition	O
of	O
dynamin-related	O
protein1	O
(	O
Drp1	O
)	O
,	O
a	O
protein	O
that	O
is	O
critical	O
to	O
regulate	O
mitochondrial	O
fission	O
,	O
blocked	O
senecionine	O
-	O
induced	O
mitochondrial	O
fragmentation	O
and	O
mitochondrial	O
release	O
of	O
cytochrome	O
c	O
and	O
apoptosis	O
.	O

More	O
importantly	O
,	O
hepatocyte	O
-specific	O
Drp1	O
knockout	O
mice	O
were	O
resistant	O
to	O
senecionine	O
-	O
induced	O
liver	O
injury	O
due	O
to	O
decreased	O
mitochondrial	O
damage	O
and	O
apoptosis	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
uncovered	O
a	O
novel	O
mechanism	O
of	O
Drp1	O
-mediated	O
mitochondrial	O
fragmentation	O
in	O
senecionine	O
-	O
induced	O
liver	O
injury	O
.	O

Targeting	O
Drp1	O
-mediated	O
mitochondrial	O
fragmentation	O
and	O
apoptosis	O
may	O
be	O
a	O
potential	O
avenue	O
to	O
prevent	O
and	O
treat	O
hepatotoxicity	O
induced	O
by	O
PAs	O
.	O

Parametric	B-P
Surface	I-P
Diffeomorphometry	I-P
for	O
Low	B-P
Dimensional	I-P
Embeddings	I-P
of	O
Dense	O
Segmentations	O
and	O
Imagery	O
.	O

In	O
the	O
field	O
of	O
Computational	B-P
Anatomy	I-P
,	O
biological	O
form	O
(	O
including	O
our	O
focus	O
,	O
neuroanatomy	O
)	O
is	O
studied	O
quantitatively	O
through	O
the	O
action	O
of	O
the	O
diffeomorphism	O
group	O
on	O
example	O
anatomies	O
-	O
a	O
technique	O
called	O
diffeomorphometry	B-P
.	O

Here	O
we	O
design	O
an	O
algorithm	O
within	O
this	O
framework	O
to	O
pass	O
from	O
dense	O
objects	O
common	O
in	O
neuromaging	B-P
studies	O
(	O
binary	O
segmentations	O
,	O
structural	O
images	O
)	O
to	O
a	O
sparse	O
representation	O
defined	O
on	O
the	O
surface	O
boundaries	O
of	O
anatomical	O
structures	O
,	O
and	O
embedded	B-P
into	O
the	O
low	O
dimensional	O
coordinates	O
of	O
a	O
parametric	O
model	O
.	O

Our	O
main	O
new	O
contribution	O
is	O
to	O
introduce	O
an	O
expanded	O
group	O
action	O
to	O
simultaneously	O
deform	O
surfaces	O
through	O
direct	O
mapping	O
of	O
points	O
,	O
as	O
well	O
as	O
images	O
through	O
functional	O
composition	O
with	O
the	O
inverse	O
.	O

This	O
allows	O
us	O
to	O
index	O
the	O
diffeomorphisms	O
with	O
respect	O
to	O
two-dimensional	O
surface	O
geometries	O
like	O
subcortical	O
gray	O
matter	O
structures	O
,	O
but	O
explicitly	O
map	O
onto	O
cost	O
functions	O
determined	O
by	O
noisy	O
3-dimensional	O
measurements	O
.	O

We	O
consider	O
models	O
generated	O
from	O
empirical	O
covariance	O
of	O
training	O
data	O
,	O
as	O
well	O
as	O
bandlimited	O
(	O
Laplace-Beltrami	O
eigenfunction	O
)	O
models	O
when	O
no	O
such	O
data	O
is	O
available	O
.	O

We	O
show	O
applications	O
to	O
noisy	O
or	O
anomalous	O
segmentations	O
,	O
and	O
other	O
typical	O
problems	O
in	O
neuroimaging	B-P
studies	O
.	O

We	O
reproduce	O
statistical	O
results	O
detecting	O
changes	O
in	O
Alzheimer	O
's	O
disease	O
,	O
despite	O
dimensionality	O
reduction	O
.	O

Lastly	O
we	O
apply	O
our	O
algorithm	O
to	O
the	O
common	O
problem	O
of	O
segmenting	O
subcortical	O
structures	O
from	O
T1	B-P
MR	I-P
images	I-P
.	O

Personalized	O
Medicine	O
applied	O
to	O
Forensic	O
Sciences	O
:	O
new	O
advances	O
and	O
perspectives	O
for	O
a	O
tailored	O
forensic	O
approach	O
.	O

Personalized	O
medicine	O
(	O
PM	O
)	O
,	O
included	O
in	O
P5	O
medicine	O
(	O
Personalized	O
,	O
Predictive	O
,	O
Preventive	O
,	O
Participative	O
and	O
Precision	O
medicine	O
)	O
is	O
an	O
innovative	O
approach	O
to	O
the	O
patient	O
,	O
emerging	O
from	O
the	O
need	O
to	O
tailor	O
and	O
to	O
fit	O
the	O
profile	O
of	O
each	O
individual	O
.	O

PM	O
promises	O
to	O
dramatically	O
impact	O
also	O
on	O
forensic	O
sciences	O
and	O
justice	O
system	O
in	O
ways	O
we	O
are	O
only	O
beginning	O
to	O
understand	O
.	O

The	O
application	O
of	O
omics	O
(	O
genomic	O
,	O
transcriptomics	O
,	O
epigenetics/imprintomics	O
,	O
proteomic	O
and	O
metabolomics	O
)	O
is	O
ever	O
more	O
fundamental	O
in	O
the	O
so	O
called	O
``	O
molecular	B-P
autopsy	I-P
``	O
.	O

Emerging	O
fields	O
of	O
interest	O
in	O
forensic	O
pathology	O
are	O
represented	O
by	O
diagnosis	O
and	O
detection	O
of	O
predisposing	O
conditions	O
to	O
fatal	O
thromboembolic	O
and	O
hypertensive	O
events	O
,	O
determination	O
of	O
genetic	O
variants	O
related	O
to	O
sudden	O
death	O
,	O
such	O
as	O
congenital	O
long	O
QT	O
syndromes	O
,	O
demonstration	O
of	O
lesions	O
vitality	O
,	O
identification	O
of	O
biological	O
matrices	O
and	O
species	O
diagnosis	O
of	O
a	O
forensic	O
trace	O
on	O
crime	O
scenes	O
without	O
destruction	O
of	O
the	O
DNA	O
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
describe	O
the	O
state-of-art	O
in	O
the	O
application	O
of	O
personalized	O
medicine	O
in	O
forensic	O
sciences	O
,	O
to	O
understand	O
the	O
possibilities	O
of	O
integration	O
in	O
routine	O
investigation	O
of	O
these	O
procedures	O
with	O
classical	O
post-mortem	B-P
studies	I-P
and	O
to	O
underline	O
the	O
importance	O
of	O
these	O
new	O
updates	O
in	O
medical	O
examiners	O
'	O
armamentarium	O
in	O
determining	O
cause	O
of	O
death	O
or	O
contributing	O
factors	O
to	O
death	O
.	O

Is	O
Localized	O
Scleroderma	O
Caused	O
by	O
Borrelia	O
burgdorferi	O
?	O
.	O

Despite	O
considerable	O
achievements	O
in	O
the	O
study	O
of	O
localized	O
scleroderma	O
,	O
the	O
etiology	O
of	O
the	O
disease	O
has	O
not	O
been	O
investigated	O
completely	O
.	O

Borrelia	O
burgdorferi	O
-the	O
agent	O
of	O
Lyme	O
disease	O
-is	O
suggested	O
to	O
be	O
one	O
of	O
the	O
possible	O
etiological	O
factors	O
of	O
localized	O
scleroderma	O
.	O

However	O
,	O
among	O
scientists	O
,	O
this	O
hypothesis	O
is	O
quite	O
controversial	O
.	O

We	O
have	O
conducted	O
investigations	O
of	O
the	O
level	O
of	O
IgM	O
and	O
IgG	O
class	O
antibodies	O
to	O
B.	O
burgdorferi	O
in	O
the	O
serum	O
of	O
patients	O
with	O
localized	O
scleroderma	O
.	O

To	O
rationally	O
substantiate	O
the	O
role	O
of	O
B.	O
burgdorferi	O
in	O
the	O
occurrence	O
of	O
localized	O
scleroderma	O
,	O
thirty-two	O
patients	O
with	O
localized	O
scleroderma	O
treated	O
at	O
an	O
in-patient	O
department	O
were	O
examined	O
.	O

The	O
level	O
of	O
anti-Borrelia	O
antibodies	O
was	O
determined	O
in	O
ELISA	B-P
.	O

Diagnostic	O
levels	O
of	O
IgM	O
and/or	O
IgG	O
were	O
detected	O
in	O
18.8	O
%	O
of	O
patients	O
with	O
localized	O
scleroderma	O
,	O
which	O
is	O
more	O
than	O
in	O
the	O
population	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Positive	O
levels	O
of	O
anti-Borrelia	O
antibodies	O
in	O
patients	O
with	O
localized	O
scleroderma	O
confirm	O
the	O
borreliosis	O
nature	O
of	O
the	O
disease	O
,	O
requiring	O
conduction	O
of	O
complex	O
antimicrobial	O
treatment	O
.	O

Dry	O
skin	O
conditions	O
are	O
related	O
to	O
the	O
recovery	O
rate	O
of	O
skin	O
temperature	O
after	O
cold	O
stress	O
rather	O
than	O
to	O
blood	O
flow	O
.	O

Cutaneous	O
blood	O
flow	O
plays	O
an	O
important	O
role	O
in	O
the	O
thermoregulation	O
,	O
oxygen	O
supply	O
,	O
and	O
nutritional	O
support	O
necessary	O
to	O
maintain	O
the	O
skin	O
.	O

However	O
,	O
there	O
is	O
little	O
evidence	O
for	O
a	O
link	O
between	O
blood	O
flow	O
and	O
skin	O
physiology	O
.	O

Therefore	O
,	O
we	O
conducted	O
surveys	O
of	O
healthy	O
volunteers	O
to	O
determine	O
the	O
relationship	O
(	O
s	O
)	O
between	O
dry	O
skin	O
properties	O
and	O
cutaneous	O
vascular	O
function	O
.	O

Water	O
content	O
of	O
the	O
stratum	O
corneum	O
,	O
transepidermal	O
water	O
loss	O
,	O
and	O
visual	O
dryness	O
score	O
were	O
investigated	O
as	O
dry	O
skin	O
parameters	O
.	O

Cutaneous	O
blood	O
flow	O
in	O
the	O
resting	O
state	O
,	O
the	O
recovery	O
rate	O
(	O
RR	O
)	O
of	O
skin	O
temperature	O
on	O
the	O
hand	O
after	O
a	O
cold-stress	B-P
test	I-P
,	O
and	O
the	O
responsiveness	O
of	O
facial	O
skin	O
blood	O
flow	O
to	O
local	O
cooling	O
were	O
examined	O
as	O
indices	O
of	O
cutaneous	O
vascular	O
functions	O
.	O

The	O
relationships	O
between	O
dry	O
skin	O
parameters	O
and	O
cutaneous	O
vascular	O
functions	O
were	O
assessed	O
.	O

The	O
RR	O
correlated	O
negatively	O
with	O
the	O
visual	O
dryness	O
score	O
of	O
skin	O
on	O
the	O
leg	O
but	O
correlated	O
positively	O
with	O
water	O
content	O
of	O
the	O
stratum	O
corneum	O
on	O
the	O
arm	O
.	O

No	O
significant	O
correlation	O
between	O
the	O
resting	O
state	O
of	O
blood	O
flow	O
and	O
dry	O
skin	O
parameters	O
was	O
observed	O
.	O

In	O
both	O
the	O
face	O
and	O
the	O
body	O
,	O
deterioration	O
in	O
skin	O
dryness	O
from	O
summer	O
to	O
winter	O
was	O
significant	O
in	O
subjects	O
with	O
low	O
RR	O
.	O

The	O
RR	O
correlated	O
well	O
with	O
the	O
responsiveness	O
of	O
facial	O
skin	O
blood	O
flow	O
to	O
local	O
cooling	O
,	O
indicating	O
that	O
the	O
RR	O
affects	O
systemic	O
dry	O
skin	O
conditions	O
.	O

These	O
results	O
suggest	O
that	O
the	O
RR	O
but	O
not	O
blood	O
flow	O
at	O
the	O
resting	O
state	O
is	O
associated	O
with	O
dry	O
skin	O
conditions	O
and	O
is	O
involved	O
in	O
skin	O
homeostasis	O
during	O
seasonal	O
environmental	O
changes	O
.	O

Alanine	O
Aminotransferase	O
Is	O
a	O
Marker	O
of	O
Lipotoxicity	O
Consequences	O
and	O
Hyperandrogenemia	O
in	O
Women	O
with	O
Polycystic	O
Ovary	O
Syndrome	O
.	O

Several	O
studies	O
have	O
reported	O
higher	O
levels	O
of	O
Alanine	O
aminotransferase	O
(	O
ALT	O
)	O
in	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
compared	O
with	O
control	O
subjects	O
.	O

Plasma	B-P
ALT	I-P
levels	I-P
are	O
considered	O
a	O
marker	O
of	O
hepatic	O
lipotoxicity	O
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	O
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	O
steatosis	O
and	O
hepatic	O
insulin	O
resistance	O
.	O

Retrospective	O
chart	O
review	O
aiming	O
to	O
assess	O
,	O
in	O
PCOS	O
women	O
,	O
the	O
relationship	O
between	O
ALT	B-P
levels	I-P
and	O
measures	O
of	O
lipotoxicity	O
consequences	O
that	O
are	O
available	O
clinically	O
,	O
both	O
during	O
fasting	B-P
and	O
using	O
the	O
oral	B-P
glucose	I-P
tolerance	I-P
test	I-P
.	O

Women	O
(	O
n	O
=	O
132	O
)	O
with	O
PCOS	O
,	O
were	O
in	O
average	O
27.9	O
years	O
of	O
age	O
,	O
with	O
a	O
mean	O
body	O
mass	O
index	O
of	O
34.1	O
kg/m	O
(	O
2	O
)	O
and	O
49	O
%	O
had	O
a	O
metabolic	O
syndrome	O
(	O
MetS	O
)	O
.	O

ALT	B-P
levels	I-P
were	O
significantly	O
correlated	O
with	O
homeostatic	B-P
model	I-P
assessment	I-P
for	I-P
insulin	I-P
resistance	I-P
(	O
r	O
=	O
0.42	O
,	O
P	O
<	O
0.001	O
)	O
,	O
HDL-C	O
(	O
r	O
=	O
-0.31	O
,	O
P	O
<	O
0.001	O
)	O
,	O
Matsuda	O
index	O
(	O
-0.45	O
,	O
P	O
<	O
0.001	O
)	O
,	O
insulin	B-P
secretion-sensitivity	I-P
index-2	I-P
(	O
-0.26	O
,	O
P	O
=	O
0.043	O
)	O
,	O
and	O
free	O
testosterone	O
(	O
0.38	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
with	O
fasting	O
glucose	O
and	O
triglyceride	O
levels	O
.	O

ALT	O
cutoff	O
â¥24	O
IU/L	O
was	O
associated	O
with	O
all	O
these	O
parameters	O
,	O
including	O
fasting	O
glucose	O
(	O
P	O
=	O
0.021	O
)	O
and	O
triglyceride	O
levels	O
(	O
P	O
=	O
0.041	O
)	O
,	O
and	O
detected	O
more	O
women	O
with	O
the	O
MetS	O
(	O
59.2	O
%	O
vs.	O
36.1	O
%	O
,	O
P	O
=	O
0.008	O
)	O
and	O
whole-body	O
insulin	O
resistance	O
(	O
Matsuda	O
index	O
<	O
12.3	O
L	O
(	O
2	O
)	O
Â·10/mmol	O
(	O
2	O
)	O
,	O
85.3	O
%	O
vs.	O
51.9	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O

Plasma	B-P
ALT	I-P
levels	I-P
seem	O
to	O
be	O
a	O
strong	O
predictor	O
not	O
only	O
of	O
liver	O
lipotoxicity	O
but	O
also	O
of	O
systemic	O
lipotoxic	O
consequences	O
and	O
hyperandrogenemia	O
in	O
women	O
with	O
PCOS	O
.	O

Although	O
it	O
requires	O
validation	O
in	O
another	O
study	O
,	O
an	O
ALT	O
cutoff	O
of	O
â¥24	O
IU/L	O
may	O
help	O
clinicians	O
identify	O
women	O
with	O
increased	O
metabolic	O
risks	O
.	O

Assessment	O
of	O
the	O
Relationship	O
Between	O
Clinicophysiologic	O
and	O
Magnetic	B-P
Resonance	I-P
Imaging	I-P
Findings	O
of	O
the	O
Temporomandibular	O
Disorder	O
Patients	O
.	O

Temporomandibular	O
joint	O
disorders	O
(	O
TMJDs	O
)	O
are	O
a	O
complex	O
group	O
of	O
disorders	O
that	O
comprise	O
dysfunctions	O
of	O
the	O
temporomandibular	O
joint	O
(	O
TMJ	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
objective	O
and	O
subjective	O
findings	O
of	O
the	O
TMJD	O
patients	O
by	O
using	O
Helkimo	O
anamnesis	O
(	O
Ai	O
)	O
and	O
clinical	O
dysfunction	O
(	O
Di	O
)	O
indices	O
,	O
and	O
tried	O
to	O
document	O
a	O
relation	O
between	O
these	O
findings	O
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
results.Ninety-eight	O
patients	O
who	O
were	O
admitted	O
to	O
our	O
clinic	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
clinical	O
evaluation	O
was	O
performed	O
by	O
using	O
Ai	O
,	O
an	O
8-question-survey	O
based	O
on	O
the	O
objective	O
symptoms	O
of	O
patients	O
;	O
Di	O
,	O
concluded	O
as	O
the	O
score	O
of	O
5	O
objective	O
measurements	O
of	O
physical	O
examination	O
.	O

The	O
morphology	O
of	O
the	O
TMJ	O
was	O
evaluated	O
by	O
MRI	B-P
,	O
and	O
the	O
findings	O
were	O
analyzed	O
and	O
statistically	O
compared	O
with	O
respect	O
to	O
the	O
Di	O
.The	O
most	O
commonly	O
seen	O
symptoms	O
were	O
noise	O
during	O
mandibular	O
movement	O
(	O
58	O
%	O
)	O
,	O
pain	O
around	O
the	O
joint	O
(	O
42.5	O
%	O
)	O
,	O
and	O
pain	O
with	O
mandibular	O
movements	O
(	O
40	O
%	O
)	O
.	O

Seventeen	O
patients	O
(	O
17.3	O
%	O
)	O
were	O
Di0	O
,	O
47	O
(	O
48	O
%	O
)	O
were	O
DiI	O
,	O
24	O
(	O
24.5	O
%	O
)	O
were	O
DiII	O
,	O
and	O
10	O
(	O
10.2	O
%	O
)	O
were	O
DiIII	O
.	O

Thirty-seven	O
patients	O
(	O
37.8	O
%	O
)	O
had	O
abnormal	O
MRI	B-P
findings	O
,	O
whereas	O
61	O
patients	O
(	O
62.2	O
%	O
)	O
had	O
normal	O
MRI	B-P
.	O

The	O
most	O
commonly	O
encountered	O
pathology	O
was	O
anterior	O
disc	O
displacement	O
with	O
reduction	O
,	O
which	O
was	O
reported	O
in	O
15	O
patients	O
.	O

Increased	O
TMJ	O
Di	O
,	O
which	O
points	O
a	O
more	O
progressed	O
TMJD	O
,	O
was	O
found	O
to	O
be	O
significantly	O
related	O
with	O
the	O
pathological	O
MRI	B-P
findings	O
(	O
P	O
<	O
0.05	O
)	O
.	O

MRI	B-P
is	O
especially	O
effective	O
in	O
particularly	O
those	O
with	O
high	O
Di	O
;	O
therefore	O
,	O
the	O
results	O
of	O
the	O
study	O
may	O
give	O
a	O
prospect	O
in	O
which	O
types	O
of	O
patients	O
does	O
MRI	B-P
give	O
a	O
valuable	O
data	O
toward	O
diagnosis	O
,	O
in	O
which	O
stages	O
of	O
the	O
TMJD	O
should	O
we	O
expect	O
pathological	O
findings	O
,	O
and	O
thereby	O
preventing	O
unnecessary	O
use	O
of	O
MRI	B-P
in	O
patients	O
with	O
symptoms	O
of	O
TMJD	O
.	O

Targeting	O
Conserved	O
Genes	O
in	O
Alternaria	O
Species	O
.	O

Real-time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
is	O
a	O
molecular	B-P
biology	I-P
technique	I-P
based	O
on	O
the	O
detection	O
of	O
the	O
fluorescence	O
produced	O
by	O
a	O
reporter	O
molecule	O
,	O
which	O
increases	O
as	O
the	O
reaction	O
proceeds	O
proportionally	O
to	O
the	O
accumulation	O
of	O
the	O
PCR	O
product	O
within	O
each	O
amplification	O
cycle	O
.	O

The	O
fluorescent	O
reporter	O
molecules	O
include	O
dyes	O
that	O
bind	O
to	O
the	O
double-stranded	O
DNA	O
(	O
i.e.	O
,	O
SYBR	O
(	O
Â®	O
)	O
Green	O
)	O
or	O
sequence-specific	O
probes	O
(	O
i.e.	O
,	O
Molecular	O
Beacons	O
or	O
TaqMan	O
(	O
Â®	O
)	O
Probes	O
)	O
.	O

Real-time	O
PCR	O
provides	O
a	O
tool	O
for	O
accurate	O
and	O
sensitive	O
quantification	O
of	O
target	O
fungal	O
DNA	O
.	O

Here	O
,	O
we	O
describe	O
a	O
TaqMan	O
real-time	O
PCR	O
method	O
for	O
specific	O
detection	O
and	O
quantification	O
of	O
Alternaria	O
spp	O
.	O

The	O
method	B-P
uses	O
Alternaria-specific	O
primers	O
and	O
probe	O
,	O
targeting	O
the	O
internal	O
transcribed	O
spacer	O
regions	O
ITS1	O
and	O
ITS2	O
of	O
the	O
rRNA	O
gene	O
,	O
and	O
a	O
positive	O
amplification	O
control	O
based	O
on	O
18S	O
rRNA	O
gene	O
.	O

Safety	O
of	O
Adding	O
Oats	O
to	O
a	O
Gluten-free	O
Diet	O
for	O
Patients	O
with	O
Celiac	O
Disease	O
:	O
Systematic	O
Review	O
and	O
Meta-analysis	O
of	O
Clinical	O
and	O
Observational	O
Studies	O
.	O

Patients	O
with	O
celiac	O
disease	O
should	O
maintain	O
a	O
gluten-free	O
diet	O
(	O
GFD	O
)	O
,	O
excluding	O
wheat	O
,	O
rye	O
,	O
and	O
barley	O
.	O

Oats	O
might	O
increase	O
the	O
nutritional	O
value	O
of	O
a	O
GFD	O
,	O
but	O
their	O
including	O
is	O
controversial	O
.	O

We	O
performed	O
a	O
systematic	O
review	O
and	O
meta-analysis	O
to	O
evaluate	O
the	O
safety	O
of	O
oats	O
as	O
part	O
of	O
a	O
GFD	O
in	O
patients	O
with	O
celiac	O
disease	O
.	O

We	O
searched	O
the	O
Cochrane	O
Central	O
Register	O
of	O
Controlled	O
Trials	O
,	O
MEDLINE	O
,	O
and	O
EMBASE	O
databases	O
for	O
clinical	O
trials	O
and	O
observational	O
studies	O
of	O
the	O
effects	O
of	O
including	O
oats	O
in	O
GFD	O
of	O
patients	O
with	O
celiac	O
disease	O
.	O

The	O
studies	O
reported	O
patients	O
'	O
symptoms	O
,	O
results	O
from	O
serology	B-P
tests	I-P
,	O
and	O
findings	O
from	O
histologic	B-P
analyses	I-P
.	O

We	O
used	O
the	O
GRADE	O
approach	O
to	O
assess	O
the	O
quality	O
of	O
evidence	O
.	O

We	O
identified	O
433	O
studies	O
;	O
28	O
were	O
eligible	O
for	O
analysis	O
.	O

Of	O
these	O
,	O
6	O
were	O
randomized	O
and	O
2	O
were	O
not-randomized	O
controlled	O
trials	O
comprising	O
a	O
total	O
of	O
661	O
patients	O
-the	O
remaining	O
studies	O
were	O
observational	O
.	O

All	O
randomized	O
controlled	O
trials	O
used	O
pure/uncontaminated	O
oats	O
.	O

Oat	O
consumption	O
for	O
12	O
months	O
did	O
not	O
affect	O
symptoms	O
(	O
standardized	O
mean	O
difference	O
:	O
reduction	O
in	O
symptom	O
scores	O
in	O
patients	O
who	O
did	O
and	O
did	O
not	O
consumed	O
oats	O
,	O
-0.22	O
;	O
95	O
%	O
CI	O
:	O
-0.56	O
to	O
0.13	O
;	O
P=.22	O
)	O
,	O
histologic	O
scores	O
(	O
relative	O
risk	O
for	O
histologic	O
findings	O
in	O
patients	O
who	O
consumed	O
oats	O
,	O
0.24	O
;	O
95	O
%	O
CI	O
,	O
0.01	O
to	O
4.8	O
;	O
P=.35	O
)	O
,	O
intraepithelial	O
lymphocyte	B-P
counts	I-P
(	O
standardized	O
mean	O
difference	O
:	O
0.21	O
;	O
95	O
%	O
CI	O
,	O
reduction	O
of	O
1.44	O
to	O
increase	O
in	O
1.86	O
)	O
,	O
or	O
results	O
from	O
serologic	B-P
tests	I-P
.	O

Subgroup	O
analyses	O
of	O
adults	O
vs	O
children	O
did	O
not	O
reveal	O
differences	O
.	O

The	O
overall	O
quality	O
of	O
evidence	O
was	O
low	O
.	O

In	O
a	O
systematic	O
review	O
and	O
meta-analysis	O
,	O
we	O
found	O
no	O
evidence	O
that	O
addition	O
of	O
oats	O
to	O
a	O
GFD	O
affects	O
symptoms	O
,	O
histology	O
,	O
immunity	O
,	O
or	O
serologic	O
features	O
of	O
patients	O
with	O
celiac	O
disease	O
.	O

However	O
,	O
there	O
were	O
few	O
studies	O
for	O
many	O
endpoints	O
,	O
as	O
well	O
as	O
limited	O
geographic	O
distribution	O
and	O
low	O
quality	O
of	O
evidence	O
.	O

Rigorous	O
double-blind	O
,	O
placebo-controlled	O
,	O
randomized	O
controlled	O
trials	O
,	O
using	O
commonly	O
available	O
oats	O
sourced	O
from	O
different	O
regions	O
,	O
are	O
needed	O
.	O

Doxorubicin	O
Has	O
Dose-Dependent	O
Toxicity	O
on	O
Mouse	O
Ovarian	O
Follicle	O
Development	O
,	O
Hormone	O
Secretion	O
,	O
and	O
Oocyte	O
Maturation	O
.	O

Doxorubicin	O
(	O
DOX	O
)	O
,	O
one	O
of	O
the	O
most	O
commonly	O
used	O
anticancer	O
medications	O
,	O
has	O
been	O
reported	O
to	O
affect	O
fertility	O
by	O
damaging	O
ovarian	O
follicles	O
;	O
however	O
,	O
the	O
dose-dependent	O
toxicity	O
of	O
DOX	O
on	O
the	O
dynamic	O
follicle	O
development	O
and	O
oocyte	O
maturation	O
has	O
not	O
been	O
well-defined	O
.	O

Our	O
objective	O
is	O
to	O
determine	O
the	O
effects	O
of	O
human	O
-	O
relevant	O
exposure	O
levels	O
of	O
DOX	O
on	O
follicular	O
functions	O
across	O
developmental	O
time	O
.	O

In	O
vitro	O
cultured	B-P
multilayered	O
secondary	O
mouse	O
follicles	O
were	O
treated	O
with	O
DOX	O
at	O
0	O
,	O
2	O
,	O
20	O
,	O
100	O
,	O
and	O
200	O
nM	O
for	O
24	O
h	O
,	O
and	O
follicle	O
development	O
,	O
hormone	O
secretion	O
,	O
and	O
oocyte	O
maturation	O
were	O
analyzed	O
.	O

DOX	O
caused	O
dose-dependent	O
toxicity	O
on	O
follicle	O
growth	O
,	O
survival	O
,	O
and	O
secretion	O
of	O
17Î²-estradiol	O
(	O
E2	O
)	O
.	O

At	O
200	O
nM	O
,	O
DOX	O
induced	O
DNA	O
damage	O
and	O
apoptosis	O
in	O
follicle	O
somatic	O
cells	O
first	O
and	O
then	O
in	O
oocytes	O
,	O
which	O
was	O
correlated	O
with	O
the	O
uptake	O
of	O
DOX	O
first	O
to	O
the	O
somatic	O
cells	O
followed	O
by	O
germ	O
cells	O
.	O

Follicles	O
treated	O
with	O
DOX	O
at	O
0	O
,	O
2	O
,	O
and	O
20	O
nM	O
showed	O
similar	O
oocyte	O
metaphase	O
II	O
(	O
MII	O
)	O
percentages	O
after	O
in	O
vitro	O
oocyte	O
maturation	O
;	O
however	O
,	O
20	O
nM	O
DOX	O
significantly	O
increased	O
the	O
number	O
of	O
MII	O
oocytes	O
with	O
abnormal	O
spindle	O
morphology	O
and	O
chromosome	O
misalignment	O
.	O

In	O
an	O
effort	O
to	O
harmonize	O
the	O
in	O
vitro	O
study	O
to	O
in	O
vivo	O
treatment	O
,	O
dose-dependent	O
toxicity	O
on	O
oocyte	O
meiotic	O
maturation	O
was	O
found	O
in	O
16-day-old	O
CD-1	O
mice	O
treated	O
with	O
DOX	O
at	O
0	O
,	O
0.4	O
,	O
2	O
,	O
and	O
10	O
mg/kg	O
,	O
consistent	O
with	O
the	O
in	O
vitro	O
oocyte	O
maturation	O
outcomes	O
.	O

Our	O
study	O
demonstrates	O
that	O
DOX	O
has	O
dose-dependent	O
toxicity	O
on	O
ovarian	O
follicle	O
development	O
,	O
hormone	O
secretion	O
,	O
and	O
oocyte	O
maturation	O
,	O
which	O
are	O
three	O
key	O
factors	O
to	O
support	O
the	O
female	O
reproductive	O
and	O
endocrine	O
functions	O
.	O

Metabolomics	O
,	O
Nutrition	O
,	O
and	O
Potential	O
Biomarkers	O
of	O
Food	O
Quality	O
,	O
Intake	O
,	O
and	O
Health	O
Status	O
.	O

Diet	O
,	O
dietary	O
patterns	O
,	O
and	O
other	O
environmental	O
factors	O
such	O
as	O
exposure	O
to	O
toxins	O
are	O
playing	O
an	O
important	O
role	O
in	O
the	O
prevention	O
/	O
development	O
of	O
many	O
diseases	O
,	O
like	O
obesity	O
,	O
type	O
2	O
diabetes	O
,	O
and	O
consequently	O
on	O
the	O
health	O
status	O
of	O
individuals	O
.	O

A	O
major	O
challenge	O
nowadays	O
is	O
to	O
identify	O
novel	O
biomarkers	O
to	O
detect	O
as	O
early	O
as	O
possible	O
metabolic	O
dysfunction	O
and	O
to	O
predict	O
evolution	O
of	O
health	O
status	O
in	O
order	O
to	O
refine	O
nutritional	O
advices	O
to	O
specific	O
population	O
groups	O
.	O

Omics	O
technologies	O
such	O
as	O
genomics	O
,	O
transcriptomics	O
,	O
proteomics	O
,	O
and	O
metabolomics	O
coupled	O
with	O
statistical	O
and	O
bioinformatics	O
tools	O
have	O
already	O
shown	O
great	O
potential	O
in	O
this	O
research	O
field	O
even	O
if	O
so	O
far	O
only	O
few	O
biomarkers	O
have	O
been	O
validated	O
.	O

For	O
the	O
past	O
two	O
decades	O
,	O
important	O
analytical	B-P
techniques	I-P
have	O
been	O
developed	O
to	O
detect	O
as	O
many	O
metabolites	O
as	O
possible	O
in	O
human	O
biofluids	O
such	O
as	O
urine	O
,	O
blood	O
,	O
and	O
saliva	O
.	O

In	O
the	O
field	O
of	O
food	O
science	O
and	O
nutrition	O
,	O
many	O
studies	O
have	O
been	O
carried	O
out	O
for	O
food	O
authenticity	O
,	O
quality	O
,	O
and	O
safety	O
,	O
as	O
well	O
as	O
for	O
food	O
processing	O
.	O

Furthermore	O
,	O
metabolomic	O
investigations	O
have	O
been	O
carried	O
out	O
to	O
discover	O
new	O
early	O
biomarkers	O
of	O
metabolic	O
dysfunction	O
and	O
predictive	O
biomarkers	O
of	O
developing	O
pathologies	O
(	O
obesity	O
,	O
metabolic	O
syndrome	O
,	O
type-2	O
diabetes	O
,	O
etc.	O
)	O
.	O

Great	O
emphasis	O
is	O
also	O
placed	O
in	O
the	O
development	O
of	O
methodologies	O
to	O
identify	O
and	O
validate	O
biomarkers	O
of	O
nutrients	O
exposure	O
.	O

Incidence	O
of	O
Diabetes	O
Mellitus	O
and	O
Obesity	O
and	O
the	O
Overlap	O
of	O
Comorbidities	O
in	O
HIV+	O
Hispanics	O
Initiating	O
Antiretroviral	O
Therapy	O
.	O

Cardiovascular	O
disease	O
(	O
CVD	O
)	O
is	O
a	O
leading	O
health	O
threat	O
for	O
HIV+	O
patients	O
on	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
;	O
cardiometabolic	O
comorbidities	O
are	O
key	O
predictors	O
of	O
risk	O
.	O

Data	O
are	O
limited	O
on	O
incidence	O
of	O
metabolic	O
comorbidities	O
in	O
HIV+	O
individuals	O
initiating	O
ART	O
in	O
low	O
and	O
middle	O
income	O
countries	O
(	O
LMICs	O
)	O
,	O
particularly	O
for	O
Hispanics	O
.	O

We	O
examined	O
incidence	O
of	O
diabetes	O
and	O
obesity	O
in	O
a	O
prospective	O
cohort	O
of	O
those	O
initiating	O
ART	O
in	O
the	O
Dominican	O
Republic	O
.	O

Participants	O
â¥18	O
years	O
,	O
initiating	O
ART	O
<	O
90	O
days	O
prior	O
to	O
study	O
enrollment	O
,	O
were	O
examined	O
for	O
incidence	O
of	O
impaired	O
fasting	O
glucose	O
(	O
IFG	O
)	O
,	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
,	O
overweight	O
,	O
and	O
obesity	O
.	O

Fasting	B-P
plasma	I-P
glucose	I-P
(	O
FPG	B-P
)	O
100-125mg/dl	O
defined	O
IFG	O
;	O
FPG	B-P
â¥126	O
mg/dl	O
,	O
diagnosis	O
per	O
medical	O
record	O
,	O
or	O
use	O
of	O
hypoglycemic	O
medication	O
defined	O
DM	O
.	O

Overweight	O
and	O
obesity	O
were	O
BMI	O
25-30	O
and	O
â¥30kg/m2	O
,	O
respectively	O
.	O

Dyslipidemia	O
was	O
total	O
cholesterol	O
â¥240mg/dl	O
or	O
use	O
of	O
lipid-lowering	O
medication	O
.	O

Framingham	O
risk	O
equation	O
was	O
used	O
to	O
determine	O
ten-year	O
CVD	O
risk	O
at	O
the	O
end	O
of	O
observation	O
.	O

Of	O
153	O
initiating	O
ART	O
,	O
8	O
(	O
6	O
%	O
)	O
had	O
DM	O
and	O
23	O
(	O
16	O
%	O
)	O
had	O
IFG	O
at	O
baseline	O
,	O
6	O
developed	O
DM	O
(	O
28/1000	O
person	O
-	O
years	O
follow	O
up	O
[	O
PYFU	O
]	O
)	O
and	O
46	O
developed	O
IFG	O
(	O
329/1000	O
PYFU	O
)	O
.	O

At	O
baseline	O
,	O
24	O
(	O
18	O
%	O
)	O
were	O
obese	O
and	O
36	O
(	O
27	O
%	O
)	O
were	O
overweight	O
,	O
15	O
became	O
obese	O
(	O
69/1000	O
PYFU	O
)	O
and	O
22	O
became	O
overweight	O
(	O
163/1000	O
PYFU	O
)	O
.	O

Median	O
observation	O
periods	O
for	O
the	O
diabetes	O
and	O
obesity	O
analyses	O
were	O
23.5	O
months	O
and	O
24.3	O
months	O
,	O
respectively	O
.	O

Increased	O
CVD	O
risk	O
(	O
â¥10	O
%	O
10-year	O
Framingham	O
risk	O
score	O
)	O
was	O
present	O
for	O
13	O
%	O
of	O
the	O
cohort	O
;	O
79	O
%	O
of	O
the	O
cohort	O
had	O
â¥1	O
cardiometabolic	O
comorbidity	O
,	O
48	O
%	O
had	O
â¥2	O
,	O
and	O
13	O
%	O
had	O
all	O
three	O
.	O

In	O
this	O
Hispanic	O
cohort	O
in	O
an	O
LMIC	O
,	O
incidences	O
of	O
IFG	O
/	O
DM	O
and	O
overweight	O
/	O
obesity	O
were	O
similar	O
to	O
or	O
higher	O
than	O
that	O
found	O
in	O
high	O
income	O
countries	O
,	O
and	O
cardiometabolic	O
disorders	O
affected	O
three-quarters	O
of	O
those	O
initiating	O
ART	O
.	O

Care	O
models	O
incorporating	O
cardiovascular	O
risk	O
reduction	O
into	O
HIV	O
treatment	O
programs	O
are	O
needed	O
to	O
prevent	O
CVD	O
-	O
associated	O
mortality	O
in	O
this	O
vulnerable	O
population	O
.	O

Size	O
effect	O
of	O
Au	O
/	O
PAMAM	O
contrast	O
agent	O
on	O
CT	B-P
imaging	I-P
of	O
reticuloendothelial	O
system	O
and	O
tumor	O
tissue	O
.	O

Polyamidoamine	O
(	O
PAMAM	O
)	O
-entrapped	O
Au	O
nanoparticles	O
were	O
synthesized	O
with	O
distinct	O
sizes	O
to	O
figure	O
out	O
the	O
size	O
effect	O
of	O
Au	O
-based	O
contrast	O
agent	O
on	O
CT	B-P
imaging	I-P
of	O
passively	O
targeted	O
tissues	O
.	O

Au	O
/	O
PAMAM	O
nanoparticles	O
were	O
first	O
synthesized	O
with	O
narrow	O
distribution	O
of	O
particles	O
size	O
of	O
22.2	O
Â±	O
3.1	O
,	O
54.2	O
Â±	O
3.7	O
,	O
and	O
104.9	O
Â±	O
4.7	O
nm	O
in	O
diameters	O
.	O

Size	O
effect	O
leads	O
no	O
significant	O
difference	O
on	O
X-ray	B-P
attenuation	O
when	O
Au	O
/	O
PAMAM	O
was	O
â¤0.05	O
mol/L	O
.	O

For	O
CT	B-P
imaging	I-P
of	O
a	O
tumor	O
model	O
,	O
small	O
Au	O
/	O
PAMAM	O
were	O
more	O
easily	O
internalized	O
via	O
endocytosis	O
in	O
the	O
liver	O
,	O
leading	O
to	O
more	O
obviously	O
enhanced	B-P
contrast	I-P
.	O

Similarly	O
,	O
contrast	O
agents	O
with	O
small	O
sizes	O
were	O
more	O
effective	O
in	O
tumor	O
imaging	B-P
because	O
of	O
the	O
enhanced	O
permeability	O
and	O
retention	O
effect	O
.	O

Overall	O
,	O
the	O
particle	O
size	O
of	O
Au	O
/	O
PAMAM	O
heavily	O
affected	O
the	O
efficiency	O
of	O
CT	O
enhancement	O
in	O
imaging	B-P
RES	O
and	O
tumors	O
.	O

Depletion	O
of	O
NFBD1	O
/	O
MDC1	O
Induces	O
Apoptosis	O
in	O
Nasopharyngeal	O
Carcinoma	O
Cells	O
Through	O
the	O
p53	O
-	O
ROS	O
-	O
Mitochondrial	O
Pathway	O
.	O

NFBD1	O
,	O
a	O
signal	O
amplifier	O
of	O
the	O
p53	O
pathway	O
,	O
is	O
vital	O
for	O
protecting	O
cells	O
from	O
p53	O
-mediated	O
apoptosis	O
and	O
the	O
early	O
phase	O
of	O
DNA	O
damage	O
response	O
under	O
normal	B-P
culture	I-P
conditions	I-P
.	O

Here	O
we	O
investigated	O
its	O
expression	O
in	O
patients	O
with	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
,	O
and	O
we	O
describe	O
the	O
biological	O
functions	O
of	O
the	O
NFBD1	O
gene	O
.	O

We	O
found	O
that	O
NFBD1	O
mRNA	O
and	O
protein	O
were	O
more	O
highly	O
expressed	O
in	O
NPC	O
tissues	O
than	O
in	O
nontumorous	O
tissues	O
.	O

To	O
investigate	O
the	O
function	O
of	O
NFBD1	O
,	O
we	O
created	O
NFBD1	O
-	O
depleted	O
NPC	O
cell	O
lines	O
that	O
exhibited	O
decreased	O
cellular	O
proliferation	O
and	O
colony	O
formation	O
,	O
an	O
increase	O
in	O
their	O
rate	O
of	O
apoptosis	O
,	O
and	O
an	O
enhanced	O
sensitivity	O
to	O
chemotherapeutic	O
agents	O
compared	O
with	O
in	O
vitro	O
controls	O
.	O

However	O
,	O
N-acetyl	O
cysteine	O
(	O
NAC	O
)	O
and	O
downregulation	O
of	O
p53	O
expression	O
could	O
partially	O
reverse	O
the	O
apoptosis	O
caused	O
by	O
the	O
loss	O
of	O
NFBD1	O
.	O

Further	O
analysis	O
showed	O
that	O
loss	O
of	O
NFBD1	O
resulted	O
in	O
increased	O
production	O
of	O
intracellular	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
depending	O
on	O
p53	O
,	O
which	O
subsequently	O
triggered	O
the	O
mitochondrial	O
apoptotic	O
pathwa	O
y	O
.	O

Using	O
a	O
xenograft	O
model	O
in	O
nude	O
mice	O
,	O
we	O
showed	O
that	O
silencing	O
NFBD1	O
also	O
significantly	O
inhibited	O
tumor	O
growth	O
and	O
led	O
to	O
apoptosis	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
inhibition	O
of	O
NFBD1	O
in	O
NPC	O
could	O
be	O
therapeutically	O
useful	O
.	O

Voriconazole	O
metabolism	O
is	O
influenced	O
by	O
severe	O
inflammation	O
:	O
a	O
prospective	O
study	O
.	O

During	O
an	O
infection	O
or	O
inflammation	O
,	O
several	O
drug	O
-	O
metabolizing	O
enzymes	O
in	O
the	O
liver	O
are	O
down-regulated	O
,	O
including	O
cytochrome	O
P450	O
iso-enzymes	O
.	O

Since	O
voriconazole	O
is	O
extensively	O
metabolized	O
by	O
cytochrome	O
P450	O
iso-enzymes	O
,	O
the	O
metabolism	O
of	O
voriconazole	O
can	O
be	O
influenced	O
during	O
inflammation	O
via	O
reduced	O
clearance	O
of	O
the	O
drug	O
,	O
resulting	O
in	O
higher	O
voriconazole	O
trough	O
concentrations	O
.	O

To	O
investigate	O
prospectively	O
the	O
influence	O
of	O
inflammation	O
on	O
voriconazole	O
metabolism	O
and	O
voriconazole	O
trough	O
concent	O
ratio	O
ns	O
.	O

A	O
prospective	O
observational	O
study	O
was	O
performed	O
at	O
the	O
University	O
Medical	O
Center	O
Groningen	O
.	O

Patients	O
were	O
eligible	O
for	O
inclusion	O
if	O
they	O
were	O
â¥18	O
years	O
old	O
and	O
treated	O
with	O
voriconazole	O
.	O

Voriconazole	O
and	O
voriconazole-N-oxide	O
concentrations	O
were	O
determined	O
in	O
discarded	O
blood	O
samples	O
.	O

To	O
determine	O
the	O
degree	O
of	O
inflammation	O
,	O
C-reactive	B-P
protein	I-P
(	I-P
CRP	I-P
)	I-P
concentrations	I-P
were	O
used	O
.	O

Subsequently	O
,	O
a	O
longitudinal	O
data	O
analysis	O
was	O
performed	O
to	O
assess	O
the	O
effect	O
of	O
inflammation	O
on	O
the	O
metabolic	O
ratio	O
and	O
voriconazole	O
trough	O
concentration	O
.	O

Thirty-four	O
patients	O
were	O
included	O
.	O

In	O
total	O
489	O
voriconazole	O
trough	O
concentrations	O
were	O
included	O
in	O
the	O
longitudinal	O
data	O
analysis	O
.	O

This	O
analysis	O
showed	O
that	O
inflammation	O
,	O
reflected	O
by	O
CRP	B-P
concentrations	I-P
,	O
significantly	O
influence	O
d	O
the	O
metabolic	O
ratio	O
,	O
voriconazole	O
trough	O
concentration	O
and	O
voriconazole-N-oxide	O
concentration	O
(	O
all	O
P	O
<	O
0.001	O
)	O
,	O
when	O
corrected	O
for	O
other	O
factors	O
that	O
could	O
influence	O
voriconazole	O
metabolism	O
.	O

The	O
metabolic	O
ratio	O
was	O
decreased	O
by	O
0.99229	O
(	O
N	O
)	O
and	O
the	O
voriconazole-N-oxide	O
concentration	O
by	O
0.99775	O
(	O
N	O
)	O
,	O
while	O
the	O
voriconazole	O
trough	O
concentration	O
was	O
increased	O
by	O
1.005321	O
(	O
N	O
)	O
,	O
where	O
N	O
is	O
the	O
difference	O
in	O
CRP	O
units	O
(	O
in	O
mg/L	O
)	O
.	O

This	O
study	O
shows	O
that	O
voriconazole	O
metabolism	O
is	O
decreased	O
during	O
inflammation	O
,	O
resulting	O
in	O
higher	O
voriconazole	O
trough	O
concentration	O
s.	O
Therefore	O
,	O
frequent	O
monitoring	O
of	O
voriconazole	O
serum	O
concentrations	O
is	O
recommended	O
during	O
and	O
following	O
severe	O
inflammation	O
.	O

Determination	O
of	O
volatile	O
organic	O
compounds	O
exhaled	O
by	O
cell	O
lines	O
derived	O
from	O
hematological	O
malignancies	O
.	O

Background	O
:	O
The	O
gas	O
human	O
exhaled	O
contains	O
many	O
volatile	O
organic	O
compounds	O
(	O
VOCs	O
)	O
,	O
which	O
is	O
related	O
to	O
the	O
health	O
status	O
of	O
body	O
.	O

Analysis	O
of	O
VOCs	O
has	O
been	O
proposed	O
as	O
a	O
noninvasive	O
diagnostic	B-P
tool	I-P
for	O
certain	O
cancers	O
.	O

Detailed	O
research	O
on	O
the	O
VOCs	O
in	O
gas	O
exhaled	O
by	O
cell	O
can	O
characterize	O
cell	O
type	O
specific	O
metabolites	O
and	O
may	O
be	O
helpful	O
to	O
detect	O
the	O
cancer	O
markers	O
in	O
clinical	O
practice	O
.	O

Methods	O
:	O
Solid	B-P
phase	I-P
microextraction	I-P
-	O
gas	B-P
chromatography	I-P
-	O
mass	B-P
spectrometry	I-P
was	O
used	O
to	O
detect	O
VOCs	O
in	O
the	O
headspace	O
of	O
tissue	O
culture	O
flask	O
in	O
non-Hodgkin	O
's	O
lymphoma	O
cell	O
line	O
JEKO	O
and	O
acute	O
mononuclear	O
leukemia	O
cell	O
line	O
SHI-1	O
,	O
to	O
elaborate	O
the	O
characteristic	O
gaseous	O
biomarkers	O
of	O
hematological	O
malignancies	O
.	O

While	O
macrophage	O
cells	O
and	O
lymphocytic	O
cells	O
were	O
acted	O
as	O
control	O
.	O

The	O
blank	O
group	O
was	O
only	O
the	O
RPMI	O
1640	O
medium	O
containing	O
10	O
%	O
fetal	O
calf	O
serum	O
that	O
without	O
cells	O
.	O

Results	O
:	O
Comparing	O
to	O
control	O
group	O
,	O
the	O
concentration	O
of	O
dimethyl	O
sulphide	O
,	O
2,4-dimethyl-heptane	O
,	O
methylbenzene	O
,	O
o-xylene	O
,	O
dodecane	O
and	O
1,3-ditert-butylbenzene	O
in	O
JEKO	O
cells	O
were	O
relatively	O
higher	O
,	O
while	O
the	O
concentration	O
of	O
ethanol	O
,	O
hexanal	O
and	O
benzaldehyde	O
was	O
lower	O
.	O

In	O
SHI-1	O
cells	O
,	O
the	O
levels	O
of	O
2,4-dimethyl-heptane	O
,	O
benzene	O
,	O
4-methyldecane	O
,	O
chloroform	O
,	O
3,7-dimethyl	O
dodecane	O
and	O
hexadecane	O
were	O
significantly	O
elevated	O
,	O
but	O
the	O
levels	O
of	O
hexanol	O
and	O
cyclohexanol	O
were	O
distinctly	O
reduced	O
.	O

Conclusions	O
:	O
This	O
pilot	O
study	O
revealed	O
that	O
the	O
malignant	O
hematological	O
cells	O
could	O
change	O
the	O
components	O
of	O
VOCs	O
in	O
the	O
cell	B-P
culture	I-P
flask	I-P
in	O
a	O
cell	O
type	O
specific	O
pattern	O
.	O

The	O
traits	O
of	O
VOCs	O
in	O
our	O
setting	O
offered	O
new	O
strategy	O
for	O
hematological	O
malignancies	O
tracing	O
,	O
and	O
would	O
act	O
as	O
potential	O
biomarkers	O
in	O
diagnosis	O
of	O
malignant	O
hematological	O
diseases	O
.	O

Homogeneous	O
synthesis	O
of	O
Ag	O
nanoparticles	O
-doped	O
water-soluble	O
cellulose	O
acetate	O
for	O
versatile	O
applications	O
.	O

We	O
report	O
a	O
facile	O
and	O
efficient	O
approach	O
for	O
synthesis	O
of	O
well-dispersed	O
and	O
stable	O
silver	O
nanoparticles	O
(	O
Ag	O
NPs	O
)	O
using	O
water-soluble	O
cellulose	O
acetate	O
(	O
CA	O
)	O
as	O
both	O
reductant	O
and	O
stabilizer	O
.	O

Partially	O
substituted	O
CA	O
with	O
highly	O
active	O
hydroxyl	O
groups	O
and	O
excellent	O
water-solubility	O
is	O
able	O
to	O
reduce	O
silver	O
ions	O
in	O
homogeneous	O
aqueous	O
medium	O
effectively	O
.	O

The	O
synthesized	O
Ag	O
NPs	O
were	O
characterized	O
by	O
UV-vis	B-P
spectroscopy	I-P
,	O
X-ray	B-P
diffraction	I-P
,	O
X-ray	B-P
photoelectron	I-P
spectroscopy	I-P
,	O
transmission	B-P
electron	I-P
microscopy	I-P
and	O
energy	B-P
dispersive	I-P
X-ray	I-P
spectroscope	I-P
analysis	B-P
.	O

The	O
as-	O
prepared	O
Ag	O
NPs	O
were	O
well-dispersed	O
,	O
showing	O
a	O
surface	O
plasmon	O
resonance	O
peak	O
at	O
426	O
nm	O
.	O

The	O
resulted	O
Ag	O
NPs	O
@	O
CA	O
nanohybrids	O
exhibit	O
high	O
catalytic	O
activity	O
for	O
the	O
reduction	O
of	O
4-nitrophenol	O
to	O
4-aminophenol	O
in	O
the	O
presence	O
of	O
NaBH4	O
.	O

Meanwhile	O
,	O
the	O
nanohybrids	O
are	O
also	O
effective	O
in	O
inhibiting	O
the	O
growth	O
of	O
bacterial	O
.	O

This	O
environmentally	O
friendly	O
method	O
promotes	O
the	O
use	O
of	O
renewable	O
natural	O
resources	O
to	O
prepare	O
a	O
variety	O
of	O
inorganic-organic	O
materials	O
for	O
catalysis	O
,	O
antibacterial	O
,	O
sensors	O
and	O
other	O
applications	O
.	O

Clinical	O
outcomes	O
of	O
ERCP	B-P
-related	O
retroperitoneal	O
perforations	O
.	O

Endoscopic	B-P
retrograde	I-P
cholangiopancreatography	I-P
(	O
ERCP	B-P
)	O
-related	O
perforations	O
represent	O
rare	O
but	O
often	O
severe	O
conditions	O
.	O

While	O
lesions	O
with	O
intraperitoneal	O
perforation	O
have	O
an	O
almost	O
imperative	O
indication	O
to	O
surgery	O
,	O
whether	O
or	O
not	O
to	O
manage	O
retroperitoneal	O
perforations	O
surgically	O
is	O
still	O
an	O
area	O
of	O
debate	O
.	O

The	O
aim	O
of	O
the	O
present	O
work	O
was	O
to	O
review	O
the	O
available	O
clinical	O
evidence	O
on	O
the	O
operatively	O
and	O
medically	O
treated	O
ERCP	B-P
-related	O
retroperitoneal	O
perforations	O
.	O

From	O
MEDLINE	O
/	O
PubMed	O
databases	O
137	O
patients	O
with	O
retroperitoneal	O
perforation	O
were	O
included	O
from	O
12	O
studies	O
that	O
met	O
the	O
selection	O
criteria	O
for	O
data	O
investigation	O
and	O
analysis	O
.	O

Twenty-four	O
patients	O
were	O
treated	O
by	O
prompt	O
surgery	O
;	O
113	O
were	O
primarily	O
managed	O
conservatively	O
and	O
about	O
20	O
%	O
of	O
these	O
patients	O
required	O
surgery	O
subsequently	O
.	O

Overall	O
,	O
the	O
morbidity	O
and	O
mortality	O
were	O
15.4	O
%	O
and	O
6.6	O
%	O
,	O
respectively	O
.	O

Although	O
most	O
patients	O
with	O
retroperitoneal	O
perforation	O
may	O
benefit	O
from	O
a	O
non-operative	O
management	O
,	O
a	O
considerable	O
number	O
of	O
patients	O
fail	O
to	O
respond	O
to	O
medical	O
treatment	O
and	O
require	O
surgery	O
afterwards	O
.	O

Identifying	O
those	O
patients	O
who	O
are	O
at	O
highest	O
risk	O
of	O
poor	O
outcome	O
after	O
conservative	O
treatment	O
should	O
be	O
considered	O
a	O
research	O
priority	O
.	O

Albumin	O
-Bioinspired	O
Gd	O
:	O
CuS	O
Nanotheranostic	O
Agent	O
for	O
In	O
Vivo	O
Photoacoustic	B-P
/	O
Magnetic	B-P
Resonance	I-P
Imaging	I-P
-Guided	O
Tumor	O
-Targeted	O
Photothermal	O
Therapy	O
.	O

Photothermal	O
therapy	O
(	O
PTT	O
)	O
is	O
attracting	O
increasing	O
interest	O
and	O
becoming	O
more	O
widely	O
used	O
for	O
skin	O
cancer	O
therapy	O
in	O
the	O
clinic	O
,	O
as	O
a	O
result	O
of	O
its	O
noninvasiveness	O
and	O
low	O
systemic	O
adverse	O
effects	O
.	O

However	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
biocompatible	O
PTT	O
agents	O
,	O
which	O
enable	O
accurate	O
imaging	B-P
,	O
monitoring	O
,	O
and	O
diagnosis	O
.	O

Herein	O
,	O
a	O
biocompatible	O
Gd	O
-integrated	O
CuS	O
nanotheranostic	O
agent	O
(	O
Gd	O
:	O
CuS	O
@	O
BSA	O
)	O
was	O
synthesized	O
via	O
a	O
facile	O
and	O
environmentally	O
friendly	O
biomimetic	O
strategy	O
,	O
using	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
as	O
a	O
biotemplate	O
at	O
physiological	O
temperature	O
.	O

The	O
as-prepared	O
Gd	O
:	O
CuS	O
@	O
BSA	O
nanoparticles	O
(	O
NPs	O
)	O
with	O
ultrasmall	O
sizes	O
(	O
ca	O
.	O

9	O
nm	O
)	O
exhibited	O
high	O
photothermal	O
conversion	O
efficiency	O
and	O
good	O
photostability	O
under	O
near-infrared	O
(	O
NIR	O
)	O
laser	O
irradiation	O
.	O

With	O
doped	O
Gd	O
species	O
and	O
strong	O
tunable	O
NIR	O
absorbance	O
,	O
Gd	O
:	O
CuS	O
@	O
BSA	O
NPs	O
demonstrate	O
prominent	O
tumor-contrasted	B-P
imaging	I-P
performance	O
both	O
on	O
the	O
photoacoustic	B-P
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
modalities	O
.	O

The	O
subsequent	O
Gd	O
:	O
CuS	O
@	O
BSA	O
-mediated	O
PTT	O
result	O
shows	O
high	O
therapy	O
efficacy	O
as	O
a	O
result	O
of	O
their	O
potent	O
NIR	O
absorption	O
and	O
high	O
photothermal	O
conversion	O
efficiency	O
.	O

The	O
immune	O
response	O
triggered	O
by	O
Gd	O
:	O
CuS	O
@	O
BSA	O
-mediated	O
PTT	O
is	O
preliminarily	O
explored	O
.	O

In	O
addition	O
,	O
toxicity	B-P
studies	I-P
in	O
vitro	O
and	O
in	O
vivo	O
verify	O
that	O
Gd	O
:	O
CuS	O
@	O
BSA	O
NPs	O
qualify	O
as	O
biocompatible	O
agents	O
.	O

A	O
biodistribution	O
study	O
demonstrated	O
that	O
the	O
NPs	O
can	O
undergo	O
hepatic	O
clearance	O
from	O
the	O
body	O
.	O

This	O
study	O
highlights	O
the	O
practicality	O
and	O
versatility	O
of	O
albumin	O
-mediated	O
biomimetic	O
mineralization	O
of	O
a	O
nanotheranostic	O
agent	O
and	O
also	O
suggests	O
that	O
bioinspired	O
Gd	O
:	O
CuS	O
@	O
BSA	O
NPs	O
possess	O
promising	O
imaging	O
guidance	O
and	O
effective	O
tumor	O
ablation	O
properties	O
,	O
with	O
high	O
spatial	O
resolution	O
and	O
deep	O
tissue	O
penetration	O
.	O

Lowering	O
the	O
overall	O
charge	O
on	O
TMPyP4	O
improves	O
its	O
selectivity	O
for	O
G-quadruplex	O
DNA	O
.	O

Ligands	O
that	O
stabilize	O
non-canonical	O
DNA	O
structures	O
called	O
G-quadruplexes	O
(	O
GQs	O
)	O
might	O
have	O
applications	O
in	O
medicine	O
as	O
anti-cancer	O
agents	O
,	O
due	O
to	O
the	O
involvement	O
of	O
GQ	O
DNA	O
in	O
a	O
variety	O
of	O
cancer-related	O
biological	O
processes	O
.	O

Five	O
derivatives	O
of	O
5,10,15,20-tetrakis	O
(	O
N-methyl-4-pyridyl	O
)	O
porphyrin	O
(	O
TMPyP4	O
)	O
,	O
where	O
a	O
N-methylpyridyl	O
group	O
was	O
replaced	O
with	O
phenyl	O
(	O
4P3	O
)	O
,	O
4-aminopheny	O
l	O
(	O
PN3M	O
)	O
,	O
4-phenylamidoproline	O
(	O
PL3M	O
)	O
,	O
or	O
4-carboxyphenyl	O
(	O
PC3M	O
and	O
P2C2M	O
)	O
were	O
investigated	O
for	O
their	O
interactions	O
with	O
human	O
telomeric	O
DNA	O
(	O
Tel22	O
)	O
using	O
fluorescence	B-P
resonance	I-P
energy	I-P
transfer	I-P
(	O
FRET	B-P
)	O
assay	O
,	O
and	O
UV-visible	O
and	O
circular	O
dichroism	O
spectroscopies	O
in	O
K	O
(	O
+	O
)	O
buffer	O
.	O

The	O
molecules	O
are	O
cationic	O
or	O
zwitterionic	O
with	O
an	O
overall	O
charge	O
of	O
3+	O
(	O
4P3	O
,	O
PN3M	O
,	O
and	O
PL3M	O
)	O
,	O
2+	O
(	O
PC3M	O
)	O
or	O
neutral	O
(	O
P2C2M	O
)	O
.	O

All	O
porphyrins	O
except	O
P2C2M	O
stabilize	O
human	O
telomeric	O
DNA	O
in	O
FRET	B-P
assays	I-P
by	O
â¼20	O
Â°C	O
at	O
5	O
eq	O
CD	B-P
melting	I-P
experiments	I-P
suggest	O
that	O
4P3	O
is	O
the	O
most	O
stabilizing	O
ligand	O
with	O
a	O
stabilization	O
temperature	O
of	O
16.8	O
Â°C	O
at	O
4	O
eq	O
.	O

Importantly	O
,	O
4P3	O
,	O
PC3M	O
and	O
PL3M	O
demonstrate	O
excellent	O
selectivity	O
for	O
quadruplexes	O
,	O
far	O
superior	O
to	O
that	O
of	O
TMPyP4	O
.	O

Binding	O
constants	O
,	O
determined	O
using	O
UV-vis	B-P
titrations	I-P
,	O
correlate	O
with	O
charge	O
:	O
triply	O
cationic	O
4P3	O
,	O
PN3M	O
and	O
PL3M	O
display	O
Ka	O
of	O
5-9	O
Î¼M	O
(	O
-1	O
)	O
,	O
doubly	O
cationic	O
PC3M	O
displays	O
Ka	O
of	O
1	O
Î¼M	O
(	O
-1	O
)	O
,	O
and	O
neutral	O
P2C2M	O
displays	O
weak-to-no	O
binding	O
.	O

UV-vis	O
data	O
suggest	O
that	O
binding	O
interactions	O
are	O
driven	O
by	O
electrostatic	O
attractions	O
and	O
that	O
the	O
binding	O
mode	O
may	O
be	O
base-stacking	O
(	O
or	O
end-stacking	O
)	O
judging	O
by	O
the	O
high	O
values	O
of	O
red	O
shift	O
(	O
15-20	O
nm	O
)	O
and	O
hypochromicity	O
(	O
40-50	O
%	O
)	O
.	O

We	O
conclude	O
that	O
lowering	O
the	O
charge	O
on	O
TMPyP4	O
to	O
3+	O
can	O
achieve	O
the	O
desired	O
balance	O
between	O
stabilizing	O
ability	O
,	O
affinity	O
,	O
and	O
high	O
selectivity	O
required	O
for	O
an	O
excellent	O
quadruplex	O
ligand	O
.	O

Mass-spectrometry	B-P
analysis	O
of	O
histone	O
post-translational	O
modifications	O
in	O
pathology	O
tissue	O
using	O
the	O
PAT-H-MS	B-P
approach	O
.	O

Aberrant	O
histone	O
post-translational	O
modifications	O
(	O
hPTMs	O
)	O
have	O
been	O
implicated	O
with	O
various	O
pathologies	O
,	O
including	O
cancer	O
,	O
and	O
may	O
represent	O
useful	O
epigenetic	O
biomarkers	O
.	O

The	O
data	O
described	O
here	O
provide	O
a	O
mass	B-P
spectrometry	I-P
-based	O
quantitative	O
analysis	O
of	O
hPTMs	O
from	O
formalin-fixed	O
paraffin-embedded	O
(	O
FFPE	O
)	O
tissues	O
,	O
from	O
which	O
histones	O
were	O
extracted	O
through	O
the	O
recently	O
developed	O
PAT-H-MS	B-P
method	I-P
.	O

First	O
,	O
we	O
analyzed	O
FFPE	O
samples	O
from	O
mouse	O
spleen	O
and	O
liver	O
or	O
human	O
breast	O
cancer	O
up	O
to	O
six	O
years	O
old	O
,	O
together	O
with	O
their	O
corresponding	O
fresh	O
frozen	O
tissue	O
.	O

We	O
then	O
combined	O
the	O
PAT-H-MS	B-P
approach	O
with	O
a	O
histone	O
-focused	O
version	O
of	O
the	O
super-SILAC	O
strategy	O
-using	O
a	O
mix	O
of	O
histones	O
from	O
four	O
breast	O
cancer	O
cell	O
lines	O
as	O
a	O
spike-in	O
standard	O
-	O
to	O
accurately	O
quantify	O
hPTMs	O
from	O
breast	O
cancer	O
specimens	O
belonging	O
to	O
different	O
subtypes	O
.	O

The	O
data	O
,	O
which	O
are	O
associated	O
with	O
a	O
recent	O
publication	O
(	O
Pathology	O
tissue	O
-	O
quantitative	B-P
mass	I-P
spectrometry	I-P
analysis	O
to	O
profile	B-P
histone	O
post-translational	O
modification	O
patterns	O
in	O
patient	O
samples	O
(	O
Noberini	O
,	O
2015	O
)	O
[	O
1	O
]	O
)	O
,	O
are	O
deposited	O
at	O
the	O
ProteomeXchange	O
Consortium	O
via	O
the	O
PRIDE	O
partner	O
repository	O
with	O
the	O
dataset	O
identifier	O
PXD002669	O
.	O

Biopersistence	O
and	O
translocation	O
to	O
extrapulmonary	O
organs	O
of	O
titanium	O
dioxide	O
nanoparticles	O
after	O
subacute	O
inhalation	O
exposure	O
to	O
aerosol	O
in	O
adult	O
and	O
elderly	O
rats	O
.	O

The	O
increasing	O
industrial	O
use	O
of	O
nanoparticles	O
(	O
NPs	O
)	O
has	O
raised	O
concerns	O
about	O
their	O
impact	O
on	O
human	O
health	O
.	O

Since	O
aging	O
and	O
exposure	O
to	O
environmental	O
factors	O
are	O
linked	O
to	O
the	O
risk	O
for	O
developing	O
pathologies	O
,	O
we	O
address	O
the	O
question	O
of	O
TiO2	O
NPs	O
toxicokinetics	O
in	O
the	O
context	O
of	O
a	O
realistic	O
occupational	O
exposure	O
.	O

We	O
report	O
the	O
biodistribution	O
of	O
titanium	O
in	O
healthy	O
young	O
adults	O
(	O
12-13-week-old	O
)	O
and	O
in	O
elderly	O
rats	O
(	O
19-month-old	O
)	O
exposed	O
to	O
10mg/m	O
(	O
3	O
)	O
of	O
a	O
TiO2	O
nanostructured	O
aerosol	O
6h/day	O
,	O
5days/week	O
for	O
4	O
weeks	O
.	O

We	O
measured	O
Ti	O
content	O
in	O
major	O
organs	O
using	O
inductively	B-P
coupled	I-P
plasma	I-P
mass	I-P
spectrometry	I-P
immediately	O
and	O
up	O
to	O
180days	O
after	O
the	O
end	O
of	O
exposure	O
.	O

Large	O
amounts	O
of	O
titanium	O
were	O
initially	O
found	O
in	O
lung	O
which	O
were	O
slowly	O
cleared	O
during	O
the	O
post-exposure	O
period	O
.	O

From	O
day	O
28	O
,	O
a	O
small	O
increase	O
of	O
Ti	O
was	O
found	O
in	O
the	O
spleen	O
and	O
liver	O
of	O
exposed	O
young	O
adult	O
rats	O
.	O

Such	O
an	O
increase	O
was	O
however	O
never	O
found	O
in	O
their	O
blood	O
,	O
kidneys	O
or	O
brain	O
.	O

In	O
the	O
elderly	O
group	O
,	O
translocation	O
to	O
extra-pulmonary	O
organs	O
was	O
significant	O
at	O
day	O
90	O
.	O

Ti	O
recovered	O
from	O
the	O
spleen	O
and	O
liver	O
of	O
exposed	O
elderly	O
rats	O
was	O
higher	O
than	O
in	O
exposed	O
young	O
adults	O
.	O

These	O
data	O
suggest	O
that	O
TiO2	O
NPs	O
may	O
translocate	O
from	O
the	O
lung	O
to	O
extra-pulmonary	O
organs	O
where	O
they	O
could	O
possibly	O
promote	O
systemic	O
health	O
effects	O
.	O

Body	O
Diffusion	B-P
Weighted	I-P
Imaging	I-P
Using	O
Non-CPMG	B-P
Fast	I-P
Spin	I-P
Echo	I-P
.	O

SS-FSE	B-P
is	O
a	O
fast	O
technique	B-P
that	O
does	O
not	O
suffer	O
from	O
off-resonance	O
distortions	O
to	O
the	O
degree	O
that	O
EPI	B-P
does	O
.	O

Unlike	O
EPI	B-P
,	O
SS-FSE	B-P
is	O
ill-suited	O
to	O
diffusion	B-P
weighted	I-P
imaging	I-P
(	O
DWI	B-P
)	O
due	O
to	O
the	O
Carr-Purcell-Meiboom-Geill	O
(	O
CPMG	O
)	O
condition	O
.	O

Non-CPMG	O
phase	O
cycling	O
does	O
accommodate	O
SS-FSE	B-P
and	O
DWI	B-P
but	O
places	O
constraints	O
on	O
reconstruction	O
,	O
which	O
are	O
resolved	O
here	O
through	O
parallel	B-P
imaging	I-P
.	O

Additionally	O
,	O
improved	O
echo	O
stability	O
can	O
be	O
achieved	O
by	O
using	O
short	O
duration	O
and	O
highly	O
selective	O
DIVERSE	O
radiofrequency	O
pulses	O
.	O

Here	O
,	O
signal-to-noise	O
ratio	O
(	O
SNR	O
)	O
comparisons	O
between	O
EPI	B-P
and	O
nCPMG	O
SS-FSE	B-P
acquisitions	O
and	O
reconstruction	O
techniques	O
give	O
similar	O
values	O
.	O

Diffusion	B-P
imaging	I-P
with	O
nCPMG	O
SS-FSE	B-P
gives	O
similar	O
SNR	O
to	O
an	O
EPI	B-P
acquisition	O
,	O
though	O
apparent	O
diffusion	O
coefficient	O
values	O
are	O
higher	O
than	O
seen	O
with	O
EPI	B-P
.	O

In	O
vivo	O
images	O
have	O
good	O
image	O
quality	O
with	O
little	O
distortion	O
.	O

This	O
method	O
has	O
the	O
ability	O
to	O
capture	O
distortion	O
-	O
free	O
DWI	B-P
images	O
near	O
areas	O
of	O
significant	O
off-resonance	O
as	O
well	O
as	O
preserve	O
adequate	O
SNR	O
.	O

Parallel	B-P
imaging	I-P
and	O
DIVERSE	O
refocusing	O
RF	O
pulses	O
allow	O
shorter	O
ETL	O
compared	O
to	O
previous	O
implementations	O
and	O
thus	O
reduces	O
phase	O
encode	O
direction	O
blur	O
and	O
SAR	O
accumulation	O
.	O

Corneal	O
Ring	O
Infiltrates	O
Caused	O
by	O
Serratia	O
marcescens	O
in	O
a	O
Patient	O
with	O
Human	O
Immunodeficiency	O
Virus	O
.	O

To	O
describe	O
corneal	O
ring	O
infiltrates	O
caused	O
by	O
Serratia	O
marcescens	O
in	O
a	O
patient	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
who	O
wore	O
contact	O
lenses	O
.	O

A	O
case	O
study	O
of	O
a	O
patient	O
with	O
keratitis	O
due	O
to	O
an	O
infection	O
caused	O
by	O
S.	O
marcescens	O
and	O
exhibiting	O
corneal	O
ring	O
infiltrates	O
was	O
reviewed	O
for	O
history	O
,	O
clinical	O
manifestation	O
,	O
microscopic	B-P
study	I-P
,	O
and	O
management	O
.	O

A	O
29-year-old	O
man	O
who	O
had	O
a	O
history	O
of	O
contact	O
lens	O
wear	O
and	O
HIV-1	O
infection	O
was	O
admitted	O
to	O
hospital	O
because	O
of	O
blurred	O
vision	O
,	O
redness	O
,	O
and	O
corneal	O
infiltrates	O
in	O
the	O
shape	O
of	O
a	O
ring	O
in	O
the	O
left	O
eye	O
.	O

The	O
visual	O
acuity	O
(	O
VA	O
)	O
in	O
both	O
eyes	O
was	O
hand	O
movement	O
(	O
uncorrected	O
)	O
.	O

Corneal	B-P
scrapings	I-P
were	O
performed	O
.	O

The	O
culture	B-P
results	O
of	O
the	O
corneal	O
specimens	O
revealed	O
S.	O
marcescens	O
.	O

The	O
culture	O
results	O
of	O
the	O
contact	O
lens	O
disclosed	O
the	O
same	O
organism	O
.	O

The	O
corneal	O
ulcer	O
responded	O
well	O
to	O
treatment	O
with	O
topical	O
gentamycin	O
sulfate	O
14	O
mg/ml	O
.	O

The	O
final	O
VA	O
remained	O
hand	O
movemen	O
t.	O
S.	O
marcescens	O
can	O
cause	O
ring	O
infiltrates	O
in	O
a	O
HIV-1	O
patient	O
who	O
wears	O
contact	O
lenses	O
.	O

The	O
treatment	O
result	O
for	O
S.	O
marcescens	O
keratitis	O
in	O
a	O
HIV-1	O
patient	O
who	O
wore	O
contact	O
lenses	O
was	O
favorable	O
after	O
intensive	O
use	O
of	O
fortified	O
topical	O
antibiotics	O
.	O

Tenofovir	O
alafenamide	O
versus	O
tenofovir	O
disoproxil	O
fumarate	O
for	O
the	O
treatment	O
of	O
HBeAg-positive	O
chronic	O
hepatitis	O
B	O
virus	O
infection	O
:	O
a	O
randomised	O
,	O
double-blind	O
,	O
phase	O
3	O
,	O
non-inferiority	O
trial	O
.	O

Tenofovir	O
alafenamide	O
is	O
a	O
novel	O
prodrug	O
formulated	O
to	O
deliver	O
the	O
active	O
metabolite	O
to	O
target	O
cells	O
more	O
efficiently	O
than	O
tenofovir	O
disoproxil	O
fumarate	O
at	O
a	O
lower	O
dose	O
,	O
thereby	O
reducing	O
systemic	O
exposure	O
.	O

In	O
patients	O
with	O
HIV	O
,	O
tenofovir	O
alafenamide	O
was	O
as	O
efficacious	O
as	O
tenofovir	O
disoproxil	O
fumarate	O
,	O
with	O
reduced	O
bone	O
and	O
renal	O
toxic	O
effects	O
.	O

We	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
two	O
drugs	O
in	O
patients	O
with	O
HBeAg-positive	O
chronic	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
infection	O
in	O
a	O
non-inferiority	O
study	O
.	O

We	O
did	O
this	O
ongoing	O
double-blind	O
,	O
non-inferiority	O
study	O
in	O
161	O
outpatient	O
centres	O
in	O
19	O
countries	O
.	O

Patients	O
with	O
chronic	O
HBV	O
infection	O
who	O
were	O
positive	O
for	O
the	O
hepatitis	O
B	O
e	O
antigen	O
(	O
HBeAg	O
)	O
were	O
randomly	O
assigned	O
(	O
2:1	O
)	O
to	O
receive	O
either	O
25	O
mg	O
tenofovir	O
alafenamide	O
or	O
300	O
mg	O
tenofovir	O
disoproxil	O
fumarate	O
with	O
matching	O
placebo	O
.	O

Randomisation	O
was	O
done	O
by	O
a	O
computer	O
-	O
generated	O
allocation	O
sequence	O
(	O
block	O
size	O
six	O
)	O
stratified	O
by	O
plasma	B-P
HBV	I-P
DNA	I-P
concentration	I-P
and	O
previous	O
treatment	O
experience	O
.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
the	O
proportion	O
of	O
patients	O
with	O
HBV	O
DNA	O
less	O
than	O
29	O
IU/mL	O
at	O
week	O
48	O
in	O
all	O
patients	O
who	O
were	O
randomly	O
assigned	O
and	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
using	O
a	O
missing-equals-failed	O
approach	O
.	O

The	O
pre-specified	O
non-inferiority	O
margin	O
was	O
10	O
%	O
.	O

Key	O
prespecified	O
safety	O
endpoints	O
were	O
bone	O
and	O
renal	O
parameters	O
at	O
week	O
48	O
.	O

This	O
study	O
is	O
registered	O
with	O
ClinicalTrials.gov	O
,	O
number	O
NCT01940471	O
.	O

Of	O
the	O
1473	O
patients	O
screened	O
from	O
Sept	O
11	O
,	O
2013	O
,	O
to	O
Dec	O
20	O
,	O
2014	O
,	O
875	O
eligible	O
patients	O
were	O
randomly	O
assigned	O
and	O
873	O
received	O
treatment	O
(	O
581	O
with	O
tenofovir	O
alafenamide	O
and	O
292	O
with	O
tenofovir	O
disoproxil	O
fumarate	O
)	O
.	O

371	O
(	O
64	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
alafenamide	O
had	O
HBV	O
DNA	O
less	O
than	O
29	O
IU/mL	O
at	O
week	O
48	O
,	O
which	O
was	O
non-inferior	O
to	O
the	O
195	O
(	O
67	O
%	O
)	O
of	O
patients	O
receiving	O
tenofovir	O
disoproxil	O
fumarate	O
who	O
had	O
HBV	O
DNA	O
less	O
than	O
29	O
IU/mL	O
(	O
adjusted	O
difference	O
-3Â·6	O
%	O
[	O
95	O
%	O
CI	O
-9Â·8	O
to	O
2Â·6	O
]	O
;	O
p	O
=0Â·25	O
)	O
.	O

Patients	O
given	O
tenofovir	O
alafenamide	O
had	O
a	O
significantly	O
smaller	O
decrease	O
in	O
bone	O
mineral	O
density	O
at	O
hip	O
(	O
mean	O
change	O
-0Â·10	O
%	O
[	O
95	O
%	O
CI	O
-0Â·29	O
to	O
0Â·09	O
]	O
vs	O
-1Â·72	O
%	O
[	O
-2Â·02	O
to	O
-1Â·41	O
]	O
;	O
adjusted	O
difference	O
1Â·62	O
[	O
1Â·27	O
to	O
1Â·96	O
]	O
;	O
p	O
<	O
0Â·0001	O
)	O
and	O
at	O
spine	O
(	O
mean	O
change	O
-0Â·42	O
%	O
[	O
-0Â·66	O
to	O
-0Â·17	O
]	O
vs	O
-2Â·29	O
%	O
[	O
-2Â·67	O
to	O
-1Â·92	O
]	O
;	O
adjusted	O
difference	O
1Â·88	O
[	O
1Â·44	O
to	O
2Â·31	O
]	O
;	O
p	O
<	O
0Â·0001	O
)	O
as	O
well	O
as	O
smaller	O
mean	O
increases	O
in	O
serum	O
creatinine	O
at	O
week	O
48	O
(	O
0Â·01	O
mg/dL	O
[	O
0Â·00-0Â·02	O
]	O
vs	O
0Â·03	O
mg/dL	O
[	O
0Â·02-0Â·04	O
]	O
;	O
p	O
=0Â·02	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	O
overall	O
were	O
upper	O
respiratory	O
tract	O
infection	O
(	O
51	O
[	O
9	O
%	O
]	O
of	O
581	O
patients	O
receiving	O
tenofovir	O
alafenamide	O
vs	O
22	O
[	O
8	O
%	O
]	O
of	O
292	O
patients	O
receiving	O
tenofovir	O
disoproxil	O
fumarate	O
)	O
,	O
nasopharyngitis	O
(	O
56	O
[	O
10	O
%	O
]	O
vs	O
16	O
[	O
5	O
%	O
]	O
)	O
,	O
and	O
headache	O
(	O
42	O
[	O
7	O
%	O
]	O
vs	O
22	O
[	O
8	O
%	O
]	O
)	O
.	O

22	O
(	O
4	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
alafenamide	O
and	O
12	O
(	O
4	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
disoproxil	O
fumarate	O
experienced	O
serious	O
adverse	O
events	O
,	O
none	O
of	O
which	O
was	O
deemed	O
by	O
the	O
investigator	O
to	O
be	O
related	O
to	O
study	O
treatment	O
.	O

187	O
(	O
32	O
%	O
)	O
of	O
581	O
patients	O
in	O
the	O
tenofovir	O
alafenamide	O
group	O
and	O
96	O
(	O
33	O
%	O
)	O
of	O
292	O
patients	O
in	O
the	O
tenofovir	O
disoproxil	O
fumarate	O
group	O
had	O
grade	O
3	O
or	O
4	O
laboratory	O
abnormalities	O
,	O
the	O
most	O
common	O
of	O
which	O
were	O
elevations	O
in	O
ALT	B-P
(	O
62	O
[	O
11	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	O
and	O
36	O
[	O
13	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	O
fumarate	O
)	O
and	O
AST	B-P
(	O
20	O
[	O
3	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	O
and	O
19	O
[	O
7	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	O
fumarate	O
)	O
.	O

In	O
patients	O
with	O
HBeAg-positive	O
HBV	O
infection	O
,	O
tenofovir	O
alafenamide	O
was	O
non-inferior	O
to	O
tenofovir	O
disoproxil	O
fumarate	O
,	O
and	O
had	O
improved	O
bone	O
and	O
renal	O
effects	O
.	O

Longer	O
term	O
follow-up	O
is	O
needed	O
to	O
better	O
understand	O
the	O
clinical	O
impact	O
of	O
these	O
changes	O
.	O

Gilead	O
Sciences	O
.	O

Transcriptional	O
reprogramming	O
in	O
yeast	O
using	O
dCas9	O
and	O
combinatorial	O
gRNA	O
strategies	O
.	O

Transcriptional	O
reprogramming	O
is	O
a	O
fundamental	O
process	O
of	O
living	O
cells	O
in	O
order	O
to	O
adapt	O
to	O
environmental	O
and	O
endogenous	O
cues	O
.	O

In	O
order	O
to	O
allow	O
flexible	O
and	O
timely	O
control	O
over	O
gene	O
expression	O
without	O
the	O
interference	O
of	O
native	O
gene	O
expression	O
machinery	O
,	O
a	O
large	O
number	O
of	O
studies	O
have	O
focused	O
on	O
developing	O
synthetic	O
biology	O
tools	O
for	O
orthogonal	O
control	O
of	O
transcription	O
.	O

Most	O
recently	O
,	O
the	O
nuclease-deficient	O
Cas9	O
(	O
dCas9	O
)	O
has	O
emerged	O
as	O
a	O
flexible	O
tool	O
for	O
controlling	O
activation	O
and	O
repression	O
of	O
target	O
genes	O
,	O
by	O
the	O
simple	O
RNA-guided	O
positioning	O
of	O
dCas9	O
in	O
the	O
vicinity	O
of	O
the	O
target	O
gene	O
transcription	O
start	O
site	O
.	O

In	O
this	O
study	O
we	O
compared	O
two	O
different	O
systems	O
of	O
dCas9	O
-mediated	O
transcriptional	O
reprogramming	O
,	O
and	O
applied	O
them	O
to	O
genes	O
controlling	O
two	O
biosynthetic	O
pathways	O
for	O
biobased	O
production	O
of	O
isoprenoids	O
and	O
triacylglycerols	O
(	O
TAGs	O
)	O
in	O
baker	O
's	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

By	O
testing	O
101	O
guide-RNA	O
(	O
gRNA	O
)	O
structures	O
on	O
a	O
total	O
of	O
14	O
different	O
yeast	O
promoters	O
,	O
we	O
identified	O
the	O
best-performing	O
combinations	O
based	O
on	O
reporter	O
assays	B-P
.	O

Though	O
a	O
larger	O
number	O
of	O
gRNA	O
-	O
promoter	O
combinations	O
do	O
not	O
perturb	O
gene	O
expression	O
,	O
some	O
gRNAs	O
support	O
expression	O
perturbations	O
up	O
to	O
~threefold	O
.	O

The	O
best-performing	O
gRNAs	O
were	O
used	O
for	O
single	O
and	O
multiplex	O
reprogramming	O
strategies	O
for	O
redirecting	O
flux	O
related	O
to	O
isoprenoid	O
production	O
and	O
optimization	O
of	O
TAG	O
profiles	O
.	O

From	O
these	O
studies	O
,	O
we	O
identified	O
both	O
constitutive	O
and	O
inducible	O
multiplex	O
reprogramming	O
strategies	O
enabling	O
significant	O
changes	O
in	O
isoprenoid	O
production	O
and	O
increases	O
in	O
TAG	O
.	O

Taken	O
together	O
,	O
we	O
show	O
similar	O
performance	O
for	O
a	O
constitutive	O
and	O
an	O
inducible	O
dCas9	O
approach	O
,	O
and	O
identify	O
multiplex	O
gRNA	O
designs	O
that	O
can	O
significantly	O
perturb	O
isoprenoid	O
production	O
and	O
TAG	O
profiles	O
in	O
yeast	O
without	O
editing	O
the	O
genomic	O
context	O
of	O
the	O
target	O
genes	O
.	O

We	O
also	O
identify	O
a	O
large	O
number	O
of	O
gRNA	O
positions	O
in	O
14	O
native	O
yeast	O
target	O
pomoters	O
that	O
do	O
not	O
affect	O
expression	O
,	O
suggesting	O
the	O
need	O
for	O
further	O
optimization	O
of	O
gRNA	O
design	O
tools	O
and	O
dCas9	O
engineering	O
.	O

The	O
underlying	O
inflammatory	O
chronic	O
disease	O
influences	O
infliximab	O
pharmacokinetics	O
.	O

Infliximab	O
is	O
an	O
anti-tumor	O
necrosis	O
factor	O
monoclonal	O
antibody	O
approved	O
in	O
chronic	O
inflammatory	O
diseases	O
such	O
as	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
,	O
ankylosing	O
spondylitis	O
(	O
AS	O
)	O
,	O
Crohn	O
's	O
disease	O
(	O
CD	O
)	O
and	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
.	O

Infliximab	O
pharmacokinetics	O
is	O
variable	O
between	O
patients	O
,	O
but	O
influence	O
of	O
the	O
underlying	O
disease	O
was	O
never	O
assessed	O
.	O

This	O
study	O
aimed	O
at	O
assessing	O
this	O
influence	O
using	O
a	O
cohort	O
of	O
patients	O
monitored	O
in	O
a	O
single	O
center	O
and	O
with	O
the	O
same	O
assay	B-P
.	O

Infliximab	O
trough	O
concentrations	O
were	O
determined	O
on	O
samples	B-P
collected	I-P
between	O
weeks	O
0	O
and	O
22	O
after	O
treatment	O
initiation	O
in	O
218	O
patients	O
treated	O
for	O
RA	O
,	O
PsA	O
,	O
AS	O
,	O
CD	O
or	O
UC	O
.	O

Infliximab	O
pharmacokinetics	O
was	O
analyzed	O
by	O
a	O
one-compartment	O
population	O
model	O
with	O
first-order	O
elimination	O
rate	O
constant	O
.	O

In	O
AS	O
patients	O
,	O
volume	O
of	O
distribution	O
(	O
V	O
)	O
and	O
elimination	O
clearance	O
(	O
CL	O
)	O
were	O
5.4	O
L	O
and	O
0.24	O
L/day	O
,	O
respectively	O
.	O

In	O
CD	O
and	O
UC	O
patients	O
,	O
V	O
was	O
49	O
%	O
and	O
52	O
%	O
higher	O
than	O
in	O
AS	O
,	O
respectively	O
,	O
and	O
CL	O
was	O
47	O
%	O
and	O
60	O
%	O
higher	O
than	O
in	O
AS	O
,	O
respectively	O
.	O

In	O
RA	O
patients	O
,	O
CL	O
was	O
49	O
%	O
higher	O
than	O
in	O
AS	O
patients	O
.	O

Simulations	O
showed	O
that	O
without	O
methotrexate	O
,	O
a	O
3	O
mg/kg	O
dosing	O
regimen	O
would	O
lead	O
only	O
16	O
%	O
of	O
RA	O
patients	O
to	O
reach	O
the	O
target	O
concentration	O
(	O
2.5	O
mg/L	O
)	O
at	O
week	O
22	O
,	O
whereas	O
target	O
concentrations	O
would	O
be	O
reached	O
in	O
approximately	O
half	O
of	O
RA	O
patients	O
cotreated	O
with	O
methotrexate	O
,	O
as	O
well	O
as	O
half	O
of	O
CD	O
(	O
3.5	O
mg/L	O
)	O
and	O
UC	O
(	O
3.7	O
mg/L	O
)	O
patients	O
.	O

The	O
suboptimality	O
of	O
approved	O
dosing	O
regimens	O
supports	O
the	O
development	O
of	O
dosing	O
optimization	O
based	O
on	O
concentration	O
measurements	O
.	O

Levels	O
of	O
the	O
soluble	O
LDL	O
receptor-relative	O
LR11	O
decrease	O
in	O
overweight	O
individuals	O
with	O
type	O
2	O
diabetes	O
upon	O
diet-induced	O
weight	O
loss	O
.	O

Cardiovascular	O
disease	O
(	O
CVD	O
)	O
is	O
a	O
major	O
complication	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
,	O
especially	O
in	O
those	O
with	O
obesity	O
.	O

Plasma	O
soluble	O
low	O
density	O
lipoprotein	O
receptor-relative	O
with	O
11	O
ligand-binding	O
repeats	O
(	O
sLR11	O
)	O
plays	O
a	O
role	O
in	O
the	O
development	O
of	O
atherosclerosis	O
and	O
has	O
been	O
linked	O
to	O
the	O
metabolism	O
of	O
triglyceride-rich	O
lipoproteins	O
,	O
adiposity	O
,	O
and	O
vascular	O
complications	O
in	O
T2D	O
.	O

We	O
aimed	O
to	O
determine	O
the	O
effect	O
of	O
diet-induced	O
weight	O
loss	O
on	O
plasma	O
sLR11	O
levels	O
in	O
overweight	O
and	O
obese	O
individuals	O
with	O
T2D	O
.	O

Plasma	O
sLR11	O
levels	O
were	O
determined	O
in	O
64	O
individuals	O
with	O
T2D	O
and	O
BMI	O
>	O
27	O
kg/m	O
(	O
2	O
)	O
before	O
and	O
after	O
a	O
20-	O
week	O
weight	O
loss	O
diet	O
.	O

As	O
a	O
reference	O
,	O
sLR11	O
levels	O
were	O
also	O
determined	O
in	O
64	O
healthy	O
,	O
non-obese	O
controls	O
,	O
matched	O
as	O
a	O
group	O
for	O
age	O
and	O
sex	O
.	O

Median	O
plasma	O
sLR11	O
levels	O
of	O
the	O
T2D	O
study-group	O
at	O
baseline	O
(	O
15.4	O
ng/mL	O
(	O
IQR	O
12.9-19.5	O
)	O
)	O
were	O
higher	O
than	O
in	O
controls	O
(	O
10.2	O
(	O
IQR	O
:	O
8.7-12.2	O
)	O
ng/mL	O
;	O
p	O
=	O
0.001	O
)	O
.	O

The	O
diet	O
resulted	O
in	O
a	O
weight	O
loss	O
of	O
9.7	O
Â±	O
5.2	O
%	O
(	O
p	O
=	O
0.001	O
)	O
and	O
improved	O
CVD	O
risk	O
factors	O
.	O

sLR11	O
levels	O
were	O
reduced	O
to	O
13.3	O
ng/mL	O
(	O
IQR	O
11.0-17.1	O
;	O
p	O
=	O
0.001	O
)	O
.	O

Changes	O
in	O
sLR11	O
levels	O
positively	O
associated	O
with	O
changes	O
in	O
non-HDL	O
cholesterol	O
(	O
B	O
=	O
1.54	O
,	O
R	O
(	O
2	O
)	O
=	O
0.17	O
,	O
p	O
=	O
0.001	O
)	O
and	O
HbA1c	O
(	O
B	O
=	O
0.07	O
,	O
R	O
(	O
2	O
)	O
=	O
0.11	O
,	O
p	O
=	O
0.007	O
)	O
,	O
but	O
not	O
with	O
weight	O
loss	O
(	O
B	O
=	O
0.04	O
,	O
R	O
(	O
2	O
)	O
=	O
0.05	O
,	O
p	O
=	O
0.076	O
)	O
.	O

The	O
changes	O
in	O
non-HDL	O
cholesterol	O
and	O
HbA1c	O
together	O
explained	O
24	O
%	O
of	O
the	O
variance	O
of	O
sLR11	O
reduction	O
(	O
p	O
=	O
0.001	O
)	O
.	O

Weight	O
loss	O
dieting	O
in	O
overweight	O
and	O
obese	O
individuals	O
with	O
T2D	O
resulted	O
in	O
a	O
reduction	O
in	O
plasma	O
sLR11	O
levels	O
that	O
was	O
associated	O
with	O
improvements	O
in	O
lipid-profile	B-P
and	O
glycemic	O
state	O
.	O

Sphincter	O
-Preserving	O
Surgery	O
for	O
Low	O
Rectal	O
Cancer	O
:	O
Do	O
We	O
Overshoot	O
the	O
Mark	O
?	O
.	O

Intersphincteric	O
resection	O
(	O
ISR	O
)	O
is	O
an	O
alternative	O
to	O
abdominoperineal	O
resection	O
(	O
APR	O
)	O
for	O
a	O
selected	O
subset	O
of	O
patients	O
with	O
low	O
rectal	O
cancer	O
,	O
combining	O
equivalent	O
oncological	O
outcome	O
and	O
sphincter	O
preservation	B-P
.	O

However	O
,	O
functional	O
results	O
are	O
heterogeneous	O
and	O
often	O
imperfect	O
.	O

The	O
aim	O
of	O
the	O
present	O
investigation	O
was	O
to	O
determine	O
the	O
long-term	O
functional	O
results	O
and	O
quality	O
of	O
life	O
after	O
ISR	O
.	O

One	O
hundred	O
forty-three	O
consecutive	O
patients	O
who	O
underwent	O
surgery	O
for	O
low	O
rectal	O
cancer	O
were	O
analysed	O
.	O

Sixty	O
patients	O
received	O
ISR	O
and	O
83	O
patients	O
APR	O
,	O
respectively	O
.	O

Kaplan-Meier	O
estimate	O
was	O
used	O
to	O
analyse	O
patients	O
'	O
survival	O
.	O

The	O
EORTC	O
QLQ-C30	O
,	O
-	O
C29	O
and	O
the	O
Wexner	O
score	O
were	O
used	O
to	O
determine	O
functional	O
outcome	O
and	O
quality	O
of	O
life	O
.	O

ISR	O
and	O
APR	O
were	O
both	O
associated	O
with	O
comparable	O
morbidity	O
and	O
no	O
mortality	O
.	O

Patients	O
'	O
disease	O
-	O
and	O
recurrence-free	O
survival	O
after	O
ISR	O
and	O
APR	O
were	O
similar	O
(	O
p	O
=	O
0.2872	O
and	O
p	O
=	O
0.4635	O
)	O
.	O

Closure	O
of	O
ileostomy	O
was	O
performed	O
in	O
73	O
%	O
of	O
all	O
patients	O
after	O
ISR	O
.	O

Long-term	O
outcome	O
showed	O
a	O
rate	O
of	O
incontinence	O
(	O
Wexner	O
score	O
â¥10	O
)	O
in	O
66	O
%	O
of	O
the	O
patients	O
.	O

Despite	O
this	O
,	O
patients	O
'	O
quality	O
of	O
life	O
was	O
significantly	O
better	O
after	O
ISR	O
compared	O
to	O
APR	O
in	O
terms	O
of	O
abdominal	O
complaints	O
and	O
psycho-emotional	O
functioning	O
.	O

ISR	O
is	O
technically	O
feasible	O
with	O
acceptable	O
postoperative	O
morbidity	O
rates	O
.	O

Functional	O
results	O
following	O
ISR	O
are	O
compromised	O
by	O
incontinence	O
as	O
the	O
most	O
important	O
complication	O
.	O

However	O
,	O
long-term	O
quality	O
of	O
life	O
is	O
superior	O
to	O
APR	O
,	O
which	O
should	O
be	O
considered	O
when	O
selecting	O
patients	O
for	O
ISR	O
.	O

Synthesis	O
,	O
EGFR	O
inhibition	O
and	O
anti-cancer	O
activity	O
of	O
new	O
3,6-dimethyl-1-phenyl-4-	O
(	O
substituted-methoxy	O
)	O
pyrazolo	O
[	O
3,4-d	O
]	O
pyrimidine	O
derivatives	O
.	O

A	O
new	O
series	O
of	O
hybrid	O
pyrazolo	O
[	O
3,4-d	O
]	O
pyrimidine	O
scaffold	O
with	O
a	O
heteroaryl	O
moiety	O
as	O
pyrazole	O
,	O
oxadiazole	O
,	O
triazole	O
or	O
phthalimide	O
moiety	O
(	O
14a-f	O
,	O
16	O
,	O
17	O
,	O
19	O
,	O
20	O
)	O
was	O
synthesized	O
and	O
biologically	O
evaluated	O
for	O
the	O
cytotoxicity	O
against	O
human	O
liver	O
cancer	O
cell	O
line	O
(	O
HEPG-2	O
)	O
,	O
human	O
breast	O
cancer	O
cell	O
line	O
(	O
MCF-7	O
)	O
and	O
human	O
colon	O
cancer	O
cell	O
line	O
(	O
HCT-116	O
)	O
.	O

While	O
the	O
pyrazolo	O
hybrid	O
compounds	O
(	O
14a-f	O
)	O
showed	O
good	O
activity	O
against	O
HEPG-2	O
,	O
MCF-7	O
and	O
HCT-116	O
cell	O
lines	O
(	O
IC50	O
=	O
3.65	O
-	O
39.98	O
,	O
1.45	O
-	O
54.19	O
and	O
2.00	O
-	O
50.6	O
ÂµM	O
respectively	O
)	O
in	O
comparison	O
with	O
doxorubicin	O
(	O
IC50	O
=	O
5.66	O
,	O
2.60	O
and	O
8.48	O
ÂµM	O
respectively	O
)	O
,	O
the	O
triazolo	O
derivatives	O
(	O
17	O
,	O
19	O
)	O
showed	O
considerable	O
potency	O
(	O
IC50	O
=	O
22.20	O
-	O
54.61	O
,	O
14.98	O
-	O
88.78	O
,	O
and	O
10.79	O
-	O
53.40	O
ÂµM	O
respectively	O
)	O
,	O
the	O
oxadiazolo	O
hybrid	O
compound	O
(	O
16	O
,	O
IC50	O
=	O
149.91	O
,	O
115.89	O
and	O
110.07	O
ÂµM	O
respectively	O
)	O
and	O
phthalimido	O
hybrid	O
compound	O
(	O
20	O
,	O
IC50	O
=	O
96.02	O
,	O
131.19	O
and	O
120.36	O
ÂµM	O
respectively	O
)	O
showed	O
low	O
potency	O
.	O

The	O
pyrazolo	O
derivative	O
(	O
14d	O
,	O
IC50	O
=	O
3.65	O
,	O
1.45	O
and	O
2.00	O
ÂµM	O
)	O
was	O
the	O
most	O
potent	O
among	O
all	O
compounds	O
against	O
HEPG-2	O
,	O
MCF-7	O
and	O
HCT-116	O
cell	O
lines	O
respectively	O
.	O

Also	O
,	O
the	O
hybrid	O
pyrazolo	O
[	O
3,4-d	O
]	O
pyrimidine	O
derivatives	O
were	O
evaluated	O
for	O
their	O
inhibitory	O
activity	O
to	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
(	O
EGFR-TK	O
)	O
and	O
they	O
showed	O
a	O
good	O
inhibitory	O
activity	O
(	O
IC50	O
=	O
8.27	O
-	O
19.03	O
ÂµM	O
)	O
.	O

With	O
the	O
exception	O
of	O
the	O
pyrazolo	O
derivative	O
(	O
14c	O
,	O
IC50	O
=	O
18.82	O
ÂµM	O
)	O
,	O
the	O
inhibitory	O
activity	O
against	O
EGFR-TK	O
was	O
consistent	O
with	O
the	O
in	O
vitro	O
cytotoxic	O
activity	O
against	O
HEPG-2	O
,	O
MCF-7	O
and	O
HCT-116	O
cell	O
lines	O
.	O

Moreover	O
,	O
molecular	O
docking	O
studies	O
were	O
performed	O
and	O
the	O
results	O
were	O
in	O
agreement	O
with	O
that	O
obtained	O
from	O
the	O
in	O
vitro	O
inhibition	B-P
assays	I-P
.	O

A	O
Strategy	O
to	O
Establish	O
a	O
Quality	O
Assurance	O
/	O
Quality	O
Control	O
Plan	O
for	O
the	O
Application	O
of	O
Biosensors	O
for	O
the	O
Detection	O
of	O
E.	O
coli	O
in	O
Water	O
.	O

Rapid	O
bacterial	O
detection	O
using	O
biosensors	O
is	O
a	O
novel	O
approach	O
for	O
microbiological	B-P
testing	I-P
applications	O
.	O

Validation	O
of	O
such	O
methods	O
is	O
an	O
obstacle	O
in	O
the	O
adoption	O
of	O
new	O
bio-sensing	B-P
technologies	I-P
for	O
water	O
testing	O
.	O

Therefore	O
,	O
establishing	O
a	O
quality	O
assurance	O
and	O
quality	O
control	O
(	O
QA	O
/	O
QC	O
)	O
plan	O
is	O
essential	O
to	O
demonstrate	O
accuracy	O
and	O
reliability	O
of	O
the	O
biosensor	O
method	O
for	O
the	O
detection	O
of	O
E.	O
coli	O
in	O
drinking	O
water	O
samples	O
.	O

In	O
this	O
study	O
,	O
different	O
reagents	O
and	O
assay	B-P
conditions	O
including	O
temperatures	O
,	O
holding	O
time	O
,	O
E.	O
coli	O
strains	O
and	O
concentrations	O
,	O
dissolving	O
agents	O
,	O
salinity	O
and	O
pH	O
effects	O
,	O
quality	O
of	O
substrates	O
of	O
various	O
suppliers	O
of	O
4-methylumbelliferyl	O
glucuronide	O
(	O
MUG	O
)	O
,	O
and	O
environmental	O
water	O
samples	O
were	O
included	O
in	O
the	O
QA	O
/	O
QC	O
plan	O
and	O
used	O
in	O
the	O
assay	B-P
optimization	O
and	O
documentation	O
.	O

Furthermore	O
,	O
the	O
procedural	O
QA	O
/	O
QC	O
for	O
the	O
monitoring	O
of	O
drinking	O
water	O
samples	O
was	O
established	O
to	O
validate	O
the	O
performance	O
of	O
the	O
biosensor	O
platform	O
for	O
the	O
detection	O
of	O
E.	O
coli	O
using	O
a	O
culture	B-P
-based	O
standard	O
technique	O
.	O

Implementing	O
the	O
developed	O
QA	O
/	O
QC	O
plan	O
,	O
the	O
same	O
level	O
of	O
precision	O
and	O
accuracy	O
was	O
achieved	O
using	O
both	O
the	O
standard	O
and	O
the	O
biosensor	O
methods	O
.	O

The	O
established	O
procedural	O
QA	O
/	O
QC	O
for	O
the	O
biosensor	O
will	O
provide	O
a	O
reliable	O
tool	O
for	O
a	O
near	O
real-time	O
monitoring	O
of	O
E.	O
coli	O
in	O
drinking	O
water	O
samples	O
to	O
both	O
industry	O
and	O
regulatory	O
authorities	O
.	O

Morphology	O
of	O
root	O
canal	O
surface	O
:	O
A	O
reflection	O
on	O
the	O
process	O
of	O
cementation	O
of	O
the	O
composite	O
relined	O
glass	O
fiber	O
post	O
.	O

The	O
present	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
bond	O
strength	O
in	O
the	O
different	O
root	O
thirds	O
(	O
premolars	O
and	O
maxillary	O
central	O
incisors	O
)	O
of	O
composite	O
relined	O
glass	O
fiber	O
posts	O
compared	O
to	O
untreated	O
glass	O
fiber	O
posts	O
cemented	O
with	O
dual-	O
or	O
chemical-cure	O
cements	O
.	O

Sixty	O
human	O
single-rooted	O
premolars	O
(	O
flat	O
canal	O
)	O
(	O
n	O
=	O
15	O
)	O
and	O
12	O
maxillary	O
central	O
incisors	O
were	O
used	O
(	O
round	O
canal	O
)	O
(	O
n	O
=	O
3	O
)	O
.	O

The	O
teeth	O
were	O
sectioned	O
,	O
and	O
the	O
roots	O
received	O
endodontic	O
treatment	O
.	O

The	O
standardized	O
preparation	O
of	O
the	O
canals	O
was	O
carried	O
out	O
,	O
and	O
the	O
roots	O
were	O
randomly	O
divided	O
into	O
four	O
groups	O
according	O
to	O
the	O
cementation	O
systems	O
:	O
G1	O
:	O
cemented	O
posts	O
(	O
dual	O
:	O
Ambar	O
/	O
Allcem	O
)	O
;	O
G2	O
:	O
relined	O
posts	O
(	O
dual	O
:	O
Ambar	O
/	O
Allcem	O
)	O
;	O
G3	O
:	O
cemented	O
posts	O
(	O
chemical	O
:	O
Fusion	O
Duralink	O
/	O
Cement	O
Post	O
)	O
;	O
and	O
G4	O
:	O
relined	O
posts	O
(	O
chemical	O
:	O
Fusion	O
Duralink	O
/	O
Cement	O
Post	O
)	O
.	O

The	O
roots	O
were	O
cut	O
to	O
give	O
two	O
slices	O
of	O
each	O
third	O
of	O
the	O
root	O
canal	O
per	O
specimen	O
.	O

Push-out	B-P
test	I-P
was	O
conducted	O
at	O
a	O
speed	O
of	O
0.5	O
mm/min	O
.	O

Data	O
were	O
analyzed	O
by	O
analysis	O
of	O
variance	O
and	O
Tukey	B-P
's	I-P
post	I-P
hoc	I-P
test	I-P
(	O
Î±	O
=	O
0.05	O
)	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
groups	O
for	O
the	O
premolars	O
(	O
flat	O
canal	O
)	O
(	O
P	O
=	O
0.959	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
central	O
incisors	O
between	O
the	O
middle	O
and	O
apical	O
thirds	O
in	O
the	O
cemented	O
group	O
when	O
using	O
the	O
dual	O
system	O
(	O
P	O
=	O
0.04	O
)	O
and	O
between	O
the	O
middle	O
and	O
apical	O
thirds	O
(	O
P	O
=	O
0.003	O
)	O
and	O
cervical	O
and	O
apical	O
thirds	O
(	O
P	O
=	O
0.033	O
)	O
when	O
using	O
the	O
chemical	B-P
system	I-P
.	O

Due	O
to	O
the	O
anatomy	O
of	O
the	O
root	O
canal	O
,	O
flat	O
canal	O
of	O
the	O
premolars	O
does	O
not	O
require	O
relining	O
,	O
but	O
round	O
canal	O
of	O
the	O
maxillary	O
central	O
incisors	O
demands	O
it	O
for	O
more	O
secure	O
in	O
the	O
bond	O
strength	O
.	O

12-Lead	B-P
electrocardiogram	I-P
as	O
a	O
predictor	O
of	O
sudden	O
cardiac	O
death	O
:	O
from	O
epidemiology	O
to	O
clinical	O
practice	O
.	O

Sudden	O
cardiac	O
death	O
(	O
SCD	O
)	O
causes	O
a	O
high	O
burden	O
of	O
premature	O
deaths	O
in	O
the	O
population	O
affecting	O
subjects	O
of	O
all	O
ages	O
.	O

The	O
identification	O
of	O
subjects	O
at	O
high	O
risk	O
for	O
SCD	O
is	O
of	O
great	O
importance	O
as	O
the	O
prevention	O
of	O
many	O
of	O
these	O
events	O
would	O
be	O
possible	O
with	O
the	O
treatment	O
of	O
underlying	O
cardiac	O
diseases	O
and	O
the	O
use	O
of	O
implantable	O
cardioverter-defibrillators	O
(	O
ICD	O
)	O
.	O

However	O
,	O
the	O
current	O
selection	O
of	O
patients	O
for	O
ICD	O
therapy	O
is	O
based	O
solely	O
on	O
left	O
ventricular	O
ejection	O
fraction	O
,	O
and	O
thus	O
a	O
substantial	O
portion	O
of	O
patients	O
at	O
high	O
risk	O
does	O
not	O
qualify	O
for	O
the	O
therapy	O
.	O

Role	O
of	O
the	O
standard	B-P
electrocardiogram	I-P
(	O
ECG	B-P
)	O
in	O
SCD	O
risk	O
stratification	O
has	O
been	O
under	O
active	O
research	O
during	O
the	O
last	O
decade	O
and	O
multiple	O
abnormalities	O
of	O
depolarization	O
and	O
repolarization	O
on	O
the	O
ECG	B-P
associated	O
with	O
an	O
increased	O
risk	O
of	O
SCD	O
have	O
been	O
identified	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
basic	O
pathophysiological	O
principles	O
behind	O
these	O
changes	O
.	O

We	O
also	O
review	O
the	O
current	O
knowledge	O
of	O
the	O
prognostic	O
significance	O
of	O
ECG	B-P
predictors	O
of	O
SCD	O
in	O
the	O
general	O
population	O
,	O
and	O
in	O
patients	O
with	O
coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
,	O
heart	O
failure	O
,	O
cardiomyopathies	O
,	O
and	O
in	O
inheritable	O
arrhythmia	O
syndromes	O
.	O

Also	O
,	O
insights	O
into	O
the	O
novel	O
digital	O
ECG	B-P
signal	O
processing	O
techniques	O
are	O
provided	O
.	O

Tips	O
and	O
Pitfalls	O
in	O
Direct	O
Ligation	O
of	O
Large	O
Spontaneous	O
Splenorenal	O
Shunt	O
during	O
Liver	O
Transplantation	O
.	O

Patients	O
with	O
large	O
spontaneous	O
splenorenal	O
shunt	O
(	O
SRS	O
)	O
prove	O
challenging	O
during	O
liver	O
transplantation	O
(	O
LT	O
)	O
,	O
irrespective	O
of	O
organizing	O
portal	O
vein	O
(	O
PV	O
)	O
thrombosis	O
.	O

Here	O
,	O
we	O
detail	O
the	O
clinical	O
outcomes	O
of	O
26	O
patients	O
who	O
underwent	O
direct	O
ligation	O
of	O
large	O
SRS	O
during	O
LT	O
.	O

Direct	O
ligation	O
of	O
large	O
SRS	O
was	O
applied	O
in	O
poor	O
portal	O
flow	O
during	O
LT.	O
We	O
performed	O
temporary	B-P
test	I-P
clamping	O
of	O
the	O
SRS	O
before	O
direct	O
ligation	O
and	O
applied	O
PV	O
pressure	O
monitoring	O
in	O
patients	O
who	O
showed	O
signs	O
of	O
portal	O
hypertension	O
,	O
such	O
as	O
bowel	O
edema	O
.	O

We	O
retrospectively	O
reviewed	O
and	O
evaluated	O
their	O
clinical	O
outcomes	O
.	O

Among	O
843	O
patients	O
who	O
underwent	O
LT	O
between	O
2010	O
and	O
2015	O
,	O
26	O
(	O
3.9	O
%	O
)	O
underwent	O
direct	O
ligation	O
of	O
SRS	O
without	O
any	O
intraoperative	O
event	O
.	O

Mean	O
preoperative	O
MELD	O
score	O
was	O
16.7Â±9.0	O
.	O

The	O
main	O
PV	O
diameter	O
on	O
preoperative	O
computed	B-P
tomography	I-P
was	O
8.3Â±3.4	O
mm	O
(	O
range	O
,	O
3.0-14.0	O
mm	O
)	O
.	O

SRS	O
was	O
easily	O
identified	O
at	O
just	O
below	O
the	O
distal	O
pancreas	O
and	O
beside	O
the	O
inferior	O
mesenteric	O
vein	O
in	O
all	O
patients	O
.	O

Accompanying	O
PV	O
thrombectomy	O
was	O
done	O
in	O
42.3	O
%	O
of	O
patients	O
.	O

Among	O
26	O
patients	O
,	O
massive	O
and	O
prolonged	O
ascites	O
was	O
evident	O
in	O
15.4	O
%	O
(	O
n	O
=	O
4	O
)	O
postoperatively	O
.	O

They	O
were	O
all	O
living	O
donor	O
LT	O
recipients	O
with	O
a	O
small	O
PV	O
diameter	O
(	O
4.0-6.7	O
mm	O
)	O
.	O

Except	O
for	O
one	O
patient	O
who	O
underwent	O
splenic	O
artery	O
embolization	O
,	O
ascites	O
was	O
tolerable	O
and	O
well	O
controlled	O
by	O
conservative	O
management	O
.	O

There	O
was	O
a	O
7.7	O
%	O
rate	O
of	O
major	O
complications	O
related	O
to	O
direct	O
ligation	O
,	O
including	O
reoperation	O
due	O
to	O
combined	O
ligation	O
of	O
SRS	O
along	O
with	O
a	O
left	O
renal	O
vein	O
at	O
the	O
confluence	O
.	O

Except	O
for	O
one	O
hospital	O
mortality	O
due	O
to	O
sepsis	O
,	O
25	O
patients	O
(	O
96.2	O
%	O
)	O
are	O
alive	O
with	O
no	O
evidence	O
of	O
further	O
PV	O
complications	O
.	O

In	O
conclusion	O
,	O
direct	O
ligation	O
of	O
large	O
SRS	O
during	O
LT	O
is	O
a	O
safe	O
and	O
feasible	O
method	O
to	O
overcome	O
the	O
effects	O
of	O
a	O
large	O
SRS	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

A	O
parametric	O
ribcage	O
geometry	O
model	O
accounting	O
for	O
variations	O
among	O
the	O
adult	O
population	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
develop	O
a	O
parametric	O
ribcage	O
model	O
that	O
can	O
account	O
for	O
morphological	O
variations	O
among	O
the	O
adult	O
population	O
.	O

Ribcage	O
geometries	O
,	O
including	O
12	O
pair	O
of	O
ribs	O
,	O
sternum	O
,	O
and	O
thoracic	O
spine	O
,	O
were	O
collected	O
from	O
CT	B-P
scans	I-P
of	O
101	O
adult	O
subjects	O
through	O
image	O
segmentation	O
,	O
landmark	O
identification	O
(	O
1016	O
for	O
each	O
subject	O
)	O
,	O
symmetry	O
adjustment	O
,	O
and	O
template	O
mesh	O
mapping	O
(	O
26,180	O
elements	O
for	O
each	O
subject	O
)	O
.	O

Generalized	O
procrustes	O
analysis	O
(	O
GPA	O
)	O
,	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
,	O
and	O
regression	O
analysis	O
were	O
used	O
to	O
develop	O
a	O
parametric	O
ribcage	O
model	O
,	O
which	O
can	O
predict	O
nodal	O
locations	O
of	O
the	O
template	O
mesh	O
according	O
to	O
age	O
,	O
sex	O
,	O
height	O
,	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
.	O

Two	O
regression	O
models	O
,	O
a	O
quadratic	O
model	O
for	O
estimating	O
the	O
ribcage	O
size	O
and	O
a	O
linear	O
model	O
for	O
estimating	O
the	O
ribcage	O
shape	O
,	O
were	O
developed	O
.	O

The	O
results	O
showed	O
that	O
the	O
ribcage	O
size	O
was	O
dominated	O
by	O
the	O
height	O
(	O
p=0.000	O
)	O
and	O
age	O
-	O
sex	O
-	O
interaction	O
(	O
p=0.007	O
)	O
and	O
the	O
ribcage	O
shape	O
was	O
significantly	O
affected	O
by	O
the	O
age	O
(	O
p=0.0005	O
)	O
,	O
sex	O
(	O
p=0.0002	O
)	O
,	O
height	O
(	O
p=0.0064	O
)	O
and	O
BMI	O
(	O
p=0.0000	O
)	O
.	O

Along	O
with	O
proper	O
assignment	O
of	O
cortical	O
bone	O
thickness	O
,	O
material	O
properties	O
and	O
failure	O
properties	O
,	O
this	O
parametric	O
ribcage	O
model	O
can	O
directly	O
serve	O
as	O
the	O
mesh	O
of	O
finite	O
element	O
ribcage	O
models	O
for	O
quantifying	O
effects	O
of	O
human	O
characteristics	O
on	O
thoracic	O
injury	O
risks	O
.	O

Simultaneous	O
thrombosis	O
of	O
multiple	O
coronary	O
arteries	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
.	O

We	O
present	O
a	O
case	O
of	O
simultaneous	O
coronary	O
thrombosis	O
of	O
the	O
left	O
main	O
,	O
the	O
left	O
anterior	O
descending	O
artery	O
and	O
the	O
right	O
coronary	O
artery	O
in	O
a	O
patient	O
,	O
recently	O
diagnosed	B-P
with	O
rheumatoid	O
arthritis	O
.	O

Water	O
pipe	O
(	O
Shisha	O
,	O
Hookah	O
,	O
Arghile	O
)	O
Smoking	O
and	O
Secondhand	O
Tobacco	O
Smoke	O
Effects	O
on	O
CYP1A2	O
and	O
CYP2A6	O
Phenotypes	O
as	O
Measured	O
by	O
Caffeine	B-P
Urine	I-P
Test	I-P
.	O

Public	O
policies	O
to	O
stop	O
or	O
reduce	O
cigarette	O
smoking	O
and	O
exposure	O
to	O
secondhand	O
smoke	O
and	O
associated	O
diseases	O
have	O
yielded	O
successful	O
results	O
over	O
the	O
past	O
decade	O
.	O

Yet	O
,	O
the	O
growing	O
worldwide	O
popularity	O
of	O
another	O
form	O
of	O
tobacco	O
consumption	O
,	O
water	O
pipe	O
smoking	O
,	O
has	O
received	O
relatively	O
less	O
attention	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
study	O
to	O
date	O
has	O
evaluated	O
the	O
effects	O
of	O
water	O
pipe	O
smoking	O
on	O
cytochrome	O
P450	O
(	O
CYP450	O
)	O
activities	O
and	O
drug	O
interaction	O
potential	O
in	O
humans	O
,	O
whereas	O
only	O
limited	O
information	O
is	O
available	O
on	O
the	O
impact	O
of	O
secondhand	O
smoke	O
on	O
drug	O
metabolism	O
.	O

In	O
a	O
sample	O
of	O
99	O
healthy	O
volunteers	O
(	O
28	O
water	O
pipe	O
smokers	O
,	O
30	O
secondhand	O
tobacco	O
smoke	O
exposed	O
persons	O
,	O
and	O
41	O
controls	O
)	O
,	O
we	O
systematically	O
compared	O
CYP1A2	O
and	O
CYP2A6	O
enzyme	O
activities	O
in	O
vivo	O
using	O
caffeine	B-P
urine	I-P
test	I-P
.	O

The	O
median	O
self-reported	O
duration	O
of	O
water	O
pipe	O
smoking	O
was	O
7.5	O
h	O
/	O
week	O
and	O
3	O
years	O
of	O
exposure	O
in	O
total	O
.	O

The	O
secondhand	O
smoke	O
group	O
had	O
a	O
median	O
of	O
14	O
h	O
of	O
self-reported	O
weekly	O
exposure	O
to	O
tobacco	O
smoke	O
indoor	O
where	O
a	O
minimum	O
of	O
five	O
cigarettes	O
were	O
smoked	O
/	O
hour	O
for	O
a	O
total	O
of	O
3.5	O
years	O
(	O
median	O
)	O
.	O

Analysis	O
of	O
variance	O
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
CYP1A2	O
and	O
CYP2A6	O
activities	O
among	O
the	O
three	O
study	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Nor	O
was	O
there	O
a	O
significant	O
association	O
between	O
the	O
extent	O
of	O
water	O
pipe	O
or	O
secondhand	O
smoke	O
exposure	O
and	O
the	O
CYP1A2	O
and	O
CYP2A6	O
activities	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Further	O
analysis	O
in	O
a	O
subsample	O
with	O
smoke	O
exposure	O
more	O
than	O
the	O
median	O
values	O
also	O
did	O
not	O
reveal	O
a	O
significant	O
difference	O
from	O
the	O
controls	O
.	O

Although	O
we	O
do	O
not	O
rule	O
out	O
an	O
appreciable	O
possible	O
impact	O
of	O
water	O
pipe	O
smoke	O
and	O
secondhand	O
smoke	O
on	O
in	O
vivo	O
activities	O
of	O
these	O
two	O
drug	O
metabolism	O
pathways	O
,	O
variability	O
in	O
smoke	O
constituents	O
from	O
different	O
tobacco	O
consumption	O
methods	O
(	O
e.g.	O
,	O
water	O
pipe	O
)	O
might	O
affect	O
drug	O
metabolism	O
in	O
ways	O
that	O
might	O
differ	O
from	O
that	O
of	O
cigarette	O
smoke	O
.	O

Further	O
studies	O
in	O
larger	O
prospective	O
samples	O
are	O
recommended	O
to	O
evaluate	O
water	O
pipe	O
and	O
secondhand	O
tobacco	O
smoke	O
effects	O
on	O
CYP450	O
function	O
,	O
particularly	O
at	O
higher	O
smoke	O
exposure	O
conditions	O
.	O

Stochastic	O
Subcellular	O
Organization	O
of	O
Dense-Core	O
Vesicles	O
Revealed	O
by	O
Point	O
Pattern	O
Analysis	O
.	O

Dense-core	O
vesicles	O
(	O
DCVs	O
)	O
are	O
regulated	O
secretory	O
organelles	O
found	O
in	O
many	O
types	O
of	O
neurons	O
.	O

In	O
neurons	O
of	O
the	O
hippocampus	O
,	O
their	O
cargo	O
includes	O
proteins	O
that	O
mediate	O
several	O
pivotal	O
processes	O
,	O
including	O
differentiation	O
and	O
synaptic	O
plasticity	O
.	O

Motivated	O
by	O
interest	O
in	O
DCV	O
distribution	O
and	O
its	O
impact	O
on	O
cargo	O
action	O
,	O
we	O
have	O
used	O
fluorescence	B-P
microscopy	I-P
and	O
statistical	O
analysis	O
to	O
develop	O
a	O
quantitative	O
model	O
of	O
the	O
subcellular	O
organization	O
of	O
DCVs	O
in	O
hippocampal	O
neurons	O
that	O
are	O
spontaneously	O
active	O
(	O
their	O
most	O
prevalent	O
state	O
)	O
.	O

We	O
also	O
have	O
tested	O
the	O
functionally	O
motivated	O
hypothesis	O
that	O
these	O
organelles	O
are	O
synaptically	O
enriched	O
.	O

Variance-to-mean	O
ratio	O
,	O
frequency	O
distribution	O
,	O
and	O
Moran	O
's	O
autocorrelation	O
analyses	O
reveal	O
that	O
DCV	O
distribution	O
along	O
shafts	O
,	O
and	O
within	O
synapses	O
,	O
follows	O
Poisson	O
statistics	O
,	O
establishing	O
that	O
stochastically	O
dictated	O
organization	O
sustains	O
cargo	O
function	O
.	O

Occupancy	O
in	O
boutons	O
exceeds	O
that	O
at	O
nearby	O
extrasynaptic	O
axonal	O
sites	O
by	O
approximately	O
threefold	O
,	O
revealing	O
significant	O
local	O
presynaptic	O
enrichment	O
.	O

Widespread	O
stochastic	O
organization	O
is	O
consistent	O
with	O
the	O
emerging	O
functional	O
importance	O
of	O
synaptically	O
and	O
extrasynaptically	O
localized	O
DCVs	O
.	O

Presynaptic	O
enrichment	O
is	O
consistent	O
with	O
the	O
established	O
importance	O
of	O
protecting	O
presynaptic	O
sites	O
from	O
depletion	O
of	O
DCV	O
cargo	O
.	O

These	O
results	O
enhance	O
understanding	O
of	O
the	O
link	O
between	O
DCV	O
organization	O
and	O
mechanisms	O
of	O
cargo	O
action	O
,	O
and	O
they	O
reinforce	O
the	O
emerging	O
theme	O
that	O
randomness	O
is	O
a	O
prevalent	O
aspect	O
of	O
synaptic	O
organization	O
and	O
composition	O
.	O

Impact	O
of	O
femoral	O
artery	O
puncture	O
using	O
digital	B-P
subtraction	I-P
angiography	I-P
and	O
road	O
mapping	O
on	O
vascular	O
and	O
bleeding	O
complications	O
after	O
transfemoral	O
transcatheter	O
aortic	O
valve	O
implantation	O
.	O

The	O
use	O
of	O
large	O
-	O
diameter	O
sheaths	O
carries	O
the	O
risk	O
of	O
significant	O
vascular	O
and	O
bleeding	O
complications	O
after	O
transfemoral	O
transcatheter	O
aortic	O
valve	O
implantation	O
(	O
TAVI	O
)	O
.	O

In	O
this	O
analysis	O
,	O
we	O
sought	O
to	O
assess	O
the	O
impact	O
of	O
a	O
modified	O
femoral	O
artery	O
puncture	O
technique	O
using	O
digital	B-P
subtraction	I-P
angiography	I-P
(	O
DSA	B-P
)	O
and	O
road	O
mapping	O
during	O
transfemoral	O
TAVI	O
on	O
periprocedural	O
vascular	O
and	O
bleeding	O
events	O
.	O

This	O
is	O
a	O
retrospective	O
analysis	O
of	O
transfemoral	O
TAVI	O
patients	O
included	O
in	O
a	O
prospective	O
institutional	O
database	O
.	O

The	O
modified	O
femoral	O
artery	O
puncture	O
technique	O
using	O
DSA	B-P
-derived	O
road	O
mapping	O
guidance	O
was	O
introduced	O
in	O
October	O
2012	O
.	O

Before	O
the	O
introduction	O
of	O
this	O
technique	O
,	O
vascular	O
puncture	O
was	O
acquired	O
based	O
on	O
an	O
integration	O
of	O
angiographic	B-P
data	O
,	O
the	O
bony	O
iliofemoral	O
landmarks	O
and	O
a	O
radiopaque	O
object	O
.	O

Consecutive	O
patients	O
who	O
underwent	O
TAVI	O
with	O
the	O
road	O
mapping	O
technique	O
(	O
RM	O
group	O
,	O
n=160	O
)	O
were	O
compared	O
with	O
consecutive	O
patients	O
who	O
underwent	O
TAVI	O
without	O
road	O
mapping	O
(	O
control	O
group	O
,	O
n=160	O
)	O
prior	O
to	O
its	O
introduction	O
.	O

A	O
standardised	O
strategy	O
of	O
periprocedural	O
anticoagulation	O
was	O
adopted	O
in	O
both	O
groups	O
as	O
well	O
as	O
the	O
use	O
of	O
a	O
single	O
suture-based	O
closure	O
device	O
.	O

All	O
endpoints	O
were	O
defined	O
according	O
to	O
the	O
VARC-2	O
criteria	O
for	O
event	O
definition	O
.	O

The	O
mean	O
age	O
in	O
the	O
RM	O
group	O
was	O
80Â±7.7	O
years	O
compared	O
to	O
81Â±5.9	O
years	O
in	O
the	O
control	O
group	O
(	O
p=0.19	O
)	O
,	O
and	O
females	O
were	O
equally	O
distributed	O
between	O
both	O
groups	O
(	O
63.1	O
%	O
vs.	O
58.1	O
%	O
,	O
p=0.36	O
)	O
.	O

The	O
baseline	O
logistic	O
EuroSCORE	O
was	O
20.7Â±14.4	O
%	O
vs.	O
24.9Â±15.2	O
%	O
in	O
the	O
RM	O
and	O
control	O
group	O
,	O
respectively	O
(	O
p=0.01	O
)	O
.	O

Notably	O
,	O
sheath	O
size	O
was	O
significantly	O
larger	O
in	O
the	O
RM	O
compared	O
to	O
the	O
control	O
group	O
due	O
to	O
the	O
more	O
frequent	O
use	O
of	O
the	O
20	O
Fr	O
sheath	O
(	O
23.8	O
%	O
vs.	O
1.8	O
%	O
,	O
p	O
<	O
0.001	O
,	O
respectively	O
)	O
associated	O
with	O
the	O
more	O
frequent	O
implantation	O
of	O
the	O
29	O
mm	O
Edwards	O
SAPIEN	O
XT	O
valve	O
in	O
the	O
RM	O
group	O
(	O
43.8	O
%	O
vs.	O
7	O
%	O
,	O
respectively	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Despite	O
the	O
latter	O
finding	O
,	O
both	O
major	O
vascular	O
complications	O
and	O
major	O
bleeding	O
at	O
30	O
days	O
were	O
significantly	O
lower	O
in	O
the	O
RM	O
group	O
compared	O
to	O
the	O
control	O
group	O
(	O
4.3	O
%	O
vs.	O
11.8	O
%	O
,	O
p=0.01	O
,	O
and	O
14.4	O
%	O
vs.	O
25.6	O
%	O
,	O
p=0.01	O
)	O
.	O

An	O
analysis	O
limited	O
to	O
access	O
site-related	O
complications	O
also	O
revealed	O
lower	O
events	O
in	O
the	O
road	O
map	O
group	O
but	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
8.1	O
%	O
vs.	O
13.8	O
%	O
,	O
p=0.1	O
)	O
.	O

Other	O
forms	O
of	O
vascular	O
and	O
bleeding	O
complications	O
as	O
well	O
as	O
all-cause	O
mortality	O
were	O
comparable	O
in	O
both	O
groups	O
.	O

A	O
modified	O
femoral	O
artery	O
puncture	O
technique	O
using	O
DSA	B-P
and	O
road	O
mapping	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
major	O
vascular	O
and	O
bleeding	O
complications	O
after	O
transfemoral	O
TAVI	O
,	O
and	O
provides	O
a	O
simple	O
and	O
effective	O
strategy	O
for	O
potentially	O
improving	O
patient	O
outcomes	O
.	O

Discovery	O
and	O
Optimization	O
of	O
a	O
Novel	O
Triazole	O
Series	O
of	O
GPR142	O
Agonists	O
for	O
the	O
Treatment	O
of	O
Type	O
2	O
Diabetes	O
.	O

GPR142	O
has	O
been	O
identified	O
as	O
a	O
potential	O
glucose-stimulated	O
insulin	O
secretion	O
(	O
GSIS	O
)	O
target	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
.	O

A	O
class	O
of	O
triazole	O
GPR142	O
agonists	O
was	O
discovered	O
through	O
a	O
high	B-P
throughput	I-P
screen	I-P
.	O

The	O
lead	O
compound	O
4	O
suffered	O
from	O
poor	O
metabolic	O
stability	O
and	O
poor	O
solubility	O
.	O

Lead	O
optimization	O
strategies	O
to	O
improve	O
potency	O
,	O
efficacy	O
,	O
metabolic	O
stability	O
,	O
and	O
solubility	O
are	O
described	O
.	O

This	O
optimization	O
led	O
to	O
compound	O
20e	O
,	O
which	O
showed	O
significant	O
reduction	O
of	O
glucose	O
excursion	O
in	O
wild-type	O
but	O
not	O
in	O
GPR142	O
deficient	O
mice	O
in	O
an	O
oral	B-P
glucose	I-P
tolerance	I-P
test	I-P
(	O
oGTT	B-P
)	O
study	O
.	O

These	O
studies	O
provide	O
strong	O
evidence	O
that	O
reduction	O
of	O
glucose	O
excursion	O
through	O
treatment	O
with	O
20e	O
is	O
GPR142	O
-mediated	O
,	O
and	O
GPR142	O
agonists	O
could	O
be	O
used	O
as	O
a	O
potential	O
treatment	O
for	O
type	O
2	O
diabetes	O
.	O

Patterns	O
of	O
coronary	O
plaque	O
progression	O
:	O
phasic	O
versus	O
gradual	O
.	O

A	O
combined	O
optical	O
coherence	O
tomography	O
and	O
intravascular	O
ultrasound	O
study	O
.	O

Some	O
plaques	O
grow	O
slowly	O
in	O
a	O
linear	O
manner	O
,	O
whereas	O
others	O
undergo	O
a	O
rapid	O
phasic	O
progression	O
.	O

However	O
,	O
the	O
detailed	O
in-vivo	O
relationship	O
between	O
plaque	O
characteristics	O
and	O
plaque	O
progression	O
pattern	O
has	O
not	O
been	O
reported	O
.	O

The	O
current	O
study	O
aimed	O
to	O
investigate	O
the	O
plaque	O
progression	O
patterns	O
with	O
serial	O
intravascular	B-P
ultrasound	I-P
(	O
IVUS	B-P
)	O
examinations	B-P
,	O
and	O
to	O
correlate	O
baseline	O
plaque	O
characteristics	O
assessed	O
by	O
optical	B-P
coherence	I-P
tomography	I-P
and	O
IVUS	B-P
with	O
plaque	O
progression	O
patterns	O
.	O

A	O
total	O
of	O
248	O
coronary	O
lesions	O
from	O
157	O
patients	O
were	O
identified	O
and	O
imaged	B-P
by	O
both	O
optical	B-P
coherence	I-P
tomography	I-P
and	O
IVUS	B-P
at	O
baseline	O
.	O

IVUS	B-P
examination	B-P
was	O
repeated	O
at	O
6	O
and	O
12	O
months	O
.	O

Plaque	O
progression	O
was	O
defined	O
as	O
greater	O
than	O
or	O
equal	O
to	O
5	O
%	O
increase	O
in	O
percent	O
atheroma	O
volume	O
by	O
IVUS	B-P
.	O

The	O
progression	O
patterns	O
were	O
divided	O
into	O
three	O
groups	O
:	O
no	O
progression	O
,	O
rapid	O
phasic	O
progression	O
,	O
and	O
gradual	O
progression	O
.	O

Among	O
248	O
lesions	O
,	O
190	O
(	O
77	O
%	O
)	O
showed	O
no	O
progression	O
.	O

Among	O
58	O
lesions	O
with	O
progression	O
,	O
20	O
(	O
34	O
%	O
)	O
showed	O
gradual	O
progression	O
,	O
whereas	O
38	O
(	O
66	O
%	O
)	O
showed	O
rapid	O
phasic	O
progression	O
.	O

Multivariate	O
analysis	O
indicated	O
that	O
thin-cap	O
fibroatheroma	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=5.24	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
2.04-13.4	O
;	O
P=0.001	O
]	O
,	O
microvessel	O
(	O
OR	O
=2.20	O
,	O
95	O
%	O
CI	O
1.10-4.79	O
;	O
P=0.045	O
)	O
,	O
and	O
positive	O
remodeling	O
(	O
OR	O
=2.64	O
,	O
95	O
%	O
CI	O
1.19-5.81	O
;	O
P=0.016	O
)	O
were	O
associated	O
independently	O
with	O
rapid	O
phasic	O
progression	O
.	O

Three-quarters	O
of	O
coronary	O
plaques	O
did	O
not	O
progress	O
over	O
time	O
with	O
contemporary	O
medical	O
treatment	O
.	O

Among	O
the	O
lesions	O
with	O
progression	O
,	O
one-third	O
showed	O
a	O
gradual	O
pattern	O
and	O
two-thirds	O
showed	O
a	O
rapid	O
phasic	O
pattern	O
.	O

The	O
presence	O
of	O
thin-cap	O
fibroatheroma	O
,	O
microvessel	O
,	O
and	O
positive	O
remodeling	O
were	O
the	O
independent	O
predictors	O
for	O
rapid	O
phasic	O
pattern	O
progression	O
of	O
coronary	O
atherosclerotic	O
plaques	O
.	O

Osteomyelitis	O
of	O
Humerus	O
and	O
Intramuscular	O
Abscess	O
Due	O
to	O
Melioidosis	O
.	O

Melioidosis	O
is	O
a	O
clinically	O
diverse	O
disease	O
caused	O
by	O
gram	O
negative	O
bacterium	O
Burkholderia	O
pseudomallei	O
.	O

It	O
is	O
a	O
potential	O
bioterrorism	O
agent	O
.	O

The	O
high	O
risk	O
group	O
includes	O
the	O
agricultural	O
and	O
construction	O
workers	O
whose	O
contact	O
with	O
contaminated	O
soil	O
and	O
water	O
may	O
expose	O
them	O
to	O
bacteria	O
.	O

The	O
clinical	O
manifestations	O
varies	O
from	O
asymptomatic	O
infection	O
to	O
overwhelming	O
sepsis	O
.	O

To	O
diagnose	O
melioidosis	O
a	O
high	O
index	O
of	O
suspicion	O
along	O
with	O
isolation	O
and	O
identification	O
of	O
the	O
organism	O
from	O
the	O
clinical	O
samples	O
is	O
needed	O
.	O

Early	B-P
diagnosis	I-P
and	O
treatment	O
is	O
essential	O
for	O
better	O
outcome	O
.	O

We	O
are	O
reporting	O
a	O
case	O
of	O
melioidosis	O
which	O
presented	O
as	O
osteomyelitis	O
of	O
humerus	O
with	O
intramuscular	O
abscess	O
.	O

Critical	O
role	O
for	O
GLP-1	O
in	O
symptomatic	O
post-bariatric	O
hypoglycaemia	O
.	O

Post-bariatric	O
hypoglycaemia	O
(	O
PBH	O
)	O
is	O
a	O
rare	O
,	O
but	O
severe	O
,	O
metabolic	O
disorder	O
arising	O
months	O
to	O
years	O
after	O
bariatric	O
surgery	O
.	O

It	O
is	O
characterised	O
by	O
symptomatic	O
postprandial	O
hypoglycaemia	O
,	O
with	O
inappropriately	O
elevated	O
insulin	O
concentrations	O
.	O

The	O
relative	O
contribution	O
of	O
exaggerated	O
incretin	O
hormone	O
signalling	O
to	O
dysregulated	O
insulin	O
secretion	O
and	O
symptomatic	O
hypoglycaemia	O
is	O
a	O
subject	O
of	O
ongoing	O
inquiry	O
.	O

This	O
study	O
was	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
PBH	O
and	O
associated	O
symptoms	O
are	O
primarily	O
mediated	O
by	O
glucagon-like	O
peptide-1	O
(	O
GLP-1	O
)	O
.	O

We	O
conducted	O
a	O
double-blinded	O
crossover	O
study	O
wherein	O
eight	O
participants	O
with	O
confirmed	O
PBH	O
were	O
assigned	O
in	O
random	O
order	O
to	O
intravenous	O
infusion	O
of	O
the	O
GLP-1	O
receptor	O
(	O
GLP-1r	O
)	O
antagonist	O
.	O

Exendin	O
(	O
9-39	O
)	O
(	O
Ex-9	O
)	O
,	O
or	O
placebo	O
during	O
an	O
OGTT	B-P
on	O
two	O
separate	O
days	O
at	O
the	O
Stanford	O
University	O
Clinical	O
and	O
Translational	O
Research	O
Unit	O
.	O

Metabolic	O
,	O
symptomatic	O
and	O
pharmacokinetic	O
variables	O
were	O
evaluated	O
.	O

Results	O
were	O
compared	O
with	O
a	O
cohort	O
of	O
BMI	O
-	O
and	O
glucose	O
-matched	O
non-surgical	O
controls	O
(	O
NSCs	O
)	O
.	O

Infusion	O
of	O
Ex-9	O
decreased	O
the	O
time	O
to	O
peak	O
glucose	O
and	O
rate	O
of	O
glucose	O
decline	O
during	O
OGTT	B-P
,	O
and	O
raised	O
the	O
postprandial	O
nadir	O
by	O
over	O
70	O
%	O
,	O
normalising	O
it	O
relative	O
to	O
NSCs	O
and	O
preventing	O
hypoglycaemia	O
in	O
all	O
PBH	O
participants	O
.	O

Insulin	O
AUC	O
and	O
secretion	O
rate	O
decreased	O
by	O
57	O
%	O
and	O
71	O
%	O
respectively	O
,	O
and	O
peak	O
postprandial	O
insulin	O
was	O
normalised	O
relative	O
to	O
NSCs	O
.	O

Autonomic	O
and	O
neuroglycopenic	O
symptoms	O
were	O
significantly	O
reduced	O
during	O
Ex-9	O
infusion	O
.	O

GLP-1r	O
blockade	O
prevented	O
hypoglycaemia	O
in	O
100	O
%	O
of	O
individuals	O
,	O
normalised	O
beta	O
cell	O
function	O
and	O
reversed	O
neuroglycopenic	O
symptoms	O
,	O
supporting	O
the	O
conclusion	O
that	O
GLP-1	O
plays	O
a	O
primary	O
role	O
in	O
mediating	O
hyperinsulinaemic	O
hypoglycaemia	O
in	O
PBH	O
.	O

Competitive	O
antagonism	O
at	O
the	O
GLP-1r	O
merits	O
consideration	O
as	O
a	O
therapeutic	O
strategy	O
.	O

ClinicalTrials.gov	O
NCT02550145	O
.	O

The	O
use	O
of	O
intraosseous	O
needles	O
for	O
injection	O
of	O
contrast	O
media	O
for	O
computed	B-P
tomographic	I-P
angiography	I-P
of	O
the	O
thoracic	O
aorta	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
safety	O
and	O
quality	O
of	O
computed	B-P
tomographic	I-P
angiography	I-P
of	O
the	O
thoracic	O
aorta	O
(	O
CTA-TA	B-P
)	O
exams	O
performed	O
using	O
intraosseous	B-P
needle	I-P
intravenous	I-P
access	I-P
(	O
ION-IVA	B-P
)	O
for	O
contrast	B-P
media	I-P
injection	I-P
(	O
CMI	B-P
)	O
.	O

All	O
CTA-TA	B-P
exams	O
at	O
the	O
study	O
institution	O
performed	O
between	O
1/1/2013	O
and	O
8/14/2015	O
were	O
reviewed	O
retrospectively	O
to	O
identify	O
those	O
exams	O
which	O
had	O
been	O
performed	O
using	O
ION-IVA	B-P
(	O
ION-exams	B-P
)	O
.	O

ION-exams	B-P
were	O
then	O
analyzed	O
to	O
determine	O
aortic	O
attenuation	O
and	O
contrast-to-noise	O
ratio	O
(	O
CNR	O
)	O
.	O

Linear	O
regression	O
was	O
used	O
to	O
determine	O
how	O
injection	O
rate	O
and	O
other	O
variables	O
affected	O
image	O
quality	O
for	O
ION-exams	B-P
.	O

Patient	O
electronic	O
medical	O
records	O
were	O
reviewed	O
to	O
identify	O
any	O
adverse	O
events	O
related	O
to	O
CTA-TA	B-P
or	O
ION-IVA	B-P
.	O

17	O
(	O
â¼0.2	O
%	O
)	O
of	O
7401	O
exams	O
were	O
ION-exams	B-P
.	O

ION-exam	B-P
CMI	B-P
rates	O
varied	O
between	O
2.5	O
and	O
4	O
ml/s	O
.	O

Mean	O
attenuation	O
was	O
312	O
HU	O
(	O
SD	O
88	O
HU	O
)	O
and	O
mean	O
CNR	O
was	O
25	O
(	O
SD	O
9.9	O
)	O
.	O

A	O
strong	O
positive	O
linear	O
association	O
between	O
attenuation	O
and	O
injection	O
rate	O
was	O
found	O
.	O

No	O
immediate	O
or	O
delayed	O
complications	O
related	O
to	O
the	O
ION-exams	B-P
,	O
or	O
intraosseous	O
needle	O
use	O
in	O
general	O
,	O
occurred	O
.	O

For	O
CTA-TA	B-P
,	O
ION-IVA	B-P
appears	O
to	O
be	O
a	O
safe	O
and	O
effective	O
route	O
for	O
CMI	B-P
at	O
rates	O
up	O
to	O
4	O
ml/s	O
.	O

Bone	O
extracellular	O
matrix	O
hydrogel	O
enhances	O
osteogenic	O
differentiation	O
of	O
C2C12	O
myoblasts	O
and	O
mouse	O
primary	O
calvarial	O
cells	O
.	O

Hydrogel	O
scaffolds	O
derived	O
from	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
of	O
mammalian	O
tissues	O
have	O
been	O
successfully	O
used	O
to	O
promote	O
tissue	O
repair	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
osteogenic	O
potential	O
of	O
ECM	O
hydrogels	O
prepared	O
from	O
demineralized	O
and	O
decellularized	O
bovine	O
bone	O
in	O
the	O
presence	O
and	O
absence	O
of	O
osteogenic	O
medium	O
.	O

Culture	B-P
of	O
C2C12	O
and	O
mouse	O
primary	O
calvarial	O
cells	O
(	O
mPCs	O
)	O
on	O
decellularized	O
bone	O
ECM	O
(	O
bECM	O
)	O
and	O
demineralized	O
bone	O
matrix	O
(	O
DBM	O
)	O
gels	O
resulted	O
in	O
increased	O
expression	B-P
of	O
osteogenic	O
gene	O
markers	O
,	O
including	O
a	O
3.6-	O
and	O
13.4-fold	O
increase	O
in	O
osteopontin	O
and	O
15.7-	O
and	O
27.1-fold	O
increase	O
in	O
osteocalcin	O
when	O
mPCs	O
were	O
cultured	B-P
upon	O
bECM	O
with	O
basal	O
and	O
osteogenic	O
media	O
,	O
respectively	O
.	O

bECM	O
hydrogels	O
stimulated	O
the	O
osteogenic	O
differentiation	O
of	O
C2C12	O
and	O
mPCs	O
even	O
in	O
the	O
absence	O
of	O
osteogenic	O
medium	O
.	O

These	O
results	O
suggest	O
that	O
bECM	O
hydrogel	O
scaffolds	O
may	O
have	O
great	O
utility	O
in	O
future	O
clinical	O
applications	O
for	O
bone	O
tissue	O
engineering	O
.	O

Â©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc.	O
J	O
Biomed	O
Mater	O
Res	O
Part	O
B	O
:	O
Appl	O
Biomater	O
,	O
2017	O
.	O

Extending	O
'	O
Contact	O
Tracing	O
'	O
into	O
the	O
Community	O
within	O
a	O
50-Metre	O
Radius	O
of	O
an	O
Index	O
Tuberculosis	O
Patient	O
Using	O
Xpert	B-P
MTB/RIF	I-P
in	O
Urban	O
,	O
Pakistan	O
:	O
Did	O
It	O
Increase	O
Case	O
Detection	O
?	O
.	O

Currently	O
,	O
only	O
62	O
%	O
of	O
incident	O
tuberculosis	O
(	O
TB	O
)	O
cases	O
are	O
reported	O
to	O
the	O
national	O
programme	O
in	O
Pakistan	O
.	O

Several	O
innovative	O
interventions	O
are	O
being	O
recommended	O
to	O
detect	O
the	O
remaining	O
'missed	O
'	O
TB	O
cases	O
.	O

One	O
such	O
intervention	O
involved	O
expanding	O
contact	O
investigation	O
to	O
the	O
community	O
using	O
the	O
Xpert	B-P
MTB/RIF	I-P
test	I-P
.	O

This	O
was	O
a	O
before	O
and	O
after	O
intervention	O
study	O
involving	O
retrospective	O
record	O
review	O
.	O

Passive	O
case	O
finding	O
and	O
household	O
contact	O
investigation	O
was	O
routinely	O
done	O
in	O
the	O
pre-	O
intervention	O
period	O
July	O
2011-June	O
2013	O
.	O

Four	O
districts	O
with	O
a	O
high	O
concentration	O
of	O
slums	O
were	O
selected	O
as	O
intervention	O
areas	O
;	O
Lahore	O
,	O
Rawalpindi	O
,	O
Faisalabad	O
and	O
Islamabad	O
.	O

Here	O
,	O
in	O
the	O
intervention	O
period	O
,	O
July	O
2013-June	O
2015	O
,	O
contact	O
investigation	O
beyond	O
household	O
was	O
conducted	O
:	O
all	O
people	O
staying	O
within	O
a	O
radius	O
of	O
50	O
metres	O
(	O
using	O
Geographical	O
Information	O
System	O
)	O
from	O
the	O
household	O
of	O
smear	O
positive	O
TB	O
patients	O
were	O
screened	O
for	O
tuberculosis	O
.	O

Those	O
with	O
presumptive	O
TB	O
were	O
investigated	O
using	O
smear	B-P
microscopy	I-P
and	O
the	O
Xpert	B-P
MTB/RIF	I-P
test	I-P
was	O
performed	O
on	O
smear	O
negative	O
patients	O
.	O

All	O
the	O
diagnosed	O
TB	O
patients	O
were	O
linked	O
to	O
TB	O
treatment	O
and	O
care	O
.	O

A	O
total	O
of	O
783043	O
contacts	O
were	O
screened	O
for	O
tuberculosis	O
:	O
23741	O
(	O
3.0	O
%	O
)	O
presumptive	O
TB	O
patients	O
were	O
identified	O
of	O
whom	O
,	O
4710	O
(	O
19.8	O
%	O
)	O
all	O
forms	O
and	O
4084	O
(	O
17.2	O
%	O
)	O
bacteriologically	O
confirmed	O
TB	O
patients	O
were	O
detected	O
.	O

The	O
contribution	O
of	O
Xpert	B-P
MTB/RIF	I-P
to	O
bacteriologically	O
confirmed	O
TB	O
patients	O
was	O
7.6	O
%	O
.	O

The	O
yield	O
among	O
investigated	O
presumptive	O
child	O
TB	O
patients	O
was	O
5.1	O
%	O
.	O

The	O
overall	O
yield	O
of	O
all	O
forms	O
TB	O
patients	O
among	O
investigated	O
was	O
22.3	O
%	O
among	O
household	O
and	O
19.1	O
%	O
in	O
close	O
community	O
.	O

The	O
intervention	O
contributed	O
an	O
increase	O
of	O
case	O
detection	O
of	O
bacteriologically	O
confirmed	O
tuberculosis	O
by	O
6.8	O
%	O
and	O
all	O
forms	O
TB	O
patients	O
by	O
7.9	O
%	O
.	O

Community	O
contact	O
investigation	O
beyond	O
household	O
not	O
only	O
detected	O
additional	O
TB	O
patients	O
but	O
also	O
increased	O
TB	O
case	O
detection	O
.	O

However	O
,	O
further	O
long	O
term	O
assessments	O
and	O
cost-effectiveness	O
studies	O
are	O
required	O
before	O
national	O
scale-up	O
.	O

Effect	O
of	O
magnesium	O
supplementation	O
on	O
depression	O
status	O
in	O
depressed	O
patients	O
with	O
magnesium	O
deficiency	O
:	O
A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
magnesium	O
supplementation	O
on	O
the	O
depression	O
status	O
of	O
depressed	O
patients	O
suffering	O
from	O
magnesium	O
deficiency	O
.	O

Sixty	O
depressed	O
people	O
suffering	O
from	O
hypomagnesemia	O
participated	O
in	O
this	O
trial	O
.	O

The	O
individuals	O
were	O
randomly	O
categorized	O
into	O
two	O
groups	O
of	O
30	O
members	O
;	O
one	O
receiving	O
two	O
250-mg	O
tablets	O
of	O
magnesium	O
oxide	O
(	O
MG	O
)	O
daily	O
and	O
the	O
other	O
receiving	O
placebo	O
(	O
PG	O
)	O
for	O
8	O
wk	O
.	O

The	O
Beck	B-P
Depression	I-P
Inventory-II	I-P
was	O
conducted	O
and	O
the	O
concentration	O
of	O
serum	B-P
magnesium	I-P
was	I-P
measured	I-P
.	O

At	O
the	O
end	O
of	O
intervention	O
,	O
88.5	O
%	O
of	O
the	O
MG	O
and	O
48.1	O
%	O
of	O
the	O
PG	O
(	O
P	O
=	O
0.002	O
)	O
had	O
a	O
normal	O
level	O
of	O
magnesium	O
.	O

The	O
mean	O
changes	O
of	O
serum	O
magnesium	O
were	O
significantly	O
different	O
across	O
the	O
two	O
groups	O
.	O

After	O
the	O
intervention	O
,	O
the	O
mean	O
Beck	O
score	O
significantly	O
declined	O
.	O

However	O
,	O
in	O
the	O
MG	O
,	O
this	O
reduction	O
was	O
more	O
significant	O
than	O
in	O
the	O
PG	O
(	O
P	O
=	O
0.02	O
)	O
,	O
so	O
that	O
the	O
mean	O
changes	O
in	O
this	O
group	O
experienced	O
15.65	O
Â±	O
8.9	O
reduction	O
,	O
but	O
in	O
the	O
PG	O
,	O
it	O
declined	O
by	O
10.40	O
Â±	O
7.9	O
.	O

Daily	O
consumption	O
of	O
500	O
mg	O
magnesium	O
oxide	O
tablets	O
for	O
â¥8	O
wk	O
by	O
depressed	O
patients	O
suffering	O
from	O
magnesium	O
deficiency	O
leads	O
to	O
improvements	O
in	O
depression	O
status	O
and	O
magnesium	O
levels	O
.	O

Therefore	O
,	O
assessment	B-P
of	I-P
the	I-P
magnesium	I-P
serum	I-P
and	O
resolving	O
this	O
deficiency	O
positively	O
influence	O
the	O
treatment	O
of	O
depressed	O
patients	O
.	O

Prevalence	O
of	O
high-risk	O
human	O
papillomavirus	O
infection	O
among	O
women	O
in	O
Shaanxi	O
province	O
of	O
China	O
:	O
A	O
hospital	O
-based	O
investigation	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
characteristics	O
of	O
female	O
high-risk	O
human	O
papillomavirus	O
(	O
HR-HPV	O
)	O
infection	O
in	O
Shaanxi	O
province	O
of	O
China	O
.	O

A	O
total	O
of	O
14	O
111	O
women	O
were	O
enrolled	O
for	O
HPV	O
genotyping	B-P
test	I-P
,	O
and	O
a	O
cytology	B-P
,	O
and/or	O
cervix	B-P
biopsy	I-P
were	O
performed	O
in	O
partial	O
women	O
.	O

Of	O
these	O
women	O
,	O
the	O
HPV	O
infection	O
rate	O
was	O
30.21	O
%	O
,	O
and	O
26.73	O
%	O
were	O
caused	O
by	O
HR-HPV	O
.	O

The	O
most	O
common	O
HR-HPV	O
genotypes	O
were	O
HPV-16	O
,	O
HPV-58	O
,	O
HPV-52	O
,	O
HPV-18	O
,	O
and	O
HPV-31	O
.	O

The	O
prevalence	O
of	O
HR-HPV	O
among	O
women	O
older	O
than	O
50	O
years	O
was	O
significantly	O
higher	O
than	O
the	O
other	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
main	O
carcinogenic	O
genotypes	O
were	O
HPV-16	O
,	O
HPV-18	O
,	O
HPV-58	O
,	O
HPV-52	O
,	O
and	O
HPV-31	O
.	O

HPV-16	O
and	O
HPV-18	O
combined	O
caused	O
80.79	O
%	O
of	O
cervical	O
cancer	O
cases	O
.	O

The	O
infection	O
with	O
multiple	O
HR-HPVs	O
was	O
not	O
a	O
risk	O
factor	O
for	O
cervical	O
lesions	O
.	O

In	O
conclusion	O
,	O
HPV	O
infection	O
was	O
common	O
among	O
women	O
in	O
Shaanxi	O
province	O
.	O

Women	O
older	O
than	O
50	O
years	O
were	O
a	O
high-risk	O
group	O
for	O
HR-HPV	O
infection	O
and	O
cervical	O
cancer	O
.	O

HPV-16	O
and	O
HPV-18	O
were	O
the	O
main	O
carcinogenic	O
genotypes	O
in	O
this	O
region	O
.	O

Isradipine	O
attenuates	O
MPTP	O
-	O
induced	O
dopamine	O
neuron	O
degeneration	O
by	O
inhibiting	O
up-regulation	O
of	O
L-type	O
calcium	O
channels	O
and	O
iron	O
accumulation	O
in	O
the	O
substantia	O
nigra	O
of	O
mice	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
L-type	O
calcium	O
channels	O
(	O
LTCCs	O
)	O
on	O
MPTP	O
-	O
induced	O
dopamine	O
(	O
DA	O
)	O
neuron	O
degeneration	O
and	O
iron	O
accumulation	O
in	O
the	O
substantia	O
nigra	O
(	O
SN	O
)	O
of	O
mice	O
.	O

By	O
real-time	O
PCR	O
and	O
western	B-P
blots	I-P
,	O
we	O
first	O
quatified	O
expressions	O
of	O
L-type	O
Cav1.2	O
and	O
Cav1.3	O
calcium	O
channel	O
Î±1	O
subunits	O
in	O
the	O
SN	O
of	O
experimental	O
mice	O
treated	O
with	O
MPTP	O
.	O

We	O
found	O
that	O
the	O
expressions	O
of	O
Cav1.2	O
and	O
Cav1.3	O
calcium	O
channel	O
Î±1	O
subunits	O
markedly	O
increased	O
after	O
MPTP	O
treatment	O
for	O
2	O
and	O
3	O
weeks	O
.	O

Secondly	O
,	O
we	O
observed	O
the	O
effects	O
of	O
isradipine	O
,	O
a	O
LTCC	O
antagonist	O
,	O
on	O
MPTP	O
-	O
induced	O
DA	O
neuron	O
degeneration	O
and	O
iron	O
accumulation	O
in	O
the	O
SN	O
.	O

Our	O
results	O
showed	O
that	O
isradipine	O
treatment	O
prevented	O
against	O
MPTP	O
-	O
induced	O
Cav1.2	O
and	O
Cav1.3	O
calcium	O
channel	O
Î±1	O
subunits	O
up-regulation	O
in	O
the	O
SN	O
.	O

We	O
also	O
found	O
that	O
isradipine	O
prevented	O
against	O
MPTP	O
-	O
induced	O
DA	O
neuron	O
depletion	O
in	O
the	O
SN	O
and	O
partly	O
restored	O
the	O
DA	B-P
content	I-P
in	O
the	O
striatum	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
isradipine	O
inhibited	O
the	O
increase	O
of	O
iron	O
positive	O
cells	O
in	O
the	O
SN	O
of	O
the	O
MPTP	O
-	O
treated	O
mice	O
.	O

Finally	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
isradipine	O
on	O
cellular	O
iron	O
accumulation	O
in	O
the	O
dopaminergic	O
MES23.5	O
cell	O
line	O
.	O

Our	O
studies	O
showed	O
that	O
MPP+	O
treatment	O
accelerated	O
iron	O
influx	O
in	O
the	O
MES23.5	O
cells	O
.	O

Treatment	O
with	O
Bayk8644	O
further	O
aggravated	O
iron	O
accumulation	O
.	O

Treatment	O
with	O
isradipine	O
prevented	O
against	O
MPP+	O
-	O
induced	O
iron	O
influx	O
in	O
the	O
MES23.5	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
up-regulation	O
of	O
LTCCs	O
may	O
be	O
responsible	O
for	O
the	O
DA	O
neuron	O
degeneration	O
in	O
the	O
MPTP	O
-	O
treated	O
mice	O
,	O
The	O
LTCCs	O
may	O
directly	O
contribute	O
to	O
iron	O
influx	O
into	O
DA	O
neurons	O
,	O
and	O
isradipine	O
may	O
suppress	O
cellular	O
iron	O
accumulation	O
and	O
prevents	O
neurodegeneration	O
.	O

Hepatic	O
and	O
renal	O
toxicological	O
evaluations	O
of	O
an	O
industrial	O
ovotoxic	O
chemical	O
,	O
4-vinylcyclohexene	O
diepoxide	O
,	O
in	O
both	O
sexes	O
of	O
Wistar	O
rats	O
.	O

4-Vinylcyclohexene	O
diepoxide	O
(	O
VCD	O
)	O
is	O
an	O
industrial	O
occupational	O
health	O
hazard	O
chemical	O
because	O
it	O
induces	O
ovotoxicity	O
in	O
rodents	O
.	O

The	O
current	O
study	O
investigated	O
the	O
impacts	O
of	O
VCD	O
on	O
selected	O
hepatic	O
and	O
renal	O
markers	O
of	O
oxidative	O
stress	O
and	O
inflammation	O
in	O
both	O
sexes	O
of	O
Wistar	O
rats	O
.	O

Thus	O
,	O
male	O
and	O
female	O
rats	O
were	O
randomly	O
distributed	O
into	O
four	O
groups	O
of	O
ten	O
rats	O
per	O
group	O
,	O
and	O
dosed	O
orally	O
with	O
VCD	O
for	O
28	O
days	O
.	O

The	O
control	O
male	O
and	O
female	O
groups	O
of	O
rats	O
received	O
corn	O
oil	O
only	O
,	O
while	O
each	O
of	O
the	O
three	O
remaining	O
groups	O
of	O
both	O
sexes	O
of	O
rats	O
received	O
VCD	O
(	O
100	O
,	O
250	O
and	O
500	O
mg/kg	O
BW	O
)	O
respectively	O
.	O

Thereafter	O
,	O
biomarkers	O
of	O
hepatic	O
and	O
renal	O
oxidative	O
damage	O
,	O
inflammation	O
and	O
immunohistochemical	B-P
expressions	I-P
of	O
iNOS	O
,	O
COX-2	O
,	O
caspase-9	O
and	O
caspase-3	O
were	O
evaluated	O
.	O

The	O
results	O
revealed	O
that	O
VCD	O
increased	O
markers	O
of	O
liver	O
and	O
kidney	O
functions	O
,	O
oxidative	O
damage	O
and	O
inflammation	O
,	O
and	O
disrupted	O
the	O
antioxidant	O
homeostasis	O
of	O
the	O
rats	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Lastly	O
,	O
VCD	O
enhanced	O
the	O
immunohistochemical	B-P
expressions	I-P
of	O
iNOS	O
,	O
COX-2	O
,	O
caspase-9	O
and	O
caspase-3	O
in	O
the	O
liver	O
of	O
the	O
rats	O
.	O

Thus	O
,	O
our	O
data	O
imply	O
that	O
VCD	O
induced	O
toxicity	O
in	O
the	O
liver	O
and	O
kidney	O
of	O
rats	O
via	O
the	O
combined	O
impacts	O
of	O
oxidative	O
damage	O
and	O
inflammation	O
.	O

Selective	O
and	O
sensitive	O
electrochemical	O
device	O
for	O
direct	O
VB2	O
determination	B-P
in	O
real	O
products	O
.	O

The	O
developed	O
by	O
us	O
electrochemical	O
device	O
for	O
vitamin	O
B2	O
(	O
VB2	O
;	O
riboflavin	O
)	O
determination	B-P
,	O
without	O
preconcentration	O
step	O
,	O
in	O
real	O
products	O
exhibits	O
high	O
sensitivity	O
,	O
selectivity	O
,	O
stability	O
and	O
low	O
detection	O
limit	O
compared	O
to	O
those	O
described	O
in	O
the	O
literature	O
.	O

The	O
determination	B-P
procedure	O
was	O
based	O
on	O
the	O
monitoring	O
of	O
the	O
reduction	O
current	O
signal	O
of	O
VB2	O
bound	O
with	O
dsDNA	O
anchored	O
to	O
the	O
electrode	O
surface	O
through	O
intermediary	O
-	O
carboxyphenyl	O
layer	O
.	O

The	O
application	O
of	O
such	O
intermediary	O
layer	O
formed	O
during	O
electroreduction	O
of	O
appropriate	O
diazonium	O
salt	O
at	O
CV	O
peak	O
potential	O
guarantees	O
high	O
efficiency	O
of	O
hybridization	O
process	O
and	O
thus	O
fully	O
available	O
places	O
for	O
VB2	O
interaction	O
.	O

Moreover	O
,	O
such	O
intermediary	O
layer	O
provides	O
good	O
electrical	O
contact	O
,	O
what	O
is	O
very	O
important	O
in	O
the	O
case	O
of	O
electrochemical	O
sensors	O
.	O

The	O
analytical	O
range	O
of	O
work	O
of	O
the	O
proposed	O
VB2	O
sensor	O
was	O
between	O
0.08-1ÂµM	O
(	O
30-377Î¼gL	O
(	O
-1	O
)	O
)	O
of	O
riboflavin	O
concentration	O
.	O

The	O
obtained	O
detection	O
(	O
LOD	O
)	O
and	O
quantification	O
limits	O
(	O
LOQ	O
)	O
were	O
24Â±2	O
and	O
55Â±5Î¼gL	O
(	O
-1	O
)	O
,	O
respectively	O
.	O

The	O
proposed	O
VB2	O
detection	O
method	O
was	O
used	O
for	O
determination	B-P
of	O
riboflavin	O
content	O
in	O
commercially	O
available	O
dietary	O
supplements	O
and	O
yolk	O
of	O
hen	O
egg	O
samples	O
.	O

The	O
accuracy	O
of	O
the	O
obtained	O
data	O
was	O
proved	O
using	O
comparison	O
with	O
an	O
independent	O
method	O
(	O
HPLC	B-P
FLD	I-P
)	O
.	O

Development	O
of	O
a	O
Curcumin	O
Bioadhesive	O
Monolithic	O
Tablet	O
for	O
Treatment	O
of	O
Vaginal	O
Candidiasis	O
.	O

The	O
present	O
investigation	O
was	O
designed	O
to	O
formulate	O
a	O
natural	O
tablet	O
for	O
the	O
treatment	O
of	O
vaginal	O
candidiasis	O
in	O
order	O
to	O
eliminate	O
side	O
effects	O
that	O
are	O
caused	O
by	O
existing	O
antifungal	O
drugs	O
.	O

Curcumin	O
has	O
promising	O
antifungal	O
activity	O
in	O
comparison	O
with	O
the	O
existing	O
azole	O
antifungal	O
drugs	O
.	O

Bioadhesive	O
curcumin	O
vaginal	O
tablets	O
were	O
prepared	O
by	O
direct	O
compression	O
with	O
different	O
ratios	O
of	O
biadhesive	O
polymers	O
like	O
xanthan	O
gum	O
,	O
guar	O
gum	O
and	O
HPMC	O
.	O

Curcumin	O
tablets	O
were	O
characterized	O
by	O
studies	O
of	O
friability	O
,	O
hardness	O
,	O
hydration	O
,	O
DSC	B-P
,	O
mucoadhesion	O
,	O
In-vitro	O
release	O
and	O
antifungal	O
activity	O
.	O

DSC	B-P
and	O
FT-IR	B-P
data	O
indicate	O
there	O
was	O
no	O
interaction	O
between	O
the	O
drug	O
and	O
the	O
excipients	O
and	O
also	O
polymer	O
concentration	O
has	O
some	O
effects	O
on	O
melting	O
point	O
of	O
curcumin	O
.	O

Formulation	O
F3	O
showed	O
the	O
best	O
results	O
in	O
terms	O
of	O
swelling	O
and	O
mucoadhesion	O
together	O
with	O
prolonged	O
drug	O
release	O
.	O

The	O
antifungal	O
activity	O
of	O
the	O
Curcumin	O
tablet	O
has	O
demonstrated	O
a	O
significant	O
effect	O
against	O
Candida	O
albicans	O
.	O

Hence	O
,	O
the	O
study	O
indicates	O
the	O
possible	O
and	O
effective	O
use	O
of	O
curcumin	O
bioadhesive	O
monolithic	O
vaginal	O
tablet	O
for	O
vaginal	O
candidiasis	O
as	O
a	O
promising	O
natural	O
antifungal	O
treatment	O
.	O

De	O
novo	O
assembly	O
of	O
the	O
blunt	O
snout	O
bream	O
(	O
Megalobrama	O
amblycephala	O
)	O
gill	O
transcriptome	O
to	O
identify	O
ammonia	O
exposure	O
associated	O
microRNAs	O
and	O
their	O
targets	O
.	O

De	O
novo	O
transcriptome	O
sequencing	O
is	O
a	O
robust	O
method	O
for	O
microRNA	O
(	O
miRNA	O
)	O
target	O
gene	O
prediction	O
,	O
especially	O
for	O
organisms	O
without	O
reference	O
genomes	O
.	O

Following	O
exposure	O
of	O
Megalobrama	O
amblycephala	O
to	O
ammonia	O
(	O
0.1	O
or	O
20	O
mg	O
L	O
(	O
-1	O
)	O
)	O
,	O
two	O
cDNA	O
libraries	O
were	O
constructed	O
from	O
the	O
fish	O
gills	O
and	O
sequenced	O
using	O
Illumina	O
HiSeq	O
2000	O
.	O

Over	O
90	O
million	O
reads	O
were	O
generated	O
and	O
de	O
novo	O
assembled	O
into	O
46	O
,	O
615	O
unigenes	O
,	O
which	O
were	O
then	O
extensively	O
annotated	O
by	O
comparing	O
to	O
different	O
protein	O
databases	O
,	O
followed	O
by	O
biochemical	O
pathway	O
prediction	O
.	O

The	O
expression	O
of	O
2666	O
unigenes	O
significantly	O
differed	O
;	O
1961	O
were	O
up-regulated	O
,	O
while	O
975	O
were	O
down-regulated	O
.	O

Among	O
these	O
,	O
250	O
unigenes	O
were	O
identified	O
as	O
the	O
targets	O
for	O
10	O
conserved	O
and	O
4	O
putative	O
novel	O
miRNA	O
families	O
by	O
miRNA	O
target	O
computational	B-P
prediction	I-P
.	O

We	O
examined	O
expression	O
of	O
ssa-miRNA-21	O
and	O
its	O
target	O
genes	O
by	O
real-time	O
quantitative	O
PCR	O
and	O
found	O
agreement	O
with	O
the	O
sequencing	O
data	O
.	O

This	O
study	O
demonstrates	O
the	O
feasibility	O
of	O
identifying	O
miRNA	O
targets	O
by	O
transcriptome	O
analysis	O
.	O

The	O
transcriptome	O
assembly	O
data	O
represent	O
a	O
substantial	O
increase	O
in	O
the	O
genomic	O
resources	O
available	O
for	O
Megalobrama	O
amblycephala	O
and	O
will	O
be	O
useful	O
for	O
gene	O
expression	O
profile	O
analysis	O
and	O
miRNA	O
functional	O
annotation	O
.	O

Contraction	O
Timing	O
Patterns	O
in	O
Patients	O
Treated	O
for	O
Breast	O
Cancer	O
Before	O
and	O
After	O
Anthracyclines	O
Therapy	O
.	O

During	O
the	O
development	O
of	O
heart	O
failure	O
(	O
HF	O
)	O
,	O
the	O
changes	O
of	O
contraction	O
timing	O
pattern	O
and	O
temporal	O
heterogeneity	O
of	O
segmental	O
contraction	O
happen	O
early	O
and	O
may	O
precede	O
both	O
symptomatic	O
HF	O
and	O
the	O
decrease	O
in	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
.	O

In	O
patients	O
treated	O
with	O
anthracyclines	O
,	O
both	O
symptomatic	O
HF	O
and	O
the	O
decrease	O
of	O
LVEF	O
are	O
detected	O
once	O
significant	O
myocardial	O
injury	O
has	O
occurred	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
whether	O
changes	O
in	O
the	O
timing	O
of	O
contraction	O
can	O
be	O
detected	O
early	O
after	O
anthracyclines	O
therapy	O
.	O

Forty-one	O
women	O
(	O
50	O
Â±	O
11	O
years	O
old	O
)	O
with	O
newly	O
diagnosed	O
breast	O
cancer	O
were	O
prospectively	O
enrolled	O
in	O
two	O
centers	O
and	O
underwent	O
an	O
echocardiogram	O
before	O
and	O
after	O
anthracyclines	O
.	O

Peak	B-P
longitudinal	I-P
myocardial	I-P
systolic	I-P
strain	I-P
was	O
measured	O
on	O
the	O
apical	O
four	O
-	O
and	O
two-chamber	O
views	O
.	O

The	O
time	O
to	O
peak	O
systolic	O
longitudinal	O
strain	O
(	O
TP	O
)	O
,	O
ejection	O
time	O
(	O
ET	O
)	O
,	O
isovolumic	O
contraction	O
time	O
(	O
IVCT	O
)	O
,	O
systolic	O
time	O
,	O
and	O
diastolic	O
time	O
were	O
measured	O
using	O
strain	B-P
curves	O
and	O
Doppler	B-P
tracings	I-P
and	O
compared	O
before	O
and	O
after	O
anthracyclines	O
.	O

The	O
heterogeneity	O
of	O
contraction	O
(	O
dyssynchrony	O
)	O
was	O
measured	O
by	O
the	O
SD	O
of	O
the	O
TP	O
of	O
all	O
segments	O
.	O

Anthracyclines	O
treatment	O
was	O
associated	O
with	O
an	O
increase	O
in	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
a	O
decrease	O
in	O
TP	O
.	O

TP	O
was	O
correlated	O
with	O
HR	O
.	O

TP	O
/	O
ET	O
was	O
independent	O
of	O
HR	O
and	O
inversely	O
correlated	O
to	O
peak	O
strain	B-P
both	O
at	O
baseline	O
and	O
after	O
anthracyclines	O
.	O

TP	O
/	O
ET	O
increased	O
after	O
anthracyclines	O
(	O
1.26	O
Â±	O
0.19	O
to	O
1.31	O
Â±	O
0.22	O
;	O
P	O
<	O
.001	O
)	O
,	O
and	O
this	O
increase	O
was	O
correlated	O
with	O
the	O
decrease	O
in	O
strain	B-P
.	O

The	O
increase	O
in	O
TP	O
/	O
ET	O
was	O
due	O
to	O
an	O
increase	O
in	O
IVCT	O
/	O
ET	O
.	O

A	O
similar	O
degree	O
of	O
dyssynchrony	O
was	O
found	O
at	O
baseline	O
and	O
after	O
anthracyclines	O
.	O

Anthracyclines	O
treatment	O
induces	O
an	O
increase	O
in	O
the	O
duration	O
of	O
contraction	O
,	O
mainly	O
by	O
increasing	O
the	O
IVCT	O
.	O

This	O
increase	O
is	O
correlated	O
to	O
the	O
decrease	O
in	O
strain	B-P
and	O
may	O
therefore	O
have	O
additional	O
prognostic	O
value	O
.	O

Structural	O
Basis	O
for	O
Simvastatin	O
Competitive	O
Antagonism	O
of	O
Complement	O
Receptor	O
3	O
.	O

The	O
complement	O
system	O
is	O
an	O
important	O
part	O
of	O
the	O
innate	O
immune	O
response	O
to	O
infection	O
but	O
may	O
also	O
cause	O
severe	O
complications	O
during	O
inflammation	O
.	O

Small	O
molecule	O
antagonists	O
to	O
complement	O
receptor	O
3	O
(	O
CR3	O
)	O
have	O
been	O
widely	O
sought	O
,	O
but	O
a	O
structural	O
basis	O
for	O
their	O
mode	O
of	O
action	O
is	O
not	O
available	O
.	O

We	O
report	O
here	O
on	O
the	O
structure	O
of	O
the	O
human	O
CR3	O
ligand-binding	O
I	O
domain	O
in	O
complex	O
with	O
simvastatin	O
.	O

Simvastatin	O
targets	O
the	O
metal	O
ion-dependent	O
adhesion	O
site	O
of	O
the	O
open	O
,	O
ligand-binding	O
conformation	O
of	O
the	O
CR3	O
I	O
domain	O
by	O
direct	O
contact	O
with	O
the	O
chelated	O
Mg	O
(	O
2+	O
)	O
ion	O
.	O

Simvastatin	O
antagonizes	O
I	O
domain	O
binding	O
to	O
the	O
complement	O
fragments	O
iC3b	O
and	O
C3d	O
but	O
not	O
to	O
intercellular	O
adhesion	O
molecule-1	O
.	O

By	O
virtue	O
of	O
the	O
I	O
domain	O
's	O
wide	O
distribution	O
in	O
binding	O
kinetics	O
to	O
ligands	O
,	O
it	O
was	O
possible	O
to	O
identify	O
ligand	O
binding	O
kinetics	O
as	O
discriminator	O
for	O
simvastatin	O
antagonism	O
.	O

In	O
static	O
cellular	B-P
experiments	O
,	O
15-25	O
Î¼m	O
simvastatin	O
reduced	O
adhesion	O
by	O
K562	O
cells	O
expressing	O
recombinant	O
CR3	O
and	O
by	O
primary	O
human	O
monocytes	O
,	O
with	O
an	O
endogenous	O
expression	O
of	O
this	O
receptor	O
.	O

Application	O
of	O
force	O
to	O
adhering	O
monocytes	O
potentiated	O
the	O
effects	O
of	O
simvastatin	O
where	O
only	O
a	O
50-100	O
nm	O
concentration	O
of	O
the	O
drug	O
reduced	O
the	O
adhesion	O
by	O
20-40	O
%	O
compared	O
with	O
untreated	O
cells	O
.	O

The	O
ability	O
of	O
simvastatin	O
to	O
target	O
CR3	O
in	O
its	O
ligand	O
binding	O
-	O
activated	O
conformation	O
is	O
a	O
novel	O
mechanism	O
to	O
explain	O
the	O
known	O
anti-inflammatory	O
effects	O
of	O
this	O
compound	O
,	O
in	O
particular	O
because	O
this	O
CR3	O
conformation	O
is	O
found	O
in	O
pro-inflammatory	O
environments	O
.	O

Our	O
report	O
points	O
to	O
new	O
designs	O
of	O
CR3	O
antagonists	O
and	O
opens	O
new	O
perspectives	O
and	O
identifies	O
druggable	O
receptors	O
from	O
characterization	O
of	O
the	O
ligand	O
binding	O
kinetics	O
in	O
the	O
presence	O
of	O
antagonists	O
.	O

Vitamin	B-P
D	I-P
serum	I-P
levels	I-P
are	O
cross-sectionally	O
but	O
not	O
prospectively	O
associated	O
with	O
late-life	O
depression	O
.	O

The	O
evidence	O
for	O
a	O
prospective	O
association	O
of	O
vitamin	O
D	O
deficiency	O
with	O
the	O
occurrence	O
of	O
late-life	O
depression	O
is	O
limited	O
.	O

We	O
aimed	O
to	O
study	O
the	O
long-term	O
association	O
between	O
vitamin	B-P
D	I-P
serum	I-P
levels	I-P
and	O
depression	O
in	O
a	O
large	O
population-based	O
study	O
of	O
older	O
adults	O
.	O

We	O
included	O
3251	O
participants	O
from	O
the	O
Rotterdam	O
Study	O
,	O
aged	O
55	O
and	O
older	O
with	O
32	O
400	O
person-years	O
follow-up	O
for	O
depression	O
.	O

Baseline	O
25-hydroxyvitamin	B-P
D	I-P
(	I-P
25	I-P
(	I-P
OH	I-P
)	I-P
D	I-P
)	I-P
serum	I-P
levels	I-P
were	O
analyzed	O
continuously	O
and	O
categorically	O
.	O

Repeated	O
depressive	O
symptoms	O
'	O
questionnaire	O
assessments	O
were	O
used	O
to	O
assess	O
the	O
change	O
of	O
depressive	O
symptoms	O
.	O

Semistructured	B-P
psychiatric	I-P
interviews	I-P
,	O
and	O
GP	O
records	O
were	O
used	O
to	O
assess	O
incident	O
major	O
depressive	O
disorder	O
according	O
to	O
DSM-IV	O
criteria	O
.	O

Low	O
serum	B-P
vitamin	I-P
D	I-P
levels	I-P
were	O
cross-sectionally	O
associated	O
with	O
more	O
depressive	O
symptoms	O
.	O

However	O
,	O
low	O
25	B-P
(	I-P
OH	I-P
)	I-P
D	I-P
serum	I-P
levels	I-P
were	O
not	O
prospectively	O
associated	O
with	O
change	O
of	O
depressive	O
symptoms	O
(	O
unstandardized	O
beta	O
=	O
0.02	O
,	O
95	O
%	O
CI	O
=	O
-0.23	O
;	O
0.26	O
)	O
or	O
incident	O
MDD	O
(	O
hazard	O
ratio	O
=	O
0.95	O
,	O
95	O
%	O
CI	O
=	O
0.86	O
;	O
1.05	O
)	O
.	O

We	O
observed	O
a	O
cross-sectional	O
but	O
no	O
prospective	O
association	O
between	O
serum	B-P
vitamin	I-P
D	I-P
levels	I-P
and	O
depression	O
.	O

A	O
cross-sectional	O
association	O
in	O
the	O
absence	O
of	O
the	O
longitudinal	O
association	O
can	O
mostly	O
be	O
attributed	O
to	O
reverse	O
causality	O
or	O
residual	O
confounding	O
.	O

Probably	O
,	O
vitamin	O
D	O
deficiency	O
is	O
not	O
an	O
independent	O
risk	O
factor	O
for	O
depression	O
but	O
co-occurs	O
with	O
late-life	O
depression	O
.	O

Development	O
of	O
molecularly	O
imprinted	O
polymers	O
specific	O
for	O
blood	O
antigens	O
for	O
application	O
in	O
antibody-free	B-P
blood	I-P
typing	I-P
.	O

A	O
novel	O
approach	O
in	O
antibody-free	B-P
blood	I-P
typing	I-P
based	O
on	O
molecularly	O
imprinted	O
polymeric	O
nanoparticles	O
is	O
described	O
.	O

Total	O
Arsenic	O
,	O
Cadmium	O
,	O
and	O
Lead	O
Determination	B-P
in	O
Brazilian	O
Rice	O
Samples	O
Using	O
ICP-MS	B-P
.	O

This	O
study	O
is	O
aimed	O
at	O
investigating	O
a	O
suitable	O
method	O
for	O
rice	O
sample	O
preparation	O
as	O
well	O
as	O
validating	O
and	O
applying	O
the	O
method	O
for	O
monitoring	O
the	O
concentration	O
of	O
total	O
arsenic	O
,	O
cadmium	O
,	O
and	O
lead	O
in	O
rice	O
by	O
using	O
Inductively	B-P
Coupled	I-P
Plasma	I-P
Mass	I-P
Spectrometry	I-P
(	O
ICP-MS	B-P
)	O
.	O

Various	O
rice	O
sample	O
preparation	O
procedures	O
were	O
evaluated	O
.	O

The	O
analytical	O
method	O
was	O
validated	O
by	O
measuring	O
several	O
parameters	O
including	O
limit	O
of	O
detection	O
(	O
LOD	O
)	O
,	O
limit	O
of	O
quantification	O
(	O
LOQ	O
)	O
,	O
linearity	O
,	O
relative	O
bias	O
,	O
and	O
repeatability	O
.	O

Regarding	O
the	O
sample	O
preparation	O
,	O
recoveries	O
of	O
spiked	O
samples	O
were	O
within	O
the	O
acceptable	O
range	O
from	O
89.3	O
to	O
98.2	O
%	O
for	O
muffle	O
furnace	O
,	O
94.2	O
to	O
103.3	O
%	O
for	O
heating	O
block	O
,	O
81.0	O
to	O
115.0	O
%	O
for	O
hot	O
plate	O
,	O
and	O
92.8	O
to	O
108.2	O
%	O
for	O
microwave	O
.	O

Validation	O
parameters	O
showed	O
that	O
the	O
method	O
fits	O
for	O
its	O
purpose	O
,	O
being	O
the	O
total	O
arsenic	O
,	O
cadmium	O
,	O
and	O
lead	O
within	O
the	O
Brazilian	O
Legislation	O
limits	O
.	O

The	O
method	O
was	O
applied	O
for	O
analyzing	O
37	O
rice	O
samples	O
(	O
including	O
polished	O
,	O
brown	O
,	O
and	O
parboiled	O
)	O
,	O
consumed	O
by	O
the	O
Brazilian	O
population	O
.	O

The	O
total	O
arsenic	O
,	O
cadmium	O
,	O
and	O
lead	O
contents	O
were	O
lower	O
than	O
the	O
established	O
legislative	O
values	O
,	O
except	O
for	O
total	O
arsenic	O
in	O
one	O
brown	O
rice	O
sample	O
.	O

This	O
study	O
indicated	O
the	O
need	O
to	O
establish	O
monitoring	O
programs	O
for	O
emphasizing	O
the	O
study	O
on	O
this	O
type	O
of	O
cereal	O
,	O
aiming	O
at	O
promoting	O
the	O
Public	O
Health	O
.	O

Gastrointestinal	O
tract	O
cancers	O
:	O
Genetics	O
,	O
heritability	O
and	O
germ	O
line	O
mutations	O
.	O

Gastrointestinal	O
(	O
GI	O
)	O
tract	O
cancers	O
that	O
arise	O
due	O
to	O
genetic	O
mutations	O
affect	O
a	O
large	O
number	O
of	O
individuals	O
worldwide	O
.	O

Even	O
though	O
many	O
of	O
the	O
GI	O
tract	O
cancers	O
arise	O
sporadically	O
,	O
few	O
of	O
these	O
GI	O
tract	O
cancers	O
harboring	O
a	O
hereditary	O
predisposition	O
are	O
now	O
recognized	O
and	O
well	O
characterized	O
.	O

These	O
include	O
Cowden	O
syndrome	O
,	O
MUTYH-associated	O
polyposis	O
,	O
hereditary	O
pancreatic	O
cancer	O
,	O
Lynch	O
syndrome	O
,	O
Peutz-Jeghers	O
syndrome	O
,	O
familial	O
adenomatous	O
polyposis	O
(	O
FAP	O
)	O
,	O
attenuated	O
FAP	O
,	O
serrated	O
polyposis	O
syndrome	O
,	O
and	O
hereditary	O
gastric	O
cancer	O
.	O

Molecular	O
characterization	O
of	O
the	O
genes	O
that	O
are	O
involved	O
in	O
these	O
syndromes	O
was	O
useful	O
in	O
the	O
development	O
of	O
genetic	B-P
testing	I-P
for	O
diagnosis	B-P
and	O
also	O
facilitated	O
understanding	O
of	O
the	O
genetic	O
basis	O
of	O
GI	O
cancers	O
.	O

Current	O
knowledge	O
on	O
the	O
genetics	O
of	O
GI	O
cancers	O
with	O
emphasis	O
on	O
heritability	O
and	O
germ	O
line	O
mutations	O
forms	O
the	O
basis	O
of	O
the	O
present	O
review	O
.	O

What	O
Is	O
the	O
Real	O
Impact	O
of	O
Urinary	O
Incontinence	O
on	O
Female	O
Sexual	O
Dysfunction	O
?	O

A	O
Case	O
Control	O
Study	O
.	O

Urinary	O
incontinence	O
(	O
UI	O
)	O
has	O
been	O
associated	O
with	O
negative	O
effects	O
on	O
women	O
's	O
sexuality	O
.	O

Women	O
's	O
sexuality	O
and	O
sexual	O
function	O
are	O
a	O
complex	O
issue	O
,	O
and	O
the	O
role	O
of	O
UI	O
is	O
not	O
completely	O
clear	O
.	O

To	O
assess	O
the	O
impact	O
of	O
UI	O
on	O
female	O
sexual	O
function	O
by	O
comparing	O
this	O
population	O
with	O
a	O
control	O
group	O
of	O
continent	O
women	O
.	O

We	O
performed	O
a	O
case-control	O
study	O
from	O
August	O
2012	O
to	O
September	O
2013	O
.	O

We	O
evaluated	O
continent	O
and	O
incontinent	O
women	O
(	O
age	O
range	O
=	O
30-70	O
years	O
)	O
for	O
their	O
sexuality	O
.	O

All	O
patients	O
were	O
evaluated	O
by	O
anamnesis	O
,	O
physical	O
examination	O
,	O
and	O
self-report	O
quality-of-life	O
questionnaires	O
.	O

In	O
addition	O
,	O
incontinent	O
women	O
underwent	O
a	O
1-hour	O
pad	B-P
test	I-P
.	O

Patients	O
without	O
sexual	O
activity	O
were	O
evaluated	O
for	O
the	O
role	O
of	O
UI	O
in	O
their	O
sexual	O
abstinence	O
.	O

Sexual	O
abstinence	O
was	O
defined	O
as	O
the	O
absence	O
of	O
sexual	O
activity	O
for	O
more	O
than	O
6	O
months	O
.	O

All	O
sexually	O
active	O
women	O
completed	O
the	O
self-report	O
Sexuality	O
Quotient	O
-	O
Female	O
Version	O
(	O
SQ-F	O
)	O
questionnaire	O
.	O

A	O
total	O
of	O
356	O
women	O
were	O
included	O
in	O
the	O
study	O
(	O
incontinent	O
,	O
n	O
=	O
243	O
;	O
continent	O
,	O
n	O
=	O
113	O
)	O
.	O

Sexual	O
abstinence	O
was	O
found	O
in	O
162	O
women	O
(	O
45	O
%	O
)	O
.	O

Incontinent	O
women	O
presented	O
a	O
higher	O
prevalence	O
(	O
P	O
<	O
.001	O
)	O
of	O
sexual	O
abstinence	O
than	O
their	O
counterparts	O
(	O
129	O
[	O
53	O
%	O
]	O
and	O
33	O
[	O
29.2	O
%	O
]	O
,	O
respectively	O
)	O
.	O

Age	O
,	O
marital	O
status	O
,	O
and	O
UI	O
were	O
found	O
to	O
be	O
isolated	O
predictive	O
factors	O
for	O
more	O
sexual	O
abstinence	O
in	O
incontinent	O
women	O
.	O

Sexually	O
active	O
women	O
(	O
incontinent	O
,	O
n	O
=	O
114	O
;	O
continent	O
,	O
n	O
=	O
80	O
)	O
presented	O
similar	O
demographic	O
data	O
.	O

Despite	O
a	O
similar	O
frequency	O
of	O
sexual	O
activity	O
,	O
incontinent	O
women	O
had	O
less	O
sexual	O
desire	O
,	O
foreplay	O
,	O
harmony	O
with	O
a	O
partner	O
,	O
sexual	O
comfort	O
,	O
and	O
sexual	O
satisfaction	O
than	O
their	O
counterparts	O
.	O

Women	O
with	O
greater	O
urinary	O
leakage	O
during	O
the	O
1-hour	O
pad	B-P
test	I-P
(	O
weight	O
>	O
11	O
g	O
)	O
had	O
the	O
worst	O
sexual	O
function	O
(	O
SQ-F	O
)	O
score	O
.	O

Women	O
with	O
UI	O
were	O
more	O
likely	O
to	O
be	O
sexual	O
abstinent	O
than	O
continent	O
women	O
.	O

Furthermore	O
,	O
women	O
with	O
UI	O
showed	O
less	O
sexual	O
desire	O
,	O
sexual	O
comfort	O
,	O
and	O
sexual	O
satisfaction	O
than	O
their	O
counterparts	O
despite	O
having	O
a	O
similar	O
frequency	O
of	O
sexual	O
activity	O
.	O

Toward	O
optimizing	O
dental	O
implant	O
performance	O
:	O
Surface	O
characterization	O
of	O
Ti	O
and	O
TiZr	O
implant	O
materials	O
.	O

Targeting	O
understanding	O
enhanced	O
osseointegration	O
kinetics	O
,	O
the	O
goal	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
surface	O
morphology	O
and	O
composition	O
of	O
Ti	O
and	O
TiZr	O
dental	O
implant	O
substrates	O
subjected	O
to	O
one	O
of	O
two	O
surface	O
treatments	O
developed	O
by	O
Straumann	O
.	O

These	O
two	O
treatments	O
are	O
typically	O
known	O
as	O
SLA	O
and	O
SLActive	O
,	O
with	O
the	O
latter	O
resulting	O
in	O
more	O
rapid	O
osseointegration	O
.	O

A	O
range	O
of	O
techniques	O
was	O
applied	O
to	O
characterize	O
four	O
different	O
substrate	O
/	O
surface	O
treatment	O
combinations	O
(	O
TiSLA	O
,	O
TiSLActive	O
,	O
TiZrSLA	O
,	O
and	O
TiZrSLActive	O
)	O
.	O

Contact	O
angle	O
measurements	O
establish	O
establish	O
their	O
hydrophilic	O
/	O
hydrophobic	O
nature	O
.	O

Surface	O
morphology	O
was	O
probed	O
with	O
scanning	B-P
electron	I-P
microscopy	I-P
.	O

X-ray	B-P
diffraction	I-P
,	O
Raman	B-P
Î¼-spectroscopy	I-P
,	O
and	O
X-ray	B-P
photoelectron	I-P
spectroscopy	I-P
were	O
used	O
to	O
elucidate	O
the	O
composition	O
of	O
the	O
near-	O
surface	O
region	O
.	O

Consistent	O
with	O
previous	O
work	O
,	O
surface	O
morphology	O
was	O
found	O
to	O
differ	O
only	O
at	O
the	O
nanoscale	O
,	O
with	O
both	O
SLActive	O
substrates	O
displaying	O
nano	O
-	O
protrusions	O
.	O

Spectroscopic	B-P
data	O
indicate	O
that	O
all	O
substrates	O
exhibit	O
surface	O
films	O
of	O
titanium	O
oxide	O
displaying	O
near	O
TiO2	O
stoichiometry	O
.	O

Raman	B-P
Î¼-spectroscopy	I-P
reveals	O
that	O
amorphous	O
TiO2	O
is	O
most	O
likely	O
the	O
only	O
phase	O
present	O
on	O
TiSLA	O
,	O
whilst	O
rutile	O
-	O
TiO2	O
is	O
also	O
evidenced	O
on	O
TiSLActive	O
,	O
TiZrSLA	O
,	O
and	O
TiZrSLActive	O
.	O

For	O
TiZr	O
alloy	O
substrates	O
,	O
there	O
is	O
no	O
evidence	O
of	O
discrete	O
phases	O
of	O
oxidized	O
Zr	O
.	O

X-ray	B-P
photoelectron	I-P
spectra	I-P
demonstrate	O
that	O
all	O
samples	O
are	O
terminated	O
by	O
adventitious	O
carbon	O
,	O
with	O
it	O
being	O
somewhat	O
thicker	O
(	O
â¼1nm	O
)	O
on	O
TiSLA	O
and	O
TiZrSLA	O
.	O

Given	O
previous	O
in	O
vivo	O
studies	O
,	O
acquired	O
data	O
suggest	O
that	O
both	O
nanoscale	O
protrusions	O
,	O
and	O
a	O
thinner	O
layer	O
of	O
adventitious	O
carbon	O
contribute	O
to	O
the	O
more	O
rapid	O
osseointegration	O
of	O
SLActive	O
dental	O
implants	O
.	O

Composition	O
of	O
the	O
surface	O
oxide	O
layer	O
is	O
apparently	O
less	O
important	O
in	O
determining	O
osseointegration	O
kinetics	O
.	O

Dopamine	O
modulates	O
astroglial	O
and	O
microglial	O
activity	O
via	O
glial	O
renin-angiotensin	O
system	O
in	O
cultures	B-P
.	O

Dopamine	O
is	O
an	O
immunomodulatory	O
molecule	O
that	O
acts	O
on	O
immune	O
effector	O
cells	O
both	O
in	O
the	O
CNS	O
and	O
peripheral	O
tissues	O
.	O

However	O
,	O
the	O
role	O
of	O
changes	O
in	O
dopamine	B-P
levels	I-P
in	O
the	O
neuroinflammatory	O
response	O
is	O
controversial	O
.	O

The	O
local/	O
paracrine	O
renin-angiotensin	O
system	O
(	O
RAS	O
)	O
plays	O
a	O
major	O
role	O
in	O
inflammatory	O
processes	O
in	O
peripheral	O
tissues	O
and	O
brain	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
possible	O
role	O
of	O
the	O
brain	O
RAS	O
in	O
the	O
effects	O
of	O
dopamine	O
on	O
the	O
glial	O
inflammatory	O
responses	O
.	O

Astrocytes	O
are	O
the	O
major	O
source	O
of	O
the	O
precursor	O
protein	O
angiotensinogen	O
and	O
angiotensin	O
II	O
(	O
AII	O
)	O
in	O
the	O
brain	O
.	O

Neurotoxins	O
such	O
as	O
MPP	O
(	O
+	O
)	O
(	O
1-methyl-4-phenylpyridinium	O
)	O
can	O
act	O
directly	O
on	O
astrocytes	O
to	O
increase	O
levels	O
of	O
angiotensinogen	O
and	O
AII	O
.	O

Conversely	O
,	O
dopamine	O
,	O
via	O
type-2	O
(	O
D2	O
)	O
receptors	O
,	O
inhibited	O
production	O
of	O
angiotensinogen	O
,	O
decreased	O
expression	O
of	O
angiotensin	O
type-1	O
(	O
AT1	O
)	O
receptors	O
and	O
increased	O
expression	O
of	O
AT2	O
receptors	O
.	O

In	O
microglia	O
,	O
dopamine	O
and	O
dopamine	O
agonists	O
also	O
regulated	O
RAS	O
activity	O
.	O

First	O
,	O
indirectly	O
,	O
via	O
downregulation	O
of	O
the	O
astrocyte-derived	O
AII	O
.	O

Second	O
,	O
via	O
dopamine	O
-	O
induced	O
regulation	O
of	O
microglial	O
angiotensin	O
receptors	O
.	O

Dopamine	O
decreased	O
the	O
microglial	O
AT1	O
/	O
AT2	O
ratio	O
leading	O
to	O
inhibition	O
of	O
the	O
pro-inflammatory	O
AT1	O
/	O
NADPH-oxidase	O
/	O
superoxide	O
axis	O
.	O

D2	O
receptors	O
were	O
particularly	O
responsible	O
for	O
microglial	O
RAS	O
inhibition	O
in	O
basal	O
culture	B-P
conditions	O
.	O

However	O
,	O
both	O
D1	O
and	O
D2	O
agonists	O
inhibited	O
the	O
AT1	O
/	O
NADPH-oxidase	O
axis	O
in	O
lipopolysaccharide	O
-	O
treated	O
(	O
LPS	O
;	O
i.e	O
.	O

activated	O
)	O
microglia	O
.	O

The	O
results	O
indicate	O
that	O
the	O
decrease	O
in	O
dopamine	B-P
levels	I-P
observed	O
in	O
early	O
stages	O
of	O
Parkinson	O
's	O
disease	O
and	O
aging	O
may	O
promote	O
neuroinflammation	O
and	O
disease	O
progression	O
via	O
glial	O
RAS	O
exacerbation	O
.	O

Unilateral	O
Laryngeal	O
Pacing	O
System	O
and	O
Its	O
Functional	O
Evaluation	O
.	O

Goal	O
.	O

To	O
establish	O
a	O
reliable	O
instrumental	O
system	O
for	O
synchronized	O
reactivation	O
of	O
a	O
unilaterally	O
paralyzed	O
vocal	O
fold	O
and	O
evaluate	O
its	O
functional	O
feasibility	O
.	O

Methods	O
.	O

Unilateral	O
vocal	O
fold	O
paralysis	O
model	O
was	O
induced	O
by	O
destruction	O
of	O
the	O
left	O
recurrent	O
laryngeal	O
nerve	O
(	O
RLN	O
)	O
in	O
anesthetized	O
dogs	O
.	O

With	O
a	O
micro	O
controller-based	O
electronic	O
system	O
,	O
electromyography	B-P
(	O
EMG	B-P
)	O
signals	O
from	O
cricothyroid	O
(	O
CT	O
)	O
muscle	O
on	O
the	O
ipsilateral	O
side	O
were	O
recorded	O
and	O
used	O
to	O
trigger	O
pacing	O
of	O
paralyzed	O
vocalis	O
muscles	O
.	O

The	O
dynamic	O
movement	O
of	O
vocal	O
folds	O
was	O
continuously	O
monitored	O
using	O
an	O
endoscope	O
,	O
and	O
the	O
opening	O
and	O
closing	O
of	O
the	O
glottis	O
were	O
quantified	O
with	O
customized	O
imaging	O
processing	O
software	O
.	O

Results	O
.	O

The	O
recorded	O
video	O
images	O
showed	O
that	O
left	O
side	O
vocal	O
fold	O
was	O
obviously	O
paralyzed	O
after	O
destructing	O
the	O
RLN	O
.	O

Using	O
the	O
pacing	O
system	O
with	O
feedback	O
triggering	O
EMG	B-P
signals	O
from	O
the	O
ipsilateral	O
CT	O
muscle	O
,	O
the	O
paralyzed	O
vocal	O
fold	O
was	O
successfully	O
reactivated	O
,	O
and	O
its	O
movement	O
was	O
shown	O
to	O
be	O
synchronized	O
with	O
the	O
healthy	O
side	O
.	O

Significance	O
.	O

The	O
developed	O
unilateral	O
laryngeal	O
pacing	O
system	O
triggered	O
by	O
EMG	B-P
from	O
the	O
ipsilateral	O
side	O
CT	O
muscle	O
could	O
be	O
successfully	O
used	O
in	O
unilateral	O
vocal	O
fold	O
paralysis	O
with	O
the	O
advantage	O
of	O
avoiding	O
disturbance	O
to	O
the	O
healthy	O
side	O
muscles	O
.	O

Impact	O
of	O
cofactor	O
-	O
binding	O
loop	O
mutations	O
on	O
thermotolerance	O
and	O
activity	O
of	O
E.	O
coli	O
transketolase	O
.	O

Improvement	O
of	O
thermostability	O
in	O
engineered	O
enzymes	O
can	O
allow	O
biocatalysis	O
on	O
substrates	O
with	O
poor	O
aqueous	O
solubility	O
.	O

Denaturation	O
of	O
the	O
cofactor	O
-	O
binding	O
loops	O
of	O
Escherichia	O
coli	O
transketolase	O
(	O
TK	O
)	O
was	O
previously	O
linked	O
to	O
the	O
loss	O
of	O
enzyme	O
activity	O
under	O
conditions	O
of	O
high	O
pH	O
or	O
urea	O
.	O

Incubation	B-P
at	O
temperatures	O
just	O
below	O
the	O
thermal	O
melting	O
transition	O
,	O
above	O
which	O
the	O
protein	O
aggregates	O
,	O
was	O
also	O
found	O
to	O
anneal	O
the	O
enzyme	O
to	O
give	O
an	O
increased	O
specific	O
activity	O
.	O

The	O
potential	O
role	O
of	O
cofactor	O
-	O
binding	O
loop	O
instability	O
in	O
this	O
process	O
remained	O
unclear	O
.	O

In	O
this	O
work	O
,	O
the	O
two	O
cofactor	O
-	O
binding	O
loops	O
(	O
residues	O
185-192	O
and	O
382-392	O
)	O
were	O
progressively	O
mutated	O
towards	O
the	O
equivalent	O
sequence	O
from	O
the	O
thermostable	O
Thermus	O
thermophilus	O
TK	O
and	O
variants	O
assessed	O
for	O
their	O
impact	O
on	O
both	O
thermostability	O
and	O
activity	O
.	O

Cofactor-binding	O
loop	O
2	O
variants	O
had	O
detrimental	O
effects	O
on	O
specific	O
activity	O
at	O
elevated	O
temperatures	O
,	O
whereas	O
the	O
H192P	O
mutation	O
in	O
cofactor-binding	O
loop	O
1	O
resulted	O
in	O
a	O
two-fold	O
improved	O
stability	O
to	O
inactivation	O
at	O
elevated	O
temperatures	O
,	O
and	O
increased	O
the	O
critical	O
onset	O
temperature	O
for	O
aggregation	O
.	O

The	O
specific	O
activity	O
of	O
H192P	O
was	O
3-fold	O
and	O
19-fold	O
higher	O
than	O
that	O
for	O
wild-type	O
at	O
60Â°C	O
and	O
65Â°C	O
respectively	O
,	O
and	O
also	O
remained	O
2.7-4	O
fold	O
higher	O
after	O
re-cooling	O
from	O
pre-incubations	B-P
at	O
either	O
55Â°C	O
or	O
60Â°C	O
for	O
1h	O
.	O

Interestingly	O
,	O
H192P	O
was	O
also	O
2-times	O
more	O
active	O
than	O
wild-type	O
TK	O
at	O
25Â°C	O
.	O

Optimal	O
activity	O
was	O
achieved	O
at	O
60Â°C	O
for	O
H192P	O
compared	O
to	O
55Â°C	O
for	O
wild	O
type	O
.	O

These	O
results	O
show	O
that	O
cofactor-binding	O
loop	O
1	O
,	O
plays	O
a	O
pivotal	O
role	O
in	O
partial	O
denaturation	O
and	O
aggregation	O
at	O
elevated	O
temperatures	O
.	O

Furthermore	O
,	O
a	O
single	O
rigidifying	O
mutation	O
within	O
this	O
loop	O
can	O
significantly	O
improve	O
the	O
enzyme	O
specific	O
activity	O
,	O
as	O
well	O
as	O
the	O
stability	O
to	O
thermal	O
denaturation	O
and	O
aggregation	O
,	O
to	O
give	O
an	O
increased	O
temperature	O
optimum	O
for	O
activity	O
.	O

Thieno	O
[	O
2,3-b	O
]	O
pyridine	O
derivatives	O
:	O
a	O
new	O
class	O
of	O
antiviral	O
drugs	O
against	O
Mayaro	O
virus	O
.	O

Mayaro	O
virus	O
(	O
MAYV	O
)	O
is	O
an	O
arthropod-borne	O
virus	O
and	O
a	O
member	O
of	O
the	O
family	O
Togaviridae	O
,	O
genus	O
Alphavirus	O
.	O

Its	O
infection	O
leads	O
to	O
an	O
acute	O
illness	O
accompanied	O
by	O
long-lasting	O
arthralgia	O
.	O

To	O
date	O
,	O
there	O
are	O
no	O
antiviral	O
drugs	O
or	O
vaccines	O
against	O
infection	O
with	O
MAYV	O
and	O
resources	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
other	O
alphaviruses	O
are	O
very	O
limited	O
.	O

MAYV	O
has	O
served	O
as	O
a	O
model	O
to	O
study	O
the	O
antiviral	O
potential	O
of	O
several	O
substances	O
on	O
alphavirus	O
replication	O
.	O

In	O
this	O
work	O
we	O
evaluated	O
the	O
antiviral	O
effect	O
of	O
seven	O
new	O
derivatives	O
of	O
thieno	O
[	O
2,3-b	O
]	O
pyridine	O
against	O
MAYV	O
replication	O
in	O
a	O
mammalian	O
cell	O
line	O
.	O

All	O
derivatives	O
were	O
able	O
to	O
reduce	O
viral	O
production	O
effectively	O
at	O
concentrations	O
that	O
were	O
non-toxic	O
for	O
Vero	O
cells	O
.	O

Molecular	B-P
modeling	I-P
assays	I-P
predicted	O
low	O
toxicity	O
risk	O
and	O
good	O
oral	O
bioavailability	O
of	O
the	O
substances	O
in	O
humans	O
.	O

One	O
of	O
the	O
molecules	O
,	O
selected	O
for	O
further	O
study	O
,	O
demonstrated	O
a	O
strong	O
anti-MAYV	O
effect	O
at	O
early	O
stages	O
of	O
replication	O
,	O
as	O
it	O
protected	O
pre-treated	O
cells	O
and	O
also	O
during	O
the	O
late	O
stages	O
,	O
affecting	O
virus	O
morphogenesis	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
antiviral	O
effect	O
of	O
thienopyridine	O
derivatives	O
on	O
MAYV	O
replication	O
in	O
vitro	O
,	O
suggesting	O
the	O
potential	O
application	O
of	O
these	O
substances	O
as	O
antiviral	O
molecules	O
against	O
alphaviruses	O
.	O

Additional	O
in	O
vivo	O
research	O
will	O
be	O
needed	O
to	O
expand	O
the	O
putative	O
therapeutic	O
applications	O
.	O

Fading	O
With	O
Time	O
of	O
PD-L1	O
Immunoreactivity	O
in	O
Non-Small	O
Cells	O
Lung	O
Cancer	O
Tissues	O
:	O
A	O
Methodological	O
Study	O
.	O

Blockade	O
of	O
inhibitory	O
immune	O
checkpoints	O
is	O
currently	O
arising	O
as	O
a	O
potential	O
immunologic	O
option	O
for	O
tumor	O
therapy	O
.	O

Inhibition	O
of	O
programmed	O
cell	O
death	O
protein	O
1	O
and/or	O
its	O
specific	O
ligand	O
programmed	O
death-ligand	O
1	O
(	O
PD-L1	O
)	O
was	O
effective	O
in	O
clinical	O
trials	O
in	O
advanced	O
melanoma	O
,	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
bladder	O
and	O
kidney	O
cancer	O
.	O

The	O
predictive	O
role	O
of	O
the	O
immunohistochemical	B-P
(	O
IHC	B-P
)	O
expression	O
of	O
PD-L1	O
is	O
highly	O
debated	O
.	O

Different	O
reagents	O
,	O
clones	O
,	O
cutoffs	O
of	O
cell	O
expression	O
and	O
subjective	O
interpretation	O
of	O
PD-L1	O
immunoreactivity	O
in	O
epithelial	O
cells	O
and	O
lymphocytes	O
are	O
the	O
main	O
issue	O
.	O

In	O
this	O
study	O
we	O
selected	O
58	O
consecutive	O
NSCLC	O
surgical	O
specimens	O
that	O
underwent	O
pathologic	B-P
examination	I-P
from	O
January	O
2014	O
to	O
July	O
2015	O
.	O

Using	O
a	O
tissue	O
microarray	B-P
approach	I-P
we	O
evaluated	O
the	O
IHC	B-P
expression	I-P
of	O
PD-L1	O
in	O
tumor-infiltrating	O
lymphocytes	O
and	O
tumor	O
cells	O
(	O
TCs	O
)	O
and	O
compared	O
the	O
ICH	B-P
staining	I-P
with	O
tumor	O
histology	O
,	O
grade	O
and	O
the	O
age	O
of	O
the	O
tissue	O
blocks	O
.	O

The	O
main	O
new	O
finding	O
was	O
the	O
fading	O
of	O
PD-L1	O
IHC	B-P
expression	I-P
in	O
TCs	O
in	O
tissues	O
processed	O
in	O
2014	O
compared	O
with	O
2015	O
.	O

PD-L1	O
expression	O
in	O
tumor-infiltrating	O
lymphocytes	O
in	O
the	O
2	O
years	O
was	O
similar	O
.	O

We	O
also	O
found	O
a	O
significant	O
higher	O
immunoreactivity	O
of	O
TCs	O
in	O
high	O
grade	O
NSCLC	O
and	O
in	O
the	O
squamous	O
carcinoma	O
histotype	O
compared	O
with	O
low	O
grade	O
tumors	O
and	O
the	O
adenocarcinoma	O
histology	O
(	O
P=0.013	O
)	O
.	O

We	O
demonstrated	O
that	O
the	O
IHC	B-P
evaluation	I-P
of	O
PD-L1	O
in	O
NSCLC	O
archival	O
tissues	O
is	O
feasible	O
and	O
can	O
be	O
implemented	O
in	O
a	O
routine	O
pathology	O
setting	O
,	O
but	O
it	O
should	O
be	O
carefully	O
assessed	O
in	O
tissue	O
blocks	O
older	O
than	O
1	O
year	O
.	O

Development	O
and	O
initial	O
validation	O
of	O
the	O
Respirator	O
Comfort	O
,	O
Wearing	O
Experience	O
,	O
and	O
Function	O
Instrument	O
[	O
R-COMFI	O
.	O

Filtering	O
face-piece	O
respirators	O
(	O
FFRs	O
)	O
are	O
worn	O
to	O
protect	O
health	O
care	O
personnel	O
from	O
airborne	O
particles	O
;	O
however	O
,	O
clinical	O
studies	O
have	O
demonstrated	O
that	O
FFR	O
adherence	O
is	O
relatively	O
low	O
in	O
some	O
settings	O
,	O
in	O
part	O
,	O
due	O
to	O
discomfort	O
and	O
intolerance	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
initially	O
evaluate	O
the	O
psychometric	O
properties	O
of	O
an	O
instrument	O
designed	O
to	O
measure	O
the	O
comfort	O
and	O
tolerability	O
of	O
FFRs	O
.	O

Instrument	O
items	O
were	O
developed	O
through	O
literature	O
reviews	O
,	O
focus	O
groups	O
,	O
and	O
several	O
iterations	O
of	O
ranking	O
and	O
refining	O
by	O
experts	O
.	O

Psychometric	B-P
evaluation	I-P
of	O
the	O
instrument	O
was	O
conducted	O
using	O
Rasch	O
partial	O
credit	O
model	O
(	O
PCM	O
)	O
analysis	O
.	O

Pivot	O
anchoring	O
was	O
used	O
to	O
specify	O
the	O
threshold	O
defining	O
item	O
difficulty	O
;	O
in	O
our	O
analyses	O
,	O
this	O
was	O
the	O
point	O
that	O
participants	O
moved	O
from	O
possessing	O
none	O
of	O
the	O
trait	O
to	O
some	O
of	O
the	O
trait	O
.	O

The	O
final	O
instrument	O
was	O
completed	O
by	O
165	O
health	O
care	O
personnel	O
from	O
3	O
Veterans	O
Health	O
Administration	O
facilities	O
,	O
and	O
data	O
were	O
analyzed	O
using	O
Rasch	O
PCM	O
.	O

Seven	O
items	O
were	O
removed	O
because	O
they	O
:	O
(	O
1	O
)	O
violated	O
the	O
assumption	O
of	O
independence	O
;	O
(	O
2	O
)	O
were	O
mis-fitting	O
;	O
and/or	O
(	O
3	O
)	O
were	O
deemed	O
not	O
relevant	O
.	O

Category	O
function	O
analysis	O
demonstrated	O
that	O
all	O
categories	O
progressed	O
monotonically	O
.	O

Principal	O
components	O
analysis	O
demonstrated	O
the	O
existence	O
of	O
three	O
subscales	O
(	O
Discomfort	O
,	O
General	O
Wearing	O
Experience	O
,	O
and	O
Function	O
)	O
.	O

Final	O
reliability	O
analyses	O
showed	O
that	O
the	O
scale	O
had	O
moderate	O
to	O
high	O
person	O
reliability	O
and	O
high	O
item	O
reliability	O
.	O

The	O
final	O
instrument	O
contained	O
21	O
items	O
.	O

Until	O
now	O
,	O
to	O
our	O
knowledge	O
no	O
instrument	O
with	O
evidence	O
supporting	O
its	O
reliability	O
and	O
validity	O
to	O
assess	O
discomfort	O
and	O
tolerance	O
of	O
FFRs	O
among	O
health	O
care	O
personnel	O
has	O
been	O
published	O
.	O

A	O
21-item	O
psychometrically	O
sound	O
measure	O
of	O
comfort	O
and	O
tolerability	O
of	O
FFRs	O
,	O
Respirator	O
Comfort	O
,	O
Wearing	O
Experience	O
,	O
and	O
Function	O
Instrument	O
(	O
R-COMFI	O
)	O
,	O
was	O
developed	O
.	O

The	O
significance	O
of	O
developing	O
such	O
an	O
instrument	O
is	O
that	O
it	O
will	O
help	O
identify	O
respirators	O
that	O
are	O
likely	O
to	O
have	O
better	O
adherence	O
in	O
practice	O
settings	O
.	O

The	O
R-COMFI	O
may	O
be	O
used	O
within	O
and	O
beyond	O
the	O
VA	O
healthcare	O
system	O
as	O
a	O
psychometrically	O
sound	O
instrument	O
to	O
evaluate	O
the	O
comfort	O
and	O
tolerability	O
of	O
respirators	O
,	O
including	O
developmental	O
prototypes	O
.	O

Disease	O
evolution	O
in	O
late-onset	O
and	O
early-onset	O
systemic	O
lupus	O
erythematosus	O
.	O

Objective	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
clinical	O
features	O
,	O
disease	B-P
activity	I-P
,	O
and	O
outcome	O
in	O
late-onset	O
versus	O
early-onset	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
over	O
5	O
years	O
of	O
follow	O
up	O
Method	O
Patients	O
with	O
SLE	O
since	O
1970	O
were	O
followed	O
prospectively	O
according	O
to	O
standard	O
protocol	O
and	O
tracked	O
on	O
a	O
computerized	O
database	O
.	O

Patients	O
entering	O
the	O
cohort	O
within	O
one	O
year	O
of	O
diagnosis	O
constitute	O
the	O
inception	O
cohort	O
.	O

Patients	O
with	O
late-onset	O
(	O
age	O
at	O
diagnosis	O
â¥50	O
)	O
disease	O
were	O
identified	O
and	O
matched	O
1:2	O
based	O
on	O
gender	O
and	O
first	O
clinic	O
visit	O
(	O
Â±5	O
)	O
years	O
with	O
patients	O
with	O
early-onset	O
disease	O
(	O
age	O
at	O
diagnosis	O
18-40	O
years	O
)	O
.	O

Results	O
A	O
total	O
of	O
86	O
patients	O
with	O
late-onset	O
disease	O
(	O
84.9	O
%	O
female	O
,	O
81.4	O
%	O
Caucasian	O
,	O
mean	O
age	O
at	O
SLE	O
diagnosis	O
Â±	O
SD	O
58.05	O
Â±	O
7.30	O
)	O
and	O
169	O
patients	O
with	O
early-onset	O
disease	O
(	O
86.4	O
%	O
female	O
,	O
71	O
%	O
Caucasian	O
,	O
mean	O
age	O
at	O
SLE	O
diagnosis	O
Â±	O
SD	O
27.80	O
Â±	O
5.90	O
)	O
were	O
identified	O
.	O

At	O
enrollment	O
,	O
late-onset	O
SLE	O
patients	O
had	O
a	O
lower	O
total	O
number	O
of	O
American	O
College	O
of	O
Rheumatology	O
(	O
ACR	O
)	O
criteria	O
,	O
with	O
less	O
renal	O
and	O
neurologic	O
manifestations	O
.	O

Mean	O
SLE	O
Disease	O
Activity	O
Index	O
2000	O
(	O
SLEDAI-2K	O
)	O
scores	O
were	O
lower	O
in	O
late-onset	O
SLE	O
,	O
especially	O
renal	O
features	O
and	O
anti-dsDNA	O
positivity	O
.	O

Over	O
5	O
years	O
,	O
mean	O
SLEDAI-2K	O
scores	O
decreased	O
in	O
both	O
groups	O
,	O
while	O
mean	O
Systemic	O
Lupus	O
International	O
Collaborating	O
Clinics/ACR	O
Damage	O
Index	O
(	O
SDI	O
)	O
scores	O
increased	O
more	O
significantly	O
in	O
the	O
late-onset	O
group	O
;	O
they	O
developed	O
more	O
cardiovascular	O
,	O
renal	O
,	O
and	O
ocular	O
damage	O
,	O
and	O
had	O
higher	O
prevalence	O
of	O
cardiovascular	O
risk	O
factors	O
.	O

Conclusion	O
Although	O
the	O
late-onset	O
SLE	O
group	O
had	O
a	O
milder	O
presentation	O
and	O
less	O
active	O
disease	O
,	O
with	O
the	O
evolution	O
of	O
disease	O
,	O
they	O
developed	O
more	O
organ	O
damage	O
likely	O
as	O
a	O
consequence	O
of	O
cardiovascular	O
risk	O
factors	O
and	O
aging	O
.	O

Clinical	O
heterogeneity	O
of	O
LRRK2	O
p.I2012T	O
mutation	O
.	O

Leucine-rich	O
repeat	O
kinase	O
2	O
(	O
LRRK2	O
)	O
mutations	O
are	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

However	O
,	O
only	O
few	O
cases	O
carrying	O
LRRK2	O
mutations	O
have	O
been	O
reported	O
in	O
Taiwanese	O
PD	O
patients	O
.	O

We	O
used	O
targeted	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
,	O
covering	O
24	O
candidate	O
genes	O
involved	O
in	O
neurodegenerative	O
disorders	O
,	O
to	O
analyze	O
40	O
probands	O
with	O
familial	O
PD	O
,	O
and	O
10	O
patients	O
with	O
mixed	O
neurodegenerative	O
disorders	O
.	O

Sanger	O
sequencing	O
of	O
the	O
identified	O
mutation	O
in	O
the	O
first	O
set	O
of	O
the	O
study	O
was	O
performed	O
in	O
additional	O
270	O
PD	O
patients	O
,	O
including	O
139	O
familial	O
PD	O
and	O
131	O
early-onset	O
PD	O
(	O
onset	O
age	O
less	O
than	O
50	O
years	O
old	O
)	O
,	O
and	O
300	O
age/gender	O
matched	O
control	O
subjects	O
.	O

We	O
found	O
a	O
missense	O
variant	O
,	O
p.I2012T	O
,	O
in	O
the	O
LRRK2	O
gene	O
in	O
one	O
sporadic	O
patient	O
having	O
early-onset	O
frontotemporal	O
dementia	O
with	O
parkinsonism	O
and	O
dystonia	O
.	O

Sanger	O
sequencing	O
this	O
substitution	O
in	O
additional	O
270	O
PD	O
patients	O
in	O
the	O
second	O
set	O
of	O
the	O
study	O
revealed	O
two	O
additional	O
variant	O
carriers	O
:	O
one	O
having	O
autosomal-dominant	O
familial	O
PD	O
,	O
and	O
one	O
with	O
sporadic	O
PD	O
.	O

The	O
p.I2012T	O
substitution	O
was	O
absent	O
in	O
300	O
normal	O
control	O
subjects	O
.	O

Analyzing	O
family	O
members	O
of	O
the	O
proband	O
with	O
p.I2012T	O
revealed	O
co-segregation	O
of	O
the	O
variant	O
and	O
parkinsonism	O
.	O

Clinical	O
presentations	O
,	O
levodopa	O
responses	O
,	O
and	O
(	O
Tc99m	O
)	O
TRODAT	O
-	O
SPECT	O
imaging	O
findings	O
of	O
this	O
index	O
family	O
were	O
similar	O
to	O
idiopathic	O
PD	O
.	O

Our	O
results	O
revealed	O
clinical	O
heterogeneity	O
of	O
the	O
LRRK2	O
p.I2012T	O
substitution	O
,	O
and	O
demonstrated	O
the	O
use	O
of	O
targeted	O
NGS	O
for	O
genetic	B-P
diagnosis	I-P
in	O
multiplex	O
families	O
with	O
PD	O
or	O
mixed	O
neurodegenerative	O
disorders	O
.	O

Platelet	O
proteome	O
reveals	O
novel	O
pathways	O
of	O
platelet	O
activation	O
and	O
platelet	O
-	O
mediated	O
immunoregulation	O
in	O
dengue	O
.	O

Dengue	O
is	O
the	O
most	O
prevalent	O
human	O
arbovirus	O
disease	O
worldwide	O
.	O

Dengue	O
virus	O
(	O
DENV	O
)	O
infection	O
causes	O
syndromes	O
varying	O
from	O
self-limiting	O
febrile	O
illness	O
to	O
severe	O
dengue	O
.	O

Although	O
dengue	O
pathophysiology	O
is	O
not	O
completely	O
understood	O
,	O
it	O
is	O
widely	O
accepted	O
that	O
increased	O
inflammation	O
plays	O
important	O
roles	O
in	O
dengue	O
pathogenesis	O
.	O

Platelets	O
are	O
blood	O
cells	O
classically	O
known	O
as	O
effectors	O
of	O
hemostasis	O
which	O
have	O
been	O
increasingly	O
recognized	O
to	O
have	O
major	O
immune	O
and	O
inflammatory	O
activities	O
.	O

Nevertheless	O
,	O
the	O
phenotype	O
and	O
effector	O
functions	O
of	O
platelets	O
in	O
dengue	O
pathogenesis	O
are	O
not	O
completely	O
understood	O
.	O

Here	O
we	O
used	O
quantitative	O
proteomics	B-P
to	O
investigate	O
the	O
protein	B-P
content	I-P
of	O
platelets	O
in	O
clinical	O
samples	O
from	O
patients	O
with	O
dengue	O
compared	O
to	O
platelets	O
from	O
healthy	O
donors	O
.	O

Our	O
assays	B-P
revealed	O
a	O
set	O
of	O
252	O
differentially	O
abundant	O
proteins	O
.	O

In	O
silico	O
analyses	O
associated	O
these	O
proteins	O
with	O
key	O
molecular	O
events	O
including	O
platelet	O
activation	O
and	O
inflammatory	O
responses	O
,	O
and	O
with	O
events	O
not	O
previously	O
attributed	O
to	O
platelets	O
during	O
dengue	O
infection	O
including	O
antigen	O
processing	O
and	O
presentation	O
,	O
proteasome	O
activity	O
,	O
and	O
expression	O
of	O
histones	O
.	O

From	O
these	O
results	O
,	O
we	O
conducted	O
functional	O
assays	B-P
using	O
samples	O
from	O
a	O
larger	O
cohort	O
of	O
patients	O
and	O
demonstrated	O
evidence	O
for	O
platelet	O
activation	O
indicated	O
by	O
P-selectin	O
(	O
CD62P	O
)	O
translocation	O
and	O
secretion	O
of	O
granule-stored	O
chemokines	O
by	O
platelets	O
.	O

In	O
addition	O
,	O
we	O
found	O
evidence	O
that	O
DENV	O
infection	O
triggers	O
HLA	O
class	O
I	O
synthesis	O
and	O
surface	O
expression	O
by	O
a	O
mechanism	O
depending	O
on	O
functional	O
proteasome	O
activity	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
cell-free	O
histone	O
H2A	O
released	O
during	O
dengue	O
infection	O
binds	O
to	O
platelets	O
,	O
increasing	O
platelet	O
activation	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
functional	O
importance	O
of	O
HLA	O
class	O
I	O
,	O
proteasome	O
subunits	O
,	O
and	O
histones	O
that	O
we	O
found	O
exclusively	O
in	O
proteome	O
analysis	O
of	O
platelets	O
in	O
samples	O
from	O
dengue	O
patients	O
.	O

Our	O
study	O
provides	O
the	O
first	O
in-depth	O
characterization	O
of	O
the	O
platelet	O
proteome	O
in	O
dengue	O
,	O
and	O
sheds	O
light	O
on	O
new	O
mechanisms	O
of	O
platelet	O
activation	O
and	O
platelet	O
-	O
mediated	O
immune	O
and	O
inflammatory	O
responses	O
.	O

MyHEART	O
:	O
A	O
Non	O
Randomized	O
Feasibility	O
Study	O
of	O
a	O
Young	O
Adult	O
Hypertension	O
Intervention	O
.	O

In	O
the	O
United	O
States	O
,	O
young	O
adults	O
(	O
18-39	O
year-olds	O
)	O
have	O
the	O
lowest	O
hypertension	O
control	O
rates	O
(	O
35	O
%	O
)	O
compared	O
to	O
middle-aged	O
(	O
58	O
%	O
)	O
and	O
older	O
(	O
54	O
%	O
)	O
adults	O
.	O

Ambulatory	O
care	O
for	O
hypertension	O
management	O
often	O
focuses	O
on	O
medication	O
with	O
little	O
time	O
for	O
self-management	O
and	O
behavioral	O
counseling	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
feasibility	O
of	O
MyHEART	O
,	O
a	O
telephone-based	O
health	O
coach	O
self-management	O
intervention	O
for	O
young	O
adults	O
.	O

The	O
goals	O
were	O
to	O
determine	O
the	O
intervention	O
's	O
ability	O
to	O
:	O
1	O
)	O
recruit	O
young	O
adults	O
with	O
uncontrolled	O
hypertension	O
,	O
2	O
)	O
maintain	O
ongoing	O
communication	O
between	O
the	O
coach	O
and	O
participants	O
,	O
3	O
)	O
increase	O
participants	O
'	O
engagement	O
in	O
self-management	O
,	O
4	O
)	O
document	O
coach	O
-	O
patient	O
communication	O
in	O
the	O
electronic	O
health	O
record	O
,	O
and	O
5	O
)	O
assess	O
patient	O
acceptability	O
.	O

Eligible	O
participants	O
were	O
identified	O
through	O
the	O
electronic	O
health	O
record	O
.	O

Inclusion	O
criteria	O
included	O
18-39	O
year-olds	O
,	O
with	O
ICD-9	O
hypertension	O
diagnoses	O
and	O
uncontrolled	O
hypertension	O
(	O
â¥	O
140/90	O
mmHg	O
)	O
,	O
receiving	O
regular	O
primary	O
care	O
at	O
a	O
large	O
multispecialty	O
group	O
practice	O
.	O

The	O
intervention	O
consisted	O
of	O
6	O
telephone	O
self-management	O
sessions	O
by	O
a	O
health	O
coach	O
targeting	O
lifestyle	O
modifications	O
.	O

Patients	O
completed	O
an	O
open-ended	O
acceptability	O
survey	O
.	O

Study	O
uptake	O
was	O
47	O
%	O
(	O
9	O
enrolled/19	O
eligible	O
)	O
.	O

Mean	O
(	O
SD	O
)	O
age	O
was	O
35.8	O
(	O
2.6	O
)	O
years	O
,	O
78	O
%	O
male	O
,	O
and	O
33	O
%	O
Black	O
.	O

Over	O
85	O
%	O
of	O
enrolled	O
young	O
adults	O
maintained	O
communication	O
with	O
their	O
health	O
coach	O
.	O

At	O
baseline	O
,	O
11	O
%	O
reported	O
checking	O
their	O
blood	O
pressure	O
outside	O
of	O
clinic	O
;	O
44	O
%	O
reported	O
blood	O
pressure	O
monitoring	O
after	O
the	O
study	O
.	O

All	O
coach	O
-	O
patient	O
encounters	O
were	O
successfully	O
documented	O
in	O
the	O
electronic	O
health	O
record	O
for	O
primary	O
care	O
provider	O
review	O
.	O

Open-ended	O
responses	O
from	O
all	O
surveys	O
indicated	O
that	O
participants	O
had	O
a	O
positive	O
experience	O
with	O
the	O
MyHEART	O
intervention	O
.	O

This	O
study	O
demonstrated	O
that	O
MyHEART	O
was	O
feasible	O
and	O
acceptable	O
to	O
young	O
adults	O
with	O
uncontrolled	O
hypertension	O
.	O

Health	O
coaches	O
can	O
effectively	O
maintain	O
ongoing	O
communication	O
with	O
young	O
adults	O
,	O
document	O
communication	O
in	O
the	O
electronic	O
health	O
record	O
,	O
and	O
increase	O
engagement	O
with	O
home	B-P
blood	I-P
pressure	I-P
monitoring	I-P
.	O

The	O
results	O
of	O
this	O
study	O
will	O
inform	O
a	O
multi-center	O
young	O
adult	O
randomized	O
controlled	O
trial	O
of	O
MyHEART	O
.	O

Omega	O
3	O
Fatty	O
Acids	O
Reduce	O
Bone	O
Resorption	O
While	O
Promoting	O
Bone	O
Generation	O
in	O
Rat	O
Apical	O
Periodontitis	O
.	O

This	O
study	O
evaluated	O
the	O
effects	O
of	O
the	O
dietary	O
supplement	O
omega	O
3	O
polyunsaturated	O
fatty	O
acids	O
(	O
Ï-3	O
PUFAs	O
)	O
on	O
pulp	O
exposure	O
-induced	O
apical	O
periodontitis	O
(	O
AP	O
)	O
in	O
rats	O
.	O

Twenty-eight	O
male	O
rats	O
were	O
divided	O
into	O
groups	O
:	O
control	O
untreated	O
rats	O
(	O
C	O
)	O
,	O
control	O
rats	O
treated	O
with	O
Ï-3	O
PUFAs	O
alone	O
(	O
C-O	O
)	O
,	O
rats	O
with	O
pulp	O
exposure	O
-induced	O
AP	O
,	O
and	O
rats	O
with	O
pulp	O
exposure	O
-induced	O
AP	O
treated	O
with	O
Ï-3	O
PUFAs	O
(	O
AP	O
-O	O
)	O
.	O

The	O
Ï-3	O
PUFAs	O
were	O
administered	O
orally	O
,	O
once	O
a	O
day	O
,	O
for	O
15	O
days	O
before	O
pulp	O
exposure	O
and	O
,	O
subsequently	O
,	O
30	O
days	O
after	O
pulp	O
exposure	O
.	O

Rats	O
were	O
killed	O
30	O
days	O
after	O
pulp	O
exposure	O
,	O
and	O
jaws	O
were	O
subjected	O
to	O
histologic	O
and	O
immunohistochemical	B-P
analyses	O
.	O

Immunohistochemical	B-P
analyses	O
were	O
performed	O
to	O
detect	O
tartrate-resistant	O
acid	O
phosphatase	O
-	O
positive	O
osteoclasts	O
and	O
osteocalcin	O
-	O
positive	O
osteoblasts	O
on	O
the	O
bone	O
surface	O
of	O
periapical	O
area	O
.	O

Results	O
were	O
statistically	O
evaluated	O
by	O
using	O
analysis	O
of	O
variance	O
and	O
Tukey	O
honestly	O
significant	O
difference	O
,	O
and	O
P	O
<	O
.05	O
was	O
considered	O
statistically	O
significant	O
.	O

The	O
bone	O
resorption	O
lesion	O
was	O
significantly	O
larger	O
in	O
the	O
AP	O
group	O
compared	O
with	O
AP	O
-O	O
,	O
C	O
,	O
and	O
C-O	O
groups	O
(	O
P	O
<	O
.05	O
)	O
.	O

The	O
level	O
of	O
inflammatory	O
cell	O
infiltration	O
was	O
significantly	O
elevated	O
,	O
and	O
the	O
number	O
of	O
tartrate-resistant	O
acid	O
phosphatase	O
-	O
positive	O
osteoclasts	O
was	O
significantly	O
higher	O
in	O
the	O
periapical	O
lesions	O
of	O
the	O
AP	O
group	O
compared	O
with	O
AP	O
-O	O
,	O
C	O
,	O
and	O
C-O	O
groups	O
(	O
P	O
<	O
.05	O
)	O
.	O

The	O
number	O
of	O
osteocalcin	O
-	O
positive	O
osteoblasts	O
was	O
significantly	O
increased	O
in	O
the	O
AP	O
-O	O
group	O
compared	O
with	O
the	O
AP	O
group	O
(	O
P	O
>	O
.05	O
)	O
.	O

Supplementation	O
with	O
Ï-3	O
PUFAs	O
not	O
only	O
suppresses	O
bone	O
resorption	O
but	O
also	O
promotes	O
new	O
bone	O
formation	O
in	O
the	O
periapical	O
area	O
of	O
rats	O
with	O
AP	O
in	O
conjunction	O
with	O
downregulation	O
of	O
inflammatory	O
cell	O
infiltration	O
into	O
the	O
lesion	O
.	O

Antenatal	O
consultation	O
following	O
limb	O
malformation	O
discovery	O
using	O
ultrasound	B-P
scan	I-P
.	O

Our	O
unit	O
has	O
been	O
providing	O
antenatal	O
consultations	O
for	O
30	O
years	O
following	O
the	O
discovery	O
of	O
limb	O
malformation	O
with	O
the	O
fetus	O
.	O

Each	O
of	O
these	O
consultations	O
is	O
specific	O
and	O
carried	O
out	O
by	O
a	O
multi-professional	O
team	O
.	O

It	O
requires	O
a	O
physical	O
and	O
rehabilitation	O
doctor	O
,	O
an	O
orthopedic	O
surgeon	O
,	O
an	O
occupational	O
therapist	O
for	O
upper	O
limb	O
malformation	O
,	O
a	O
physiotherapist	O
for	O
lower	O
malformation	O
and	O
a	O
psychologist	O
.	O

This	O
multidisciplinary	O
consultation	O
is	O
unique	O
because	O
of	O
each	O
pregnancy	O
story	O
,	O
because	O
of	O
each	O
patient	O
life	O
story	O
but	O
also	O
because	O
of	O
the	O
words	O
used	O
by	O
the	O
sonologist	O
when	O
announcing	O
the	O
diagnosis	O
.	O

We	O
deal	O
with	O
couples	O
shocked	O
by	O
the	O
prenatal	B-P
diagnosis	I-P
.	O

We	O
help	O
them	O
get	O
acceptance	O
of	O
the	O
child	O
to	O
be	O
born	O
and	O
to	O
forget	O
about	O
their	O
imaginary	O
child	O
.	O

Medical	O
information	O
is	O
often	O
perceived	O
as	O
being	O
``	O
a	O
surfeit	O
of	O
information	O
``	O
difficult	O
to	O
handle	O
by	O
the	O
couple	O
stunned	O
by	O
the	O
overwhelming	O
diagnosis	O
.	O

We	O
must	O
stress	O
that	O
it	O
is	O
critical	O
to	O
not	O
only	O
have	O
a	O
good	O
medical	O
description	O
of	O
the	O
malformations	O
and	O
potential	O
treatments	O
but	O
also	O
a	O
good	O
psychological	O
support	O
(	O
parents	O
personal	O
life	O
story	O
,	O
self-defense	O
mechanism	O
,	O
guilt	O
feeling	O
)	O
.	O

The	O
ethical	O
aspect	O
of	O
this	O
consultation	O
is	O
also	O
important	O
.	O

Team	O
members	O
must	O
be	O
as	O
neutral	O
as	O
possible	O
in	O
their	O
assessments	O
in	O
order	O
to	O
let	O
the	O
couple	O
take	O
the	O
final	O
decision	O
:	O
the	O
continuation	O
of	O
the	O
pregnancy	O
or	O
a	O
request	O
of	O
voluntary	O
termination	O
of	O
pregnancy	O
.	O

These	O
prenatal	O
consultations	O
highlight	O
the	O
importance	O
of	O
the	O
multidisciplinary	O
global	O
care	O
.	O

MiR-495	O
functions	O
as	O
an	O
adjuvant	O
to	O
radiation	O
therapy	O
by	O
reducing	O
the	O
radiation-induced	O
bystander	O
effect	O
.	O

The	O
radiation-induced	O
bystander	O
effect	O
(	O
RIBE	O
)	O
is	O
an	O
important	O
factor	O
in	O
tumor	O
radiation	O
therapy	O
because	O
it	O
may	O
increase	O
the	O
probability	O
of	O
normal	O
cellular	O
injury	O
and	O
the	O
likelihood	O
of	O
secondary	O
cancers	O
after	O
radiotherapy	O
.	O

Here	O
,	O
we	O
identified	O
the	O
role	O
of	O
miR-495	O
in	O
alleviating	O
RIBEs	O
during	O
radiotherapy	O
.	O

Luciferase	B-P
reporter	I-P
assay	I-P
results	O
confirmed	O
that	O
miR-495	O
regulated	O
endothelial	O
nitric	O
oxide	O
synthase	O
(	O
eNOS	O
)	O
by	O
targeting	O
the	O
Sp1	O
3'-untranslated	O
region	O
.	O

Consequently	O
,	O
after	O
radiation	O
,	O
tumor	O
cells	O
expressed	O
less	O
eNOS	O
and	O
Sp1	O
than	O
controls	O
.	O

In	O
vitro	O
cell	O
irradiation	O
data	O
based	O
on	O
flow-cytometric	O
analysis	O
and	O
enzymed	B-P
linked	I-P
immunosorbent	I-P
assay	I-P
confirmed	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
and	O
its	O
downstream	O
product	O
transforming	O
growth	O
factor	O
Î²1	O
(	O
TGF-Î²1	O
)	O
were	O
critical	O
signaling	O
factors	O
contributing	O
to	O
RIBEs	O
.	O

Fewer	O
normal	O
LO2	O
liver	O
cells	O
were	O
injured	O
and	O
fewer	O
micronuclei	O
were	O
observed	O
when	O
treated	O
with	O
the	O
medium	O
of	O
the	O
miR-495	O
overexpressing	O
HepG2	O
and	O
ZR75-1	O
tumor	O
cells	O
.	O

Accordingly	O
,	O
treatment	O
with	O
the	O
miR-495	O
antagomir	O
led	O
to	O
higher	O
NO	O
and	O
TGF-Î²1	O
levels	O
and	O
more	O
injured	O
LO2	O
cells	O
.	O

In	O
vivo	O
experiments	O
indicated	O
that	O
local	O
irradiation	O
of	O
tumors	O
overexpressing	O
miR-495	O
produced	O
fewer	O
necrotic	O
foci	O
in	O
non-irradiated	O
liver	O
tissue	O
compared	O
with	O
controls	O
.	O

miR-495	O
was	O
upregulated	O
in	O
clinical	O
cancer	O
tissues	O
compared	O
with	O
adjacent	O
non-cancerous	O
tissues	O
,	O
and	O
radiation	O
significantly	O
reduced	O
the	O
expression	O
level	O
of	O
miR-495	O
in	O
carcinoma	O
cell	O
lines	O
.	O

In	O
summary	O
,	O
miR-495	O
may	O
have	O
promise	O
as	O
an	O
adjuvant	O
for	O
tumor	O
radiation	O
therapy	O
to	O
decrease	O
RIBEs	O
involving	O
the	O
Sp1	O
/	O
eNOS	O
pathway	O
.	O

